S8227661B2	NNP	O
-	:	O
Methods	NNS	O
of	IN	O
identifying	VBG	O
agents	NNS	O
that	WDT	O
ameliorate	VBP	O
or	CC	O
modulate	JJ	O
effects	NNS	O
of	IN	O
PRO1328	NNP	O
gene	NN	O
disruptions	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	NN	O
of,	,	O
and	CC	O
claims	VBZ	O
the	DT	O
benefit	NN	O
under	IN	O
35	CD	O
U.S.C.	.	O
§120	NN	O
of,	,	O
parent	NN	O
application	NN	O
Ser.	.	O
No.	.	O
12/221,669,	,	O
filed	VBN	O
Aug.	NNP	O
4,	,	O
2008	CD	O
now	RB	O
abandoned,	,	O
which	WDT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/457,708,	,	O
filed	VBN	O
Jun.	.	O
3,	,	O
2009,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of,	,	O
and	CC	O
claims	VBZ	O
the	DT	O
benefit	NN	O
under	IN	O
35	CD	O
U.S.C.	.	O
§120	NN	O
of,	,	O
international	JJ	O
application	NN	O
PCT/US2005/02723,	,	O
filed	VBD	O
Jan.	NNP	O
27,	,	O
2005,	,	O
which	WDT	O
claims	VBZ	O
priority	NN	O
under	IN	O
35	CD	O
U.S.C.	.	O
§119(e)	)	O
to	TO	O
U.S.	.	O
Provisional	JJ	O
Application	NNP	O
Ser.	.	O
No.	.	O
60/544,195	CD	O
filed	VBD	O
Feb.	NNP	O
12,	,	O
2004.	.	O
INCORPORATION-BY-REFERENCE	NNP	O
The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
text	NN	O
file	NN	O
named	VBN	O
“Sequence	NN	O
Listing	VBG	O
P5202R1”	NNP	O
and	CC	O
created	VBD	O
Sep.	NNP	O
6,	,	O
2006,	,	O
being	VBG	O
62	CD	O
kB	NN	O
in	IN	O
size,	,	O
which	WDT	O
was	VBD	O
filed	VBN	O
with	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
Patent	NNP	O
and	CC	O
Trademark	NNP	O
Office	NNP	O
on	IN	O
Sep.	NNP	O
27,	,	O
2006	CD	O
regarding	VBG	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/457,708,	,	O
and	CC	O
which	WDT	O
was	VBD	O
later	RBR	O
filed	VBN	O
regarding	VBG	O
related	JJ	O
application	NN	O
U.S.	NNP	O
Ser.	.	O
No.	.	O
12/221,669,	,	O
filed	VBN	O
Aug.	NNP	O
4,	,	O
2008,	,	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
compositions,	,	O
including	VBG	O
transgenic	JJ	O
and	CC	O
knockout	NN	O
animals	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
such	JJ	O
compositions	NNS	O
for	IN	O
the	DT	O
diagnosis	NN	O
and	CC	O
treatment	NN	O
of	IN	O
diseases	NNS	O
or	CC	O
disorders.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Extracellular	NNP	O
proteins	VBZ	O
play	VB	O
important	JJ	O
roles	NNS	O
in,	,	O
among	IN	O
other	JJ	O
things,	,	O
the	DT	O
formation,	,	O
differentiation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
multicellular	JJ	O
organisms.	.	O
The	DT	O
fate	NN	O
of	IN	O
many	JJ	O
individual	JJ	O
cells,	,	O
e.g.,	,	O
proliferation,	,	O
migration,	,	O
differentiation,	,	O
or	CC	O
interaction	NN	O
with	IN	O
other	JJ	O
cells,	,	O
is	VBZ	O
typically	RB	O
governed	VBN	O
by	IN	O
information	NN	O
received	VBN	O
from	IN	O
other	JJ	O
cells	NNS	O
and/or	IN	O
the	DT	O
immediate	JJ	O
environment.	.	O
This	DT	O
information	NN	O
is	VBZ	O
often	RB	O
transmitted	VBN	O
by	IN	O
secreted	JJ	O
polypeptides	NNS	O
(for	IN	O
instance,	,	O
mitogenic	JJ	O
factors,	,	O
survival	JJ	O
factors,	,	O
cytotoxic	JJ	O
factors,	,	O
differentiation	NN	O
factors,	,	O
neuropeptides,	,	O
and	CC	O
hormones)	)	O
which	WDT	O
are,	,	O
in	IN	O
turn,	,	O
received	VBD	O
and	CC	O
interpreted	VBN	O
by	IN	O
diverse	NN	O
cell	NN	O
receptors	NNS	O
or	CC	O
membrane-bound	JJ	O
proteins.	.	O
These	DT	O
secreted	VBD	O
polypeptides	NNS	O
or	CC	O
signaling	VBG	O
molecules	NNS	O
normally	RB	O
pass	VBP	O
through	IN	O
the	DT	O
cellular	JJ	O
secretory	NN	O
pathway	NN	O
to	TO	O
reach	VB	O
their	PRP$	O
site	NN	O
of	IN	O
action	NN	O
in	IN	O
the	DT	O
extracellular	JJ	O
environment.	.	O
Secreted	VBN	O
proteins	NNS	O
have	VBP	O
various	JJ	O
industrial	JJ	O
applications,	,	O
including	VBG	O
as	IN	O
pharmaceuticals,	,	O
diagnostics,	,	O
biosensors	NNS	O
and	CC	O
bioreactors.	.	O
Most	JJS	O
protein	NN	O
drugs	NNS	O
available	JJ	O
at	IN	O
present,	,	O
such	JJ	O
as	IN	O
thrombolytic	JJ	O
agents,	,	O
interferons,	,	O
interleukins,	,	O
erythropoietins,	,	O
colony	NN	O
stimulating	NN	O
factors,	,	O
and	CC	O
various	JJ	O
other	JJ	O
cytokines,	,	O
are	VBP	O
secretory	JJ	O
proteins.	.	O
Their	PRP$	O
receptors,	,	O
which	WDT	O
are	VBP	O
membrane	JJ	O
proteins,	,	O
also	RB	O
have	VBP	O
potential	JJ	O
as	IN	O
therapeutic	JJ	O
or	CC	O
diagnostic	JJ	O
agents.	.	O
Efforts	NNS	O
are	VBP	O
being	VBG	O
undertaken	VBN	O
by	IN	O
both	DT	O
industry	NN	O
and	CC	O
academia	NN	O
to	TO	O
identify	VB	O
new,	,	O
native	JJ	O
secreted	VBD	O
proteins.	.	O
Many	JJ	O
efforts	NNS	O
are	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
screening	NN	O
of	IN	O
mammalian	JJ	O
recombinant	NN	O
DNA	NNP	O
libraries	VBZ	O
to	TO	O
identify	VB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
novel	NN	O
secreted	VBN	O
proteins.	.	O
Examples	NNS	O
of	IN	O
screening	VBG	O
methods	NNS	O
and	CC	O
techniques	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
the	DT	O
literature	NN	O
[see,	,	O
for	IN	O
example,	,	O
Klein	NNP	B
et	VBZ	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
93:7108-7113	CD	I
(1996);	:	I
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,536,637)].	.	O
Membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
receptors	NNS	O
can	MD	O
play	VB	O
important	JJ	O
roles	NNS	O
in,	,	O
among	IN	O
other	JJ	O
things,	,	O
the	DT	O
formation,	,	O
differentiation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
multicellular	JJ	O
organisms.	.	O
The	DT	O
fate	NN	O
of	IN	O
many	JJ	O
individual	JJ	O
cells,	,	O
e.g.,	,	O
proliferation,	,	O
migration,	,	O
differentiation,	,	O
or	CC	O
interaction	NN	O
with	IN	O
other	JJ	O
cells,	,	O
is	VBZ	O
typically	RB	O
governed	VBN	O
by	IN	O
information	NN	O
received	VBN	O
from	IN	O
other	JJ	O
cells	NNS	O
and/or	IN	O
the	DT	O
immediate	JJ	O
environment.	.	O
This	DT	O
information	NN	O
is	VBZ	O
often	RB	O
transmitted	VBN	O
by	IN	O
secreted	JJ	O
polypeptides	NNS	O
(for	IN	O
instance,	,	O
mitogenic	JJ	O
factors,	,	O
survival	JJ	O
factors,	,	O
cytotoxic	JJ	O
factors,	,	O
differentiation	NN	O
factors,	,	O
neuropeptides,	,	O
and	CC	O
hormones)	)	O
which	WDT	O
are,	,	O
in	IN	O
turn,	,	O
received	VBD	O
and	CC	O
interpreted	VBN	O
by	IN	O
diverse	NN	O
cell	NN	O
receptors	NNS	O
or	CC	O
membrane-bound	JJ	O
proteins.	.	O
Such	JJ	O
membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
cell	NN	O
receptors	NNS	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
cytokine	JJ	O
receptors,	,	O
receptor	NN	O
kinases,	,	O
receptor	NN	O
phosphatases,	,	O
receptors	NNS	O
involved	VBN	O
in	IN	O
cell-cell	JJ	O
interactions,	,	O
and	CC	O
cellular	JJ	O
adhesion	NN	O
molecules	NNS	O
like	IN	O
selectins	NNS	O
and	CC	O
integrins.	.	O
For	IN	O
instance,	,	O
transduction	NN	O
of	IN	O
signals	NNS	O
that	WDT	O
regulate	VBP	O
cell	NN	O
growth	NN	O
and	CC	O
differentiation	NN	O
is	VBZ	O
regulated	VBN	O
in	IN	O
part	NN	O
by	IN	O
phosphorylation	NN	O
of	IN	O
various	JJ	O
cellular	JJ	O
proteins.	.	O
Protein	NNP	O
tyrosine	NN	O
kinases,	,	O
enzymes	NNS	O
that	IN	O
catalyze	VBP	O
that	DT	O
process,	,	O
can	MD	O
also	RB	O
act	VB	O
as	IN	O
growth	NN	O
factor	NN	O
receptors.	.	O
Examples	NNS	O
include	VBP	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
and	CC	O
nerve	NN	O
growth	NN	O
factor	NN	O
receptor.	.	O
Membrane-bound	JJ	O
proteins	NNS	O
and	CC	O
receptor	NN	O
molecules	NNS	O
have	VBP	O
various	JJ	O
industrial	JJ	O
applications,	,	O
including	VBG	O
as	IN	O
pharmaceutical	JJ	O
and	CC	O
diagnostic	JJ	O
agents.	.	O
Receptor	NNP	O
immuno-adhesions,	,	O
for	IN	O
instance,	,	O
can	MD	O
be	VB	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
to	TO	O
block	VB	O
receptor-ligand	JJ	O
interactions.	.	O
The	DT	O
membrane-bound	JJ	O
proteins	NNS	O
can	MD	O
also	RB	O
be	VB	O
employed	VBN	O
for	IN	O
screening	NN	O
of	IN	O
potential	JJ	O
peptide	NN	O
or	CC	O
small	JJ	O
molecule	NN	O
inhibitors	NNS	O
of	IN	O
the	DT	O
relevant	JJ	O
receptor/ligand	NN	O
interaction.	.	O
Efforts	NNS	O
are	VBP	O
being	VBG	O
undertaken	VBN	O
by	IN	O
both	DT	O
industry	NN	O
and	CC	O
academia	NN	O
to	TO	O
identify	VB	O
new,	,	O
native	JJ	O
receptor	NN	O
or	CC	O
membrane-bound	JJ	O
proteins.	.	O
Many	JJ	O
efforts	NNS	O
are	VBP	O
focused	VBN	O
on	IN	O
the	DT	O
screening	NN	O
of	IN	O
mammalian	JJ	O
recombinant	NN	O
DNA	NNP	O
libraries	VBZ	O
to	TO	O
identify	VB	O
the	DT	O
coding	NN	O
sequences	NNS	O
for	IN	O
novel	JJ	O
receptor	NN	O
or	CC	O
membrane-bound	JJ	O
proteins.	.	O
Given	VBN	O
the	DT	O
importance	NN	O
of	IN	O
secreted	JJ	O
and	CC	O
membrane-bound	JJ	O
proteins	NNS	O
in	IN	O
biological	JJ	O
and	CC	O
disease	NN	O
processes,	,	O
in	IN	O
vivo	JJ	O
studies	NNS	O
and	CC	O
characterizations	NNS	O
may	MD	O
provide	VB	O
valuable	JJ	O
identification	NN	O
and	CC	O
discovery	NN	O
of	IN	O
therapeutics	NNS	O
and/or	JJ	O
treatments	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
prevention,	,	O
amelioration	NN	O
or	CC	O
correction	NN	O
of	IN	O
diseases	NNS	O
or	CC	O
dysfunctions.	.	O
In	IN	O
this	DT	O
regard,	,	O
genetically	RB	O
engineered	VBN	O
mice	NNS	O
have	VBP	O
proven	VBN	O
to	TO	O
be	VB	O
invaluable	JJ	O
tools	NNS	O
for	IN	O
the	DT	O
functional	JJ	O
dissection	NN	O
of	IN	O
biological	JJ	O
processes	NNS	O
relevant	VBP	O
to	TO	O
human	JJ	O
disease,	,	O
including	VBG	O
immunology,	,	O
cancer,	,	O
neuro-biology,	,	O
cardiovascular	JJ	O
biology,	,	O
obesity	NN	O
and	CC	O
many	JJ	O
others.	.	O
Gene	NNP	O
knockouts	NNS	O
can	MD	O
be	VB	O
viewed	VBN	O
as	IN	O
modeling	VBG	O
the	DT	O
biological	JJ	O
mechanism	NN	O
of	IN	O
drug	NN	O
action	NN	O
by	IN	O
presaging	VBG	O
the	DT	O
activity	NN	O
of	IN	O
highly	RB	O
specific	JJ	O
antagonists	NNS	O
in	IN	O
vivo.	.	O
Knockout	NNP	O
mice	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
model	VB	O
drug	NN	O
activity;	:	O
phenotypes	NNS	O
of	IN	O
mice	JJ	O
deficient	NN	O
for	IN	O
specific	JJ	O
pharmaceutical	JJ	O
target	NN	O
proteins	NNS	O
can	MD	O
resemble	VB	O
the	DT	O
human	JJ	O
clinical	JJ	O
phenotype	NN	O
caused	VBN	O
by	IN	O
the	DT	O
corresponding	JJ	O
antagonist	JJ	O
drug.	.	O
Gene	NNP	O
knockouts	NNS	O
enable	VBP	O
the	DT	O
discovery	NN	O
of	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
the	DT	O
target,	,	O
the	DT	O
predominant	JJ	O
physiological	JJ	O
role	NN	O
of	IN	O
the	DT	O
target,	,	O
and	CC	O
mechanism-based	JJ	O
side-effects	NNS	O
that	WDT	O
might	MD	O
result	VB	O
from	IN	O
inhibition	NN	O
of	IN	O
the	DT	O
target	NN	O
in	IN	O
mammals.	.	O
Examples	NNS	O
of	IN	O
this	DT	O
type	NN	O
include	VBP	O
mice	JJ	O
deficient	NN	O
in	IN	O
the	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	NN	O
(ACE)	)	O
Esther,	,	B
C.	NNP	I
R.	NNP	I
et	FW	I
al.,	,	I
Lab.	.	I
Invest.,	,	I
74:953-965	NNP	I
(1996)]	NN	I
[and	CC	O
cyclooxygenase-1	NN	O
(COX1)	)	O
genes	NNS	O
Langenbach,	,	B
R.	NNP	I
et	FW	I
al.,	,	I
Cell,	,	I
83:483-492	CD	I
(1995)].[	.	O
Conversely,	,	O
knocking	VBG	O
the	DT	O
gene	NN	O
out	RP	O
in	IN	O
the	DT	O
mouse	NN	O
can	MD	O
have	VB	O
an	DT	O
opposite	JJ	O
phenotypic	NN	O
effect	NN	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
humans	NNS	O
after	IN	O
administration	NN	O
of	IN	O
an	DT	O
agonist	JJ	O
drug	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
target.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
erythropoietin	NN	O
knockout	NN	O
Wu,	,	B
C.	NNP	I
S.	NNP	I
et	FW	I
al.,	,	I
Cell,	,	I
83:59-67	CD	I
(1996)],[	,	O
in	IN	O
which	WDT	O
a	DT	O
consequence	NN	O
of	IN	O
the	DT	O
mutation	NN	O
is	VBZ	O
deficient	JJ	O
red	JJ	O
blood	NN	O
cell	NN	O
production,	,	O
and	CC	O
the	DT	O
GABA(A)-R-β3	NN	O
knockout	NN	O
DeLorey,	,	B
T.	NNP	I
M.,	,	I
J.	.	I
Neurosci.,	,	I
18:8505-8514	CD	I
(1998)],[	,	O
in	IN	O
which	WDT	O
the	DT	O
mutant	NN	O
mice	NN	O
show	NN	O
hyperactivity	NN	O
and	CC	O
hyper-responsiveness.	.	O
Both	DT	O
these	DT	O
phenotypes	NNS	O
are	VBP	O
opposite	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
erythropoietin	NN	O
and	CC	O
benzodiazepine	JJ	O
administration	NN	O
in	IN	O
humans.	.	O
A	DT	O
striking	JJ	O
example	NN	O
of	IN	O
a	DT	O
target	NN	O
validated	VBN	O
using	VBG	O
mouse	NN	O
genetics	NNS	O
is	VBZ	O
the	DT	O
ACC2	NNP	O
gene.	.	O
Although	IN	O
the	DT	O
human	JJ	O
ACC2	NNP	O
gene	NN	O
had	VBD	O
been	VBN	O
identified	VBN	O
several	JJ	O
years	NNS	O
ago,	,	O
interest	NN	O
in	IN	O
ACC2	NNP	O
as	IN	O
a	DT	O
target	NN	O
for	IN	O
drug	NN	O
development	NN	O
was	VBD	O
stimulated	VBN	O
only	RB	O
recently	RB	O
after	IN	O
analysis	NN	O
of	IN	O
ACC2	NNP	O
function	NN	O
using	VBG	O
a	DT	O
knockout	NN	O
mouse.	.	O
ACC2	NNP	O
mutant	JJ	O
mice	NN	O
eat	NN	O
more	JJR	O
than	IN	O
their	PRP$	O
wild-type	JJ	O
littermates,	,	O
yet	RB	O
burn	VBP	O
more	JJR	O
fat	JJ	O
and	CC	O
store	NN	O
less	JJR	O
fat	JJ	O
in	IN	O
their	PRP$	O
adipocytes,	,	O
making	VBG	O
this	DT	O
enzyme	NN	O
a	DT	O
probable	JJ	O
target	NN	O
for	IN	O
chemical	JJ	O
antagonism	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obesity	NN	O
Abu-Elheiga,	,	B
L.	NNP	I
et	FW	I
al.,	,	I
Science,	,	I
291:2613-2616	CD	I
(2001)].[	.	O
In	IN	O
the	DT	O
instant	JJ	O
application,	,	O
mutated	VBN	O
gene	NN	O
disruptions	NNS	O
have	VBP	O
resulted	VBN	O
in	IN	O
phenotypic	NN	O
observations	NNS	O
related	VBN	O
to	TO	O
various	JJ	O
disease	JJ	O
conditions	NNS	O
or	CC	O
dysfunctions	NNS	O
including:	:	O
CNS/neurological	JJ	O
disturbances	NNS	O
or	CC	O
disorders	NNS	O
such	JJ	O
as	IN	O
anxiety;	:	O
eye	NN	O
abnormalities	NNS	O
and	CC	O
associated	JJ	O
diseases;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
including	VBG	O
atherosclerosis;	:	O
abnormal	JJ	O
metabolic	NN	O
disorders	NNS	O
including	VBG	O
diabetes	NNS	O
and	CC	O
dyslipidemias	NNS	O
associated	VBN	O
with	IN	O
elevated	JJ	O
serum	NN	O
triglycerides	NNS	O
and	CC	O
cholesterol	NN	O
levels;	:	O
immunological	JJ	O
and	CC	O
inflammatory	JJ	O
disorders;	:	O
oncological	JJ	O
disorders;	:	O
bone	CD	O
metabolic	JJ	O
abnormalities	NNS	O
or	CC	O
disorders	NNS	O
such	JJ	O
as	IN	O
arthritis,	,	O
osteoporosis	NN	O
and	CC	O
osteopetrosis;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
embryonic	JJ	O
lethality.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
A.	NN	O
Embodiments	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprises	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(a)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
encoding	VBG	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
having	VBG	O
a	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
protein,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
or	CC	O
(b)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(a).	.	O
In	IN	O
other	JJ	O
aspects,	,	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprises	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(a)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
comprising	VBG	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
a	DT	O
full-length	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
cDNA	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
or	CC	O
(b)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(a).	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
(a)	)	O
a	DT	O
DNA	NN	O
molecule	NN	O
that	WDT	O
encodes	VBZ	O
the	DT	O
same	JJ	O
mature	NN	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
human	JJ	O
protein	NN	O
cDNAs	NN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
as	IN	O
disclosed	VBN	O
herein,	,	O
or	CC	O
(b)	)	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
DNA	NNP	O
molecule	NN	O
of	IN	O
(a).	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
either	DT	O
transmembrane	JJ	O
domain-deleted	JJ	O
or	CC	O
transmembrane	JJ	O
domain-inactivated,	,	O
or	CC	O
is	VBZ	O
complementary	JJ	O
to	TO	O
such	JJ	O
encoding	JJ	O
nucleotide	JJ	O
sequence,	,	O
wherein	VBP	O
the	DT	O
transmembrane	NN	O
domain(s)	)	O
of	IN	O
such	JJ	O
polypeptide	NN	O
are	VBP	O
disclosed	VBN	O
herein.	.	O
Therefore,	,	O
soluble	JJ	O
extracellular	JJ	O
domains	NNS	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
are	VBP	O
contemplated.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
coding	VBG	O
sequence,	,	O
or	CC	O
the	DT	O
complement	NN	O
thereof,	,	O
that	WDT	O
may	MD	O
find	VB	O
use	NN	O
as,	,	O
for	IN	O
example,	,	O
hybridization	NN	O
probes,	,	O
for	IN	O
encoding	VBG	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
that	DT	O
may	MD	O
optionally	RB	O
encode	VB	O
a	DT	O
polypeptide	NN	O
comprising	VBG	O
a	DT	O
binding	NN	O
site	NN	O
for	IN	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
or	CC	O
as	IN	O
antisense	JJ	O
oligonucleotide	IN	O
probes.	.	O
Such	JJ	O
nucleic	JJ	O
acid	NN	O
fragments	NNS	O
usually	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
15	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
30	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
40	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
60	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
70	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
100	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
110	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
120	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
130	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
140	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
150	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
160	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
170	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
180	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
190	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
200	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
250	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
300	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
350	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
400	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
450	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
500	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
600	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
700	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
800	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
900	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
and	CC	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
1000	CD	O
nucleotides	NNS	O
in	IN	O
length,	,	O
wherein	NN	O
in	IN	O
this	DT	O
context	NN	O
the	DT	O
term	NN	O
“about”	NN	O
means	VBZ	O
the	DT	O
referenced	JJ	O
nucleotide	JJ	O
sequence	NN	O
length	NN	O
plus	CC	O
or	CC	O
minus	CC	O
10%	NN	O
of	IN	O
that	DT	O
referenced	VBD	O
length.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
novel	JJ	O
fragments	NNS	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
may	MD	O
be	VB	O
determined	VBN	O
in	IN	O
a	DT	O
routine	JJ	O
manner	NN	O
by	IN	O
aligning	VBG	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
with	IN	O
other	JJ	O
known	VBN	O
nucleotide	JJ	O
sequences	NNS	O
using	VBG	O
any	DT	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
well	RB	O
known	VBN	O
sequence	NN	O
alignment	NN	O
programs	NNS	O
and	CC	O
determining	VBG	O
which	WDT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	JJ	O
sequence	NN	O
fragment(s)	)	O
are	VBP	O
novel.	.	O
All	DT	O
of	IN	O
such	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide-encoding	JJ	O
nucleotide	NN	O
sequences	NNS	O
are	VBP	O
contemplated	VBN	O
herein.	.	O
Also	RB	O
contemplated	VBN	O
are	VBP	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
encoded	VBN	O
by	IN	O
these	DT	O
nucleotide	JJ	O
molecule	NN	O
fragments,	,	O
preferably	RB	O
those	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
fragments	NNS	O
that	WDT	O
comprise	VBP	O
a	DT	O
binding	NN	O
site	NN	O
for	IN	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
isolated	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
isolated	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
hereinabove	VBP	O
identified.	.	O
In	IN	O
a	DT	O
certain	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
comprising	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
having	VBG	O
a	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
lacking	VBG	O
the	DT	O
signal	JJ	O
peptide	NN	O
as	IN	O
disclosed	JJ	O
herein,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
transmembrane	NN	O
protein,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
signal	NN	O
peptide,	,	O
as	IN	O
disclosed	VBN	O
herein	NN	O
or	CC	O
any	DT	O
other	JJ	O
specifically	RB	O
defined	JJ	O
fragment	NN	O
of	IN	O
the	DT	O
full-length	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
disclosed	JJ	O
herein.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
concerns	VBZ	O
an	DT	O
isolated	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
comprising	VBG	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
about	IN	O
80%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
81%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
82%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
83%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
84%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
86%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
87%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
88%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
89%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
90%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
91%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
92%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
93%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
94%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
95%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
96%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
97%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
98%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
and	CC	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
encoded	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
human	JJ	O
protein	NN	O
cDNAs	NN	O
deposited	VBN	O
with	IN	O
the	DT	O
ATCC	NNP	O
as	IN	O
disclosed	VBN	O
herein.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
invention	NN	O
concerns	NNS	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	NN	O
polypeptides	NNS	O
which	WDT	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length,	,	O
alternatively	RB	O
are	VBP	O
or	CC	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
20,	,	O
30,	,	O
40,	,	O
50,	,	O
60,	,	O
70,	,	O
80,	,	O
90,	,	O
100,	,	O
110,	,	O
120,	,	O
130,	,	O
140,	,	O
150,	,	O
160,	,	O
170,	,	O
180,	,	O
190,	,	O
200,	,	O
210,	,	O
220,	,	O
230,	,	O
240,	,	O
250,	,	O
260,	,	O
270,	,	O
280,	,	O
290,	,	O
300,	,	O
310,	,	O
320,	,	O
330,	,	O
340,	,	O
350,	,	O
360,	,	O
370,	,	O
380,	,	O
390,	,	O
400,	,	O
410,	,	O
420,	,	O
430,	,	O
440,	,	O
450,	,	O
460,	,	O
470,	,	O
480,	,	O
490,	,	O
500,	,	O
510,	,	O
520,	,	O
530,	,	O
540,	,	O
550,	,	O
560,	,	O
570,	,	O
580,	,	O
590,	,	O
600	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length,	,	O
or	CC	O
more.	.	O
Optionally,	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
variant	JJ	O
polypeptides	NNS	O
will	MD	O
have	VB	O
or	CC	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
one	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence,	,	O
alternatively	RB	O
will	MD	O
have	VB	O
or	CC	O
will	MD	O
have	VB	O
no	DT	O
more	JJR	O
than	IN	O
2,	,	O
3,	,	O
4,	,	O
5,	,	O
6,	,	O
7,	,	O
8,	,	O
9,	,	O
or	CC	O
10	CD	O
conservative	JJ	O
amino	NN	O
acid	JJ	O
substitution	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
native	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	JJ	O
sequence.	.	O
In	IN	O
a	DT	O
specific	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
without	IN	O
the	DT	O
N-terminal	JJ	O
signal	JJ	O
sequence	NN	O
and/or	VBD	O
the	DT	O
initiating	NN	O
methionine	NN	O
and	CC	O
is	VBZ	O
encoded	VBN	O
by	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
encodes	VBZ	O
such	PDT	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
hereinbefore	NN	O
described.	.	O
Processes	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
same	JJ	O
are	VBP	O
also	RB	O
herein	RB	O
described,	,	O
wherein	VBP	O
those	DT	O
processes	NNS	O
comprise	VBP	O
culturing	VBG	O
a	DT	O
host	NN	O
cell	NN	O
comprising	VBG	O
a	DT	O
vector	NN	O
which	WDT	O
comprises	VBZ	O
the	DT	O
appropriate	JJ	O
encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
from	IN	O
the	DT	O
cell	NN	O
culture.	.	O
Another	DT	O
aspect	VBP	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
either	DT	O
transmembrane	JJ	O
domain-deleted	JJ	O
or	CC	O
transmembrane	JJ	O
domain-inactivated.	.	O
Processes	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
same	JJ	O
are	VBP	O
also	RB	O
herein	RB	O
described,	,	O
wherein	VBP	O
those	DT	O
processes	NNS	O
comprise	VBP	O
culturing	VBG	O
a	DT	O
host	NN	O
cell	NN	O
comprising	VBG	O
a	DT	O
vector	NN	O
which	WDT	O
comprises	VBZ	O
the	DT	O
appropriate	JJ	O
encoding	NN	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
from	IN	O
the	DT	O
cell	NN	O
culture.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
agonists	NNS	O
and	CC	O
antagonists	NNS	O
of	IN	O
a	DT	O
native	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
defined	VBN	O
herein.	.	O
In	IN	O
particular,	,	O
the	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody	NN	O
or	CC	O
a	DT	O
small	JJ	O
molecule.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
to	TO	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
comprise	NN	O
contacting	VBG	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
with	IN	O
a	DT	O
candidate	NN	O
molecule	NN	O
and	CC	O
monitoring	VBG	O
a	DT	O
biological	JJ	O
activity	NN	O
mediated	VBN	O
by	IN	O
said	VBD	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
Preferably,	,	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
is	VBZ	O
a	DT	O
native	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
composition	NN	O
of	IN	O
matter	NN	O
comprising	VBG	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	RB	O
as	IN	O
herein	NN	O
described,	,	O
or	CC	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody,	,	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
carrier.	.	O
Optionally,	,	O
the	DT	O
carrier	NN	O
is	VBZ	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
or	CC	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	JJ	O
thereof	NN	O
as	IN	O
hereinbefore	NN	O
described,	,	O
or	CC	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody,	,	O
for	IN	O
the	DT	O
preparation	NN	O
of	IN	O
a	DT	O
medicament	NN	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
condition	NN	O
which	WDT	O
is	VBZ	O
responsive	JJ	O
to	TO	O
the	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
vectors	NNS	O
comprising	VBG	O
DNA	NNP	O
encoding	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides.	.	O
Host	NNP	O
cell	NN	O
comprising	VBG	O
any	DT	O
such	JJ	O
vector	NN	O
are	VBP	O
also	RB	O
provided.	.	O
By	IN	O
way	NN	O
of	IN	O
example,	,	O
the	DT	O
host	NN	O
cells	NNS	O
may	MD	O
be	VB	O
CHO	NNP	O
cells,	,	O
E.	NNP	O
coli,	,	O
or	CC	O
yeast.	.	O
A	DT	O
process	NN	O
for	IN	O
producing	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
is	VBZ	O
further	JJ	O
provided	VBN	O
and	CC	O
comprises	VBZ	O
culturing	VBG	O
host	NN	O
cells	NNS	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
desired	JJ	O
polypeptide	NN	O
and	CC	O
recovering	VBG	O
the	DT	O
desired	VBN	O
polypeptide	NN	O
from	IN	O
the	DT	O
cell	NN	O
culture.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
chimeric	JJ	O
molecules	NNS	O
comprising	VBG	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
fused	VBN	O
to	TO	O
a	DT	O
heterologous	JJ	O
polypeptide	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequence.	.	O
Example	NN	O
of	IN	O
such	JJ	O
chimeric	JJ	O
molecules	NNS	O
comprise	VBP	O
any	DT	O
of	IN	O
the	DT	O
herein	NN	O
described	VBD	O
polypeptides	NNS	O
fused	VBN	O
to	TO	O
an	DT	O
epitope	NN	O
tag	NN	O
sequence	NN	O
or	CC	O
a	DT	O
Fc	JJ	O
region	NN	O
of	IN	O
an	DT	O
immunoglobulin.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
antibody	NN	O
which	WDT	O
binds,	,	O
preferably	RB	O
specifically,	,	O
to	TO	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
or	CC	O
below	IN	O
described	VBN	O
polypeptides.	.	O
Optionally,	,	O
the	DT	O
antibody	NN	O
is	VBZ	O
a	DT	O
monoclonal	JJ	O
antibody,	,	O
humanized	VBN	O
antibody,	,	O
antibody	NN	O
fragment	NN	O
or	CC	O
single-chain	NN	O
antibody.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
oligonucleotide	IN	O
probes	NNS	O
which	WDT	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
isolating	VBG	O
genomic	JJ	O
and	CC	O
cDNA	JJ	O
nucleotide	NN	O
sequences,	,	O
measuring	VBG	O
or	CC	O
detecting	VBG	O
expression	NN	O
of	IN	O
an	DT	O
associated	JJ	O
gene	NN	O
or	CC	O
as	IN	O
antisense	JJ	O
probes,	,	O
wherein	VBP	O
those	DT	O
probes	NNS	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
the	DT	O
above	NN	O
or	CC	O
below	IN	O
described	VBN	O
nucleotide	JJ	O
sequences.	.	O
Preferred	NNP	O
probe	NN	O
lengths	NNS	O
are	VBP	O
described	VBN	O
above.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
and	CC	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rodent.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
mammal	NN	O
is	VBZ	O
a	DT	O
rat	NN	O
or	CC	O
a	DT	O
mouse.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
phenotype	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
as	IN	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following:	:	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
cell	NN	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
isolated	JJ	O
cell	NN	O
is	VBZ	O
a	DT	O
murine	NN	O
cell.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
murine	NN	O
cell	NN	O
is	VBZ	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
isolated	JJ	O
cell	NN	O
is	VBZ	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
which	WDT	O
exhibits	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
phenotypes	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
identified	JJ	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
comprises	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism,	,	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
is	VBZ	O
modulated.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
observing	VBG	O
the	DT	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
observed	JJ	O
behavior	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
modulates	VBZ	O
the	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
observed	JJ	O
behavior	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
and	CC	O
(c)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
eye	NN	O
abnormality;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
contacting	VBG	O
a	DT	O
test	NN	O
agent	NN	O
with	IN	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
and	CC	O
(b)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
the	DT	O
host	NN	O
cell.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
evaluating	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
condition	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
on	IN	O
the	DT	O
identified	JJ	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
condition	NN	O
is	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
which	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
comprising	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
the	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
in	IN	O
need	NN	O
of	IN	O
such	JJ	O
treatment	NN	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
disorder,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
disorder	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
disorder	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
agent,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder	NN	O
or	CC	O
disease.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis.	.	O
In	IN	O
another	DT	O
aspect	NN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
cell	JJ	O
culture;	:	O
and	CC	O
(c)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
eye	NN	O
abnormality;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
said	VBD	O
culture.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
neurological	JJ	O
disorder	NN	O
includes	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
and	CC	O
sensory	JJ	O
disorders.	.	O
Such	JJ	O
neurological	JJ	O
disorders	NNS	O
include	VBP	O
the	DT	O
category	NN	O
defined	VBD	O
as	IN	O
“anxiety	NN	O
disorders”	NN	O
which	WDT	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to:	:	O
mild	VB	O
to	TO	O
moderate	VB	O
anxiety,	,	O
anxiety	NN	O
disorder	NN	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	NN	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
generalized	VBN	O
anxiety	NN	O
disorder,	,	O
panic	JJ	O
attack,	,	O
panic	JJ	O
disorder	NN	O
with	IN	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	,	O
social	JJ	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	,	O
specific	JJ	O
phobia,	,	O
substance-induced	JJ	O
anxiety	NN	O
disorder,	,	O
acute	JJ	O
alcohol	NN	O
withdrawal,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	,	O
bipolar	JJ	O
disorder	NN	O
I	PRP	O
or	CC	O
II,	,	O
bipolar	JJ	O
disorder	NN	O
not	RB	O
otherwise	RB	O
specified,	,	O
cyclothymic	JJ	O
disorder,	,	O
depressive	JJ	O
disorder,	,	O
major	JJ	O
depressive	JJ	O
disorder,	,	O
mood	NN	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	,	O
enhancement	NN	O
of	IN	O
cognitive	JJ	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	NN	O
associated	VBN	O
with	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
Alzheimer's	POS	O
disease,	,	O
stroke,	,	O
or	CC	O
traumatic	JJ	O
injury	NN	O
to	TO	O
the	DT	O
brain,	,	O
seizures	NNS	O
resulting	VBG	O
from	IN	O
disease	NN	O
or	CC	O
injury	NN	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
epilepsy,	,	O
learning	VBG	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	.	O
In	IN	O
addition,	,	O
anxiety	NN	O
disorders	NNS	O
may	MD	O
apply	VB	O
to	TO	O
personality	NN	O
disorders	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
following	JJ	O
types:	:	O
paranoid,	,	O
antisocial,	,	O
avoidant	JJ	O
behavior,	,	O
borderline	JJ	O
personality	NN	O
disorders,	,	O
dependent,	,	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	CC	O
schizotypal.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa	NN	O
or	CC	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
retinal	JJ	O
abnormalities	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
In	IN	O
still	RB	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
lupus	NN	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis,	,	O
osteopenia	NN	O
or	CC	O
osteopetrosis.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
which	WDT	O
is	VBZ	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
said	VBD	O
culture.	.	O
In	IN	O
one	CD	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
In	IN	O
yet	RB	O
another	DT	O
aspect,	,	O
the	DT	O
agonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
In	IN	O
still	RB	O
another	DT	O
aspect,	,	O
the	DT	O
antagonist	NN	O
agent	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
genewhich	JJ	O
encodes	NNS	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
phenotype,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
phenotype	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
phenotype	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
phenotype,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
phenotype.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
physiological	JJ	O
characteristic,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
physiological	JJ	O
characteristic.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
genewhich	JJ	O
encodes	NNS	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
behavior,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
behavior	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
exhibited	JJ	O
behavior	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
behavior,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
behavior.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
said	VBD	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
expression,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
said	VBD	O
polypeptide.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
have	VB	O
the	DT	O
condition,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
condition	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
condition	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
as	IN	O
modulating	NN	O
said	VBD	O
condition,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
condition.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
identified	VBN	O
as	IN	O
treating	NN	O
or	CC	O
preventing	NN	O
or	CC	O
ameliorating	NN	O
said	VBD	O
disorder,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder.	.	O
In	IN	O
yet	RB	O
further	JJ	O
embodiments,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
the	DT	O
following	JJ	O
set	NN	O
of	IN	O
potential	JJ	O
claims	NNS	O
for	IN	O
this	DT	O
application:	:	O
1.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
and	CC	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
2.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
is	VBZ	O
heterozygous	JJ	O
for	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
3.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1,	,	O
wherein	VBD	O
the	DT	O
phenotype	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
as	IN	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates	NNS	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following:	:	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
4.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
5.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
6.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
7.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
8.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
9.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
10.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
11.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
12.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa.	.	O
13.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
14.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
10,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
15.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
16.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
15,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
17.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
18.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
19.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonias,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
20.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
3,	,	O
wherein	VBD	O
the	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis.	.	O
21.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
1,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
22.	.	O
An	DT	O
isolated	JJ	O
cell	NN	O
derived	VBN	O
from	IN	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
23.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
22	CD	O
which	WDT	O
is	VBZ	O
a	DT	O
murine	NN	O
cell.	.	O
24.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
23,	,	O
wherein	VBD	O
the	DT	O
murine	NN	O
cell	NN	O
is	VBZ	O
an	DT	O
embryonic	JJ	O
stem	NN	O
cell.	.	O
25.	.	O
The	DT	O
isolated	JJ	O
cell	NN	O
of	IN	O
claim	NN	O
22,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
phenotypes	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
26.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
phenotype	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
identified	JJ	O
phenotype	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
27.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
26,	,	O
wherein	VBD	O
the	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
comprises	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
28.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
29.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
30.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
31.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
32.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
33.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
34.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
35.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
36.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa.	.	O
37.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
38.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
34,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
39.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
40.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
39,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
systemic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
41.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
42.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
43.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation-associated	JJ	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
44.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
27,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis.	.	O
45.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
26,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
46.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
26.	.	O
47.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
46	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
48.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
47,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
49.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
47,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
50.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
is	VBZ	O
modulated.	.	O
51.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
50,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
52.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
50.	.	O
53.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
52	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
54.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
53,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
55.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
53,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
56.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
which	WDT	O
modulates	VBZ	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
observing	VBG	O
the	DT	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
observed	JJ	O
behavior	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
observed	JJ	O
behavior	NN	O
exhibited	VBN	O
by	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
modulates	VBZ	O
the	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption.	.	O
57.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
58.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
59.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
60.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
61.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
62.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
56,	,	O
wherein	VBD	O
the	DT	O
behavior	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
63.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
56.	.	O
64.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
63	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
65.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
64,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
66.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
64,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
67.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
and	CC	O
(c)	)	O
determining	VBG	O
whether	IN	O
said	VBD	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
eye	NN	O
abnormality;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
68.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
69.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
70.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
71.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
72.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
73.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
74.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
75.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
76.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa.	.	O
77.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
78.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
74,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
79.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
80.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
79,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
81.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
82.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
83.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
84.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis.	.	O
85.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
67,	,	O
wherein	VBD	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
exhibits	NNS	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
physiological	JJ	O
characteristics	NNS	O
compared	VBN	O
with	IN	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
littermates:	:	O
an	DT	O
increased	VBN	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
anxiety	NN	O
response	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing	NN	O
(circadian	JJ	O
test)	)	O
and	CC	O
in	IN	O
functional	JJ	O
observation	NN	O
battery	NN	O
(FOB)	)	O
testing	VBG	O
resulting	VBG	O
in	IN	O
balding,	,	O
absent	JJ	O
whiskers	NNS	O
and	CC	O
exothalamus	JJ	O
observations;	:	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
testing;	:	O
depigmentation	NN	O
spots	NNS	O
and	CC	O
an	DT	O
increased	JJ	O
mean	NN	O
artery-to-vein	JJ	O
ratio	NN	O
associated	VBN	O
with	IN	O
retinal	JJ	O
degeneration;	:	O
yellow-tinted	JJ	O
coats	NNS	O
in	IN	O
albino	NN	O
male	NN	O
(0/−)	)	O
mice	NN	O
and	CC	O
female	NN	O
(+/−)	)	O
mice;	:	O
an	DT	O
increased	VBN	O
blood	NN	O
glucose	JJ	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
cholesterol	NN	O
level;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
triglyceride	IN	O
level;	:	O
increased	VBN	O
levels	NNS	O
of	IN	O
urobilinogen,	,	O
ketones	NNS	O
and	CC	O
blood	NN	O
in	IN	O
the	DT	O
urine;	:	O
a	DT	O
decreased	JJ	O
mean	JJ	O
percentage	NN	O
of	IN	O
B	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
CD4+	NNP	O
cells	NNS	O
in	IN	O
peripheral	JJ	O
blood;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentage	NN	O
of	IN	O
mature	NN	O
B	NNP	O
cells	NNS	O
and	CC	O
increased	VBD	O
mean	JJ	O
percentages	NNS	O
of	IN	O
IgM+	NNP	O
and	CC	O
B220Hi	NNP	O
IgD+	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
in	IN	O
an	DT	O
increased	JJ	O
percentage	NN	O
of	IN	O
immature	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
bone	NN	O
marrow;	:	O
an	DT	O
increased	VBN	O
cell	NN	O
number	NN	O
for	IN	O
TcR+	NNP	O
cells,	,	O
CD19+	NNP	O
cells	NNS	O
and	CC	O
GR1-cells	NNP	O
in	IN	O
lymph	JJ	O
node;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
percentages	NNS	O
of	IN	O
TcR	NNP	O
Beta,	,	O
CD4	NNP	O
and	CC	O
CD8	NNP	O
cells	NNS	O
in	IN	O
thymus;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
serum	NN	O
IgG2a	NNP	O
response	NN	O
to	TO	O
an	DT	O
ovalbumin	JJ	O
challenge;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
TNF-alpha	NNP	O
response	NN	O
and	CC	O
MCP-1	NNP	O
response	NN	O
to	TO	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
an	DT	O
increased	VBN	O
mean	NN	O
IL-6	NNP	O
response	NN	O
to	TO	O
a	DT	O
LPS	NNP	O
challenge	NN	O
in	IN	O
acute	JJ	O
phase	NN	O
response	NN	O
testing;	:	O
mobilization	NN	O
of	IN	O
neutrophils	NNS	O
in	IN	O
response	NN	O
to	TO	O
peritoneal	VB	O
inflammation	NN	O
by	IN	O
a	DT	O
zymosan	JJ	O
challenge;	:	O
a	DT	O
decreased	JJ	O
mean	NN	O
bone	NN	O
mineral	NN	O
content	NN	O
and	CC	O
density	NN	O
in	IN	O
total	JJ	O
body,	,	O
femur	NN	O
and	CC	O
vertebrate	NN	O
including	VBG	O
a	DT	O
decreased	JJ	O
mean	NN	O
trabecular	JJ	O
bone	NN	O
volume,	,	O
decreased	JJ	O
thickness,	,	O
and	CC	O
decreased	VBD	O
connectivity	NN	O
density;	:	O
a	DT	O
decreased	JJ	O
femoral	JJ	O
midshaft	NN	O
cross-sectional	JJ	O
area;	:	O
growth	NN	O
retardation	NN	O
with	IN	O
decreased	JJ	O
body	NN	O
weight	NN	O
and	CC	O
length,	,	O
total	JJ	O
tissue	NN	O
mass,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass;	:	O
an	DT	O
increased	VBN	O
total	JJ	O
tissue	NN	O
mass,	,	O
increased	VBD	O
lean	JJ	O
body	NN	O
mass,	,	O
an	DT	O
increased	VBN	O
percent	NN	O
total	JJ	O
body	NN	O
fat;	:	O
increased	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content,	,	O
increased	VBD	O
total	JJ	O
body	NN	O
and	CC	O
increased	JJ	O
femoral	JJ	O
bone	NN	O
mineral	JJ	O
density;	:	O
degeneration	NN	O
of	IN	O
seminiferous	JJ	O
tubules;	:	O
embryonic	JJ	O
lethality;	:	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
wherein	VBP	O
heterozygous	JJ	O
adults	NNS	O
exhibited	VBD	O
decreased	JJ	O
serum	NN	O
IgM,	,	O
IgG1,	,	O
IgG2a,	,	O
IgG2b	NNP	O
and	CC	O
IgG3	NNP	O
levels;	:	O
embryonic	JJ	O
lethality	NN	O
wherein	NN	O
necropsy	NN	O
shows	VBZ	O
multiple	JJ	O
histological	JJ	O
defects	NNS	O
involving	VBG	O
GI,	,	O
hematopoietic,	,	O
respiratory,	,	O
neuromuscular,	,	O
and	CC	O
reproductive	JJ	O
systems.	.	O
86.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
67.	.	O
87.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
82	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
88.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
87,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
89.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
87,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
90.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
67.	.	O
91.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
contacting	VBG	O
a	DT	O
test	NN	O
agent	NN	O
with	IN	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
and	CC	O
(b)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
test	NN	O
agent	NN	O
modulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
by	IN	O
the	DT	O
host	NN	O
cell.	.	O
92.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
91.	.	O
93.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
92	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
94.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
93,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
95.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
93,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
96.	.	O
A	DT	O
method	NN	O
of	IN	O
evaluating	VBG	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
capable	JJ	O
of	IN	O
affecting	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
genome	JJ	O
comprises	VBZ	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
measuring	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
(c)	)	O
comparing	VBG	O
the	DT	O
measured	JJ	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
(b)	)	O
with	IN	O
that	DT	O
of	IN	O
a	DT	O
gender	NN	O
matched	VBN	O
wild-type	JJ	O
animal,	,	O
wherein	VBP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
transgenic	NN	O
animal	NN	O
that	WDT	O
differs	VBZ	O
from	IN	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
of	IN	O
the	DT	O
wild-type	JJ	O
animal	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
a	DT	O
condition	NN	O
resulting	VBG	O
from	IN	O
the	DT	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal;	:	O
(d)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
of	IN	O
(a);	:	O
and	CC	O
(e)	)	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
on	IN	O
the	DT	O
identified	JJ	O
condition	NN	O
associated	VBN	O
with	IN	O
gene	NN	O
disruption	NN	O
in	IN	O
the	DT	O
non-human	JJ	O
transgenic	JJ	O
animal.	.	O
97.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
96,	,	O
wherein	VBD	O
the	DT	O
condition	NN	O
is	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality.	.	O
98.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
96.	.	O
99.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
100.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
99,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
101.	.	O
The	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
99,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
102.	.	O
A	DT	O
pharmaceutical	JJ	O
composition	NN	O
comprising	VBG	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98.	.	O
103.	.	O
A	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
in	IN	O
need	NN	O
of	IN	O
such	JJ	O
treatment	NN	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
disorder,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
disorder	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
disorder	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
94,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder.	.	O
104.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
105.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
106.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
107.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
108.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
109.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
110.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
111.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
112.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa.	.	O
113.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
114.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
110,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
115.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
116.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
115,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
117.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
118.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
iseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
119.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
120.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
103,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis.	.	O
121.	.	O
A	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
a	DT	O
neurological	JJ	O
disorder;	:	O
a	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
an	DT	O
eye	NN	O
abnormality;	:	O
an	DT	O
immunological	JJ	O
disorder;	:	O
an	DT	O
oncological	JJ	O
disorder;	:	O
a	DT	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
a	DT	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
a	DT	O
developmental	JJ	O
abnormality	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising:	:	O
(a)	)	O
providing	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide;	:	O
(b)	)	O
administering	VBG	O
a	DT	O
test	NN	O
agent	NN	O
to	TO	O
said	VBD	O
cell	JJ	O
culture;	:	O
and	CC	O
(c)	)	O
determining	VBG	O
whether	IN	O
said	VBD	O
test	NN	O
agent	NN	O
ameliorates	VBZ	O
or	CC	O
modulates	VBZ	O
the	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
eye	NN	O
abnormality;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder;	:	O
lipid	JJ	O
metabolic	JJ	O
disorder;	:	O
or	CC	O
developmental	JJ	O
abnormality	NN	O
in	IN	O
said	VBD	O
cell	NN	O
culture.	.	O
122.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
increased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
123.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
decreased	JJ	O
anxiety-like	JJ	O
response	NN	O
during	IN	O
open	JJ	O
field	NN	O
activity	NN	O
testing.	.	O
124.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
abnormal	JJ	O
circadian	JJ	O
rhythm	NN	O
during	IN	O
home-cage	JJ	O
activity	NN	O
testing.	.	O
125.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
enhanced	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
126.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
motor	NN	O
coordination	NN	O
during	IN	O
inverted	JJ	O
screen	JJ	O
testing.	.	O
127.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
neurological	JJ	O
disorder	NN	O
is	VBZ	O
depression,	,	O
generalized	VBN	O
anxiety	NN	O
disorders,	,	O
attention	NN	O
deficit	NN	O
disorder,	,	O
sleep	JJ	O
disorder,	,	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	JJ	O
disorder,	,	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	,	O
hyperalgesia	NN	O
or	CC	O
sensory	JJ	O
disorders.	.	O
128.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
retinal	JJ	O
abnormality.	.	O
129.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
vision	NN	O
problems	NNS	O
or	CC	O
blindness.	.	O
130.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinitis	NN	O
pigmentosa.	.	O
131.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
retinal	JJ	O
degeneration	NN	O
or	CC	O
retinal	JJ	O
dysplasia.	.	O
132.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
128,	,	O
wherein	VBD	O
the	DT	O
retinal	JJ	O
abnormality	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
retinal	JJ	O
dysplasia,	,	O
various	JJ	O
retinopathies,	,	O
including	VBG	O
retinopathy	NN	O
of	IN	O
prematurity,	,	O
retrolental	JJ	O
fibroplasia,	,	O
neovascular	JJ	O
glaucoma,	,	O
age-related	JJ	O
macular	JJ	O
degeneration,	,	O
diabetic	JJ	O
macular	NN	O
edema,	,	O
corneal	JJ	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
neovascularization,	,	O
corneal	NN	O
graft	NN	O
rejection,	,	O
retinal/choroidal	JJ	O
neovascularization,	,	O
neovascularization	NN	O
of	IN	O
the	DT	O
angle	NN	O
(rubeosis),	,	O
ocular	JJ	O
neovascular	JJ	O
disease,	,	O
vascular	JJ	O
restenosis,	,	O
arteriovenous	JJ	O
malformations	NNS	O
(AVM),	,	O
meningioma,	,	O
hemangioma,	,	O
angiofibroma,	,	O
thyroid	JJ	O
hyperplasias	NN	O
(including	VBG	O
Grave's	POS	O
disease),	,	O
corneal	NN	O
and	CC	O
other	JJ	O
tissue	NN	O
transplantation,	,	O
retinal	JJ	O
artery	NN	O
obstruction	NN	O
or	CC	O
occlusion;	:	O
retinal	JJ	O
degeneration	NN	O
causing	VBG	O
secondary	JJ	O
atrophy	NN	O
of	IN	O
the	DT	O
retinal	JJ	O
vasculature,	,	O
retinitis	NN	O
pigmentosa,	,	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	POS	O
disease,	,	O
congenital	JJ	O
stationary	JJ	O
night	NN	O
blindness,	,	O
choroideremia,	,	O
gyrate	NN	O
atrophy,	,	O
Leber's	POS	O
congenital	JJ	O
amaurosis,	,	O
retinoschisis	NN	O
disorders,	,	O
Wagner's	POS	O
syndrome,	,	O
Usher	NNP	O
syndromes,	,	O
Zellweger	NNP	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	POS	O
syndrome,	,	O
Alstrom's	POS	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	,	O
Flynn-Aird	NNP	O
syndrome,	,	O
Friedreich	NNP	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	POS	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
olivopontocerebellar	JJ	O
atrophy,	,	O
Pierre-Marie	NNP	O
dunsdrome,	,	O
Stickler	NNP	O
syndrome,	,	O
carotinemeia,	,	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	NNP	O
syndrome,	,	O
abetalipoproteinemia,	,	O
incontinentia	NN	O
pigmenti,	,	O
Batten's	POS	O
disease,	,	O
mucopolysaccharidoses,	,	O
homocystinuria,	,	O
or	CC	O
mannosidosis.	.	O
133.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
eye	NN	O
abnormality	NN	O
is	VBZ	O
a	DT	O
cataract.	.	O
134.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
133,	,	O
wherein	VBD	O
the	DT	O
cataract	NN	O
is	VBZ	O
a	DT	O
systemic	JJ	O
disease	NN	O
such	JJ	O
as	IN	O
human	JJ	O
Down's	POS	O
syndrome,	,	O
Hallerman-Streiff	NNP	O
syndrome,	,	O
Lowe	NNP	O
syndrome,	,	O
galactosemia,	,	O
Marfan	NNP	O
syndrome,	,	O
Trismoy	NNP	O
13-15,	,	O
Alport	NNP	O
syndrome,	,	O
myotonic	JJ	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypoparathroidism	NN	O
or	CC	O
Conradi	NNP	O
syndrome.	.	O
135.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
developmental	JJ	O
abnormality	NN	O
comprises	VBZ	O
embryonic	JJ	O
lethality	NN	O
or	CC	O
reduced	JJ	O
viability.	.	O
136.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorders	NNS	O
are	VBP	O
arterial	JJ	O
diseases,	,	O
such	JJ	O
as	IN	O
diabetes	NNS	O
mellitus;	:	O
papilledema;	:	O
optic	JJ	O
atrophy;	:	O
atherosclerosis;	:	O
angina;	:	O
myocardial	JJ	O
infarctions	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
myocardial	JJ	O
infarctions,	,	O
cardiac	JJ	O
hypertrophy,	,	O
and	CC	O
heart	NN	O
failure	NN	O
such	JJ	O
as	IN	O
congestive	JJ	O
heart	NN	O
failure;	:	O
hypertension;	:	O
inflammatory	JJ	O
vasculitides;	:	O
Reynaud's	POS	O
disease	NN	O
and	CC	O
Reynaud's	POS	O
phenomenon;	:	O
aneurysms	NNS	O
and	CC	O
arterial	JJ	O
restenosis;	:	O
venous	JJ	O
and	CC	O
lymphatic	JJ	O
disorders	NNS	O
such	JJ	O
as	IN	O
thrombophlebitis,	,	O
lymphangitis,	,	O
and	CC	O
lymphedema;	:	O
peripheral	JJ	O
vascular	JJ	O
disease;	:	O
cancer	NN	O
such	JJ	O
as	IN	O
vascular	JJ	O
tumors,	,	O
e.g.,	,	O
hemangioma	NN	O
(capillary	JJ	O
and	CC	O
cavernous),	,	O
glomus	JJ	O
tumors,	,	O
telangiectasia,	,	O
bacillary	JJ	O
angiomatosis,	,	O
hemangioendothelioma,	,	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	POS	O
sarcoma,	,	O
lymphangioma,	,	O
and	CC	O
lymphangiosarcoma;	:	O
tumor	CC	O
angiogenesis;	:	O
trauma	NNS	O
such	JJ	O
as	IN	O
wounds,	,	O
burns,	,	O
and	CC	O
other	JJ	O
injured	JJ	O
tissue,	,	O
implant	JJ	O
fixation,	,	O
scarring;	:	O
ischemia	JJ	O
reperfusion	NN	O
injury;	:	O
rheumatoid	JJ	O
arthritis;	:	O
cerebrovascular	JJ	O
disease;	:	O
renal	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
acute	JJ	O
renal	JJ	O
failure,	,	O
or	CC	O
osteoporosis.	.	O
137.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	VBD	O
the	DT	O
immunological	JJ	O
disorders	NNS	O
are	VBP	O
systemic	JJ	O
lupus	JJ	O
erythematosis;	:	O
rheumatoid	JJ	O
arthritis;	:	O
juvenile	NN	O
chronic	JJ	O
arthritis;	:	O
spondyloarthropathies;	:	O
systemic	JJ	O
sclerosis	NN	O
(scleroderma);	:	O
idiopathic	JJ	O
inflammatory	NN	O
myopathies	NNS	O
(dermatomyositis,	,	O
polymyositis);	:	O
Sjögren's	POS	O
syndrome;	:	O
systemic	JJ	O
vasculitis;	:	O
sarcoidosis;	:	O
autoimmune	CC	O
hemolytic	JJ	O
anemia	NN	O
(immune	JJ	O
pancytopenia,	,	O
paroxysmal	JJ	O
nocturnal	JJ	O
hemoglobinuria);	:	O
autoimmune	VBN	O
thrombocytopenia	NN	O
(idiopathic	JJ	O
thrombocytopenic	NN	O
purpura,	,	O
immune-mediated	JJ	O
thrombocytopenia);	:	O
thyroiditis	NN	O
(Grave's	POS	O
disease,	,	O
Hashimoto's	POS	O
thyroiditis,	,	O
juvenile	JJ	O
lymphocytic	JJ	O
thyroiditis,	,	O
atrophic	JJ	O
thyroiditis);	:	O
diabetes	VBZ	O
mellitus;	:	O
immune-mediated	JJ	O
renal	JJ	O
disease	NN	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis);	:	O
demyelinating	VBG	O
diseases	NNS	O
of	IN	O
the	DT	O
central	JJ	O
and	CC	O
peripheral	JJ	O
nervous	JJ	O
systems	NNS	O
such	JJ	O
as	IN	O
multiple	JJ	O
sclerosis,	,	O
idiopathic	JJ	O
demyelinating	VBG	O
polyneuropathy	JJ	O
or	CC	O
Guillain-Barré	JJ	O
syndrome,	,	O
and	CC	O
chronic	JJ	O
inflammatory	NN	O
demyelinating	VBG	O
polyneuropathy;	:	O
hepatobiliary	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
infectious	JJ	O
hepatitis	NN	O
(hepatitis	VB	O
A,	,	O
B,	,	O
C,	,	O
D,	,	O
E	NNP	O
and	CC	O
other	JJ	O
non-hepatotropic	JJ	O
viruses),	,	O
autoimmune	JJ	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	,	O
granulomatous	JJ	O
hepatitis,	,	O
and	CC	O
sclerosing	VBG	O
cholangitis;	:	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(ulcerative	JJ	O
colitis:	:	O
Crohn's	POS	O
disease);	:	O
gluten-sensitive	JJ	O
enteropathy,	,	O
and	CC	O
Whipple's	POS	O
disease;	:	O
autoimmune	CC	O
or	CC	O
immune-mediated	JJ	O
skin	NN	O
diseases	NNS	O
including	VBG	O
bullous	JJ	O
skin	NN	O
diseases,	,	O
erythema	NN	O
multiforme	NN	O
and	CC	O
contact	NN	O
dermatitis,	,	O
psoriasis;	:	O
allergic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
asthma,	,	O
allergic	JJ	O
rhinitis,	,	O
atopic	NN	O
dermatitis,	,	O
food	NN	O
hypersensitivity	NN	O
and	CC	O
urticaria;	:	O
immunologic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
lung	NN	O
such	JJ	O
as	IN	O
eosinophilic	JJ	O
pneumonia,	,	O
idiopathic	JJ	O
pulmonary	JJ	O
fibrosis	NN	O
and	CC	O
hypersensitivity	NN	O
pneumonitis;	:	O
or	CC	O
transplantation	NN	O
associated	VBN	O
diseases	NNS	O
including	VBG	O
graft	NN	O
rejection	NN	O
and	CC	O
graft-versus-host	JJ	O
disease.	.	O
138.	.	O
The	DT	O
method	NN	O
of	IN	O
claim	NN	O
121,	,	O
wherein	NN	O
said	VBD	O
bone	NN	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder	NN	O
is	VBZ	O
arthritis,	,	O
osteoporosis	NN	O
or	CC	O
osteopetrosis.	.	O
139.	.	O
An	DT	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
121.	.	O
140.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
139	CD	O
which	WDT	O
is	VBZ	O
an	DT	O
agonist	NN	O
or	CC	O
antagonist	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide.	.	O
141.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
140,	,	O
wherein	VBD	O
the	DT	O
agonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
142.	.	O
The	DT	O
agent	NN	O
of	IN	O
claim	NN	O
140,	,	O
wherein	VBD	O
the	DT	O
antagonist	NN	O
is	VBZ	O
an	DT	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	JJ	O
or	CC	O
anti-PRO1885	JJ	O
antibody.	.	O
143.	.	O
A	DT	O
therapeutic	JJ	O
agent	NN	O
identified	VBN	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
claim	NN	O
121.	.	O
144.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
phenotype	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
have	VB	O
the	DT	O
phenotype,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
phenotype	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
phenotype	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
46,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
phenotype.	.	O
145.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
physiological	JJ	O
characteristic	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
physiological	JJ	O
characteristic	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
52,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
physiological	JJ	O
characteristic.	.	O
146.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
behavior	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
already	RB	O
exhibit	VB	O
the	DT	O
behavior,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
exhibit	VB	O
the	DT	O
behavior	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
exhibited	JJ	O
behavior	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
63,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
behavior.	.	O
147.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
host	NN	O
cell	NN	O
expressing	VBG	O
said	VBD	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
92,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
said	VBD	O
polypeptide.	.	O
148.	.	O
A	DT	O
method	NN	O
of	IN	O
modulating	VBG	O
a	DT	O
condition	NN	O
associated	VBN	O
with	IN	O
a	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
subject	JJ	O
whom	WP	O
may	MD	O
have	VB	O
the	DT	O
condition,	,	O
or	CC	O
may	MD	O
be	VB	O
prone	NN	O
to	TO	O
have	VB	O
the	DT	O
condition	NN	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
whom	WP	O
the	DT	O
condition	NN	O
is	VBZ	O
to	TO	O
be	VB	O
prevented,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
of	IN	O
claim	NN	O
98,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
modulating	VBG	O
the	DT	O
condition.	.	O
149.	.	O
A	DT	O
method	NN	O
of	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
a	DT	O
neurological	JJ	O
disorder;	:	O
cardiovascular,	,	O
endothelial	JJ	O
or	CC	O
angiogenic	JJ	O
disorder;	:	O
immunological	JJ	O
disorder;	:	O
oncological	JJ	O
disorder;	:	O
bone	CC	O
metabolic	JJ	O
abnormality	NN	O
or	CC	O
disorder,	,	O
or	CC	O
embryonic	JJ	O
lethality	NN	O
associated	VBN	O
with	IN	O
the	DT	O
disruption	NN	O
of	IN	O
a	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
cell	NN	O
culture,	,	O
each	DT	O
cell	NN	O
of	IN	O
said	VBD	O
culture	NN	O
comprising	VBG	O
a	DT	O
disruption	NN	O
of	IN	O
the	DT	O
gene	NN	O
which	WDT	O
encodes	VBZ	O
for	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
agent	NN	O
of	IN	O
claim	NN	O
139,	,	O
or	CC	O
agonists	NNS	O
or	CC	O
antagonists	NNS	O
thereof,	,	O
thereby	RB	O
effectively	RB	O
treating	VBG	O
or	CC	O
preventing	VBG	O
or	CC	O
ameliorating	VBG	O
said	VBD	O
disorder.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG.	.	O
1	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:1)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO227	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA33786-1132”	JJ	O
(UNQ201).	.	O
FIG.	.	O
2	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
1.	.	O
FIG.	.	O
3	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:3)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO233	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA34436-1238”	JJ	O
(UNQ207).	.	O
FIG.	.	O
4	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:4)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
3.	.	O
FIG.	.	O
5	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:5)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO238	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA35600-1162”	JJ	O
(UNQ212).	.	O
FIG.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:6)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:5	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
5.	.	O
FIG.	.	O
7	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:7)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO1328	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA66658-1584”	JJ	O
(UNQ688).	.	O
FIG.	.	O
8	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:8)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
7.	.	O
FIG.	.	O
9	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:9)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO4342	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA96787-2534-1”	JJ	O
(UNQ1896).	.	O
FIG.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:10)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
9.	.	O
FIG.	.	O
11	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:11)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO7423	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	NN	O
as	IN	O
“DNA108809”	NN	O
(UNQ2964).	.	O
FIG.	.	O
12	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:12)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
11.	.	O
FIG.	.	O
13	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:13)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO10096	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA125185-2806”	JJ	O
(UNQ3099).	.	O
FIG.	.	O
14	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:14)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:13	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
13.	.	O
FIG.	.	O
15	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:15)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO21384	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA177313-2982”	JJ	O
(UNQ6368).	.	O
FIG.	.	O
16	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:16)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
15.	.	O
FIG.	.	O
17	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:17)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO353	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA41234-1242-1”	JJ	O
(UNQ310).	.	O
FIG.	.	O
18	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:18)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:17	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
17.	.	O
FIG.	.	O
19	CD	O
shows	VBZ	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:19)	)	O
of	IN	O
a	DT	O
native	JJ	O
sequence	NN	O
PRO1885	NNP	O
cDNA,	,	O
wherein	WP	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
is	VBZ	O
a	DT	O
clone	NN	O
designated	VBN	O
herein	RB	O
as	IN	O
“DNA79302-2521”	JJ	O
(UNQ868).	.	O
FIG.	.	O
20	CD	O
shows	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:20)	)	O
derived	VBD	O
from	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO:19	NNP	O
shown	VBN	O
in	IN	O
FIG.	.	O
19.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
PREFERRED	NNP	O
EMBODIMENTS	NNP	O
I.	NNP	O
Definitions	NNP	O
The	DT	O
terms	NNS	O
“PRO	VBP	O
polypeptide”	NN	O
and	CC	O
“PRO”	NN	O
as	IN	O
used	VBN	O
herein	NN	O
and	CC	O
when	WRB	O
immediately	RB	O
followed	VBN	O
by	IN	O
a	DT	O
numerical	JJ	O
designation	NN	O
refer	NN	O
to	TO	O
various	JJ	O
polypeptides,	,	O
wherein	VBP	O
the	DT	O
complete	JJ	O
designation	NN	O
(i.e.,	,	O
PRO/number)	)	O
refers	NNS	O
to	TO	O
specific	JJ	O
polypeptide	JJ	O
sequences	NNS	O
as	IN	O
described	JJ	O
herein.	.	O
The	DT	O
terms	NNS	O
“PRO/number	NNP	O
polypeptide”	NN	O
and	CC	O
“PRO/number”	NNP	O
wherein	VBP	O
the	DT	O
term	NN	O
“number”	NNP	O
is	VBZ	O
provided	VBN	O
as	IN	O
an	DT	O
actual	JJ	O
numerical	JJ	O
designation	NN	O
as	IN	O
used	VBN	O
herein	NN	O
encompass	NN	O
native	JJ	O
sequence	NN	O
polypeptides	NNS	O
and	CC	O
polypeptide	JJ	O
variants	NNS	O
(which	WDT	O
are	VBP	O
further	RBR	O
defined	JJ	O
herein).	.	O
The	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
described	VBD	O
herein	NN	O
may	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources,	,	O
such	JJ	O
as	IN	O
from	IN	O
human	JJ	O
tissue	NN	O
types	NNS	O
or	CC	O
from	IN	O
another	DT	O
source,	,	O
or	CC	O
prepared	VBN	O
by	IN	O
recombinant	NN	O
or	CC	O
synthetic	JJ	O
methods.	.	O
The	DT	O
term	NN	O
“PRO	NNP	O
polypeptide”	NN	O
refers	NNS	O
to	TO	O
each	DT	O
individual	JJ	O
PRO/number	NNP	O
polypeptide	NN	O
disclosed	VBD	O
herein.	.	O
All	DT	O
disclosures	VBZ	O
in	IN	O
this	DT	O
specification	NN	O
which	WDT	O
refer	VBP	O
to	TO	O
the	DT	O
“PRO	NNP	O
polypeptide”	NN	O
refer	NN	O
to	TO	O
each	DT	O
of	IN	O
the	DT	O
polypeptides	NNS	O
individually	RB	O
as	RB	O
well	RB	O
as	IN	O
jointly.	.	O
For	IN	O
example,	,	O
descriptions	NNS	O
of	IN	O
the	DT	O
preparation	NN	O
of,	,	O
purification	NN	O
of,	,	O
derivation	NN	O
of,	,	O
formation	NN	O
of	IN	O
antibodies	NNS	O
to	TO	O
or	CC	O
against,	,	O
administration	NN	O
of,	,	O
compositions	NNS	O
containing,	,	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
with,	,	O
etc.,	,	O
pertain	VBP	O
to	TO	O
each	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
individually.	.	O
The	DT	O
term	NN	O
“PRO	NNP	O
polypeptide”	NN	O
also	RB	O
includes	VBZ	O
variants	NNS	O
of	IN	O
the	DT	O
PRO/number	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein.	.	O
A	DT	O
“native	JJ	O
sequence	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide”	VBP	O
comprises	VBZ	O
a	DT	O
polypeptide	NN	O
having	VBG	O
the	DT	O
same	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
as	IN	O
the	DT	O
corresponding	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
derived	VBN	O
from	IN	O
nature.	.	O
Such	JJ	O
native	JJ	O
sequence	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
can	MD	O
be	VB	O
isolated	VBN	O
from	IN	O
nature	NN	O
or	CC	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
recombinant	NN	O
or	CC	O
synthetic	JJ	O
means.	.	O
The	DT	O
term	NN	O
“native	JJ	O
sequence	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide”	VBP	O
specifically	RB	O
encompasses	VBZ	O
naturally-occurring	JJ	O
truncated	VBD	O
or	CC	O
secreted	VBD	O
forms	NNS	O
of	IN	O
the	DT	O
specific	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
(e.g.,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
sequence),	,	O
naturally-occurring	JJ	O
variant	NN	O
forms	NNS	O
(e.g.,	,	O
alternatively	RB	O
spliced	VBD	O
forms)	)	O
and	CC	O
naturally-occurring	JJ	O
allelic	JJ	O
variants	NNS	O
of	IN	O
the	DT	O
polypeptide.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
native	JJ	O
sequence	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
which	WDT	O
are	VBP	O
mature	JJ	O
or	CC	O
full-length	JJ	O
native	JJ	O
sequence	NN	O
polypeptides	NNS	O
comprising	VBG	O
the	DT	O
full-length	JJ	O
amino	NN	O
acids	NNS	O
sequences	NNS	O
shown	VBN	O
in	IN	O
the	DT	O
accompanying	NN	O
figures.	.	O
Start	NNP	O
and	CC	O
stop	VB	O
codons	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
bold	JJ	O
font	NN	O
and	CC	O
underlined	VBN	O
in	IN	O
the	DT	O
figures.	.	O
However,	,	O
while	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
disclosed	VBN	O
in	IN	O
the	DT	O
accompanying	NN	O
figures	NNS	O
are	VBP	O
shown	VBN	O
to	TO	O
begin	VB	O
with	IN	O
methionine	NN	O
residues	NNS	O
designated	VBN	O
herein	RB	O
as	IN	O
amino	NN	O
acid	IN	O
position	NN	O
1	CD	O
in	IN	O
the	DT	O
figures,	,	O
it	PRP	O
is	VBZ	O
conceivable	JJ	O
and	CC	O
possible	JJ	O
that	IN	O
other	JJ	O
methionine	NN	O
residues	NNS	O
located	VBN	O
either	DT	O
upstream	NN	O
or	CC	O
downstream	NN	O
from	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
position	NN	O
1	CD	O
in	IN	O
the	DT	O
figures	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
as	IN	O
the	DT	O
starting	VBG	O
amino	NN	O
acid	NNS	O
residue	VBP	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides.	.	O
The	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
“extracellular	JJ	O
domain”	NN	O
or	CC	O
“ECD”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
form	NN	O
of	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	IN	O
which	WDT	O
is	VBZ	O
essentially	RB	O
free	JJ	O
of	IN	O
the	DT	O
transmembrane	NN	O
and	CC	O
cytoplasmic	JJ	O
domains.	.	O
Ordinarily,	,	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	VBP	O
ECD	NNP	O
will	MD	O
have	VB	O
less	JJR	O
than	IN	O
1%	NN	O
of	IN	O
such	JJ	O
transmembrane	NN	O
and/or	NNS	O
cytoplasmic	JJ	O
domains	NNS	O
and	CC	O
preferably,	,	O
will	MD	O
have	VB	O
less	JJR	O
than	IN	O
0.5%	NN	O
of	IN	O
such	JJ	O
domains.	.	O
It	PRP	O
will	MD	O
be	VB	O
understood	JJ	O
that	IN	O
any	DT	O
transmembrane	NN	O
domains	NNS	O
identified	VBN	O
for	IN	O
the	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
identified	VBN	O
pursuant	JJ	O
to	TO	O
criteria	VB	O
routinely	RB	O
employed	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
identifying	VBG	O
that	DT	O
type	NN	O
of	IN	O
hydrophobic	JJ	O
domain.	.	O
The	DT	O
exact	JJ	O
boundaries	NNS	O
of	IN	O
a	DT	O
transmembrane	NN	O
domain	NN	O
may	MD	O
vary	VB	O
but	CC	O
most	JJS	O
likely	JJ	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
5	CD	O
amino	JJ	O
acids	NNS	O
at	IN	O
either	DT	O
end	NN	O
of	IN	O
the	DT	O
domain	NN	O
as	IN	O
initially	RB	O
identified	VBN	O
herein.	.	O
Optionally,	,	O
therefore,	,	O
an	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
a	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
may	MD	O
contain	VB	O
from	IN	O
about	RB	O
5	CD	O
or	CC	O
fewer	JJR	O
amino	NN	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
transmembrane	NN	O
domain/extracellular	NN	O
domain	NN	O
boundary	JJ	O
as	IN	O
identified	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
or	CC	O
specification	NN	O
and	CC	O
such	JJ	O
polypeptides,	,	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
associated	JJ	O
signal	NN	O
peptide,	,	O
and	CC	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
them,	,	O
are	VBP	O
contemplated	VBN	O
by	IN	O
the	DT	O
present	JJ	O
invention.	.	O
The	DT	O
approximate	JJ	O
location	NN	O
of	IN	O
the	DT	O
“signal	JJ	O
peptides”	NN	O
of	IN	O
the	DT	O
various	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
the	DT	O
present	JJ	O
specification	NN	O
and/or	IN	O
the	DT	O
accompanying	VBG	O
figures.	.	O
It	PRP	O
is	VBZ	O
noted,	,	O
however,	,	O
that	IN	O
the	DT	O
C-terminal	JJ	O
boundary	NN	O
of	IN	O
a	DT	O
signal	JJ	O
peptide	NN	O
may	MD	O
vary,	,	O
but	CC	O
most	JJS	O
likely	JJ	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
about	RB	O
5	CD	O
amino	JJ	O
acids	NNS	O
on	IN	O
either	DT	O
side	NN	O
of	IN	O
the	DT	O
signal	JJ	O
peptide	NN	O
C-terminal	JJ	O
boundary	NN	O
as	IN	O
initially	RB	O
identified	VBN	O
herein,	,	O
wherein	VBD	O
the	DT	O
C-terminal	JJ	O
boundary	NN	O
of	IN	O
the	DT	O
signal	JJ	O
peptide	NN	O
may	MD	O
be	VB	O
identified	VBN	O
pursuant	JJ	O
to	TO	O
criteria	VB	O
routinely	RB	O
employed	VBN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
identifying	VBG	O
that	DT	O
type	NN	O
of	IN	O
amino	NN	O
acid	NN	O
sequence	NN	O
element	NN	O
(e.g.,	,	O
Nielsen	NNP	B
et	FW	I
al.,	,	I
Prot.	.	I
Eng.	.	I
10:1-6	CD	I
(1997)	)	I
and	CC	O
von	$	B
Heinje	NNP	I
et	CC	I
al.,	,	I
Nucl.	.	I
Acids.	.	I
Res.	.	I
14:4683-4690	CD	I
(1986)).Moreover,	.	O
it	,	O
is	PRP	O
also	VBZ	O
recognized	RB	O
that,	VBN	O
in	,	O
some	IN	O
cases,	DT	O
cleavage	,	O
of	NN	O
a	IN	O
signal	DT	O
sequence	JJ	O
from	NN	O
a	IN	O
secreted	DT	O
polypeptide	JJ	O
is	NN	O
not	VBZ	O
entirely	RB	O
uniform,	RB	O
resulting	,	O
in	VBG	O
more	IN	O
than	JJR	O
one	IN	O
secreted	CD	O
species.	JJ	O
These	.	O
mature	DT	O
polypeptides,	NN	O
where	,	O
the	WRB	O
signal	DT	O
peptide	JJ	O
is	NN	O
cleaved	VBZ	O
within	VBN	O
no	IN	O
more	DT	O
than	JJR	O
about	IN	O
5	RB	O
amino	CD	O
acids	JJ	O
on	NNS	O
either	IN	O
side	DT	O
of	NN	O
the	IN	O
C-terminal	DT	O
boundary	JJ	O
of	NN	O
the	IN	O
signal	DT	O
peptide	JJ	O
as	NN	O
identified	IN	O
herein,	JJ	O
and	,	O
the	CC	O
polynucleotides	DT	O
encoding	NNS	O
them,	VBG	O
are	,	O
contemplated	VBP	O
by	VBN	O
the	IN	O
present	DT	O
invention.	JJ	O
“PRO227,	.	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
variant”	IN	O
means	NN	O
a	VBZ	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
preferably	,	O
an	RB	O
active	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
as	,	O
defined	IN	O
herein	VBN	O
having	NN	O
at	VBG	O
least	IN	O
about	JJS	O
80%	IN	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
with	NN	O
a	IN	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
a	,	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	VBP	O
lacking	NN	O
the	VBG	O
signal	DT	O
peptide	JJ	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
an	,	O
extracellular	DT	O
domain	JJ	O
of	NN	O
a	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
with	,	O
or	IN	O
without	CC	O
the	IN	O
signal	DT	O
peptide,	NN	O
as	,	O
disclosed	IN	O
herein	VBN	O
or	NN	O
any	CC	O
other	DT	O
fragment	JJ	O
of	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein	VBN	O
(such	NN	O
as	JJ	O
those	IN	O
encoded	DT	O
by	VBN	O
a	IN	O
nucleic	DT	O
acid	JJ	O
that	NN	O
represents	WDT	O
only	VBZ	O
a	RB	O
portion	DT	O
of	NN	O
the	IN	O
complete	DT	O
coding	JJ	O
sequence	NN	O
for	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide).	NNP	O
Such	.	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
variants	IN	O
include,	NNS	O
for	,	O
instance,	IN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptides	NNP	O
wherein	NNS	O
one	VBP	O
or	CD	O
more	CC	O
amino	JJR	O
acid	JJ	O
residues	NN	O
are	NNS	O
added,	VBP	O
or	,	O
deleted,	CC	O
at	,	O
the	IN	O
N-	DT	O
or	NNP	O
C-terminus	CC	O
of	NNP	O
the	IN	O
full-length	DT	O
native	JJ	O
amino	JJ	O
acid	NN	O
sequence.	NN	O
Ordinarily,	.	O
a	,	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
variant	VBP	O
will	NN	O
have	MD	O
or	VB	O
will	CC	O
have	MD	O
at	VB	O
least	IN	O
about	JJS	O
80%	IN	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity,	NN	O
alternatively	,	O
will	RB	O
have	MD	O
or	VB	O
will	CC	O
have	MD	O
at	VB	O
least	IN	O
about	JJS	O
81%,	IN	O
82%,	,	O
83%,	,	O
84%,	,	O
85%,	,	O
86%,	,	O
87%,	,	O
88%,	,	O
89%,	,	O
90%,	,	O
91%,	,	O
92%,	,	O
93%,	,	O
94%,	,	O
95%,	,	O
96%,	,	O
97%,	,	O
98%,	,	O
or	,	O
99%	CC	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity,	NN	O
to	,	O
a	TO	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
a	,	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	VBP	O
lacking	NN	O
the	VBG	O
signal	DT	O
peptide	JJ	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
an	,	O
extracellular	DT	O
domain	JJ	O
of	NN	O
a	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
with	,	O
or	IN	O
without	CC	O
the	IN	O
signal	DT	O
peptide,	NN	O
as	,	O
disclosed	IN	O
herein	VBN	O
or	NN	O
any	CC	O
other	DT	O
specifically	JJ	O
defined	RB	O
fragment	JJ	O
of	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein.	JJ	O
Ordinarily,	.	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polypeptides	JJ	O
are	NNS	O
or	VBP	O
are	CC	O
at	VBP	O
least	IN	O
about	JJS	O
10	IN	O
amino	CD	O
acids	JJ	O
in	NNS	O
length,	IN	O
alternatively	,	O
are	RB	O
or	VBP	O
are	CC	O
at	VBP	O
least	IN	O
about	JJS	O
20,	IN	O
30,	,	O
40,	,	O
50,	,	O
60,	,	O
70,	,	O
80,	,	O
90,	,	O
100,	,	O
110,	,	O
120,	,	O
130,	,	O
140,	,	O
150,	,	O
160,	,	O
170,	,	O
180,	,	O
190,	,	O
200,	,	O
210,	,	O
220,	,	O
230,	,	O
240,	,	O
250,	,	O
260,	,	O
270,	,	O
280,	,	O
290,	,	O
300,	,	O
310,	,	O
320,	,	O
330,	,	O
340,	,	O
350,	,	O
360,	,	O
370,	,	O
380,	,	O
390,	,	O
400,	,	O
410,	,	O
420,	,	O
430,	,	O
440,	,	O
450,	,	O
460,	,	O
470,	,	O
480,	,	O
490,	,	O
500,	,	O
510,	,	O
520,	,	O
530,	,	O
540,	,	O
550,	,	O
560,	,	O
570,	,	O
580,	,	O
590,	,	O
600	,	O
amino	CD	O
acids	NN	O
in	NNS	O
length,	IN	O
or	,	O
more.	CC	O
Optionally,	.	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polypeptides	JJ	O
will	NNS	O
have	MD	O
no	VB	O
more	DT	O
than	JJR	O
one	IN	O
conservative	CD	O
amino	JJ	O
acid	NN	O
substitution	JJ	O
as	NN	O
compared	IN	O
to	VBN	O
the	TO	O
native	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence,	JJ	O
alternatively	,	O
will	RB	O
have	MD	O
or	VB	O
will	CC	O
have	MD	O
no	VB	O
more	DT	O
than	JJR	O
2,	IN	O
3,	,	O
4,	,	O
5,	,	O
6,	,	O
7,	,	O
8,	,	O
9,	,	O
or	,	O
10	CC	O
conservative	CD	O
amino	JJ	O
acid	NN	O
substitution	JJ	O
as	NN	O
compared	IN	O
to	VBN	O
the	TO	O
native	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence.	JJ	O
“Percent	.	O
(%)	NN	O
amino	)	O
acid	NN	O
sequence	JJ	O
identity”	NN	O
with	NN	O
respect	IN	O
to	NN	O
the	TO	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequences	JJ	O
identified	NNS	O
herein	VBN	O
is	NN	O
defined	VBZ	O
as	VBN	O
the	IN	O
percentage	DT	O
of	NN	O
amino	IN	O
acid	NN	O
residues	NN	O
in	NNS	O
a	IN	O
candidate	DT	O
sequence	NN	O
that	NN	O
are	WDT	O
identical	VBP	O
with	JJ	O
the	IN	O
amino	DT	O
acid	NN	O
residues	NN	O
in	NNS	O
the	IN	O
specific	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence,	JJ	O
after	,	O
aligning	IN	O
the	VBG	O
sequences	DT	O
and	NNS	O
introducing	CC	O
gaps,	VBG	O
if	,	O
necessary,	IN	O
to	,	O
achieve	TO	O
the	VB	O
maximum	DT	O
percent	JJ	O
sequence	NN	O
identity,	NN	O
and	,	O
not	CC	O
considering	RB	O
any	VBG	O
conservative	DT	O
substitutions	JJ	O
as	NNS	O
part	IN	O
of	NN	O
the	IN	O
sequence	DT	O
identity.	NN	O
Alignment	.	O
for	NN	O
purposes	IN	O
of	NNS	O
determining	IN	O
percent	VBG	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
can	NN	O
be	MD	O
achieved	VB	O
in	VBN	O
various	IN	O
ways	JJ	O
that	NNS	O
are	WDT	O
within	VBP	O
the	IN	O
skill	DT	O
in	NN	O
the	IN	O
art,	DT	O
for	,	O
instance,	IN	O
using	,	O
publicly	VBG	O
available	RB	O
computer	JJ	O
software	NN	O
such	NN	O
as	JJ	O
BLAST,	IN	O
BLAST-2,	,	O
ALIGN	,	O
or	NNP	O
Megalign	CC	O
(DNASTAR)	NNP	O
software.	)	O
Those	.	O
skilled	DT	O
in	VBN	O
the	IN	O
art	DT	O
can	NN	O
determine	MD	O
appropriate	VB	O
parameters	JJ	O
for	NNS	O
measuring	IN	O
alignment,	VBG	O
including	,	O
any	VBG	O
algorithms	DT	O
needed	NN	O
to	VBN	O
achieve	TO	O
maximal	VB	O
alignment	JJ	O
over	NN	O
the	IN	O
full	DT	O
length	JJ	O
of	NN	O
the	IN	O
sequences	DT	O
being	NNS	O
compared.	VBG	O
For	.	O
purposes	IN	O
herein,	NNS	O
however,	,	O
%	,	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
values	NN	O
are	NNS	O
generated	VBP	O
using	VBN	O
the	VBG	O
sequence	DT	O
comparison	NN	O
computer	NN	O
program	NN	O
ALIGN-2,	NN	O
wherein	,	O
the	VBZ	O
complete	DT	O
source	JJ	O
code	NN	O
for	NN	O
the	IN	O
ALIGN-2	DT	O
program	JJ	O
is	NN	O
provided	VBZ	O
in	VBN	O
Table	IN	O
1	JJ	O
below.	CD	O
The	.	O
ALIGN-2	DT	O
sequence	NNP	O
comparison	NN	O
computer	NN	O
program	NN	O
was	NN	O
authored	VBD	O
by	VBN	O
Genentech,	IN	O
Inc.	,	O
and	NNP	O
the	CC	O
source	DT	O
code	NN	O
shown	NN	O
in	VBN	O
Table	IN	O
1	JJ	O
below	CD	O
has	NN	O
been	VBZ	O
filed	VBN	O
with	VBN	O
user	IN	O
documentation	JJ	O
in	NN	O
the	IN	O
U.S.	DT	O
Copyright	.	O
Office,	NNP	O
Washington	,	O
D.C.,	NNP	O
20559,	,	O
where	,	O
it	WRB	O
is	PRP	O
registered	VBZ	O
under	VBN	O
U.S.	IN	O
Copyright	.	O
Registration	NNP	O
No.	NNP	O
TXU510087.	.	O
The	.	O
ALIGN-2	DT	O
program	JJ	O
is	NN	O
publicly	VBZ	O
available	RB	O
through	JJ	O
Genentech,	IN	O
Inc.,	,	O
South	,	O
San	NNP	O
Francisco,	NNP	O
Calif.	,	O
or	NNP	O
may	CC	O
be	MD	O
compiled	VB	O
from	VBN	O
the	IN	O
source	DT	O
code	NN	O
provided	NN	O
in	VBN	O
Table	IN	O
1	JJ	O
below.	CD	O
The	.	O
ALIGN-2	DT	O
program	JJ	O
should	NN	O
be	MD	O
compiled	VB	O
for	VBN	O
use	IN	O
on	NN	O
a	IN	O
UNIX	DT	O
operating	NNP	O
system,	NN	O
preferably	,	O
digital	RB	O
UNIX	JJ	O
V4.0D.	NNP	O
All	.	O
sequence	DT	O
comparison	NN	O
parameters	NN	O
are	NNS	O
set	VBP	O
by	VBN	O
the	IN	O
ALIGN-2	DT	O
program	JJ	O
and	NN	O
do	CC	O
not	VBP	O
vary.	RB	O
In	.	O
situations	IN	O
where	NNS	O
ALIGN-2	WRB	O
is	NNP	O
employed	VBZ	O
for	VBN	O
amino	IN	O
acid	NN	O
sequence	NN	O
comparisons,	NN	O
the	,	O
%	DT	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
of	NN	O
a	IN	O
given	DT	O
amino	VBN	O
acid	NN	O
sequence	NN	O
A	NN	O
to,	DT	O
with,	,	O
or	,	O
against	CC	O
a	IN	O
given	DT	O
amino	VBN	O
acid	NN	O
sequence	NN	O
B	NN	O
(which	NNP	O
can	WDT	O
alternatively	MD	O
be	RB	O
phrased	VB	O
as	VBN	O
a	IN	O
given	DT	O
amino	VBN	O
acid	NN	O
sequence	NN	O
A	NN	O
that	NNP	O
has	WDT	O
or	VBZ	O
comprises	CC	O
a	VBZ	O
certain	DT	O
%	JJ	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
to,	NN	O
with,	,	O
or	,	O
against	CC	O
a	IN	O
given	DT	O
amino	VBN	O
acid	NN	O
sequence	NN	O
B)	NN	O
is	)	O
calculated	VBZ	O
as	VBN	O
follows:100	IN	O
times	NN	O
the	VBZ	O
fraction	DT	O
X/Ywhere	NN	O
X	NNP	O
is	NNP	O
the	VBZ	O
number	DT	O
of	NN	O
amino	IN	O
acid	JJ	O
residues	NN	O
scored	NNS	O
as	VBD	O
identical	IN	O
matches	JJ	O
by	NNS	O
the	IN	O
sequence	DT	O
alignment	NN	O
program	JJ	O
ALIGN-2	NN	O
in	NNP	O
that	IN	O
program's	DT	O
alignment	POS	O
of	NN	O
A	IN	O
and	NNP	O
B,	CC	O
and	,	O
where	CC	O
Y	WRB	O
is	NNP	O
the	VBZ	O
total	DT	O
number	JJ	O
of	NN	O
amino	IN	O
acid	JJ	O
residues	NN	O
in	NNS	O
B.	IN	O
It	.	O
will	PRP	O
be	MD	O
appreciated	VB	O
that	VBN	O
where	IN	O
the	WRB	O
length	DT	O
of	NN	O
amino	IN	O
acid	NN	O
sequence	NN	O
A	NN	O
is	NNP	O
not	VBZ	O
equal	RB	O
to	JJ	O
the	TO	O
length	DT	O
of	NN	O
amino	IN	O
acid	NN	O
sequence	NN	O
B,	NN	O
the	,	O
%	DT	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
of	NN	O
A	IN	O
to	NNP	O
B	TO	O
will	NNP	O
not	MD	O
equal	RB	O
the	VB	O
%	DT	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
of	NN	O
B	IN	O
to	NNP	O
A.	TO	O
As	.	O
examples	IN	O
of	NNS	O
%	IN	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
calculations	NN	O
using	NNS	O
this	VBG	O
method,	DT	O
Tables	,	O
2	VBZ	O
and	CD	O
3	CC	O
demonstrate	CD	O
how	NN	O
to	WRB	O
calculate	TO	O
the	VB	O
%	DT	O
amino	NN	O
acid	NN	O
sequence	JJ	O
identity	NN	O
of	NN	O
the	IN	O
amino	DT	O
acid	NN	O
sequence	JJ	O
designated	NN	O
“Comparison	VBN	O
Protein”	NNP	O
to	NNP	O
the	TO	O
amino	DT	O
acid	NN	O
sequence	JJ	O
designated	NN	O
“PRO”,	VBN	O
wherein	,	O
“PRO”	NN	O
represents	NN	O
the	VBZ	O
amino	DT	O
acid	NN	O
sequence	JJ	O
of	NN	O
a	IN	O
hypothetical	DT	O
PRO	JJ	O
polypeptide	NNP	O
of	NN	O
interest,	IN	O
“Comparison	,	O
Protein”	NNP	O
represents	NNP	O
the	VBZ	O
amino	DT	O
acid	NN	O
sequence	JJ	O
of	NN	O
a	IN	O
polypeptide	DT	O
against	NN	O
which	IN	O
the	WDT	O
“PRO”	DT	O
polypeptide	NNP	O
of	NN	O
interest	IN	O
is	NN	O
being	VBZ	O
compared,	VBG	O
and	,	O
“X,	CC	O
“Y”	,	O
and	NNP	O
“Z”	CC	O
each	NNP	O
represent	DT	O
different	NN	O
hypothetical	JJ	O
amino	JJ	O
acid	NN	O
residues.	NN	O
Unless	.	O
specifically	IN	O
stated	RB	O
otherwise,	VBN	O
all	,	O
%	DT	O
amino	NN	O
acid	JJ	O
sequence	JJ	O
identity	NN	O
values	NN	O
used	NNS	O
herein	VBN	O
are	NNS	O
obtained	VBP	O
as	VBN	O
described	IN	O
in	VBN	O
the	IN	O
immediately	DT	O
preceding	RB	O
paragraph	VBG	O
using	NN	O
the	VBG	O
ALIGN-2	DT	O
computer	JJ	O
program.	NN	O
“PRO227,	.	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polynucleotide”	JJ	O
or	NN	O
“PRO227,	CC	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
nucleic	JJ	O
acid	JJ	O
sequence”	NN	O
means	NN	O
a	VBZ	O
nucleic	DT	O
acid	JJ	O
molecule	NN	O
which	NN	O
encodes	WDT	O
a	VBZ	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
preferably	,	O
an	RB	O
active	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
as	,	O
defined	IN	O
herein	VBN	O
and	NN	O
which	CC	O
has	WDT	O
at	VBZ	O
least	IN	O
about	JJS	O
80%	IN	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
with	NN	O
a	IN	O
nucleotide	DT	O
acid	JJ	O
sequence	NN	O
encoding	NN	O
a	VBG	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
a	,	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	VBP	O
lacking	NN	O
the	VBG	O
signal	DT	O
peptide	JJ	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
an	,	O
extracellular	DT	O
domain	JJ	O
of	NN	O
a	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
with	,	O
or	IN	O
without	CC	O
the	IN	O
signal	DT	O
peptide,	NN	O
as	,	O
disclosed	IN	O
herein	VBN	O
or	NN	O
any	CC	O
other	DT	O
fragment	JJ	O
of	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein	VBN	O
(such	NN	O
as	JJ	O
those	IN	O
encoded	DT	O
by	VBN	O
a	IN	O
nucleic	DT	O
acid	JJ	O
that	NN	O
represents	WDT	O
only	VBZ	O
a	RB	O
portion	DT	O
of	NN	O
the	IN	O
complete	DT	O
coding	JJ	O
sequence	NN	O
for	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide).	NNP	O
Ordinarily,	.	O
a	,	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polynucleotide	JJ	O
will	NN	O
have	MD	O
or	VB	O
will	CC	O
have	MD	O
at	VB	O
least	IN	O
about	JJS	O
80%	IN	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity,	NN	O
alternatively	,	O
will	RB	O
have	MD	O
or	VB	O
will	CC	O
have	MD	O
at	VB	O
least	IN	O
about	JJS	O
81%,	IN	O
82%,	,	O
83%,	,	O
84%,	,	O
85%,	,	O
86%,	,	O
87%,	,	O
88%,	,	O
89%,	,	O
90%,	,	O
91%,	,	O
92%,	,	O
93%,	,	O
94%,	,	O
95%,	,	O
96%,	,	O
97%,	,	O
98%,	,	O
or	,	O
99%	CC	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
with	NN	O
a	IN	O
nucleic	DT	O
acid	JJ	O
sequence	NN	O
encoding	NN	O
a	VBG	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
a	,	O
full-length	DT	O
native	JJ	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	VBP	O
lacking	NN	O
the	VBG	O
signal	DT	O
peptide	JJ	O
as	NN	O
disclosed	IN	O
herein,	JJ	O
an	,	O
extracellular	DT	O
domain	JJ	O
of	NN	O
a	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
with	,	O
or	IN	O
without	CC	O
the	IN	O
signal	DT	O
sequence,	NN	O
as	,	O
disclosed	IN	O
herein	VBN	O
or	NN	O
any	CC	O
other	DT	O
fragment	JJ	O
of	NN	O
a	IN	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
sequence	RB	O
as	NN	O
disclosed	IN	O
herein.	JJ	O
Variants	.	O
do	NNS	O
not	VBP	O
encompass	RB	O
the	VB	O
native	DT	O
nucleotide	JJ	O
sequence.	JJ	O
Ordinarily,	.	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polynucleotides	JJ	O
are	NNS	O
or	VBP	O
are	CC	O
at	VBP	O
least	IN	O
about	JJS	O
5	IN	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
alternatively	,	O
are	RB	O
or	VBP	O
are	CC	O
at	VBP	O
least	IN	O
about	JJS	O
6,	IN	O
7,	,	O
8,	,	O
9,	,	O
10,	,	O
11,	,	O
12,	,	O
13,	,	O
14,	,	O
15,	,	O
16,	,	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
35,	,	O
40,	,	O
45,	,	O
50,	,	O
55,	,	O
60,	,	O
65,	,	O
70,	,	O
75,	,	O
80,	,	O
85,	,	O
90,	,	O
95,	,	O
100,	,	O
105,	,	O
110,	,	O
115,	,	O
120,	,	O
125,	,	O
130,	,	O
135,	,	O
140,	,	O
145,	,	O
150,	,	O
155,	,	O
160,	,	O
165,	,	O
170,	,	O
175,	,	O
180,	,	O
185,	,	O
190,	,	O
195,	,	O
200,	,	O
210,	,	O
220,	,	O
230,	,	O
240,	,	O
250,	,	O
260,	,	O
270,	,	O
280,	,	O
290,	,	O
300,	,	O
310,	,	O
320,	,	O
330,	,	O
340,	,	O
350,	,	O
360,	,	O
370,	,	O
380,	,	O
390,	,	O
400,	,	O
410,	,	O
420,	,	O
430,	,	O
440,	,	O
450,	,	O
460,	,	O
470,	,	O
480,	,	O
490,	,	O
500,	,	O
510,	,	O
520,	,	O
530,	,	O
540,	,	O
550,	,	O
560,	,	O
570,	,	O
580,	,	O
590,	,	O
600,	,	O
610,	,	O
620,	,	O
630,	,	O
640,	,	O
650,	,	O
660,	,	O
670,	,	O
680,	,	O
690,	,	O
700,	,	O
710,	,	O
720,	,	O
730,	,	O
740,	,	O
750,	,	O
760,	,	O
770,	,	O
780,	,	O
790,	,	O
800,	,	O
810,	,	O
820,	,	O
830,	,	O
840,	,	O
850,	,	O
860,	,	O
870,	,	O
880,	,	O
890,	,	O
900,	,	O
910,	,	O
920,	,	O
930,	,	O
940,	,	O
950,	,	O
960,	,	O
970,	,	O
980,	,	O
990,	,	O
or	,	O
1000	CC	O
nucleotides	CD	O
in	NNS	O
length,	IN	O
wherein	,	O
in	NN	O
this	IN	O
context	DT	O
the	NN	O
term	DT	O
“about”	NN	O
means	NN	O
the	VBZ	O
referenced	DT	O
nucleotide	JJ	O
sequence	JJ	O
length	NN	O
plus	NN	O
or	CC	O
minus	CC	O
10%	CC	O
of	NN	O
that	IN	O
referenced	DT	O
length.	VBD	O
“Percent	.	O
(%)	NN	O
nucleic	)	O
acid	NN	O
sequence	JJ	O
identity”	NN	O
with	NN	O
respect	IN	O
to	NN	O
PRO227-,	TO	O
PRO233-,	,	O
PRO238-,	,	O
PRO1328-,	,	O
PRO4342-,	,	O
PRO7423-,	,	O
PRO10096-,	,	O
PRO21384-,	,	O
PRO353-	,	O
or	NNP	O
PRO1885-encoding	CC	O
nucleic	NNP	O
acid	JJ	O
sequences	NN	O
identified	NNS	O
herein	VBN	O
is	NN	O
defined	VBZ	O
as	VBN	O
the	IN	O
percentage	DT	O
of	NN	O
nucleotides	IN	O
in	NNS	O
a	IN	O
candidate	DT	O
sequence	NN	O
that	NN	O
are	WDT	O
identical	VBP	O
with	JJ	O
the	IN	O
nucleotides	DT	O
in	NNS	O
the	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
nucleic	NNP	O
acid	JJ	O
sequence	JJ	O
of	NN	O
interest,	IN	O
after	,	O
aligning	IN	O
the	VBG	O
sequences	DT	O
and	NNS	O
introducing	CC	O
gaps,	VBG	O
if	,	O
necessary,	IN	O
to	,	O
achieve	TO	O
the	VB	O
maximum	DT	O
percent	JJ	O
sequence	NN	O
identity.	NN	O
Alignment	.	O
for	NN	O
purposes	IN	O
of	NNS	O
determining	IN	O
percent	VBG	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
can	NN	O
be	MD	O
achieved	VB	O
in	VBN	O
various	IN	O
ways	JJ	O
that	NNS	O
are	WDT	O
within	VBP	O
the	IN	O
skill	DT	O
in	NN	O
the	IN	O
art,	DT	O
for	,	O
instance,	IN	O
using	,	O
publicly	VBG	O
available	RB	O
computer	JJ	O
software	NN	O
such	NN	O
as	JJ	O
BLAST,	IN	O
BLAST-2,	,	O
ALIGN	,	O
or	NNP	O
Megalign	CC	O
(DNASTAR)	NNP	O
software.	)	O
For	.	O
purposes	IN	O
herein,	NNS	O
however,	,	O
%	,	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
values	NN	O
are	NNS	O
generated	VBP	O
using	VBN	O
the	VBG	O
sequence	DT	O
comparison	NN	O
computer	NN	O
program	NN	O
ALIGN-2,	NN	O
wherein	,	O
the	VBZ	O
complete	DT	O
source	JJ	O
code	NN	O
for	NN	O
the	IN	O
ALIGN-2	DT	O
program	JJ	O
is	NN	O
provided	VBZ	O
in	VBN	O
Table	IN	O
1	JJ	O
below.	CD	O
The	.	O
ALIGN-2	DT	O
sequence	NNP	O
comparison	NN	O
computer	NN	O
program	NN	O
was	NN	O
authored	VBD	O
by	VBN	O
Genentech,	IN	O
Inc.	,	O
and	NNP	O
the	CC	O
source	DT	O
code	NN	O
shown	NN	O
in	VBN	O
Table	IN	O
1	JJ	O
below	CD	O
has	NN	O
been	VBZ	O
filed	VBN	O
with	VBN	O
user	IN	O
documentation	JJ	O
in	NN	O
the	IN	O
U.S.	DT	O
Copyright	.	O
Office,	NNP	O
Washington	,	O
D.C.,	NNP	O
20559,	,	O
where	,	O
it	WRB	O
is	PRP	O
registered	VBZ	O
under	VBN	O
U.S.	IN	O
Copyright	.	O
Registration	NNP	O
No.	NNP	O
TXU510087.	.	O
The	.	O
ALIGN-2	DT	O
program	JJ	O
is	NN	O
publicly	VBZ	O
available	RB	O
through	JJ	O
Genentech,	IN	O
Inc.,	,	O
South	,	O
San	NNP	O
Francisco,	NNP	O
Calif.	,	O
or	NNP	O
may	CC	O
be	MD	O
compiled	VB	O
from	VBN	O
the	IN	O
source	DT	O
code	NN	O
provided	NN	O
in	VBN	O
Table	IN	O
1	JJ	O
below.	CD	O
The	.	O
ALIGN-2	DT	O
program	JJ	O
should	NN	O
be	MD	O
compiled	VB	O
for	VBN	O
use	IN	O
on	NN	O
a	IN	O
UNIX	DT	O
operating	NNP	O
system,	NN	O
preferably	,	O
digital	RB	O
UNIX	JJ	O
V4.0D.	NNP	O
All	.	O
sequence	DT	O
comparison	NN	O
parameters	NN	O
are	NNS	O
set	VBP	O
by	VBN	O
the	IN	O
ALIGN-2	DT	O
program	JJ	O
and	NN	O
do	CC	O
not	VBP	O
vary.	RB	O
In	.	O
situations	IN	O
where	NNS	O
ALIGN-2	WRB	O
is	NNP	O
employed	VBZ	O
for	VBN	O
nucleic	IN	O
acid	JJ	O
sequence	JJ	O
comparisons,	NN	O
the	,	O
%	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	NN	O
a	IN	O
given	DT	O
nucleic	VBN	O
acid	JJ	O
sequence	JJ	O
C	NN	O
to,	NNP	O
with,	,	O
or	,	O
against	CC	O
a	IN	O
given	DT	O
nucleic	VBN	O
acid	JJ	O
sequence	JJ	O
D	NN	O
(which	NNP	O
can	WDT	O
alternatively	MD	O
be	RB	O
phrased	VB	O
as	VBN	O
a	IN	O
given	DT	O
nucleic	VBN	O
acid	JJ	O
sequence	JJ	O
C	NN	O
that	NNP	O
has	WDT	O
or	VBZ	O
comprises	CC	O
a	VBZ	O
certain	DT	O
%	JJ	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
to,	NN	O
with,	,	O
or	,	O
against	CC	O
a	IN	O
given	DT	O
nucleic	VBN	O
acid	JJ	O
sequence	JJ	O
D)	NN	O
is	)	O
calculated	VBZ	O
as	VBN	O
follows:100	IN	O
times	NN	O
the	VBZ	O
fraction	DT	O
W/Zwhere	NN	O
W	NNP	O
is	NNP	O
the	VBZ	O
number	DT	O
of	NN	O
nucleotides	IN	O
scored	NNS	O
as	VBN	O
identical	IN	O
matches	JJ	O
by	NNS	O
the	IN	O
sequence	DT	O
alignment	NN	O
program	JJ	O
ALIGN-2	NN	O
in	NNP	O
that	IN	O
program's	DT	O
alignment	POS	O
of	NN	O
C	IN	O
and	NNP	O
D,	CC	O
and	,	O
where	CC	O
Z	WRB	O
is	NNP	O
the	VBZ	O
total	DT	O
number	JJ	O
of	NN	O
nucleotides	IN	O
in	NNS	O
D.	IN	O
It	NNP	O
will	PRP	O
be	MD	O
appreciated	VB	O
that	VBN	O
where	IN	O
the	WRB	O
length	DT	O
of	NN	O
nucleic	IN	O
acid	JJ	O
sequence	JJ	O
C	NN	O
is	NNP	O
not	VBZ	O
equal	RB	O
to	JJ	O
the	TO	O
length	DT	O
of	NN	O
nucleic	IN	O
acid	JJ	O
sequence	JJ	O
D,	NN	O
the	,	O
%	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	NN	O
C	IN	O
to	NNP	O
D	TO	O
will	NNP	O
not	MD	O
equal	RB	O
the	VB	O
%	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	NN	O
D	IN	O
to	NNP	O
C.	TO	O
As	NNP	O
examples	NNP	O
of	NNS	O
%	IN	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
calculations,	NN	O
Tables	,	O
4	VBZ	O
and	CD	O
5,	CC	O
demonstrate	,	O
how	VB	O
to	WRB	O
calculate	TO	O
the	VB	O
%	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
of	NN	O
the	IN	O
nucleic	DT	O
acid	JJ	O
sequence	NN	O
designated	NN	O
“Comparison	VBN	O
DNA”	NNP	O
to	NNP	O
the	TO	O
nucleic	DT	O
acid	JJ	O
sequence	NN	O
designated	NN	O
“PRO-DNA”,	VBN	O
wherein	,	O
“PRO-DNA”	JJ	O
represents	JJ	O
a	VBZ	O
hypothetical	DT	O
PRO-encoding	JJ	O
nucleic	NNP	O
acid	NN	O
sequence	NN	O
of	NN	O
interest,	IN	O
“Comparison	,	O
DNA”	NNP	O
represents	NNP	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
a	IN	O
nucleic	DT	O
acid	JJ	O
molecule	NN	O
against	NN	O
which	IN	O
the	WDT	O
“PRO-DNA”	DT	O
nucleic	JJ	O
acid	JJ	O
molecule	NN	O
of	NN	O
interest	IN	O
is	NN	O
being	VBZ	O
compared,	VBG	O
and	,	O
“N”,	CC	O
“L”	,	O
and	NNP	O
“V”	CC	O
each	NNP	O
represent	DT	O
different	NN	O
hypothetical	JJ	O
nucleotides.	JJ	O
Unless	.	O
specifically	IN	O
stated	RB	O
otherwise,	VBN	O
all	,	O
%	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
values	NN	O
used	NNS	O
herein	VBN	O
are	NNS	O
obtained	VBP	O
as	VBN	O
described	IN	O
in	VBN	O
the	IN	O
immediately	DT	O
preceding	RB	O
paragraph	VBG	O
using	NN	O
the	VBG	O
ALIGN-2	DT	O
computer	JJ	O
program.	NN	O
The	.	O
invention	DT	O
also	NN	O
provides	RB	O
PRO227,	VBZ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polynucleotides	NN	O
which	NNS	O
are	WDT	O
nucleic	VBP	O
acid	JJ	O
molecules	JJ	O
that	NNS	O
encode	WDT	O
a	VBP	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
and	NN	O
which	CC	O
are	WDT	O
capable	VBP	O
of	JJ	O
hybridizing,	IN	O
preferably	,	O
under	RB	O
stringent	IN	O
hybridization	JJ	O
and	NN	O
wash	CC	O
conditions,	NN	O
to	,	O
nucleotide	TO	O
sequences	VB	O
encoding	NNS	O
a	VBG	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
as	RB	O
disclosed	IN	O
herein.	VBN	O
PRO227,	.	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polypeptides	JJ	O
may	NNS	O
be	MD	O
those	VB	O
that	DT	O
are	WDT	O
encoded	VBP	O
by	VBN	O
a	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variant	NNP	O
polynucleotide.	JJ	O
The	.	O
term	DT	O
“full-length	NN	O
coding	JJ	O
region”	NN	O
when	NN	O
used	WRB	O
in	VBN	O
reference	IN	O
to	NN	O
a	TO	O
nucleic	DT	O
acid	JJ	O
encoding	NN	O
a	VBG	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
refers	VBP	O
to	NNS	O
the	TO	O
sequence	DT	O
of	NN	O
nucleotides	IN	O
which	NNS	O
encode	WDT	O
the	VBP	O
full-length	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
of	NN	O
the	IN	O
invention	DT	O
(which	NN	O
is	WDT	O
often	VBZ	O
shown	RB	O
between	VBN	O
start	IN	O
and	NN	O
stop	CC	O
codons,	JJ	O
inclusive	,	O
thereof,	JJ	O
in	,	O
the	IN	O
accompanying	DT	O
figures).	NN	O
The	.	O
term	DT	O
“full-length	NN	O
coding	JJ	O
region”	NN	O
when	NN	O
used	WRB	O
in	VBN	O
reference	IN	O
to	NN	O
an	TO	O
ATCC	DT	O
deposited	NNP	O
nucleic	VBD	O
acid	JJ	O
refers	NN	O
to	NNS	O
the	TO	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide-encoding	NNP	O
portion	JJ	O
of	NN	O
the	IN	O
cDNA	DT	O
that	NN	O
is	WDT	O
inserted	VBZ	O
into	VBN	O
the	IN	O
vector	DT	O
deposited	NN	O
with	VBD	O
the	IN	O
ATCC	DT	O
(which	NNP	O
is	WDT	O
often	VBZ	O
shown	RB	O
between	VBN	O
start	IN	O
and	NN	O
stop	CC	O
codons,	JJ	O
inclusive	,	O
thereof,	JJ	O
in	,	O
the	IN	O
accompanying	DT	O
figures).	NN	O
“Isolated,”	.	O
when	FW	O
used	WRB	O
to	VBN	O
describe	TO	O
the	VB	O
various	DT	O
polypeptides	JJ	O
disclosed	NNS	O
herein,	VBD	O
means	,	O
polypeptide	VBZ	O
that	NN	O
has	WDT	O
been	VBZ	O
identified	VBN	O
and	VBN	O
separated	CC	O
and/or	VBN	O
recovered	NNS	O
from	VBN	O
a	IN	O
component	DT	O
of	NN	O
its	IN	O
natural	PRP$	O
environment.	JJ	O
Contaminant	.	O
components	JJ	O
of	NNS	O
its	IN	O
natural	PRP$	O
environment	JJ	O
are	NN	O
materials	VBP	O
that	NNS	O
would	WDT	O
typically	MD	O
interfere	RB	O
with	VB	O
diagnostic	IN	O
or	JJ	O
therapeutic	CC	O
uses	JJ	O
for	NNS	O
the	IN	O
polypeptide,	DT	O
and	,	O
may	CC	O
include	MD	O
enzymes,	VB	O
hormones,	,	O
and	,	O
other	CC	O
proteinaceous	JJ	O
or	JJ	O
non-proteinaceous	CC	O
solutes.	JJ	O
The	.	O
invention	DT	O
provides	NN	O
that	VBZ	O
the	IN	O
polypeptide	DT	O
will	NN	O
be	MD	O
purified	VB	O
(1)	VBN	O
to	)	O
a	TO	O
degree	DT	O
sufficient	JJ	O
to	NN	O
obtain	TO	O
at	VB	O
least	IN	O
15	JJS	O
residues	CD	O
of	NNS	O
N-terminal	IN	O
or	NNP	O
internal	CC	O
amino	JJ	O
acid	NN	O
sequence	NNS	O
by	NN	O
use	IN	O
of	NN	O
a	IN	O
spinning	DT	O
cup	JJ	O
sequenator,	NN	O
or	,	O
(2)	CC	O
to	)	O
homogeneity	TO	O
by	NN	O
SDS-PAGE	IN	O
under	NNP	O
non-reducing	IN	O
or	NN	O
reducing	CC	O
conditions	VBG	O
using	NNS	O
Coomassie	VBG	O
blue	NNP	O
or,	NN	O
preferably,	,	O
silver	,	O
stain.	RB	O
Isolated	.	O
polypeptide	VBN	O
includes	NN	O
polypeptide	VBZ	O
in	NN	O
situ	IN	O
within	NN	O
recombinant	IN	O
cells,	JJ	O
since	,	O
at	IN	O
least	IN	O
one	JJS	O
component	CD	O
of	NN	O
the	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide	NNP	O
natural	IN	O
environment	JJ	O
will	NN	O
not	MD	O
be	RB	O
present.	VB	O
Ordinarily,	.	O
however,	,	O
isolated	,	O
polypeptide	JJ	O
will	NN	O
be	MD	O
prepared	VB	O
by	VBN	O
at	IN	O
least	IN	O
one	JJS	O
purification	CD	O
step.	NN	O
An	.	O
“isolated”	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide-encoding	NNP	O
nucleic	JJ	O
acid	JJ	O
or	NN	O
other	CC	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	JJ	O
is	NN	O
a	VBZ	O
nucleic	DT	O
acid	JJ	O
molecule	NN	O
that	NN	O
is	WDT	O
identified	VBZ	O
and	VBN	O
separated	CC	O
from	VBN	O
at	IN	O
least	IN	O
one	JJS	O
contaminant	CD	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
with	NN	O
which	IN	O
it	WDT	O
is	PRP	O
ordinarily	VBZ	O
associated	RB	O
in	VBN	O
the	IN	O
natural	DT	O
source	JJ	O
of	NN	O
the	IN	O
polypeptide-encoding	DT	O
nucleic	JJ	O
acid.	JJ	O
An	.	O
isolated	DT	O
polypeptide-encoding	JJ	O
nucleic	NN	O
acid	JJ	O
molecule	NN	O
is	NN	O
other	VBZ	O
than	JJ	O
in	IN	O
the	IN	O
form	DT	O
or	NN	O
setting	CC	O
in	NN	O
which	IN	O
it	WDT	O
is	PRP	O
found	VBZ	O
in	VBN	O
nature.	IN	O
Isolated	.	O
polypeptide-encoding	VBN	O
nucleic	JJ	O
acid	JJ	O
molecules	NN	O
therefore	NNS	O
are	RB	O
distinguished	VBP	O
from	VBN	O
the	IN	O
specific	DT	O
polypeptide-encoding	JJ	O
nucleic	JJ	O
acid	JJ	O
molecule	NN	O
as	NN	O
it	IN	O
exists	PRP	O
in	VBZ	O
natural	IN	O
cells.	JJ	O
However,	.	O
an	,	O
isolated	DT	O
polypeptide-encoding	JJ	O
nucleic	NN	O
acid	JJ	O
molecule	NN	O
includes	NN	O
polypeptide-encoding	VBZ	O
nucleic	JJ	O
acid	JJ	O
molecules	NN	O
contained	NNS	O
in	VBN	O
cells	IN	O
that	NNS	O
ordinarily	IN	O
express	RB	O
the	VB	O
polypeptide	DT	O
where,	NN	O
for	,	O
example,	IN	O
the	,	O
nucleic	DT	O
acid	JJ	O
molecule	NN	O
is	NN	O
in	VBZ	O
a	IN	O
chromosomal	DT	O
location	JJ	O
different	NN	O
from	JJ	O
that	IN	O
of	DT	O
natural	IN	O
cells.	JJ	O
The	.	O
term	DT	O
“control	NN	O
sequences”	NNP	O
refers	VBZ	O
to	NNS	O
DNA	TO	O
sequences	NNP	O
necessary	NNS	O
for	JJ	O
the	IN	O
expression	DT	O
of	NN	O
an	IN	O
operably	DT	O
linked	NN	O
coding	VBD	O
sequence	VBG	O
in	NN	O
a	IN	O
particular	DT	O
host	JJ	O
organism.	NN	O
The	.	O
control	DT	O
sequences	NN	O
that	VBZ	O
are	WDT	O
suitable	VBP	O
for	JJ	O
prokaryotes,	IN	O
for	,	O
example,	IN	O
include	,	O
a	VBP	O
promoter,	DT	O
optionally	,	O
an	RB	O
operator	DT	O
sequence,	NN	O
and	,	O
a	CC	O
ribosome	DT	O
binding	NN	O
site.	NN	O
Eukaryotic	.	O
cells	JJ	O
are	NNS	O
known	VBP	O
to	VBN	O
utilize	TO	O
promoters,	VB	O
polyadenylation	,	O
signals,	NN	O
and	,	O
enhancers.	CC	O
Nucleic	.	O
acid	NNP	O
is	NN	O
“operably	VBZ	O
linked”	RB	O
when	JJ	O
it	WRB	O
is	PRP	O
placed	VBZ	O
into	VBN	O
a	IN	O
functional	DT	O
relationship	JJ	O
with	NN	O
another	IN	O
nucleic	DT	O
acid	JJ	O
sequence.	NN	O
For	.	O
example,	IN	O
DNA	,	O
for	NNP	O
a	IN	O
presequence	DT	O
or	NN	O
secretory	CC	O
leader	JJ	O
is	NN	O
operably	VBZ	O
linked	RB	O
to	VBN	O
DNA	TO	O
for	NNP	O
a	IN	O
polypeptide	DT	O
if	NN	O
it	IN	O
is	PRP	O
expressed	VBZ	O
as	VBN	O
a	IN	O
preprotein	DT	O
that	NN	O
participates	WDT	O
in	VBZ	O
the	IN	O
secretion	DT	O
of	NN	O
the	IN	O
polypeptide;	DT	O
a	:	O
promoter	DT	O
or	NN	O
enhancer	CC	O
is	NN	O
operably	VBZ	O
linked	RB	O
to	VBN	O
a	TO	O
coding	DT	O
sequence	NN	O
if	NN	O
it	IN	O
affects	PRP	O
the	VBZ	O
transcription	DT	O
of	NN	O
the	IN	O
sequence;	DT	O
or	:	O
a	CC	O
ribosome	DT	O
binding	JJ	O
site	NN	O
is	NN	O
operably	VBZ	O
linked	RB	O
to	VBN	O
a	TO	O
coding	DT	O
sequence	NN	O
if	NN	O
it	IN	O
is	PRP	O
positioned	VBZ	O
so	VBN	O
as	RB	O
to	IN	O
facilitate	TO	O
translation.	VB	O
Generally,	.	O
“operably	,	O
linked”	RB	O
means	JJ	O
that	VBZ	O
the	IN	O
DNA	DT	O
sequences	NN	O
being	NNS	O
linked	VBG	O
are	VBN	O
contiguous,	VBP	O
and,	,	O
in	,	O
the	IN	O
case	DT	O
of	NN	O
a	IN	O
secretory	DT	O
leader,	JJ	O
contiguous	,	O
and	JJ	O
in	CC	O
reading	IN	O
phase.	VBG	O
However,	.	O
enhancers	,	O
do	NNS	O
not	VBP	O
have	RB	O
to	VB	O
be	TO	O
contiguous.	VB	O
Linking	.	O
is	VBG	O
accomplished	VBZ	O
by	VBN	O
ligation	IN	O
at	NN	O
convenient	IN	O
restriction	JJ	O
sites.	NN	O
If	.	O
such	IN	O
sites	JJ	O
do	NNS	O
not	VBP	O
exist,	RB	O
the	,	O
synthetic	DT	O
oligonucleotide	JJ	O
adaptors	NN	O
or	NNS	O
linkers	CC	O
are	NNS	O
used	VBP	O
in	VBN	O
accordance	IN	O
with	NN	O
conventional	IN	O
practice.	JJ	O
“Stringency”	.	O
of	NN	O
hybridization	IN	O
reactions	NN	O
is	NNS	O
readily	VBZ	O
determinable	RB	O
by	JJ	O
one	IN	O
of	CD	O
ordinary	IN	O
skill	JJ	O
in	NN	O
the	IN	O
art,	DT	O
and	,	O
generally	CC	O
is	RB	O
an	VBZ	O
empirical	DT	O
calculation	JJ	O
dependent	NN	O
upon	NN	O
probe	IN	O
length,	NN	O
washing	,	O
temperature,	VBG	O
and	,	O
salt	CC	O
concentration.	JJ	O
In	.	O
general,	IN	O
longer	,	O
probes	RBR	O
require	NNS	O
higher	VBP	O
temperatures	JJR	O
for	NNS	O
proper	IN	O
annealing,	JJ	O
while	,	O
shorter	IN	O
probes	JJR	O
need	NNS	O
lower	VBP	O
temperatures.	JJR	O
Hybridization	.	O
generally	NNP	O
depends	RB	O
on	VBZ	O
the	IN	O
ability	DT	O
of	NN	O
denatured	IN	O
DNA	JJ	O
to	NNP	O
reanneal	TO	O
when	VB	O
complementary	WRB	O
strands	JJ	O
are	NNS	O
present	VBP	O
in	JJ	O
an	IN	O
environment	DT	O
below	NN	O
their	IN	O
melting	PRP$	O
temperature.	NN	O
The	.	O
higher	DT	O
the	JJR	O
degree	DT	O
of	NN	O
desired	IN	O
homology	JJ	O
between	NN	O
the	IN	O
probe	DT	O
and	NN	O
hybridizable	CC	O
sequence,	JJ	O
the	,	O
higher	DT	O
the	JJR	O
relative	DT	O
temperature	JJ	O
which	NN	O
can	WDT	O
be	MD	O
used.	VB	O
As	.	O
a	IN	O
result,	DT	O
it	,	O
follows	PRP	O
that	VBZ	O
higher	IN	O
relative	JJR	O
temperatures	JJ	O
would	NNS	O
tend	MD	O
to	VB	O
make	TO	O
the	VB	O
reaction	DT	O
conditions	NN	O
more	NNS	O
stringent,	RBR	O
while	,	O
lower	IN	O
temperatures	JJR	O
less	NNS	O
so.	RBR	O
For	.	O
additional	IN	O
details	JJ	O
and	NNS	O
explanation	CC	O
of	NN	O
stringency	IN	O
of	NN	O
hybridization	IN	O
reactions,	NN	O
see	,	O
Ausubel	VBP	B
et	NNP	I
al.,	FW	I
Current	,	I
Protocols	NNP	I
in	NNP	I
Molecular	IN	I
Biology,	NNP	I
Wiley	,	I
Interscience	NNP	I
Publishers,	NNP	I
(1995).
“Stringent	,	O
conditions”	.	O
or	JJ	O
“high	NN	O
stringency	CC	O
conditions”,	JJ	O
as	NN	O
defined	,	O
herein,	IN	O
may	VBN	O
be	,	O
identified	MD	O
by	VB	O
those	VBN	O
that:	IN	O
(1)	DT	O
employ	:	O
low	)	O
ionic	NN	O
strength	JJ	O
and	JJ	O
high	NN	O
temperature	CC	O
for	JJ	O
washing,	NN	O
for	IN	O
example	,	O
0.015	IN	O
M	NN	O
sodium	CD	O
chloride/0.0015	NNP	O
M	NN	O
sodium	NN	O
citrate/0.1%	NNP	O
sodium	NN	O
dodecyl	NN	O
sulfate	NN	O
at	NN	O
50°	NN	O
C.;	IN	O
(2)	CD	O
employ	:	O
during	)	O
hybridization	NN	O
a	IN	O
denaturing	NN	O
agent,	DT	O
such	NN	O
as	,	O
formamide,	JJ	O
for	IN	O
example,	,	O
50%	IN	O
(v/v)	,	O
formamide	NN	O
with	)	O
0.1%	NN	O
bovine	IN	O
serum	NN	O
albumin/0.1%	NN	O
Ficoll/0.1%	JJ	O
polyvinylpyrrolidone/50	NN	O
mM	NN	O
sodium	NN	O
phosphate	NN	O
buffer	NN	O
at	NN	O
pH	NN	O
6.5	IN	O
with	$	O
750	CD	O
mM	IN	O
sodium	CD	O
chloride,	NNS	O
75	JJ	O
mM	,	O
sodium	CD	O
citrate	NN	O
at	NN	O
42°	NN	O
C.;	IN	O
or	CD	O
(3)	:	O
employ	CC	O
50%	)	O
formamide,	VBP	O
5×SSC	NN	O
(0.75	,	O
M	CD	O
NaCl,	CD	O
0.075	NNP	O
M	,	O
sodium	CD	O
citrate),	NNP	O
50	NN	O
mM	,	O
sodium	CD	O
phosphate	NN	O
(pH	NN	O
6.8),	NN	O
0.1%	JJ	O
sodium	,	O
pyrophosphate,	NN	O
5×Denhardt's	NN	O
solution,	,	O
sonicated	POS	O
salmon	,	O
sperm	VBD	O
DNA	JJ	O
(50	NN	O
μg/ml),	NNP	O
0.1%	CD	O
SDS,	,	O
and	NN	O
10%	,	O
dextran	CC	O
sulfate	NN	O
at	NN	O
42°	NN	O
C.,	IN	O
with	CD	O
washes	,	O
at	IN	O
42°	NNS	O
C.	IN	O
in	CD	O
0.2×SSC	NNP	O
(sodium	IN	O
chloride/sodium	CD	O
citrate)	NN	O
and	NN	O
50%	)	O
formamide	CC	O
at	NN	O
55°	NN	O
C.,	IN	O
followed	CD	O
by	,	O
a	VBN	O
high-stringency	IN	O
wash	DT	O
consisting	NN	O
of	NN	O
0.1×SSC	NN	O
containing	IN	O
EDTA	CD	O
at	VBG	O
55°	NNP	O
C.	IN	O
“Moderately	CD	O
stringent	NNP	O
conditions”	RB	O
may	JJ	O
be	NN	O
identified	MD	O
as	VB	O
described	VBN	O
by	IN	O
Sambrook	VBN	B
et	IN	I
al.,	NNP	I
Molecular	FW	I
Cloning:	,	I
A	JJ	I
Laboratory	:	I
Manual,	DT	I
New	NNP	I
York:	,	I
Cold	NNP	I
Spring	:	I
Harbor	JJ	I
Press,	NN	I
1989,	NNP	I
and	,	O
include	,	O
the	CC	O
use	VBP	O
of	DT	O
washing	NN	O
solution	IN	O
and	VBG	O
hybridization	NN	O
conditions	CC	O
(e.g.,	NN	O
temperature,	NNS	O
ionic	,	O
strength	,	O
and	JJ	O
%	NN	O
SDS)	CC	O
less	NN	O
stringent	)	O
that	RBR	O
those	JJ	O
described	IN	O
above.	DT	O
An	VBN	O
example	.	O
of	DT	O
moderately	NN	O
stringent	IN	O
conditions	RB	O
is	JJ	O
overnight	NNS	O
incubation	VBZ	O
at	JJ	O
37°	NN	O
C.	IN	O
in	CD	O
a	NNP	O
solution	IN	O
comprising:	DT	O
20%	NN	O
formamide,	:	O
5×SSC	NN	O
(150	,	O
mM	CD	O
NaCl,	CD	O
15	NN	O
mM	,	O
trisodium	CD	O
citrate),	NN	O
50	NN	O
mM	,	O
sodium	CD	O
phosphate	NN	O
(pH	NN	O
7.6),	NN	O
5×Denhardt's	JJ	O
solution,	,	O
10%	POS	O
dextran	,	O
sulfate,	NN	O
and	NN	O
20	,	O
mg/ml	CC	O
denatured	CD	O
sheared	NN	O
salmon	VBD	O
sperm	JJ	O
DNA,	JJ	O
followed	NN	O
by	,	O
washing	VBN	O
the	IN	O
filters	VBG	O
in	DT	O
1×SSC	NNS	O
at	IN	O
about	CD	O
37-50°	IN	O
C.	IN	O
The	JJ	O
skilled	NNP	O
artisan	DT	O
will	JJ	O
recognize	NN	O
how	MD	O
to	VB	O
adjust	WRB	O
the	TO	O
temperature,	VB	O
ionic	DT	O
strength,	,	O
etc.	JJ	O
as	,	O
necessary	.	O
to	IN	O
accommodate	JJ	O
factors	TO	O
such	VB	O
as	NNS	O
probe	JJ	O
length	IN	O
and	NN	O
the	NN	O
like.	CC	O
The	DT	O
term	.	O
“epitope	DT	O
tagged”	NN	O
when	NNP	O
used	NN	O
herein	WRB	O
refers	VBN	O
to	NN	O
a	NNS	O
chimeric	TO	O
polypeptide	DT	O
comprising	JJ	O
a	NN	O
PRO227,	VBG	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
fused	NNP	O
to	RB	O
a	VBD	O
“tag	TO	O
polypeptide”.	DT	O
The	JJ	O
tag	.	O
polypeptide	DT	O
has	NN	O
enough	NN	O
residues	VBZ	O
to	JJ	O
provide	NNS	O
an	TO	O
epitope	VB	O
against	DT	O
which	NN	O
an	IN	O
antibody	WDT	O
can	DT	O
be	NN	O
made,	MD	O
yet	VB	O
is	,	O
short	CC	O
enough	VBZ	O
such	JJ	O
that	RB	O
it	JJ	O
does	IN	O
not	PRP	O
interfere	VBZ	O
with	RB	O
activity	VB	O
of	IN	O
the	NN	O
polypeptide	IN	O
to	DT	O
which	NN	O
it	TO	O
is	WDT	O
fused.	PRP	O
The	VBZ	O
tag	.	O
polypeptide	DT	O
preferably	NN	O
also	NN	O
is	RB	O
fairly	RB	O
unique	VBZ	O
so	RB	O
that	JJ	O
the	IN	O
antibody	IN	O
does	DT	O
not	NN	O
substantially	VBZ	O
cross-react	RB	O
with	RB	O
other	JJ	O
epitopes.	IN	O
Suitable	JJ	O
tag	.	O
polypeptides	JJ	O
generally	NN	O
have	NNS	O
at	RB	O
least	VBP	O
six	IN	O
amino	JJS	O
acid	CD	O
residues	JJ	O
and	NN	O
usually	NNS	O
between	CC	O
about	RB	O
8	IN	O
and	IN	O
50	CD	O
amino	CC	O
acid	CD	O
residues	NN	O
(preferably,	NN	O
between	NNS	O
about	,	O
10	IN	O
and	IN	O
20	CD	O
amino	CC	O
acid	CD	O
residues).	NN	O
“Active”	NN	O
or	.	O
“activity”	NN	O
for	CC	O
the	NN	O
purposes	IN	O
herein	DT	O
refers	NNS	O
to	VBP	O
form(s)	NNS	O
of	TO	O
a	)	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
which	NNP	O
retain	IN	O
a	WDT	O
biological	VBP	O
and/or	DT	O
an	JJ	O
immunological	NN	O
activity	DT	O
of	JJ	O
native	NN	O
or	IN	O
naturally-occurring	JJ	O
PRO227,	CC	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide,	CC	O
wherein	NNP	O
“biological”	,	O
activity	JJ	O
refers	NN	O
to	NN	O
a	NNS	O
biological	TO	O
function	DT	O
(either	JJ	O
inhibitory	NN	O
or	CC	O
stimulatory)	NN	O
caused	CC	O
by	)	O
a	VBN	O
native	IN	O
or	DT	O
naturally-occurring	JJ	O
PRO227,	CC	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
other	NNP	O
than	IN	O
the	JJ	O
ability	IN	O
to	DT	O
induce	NN	O
the	TO	O
production	VB	O
of	DT	O
an	NN	O
antibody	IN	O
against	DT	O
an	NN	O
antigenic	IN	O
epitope	DT	O
possessed	JJ	O
by	NN	O
a	VBN	O
native	IN	O
or	DT	O
naturally-occurring	JJ	O
PRO227,	CC	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
and	NNP	O
an	NN	O
“immunological”	CC	O
activity	DT	O
refers	JJ	O
to	NN	O
the	NNS	O
ability	TO	O
to	DT	O
induce	NN	O
the	TO	O
production	VB	O
of	DT	O
an	NN	O
antibody	IN	O
against	DT	O
an	NN	O
antigenic	IN	O
epitope	DT	O
possessed	JJ	O
by	NN	O
a	VBN	O
native	IN	O
or	DT	O
naturally-occurring	JJ	O
PRO227,	CC	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide.	CC	O
The	NNP	O
term	.	O
“antagonist”	DT	O
is	NN	O
used	NNP	O
in	VBZ	O
the	VBN	O
broadest	IN	O
sense	DT	O
[unless	JJS	O
otherwise	NN	O
qualified],	IN	O
and	RB	O
includes	,	O
any	CC	O
molecule	VBZ	O
that	DT	O
partially	NN	O
or	WDT	O
fully	RB	O
blocks,	CC	O
inhibits,	RB	O
or	,	O
neutralizes	,	O
a	CC	O
biological	VBZ	O
activity	DT	O
of	JJ	O
a	NN	O
native	IN	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
disclosed	NNP	O
herein.	RB	O
In	VBD	O
a	.	O
similar	IN	O
manner,	DT	O
the	JJ	O
term	,	O
“agonist”	DT	O
is	NN	O
used	NNP	O
in	VBZ	O
the	VBN	O
broadest	IN	O
sense	DT	O
[unless	JJS	O
otherwise	NN	O
qualified]	IN	O
and	RB	O
includes	NN	O
any	CC	O
molecule	VBZ	O
that	DT	O
mimics	NN	O
a	IN	O
biological	VBZ	O
activity	DT	O
of	JJ	O
a	NN	O
native	IN	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
disclosed	NNP	O
herein.	RB	O
Suitable	VBD	O
agonist	.	O
or	JJ	O
antagonist	NN	O
molecules	CC	O
specifically	NN	O
include	NNS	O
agonist	RB	O
or	VBP	O
antagonist	NN	O
antibodies	CC	O
or	JJ	O
antibody	NNS	O
fragments,	CC	O
fragments	NN	O
or	,	O
amino	NNS	O
acid	CC	O
sequence	NN	O
variants	JJ	O
of	NN	O
native	NNS	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptides,	CC	O
peptides,	NNP	O
antisense	,	O
oligonucleotides,	,	O
small	NN	O
organic	,	O
molecules,	JJ	O
etc.	JJ	O
Methods	,	O
for	.	O
identifying	NNS	O
agonists	IN	O
or	VBG	O
antagonists	NNS	O
of	CC	O
a	NNS	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
may	NNP	O
comprise	NN	O
contacting	MD	O
a	VB	O
PRO227,	VBG	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
with	NNP	O
a	IN	O
candidate	IN	O
agonist	DT	O
or	JJ	O
antagonist	NN	O
molecule	CC	O
and	NN	O
measuring	NN	O
a	CC	O
detectable	VBG	O
change	DT	O
in	JJ	O
one	NN	O
or	IN	O
more	CD	O
biological	CC	O
activities	JJR	O
normally	JJ	O
associated	NNS	O
with	RB	O
the	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide.	CC	O
“Treating”	NNP	O
or	.	O
“treatment”	NN	O
or	CC	O
“alleviation”	NN	O
refers	CC	O
to	JJ	O
both	NNS	O
therapeutic	TO	O
treatment	DT	O
and	JJ	O
prophylactic	NN	O
or	CC	O
preventative	JJ	O
measures,	CC	O
wherein	JJ	O
the	,	O
object	VBD	O
is	DT	O
to	NN	O
prevent	VBZ	O
or	TO	O
slow	VB	O
down	CC	O
(lessen)	VB	O
the	RP	O
targeted	)	O
pathologic	DT	O
condition	JJ	O
or	JJ	O
disorder.	NN	O
A	CC	O
subject	.	O
in	DT	O
need	NN	O
of	IN	O
treatment	NN	O
may	IN	O
already	NN	O
have	MD	O
the	RB	O
disorder,	VB	O
or	DT	O
may	,	O
be	CC	O
prone	MD	O
to	VB	O
have	NN	O
the	TO	O
disorder	VB	O
or	DT	O
may	NN	O
be	CC	O
in	MD	O
whom	VB	O
the	IN	O
disorder	WP	O
is	DT	O
to	NN	O
be	VBZ	O
prevented.	TO	O
“Chronic”	VB	O
administration	.	O
refers	JJ	O
to	NN	O
administration	NNS	O
of	TO	O
the	NN	O
agent(s)	IN	O
in	DT	O
a	)	O
continuous	IN	O
mode	DT	O
as	JJ	O
opposed	NN	O
to	IN	O
an	VBN	O
acute	TO	O
mode,	DT	O
so	JJ	O
as	,	O
to	RB	O
maintain	IN	O
the	TO	O
initial	VB	O
therapeutic	DT	O
effect	JJ	O
(activity)	JJ	O
for	NN	O
an	)	O
extended	IN	O
period	DT	O
of	JJ	O
time.	NN	O
“Intermittent”	IN	O
administration	.	O
is	JJ	O
treatment	NN	O
that	VBZ	O
is	NN	O
not	WDT	O
consecutively	VBZ	O
done	RB	O
without	RB	O
interruption,	VBN	O
but	IN	O
rather	,	O
is	CC	O
cyclic	RB	O
in	VBZ	O
nature.	JJ	O
“Mammal”	IN	O
for	.	O
purposes	NN	O
of	IN	O
treatment	NNS	O
refers	IN	O
to	NN	O
any	NNS	O
animal	TO	O
classified	DT	O
as	JJ	O
a	VBN	O
mammal,	IN	O
including	DT	O
humans,	,	O
rodents	VBG	O
such	,	O
as	NNS	O
rats	JJ	O
or	IN	O
mice,	NNS	O
domestic	CC	O
and	,	O
farm	JJ	O
animals,	CC	O
and	NN	O
zoo,	,	O
sports,	CC	O
or	,	O
pet	,	O
animals,	CC	O
such	JJ	O
as	,	O
dogs,	JJ	O
cats,	IN	O
cattle,	,	O
horses,	,	O
sheep,	,	O
pigs,	,	O
goats,	,	O
rabbits,	,	O
etc.	,	O
Preferably,	,	O
the	.	O
mammal	,	O
is	DT	O
human.	NN	O
Administration	VBZ	O
“in	.	O
combination	NNP	O
with”	NNP	O
one	NN	O
or	VBZ	O
more	CD	O
further	CC	O
therapeutic	JJR	O
agents	JJ	O
includes	JJ	O
simultaneous	NNS	O
(concurrent)	VBZ	O
and	JJ	O
consecutive	)	O
administration	CC	O
in	JJ	O
any	NN	O
order.	IN	O
“Carriers”	DT	O
as	.	O
used	NN	O
herein	IN	O
include	VBN	O
pharmaceutically	NN	O
acceptable	VBP	O
carriers,	RB	O
excipients,	JJ	O
or	,	O
stabilizers	,	O
which	CC	O
are	NNS	O
nontoxic	WDT	O
to	VBP	O
the	JJ	O
cell	TO	O
or	DT	O
mammal	NN	O
being	CC	O
exposed	JJ	O
thereto	VBG	O
at	VBN	O
the	NN	O
dosages	IN	O
and	DT	O
concentrations	NNS	O
employed.	CC	O
Often	NNS	O
the	.	O
physiologically	RB	O
acceptable	DT	O
carrier	RB	O
is	JJ	O
an	NN	O
aqueous	VBZ	O
pH	DT	O
buffered	JJ	O
solution.	NN	O
Examples	VBD	O
of	.	O
physiologically	NNS	O
acceptable	IN	O
carriers	RB	O
include	JJ	O
buffers	NNS	O
such	VBP	O
as	NNS	O
phosphate,	JJ	O
citrate,	IN	O
and	,	O
other	,	O
organic	CC	O
acids;	JJ	O
antioxidants	JJ	O
including	:	O
ascorbic	NNS	O
acid;	VBG	O
low	JJ	O
molecular	:	O
weight	JJ	O
(less	JJ	O
than	NN	O
about	JJR	O
10	IN	O
residues)	RB	O
polypeptide;	CD	O
proteins,	)	O
such	:	O
as	,	O
serum	JJ	O
albumin,	IN	O
gelatin,	NN	O
or	,	O
immunoglobulins;	,	O
hydrophilic	CC	O
polymers	:	O
such	JJ	O
as	NNS	O
polyvinylpyrrolidone;	JJ	O
amino	IN	O
acids	:	O
such	JJ	O
as	NNS	O
glycine,	JJ	O
glutamine,	IN	O
asparagine,	,	O
arginine	,	O
or	,	O
lysine;	NN	O
monosaccharides,	CC	O
disaccharides,	:	O
and	,	O
other	,	O
carbohydrates	CC	O
including	JJ	O
glucose,	NNS	O
mannose,	VBG	O
or	,	O
dextrins;	,	O
chelating	CC	O
agents	:	O
such	VBG	O
as	NNS	O
EDTA;	JJ	O
sugar	IN	O
alcohols	:	O
such	NN	O
as	NNS	O
mannitol	JJ	O
or	IN	O
sorbitol;	NN	O
salt-forming	CC	O
counterions	:	O
such	JJ	O
as	NNS	O
sodium;	JJ	O
and/or	IN	O
nonionic	:	O
surfactants	CC	O
such	JJ	O
as	NNS	O
TWEEN™,	JJ	O
polyethylene	IN	O
glycol	,	O
(PEG),	NN	O
and	NN	O
PLURONICS™.	,	O
By	CC	O
“solid	.	O
phase”	IN	O
is	JJ	O
meant	NN	O
a	VBZ	O
non-aqueous	VBN	O
matrix	DT	O
to	JJ	O
which	NN	O
the	TO	O
antibody	WDT	O
of	DT	O
the	NN	O
present	IN	O
invention	DT	O
can	JJ	O
adhere.	NN	O
Examples	MD	O
of	.	O
solid	NNS	O
phases	IN	O
encompassed	JJ	O
herein	NNS	O
include	VBD	O
those	JJ	O
formed	VBP	O
partially	DT	O
or	VBN	O
entirely	RB	O
of	CC	O
glass	RB	O
(e.g.,	IN	O
controlled	NN	O
pore	,	O
glass),	VBD	O
polysaccharides	RB	O
(e.g.,	,	O
agarose),	NNS	O
polyacrylamides,	,	O
polystyrene,	,	O
polyvinyl	,	O
alcohol	,	O
and	NN	O
silicones.	NN	O
Depending	CC	O
on	.	O
the	VBG	O
context,	IN	O
the	DT	O
solid	,	O
phase	DT	O
can	JJ	O
comprise	NN	O
the	MD	O
well	VB	O
of	DT	O
an	NN	O
assay	IN	O
plate;	DT	O
in	JJ	O
others	:	O
it	IN	O
is	NNS	O
a	PRP	O
purification	VBZ	O
column	DT	O
(e.g.,	NN	O
an	NN	O
affinity	,	O
chromatography	DT	O
column).	NN	O
This	NN	O
term	.	O
also	DT	O
includes	NN	O
a	RB	O
discontinuous	VBZ	O
solid	DT	O
phase	JJ	O
of	JJ	O
discrete	NN	O
particles,	IN	O
such	JJ	O
as	,	O
those	JJ	O
described	IN	O
in	DT	O
U.S.	VBN	O
Pat.	IN	O
No.	NNP	O
4,275,149.	.	O
A	.	O
“liposome”	.	O
is	DT	O
a	NN	O
small	VBZ	O
vesicle	DT	O
composed	JJ	O
of	NN	O
various	VBN	O
types	IN	O
of	JJ	O
lipids,	NNS	O
phospholipids	IN	O
and/or	,	O
surfactant	NNS	O
which	VBP	O
is	JJ	O
useful	WDT	O
for	VBZ	O
delivery	JJ	O
of	IN	O
a	NN	O
drug	IN	O
(such	DT	O
as	NN	O
a	JJ	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide	CC	O
or	NNP	O
antibody	NN	O
thereto)	CC	O
to	NN	O
a	)	O
mammal.	TO	O
The	DT	O
components	.	O
of	DT	O
the	NNS	O
liposome	IN	O
are	DT	O
commonly	NN	O
arranged	VBP	O
in	RB	O
a	VBN	O
bilayer	IN	O
formation,	DT	O
similar	NN	O
to	,	O
the	JJ	O
lipid	TO	O
arrangement	DT	O
of	JJ	O
biological	NN	O
membranes.	IN	O
A	JJ	O
“small	.	O
molecule”	DT	O
is	JJ	O
defined	NN	O
herein	VBZ	O
to	VBN	O
have	NN	O
a	TO	O
molecular	VB	O
weight	DT	O
below	JJ	O
about	NN	O
500	IN	O
Daltons.	RB	O
An	CD	O
“effective	.	O
amount”	DT	O
of	JJ	O
a	NN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide,	CC	O
an	NNP	O
anti-PRO227,	,	O
anti-PRO233,	DT	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	JJ	O
antibody,	CC	O
a	JJ	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
binding	CC	O
oligopeptide,	NNP	O
a	VBG	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
binding	CC	O
organic	NNP	O
molecule	VBG	O
or	JJ	O
an	NN	O
agonist	CC	O
or	DT	O
antagonist	NN	O
thereof	CC	O
as	JJ	O
disclosed	NN	O
herein	IN	O
is	JJ	O
an	NN	O
amount	VBZ	O
sufficient	DT	O
to	NN	O
carry	NN	O
out	TO	O
a	VB	O
specifically	RP	O
stated	DT	O
purpose.	RB	O
An	VBN	O
“effective	.	O
amount”	DT	O
may	JJ	O
be	NN	O
determined	MD	O
empirically	VB	O
and	VBN	O
in	RB	O
a	CC	O
routine	IN	O
manner,	DT	O
in	JJ	O
relation	,	O
to	IN	O
the	NN	O
stated	TO	O
purpose.	DT	O
The	VBN	O
term	.	O
“therapeutically	DT	O
effective	NN	O
amount”	RB	O
refers	JJ	O
to	NN	O
an	NNS	O
amount	TO	O
of	DT	O
an	NN	O
anti-PRO227,	IN	O
anti-PRO233,	DT	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	JJ	O
antibody,	CC	O
a	JJ	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptide,	CC	O
a	NNP	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
binding	CC	O
oligopeptide,	NNP	O
a	VBG	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
binding	CC	O
organic	NNP	O
molecule	VBG	O
or	JJ	O
other	NN	O
drug	CC	O
effective	JJ	O
to	NN	O
“treat”	JJ	O
a	TO	O
disease	VB	O
or	DT	O
disorder	NN	O
in	CC	O
a	NN	O
subject	IN	O
or	DT	O
mammal.	NN	O
In	CC	O
the	.	O
case	IN	O
of	DT	O
cancer,	NN	O
the	IN	O
therapeutically	,	O
effective	DT	O
amount	RB	O
of	JJ	O
the	NN	O
drug	IN	O
may	DT	O
reduce	NN	O
the	MD	O
number	VB	O
of	DT	O
cancer	NN	O
cells;	IN	O
reduce	NN	O
the	:	O
tumor	VB	O
size;	DT	O
inhibit	NN	O
(i.e.,	:	O
slow	NN	O
to	,	O
some	VB	O
extent	TO	O
and	DT	O
preferably	NN	O
stop)	CC	O
cancer	RB	O
cell	)	O
infiltration	NN	O
into	NN	O
peripheral	NN	O
organs;	IN	O
inhibit	JJ	O
(i.e.,	:	O
slow	NN	O
to	,	O
some	VB	O
extent	TO	O
and	DT	O
preferably	NN	O
stop)	CC	O
tumor	RB	O
metastasis;	)	O
inhibit,	NN	O
to	:	O
some	,	O
extent,	TO	O
tumor	DT	O
growth;	,	O
and/or	NN	O
relieve	:	O
to	CC	O
some	VB	O
extent	TO	O
one	DT	O
or	NN	O
more	CD	O
of	CC	O
the	JJR	O
symptoms	IN	O
associated	DT	O
with	NNS	O
the	VBN	O
cancer.	IN	O
See	DT	O
the	.	O
definition	VB	O
herein	DT	O
of	NN	O
“treating”.	NN	O
To	IN	O
the	.	O
extent	TO	O
the	DT	O
drug	NN	O
may	DT	O
prevent	NN	O
growth	MD	O
and/or	VB	O
kill	NN	O
existing	IN	O
cancer	VB	O
cells,	VBG	O
it	NN	O
may	,	O
be	PRP	O
cytostatic	MD	O
and/or	VB	O
cytotoxic.	JJ	O
The	NN	O
phrases	.	O
“cardiovascular,	DT	O
endothelial	NNS	O
and	,	O
angiogenic	JJ	O
disorder”,	CC	O
“cardiovascular,	JJ	O
endothelial	,	O
and	,	O
angiogenic	JJ	O
dysfunction”,	CC	O
“cardiovascular,	JJ	O
endothelial	,	O
or	,	O
angiogenic	JJ	O
disorder”	CC	O
and	JJ	O
“cardiovascular,	NN	O
endothelial	CC	O
or	,	O
angiogenic	JJ	O
dysfunction”	CC	O
are	JJ	O
used	NN	O
interchangeably	VBP	O
and	VBN	O
refer	RB	O
in	CC	O
part	VB	O
to	IN	O
systemic	NN	O
disorders	TO	O
that	VB	O
affect	NNS	O
vessels,	WDT	O
such	VBP	O
as	,	O
diabetes	JJ	O
mellitus,	IN	O
as	NNS	O
well	,	O
as	RB	O
diseases	RB	O
of	IN	O
the	NNS	O
vessels	IN	O
themselves,	DT	O
such	NNS	O
as	,	O
of	JJ	O
the	IN	O
arteries,	IN	O
capillaries,	DT	O
veins,	,	O
and/or	,	O
lymphatics.	,	O
This	JJ	O
would	.	O
include	DT	O
indications	MD	O
that	VB	O
stimulate	NNS	O
angiogenesis	WDT	O
and/or	VBP	O
cardiovascularization,	NN	O
and	NN	O
those	,	O
that	CC	O
inhibit	DT	O
angiogenesis	WDT	O
and/or	VBP	O
cardiovascularization.	JJ	O
Such	JJ	O
disorders	.	O
include,	JJ	O
for	NNS	O
example,	,	O
arterial	IN	O
disease,	,	O
such	JJ	O
as	,	O
atherosclerosis,	JJ	O
hypertension,	IN	O
inflammatory	,	O
vasculitides,	,	O
Reynaud's	JJ	O
disease	,	O
and	POS	O
Reynaud's	NN	O
phenomenon,	CC	O
aneurysms,	POS	O
and	,	O
arterial	,	O
restenosis;	CC	O
venous	JJ	O
and	:	O
lymphatic	JJ	O
disorders	CC	O
such	JJ	O
as	NNS	O
thrombophlebitis,	JJ	O
lymphangitis,	IN	O
and	,	O
lymphedema;	,	O
and	CC	O
other	:	O
vascular	CC	O
disorders	JJ	O
such	JJ	O
as	NNS	O
peripheral	JJ	O
vascular	IN	O
disease,	JJ	O
cancer	JJ	O
such	,	O
as	NN	O
vascular	JJ	O
tumors,	IN	O
e.g.,	JJ	O
hemangioma	,	O
(capillary	,	O
and	NN	O
cavernous),	JJ	O
glomus	CC	O
tumors,	,	O
telangiectasia,	JJ	O
bacillary	,	O
angiomatosis,	,	O
hemangioendothelioma,	JJ	O
angiosarcoma,	,	O
haemangiopericytoma,	,	O
Kaposi's	,	O
sarcoma,	,	O
lymphangioma,	POS	O
and	,	O
lymphangiosarcoma,	,	O
tumor	CC	O
angiogenesis,	,	O
trauma	NN	O
such	,	O
as	NN	O
wounds,	JJ	O
burns,	IN	O
and	,	O
other	,	O
injured	CC	O
tissue,	JJ	O
implant	JJ	O
fixation,	,	O
scarring,	JJ	O
ischemia	,	O
reperfusion	,	O
injury,	JJ	O
rheumatoid	NN	O
arthritis,	,	O
cerebrovascular	JJ	O
disease,	,	O
renal	JJ	O
diseases	,	O
such	JJ	O
as	NNS	O
acute	JJ	O
renal	IN	O
failure,	JJ	O
or	JJ	O
osteoporosis.	,	O
This	CC	O
would	.	O
also	DT	O
include	MD	O
angina,	RB	O
myocardial	VB	O
infarctions	,	O
such	JJ	O
as	NNS	O
acute	JJ	O
myocardial	IN	O
infarctions,	JJ	O
cardiac	JJ	O
hypertrophy,	,	O
and	JJ	O
heart	,	O
failure	CC	O
such	NN	O
as	NN	O
CHF.	JJ	O
“Hypertrophy”,	IN	O
as	.	O
used	,	O
herein,	IN	O
is	VBN	O
defined	,	O
as	VBZ	O
an	VBN	O
increase	IN	O
in	DT	O
mass	NN	O
of	IN	O
an	NN	O
organ	IN	O
or	DT	O
structure	JJ	O
independent	CC	O
of	NN	O
natural	JJ	O
growth	IN	O
that	JJ	O
does	NN	O
not	WDT	O
involve	VBZ	O
tumor	RB	O
formation.	VB	O
Hypertrophy	NN	O
of	.	O
an	NNP	O
organ	IN	O
or	DT	O
tissue	NN	O
is	CC	O
due	NN	O
either	VBZ	O
to	JJ	O
an	RB	O
increase	TO	O
in	DT	O
the	NN	O
mass	IN	O
of	DT	O
the	NN	O
individual	IN	O
cells	DT	O
(true	JJ	O
hypertrophy),	NNS	O
or	JJ	O
to	,	O
an	CC	O
increase	TO	O
in	DT	O
the	NN	O
number	IN	O
of	DT	O
cells	NN	O
making	IN	O
up	NNS	O
the	VBG	O
tissue	RP	O
(hyperplasia),	DT	O
or	NN	O
both.	,	O
Certain	CC	O
organs,	.	O
such	NNP	O
as	,	O
the	JJ	O
heart,	IN	O
lose	DT	O
the	,	O
ability	VB	O
to	DT	O
divide	NN	O
shortly	TO	O
after	VB	O
birth.	RB	O
Accordingly,	IN	O
“cardiac	.	O
hypertrophy”	,	O
is	JJ	O
defined	NN	O
as	VBZ	O
an	VBN	O
increase	IN	O
in	DT	O
mass	NN	O
of	IN	O
the	NN	O
heart,	IN	O
which,	DT	O
in	,	O
adults,	,	O
is	IN	O
characterized	,	O
by	VBZ	O
an	VBN	O
increase	IN	O
in	DT	O
myocyte	NN	O
cell	IN	O
size	NN	O
and	NN	O
contractile	NN	O
protein	CC	O
content	NN	O
without	NN	O
concomitant	NN	O
cell	IN	O
division.	NN	O
The	NN	O
character	.	O
of	DT	O
the	NN	O
stress	IN	O
responsible	DT	O
for	NN	O
inciting	JJ	O
the	IN	O
hypertrophy,	VBG	O
(e.g.,	DT	O
increased	,	O
preload,	,	O
increased	JJ	O
afterload,	,	O
loss	VBD	O
of	,	O
myocytes,	NN	O
as	IN	O
in	,	O
myocardial	IN	O
infarction,	IN	O
or	JJ	O
primary	,	O
depression	CC	O
of	JJ	O
contractility),	NN	O
appears	IN	O
to	,	O
play	VBZ	O
a	TO	O
critical	VB	O
role	DT	O
in	JJ	O
determining	NN	O
the	IN	O
nature	VBG	O
of	DT	O
the	NN	O
response.	IN	O
The	DT	O
early	.	O
stage	DT	O
of	JJ	O
cardiac	NN	O
hypertrophy	IN	O
is	JJ	O
usually	NN	O
characterized	VBZ	O
morphologically	RB	O
by	VBN	O
increases	RB	O
in	IN	O
the	NNS	O
size	IN	O
of	DT	O
myofibrils	NN	O
and	IN	O
mitochondria,	NNS	O
as	CC	O
well	,	O
as	RB	O
by	RB	O
enlargement	IN	O
of	IN	O
mitochondria	NN	O
and	IN	O
nuclei.	NNS	O
At	CC	O
this	.	O
stage,	IN	O
while	DT	O
muscle	,	O
cells	IN	O
are	NN	O
larger	NNS	O
than	VBP	O
normal,	JJR	O
cellular	IN	O
organization	,	O
is	JJ	O
largely	NN	O
preserved.	VBZ	O
At	RB	O
a	.	O
more	IN	O
advanced	DT	O
stage	RBR	O
of	JJ	O
cardiac	NN	O
hypertrophy,	IN	O
there	JJ	O
are	,	O
preferential	EX	O
increases	VBP	O
in	JJ	O
the	NNS	O
size	IN	O
or	DT	O
number	NN	O
of	CC	O
specific	NN	O
organelles,	IN	O
such	JJ	O
as	,	O
mitochondria,	JJ	O
and	IN	O
new	,	O
contractile	CC	O
elements	JJ	O
are	NN	O
added	NNS	O
in	VBP	O
localized	VBN	O
areas	IN	O
of	JJ	O
the	NNS	O
cells,	IN	O
in	DT	O
an	,	O
irregular	IN	O
manner.	DT	O
Cells	JJ	O
subjected	.	O
to	NNS	O
long-standing	VBN	O
hypertrophy	TO	O
show	JJ	O
more	NN	O
obvious	NN	O
disruptions	RBR	O
in	JJ	O
cellular	NNS	O
organization,	IN	O
including	JJ	O
markedly	,	O
enlarged	VBG	O
nuclei	RB	O
with	VBD	O
highly	NNS	O
lobulated	IN	O
membranes,	RB	O
which	VBN	O
displace	,	O
adjacent	WDT	O
myofibrils	VBP	O
and	JJ	O
cause	NNS	O
breakdown	CC	O
of	VB	O
normal	NN	O
Z-band	IN	O
registration.	JJ	O
The	NNP	O
phrase	.	O
“cardiac	DT	O
hypertrophy”	NN	O
is	NNP	O
used	NN	O
to	VBZ	O
include	VBN	O
all	TO	O
stages	VB	O
of	DT	O
the	NNS	O
progression	IN	O
of	DT	O
this	NN	O
condition,	IN	O
characterized	DT	O
by	,	O
various	VBN	O
degrees	IN	O
of	JJ	O
structural	NNS	O
damage	IN	O
of	JJ	O
the	NN	O
heart	IN	O
muscle,	DT	O
regardless	NN	O
of	,	O
the	RB	O
underlying	IN	O
cardiac	DT	O
disorder.	JJ	O
Hence,	JJ	O
the	.	O
term	,	O
also	DT	O
includes	NN	O
physiological	RB	O
conditions	VBZ	O
instrumental	JJ	O
in	NNS	O
the	VBP	O
development	IN	O
of	DT	O
cardiac	NN	O
hypertrophy,	IN	O
such	JJ	O
as	,	O
elevated	JJ	O
blood	IN	O
pressure,	JJ	O
aortic	NN	O
stenosis,	,	O
or	JJ	O
myocardial	,	O
infarction.	CC	O
“Heart	JJ	O
failure”	.	O
refers	RB	O
to	VBZ	O
an	NNS	O
abnormality	TO	O
of	DT	O
cardiac	NN	O
function	IN	O
where	JJ	O
the	NN	O
heart	WRB	O
does	DT	O
not	NN	O
pump	VBZ	O
blood	RB	O
at	VB	O
the	NN	O
rate	IN	O
needed	DT	O
for	NN	O
the	VBN	O
requirements	IN	O
of	DT	O
metabolizing	NNS	O
tissues.	IN	O
The	VBG	O
heart	.	O
failure	DT	O
can	NN	O
be	NN	O
caused	MD	O
by	VB	O
a	VBN	O
number	IN	O
of	DT	O
factors,	NN	O
including	IN	O
ischemic,	,	O
congenital,	VBG	O
rheumatic,	,	O
or	,	O
idiopathic	,	O
forms.	CC	O
“Congestive	JJ	O
heart	.	O
failure”	JJ	O
(CHF)	NN	O
is	NN	O
a	)	O
progressive	VBZ	O
pathologic	DT	O
state	JJ	O
where	NN	O
the	NN	O
heart	WRB	O
is	DT	O
increasingly	NN	O
unable	VBZ	O
to	RB	O
supply	JJ	O
adequate	TO	O
cardiac	VB	O
output	JJ	O
(the	NNS	O
volume	NN	O
of	DT	O
blood	NN	O
pumped	IN	O
by	NN	O
the	VBN	O
heart	IN	O
over	DT	O
time)	NN	O
to	IN	O
deliver	)	O
the	TO	O
oxygenated	VB	O
blood	DT	O
to	JJ	O
peripheral	NN	O
tissues.	TO	O
As	JJ	O
CHF	.	O
progresses,	IN	O
structural	NNP	O
and	,	O
hemodynamic	JJ	O
damages	CC	O
occur.	JJ	O
While	NNS	O
these	.	O
damages	IN	O
have	DT	O
a	NNS	O
variety	VBP	O
of	DT	O
manifestations,	NN	O
one	IN	O
characteristic	,	O
symptom	CD	O
is	JJ	O
ventricular	NN	O
hypertrophy.	VBZ	O
CHF	JJ	O
is	.	O
a	NNP	O
common	VBZ	O
end	DT	O
result	JJ	O
of	NN	O
a	NN	O
number	IN	O
of	DT	O
various	NN	O
cardiac	IN	O
disorders.	JJ	O
“Myocardial	JJ	O
infarction”	.	O
generally	JJ	O
results	NN	O
from	RB	O
atherosclerosis	NNS	O
of	IN	O
the	NN	O
coronary	IN	O
arteries,	DT	O
often	JJ	O
with	,	O
superimposed	RB	O
coronary	IN	O
thrombosis.	JJ	O
It	JJ	O
may	.	O
be	PRP	O
divided	MD	O
into	VB	O
two	VBN	O
major	IN	O
types:	CD	O
transmural	JJ	O
infarcts,	:	O
in	JJ	O
which	,	O
myocardial	IN	O
necrosis	WDT	O
involves	JJ	O
the	NN	O
full	VBZ	O
thickness	DT	O
of	JJ	O
the	NN	O
ventricular	IN	O
wall,	DT	O
and	NN	O
subendocardial	,	O
(nontransmural)	CC	O
infarcts,	JJ	O
in	)	O
which	,	O
the	IN	O
necrosis	WDT	O
involves	DT	O
the	NN	O
subendocardium,	VBZ	O
the	DT	O
intramural	,	O
myocardium,	DT	O
or	JJ	O
both,	,	O
without	CC	O
extending	,	O
all	IN	O
the	VBG	O
way	PDT	O
through	DT	O
the	NN	O
ventricular	IN	O
wall	DT	O
to	JJ	O
the	NN	O
epicardium.	TO	O
Myocardial	DT	O
infarction	.	O
is	JJ	O
known	NN	O
to	VBZ	O
cause	VBN	O
both	TO	O
a	VB	O
change	DT	O
in	DT	O
hemodynamic	NN	O
effects	IN	O
and	JJ	O
an	NNS	O
alteration	CC	O
in	DT	O
structure	NN	O
in	IN	O
the	NN	O
damaged	IN	O
and	DT	O
healthy	VBN	O
zones	CC	O
of	JJ	O
the	NNS	O
heart.	IN	O
Thus,	DT	O
for	.	O
example,	,	O
myocardial	IN	O
infarction	,	O
reduces	JJ	O
the	NN	O
maximum	VBZ	O
cardiac	DT	O
output	JJ	O
and	JJ	O
the	NN	O
stroke	CC	O
volume	DT	O
of	NN	O
the	NN	O
heart.	IN	O
Also	DT	O
associated	.	O
with	RB	O
myocardial	VBN	O
infarction	IN	O
is	JJ	O
a	NN	O
stimulation	VBZ	O
of	DT	O
the	NN	O
DNA	IN	O
synthesis	DT	O
occurring	NNP	O
in	NN	O
the	VBG	O
interstice	IN	O
as	DT	O
well	NN	O
as	RB	O
an	RB	O
increase	IN	O
in	DT	O
the	NN	O
formation	IN	O
of	DT	O
collagen	NN	O
in	IN	O
the	NN	O
areas	IN	O
of	DT	O
the	NNS	O
heart	IN	O
not	DT	O
affected.	NN	O
As	RB	O
a	.	O
result	IN	O
of	DT	O
the	NN	O
increased	IN	O
stress	DT	O
or	JJ	O
strain	NN	O
placed	CC	O
on	NN	O
the	VBN	O
heart	IN	O
in	DT	O
prolonged	NN	O
hypertension	IN	O
due,	JJ	O
for	NN	O
example,	,	O
to	IN	O
the	,	O
increased	TO	O
total	DT	O
peripheral	VBN	O
resistance,	JJ	O
cardiac	JJ	O
hypertrophy	,	O
has	JJ	O
long	NN	O
been	VBZ	O
associated	RB	O
with	VBN	O
“hypertension”.	VBN	O
A	IN	O
characteristic	.	O
of	DT	O
the	NN	O
ventricle	IN	O
that	DT	O
becomes	NN	O
hypertrophic	WDT	O
as	VBZ	O
a	JJ	O
result	IN	O
of	DT	O
chronic	NN	O
pressure	IN	O
overload	JJ	O
is	NN	O
an	NN	O
impaired	VBZ	O
diastolic	DT	O
performance.	JJ	O
Fouad	JJ	B
et	.	I
al.,	NNP	I
J.	CC	I
Am.	,	I
Coll.	.	I
Cardiol.,	.	I
4:	.	I
1500-1506	,	I
(1984);	:	I
Smith	CD	B
et	:	I
al.,	NNP	I
J.	FW	I
Am.	,	I
Coll.	.	I
Cardiol.,	.	I
5:	.	I
869-874	,	I
(1985).	:	I
A	CD	O
prolonged	.	O
left	DT	O
ventricular	JJ	O
relaxation	NN	O
has	JJ	O
been	NN	O
detected	VBZ	O
in	VBN	O
early	VBN	O
essential	IN	O
hypertension,	JJ	O
in	JJ	O
spite	,	O
of	IN	O
normal	NN	O
or	IN	O
supranormal	JJ	O
systolic	CC	O
function.	JJ	O
Hartford	JJ	B
et	.	I
al.,	NNP	I
Hypertension,	CC	I
6:	,	I
329-338	,	I
(1984).	:	I
However,	CD	O
there	.	O
is	,	O
no	EX	O
close	VBZ	O
parallelism	DT	O
between	JJ	O
blood	NN	O
pressure	IN	O
levels	NN	O
and	NN	O
cardiac	NNS	O
hypertrophy.	CC	O
Although	JJ	O
improvement	.	O
in	IN	O
left	NN	O
ventricular	IN	O
function	JJ	O
in	JJ	O
response	NN	O
to	IN	O
antihypertensive	NN	O
therapy	TO	O
has	JJ	O
been	NN	O
reported	VBZ	O
in	VBN	O
humans,	VBN	O
patients	IN	O
variously	,	O
treated	NNS	O
with	RB	O
a	VBN	O
diuretic	IN	O
(hydrochlorothiazide),	DT	O
a	JJ	O
β-blocker	,	O
(propranolol),	DT	O
or	NN	O
a	,	O
calcium	CC	O
channel	DT	O
blocker	JJ	O
(diltiazem),	NN	O
have	NN	O
shown	,	O
reversal	VBP	O
of	VBN	O
left	NN	O
ventricular	IN	O
hypertrophy,	JJ	O
without	JJ	O
improvement	,	O
in	IN	O
diastolic	NN	O
function.	IN	O
Inouye	JJ	B
et	.	I
al.,	NNP	I
Am.	CC	I
J.	,	I
Cardiol.,	.	I
53:	.	I
1583-7	,	I
(1984).
Another	:	O
complex	CD	O
cardiac	.	O
disease	DT	O
associated	JJ	O
with	NN	O
cardiac	NN	O
hypertrophy	VBN	O
is	IN	O
“hypertrophic	JJ	O
cardiomyopathy”.	NN	O
This	VBZ	O
condition	JJ	O
is	.	O
characterized	DT	O
by	NN	O
a	VBZ	O
great	VBN	O
diversity	IN	O
of	DT	O
morphologic,	JJ	O
functional,	NN	O
and	IN	O
clinical	,	O
features	,	O
Maron	CC	B
et	JJ	I
al.,	NNS	I
N.	NNP	I
Engl.	RB	I
J.	,	I
Med.,	NNP	I
316:	.	I
780-789	.	I
(1987);	,	I
Spirito	:	B
et	CD	I
al.,	:	I
N.	NNP	I
Engl.	FW	I
J.	,	I
Med.,	NNP	I
320:	.	I
749-755	.	I
(1989);	,	I
Louie	:	B
and	CD	I
Edwards,	:	I
Prog.	NNP	I
Cardiovasc.	CC	I
Dis.,	,	I
36:	.	I
275-308	.	I
(1994);	,	I
Wigle	:	B
et	CD	I
al.,	:	I
Circulation,	NNP	I
92:	FW	I
1680-1692	,	I
(1995)),(	,	O
the	:	O
heterogeneity	CD	O
of	,	O
which	DT	O
is	NN	O
accentuated	IN	O
by	WDT	O
the	VBZ	O
fact	VBN	O
that	IN	O
it	DT	O
afflicts	NN	O
patients	IN	O
of	PRP	O
all	VBZ	O
ages.	NNS	O
Spirito	IN	B
et	DT	I
al.,	.	I
N.	NNP	I
Engl.	CC	I
J.	,	I
Med.,	NNP	I
336:	.	I
775-785	.	I
(1997).	,	I
The	:	O
causative	CD	O
factors	.	O
of	DT	O
hypertrophic	JJ	O
cardiomyopathy	NNS	O
are	IN	O
also	JJ	O
diverse	NN	O
and	VBP	O
little	RB	O
understood.	JJ	O
In	CC	O
general,	JJ	O
mutations	.	O
in	IN	O
genes	,	O
encoding	NNS	O
sarcomeric	IN	O
proteins	NNS	O
are	VBG	O
associated	JJ	O
with	NNS	O
hypertrophic	VBP	O
cardiomyopathy.	VBN	O
Recent	IN	O
data	JJ	O
suggest	.	O
that	JJ	O
β-myosin	NNS	O
heavy	VBP	O
chain	IN	O
mutations	JJ	O
may	JJ	O
account	NN	O
for	NNS	O
approximately	MD	O
30	VB	O
to	IN	O
40	RB	O
percent	CD	O
of	TO	O
cases	CD	O
of	NN	O
familial	IN	O
hypertrophic	NNS	O
cardiomyopathy.	IN	O
Watkins	JJ	B
et	JJ	I
al.,	.	I
N.	NNS	I
Engl.	VBP	I
J.	,	I
Med.,	NNP	I
326:	.	I
1108-1114	.	I
(1992);	,	I
Schwartz	:	B
et	CD	I
al,	:	I
Circulation,	NNP	I
91:	FW	I
532-540	,	I
(1995);	,	I
Marian	:	B
and	JJ	I
Roberts,	:	I
Circulation,	JJ	I
92:	CC	I
1336-1347	,	I
(1995);	,	I
Thierfelder	:	B
et	CD	I
al.,	:	I
Cell,	NNP	I
77:	FW	I
701-712	,	I
(1994);	,	I
Watkins	:	B
et	CD	I
al.,	:	I
Nat.	VBZ	I
Gen.,	FW	I
11:	,	I
434-437	.	I
(1995).	,	I
Besides	:	O
β-myosin	CD	O
heavy	.	O
chain,	IN	O
other	JJ	O
locations	JJ	O
of	,	O
genetic	JJ	O
mutations	NNS	O
include	IN	O
cardiac	JJ	O
troponin	NNS	O
T,	VBP	O
alpha	JJ	O
topomyosin,	NN	O
cardiac	,	O
myosin	NN	O
binding	,	O
protein	JJ	O
C,	NN	O
essential	VBG	O
myosin	NN	O
light	,	O
chain,	JJ	O
and	NN	O
regulatory	NN	O
myosin	,	O
light	CC	O
chain.	JJ	O
See,	NN	O
Malik	NN	B
and	.	I
Watkins,	,	I
Curr.	NNP	I
Opin.	CC	I
Cardiol.,	,	I
12:	.	I
295-302	.	I
(1997).
Supravalvular	,	O
“aortic	:	O
stenosis”	CD	O
is	.	O
an	JJ	O
inherited	JJ	O
vascular	NN	O
disorder	VBZ	O
characterized	DT	O
by	JJ	O
narrowing	JJ	O
of	NN	O
the	VBN	O
ascending	IN	O
aorta,	VBG	O
but	IN	O
other	DT	O
arteries,	VBG	O
including	,	O
the	CC	O
pulmonary	JJ	O
arteries,	,	O
may	VBG	O
also	DT	O
be	JJ	O
affected.	,	O
Untreated	MD	O
aortic	RB	O
stenosis	VB	O
may	.	O
lead	VBN	O
to	JJ	O
increased	NN	O
intracardiac	MD	O
pressure	VB	O
resulting	TO	O
in	JJ	O
myocardial	JJ	O
hypertrophy	NN	O
and	VBG	O
eventually	IN	O
heart	JJ	O
failure	NN	O
and	CC	O
death.	RB	O
The	NN	O
pathogenesis	NN	O
of	CC	O
this	.	O
disorder	DT	O
is	NN	O
not	IN	O
fully	DT	O
understood,	NN	O
but	VBZ	O
hypertrophy	RB	O
and	RB	O
possibly	,	O
hyperplasia	CC	O
of	NN	O
medial	CC	O
smooth	RB	O
muscle	NN	O
are	IN	O
prominent	JJ	O
features	JJ	O
of	NN	O
this	VBP	O
disorder.	JJ	O
It	NNS	O
has	IN	O
been	DT	O
reported	.	O
that	PRP	O
molecular	VBZ	O
variants	VBN	O
of	VBN	O
the	IN	O
elastin	JJ	O
gene	NNS	O
are	IN	O
involved	DT	O
in	JJ	O
the	NN	O
development	VBP	O
and	VBN	O
pathogenesis	IN	O
of	DT	O
aortic	NN	O
stenosis.	CC	O
U.S.	NN	O
Pat.	IN	O
No.	JJ	O
5,650,282	.	O
issued	NNP	O
Jul.	.	O
22,	.	O
1997.	CD	O
“Valvular	VBN	O
regurgitation”	.	O
occurs	,	O
as	.	O
a	JJ	O
result	NN	O
of	VBZ	O
heart	IN	O
diseases	DT	O
resulting	NN	O
in	IN	O
disorders	NN	O
of	NNS	O
the	VBG	O
cardiac	IN	O
valves.	NNS	O
Various	IN	O
diseases,	DT	O
like	JJ	O
rheumatic	.	O
fever,	JJ	O
can	,	O
cause	IN	O
the	JJ	O
shrinking	,	O
or	MD	O
pulling	VB	O
apart	DT	O
of	NN	O
the	CC	O
valve	VBG	O
orifice,	RB	O
while	IN	O
other	DT	O
diseases	NN	O
may	,	O
result	IN	O
in	JJ	O
endocarditis,	NNS	O
an	MD	O
inflammation	VB	O
of	IN	O
the	,	O
endocardium	DT	O
or	NN	O
lining	IN	O
membrane	DT	O
of	NN	O
the	CC	O
atrioventricular	VBG	O
orifices	NN	O
and	IN	O
operation	DT	O
of	JJ	O
the	NNS	O
heart.	CC	O
Defects	NN	O
such	IN	O
as	DT	O
the	.	O
narrowing	NNS	O
of	JJ	O
the	IN	O
valve	DT	O
stenosis	NN	O
or	IN	O
the	DT	O
defective	JJ	O
closing	NN	O
of	CC	O
the	DT	O
valve	JJ	O
result	NN	O
in	IN	O
an	DT	O
accumulation	NN	O
of	NN	O
blood	IN	O
in	DT	O
the	NN	O
heart	IN	O
cavity	NN	O
or	IN	O
regurgitation	DT	O
of	NN	O
blood	NN	O
past	CC	O
the	NN	O
valve.	IN	O
If	NN	O
uncorrected,	IN	O
prolonged	DT	O
valvular	.	O
stenosis	IN	O
or	,	O
insufficiency	VBD	O
may	JJ	O
result	NN	O
in	CC	O
cardiac	NN	O
hypertrophy	MD	O
and	VB	O
associated	IN	O
damage	JJ	O
to	NN	O
the	CC	O
heart	VBN	O
muscle,	NN	O
which	TO	O
may	DT	O
eventually	NN	O
necessitate	,	O
valve	WDT	O
replacement.	MD	O
The	RB	O
term	VB	O
“immune	JJ	O
related	.	O
disease”	DT	O
means	NN	O
a	NNP	O
disease	VBD	O
in	NN	O
which	VBZ	O
a	DT	O
component	NN	O
of	IN	O
the	WDT	O
immune	DT	O
system	NN	O
of	IN	O
a	DT	O
mammal	JJ	O
causes,	NN	O
mediates	IN	O
or	DT	O
otherwise	JJ	O
contributes	,	O
to	NNS	O
a	CC	O
morbidity	RB	O
in	NNS	O
the	TO	O
mammal.	DT	O
Also	NN	O
included	IN	O
are	DT	O
diseases	.	O
in	RB	O
which	VBN	O
stimulation	VBP	O
or	NNS	O
intervention	IN	O
of	WDT	O
the	NN	O
immune	CC	O
response	NN	O
has	IN	O
an	DT	O
ameliorative	JJ	O
effect	NN	O
on	VBZ	O
progression	DT	O
of	JJ	O
the	NN	O
disease.	IN	O
Included	NN	O
within	IN	O
this	DT	O
term	.	O
are	VBN	O
immune-mediated	IN	O
inflammatory	DT	O
diseases,	NN	O
non-immune-mediated	VBP	O
inflammatory	JJ	O
diseases,	JJ	O
infectious	,	O
diseases,	JJ	O
immunodeficiency	NN	O
diseases,	,	O
neoplasia,	JJ	O
etc.	,	O
The	NN	O
term	,	O
“T	,	O
cell	.	O
mediated	DT	O
disease”	NN	O
means	NNP	O
a	NN	O
disease	VBD	O
in	NN	O
which	VBZ	O
T	DT	O
cells	NN	O
directly	IN	O
or	WDT	O
indirectly	NNP	O
mediate	NNS	O
or	RB	O
otherwise	CC	O
contribute	RB	O
to	JJ	O
a	CC	O
morbidity	RB	O
in	JJ	O
a	TO	O
mammal.	DT	O
The	NN	O
T	IN	O
cell	DT	O
mediated	.	O
disease	DT	O
may	NNP	O
be	NN	O
associated	VBD	O
with	NN	O
cell	MD	O
mediated	VB	O
effects,	VBN	O
lymphokine	IN	O
mediated	NN	O
effects,	VBN	O
etc.,	,	O
and	NN	O
even	VBN	O
effects	,	O
associated	,	O
with	CC	O
B	RB	O
cells	NNS	O
if	VBN	O
the	IN	O
B	NNP	O
cells	NNS	O
are	IN	O
stimulated,	DT	O
for	NNP	O
example,	NNS	O
by	VBP	O
the	,	O
lymphokines	IN	O
secreted	,	O
by	IN	O
T	DT	O
cells.	NNS	O
Examples	VBN	O
of	IN	O
immune-related	NNP	O
and	.	O
inflammatory	NNS	O
diseases,	IN	O
some	JJ	O
of	CC	O
which	JJ	O
are	,	O
immune	DT	O
or	IN	O
T	WDT	O
cell	VBP	O
mediated,	JJ	O
include	CC	O
systemic	NNP	O
lupus	NN	O
erythematosis,	,	O
rheumatoid	VBP	O
arthritis,	JJ	O
juvenile	JJ	O
chronic	,	O
arthritis,	JJ	O
spondyloarthropathies,	,	O
systemic	NN	O
sclerosis	JJ	O
(scleroderma),	,	O
idiopathic	,	O
inflammatory	JJ	O
myopathies	NN	O
(dermatomyositis,	,	O
polymyositis),	JJ	O
Sjögren's	NN	O
syndrome,	NNS	O
systemic	,	O
vasculitis,	,	O
sarcoidosis,	POS	O
autoimmune	,	O
hemolytic	JJ	O
anemia	,	O
(immune	,	O
pancytopenia,	JJ	O
paroxysmal	JJ	O
nocturnal	NN	O
hemoglobinuria),	JJ	O
autoimmune	,	O
thrombocytopenia	JJ	O
(idiopathic	JJ	O
thrombocytopenic	,	O
purpura,	JJ	O
immune-mediated	NN	O
thrombocytopenia),	JJ	O
thyroiditis	NN	O
(Grave's	,	O
disease,	JJ	O
Hashimoto's	,	O
thyroiditis,	NN	O
juvenile	POS	O
lymphocytic	,	O
thyroiditis,	POS	O
atrophic	,	O
thyroiditis),	JJ	O
diabetes	JJ	O
mellitus,	,	O
immune-mediated	JJ	O
renal	,	O
disease	VBZ	O
(glomerulonephritis,	,	O
tubulointerstitial	JJ	O
nephritis),	JJ	O
demyelinating	NN	O
diseases	,	O
of	JJ	O
the	,	O
central	VBG	O
and	NNS	O
peripheral	IN	O
nervous	DT	O
systems	JJ	O
such	CC	O
as	JJ	O
multiple	JJ	O
sclerosis,	NNS	O
idiopathic	JJ	O
demyelinating	IN	O
polyneuropathy	JJ	O
or	,	O
Guillain-Barré	JJ	O
syndrome,	VBG	O
and	JJ	O
chronic	CC	O
inflammatory	JJ	O
demyelinating	,	O
polyneuropathy,	CC	O
hepatobiliary	JJ	O
diseases	NN	O
such	VBG	O
as	,	O
infectious	JJ	O
hepatitis	NNS	O
(hepatitis	JJ	O
A,	IN	O
B,	JJ	O
C,	NN	O
D,	VB	O
E	,	O
and	,	O
other	,	O
non-hepatotropic	,	O
viruses),	NNP	O
autoimmune	CC	O
chronic	JJ	O
active	JJ	O
hepatitis,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis,	JJ	O
granulomatous	,	O
hepatitis,	JJ	O
and	JJ	O
sclerosing	,	O
cholangitis,	JJ	O
inflammatory	,	O
bowel	CC	O
disease	VBG	O
(ulcerative	,	O
colitis:	JJ	O
Crohn's	NN	O
disease),	NN	O
gluten-sensitive	JJ	O
enteropathy,	:	O
and	POS	O
Whipple's	,	O
disease,	JJ	O
autoimmune	,	O
or	CC	O
immune-mediated	POS	O
skin	,	O
diseases	NN	O
including	CC	O
bullous	JJ	O
skin	NN	O
diseases,	NNS	O
erythema	VBG	O
multiforme	JJ	O
and	NN	O
contact	,	O
dermatitis,	NN	O
psoriasis,	NN	O
allergic	CC	O
diseases	NN	O
such	,	O
as	,	O
asthma,	JJ	O
allergic	NNS	O
rhinitis,	JJ	O
atopic	IN	O
dermatitis,	,	O
food	JJ	O
hypersensitivity	,	O
and	NN	O
urticaria,	,	O
immunologic	NN	O
diseases	NN	O
of	CC	O
the	,	O
lung	JJ	O
such	NNS	O
as	IN	O
eosinophilic	DT	O
pneumonia,	NN	O
idiopathic	JJ	O
pulmonary	IN	O
fibrosis	JJ	O
and	,	O
hypersensitivity	JJ	O
pneumonitis,	JJ	O
or	NN	O
transplantation	CC	O
associated	NN	O
diseases	,	O
including	CC	O
graft	NN	O
rejection	VBN	O
and	NNS	O
graft-versus-host-disease.	VBG	O
Infectious	NN	O
diseases	NN	O
including	CC	O
viral	.	O
diseases	JJ	O
such	NNS	O
as	VBG	O
AIDS	JJ	O
(HIV	NNS	O
infection),	JJ	O
hepatitis	IN	O
A,	NNP	O
B,	NNP	O
C,	,	O
D,	VBZ	O
and	,	O
E,	,	O
herpes,	,	O
etc.,	,	O
bacterial	CC	O
infections,	,	O
fungal	,	O
infections,	,	O
protozoal	JJ	O
infections	,	O
and	JJ	O
parasitic	,	O
infections.	NN	O
An	NNS	O
“autoimmune	CC	O
disease”	JJ	O
herein	.	O
is	DT	O
a	JJ	O
disease	NN	O
or	NN	O
disorder	VBZ	O
arising	DT	O
from	NN	O
and	CC	O
directed	NN	O
against	VBG	O
an	IN	O
individual's	CC	O
own	VBN	O
tissues	IN	O
or	DT	O
a	POS	O
co-segregate	JJ	O
or	NNS	O
manifestation	CC	O
thereof	DT	O
or	JJ	O
resulting	CC	O
condition	NN	O
therefrom.	NN	O
Examples	CC	O
of	VBG	O
autoimmune	NN	O
diseases	.	O
or	NNS	O
disorders	IN	O
include,	NN	O
but	NNS	O
are	CC	O
not	NNS	O
limited	,	O
to	CC	O
arthritis	VBP	O
(rheumatoid	RB	O
arthritis,	VBN	O
juvenile	TO	O
rheumatoid	VB	O
arthritis,	JJ	O
osteoarthritis,	,	O
psoriatic	NN	O
arthritis,	NN	O
and	,	O
ankylosing	,	O
spondylitis),	JJ	O
psoriasis,	,	O
dermatitis	CC	O
including	VBG	O
atopic	,	O
dermatitis;	,	O
chronic	NN	O
idiopathic	VBG	O
urticaria,	JJ	O
including	:	O
chronic	JJ	O
autoimmune	JJ	O
urticaria,	,	O
polymyositis/dermatomyositis,	VBG	O
toxic	JJ	O
epidermal	NN	O
necrolysis,	,	O
systemic	,	O
scleroderma	JJ	O
and	JJ	O
sclerosis,	,	O
responses	JJ	O
associated	NN	O
with	CC	O
inflammatory	,	O
bowel	NNS	O
disease	VBN	O
(IBD)	IN	O
(Crohn's	JJ	O
disease,	NN	O
ulcerative	NN	O
colitis),	)	O
and	POS	O
IBD	,	O
with	JJ	O
co-segregate	,	O
of	CC	O
pyoderma	NNP	O
gangrenosum,	IN	O
erythema	NN	O
nodosum,	IN	O
primary	NN	O
sclerosing	,	O
cholangitis,	NN	O
and/or	,	O
episcleritis),	JJ	O
respiratory	VBG	O
distress	,	O
syndrome,	JJ	O
including	,	O
adult	JJ	O
respiratory	NN	O
distress	,	O
syndrome	VBG	O
(ARDS),	NN	O
meningitis,	NN	O
IgE-mediated	NN	O
diseases	NN	O
such	,	O
as	,	O
anaphylaxis	JJ	O
and	NNS	O
allergic	JJ	O
rhinitis,	IN	O
encephalitis	NN	O
such	CC	O
as	JJ	O
Rasmussen's	,	O
encephalitis,	NN	O
uveitis,	JJ	O
colitis	IN	O
such	POS	O
as	,	O
microscopic	,	O
colitis	NN	O
and	JJ	O
collagenous	IN	O
colitis,	NN	O
glomerulonephritis	NN	O
(GN)	CC	O
such	JJ	O
as	,	O
membranous	NN	O
GN,	)	O
idiopathic	JJ	O
membranous	IN	O
GN,	JJ	O
membranous	,	O
proliferative	JJ	O
GN	JJ	O
(MPGN),	,	O
including	JJ	O
Type	JJ	O
I	NNP	O
and	,	O
Type	VBG	O
II,	NN	O
and	PRP	O
rapidly	CC	O
progressive	NNP	O
GN,	,	O
allergic	CC	O
conditions,	RB	O
eczema,	JJ	O
asthma,	,	O
conditions	JJ	O
involving	,	O
infiltration	,	O
of	,	O
T	NNS	O
cells	VBG	O
and	NN	O
chronic	IN	O
inflammatory	NNP	O
responses,	NNS	O
atherosclerosis,	CC	O
autoimmune	JJ	O
myocarditis,	NN	O
leukocyte	,	O
adhesion	,	O
deficiency,	JJ	O
systemic	,	O
lupus	JJ	O
erythematosus	NN	O
(SLE)	,	O
such	JJ	O
as	NN	O
cutaneous	NN	O
SLE,	)	O
lupus	JJ	O
(including	IN	O
nephritis,	JJ	O
cerebritis,	,	O
pediatric,	NN	O
non-renal,	VBG	O
discoid,	,	O
alopecia),	,	O
juvenile	,	O
onset	,	O
diabetes,	,	O
multiple	,	O
sclerosis	JJ	O
(MS)	NN	O
such	,	O
as	JJ	O
spino-optical	NN	O
MS,	)	O
allergic	JJ	O
encephalomyelitis,	IN	O
immune	JJ	O
responses	,	O
associated	JJ	O
with	,	O
acute	JJ	O
and	NNS	O
delayed	VBN	O
hypersensitivity	IN	O
mediated	NN	O
by	CC	O
cytokines	JJ	O
and	NN	O
T-lymphocytes,	VBN	O
tuberculosis,	IN	O
sarcoidosis,	NNS	O
granulomatosis	CC	O
including	,	O
Wegener's	,	O
granulomatosis,	,	O
agranulocytosis,	NN	O
vasculitis	VBG	O
(including	POS	O
Large	,	O
Vessel	,	O
vasculitis	NN	O
(including	VBG	O
Polymyalgia	NNP	O
Rheumatica	NNP	O
and	NN	O
Giant	VBG	O
Cell	NNP	O
(Takayasu's)	NNP	O
Arteritis),	CC	O
Medium	NNP	O
Vessel	NNP	O
vasculitis	)	O
(including	,	O
Kawasaki's	NNP	O
Disease	NNP	O
and	NN	O
Polyarteritis	VBG	O
Nodosa),	POS	O
CNS	NNP	O
vasculitis,	CC	O
and	NNP	O
ANCA-associated	,	O
vasculitis,	NNP	O
such	,	O
as	CC	O
Churg-Strauss	NNP	O
vasculitis	,	O
or	JJ	O
syndrome	IN	O
(CSS)),	NNP	O
aplastic	NN	O
anemia,	CC	O
Coombs	NN	O
positive	,	O
anemia,	JJ	O
Diamond	,	O
Blackfan	NNP	O
anemia,	JJ	O
immune	,	O
hemolytic	NNP	O
anemia	NNP	O
including	,	O
autoimmune	JJ	O
hemolytic	JJ	O
anemia	NN	O
(AIHA),	VBG	O
pernicious	JJ	O
anemia,	JJ	O
pure	NN	O
red	,	O
cell	JJ	O
aplasia	,	O
(PRCA),	NN	O
Factor	JJ	O
VIII	NN	O
deficiency,	NN	O
hemophilia	,	O
A,	NNP	O
autoimmune	NNP	O
neutropenia,	,	O
pancytopenia,	VB	O
leukopenia,	,	O
diseases	NN	O
involving	,	O
leukocyte	,	O
diapedesis,	,	O
CNS	VBZ	O
inflammatory	VBG	O
disorders,	JJ	O
multiple	,	O
organ	NNP	O
injury	NN	O
syndrome,	,	O
myasthenia	JJ	O
gravis,	JJ	O
antigen-antibody	NN	O
complex	,	O
mediated	NN	O
diseases,	,	O
anti-glomerular	NN	O
basement	NN	O
membrane	VBD	O
disease,	,	O
anti-phospholipid	JJ	O
antibody	NN	O
syndrome,	NN	O
allergic	,	O
neuritis,	JJ	O
Bechet	NN	O
disease,	,	O
Castleman's	JJ	O
syndrome,	,	O
Goodpasture's	NNP	O
Syndrome,	,	O
Lambert-Eaton	POS	O
Myasthenic	,	O
Syndrome,	POS	O
Reynaud's	,	O
syndrome,	NNP	O
Sjorgen's	NNP	O
syndrome,	,	O
Stevens-Johnson	POS	O
syndrome,	,	O
solid	POS	O
organ	,	O
transplant	NNP	O
rejection	,	O
(including	JJ	O
pretreatment	NN	O
for	JJ	O
high	NN	O
panel	VBG	O
reactive	NN	O
antibody	IN	O
titers,	JJ	O
IgA	NN	O
deposit	NN	O
in	NN	O
tissues,	,	O
and	NNP	O
rejection	NN	O
arising	IN	O
from	,	O
renal	CC	O
transplantation,	NN	O
liver	VBG	O
transplantation,	IN	O
intestinal	JJ	O
transplantation,	,	O
cardiac	JJ	O
transplantation,	,	O
etc.),	JJ	O
graft	,	O
versus	JJ	O
host	,	O
disease	,	O
(GVHD),	JJ	O
pemphigoid	NN	O
bullous,	NN	O
pemphigus	NN	O
(including	,	O
vulgaris,	RB	O
foliaceus,	,	O
and	JJ	O
pemphigus	VBG	O
mucus-membrane	,	O
pemphigoid),	,	O
autoimmune	CC	O
polyendocrinopathies,	JJ	O
Reiter's	JJ	O
disease,	,	O
stiff-man	JJ	O
syndrome,	,	O
immune	POS	O
complex	,	O
nephritis,	JJ	O
IgM	,	O
polyneuropathies	NN	O
or	JJ	O
IgM	,	O
mediated	NNP	O
neuropathy,	VBZ	O
idiopathic	CC	O
thrombocytopenic	NNP	O
purpura	VBD	O
(ITP),	,	O
thrombotic	JJ	O
throbocytopenic	JJ	O
purpura	NN	O
(TTP),	,	O
thrombocytopenia	JJ	O
(as	NN	O
developed	NN	O
by	,	O
myocardial	RB	O
infarction	IN	O
patients,	VBN	O
for	IN	O
example),	JJ	O
including	NN	O
autoimmune	,	O
thrombocytopenia,	IN	O
autoimmune	,	O
disease	VBG	O
of	JJ	O
the	,	O
testis	JJ	O
and	NN	O
ovary	IN	O
including	DT	O
autoimmune	NN	O
orchitis	CC	O
and	JJ	O
oophoritis,	VBG	O
primary	JJ	O
hypothyroidism;	NN	O
autoimmune	CC	O
endocrine	,	O
diseases	JJ	O
including	:	O
autoimmune	CC	O
thyroiditis,	VBP	O
chronic	NNS	O
thyroiditis	VBG	O
(Hashimoto's	NN	O
Thyroiditis),	,	O
subacute	JJ	O
thyroiditis,	NN	O
idiopathic	POS	O
hypothyroidism,	,	O
Addison's	JJ	O
disease,	,	O
Grave's	JJ	O
disease,	,	O
autoimmune	POS	O
polyglandular	,	O
syndromes	POS	O
(or	,	O
polyglandular	JJ	O
endocrinopathy	JJ	O
syndromes),	NNS	O
Type	CC	O
I	VB	O
diabetes	JJ	O
also	,	O
referred	NNP	O
to	PRP	O
as	VBZ	O
insulin-dependent	RB	O
diabetes	VBN	O
mellitus	TO	O
(IDDM),	IN	O
including	JJ	O
pediatric	NNS	O
IDDM,	FW	O
and	,	O
Sheehan's	VBG	O
syndrome;	JJ	O
autoimmune	,	O
hepatitis,	CC	O
Lymphoid	POS	O
interstitial	:	O
pneumonitis	CC	O
(HIV),	,	O
bronchiolitis	NNP	O
obliterans	JJ	O
(non-transplant)	NN	O
vs	,	O
NSIP,	NN	O
Guillain-Barré	NNS	O
Syndrome,	)	O
Berger's	NN	O
Disease	,	O
(IgA	NNP	O
nephropathy),	,	O
primary	POS	O
biliary	NNP	O
cirrhosis,	NNP	O
celiac	,	O
sprue	JJ	O
(gluten	JJ	O
enteropathy),	,	O
refractory	JJ	O
sprue	NN	O
with	VB	O
co-segregate	,	O
dermatitis	JJ	O
herpetiformis,	NN	O
cryoglobulinemia,	IN	O
amylotrophic	JJ	O
lateral	NN	O
sclerosis	,	O
(ALS;	,	O
Lou	JJ	O
Gehrig's	JJ	O
disease),	NN	O
coronary	:	O
artery	NNP	O
disease,	POS	O
autoimmune	,	O
inner	JJ	O
ear	NN	O
disease	,	O
(AIED),	JJ	O
autoimmune	JJ	O
hearing	JJ	O
loss,	NN	O
opsoclonus	,	O
myoclonus	JJ	O
syndrome	NN	O
(OMS),	,	O
polychondritis	JJ	O
such	NN	O
as	NN	O
refractory	,	O
polychondritis,	NN	O
pulmonary	JJ	O
alveolar	IN	O
proteinosis,	NN	O
amyloidosis,	,	O
giant	JJ	O
cell	JJ	O
hepatitis,	,	O
scleritis,	,	O
monoclonal	JJ	O
gammopathy	NN	O
of	,	O
uncertain/unknown	,	O
significance	JJ	O
(MGUS),	NN	O
peripheral	IN	O
neuropathy,	JJ	O
paraneoplastic	NN	O
syndrome,	,	O
channelopathies	JJ	O
such	,	O
as	JJ	O
epilepsy,	,	O
migraine,	NNS	O
arrhythmia,	JJ	O
muscular	IN	O
disorders,	,	O
deafness,	,	O
blindness,	,	O
periodic	JJ	O
paralysis,	,	O
and	,	O
channelopathies	,	O
of	JJ	O
the	,	O
CNS;	CC	O
autism,	NNS	O
inflammatory	IN	O
myopathy,	DT	O
and	:	O
focal	,	O
segmental	JJ	O
glomerulosclerosis	,	O
(FSGS).	CC	O
The	JJ	O
phrase	JJ	O
“anxiety	NN	O
related	.	O
disorders”	DT	O
refers	NN	O
to	NN	O
disorders	VBN	O
of	JJ	O
anxiety,	NNS	O
mood,	TO	O
and	NNS	O
substance	IN	O
abuse,	,	O
including	,	O
but	CC	O
not	NN	O
limited	,	O
to:	VBG	O
depression,	CC	O
generalized	RB	O
anxiety	JJ	O
disorders,	:	O
attention	,	O
deficit	VBN	O
disorder,	NN	O
sleep	,	O
disorder,	NN	O
hyperactivity	NN	O
disorder,	,	O
obsessive	JJ	O
compulsive	,	O
disorder,	NN	O
schizophrenia,	,	O
cognitive	JJ	O
disorders,	JJ	O
hyperalgesia	,	O
and	,	O
sensory	JJ	O
disorders.	,	O
Such	NN	O
disorders	CC	O
include	JJ	O
the	.	O
mild	JJ	O
to	NNS	O
moderate	VBP	O
anxiety,	DT	O
anxiety	NN	O
disorder	TO	O
due	VB	O
to	,	O
a	NN	O
general	NN	O
medical	JJ	O
condition,	TO	O
anxiety	DT	O
disorder	JJ	O
not	JJ	O
otherwise	,	O
specified,	NN	O
generalized	NN	O
anxiety	RB	O
disorder,	RB	O
panic	,	O
attack,	VBN	O
panic	NN	O
disorder	,	O
with	JJ	O
agoraphobia,	,	O
panic	JJ	O
disorder	NN	O
without	IN	O
agoraphobia,	,	O
posttraumatic	JJ	O
stress	NN	O
disorder,	IN	O
social	,	O
phobia,	JJ	O
social	NN	O
anxiety,	,	O
autism,	JJ	O
specific	,	O
phobia,	JJ	O
substance-induced	,	O
anxiety	,	O
disorder,	JJ	O
acute	,	O
alcohol	JJ	O
withdrawal,	NN	O
obsessive	,	O
compulsive	JJ	O
disorder,	NN	O
agoraphobia,	,	O
monopolar	JJ	O
disorders,	JJ	O
bipolar	,	O
disorder	,	O
I	JJ	O
or	,	O
II,	JJ	O
bipolar	NN	O
disorder	PRP	O
not	CC	O
otherwise	,	O
specified,	JJ	O
cyclothymic	NN	O
disorder,	RB	O
depressive	RB	O
disorder,	,	O
major	JJ	O
depressive	,	O
disorder,	JJ	O
mood	,	O
disorder,	JJ	O
substance-induced	JJ	O
mood	,	O
disorder,	NN	O
enhancement	,	O
of	JJ	O
cognitive	NN	O
function,	,	O
loss	NN	O
of	IN	O
cognitive	JJ	O
function	,	O
associated	NN	O
with	IN	O
but	JJ	O
not	NN	O
limited	VBN	O
to	IN	O
Alzheimer's	CC	O
disease,	RB	O
stroke,	JJ	O
or	TO	O
traumatic	POS	O
injury	,	O
to	,	O
the	CC	O
brain,	JJ	O
seizures	NN	O
resulting	TO	O
from	DT	O
disease	,	O
or	NNS	O
injury	VBG	O
including	IN	O
but	NN	O
not	CC	O
limited	NN	O
to	VBG	O
epilepsy,	CC	O
learning	RB	O
disorders/disabilities,	JJ	O
cerebral	TO	O
palsy.	,	O
In	VBG	O
addition,	,	O
anxiety	JJ	O
disorders	.	O
may	IN	O
apply	,	O
to	NN	O
personality	NNS	O
disorders	MD	O
including	VB	O
but	TO	O
not	NN	O
limited	NNS	O
to	VBG	O
the	CC	O
following	RB	O
types:	JJ	O
paranoid,	TO	O
antisocial,	DT	O
avoidant	JJ	O
behavior,	:	O
borderline	,	O
personality	,	O
disorders,	JJ	O
dependent,	,	O
histronic,	JJ	O
narcissistic,	NN	O
obsessive-compulsive,	,	O
schizoid,	,	O
and	,	O
schizotypal.	,	O
The	,	O
term	,	O
“lipid	CC	O
metabolic	.	O
disorder”	DT	O
refers	NN	O
to	NNP	O
abnormal	NN	O
clinical	NN	O
chemistry	NNS	O
levels	TO	O
of	VB	O
cholesterol	JJ	O
and	NN	O
triglycerides,	NNS	O
wherein	IN	O
elevated	NN	O
levels	CC	O
of	,	O
these	RB	O
lipids	JJ	O
is	NNS	O
an	IN	O
indication	DT	O
for	NNS	O
atherosclerosis.	VBZ	O
Additionally,	DT	O
abnormal	NN	O
serum	IN	O
lipid	.	O
levels	,	O
may	JJ	O
be	NN	O
an	JJ	O
indication	NNS	O
of	MD	O
various	VB	O
cardiovascular	DT	O
diseases	NN	O
including	IN	O
hypertension,	JJ	O
stroke,	JJ	O
coronary	NNS	O
artery	VBG	O
diseases,	,	O
diabetes	,	O
and/or	JJ	O
obesity.	NN	O
The	,	O
phrase	VBZ	O
“eye	JJ	O
abnormality”	.	O
refers	DT	O
to	NN	O
such	NNP	O
potential	VBZ	O
disorders	NNS	O
of	TO	O
the	JJ	O
eye	JJ	O
as	NNS	O
they	IN	O
may	DT	O
be	NN	O
related	IN	O
to	PRP	O
atherosclerosis	MD	O
or	VB	O
various	VBN	O
ophthalmological	TO	O
abnormalities.	VB	O
Such	CC	O
disorders	JJ	O
include	JJ	O
but	.	O
are	JJ	O
not	NNS	O
limited	VBP	O
to	CC	O
the	VBP	O
following:	RB	O
retinal	VBN	O
dysplasia,	TO	O
various	DT	O
retinopathies,	:	O
restenosis,	JJ	O
retinal	,	O
artery	JJ	O
obstruction	,	O
or	,	O
occlusion;	JJ	O
retinal	NN	O
degeneration	NN	O
causing	CC	O
secondary	:	O
atrophy	JJ	O
of	NN	O
the	VBG	O
retinal	JJ	O
vasculature,	NN	O
retinitis	IN	O
pigmentosa,	DT	O
macular	JJ	O
dystrophies,	,	O
Stargardt's	NN	O
disease,	,	O
congenital	JJ	O
stationary	,	O
night	POS	O
blindness,	,	O
choroideremia,	JJ	O
gyrate	JJ	O
atrophy,	NN	O
Leber's	,	O
congenital	,	O
amaurosis,	NN	O
retinoschisis	,	O
disorders,	POS	O
Wagner's	JJ	O
syndrome,	,	O
Usher	NN	O
syndromes,	,	O
Zellweger	POS	O
syndrome,	,	O
Saldino-Mainzer	NNP	O
syndrome,	,	O
Senior-Loken	NNP	O
syndrome,	,	O
Bardet-Biedl	NNP	O
syndrome,	,	O
Alport's	NNP	O
syndrome,	,	O
Alstrom's	NNP	O
syndrome,	,	O
Cockayne's	POS	O
syndrome,	,	O
dysplaisa	POS	O
spondyloepiphysaria	,	O
congentia,	POS	O
Flynn-Aird	,	O
syndrome,	JJ	O
Friedreich	NN	O
ataxia,	,	O
Hallgren	NNP	O
syndrome,	,	O
Marshall	NNP	O
syndrome,	,	O
Albers-Schnoberg	NNP	O
disease,	,	O
Refsum's	NNP	O
disease,	,	O
Kearns-Sayre	NNP	O
syndrome,	,	O
Waardenburg's	POS	O
syndrome,	,	O
Alagile	NNP	O
syndrome,	,	O
myotonic	POS	O
dystrophy,	,	O
olivopontocerebellar	NNP	O
atrophy,	,	O
Pierre-Marie	JJ	O
dunsdrome,	,	O
Stickler	JJ	O
syndrome,	,	O
carotinemeia,	NNP	O
cystinosis,	,	O
Wolfram	NNP	O
syndrome,	,	O
Bassen-Kornzweig	,	O
syndrome,	,	O
abetalipoproteinemia,	NNP	O
incontinentia	,	O
pigmenti,	NNP	O
Batten's	,	O
disease,	,	O
mucopolysaccharidoses,	NN	O
homocystinuria,	,	O
or	POS	O
mannosidosis.	,	O
Cataracts	,	O
are	,	O
also	CC	O
considered	.	O
an	NNS	O
eye	VBP	O
abnormality	RB	O
and	VBN	O
are	DT	O
associated	NN	O
with	NN	O
such	CC	O
systemic	VBP	O
diseases	VBN	O
as:	IN	O
Human	JJ	O
Down's	JJ	O
syndrome,	NNS	O
Hallerman-Streiff	:	O
syndrome,	NNP	O
Lowe	POS	O
syndrome,	,	O
galactosemia,	NNP	O
Marfan	,	O
syndrome,	NNP	O
Trismoy	,	O
13-15	,	O
condition,	NNP	O
Alport	,	O
syndrome,	NNP	O
myotonic	CD	O
dystrophy,	,	O
Fabry	NNP	O
disease,	,	O
hypothroidisms,	JJ	O
or	,	O
Conradi	NNP	O
syndrome.	,	O
Other	,	O
ocular	CC	O
developmental	NNP	O
anomalies	.	O
include:	JJ	O
Aniridia,	JJ	O
anterior	JJ	O
segment	NNS	O
and	:	O
dysgenesis	,	O
syndrome.	JJ	O
Cataracts	NN	O
may	CC	O
also	NN	O
occur	.	O
as	NNS	O
a	MD	O
result	RB	O
of	VB	O
an	IN	O
intraocular	DT	O
infection	NN	O
or	IN	O
inflammation	DT	O
(uveitis).	JJ	O
A	NN	O
“growth	CC	O
inhibitory	NN	O
amount”	.	O
of	DT	O
an	NN	O
anti-PRO227,	JJ	O
anti-PRO233,	NN	O
anti-PRO238,	IN	O
anti-PRO1328,	DT	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibody,	,	O
PRO227,	JJ	O
PRO233,	CC	O
PRO238,	JJ	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide,	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
oligopeptide	NNP	O
or	CC	O
PRO227,	NNP	O
PRO233,	VBG	O
PRO238,	RB	O
PRO1328,	CC	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
organic	NNP	O
molecule	CC	O
is	NNP	O
an	VBG	O
amount	JJ	O
capable	NN	O
of	VBZ	O
inhibiting	DT	O
the	NN	O
growth	JJ	O
of	IN	O
a	VBG	O
cell,	DT	O
especially	NN	O
tumor,	IN	O
e.g.,	DT	O
cancer	,	O
cell,	RB	O
either	,	O
in	,	O
vitro	NN	O
or	,	O
in	RB	O
vivo.	IN	O
A	NN	O
“growth	CC	O
inhibitory	IN	O
amount”	.	O
of	DT	O
an	NN	O
anti-PRO227,	JJ	O
anti-PRO233,	NN	O
anti-PRO238,	IN	O
anti-PRO1328,	DT	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibody,	,	O
PRO227,	JJ	O
PRO233,	CC	O
PRO238,	JJ	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide,	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
oligopeptide	NNP	O
or	CC	O
PRO227,	NNP	O
PRO233,	VBG	O
PRO238,	RB	O
PRO1328,	CC	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
organic	NNP	O
molecule	CC	O
for	NNP	O
purposes	VBG	O
of	JJ	O
inhibiting	NN	O
neoplastic	IN	O
cell	NNS	O
growth	IN	O
may	VBG	O
be	JJ	O
determined	NN	O
empirically	NN	O
and	MD	O
in	VB	O
a	VBN	O
routine	RB	O
manner.	CC	O
A	IN	O
“cytotoxic	DT	O
amount”	JJ	O
of	.	O
an	DT	O
anti-PRO227,	JJ	O
anti-PRO233,	NN	O
anti-PRO238,	IN	O
anti-PRO1328,	DT	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibody,	,	O
PRO227,	JJ	O
PRO233,	CC	O
PRO238,	JJ	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide,	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
oligopeptide	NNP	O
or	CC	O
PRO227,	NNP	O
PRO233,	VBG	O
PRO238,	RB	O
PRO1328,	CC	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
organic	NNP	O
molecule	CC	O
is	NNP	O
an	VBG	O
amount	JJ	O
capable	NN	O
of	VBZ	O
causing	DT	O
the	NN	O
destruction	JJ	O
of	IN	O
a	VBG	O
cell,	DT	O
especially	NN	O
tumor,	IN	O
e.g.,	DT	O
cancer	,	O
cell,	RB	O
either	,	O
in	,	O
vitro	NN	O
or	,	O
in	RB	O
vivo.	IN	O
A	NN	O
“cytotoxic	CC	O
amount”	IN	O
of	.	O
an	DT	O
anti-PRO227,	JJ	O
anti-PRO233,	NN	O
anti-PRO238,	IN	O
anti-PRO1328,	DT	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibody,	,	O
PRO227,	JJ	O
PRO233,	CC	O
PRO238,	JJ	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide,	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
oligopeptide	NNP	O
or	CC	O
PRO227,	NNP	O
PRO233,	VBG	O
PRO238,	RB	O
PRO1328,	CC	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
binding	,	O
organic	NNP	O
molecule	CC	O
for	NNP	O
purposes	VBG	O
of	JJ	O
inhibiting	NN	O
neoplastic	IN	O
cell	NNS	O
growth	IN	O
may	VBG	O
be	JJ	O
determined	NN	O
empirically	NN	O
and	MD	O
in	VB	O
a	VBN	O
routine	RB	O
manner.	CC	O
The	IN	O
term	DT	O
“antibody”	JJ	O
is	.	O
used	DT	O
in	NN	O
the	NNP	O
broadest	VBZ	O
sense	VBN	O
and	IN	O
specifically	DT	O
covers,	JJS	O
for	NN	O
example,	CC	O
single	RB	O
anti-PRO227,	,	O
anti-PRO233,	IN	O
anti-PRO238,	,	O
anti-PRO1328,	JJ	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
monoclonal	,	O
antibodies	JJ	O
(including	CC	O
agonist,	JJ	O
antagonist,	JJ	O
and	NNS	O
neutralizing	VBG	O
antibodies),	,	O
anti-PRO227,	,	O
anti-PRO233,	CC	O
anti-PRO238,	VBG	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibody	,	O
compositions	JJ	O
with	CC	O
polyepitopic	JJ	O
specificity,	NN	O
polyclonal	NNS	O
antibodies,	IN	O
single	NN	O
chain	,	O
anti-PRO227,	JJ	O
anti-PRO233,	,	O
anti-PRO238,	JJ	O
anti-PRO1328,	NN	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibodies,	,	O
and	JJ	O
fragments	CC	O
of	JJ	O
anti-PRO227,	,	O
anti-PRO233,	CC	O
anti-PRO238,	NNS	O
anti-PRO1328,	IN	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	,	O
or	,	O
anti-PRO1885	,	O
antibodies	,	O
(see	JJ	O
below)	CC	O
as	JJ	O
long	NNS	O
as	VB	O
they	)	O
exhibit	RB	O
the	RB	O
desired	IN	O
biological	PRP	O
or	VBP	O
immunological	DT	O
activity.	JJ	O
The	JJ	O
term	CC	O
“immunoglobulin”	JJ	O
(Ig)	.	O
is	DT	O
used	NN	O
interchangeable	NNP	O
with	)	O
antibody	VBZ	O
herein.	VBN	O
An	JJ	O
“isolated	IN	O
antibody”	NN	O
is	.	O
one	DT	O
which	JJ	O
has	NN	O
been	VBZ	O
identified	CD	O
and	WDT	O
separated	VBZ	O
and/or	VBN	O
recovered	VBN	O
from	CC	O
a	VBN	O
component	NNS	O
of	VBN	O
its	IN	O
natural	DT	O
environment.	NN	O
Contaminant	IN	O
components	PRP$	O
of	JJ	O
its	.	O
natural	JJ	O
environment	NNS	O
are	IN	O
materials	PRP$	O
which	JJ	O
would	NN	O
interfere	VBP	O
with	NNS	O
diagnostic	WDT	O
or	MD	O
therapeutic	VB	O
uses	IN	O
for	JJ	O
the	CC	O
antibody,	JJ	O
and	NNS	O
may	IN	O
include	DT	O
enzymes,	,	O
hormones,	CC	O
and	MD	O
other	VB	O
proteinaceous	,	O
or	,	O
nonproteinaceous	CC	O
solutes.	JJ	O
The	JJ	O
invention	CC	O
provides	JJ	O
that	.	O
the	DT	O
antibody	NN	O
will	VBZ	O
be	IN	O
purified	DT	O
(1)	NN	O
to	MD	O
greater	VB	O
than	VBN	O
95%	)	O
by	TO	O
weight	JJR	O
of	IN	O
antibody	NN	O
as	IN	O
determined	NN	O
by	IN	O
the	NN	O
Lowry	IN	O
method,	VBN	O
and	IN	O
most	DT	O
preferably	NNP	O
more	,	O
than	CC	O
99%	JJS	O
by	RB	O
weight,	JJR	O
(2)	IN	O
to	NN	O
a	IN	O
degree	,	O
sufficient	)	O
to	TO	O
obtain	DT	O
at	JJ	O
least	NN	O
15	TO	O
residues	VB	O
of	IN	O
N-terminal	JJS	O
or	CD	O
internal	NNS	O
amino	IN	O
acid	NNP	O
sequence	CC	O
by	JJ	O
use	NN	O
of	NNS	O
a	NN	O
spinning	IN	O
cup	NN	O
sequenator,	IN	O
or	DT	O
(3)	JJ	O
to	NN	O
homogeneity	,	O
by	CC	O
SDS-PAGE	)	O
under	TO	O
reducing	NN	O
or	IN	O
nonreducing	NNP	O
conditions	IN	O
using	VBG	O
Coomassie	CC	O
blue	JJ	O
or,	NNS	O
preferably,	VBG	O
silver	NNP	O
stain.	NN	O
Isolated	,	O
antibody	,	O
includes	RB	O
the	.	O
antibody	VBN	O
in	NN	O
situ	VBZ	O
within	DT	O
recombinant	NN	O
cells	IN	O
since	NN	O
at	IN	O
least	JJ	O
one	NNS	O
component	IN	O
of	IN	O
the	JJS	O
antibody's	CD	O
natural	NN	O
environment	IN	O
will	DT	O
not	POS	O
be	JJ	O
present.	NN	O
Ordinarily,	MD	O
however,	RB	O
isolated	VB	O
antibody	.	O
will	,	O
be	,	O
prepared	VBN	O
by	NN	O
at	MD	O
least	VB	O
one	VBN	O
purification	IN	O
step.	IN	O
The	JJS	O
basic	CD	O
4-chain	NN	O
antibody	.	O
unit	DT	O
is	JJ	O
a	JJ	O
heterotetrameric	NN	O
glycoprotein	NN	O
composed	VBZ	O
of	DT	O
two	JJ	O
identical	NN	O
light	VBN	O
(L)	IN	O
chains	CD	O
and	JJ	O
two	NN	O
identical	)	O
heavy	NNS	O
(H)	CC	O
chains	CD	O
(an	JJ	O
IgM	NN	O
antibody	)	O
consists	NNS	O
of	DT	O
5	NNP	O
of	NN	O
the	VBZ	O
basic	IN	O
heterotetramer	CD	O
unit	IN	O
along	DT	O
with	JJ	O
an	NN	O
additional	NN	O
polypeptide	IN	O
called	IN	O
J	DT	O
chain,	JJ	O
and	NN	O
therefore	VBN	O
contain	NNP	O
10	,	O
antigen	CC	O
binding	RB	O
sites,	VBP	O
while	CD	O
secreted	NN	O
IgA	NN	O
antibodies	,	O
can	IN	O
polymerize	VBN	O
to	NNP	O
form	NNS	O
polyvalent	MD	O
assemblages	VB	O
comprising	TO	O
2-5	VB	O
of	NN	O
the	NNS	O
basic	VBG	O
4-chain	CD	O
units	IN	O
along	DT	O
with	JJ	O
J	JJ	O
chain).	NNS	O
In	IN	O
the	IN	O
case	NNP	O
of	.	O
IgGs,	IN	O
the	DT	O
4-chain	NN	O
unit	IN	O
is	,	O
generally	DT	O
about	JJ	O
150,000	NN	O
daltons.	VBZ	O
Each	RB	O
L	RB	O
chain	CD	O
is	.	O
linked	DT	O
to	NNP	O
a	NN	O
H	VBZ	O
chain	VBN	O
by	TO	O
one	DT	O
covalent	NNP	O
disulfide	NN	O
bond,	IN	O
while	CD	O
the	NN	O
two	NN	O
H	,	O
chains	IN	O
are	DT	O
linked	CD	O
to	NNP	O
each	NNS	O
other	VBP	O
by	VBN	O
one	TO	O
or	DT	O
more	JJ	O
disulfide	IN	O
bonds	CD	O
depending	CC	O
on	JJR	O
the	JJ	O
H	NNS	O
chain	VBG	O
isotype.	IN	O
Each	DT	O
H	NNP	O
and	NN	O
L	.	O
chain	DT	O
also	NNP	O
has	CC	O
regularly	NNP	O
spaced	NN	O
intrachain	RB	O
disulfide	VBZ	O
bridges.	RB	O
Each	VBN	O
H	NN	O
chain	NN	O
has	.	O
at	DT	O
the	NNP	O
N-terminus,	NN	O
a	VBZ	O
variable	IN	O
domain	DT	O
(VH)	,	O
followed	DT	O
by	JJ	O
three	NN	O
constant	)	O
domains	VBN	O
(CH)	IN	O
for	CD	O
each	JJ	O
of	NNS	O
the	)	O
α	IN	O
and	DT	O
γ	IN	O
chains	DT	O
and	NN	O
four	CC	O
CH	NN	O
domains	NNS	O
for	CC	O
μ	CD	O
and	NNP	O
ε	NNS	O
isotypes.	IN	O
Each	NN	O
L	CC	O
chain	JJ	O
has	.	O
at	DT	O
the	NNP	O
N-terminus,	NN	O
a	VBZ	O
variable	IN	O
domain	DT	O
(VL)	,	O
followed	DT	O
by	JJ	O
a	NN	O
constant	)	O
domain	VBN	O
(CL)	IN	O
at	DT	O
its	JJ	O
other	NN	O
end.	)	O
The	IN	O
VL	PRP$	O
is	JJ	O
aligned	.	O
with	DT	O
the	NNP	O
VH	VBZ	O
and	VBN	O
the	IN	O
CL	DT	O
is	NNP	O
aligned	CC	O
with	DT	O
the	NNP	O
first	VBZ	O
constant	VBN	O
domain	IN	O
of	DT	O
the	JJ	O
heavy	JJ	O
chain	NN	O
(CH1).	IN	O
Particular	DT	O
amino	JJ	O
acid	NN	O
residues	.	O
are	JJ	O
believed	NN	O
to	NN	O
form	NNS	O
an	VBP	O
interface	VBN	O
between	TO	O
the	VB	O
light	DT	O
chain	NN	O
and	IN	O
heavy	DT	O
chain	NN	O
variable	NN	O
domains.	CC	O
The	JJ	O
pairing	NN	O
of	JJ	O
a	.	O
VH	DT	O
and	NN	O
VL	IN	O
together	DT	O
forms	NNP	O
a	CC	O
single	NNP	O
antigen-binding	RB	O
site.	VBZ	O
For	DT	O
the	JJ	O
structure	JJ	O
and	.	O
properties	IN	O
of	DT	O
the	NN	O
different	CC	O
classes	NNS	O
of	IN	O
antibodies,	DT	O
see,	JJ	O
e.g.,	NNS	O
Basic	IN	B
and	,	I
Clinical	,	I
Immunology,	,	I
8th	NNP	I
edition,	CC	I
Daniel	NNP	I
P.	,	I
Stites,	CD	I
Abba	,	I
I.	NNP	I
Terr	NNP	I
and	,	I
Tristram	NNP	I
G.	NNP	I
Parslow	NNP	I
(eds.),	CC	I
Appleton	NNP	I
&	NNP	I
Lange,	NNP	I
Norwalk,	,	I
Conn.,	NNP	I
1994,	CC	I
page	,	I
71	,	I
and	,	I
Chapter	,	I
6.
The	NN	O
L	CD	O
chain	CC	O
from	NNP	O
any	.	O
vertebrate	DT	O
species	NNP	O
can	NN	O
be	IN	O
assigned	DT	O
to	JJ	O
one	NNS	O
of	MD	O
two	VB	O
clearly	VBN	O
distinct	TO	O
types,	CD	O
called	IN	O
kappa	CD	O
and	RB	O
lambda,	JJ	O
based	,	O
on	VBN	O
the	NN	O
amino	CC	O
acid	,	O
sequences	VBN	O
of	IN	O
their	DT	O
constant	NN	O
domains.	JJ	O
Depending	NNS	O
on	IN	O
the	PRP$	O
amino	JJ	O
acid	.	O
sequence	VBG	O
of	IN	O
the	DT	O
constant	NN	O
domain	JJ	O
of	NN	O
their	IN	O
heavy	DT	O
chains	JJ	O
(CH),	NN	O
immunoglobulins	IN	O
can	PRP$	O
be	JJ	O
assigned	NNS	O
to	,	O
different	NNS	O
classes	MD	O
or	VB	O
isotypes.	VBN	O
There	TO	O
are	JJ	O
five	NNS	O
classes	CC	O
of	.	O
immunoglobulins:	EX	O
IgA,	VBP	O
IgD,	CD	O
IgE,	NNS	O
IgG,	IN	O
and	:	O
IgM,	,	O
having	,	O
heavy	,	O
chains	,	O
designated	CC	O
α,	,	O
δ,	VBG	O
ε,	JJ	O
γ,	NNS	O
and	VBN	O
μ,	,	O
respectively.	,	O
The	,	O
γ	,	O
and	CC	O
α	,	O
classes	.	O
are	DT	O
further	NN	O
divided	CC	O
into	NN	O
subclasses	NNS	O
on	VBP	O
the	RB	O
basis	VBN	O
of	IN	O
relatively	NNS	O
minor	IN	O
differences	DT	O
in	NN	O
CH	IN	O
sequence	RB	O
and	JJ	O
function,	NNS	O
e.g.,	IN	O
humans	NNP	O
express	NN	O
the	CC	O
following	,	O
subclasses:	,	O
IgG1,	NNS	O
IgG2,	VBP	O
IgG3,	DT	O
IgG4,	JJ	O
IgA1,	:	O
and	,	O
IgA2.	,	O
The	,	O
term	,	O
“variable”	,	O
refers	CC	O
to	.	O
the	DT	O
fact	NN	O
that	VBZ	O
certain	NNS	O
segments	TO	O
of	DT	O
the	NN	O
variable	IN	O
domains	JJ	O
differ	NNS	O
extensively	IN	O
in	DT	O
sequence	JJ	O
among	NNS	O
antibodies.	VBP	O
The	RB	O
V	IN	O
domain	NN	O
mediates	IN	O
antigen	.	O
binding	DT	O
and	NNP	O
define	NN	O
specificity	NNS	O
of	VBP	O
a	VBG	O
particular	CC	O
antibody	JJ	O
for	NN	O
its	IN	O
particular	DT	O
antigen.	JJ	O
However,	NN	O
the	IN	O
variability	PRP$	O
is	JJ	O
not	.	O
evenly	,	O
distributed	DT	O
across	NN	O
the	VBZ	O
110-amino	RB	O
acid	RB	O
span	VBN	O
of	IN	O
the	DT	O
variable	JJ	O
domains.	NN	O
Instead,	NN	O
the	IN	O
V	DT	O
regions	JJ	O
consist	.	O
of	,	O
relatively	DT	O
invariant	NNP	O
stretches	NNS	O
called	NN	O
framework	IN	O
regions	RB	O
(FRs)	JJ	O
of	NNS	O
15-30	VBN	O
amino	NN	O
acids	NNS	O
separated	)	O
by	IN	O
shorter	JJ	O
regions	NN	O
of	NNS	O
extreme	VBN	O
variability	IN	O
called	JJR	O
“hypervariable	NNS	O
regions”	IN	O
that	JJ	O
are	NN	O
each	VBN	O
9-12	JJ	O
amino	NN	O
acids	WDT	O
long.	VBP	O
The	DT	O
variable	CD	O
domains	NN	O
of	NNS	O
native	.	O
heavy	DT	O
and	JJ	O
light	NNS	O
chains	IN	O
each	JJ	O
comprise	JJ	O
four	CC	O
FRs,	JJ	O
largely	NNS	O
adopting	DT	O
a	NN	O
β-sheet	CD	O
configuration,	,	O
connected	RB	O
by	VBG	O
three	DT	O
hypervariable	JJ	O
regions,	,	O
which	VBN	O
form	IN	O
loops	CD	O
connecting,	JJ	O
and	,	O
in	WDT	O
some	VBP	O
cases	NNS	O
forming	,	O
part	CC	O
of,	IN	O
the	DT	O
β-sheet	NNS	O
structure.	VBG	O
The	NN	O
hypervariable	,	O
regions	DT	O
in	JJ	O
each	.	O
chain	DT	O
are	JJ	O
held	NNS	O
together	IN	O
in	DT	O
close	NN	O
proximity	VBP	O
by	VBN	O
the	RB	O
FRs	IN	O
and,	JJ	O
with	NN	O
the	IN	O
hypervariable	DT	O
regions	NNP	O
from	,	O
the	IN	O
other	DT	O
chain,	JJ	O
contribute	NNS	O
to	IN	O
the	DT	O
formation	JJ	O
of	,	O
the	NN	O
antigen-binding	TO	O
site	DT	O
of	NN	O
antibodies	IN	O
(see	DT	O
Kabat	JJ	B
et	NN	I
al.,	IN	I
Sequences	NNS	I
of	VB	I
Proteins	NNP	I
of	FW	I
Immunological	,	I
Interest,	NNP	I
5th	IN	I
Ed.	NNP	I
Public	IN	I
Health	NNP	I
Service,	,	I
National	CD	I
Institutes	.	I
of	NNP	I
Health,	NNP	I
Bethesda,	,	I
Md.	NNP	I
(1991)).The	NNPS	O
constant	IN	O
domains	,	O
are	,	O
not	.	O
involved	.	O
directly	DT	O
in	JJ	O
binding	NNS	O
an	VBP	O
antibody	RB	O
to	VBN	O
an	RB	O
antigen,	IN	O
but	VBG	O
exhibit	DT	O
various	NN	O
effector	TO	O
functions,	DT	O
such	,	O
as	CC	O
participation	RB	O
of	JJ	O
the	NN	O
antibody	,	O
in	JJ	O
antibody	IN	O
dependent	NN	O
cellular	IN	O
cytotoxicity	DT	O
(ADCC).	NN	O
The	IN	O
term	NN	O
“hypervariable	JJ	O
region”	JJ	O
when	NN	O
used	.	O
herein	DT	O
refers	NN	O
to	JJ	O
the	NN	O
amino	WRB	O
acid	VBN	O
residues	NN	O
of	NNS	O
an	TO	O
antibody	DT	O
which	NN	O
are	NN	O
responsible	NNS	O
for	IN	O
antigen-binding.	DT	O
The	NN	O
hypervariable	WDT	O
region	VBP	O
generally	JJ	O
comprises	IN	O
amino	.	O
acid	DT	O
residues	JJ	O
from	NN	O
a	RB	O
“complementarity	VBZ	O
determining	JJ	O
region”	NN	O
or	NNS	O
“CDR”	IN	O
(e.g.	DT	O
around	NN	O
about	VBG	O
residues	NN	O
24-34	CC	O
(L1),	NN	O
50-56	.	O
(L2)	IN	O
and	RB	O
89-97	NNS	O
(L3)	JJ	O
in	,	O
the	JJ	O
VL,	)	O
and	CC	O
around	JJ	O
about	)	O
1-35	IN	O
(H1),	DT	O
50-65	,	O
(H2)	CC	O
and	IN	O
95-102	IN	O
(H3)	JJ	O
in	,	O
the	JJ	O
VH;	)	O
Kabat	CC	B
et	JJ	I
al.,	)	I
Sequences	IN	I
of	DT	I
Proteins	:	I
of	NNP	I
Immunological	FW	I
Interest,	,	I
5th	NNP	I
Ed.	IN	I
Public	NNP	I
Health	IN	I
Service,	NNP	I
National	,	I
Institutes	CD	I
of	.	I
Health,	NNP	I
Bethesda,	NNP	I
Md.	,	I
(1991))	NNP	I
and/or	NNPS	O
those	IN	O
residues	,	O
from	,	O
a	.	O
“hypervariable	)	O
loop”	VBP	O
(e.g.	DT	O
residues	NNS	O
26-32	IN	O
(L1),	DT	O
50-52	JJ	O
(L2)	NN	O
and	.	O
91-96	NNS	O
(L3)	JJ	O
in	,	O
the	JJ	O
VL,	)	O
and	CC	O
26-32	JJ	O
(H1),	)	O
53-55	IN	O
(H2)	DT	O
and	,	O
96-101	CC	O
(H3)	JJ	O
in	,	O
the	JJ	O
VH;	)	O
Chothia	CC	B
and	JJ	I
Lesk	)	I
J.	IN	I
Mol.	DT	I
Biol.	:	I
196:901-917	NNP	I
(1987)).The	CC	O
term	NNP	O
“monoclonal	NNP	O
antibody”	.	O
as	.	O
used	CD	O
herein	.	O
refers	DT	O
to	NN	O
an	JJ	O
antibody	NN	O
obtained	IN	O
from	VBN	O
a	NN	O
population	NNS	O
of	TO	O
substantially	DT	O
homogeneous	NN	O
antibodies,	VBN	O
i.e.,	IN	O
the	DT	O
individual	NN	O
antibodies	IN	O
comprising	RB	O
the	JJ	O
population	,	O
are	,	O
identical	DT	O
except	JJ	O
for	NNS	O
possible	VBG	O
naturally	DT	O
occurring	NN	O
mutations	VBP	O
that	JJ	O
may	IN	O
be	IN	O
present	JJ	O
in	RB	O
minor	VBG	O
amounts.	NNS	O
Monoclonal	WDT	O
antibodies	MD	O
are	VB	O
highly	JJ	O
specific,	IN	O
being	JJ	O
directed	.	O
against	JJ	O
a	NNS	O
single	VBP	O
antigenic	RB	O
site.	,	O
Furthermore,	VBG	O
in	VBN	O
contrast	IN	O
to	DT	O
polyclonal	JJ	O
antibody	JJ	O
preparations	.	O
which	,	O
include	IN	O
different	NN	O
antibodies	TO	O
directed	VB	O
against	NN	O
different	NNS	O
determinants	WDT	O
(epitopes),	VBP	O
each	JJ	O
monoclonal	NNS	O
antibody	VBN	O
is	IN	O
directed	JJ	O
against	NNS	O
a	,	O
single	DT	O
determinant	JJ	O
on	NN	O
the	VBZ	O
antigen.	VBN	O
In	IN	O
addition	DT	O
to	JJ	O
their	NN	O
specificity,	IN	O
the	DT	O
monoclonal	.	O
antibodies	IN	O
are	NN	O
advantageous	TO	O
in	PRP$	O
that	,	O
they	DT	O
may	JJ	O
be	NNS	O
synthesized	VBP	O
uncontaminated	JJ	O
by	IN	O
other	DT	O
antibodies.	PRP	O
The	MD	O
modifier	VB	O
“monoclonal”	VBN	O
is	JJ	O
not	IN	O
to	JJ	O
be	.	O
construed	DT	O
as	JJR	O
requiring	NN	O
production	VBZ	O
of	RB	O
the	TO	O
antibody	VB	O
by	VBN	O
any	IN	O
particular	VBG	O
method.	NN	O
For	IN	O
example,	DT	O
the	NN	O
monoclonal	IN	O
antibodies	DT	O
useful	JJ	O
in	.	O
the	IN	O
present	,	O
invention	DT	O
may	JJ	O
be	NNS	O
prepared	JJ	O
by	IN	O
the	DT	O
hybridoma	JJ	O
methodology	NN	O
first	MD	O
described	VB	O
by	VBN	O
Kohler	IN	B
et	DT	I
al.,	NN	I
Nature,	NN	I
256:495	RB	I
(1975),	VBN	I
or	IN	O
may	NNP	O
be	FW	O
made	,	O
using	,	O
recombinant	CD	O
DNA	,	O
methods	CC	O
in	MD	O
bacterial,	VB	O
eukaryotic	VBN	O
animal	VBG	O
or	JJ	O
plant	NNP	O
cells	NNS	O
(see,	IN	O
e.g.,	,	O
U.S.	JJ	O
Pat.	NN	O
No.	CC	O
4,816,567).	NN	O
The	NNS	O
“monoclonal	,	O
antibodies”	,	O
may	NNP	O
also	.	O
be	.	O
isolated	.	O
from	DT	O
phage	JJ	O
antibody	NN	O
libraries	MD	O
using	RB	O
the	VB	O
techniques	VBN	O
described	IN	O
in	NN	O
Clackson	NN	B
et	VBZ	I
al.,	VBG	I
Nature,	DT	I
352:624-628	NNS	I
(1991)	VBN	I
and	IN	O
Marks	NNP	B
et	CC	I
al.,	,	I
J.	,	I
Mol.	NNP	I
Biol.,	)	I
222:581-597	CC	I
(1991),	NNP	I
for	VBP	O
example.	,	O
The	NNP	O
monoclonal	.	O
antibodies	,	O
herein	CD	O
include	,	O
“chimeric”	IN	O
antibodies	.	O
in	DT	O
which	JJ	O
a	NNS	O
portion	VBP	O
of	VBP	O
the	JJ	O
heavy	NNS	O
and/or	IN	O
light	WDT	O
chain	DT	O
is	NN	O
identical	IN	O
with	DT	O
or	JJ	O
homologous	NN	O
to	NN	O
corresponding	NN	O
sequences	VBZ	O
in	JJ	O
antibodies	IN	O
derived	CC	O
from	JJ	O
a	TO	O
particular	VBG	O
species	NNS	O
or	IN	O
belonging	NNS	O
to	VBN	O
a	IN	O
particular	DT	O
antibody	JJ	O
class	NNS	O
or	CC	O
subclass,	VBG	O
while	TO	O
the	DT	O
remainder	JJ	O
of	NN	O
the	NN	O
chain(s)	CC	O
is	,	O
identical	IN	O
with	DT	O
or	NN	O
homologous	IN	O
to	DT	O
corresponding	)	O
sequences	VBZ	O
in	JJ	O
antibodies	IN	O
derived	CC	O
from	JJ	O
another	TO	O
species	VBG	O
or	NNS	O
belonging	IN	O
to	NNS	O
another	VBN	O
antibody	IN	O
class	DT	O
or	NNS	O
subclass,	CC	O
as	VBG	O
well	TO	O
as	DT	O
fragments	NN	O
of	NN	O
such	CC	O
antibodies,	,	O
so	RB	O
long	RB	O
as	IN	O
they	NNS	O
exhibit	IN	O
the	JJ	O
desired	,	O
biological	RB	O
activity	RB	O
(see	IN	O
U.S.	PRP	O
Pat.	VBP	O
No.	DT	O
4,816,567;	JJ	O
and	JJ	O
Morrison	NN	B
et	VB	I
al.,	NNP	I
Proc.	.	I
Natl.	.	I
Acad.	:	I
Sci.	CC	I
USA,	NNP	I
81:6851-6855	FW	I
(1984)).Chimeric	,	O
antibodies	.	O
of	.	O
interest	.	O
herein	.	O
include	,	O
“primatized”	CD	O
antibodies	.	O
comprising	JJ	O
variable	NNS	O
domain	IN	O
antigen-binding	NN	O
sequences	NN	O
derived	VBP	O
from	JJ	O
a	NNS	O
non-human	VBG	O
primate	JJ	O
(e.g.	NN	O
Old	JJ	O
World	NNS	O
Monkey,	VBN	O
Ape	IN	O
etc),	DT	O
and	JJ	O
human	NN	O
constant	.	O
region	NNP	O
sequences.	NNP	O
An	,	O
“intact”	NNP	O
antibody	,	O
is	CC	O
one	JJ	O
which	JJ	O
comprises	NN	O
an	.	O
antigen-binding	DT	O
site	NN	O
as	NN	O
well	VBZ	O
as	CD	O
a	WDT	O
CL	VBZ	O
and	DT	O
at	JJ	O
least	NN	O
heavy	RB	O
chain	RB	O
constant	IN	O
domains,	DT	O
CH1,	NNP	O
CH2	CC	O
and	IN	O
CH3.	JJS	O
The	JJ	O
constant	NN	O
domains	JJ	O
may	,	O
be	,	O
native	NNP	O
sequence	CC	O
constant	.	O
domains	DT	O
(e.g.	JJ	O
human	NNS	O
native	MD	O
sequence	VB	O
constant	JJ	O
domains)	NN	O
or	JJ	O
amino	NNS	O
acid	.	O
sequence	JJ	O
variant	JJ	O
thereof.	NN	O
Preferably,	JJ	O
the	)	O
intact	CC	O
antibody	JJ	O
has	JJ	O
one	NN	O
or	NN	O
more	.	O
effector	,	O
functions.	DT	O
“Antibody	JJ	O
fragments”	NN	O
comprise	VBZ	O
a	CD	O
portion	CC	O
of	JJR	O
an	JJ	O
intact	.	O
antibody,	NN	O
preferably	JJ	O
the	NN	O
antigen	DT	O
binding	NN	O
or	IN	O
variable	DT	O
region	JJ	O
of	,	O
the	RB	O
intact	DT	O
antibody.	NN	O
Examples	NN	O
of	CC	O
antibody	JJ	O
fragments	NN	O
include	IN	O
Fab,	DT	O
Fab′,	JJ	O
F(ab′)2,	.	O
and	NNS	O
Fv	IN	O
fragments;	NN	O
diabodies;	NNS	O
linear	VBP	O
antibodies	,	O
(see	,	O
U.S.	,	O
Pat.	CC	O
No.	NNP	O
5,641,870,	:	O
Example	:	O
2;	JJ	O
Zapata	NNS	B
et	VB	I
al.,	NNP	I
Protein	.	I
Eng.	.	I
8(10):	,	I
1057-1062	NNP	I
[1995]);single-chain	:	O
antibody	NNP	O
molecules;	FW	O
and	,	O
multispecific	NNP	O
antibodies	.	O
formed	:	O
from	JJ	O
antibody	:	O
fragments.	JJ	O
Papain	NN	O
digestion	:	O
of	CC	O
antibodies	JJ	O
produces	NNS	O
two	VBN	O
identical	IN	O
antigen-binding	NN	O
fragments,	.	O
called	NNP	O
“Fab”	NN	O
fragments,	IN	O
and	NNS	O
a	VBZ	O
residual	CD	O
“Fc”	JJ	O
fragment,	NN	O
a	,	O
designation	VBN	O
reflecting	NN	O
the	,	O
ability	CC	O
to	DT	O
crystallize	JJ	O
readily.	NN	O
The	,	O
Fab	DT	O
fragment	NN	O
consists	VBG	O
of	DT	O
an	NN	O
entire	TO	O
L	VB	O
chain	.	O
along	DT	O
with	NNP	O
the	NN	O
variable	VBZ	O
region	IN	O
domain	DT	O
of	JJ	O
the	NNP	O
H	NN	O
chain	IN	O
(VH),	IN	O
and	DT	O
the	JJ	O
first	NN	O
constant	NN	O
domain	IN	O
of	DT	O
one	NNP	O
heavy	NN	O
chain	,	O
(CH1).	CC	O
Each	DT	O
Fab	JJ	O
fragment	JJ	O
is	NN	O
monovalent	IN	O
with	CD	O
respect	NN	O
to	NN	O
antigen	.	O
binding,	DT	O
i.e.,	NNP	O
it	NN	O
has	VBZ	O
a	JJ	O
single	IN	O
antigen-binding	NN	O
site.	TO	O
Pepsin	VB	O
treatment	,	O
of	,	O
an	PRP	O
antibody	VBZ	O
yields	DT	O
a	JJ	O
single	JJ	O
large	.	O
F(ab′)2	NNP	O
fragment	NN	O
which	IN	O
roughly	DT	O
corresponds	NN	O
to	VBZ	O
two	DT	O
disulfide	JJ	O
linked	JJ	O
Fab	CD	O
fragments	NN	O
having	WDT	O
divalent	RB	O
antigen-binding	VBZ	O
activity	TO	O
and	CD	O
is	NN	O
still	VBD	O
capable	NNP	O
of	NNS	O
cross-linking	VBG	O
antigen.	JJ	O
Fab′	JJ	O
fragments	NN	O
differ	CC	O
from	VBZ	O
Fab	RB	O
fragments	JJ	O
by	IN	O
having	JJ	O
additional	.	O
few	NNP	O
residues	NNS	O
at	VBP	O
the	IN	O
carboxy	NNP	O
terminus	NNS	O
of	IN	O
the	VBG	O
CH1	JJ	O
domain	JJ	O
including	NNS	O
one	IN	O
or	DT	O
more	JJ	O
cysteines	NN	O
from	IN	O
the	DT	O
antibody	NNP	O
hinge	NN	O
region.	VBG	O
Fab′-SH	CD	O
is	CC	O
the	JJR	O
designation	NNS	O
herein	IN	O
for	DT	O
Fab′	NN	O
in	JJ	O
which	.	O
the	NNP	O
cysteine	VBZ	O
residue(s)	DT	O
of	NN	O
the	NN	O
constant	IN	O
domains	NNP	O
bear	IN	O
a	WDT	O
free	DT	O
thiol	NN	O
group.	)	O
F(ab′)2	IN	O
antibody	DT	O
fragments	JJ	O
originally	NNS	O
were	VBP	O
produced	DT	O
as	JJ	O
pairs	NN	O
of	.	O
Fab′	CD	O
fragments	NN	O
which	NNS	O
have	RB	O
hinge	VBD	O
cysteines	VBN	O
between	IN	O
them.	NNS	O
Other	IN	O
chemical	NNP	O
couplings	NNS	O
of	WDT	O
antibody	VBP	O
fragments	VBN	O
are	NNS	O
also	IN	O
known.	.	O
The	JJ	O
Fc	JJ	O
fragment	NNS	O
comprises	IN	O
the	NN	O
carboxy-terminal	NNS	O
portions	VBP	O
of	RB	O
both	.	O
H	DT	O
chains	NNP	O
held	NN	O
together	VBZ	O
by	DT	O
disulfides.	JJ	O
The	NNS	O
effector	IN	O
functions	DT	O
of	NNP	O
antibodies	NNS	O
are	VBD	O
determined	RB	O
by	IN	O
sequences	.	O
in	DT	O
the	NN	O
Fc	NNS	O
region,	IN	O
which	NNS	O
region	VBP	O
is	VBN	O
also	IN	O
the	NNS	O
part	IN	O
recognized	DT	O
by	NNP	O
Fc	,	O
receptors	WDT	O
(FcR)	NN	O
found	VBZ	O
on	RB	O
certain	DT	O
types	NN	O
of	VBN	O
cells.	IN	O
“Fv”	NNP	O
is	NNS	O
the	)	O
minimum	VBN	O
antibody	IN	O
fragment	JJ	O
which	NNS	O
contains	IN	O
a	.	O
complete	NN	O
antigen-recognition	VBZ	O
and	DT	O
-binding	JJ	O
site.	NN	O
This	NN	O
fragment	WDT	O
consists	VBZ	O
of	DT	O
a	JJ	O
dimer	NN	O
of	CC	O
one	VBG	O
heavy-	.	O
and	DT	O
one	JJ	O
light-chain	VBZ	O
variable	IN	O
region	DT	O
domain	NN	O
in	IN	O
tight,	CD	O
non-covalent	NN	O
association.	CC	O
From	CD	O
the	NN	O
folding	JJ	O
of	NN	O
these	NN	O
two	IN	O
domains	,	O
emanate	JJ	O
six	.	O
hypervariable	IN	O
loops	DT	O
(3	NN	O
loops	IN	O
each	DT	O
from	CD	O
the	NNS	O
H	VBP	O
and	CD	O
L	JJ	O
chain)	NNS	O
that	CD	O
contribute	NNS	O
the	DT	O
amino	IN	O
acid	DT	O
residues	NNP	O
for	CC	O
antigen	NNP	O
binding	)	O
and	WDT	O
confer	VBP	O
antigen	DT	O
binding	NN	O
specificity	NN	O
to	NNS	O
the	IN	O
antibody.	NN	O
However,	NN	O
even	CC	O
a	NN	O
single	NN	O
variable	VBG	O
domain	NN	O
(or	TO	O
half	DT	O
of	.	O
an	,	O
Fv	RB	O
comprising	DT	O
only	JJ	O
three	NN	O
CDRs	NN	O
specific	CC	O
for	NN	O
an	IN	O
antigen)	DT	O
has	NNP	O
the	VBG	O
ability	RB	O
to	CD	O
recognize	NNP	O
and	NN	O
bind	IN	O
antigen,	DT	O
although	)	O
at	VBZ	O
a	DT	O
lower	NN	O
affinity	TO	O
than	VB	O
the	CC	O
entire	VB	O
binding	,	O
site.	IN	O
“Single-chain	IN	O
Fv”	DT	O
also	JJR	O
abbreviated	NN	O
as	IN	O
“sFv”	DT	O
or	JJ	O
“scFv”	NN	O
are	.	O
antibody	JJ	O
fragments	NNP	O
that	RB	O
comprise	VBD	O
the	IN	O
VH	NN	O
and	CC	O
VL	NN	O
antibody	VBP	O
domains	NN	O
connected	NNS	O
into	WDT	O
a	VBP	O
single	DT	O
polypeptide	NNP	O
chain.	CC	O
Preferably,	NNP	O
the	NN	O
sFv	VBZ	O
polypeptide	VBN	O
further	IN	O
comprises	DT	O
a	JJ	O
polypeptide	NN	O
linker	.	O
between	,	O
the	DT	O
VH	NN	O
and	IN	O
VL	JJ	O
domains	NNS	O
which	DT	O
enables	NN	O
the	NN	O
sFv	IN	O
to	DT	O
form	NNP	O
the	CC	O
desired	NNP	O
structure	NNS	O
for	WDT	O
antigen	VBZ	O
binding.	DT	O
For	NN	O
a	TO	O
review	VB	O
of	DT	O
sFv,	JJ	O
see	NN	O
Pluckthun	IN	B
in	NN	I
The	.	I
Pharmacology	IN	I
of	DT	I
Monoclonal	NN	I
Antibodies,	IN	I
vol.	,	I
113,	VBP	I
Rosenburg	NNP	I
and	IN	I
Moore	DT	I
eds.,	NNP	I
Springer-Verlag,	IN	I
New	NNP	I
York,	,	I
pp.	.	I
269-315	,	I
(1994);	NNP	I
Borrebaeck	CC	B
1995,	NNP	I
infra.	,	O
The	,	O
term	NNP	O
“diabodies”	,	O
refers	.	O
to	CD	O
small	:	O
antibody	NNP	O
fragments	,	O
prepared	.	O
by	DT	O
constructing	NN	O
sFv	VBZ	O
fragments	NNS	O
(see	TO	O
preceding	JJ	O
paragraph)	NN	O
with	NNS	O
short	VBN	O
linkers	IN	O
(about	VBG	O
5-10	NN	O
residues)	NNS	O
between	VB	O
the	VBG	O
VH	)	O
and	IN	O
VL	JJ	O
domains	NNS	O
such	IN	O
that	NNP	O
inter-chain	)	O
but	IN	O
not	DT	O
intra-chain	NNP	O
pairing	CC	O
of	NNP	O
the	NNS	O
V	JJ	O
domains	IN	O
is	NN	O
achieved,	CC	O
resulting	RB	O
in	JJ	O
a	NN	O
bivalent	IN	O
fragment,	DT	O
i.e.,	NNP	O
fragment	NNS	O
having	VBZ	O
two	,	O
antigen-binding	VBG	O
sites.	IN	O
Bispecific	DT	O
diabodies	NN	O
are	,	O
heterodimers	,	O
of	JJ	O
two	VBG	O
“crossover”	CD	O
sFv	JJ	O
fragments	.	O
in	NNP	O
which	NNS	O
the	VBP	O
VH	NNS	O
and	IN	O
VL	CD	O
domains	JJ	O
of	NN	O
the	NNS	O
two	IN	O
antibodies	WDT	O
are	DT	O
present	NNP	O
on	CC	O
different	NNP	O
polypeptide	NNS	O
chains.	IN	O
Diabodies	DT	O
are	CD	O
described	NNS	O
more	VBP	O
fully	JJ	O
in,	IN	O
for	JJ	O
example,	NN	O
EP	.	O
404,097;	NNS	O
WO	VBP	O
93/11161;	VBN	O
and	RBR	O
Hollinger	RB	B
et	,	I
al.,	IN	I
Proc.	,	I
Natl.	NNP	I
Acad.	:	I
Sci.	NNP	I
USA,	:	I
90:6444-6448	CC	I
(1993).
“Humanized”	NNP	O
forms	VBP	O
of	,	O
non-human	.	O
(e.g.,	.	O
rodent)	.	O
antibodies	.	O
are	,	O
chimeric	CD	O
antibodies	.	O
that	JJ	O
contain	NNS	O
minimal	IN	O
sequence	JJ	O
derived	,	O
from	)	O
the	NNS	O
non-human	VBP	O
antibody.	JJ	O
For	NNS	O
the	WDT	O
most	VBP	O
part,	JJ	O
humanized	NN	O
antibodies	VBN	O
are	IN	O
human	DT	O
immunoglobulins	JJ	O
(recipient	.	O
antibody)	IN	O
in	DT	O
which	JJS	O
residues	,	O
from	VBN	O
a	NNS	O
hypervariable	VBP	O
region	JJ	O
of	NNS	O
the	VB	O
recipient	)	O
are	IN	O
replaced	WDT	O
by	VBP	O
residues	IN	O
from	DT	O
a	JJ	O
hypervariable	NN	O
region	IN	O
of	DT	O
a	NN	O
non-human	VBP	O
species	VBN	O
(donor	IN	O
antibody)	NNS	O
such	IN	O
as	DT	O
mouse,	JJ	O
rat,	NN	O
rabbit	IN	O
or	DT	O
non-human	JJ	O
primate	NNS	O
having	VB	O
the	)	O
desired	JJ	O
antibody	IN	O
specificity,	,	O
affinity,	,	O
and	NN	O
capability.	CC	O
In	JJ	O
some	NN	O
instances,	VBG	O
framework	DT	O
region	VBN	O
(FR)	NN	O
residues	,	O
of	,	O
the	CC	O
human	.	O
immunoglobulin	IN	O
are	DT	O
replaced	,	O
by	NN	O
corresponding	NN	O
non-human	)	O
residues.	NNS	O
Furthermore,	IN	O
humanized	DT	O
antibodies	JJ	O
may	NN	O
comprise	VBP	O
residues	VBN	O
that	IN	O
are	VBG	O
not	JJ	O
found	.	O
in	,	O
the	JJ	O
recipient	NNS	O
antibody	MD	O
or	VB	O
in	NNS	O
the	WDT	O
donor	VBP	O
antibody.	RB	O
These	VBN	O
modifications	IN	O
are	DT	O
made	NN	O
to	NN	O
further	CC	O
refine	IN	O
antibody	DT	O
performance.	NN	O
In	.	O
general,	DT	O
the	NNS	O
humanized	VBP	O
antibody	VBN	O
will	TO	O
comprise	JJ	O
substantially	NN	O
all	NN	O
of	.	O
at	IN	O
least	,	O
one,	DT	O
and	VBN	O
typically	NN	O
two,	MD	O
variable	VB	O
domains,	RB	O
in	DT	O
which	IN	O
all	IN	O
or	JJS	O
substantially	,	O
all	CC	O
of	RB	O
the	,	O
hypervariable	JJ	O
loops	,	O
correspond	IN	O
to	WDT	O
those	DT	O
of	CC	O
a	RB	O
non-human	DT	O
immunoglobulin	IN	O
and	DT	O
all	JJ	O
or	NNS	O
substantially	NN	O
all	TO	O
of	DT	O
the	IN	O
FRs	DT	O
are	JJ	O
those	NN	O
of	CC	O
a	DT	O
human	CC	O
immunoglobulin	RB	O
sequence.	DT	O
The	IN	O
humanized	DT	O
antibody	NNP	O
optionally	VBP	O
also	DT	O
will	IN	O
comprise	DT	O
at	JJ	O
least	NN	O
a	.	O
portion	DT	O
of	VBN	O
an	NN	O
immunoglobulin	RB	O
constant	RB	O
region	MD	O
(Fc),	VB	O
typically	IN	O
that	JJS	O
of	DT	O
a	NN	O
human	IN	O
immunoglobulin.	DT	O
For	NN	O
further	JJ	O
details,	NN	O
see	,	O
Jones	RB	B
et	IN	I
al.,	IN	I
Nature	DT	I
321:522-525	JJ	I
(1986);	.	I
Riechmann	IN	B
et	JJR	I
al.,	,	I
Nature	VBP	I
332:323-329	NNP	I
(1988);	FW	I
and	,	O
Presta,	NNP	B
Curr.	CD	I
Op.	:	I
Struct.	NNP	I
Biol.	FW	I
2:593-596	,	I
(1992).
A	NNP	O
“species-dependent	CD	O
antibody,”	:	O
e.g.,	CC	O
a	,	O
mammalian	.	O
anti-human	.	O
IgE	.	O
antibody,	.	O
is	CD	O
an	.	O
antibody	DT	O
which	JJ	O
has	NNP	O
a	,	O
stronger	DT	O
binding	JJ	O
affinity	JJ	O
for	NNP	O
an	,	O
antigen	VBZ	O
from	DT	O
a	NN	O
first	WDT	O
mammalian	VBZ	O
species	DT	O
than	JJR	O
it	NN	O
has	NN	O
for	IN	O
a	DT	O
homologue	NN	O
of	IN	O
that	DT	O
antigen	JJ	O
from	JJ	O
a	NNS	O
second	IN	O
mammalian	PRP	O
species.	VBZ	O
Normally,	IN	O
the	DT	O
species-dependent	NN	O
antibody	IN	O
“bind	DT	O
specifically”	NN	O
to	IN	O
a	DT	O
human	JJ	O
antigen	JJ	O
(i.e.,	.	O
has	,	O
a	DT	O
binding	JJ	O
affinity	NN	O
(Kd)	NNP	O
value	NN	O
of	TO	O
no	DT	O
more	JJ	O
than	NN	O
about	,	O
1×10−7	VBZ	O
M,	DT	O
preferably	NN	O
no	NN	O
more	)	O
than	NN	O
about	IN	O
1×10−8	DT	O
and	JJR	O
most	IN	O
preferably	RB	O
no	CD	O
more	,	O
than	RB	O
about	DT	O
1×10−9	JJR	O
M)	IN	O
but	RB	O
has	CD	O
a	CC	O
binding	RBS	O
affinity	RB	O
for	DT	O
a	JJR	O
homologue	IN	O
of	RB	O
the	CD	O
antigen	)	O
from	CC	O
a	VBZ	O
second	DT	O
non-human	NN	O
mammalian	NN	O
species	IN	O
which	DT	O
is	NN	O
at	IN	O
least	DT	O
about	NN	O
50	IN	O
fold,	DT	O
or	JJ	O
at	JJ	O
least	NN	O
about	NNS	O
500	WDT	O
fold,	VBZ	O
or	IN	O
at	JJS	O
least	IN	O
about	CD	O
1000	,	O
fold,	CC	O
weaker	IN	O
than	JJS	O
its	IN	O
binding	CD	O
affinity	,	O
for	CC	O
the	IN	O
human	JJS	O
antigen.	IN	O
The	CD	O
species-dependent	,	O
antibody	JJR	O
can	IN	O
be	PRP$	O
of	NN	O
any	NN	O
of	IN	O
the	DT	O
various	JJ	O
types	.	O
of	DT	O
antibodies	JJ	O
as	NN	O
defined	MD	O
above,	VB	O
but	IN	O
preferably	DT	O
is	IN	O
a	DT	O
humanized	JJ	O
or	NNS	O
human	IN	O
antibody.	NNS	O
A	IN	O
“PRO227,	VBN	O
PRO233,	,	O
PRO238,	CC	O
PRO1328,	RB	O
PRO4342,	VBZ	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	CC	O
PRO353	JJ	O
or	.	O
PRO1885	DT	O
binding	,	O
oligopeptide”	,	O
is	,	O
an	,	O
oligopeptide	,	O
that	,	O
binds,	,	O
preferably	,	O
specifically,	NNP	O
to	CC	O
a	NNP	O
PRO227,	VBG	O
PRO233,	NN	O
PRO238,	VBZ	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	WDT	O
PRO10096,	,	O
PRO21384,	RB	O
PRO353	,	O
or	TO	O
PRO1885	DT	O
polypeptide	,	O
as	,	O
described	,	O
herein.	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	RB	O
PRO353	IN	O
or	VBN	O
PRO1885	.	O
binding	,	O
oligopeptides	,	O
may	,	O
be	,	O
chemically	,	O
synthesized	,	O
using	,	O
known	,	O
oligopeptide	NNP	O
synthesis	CC	O
methodology	NNP	O
or	VBG	O
may	NNS	O
be	MD	O
prepared	VB	O
and	RB	O
purified	VBN	O
using	VBG	O
recombinant	VBN	O
technology.	JJ	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	MD	O
PRO4342,	VB	O
PRO7423,	VBN	O
PRO10096,	CC	O
PRO21384,	VBN	O
PRO353	VBG	O
or	JJ	O
PRO1885	.	O
binding	,	O
oligopeptides	,	O
usually	,	O
are	,	O
or	,	O
are	,	O
at	,	O
least	,	O
about	NNP	O
5	CC	O
amino	NNP	O
acids	VBG	O
in	NNS	O
length,	RB	O
alternatively	VBP	O
are	CC	O
or	VBP	O
are	IN	O
at	JJS	O
least	IN	O
about	CD	O
6,	JJ	O
7,	NNS	O
8,	IN	O
9,	,	O
10,	RB	O
11,	VBP	O
12,	CC	O
13,	VBP	O
14,	IN	O
15,	JJS	O
16,	IN	O
17,	,	O
18,	,	O
19,	,	O
20,	,	O
21,	,	O
22,	,	O
23,	,	O
24,	,	O
25,	,	O
26,	,	O
27,	,	O
28,	,	O
29,	,	O
30,	,	O
31,	,	O
32,	,	O
33,	,	O
34,	,	O
35,	,	O
36,	,	O
37,	,	O
38,	,	O
39,	,	O
40,	,	O
41,	,	O
42,	,	O
43,	,	O
44,	,	O
45,	,	O
46,	,	O
47,	,	O
48,	,	O
49,	,	O
50,	,	O
51,	,	O
52,	,	O
53,	,	O
54,	,	O
55,	,	O
56,	,	O
57,	,	O
58,	,	O
59,	,	O
60,	,	O
61,	,	O
62,	,	O
63,	,	O
64,	,	O
65,	,	O
66,	,	O
67,	,	O
68,	,	O
69,	,	O
70,	,	O
71,	,	O
72,	,	O
73,	,	O
74,	,	O
75,	,	O
76,	,	O
77,	,	O
78,	,	O
79,	,	O
80,	,	O
81,	,	O
82,	,	O
83,	,	O
84,	,	O
85,	,	O
86,	,	O
87,	,	O
88,	,	O
89,	,	O
90,	,	O
91,	,	O
92,	,	O
93,	,	O
94,	,	O
95,	,	O
96,	,	O
97,	,	O
98,	,	O
99,	,	O
or	,	O
100	,	O
amino	,	O
acids	,	O
in	,	O
length	,	O
or	,	O
more,	,	O
wherein	,	O
such	,	O
oligopeptides	,	O
that	CC	O
are	CD	O
capable	JJ	O
of	NNS	O
binding,	IN	O
preferably	NN	O
specifically,	CC	O
to	,	O
a	WP	O
PRO227,	JJ	O
PRO233,	NNS	O
PRO238,	WDT	O
PRO1328,	VBP	O
PRO4342,	JJ	O
PRO7423,	IN	O
PRO10096,	,	O
PRO21384,	RB	O
PRO353	,	O
or	TO	O
PRO1885	DT	O
polypeptide	,	O
as	,	O
described	,	O
herein.	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	RB	O
PRO353	IN	O
or	VBN	O
PRO1885	.	O
binding	,	O
oligopeptides	,	O
may	,	O
be	,	O
identified	,	O
without	,	O
undue	,	O
experimentation	,	O
using	NNP	O
well	CC	O
known	NNP	O
techniques.	VBG	O
In	NNS	O
this	MD	O
regard,	VB	O
it	VBN	O
is	IN	O
noted	JJ	O
that	NN	O
techniques	VBG	O
for	RB	O
screening	VBN	O
oligopeptide	.	O
libraries	IN	O
for	DT	O
oligopeptides	,	O
that	PRP	O
are	VBZ	O
capable	VBN	O
of	IN	O
specifically	NNS	O
binding	IN	O
to	VBG	O
a	JJ	O
polypeptide	NNS	O
target	IN	O
are	NNS	O
well	WDT	O
known	VBP	O
in	JJ	O
the	IN	O
art	RB	O
(see,	VBG	O
e.g.,	TO	O
U.S.	DT	O
Pat.	NN	O
Nos.	NN	O
5,556,762,	VBP	O
5,750,373,	RB	O
4,708,871,	VBN	O
4,833,092,	IN	O
5,223,409,	DT	O
5,403,484,	NN	O
5,571,689,	,	O
5,663,143;	,	O
PCT	NNP	O
Publication	.	O
Nos.	.	O
WO	,	O
84/03506	,	O
and	,	O
WO84/03564;	,	O
Geysen	,	B
et	,	I
al.,	,	I
Proc.	:	I
Natl.	NNP	I
Acad.	NNP	I
Sci.	.	I
U.S.A.,	$	I
81:3998-4002	CD	I
(1984);	CC	I
Geysen	:	B
et	NNP	I
al.,	FW	I
Proc.	,	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
U.S.A.,	.	I
82:178-182	,	I
(1985);	CD	I
Geysen	:	B
et	NNP	I
al.,	FW	I
in	,	I
Synthetic	.	I
Peptides	.	I
as	.	I
Antigens,	.	I
130-149	,	I
(1986);	CD	I
Geysen	:	B
et	NNP	I
al.,	FW	I
J.	,	I
Immunol.	IN	I
Meth.,	NNP	I
102:259-274	NNP	I
(1987);	IN	I
Schoofs	,	B
et	CD	I
al.,	:	I
J.	NNP	I
Immunol.,	FW	I
140:611-616	,	I
(1988),	NNP	I
Cwirla,	.	B
S.	,	I
E.	CD	I
et	:	I
al.	NNP	I
(1990)	FW	I
Proc.	,	I
Natl.	.	I
Acad.	,	I
Sci.	CD	I
USA,	,	I
87:6378;	,	I
Lowman,	NNP	B
H.	NNP	I
B.	FW	I
et	.	I
al.	)	I
(1991)	.	I
Biochemistry,	.	I
30:10832;	.	I
Clackson,	.	B
T.	,	I
et	:	I
al.	,	I
(1991)	NNP	I
Nature,	NNP	I
352:	FW	I
624;	.	I
Marks,	)	B
J.	,	I
D.	:	I
et	,	I
al.	NNP	I
(1991),	CC	I
J.	.	I
Mol.	)	I
Biol.,	,	I
222:581;	:	I
Kang,	:	B
A.	,	I
S.	NNP	I
et	NNP	I
al.	FW	I
(1991)	.	I
Proc.	,	I
Natl.	NNP	I
Acad.	.	I
Sci.	,	I
USA,	:	I
88:8363,	,	I
and	NNP	O
Smith,	NNP	B
G.	FW	I
P.	.	I
(1991)	)	I
Current	.	I
Opin.	.	I
Biotechnol.,	.	I
2:668).A	.	O
“PRO227,	,	O
PRO233,	,	O
PRO238,	CC	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	NNP	O
PRO10096,	)	O
PRO21384,	NNP	O
PRO353	.	O
or	,	O
PRO1885	.	O
binding	DT	O
organic	,	O
molecule”	,	O
is	,	O
an	,	O
organic	,	O
molecule	,	O
other	,	O
than	,	O
an	NNP	O
oligopeptide	CC	O
or	NNP	O
antibody	VBG	O
as	JJ	O
defined	NN	O
herein	VBZ	O
that	DT	O
binds,	JJ	O
preferably	NN	O
specifically,	JJ	O
to	IN	O
a	DT	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	WDT	O
PRO21384,	,	O
PRO353	RB	O
or	,	O
PRO1885	TO	O
polypeptide	DT	O
as	,	O
described	,	O
herein.	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	RB	O
or	IN	O
PRO1885	VBN	O
binding	.	O
organic	,	O
molecules	,	O
may	,	O
be	,	O
identified	,	O
and	,	O
chemically	,	O
synthesized	,	O
using	NNP	O
known	CC	O
methodology	NNP	O
(see,	VBG	O
e.g.,	JJ	O
PCT	NNS	O
Publication	MD	O
Nos.	VB	O
WO00/00823	VBN	O
and	CC	O
WO00/39585).	RB	O
PRO227,	JJ	O
PRO233,	VBG	O
PRO238,	VBN	O
PRO1328,	NN	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	.	O
or	NNP	O
PRO1885	CC	O
binding	.	O
organic	,	O
molecules	,	O
are	,	O
usually	,	O
less	,	O
than	,	O
about	,	O
2000	,	O
daltons	NNP	O
in	CC	O
size,	NNP	O
alternatively	VBG	O
less	JJ	O
than	NNS	O
about	VBP	O
1500,	RB	O
750,	JJR	O
500,	IN	O
250	IN	O
or	CD	O
200	NNS	O
daltons	IN	O
in	,	O
size,	RB	O
wherein	JJR	O
such	IN	O
organic	IN	O
molecules	,	O
that	,	O
are	,	O
capable	CD	O
of	CC	O
binding,	CD	O
preferably	NNS	O
specifically,	IN	O
to	,	O
a	WP	O
PRO227,	JJ	O
PRO233,	JJ	O
PRO238,	NNS	O
PRO1328,	WDT	O
PRO4342,	VBP	O
PRO7423,	JJ	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	RB	O
or	,	O
PRO1885	TO	O
polypeptide	DT	O
as	,	O
described	,	O
herein	,	O
may	,	O
be	,	O
identified	,	O
without	,	O
undue	,	O
experimentation	NNP	O
using	CC	O
well	NNP	O
known	RB	O
techniques.	IN	O
In	VBN	O
this	NN	O
regard,	MD	O
it	VB	O
is	VBN	O
noted	IN	O
that	JJ	O
techniques	NN	O
for	VBG	O
screening	RB	O
organic	VBN	O
molecule	.	O
libraries	IN	O
for	DT	O
molecules	,	O
that	PRP	O
are	VBZ	O
capable	VBN	O
of	IN	O
binding	NNS	O
to	IN	O
a	VBG	O
polypeptide	JJ	O
target	NN	O
are	NNS	O
well	IN	O
known	NNS	O
in	WDT	O
the	VBP	O
art	JJ	O
(see,	IN	O
e.g.,	VBG	O
PCT	TO	O
Publication	DT	O
Nos.	NN	O
WO00/00823	NN	O
and	VBP	O
WO00/39585).	RB	O
An	VBN	O
antibody,	IN	O
oligopeptide	DT	O
or	NN	O
other	,	O
organic	,	O
molecule	NNP	O
“which	NNP	O
binds”	.	O
an	NNP	O
antigen	CC	O
of	.	O
interest,	DT	O
e.g.	,	O
a	RB	O
tumor-associated	CC	O
polypeptide	JJ	O
antigen	JJ	O
target,	NN	O
is	NNP	O
one	VBD	O
that	DT	O
binds	NN	O
the	IN	O
antigen	,	O
with	.	O
sufficient	DT	O
affinity	JJ	O
such	NN	O
that	NN	O
the	,	O
antibody,	VBZ	O
oligopeptide	CD	O
or	WDT	O
other	VBZ	O
organic	DT	O
molecule	NN	O
is	IN	O
preferably	JJ	O
useful	NN	O
as	JJ	O
a	IN	O
diagnostic	DT	O
and/or	,	O
therapeutic	RB	O
agent	CC	O
in	JJ	O
targeting	JJ	O
a	NN	O
cell	VBZ	O
or	RB	O
tissue	JJ	O
expressing	IN	O
the	DT	O
antigen,	JJ	O
and	NN	O
does	JJ	O
not	NN	O
significantly	IN	O
cross-react	VBG	O
with	DT	O
other	NN	O
proteins.	CC	O
The	NN	O
extent	VBG	O
of	DT	O
binding	,	O
of	CC	O
the	VBZ	O
antibody,	RB	O
oligopeptide	RB	O
or	JJ	O
other	IN	O
organic	JJ	O
molecule	.	O
to	DT	O
a	NN	O
“non-target”	IN	O
protein	NN	O
will	IN	O
be	DT	O
less	,	O
than	RB	O
about	CC	O
10%	JJ	O
of	JJ	O
the	NN	O
binding	TO	O
of	DT	O
the	JJ	O
antibody,	NN	O
oligopeptide	MD	O
or	VB	O
other	JJR	O
organic	IN	O
molecule	RB	O
to	NN	O
its	IN	O
particular	DT	O
target	NN	O
protein	IN	O
as	DT	O
determined	,	O
by	RB	O
fluorescence	CC	O
activated	JJ	O
cell	JJ	O
sorting	NN	O
(FACS)	TO	O
analysis	PRP$	O
or	JJ	O
radioimmunoprecipitation	NN	O
(RIA).	NN	O
With	IN	O
regard	VBN	O
to	IN	O
the	NN	O
binding	VBN	O
of	NN	O
an	VBG	O
antibody,	)	O
oligopeptide	NN	O
or	CC	O
other	NN	O
organic	.	O
molecule	IN	O
to	NN	O
a	TO	O
target	DT	O
molecule,	NN	O
the	IN	O
term	DT	O
“specific	,	O
binding”	RB	O
or	CC	O
“specifically	JJ	O
binds	JJ	O
to”	NN	O
or	TO	O
is	DT	O
“specific	NN	O
for”	,	O
a	DT	O
particular	NN	O
polypeptide	NNP	O
or	NN	O
an	CC	O
epitope	RB	O
on	VBZ	O
a	NN	O
particular	CC	O
polypeptide	VBZ	O
target	JJ	O
means	NN	O
binding	DT	O
that	JJ	O
is	NN	O
measurably	CC	O
different	DT	O
from	NN	O
a	IN	O
non-specific	DT	O
interaction.	JJ	O
Specific	NN	O
binding	NN	O
can	VBZ	O
be	VBG	O
measured,	DT	O
for	VBZ	O
example,	RB	O
by	JJ	O
determining	IN	O
binding	DT	O
of	JJ	O
a	.	O
molecule	JJ	O
compared	NN	O
to	MD	O
binding	VB	O
of	,	O
a	IN	O
control	,	O
molecule,	IN	O
which	VBG	O
generally	NN	O
is	IN	O
a	DT	O
molecule	NN	O
of	VBN	O
similar	TO	O
structure	NN	O
that	IN	O
does	DT	O
not	NN	O
have	,	O
binding	WDT	O
activity.	RB	O
For	VBZ	O
example,	DT	O
specific	NN	O
binding	IN	O
can	JJ	O
be	NN	O
determined	WDT	O
by	VBZ	O
competition	RB	O
with	VB	O
a	VBG	O
control	.	O
molecule	IN	O
that	,	O
is	JJ	O
similar	NN	O
to	MD	O
the	VB	O
target,	VBN	O
for	IN	O
example,	NN	O
an	IN	O
excess	DT	O
of	NN	O
non-labeled	NN	O
target.	WDT	O
In	VBZ	O
this	JJ	O
case,	TO	O
specific	DT	O
binding	,	O
is	IN	O
indicated	,	O
if	DT	O
the	NN	O
binding	IN	O
of	JJ	O
the	.	O
labeled	IN	O
target	DT	O
to	,	O
a	JJ	O
probe	NN	O
is	VBZ	O
competitively	VBN	O
inhibited	IN	O
by	DT	O
excess	NN	O
unlabeled	IN	O
target.	DT	O
The	JJ	O
term	NN	O
“specific	TO	O
binding”	DT	O
or	NN	O
“specifically	VBZ	O
binds	RB	O
to”	VBN	O
or	IN	O
is	NN	O
“specific	JJ	O
for”	.	O
a	DT	O
particular	NN	O
polypeptide	NNP	O
or	NN	O
an	CC	O
epitope	RB	O
on	VBZ	O
a	NN	O
particular	CC	O
polypeptide	VBZ	O
target	JJ	O
as	NN	O
used	DT	O
herein	JJ	O
can	NN	O
be	CC	O
exhibited,	DT	O
for	NN	O
example,	IN	O
by	DT	O
a	JJ	O
molecule	NN	O
having	NN	O
a	IN	O
Kd	JJ	O
for	NN	O
the	MD	O
target	VB	O
of	,	O
at	IN	O
least	,	O
about	IN	O
10−4	DT	O
M,	NN	O
alternatively	VBG	O
at	DT	O
least	NNP	O
about	IN	O
10−5	DT	O
M,	NN	O
alternatively	IN	O
at	IN	O
least	JJS	O
about	IN	O
10−6	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−7	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−8	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−9	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−10	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−11	CD	O
M,	,	O
alternatively	RB	O
at	IN	O
least	JJS	O
about	IN	O
10−12	CD	O
M,	,	O
or	RB	O
greater.	IN	O
The	JJS	O
term	IN	O
“specific	CD	O
binding”	,	O
refers	RB	O
to	IN	O
binding	JJS	O
where	IN	O
a	CD	O
molecule	,	O
binds	CC	O
to	.	O
a	DT	O
particular	NN	O
polypeptide	NNP	O
or	NN	O
epitope	NNS	O
on	TO	O
a	VBG	O
particular	WRB	O
polypeptide	DT	O
without	NN	O
substantially	VBZ	O
binding	TO	O
to	DT	O
any	JJ	O
other	NN	O
polypeptide	CC	O
or	NN	O
polypeptide	IN	O
epitope.	DT	O
An	JJ	O
antibody,	NN	O
oligopeptide	IN	O
or	RB	O
other	VBG	O
organic	TO	O
molecule	DT	O
that	JJ	O
“inhibits	NN	O
the	CC	O
growth	JJ	O
of	.	O
tumor	DT	O
cells	,	O
expressing	RB	O
a	CC	O
“PRO227,	JJ	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	VBZ	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	NN	O
or	NNS	O
PRO1885”	VBG	O
or	DT	O
a	,	O
“growth	,	O
inhibitory”	,	O
antibody,	,	O
oligopeptide	,	O
or	,	O
other	,	O
organic	,	O
molecule	NNP	O
is	CC	O
one	NNP	O
which	CC	O
results	DT	O
in	NN	O
measurable	NN	O
growth	,	O
inhibition	RB	O
of	CC	O
cancer	JJ	O
cells	JJ	O
expressing	NN	O
or	VBZ	O
overexpressing	CD	O
the	WDT	O
appropriate	NNS	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	NN	O
PRO10096,	NNS	O
PRO21384,	VBG	O
PRO353	CC	O
or	VBG	O
PRO1885	DT	O
polypeptide.	JJ	O
The	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	.	O
polypeptide	DT	O
may	,	O
be	,	O
a	,	O
transmembrane	,	O
polypeptide	,	O
expressed	,	O
on	,	O
the	,	O
surface	NNP	O
of	CC	O
a	NNP	O
cancer	NN	O
cell	MD	O
or	VB	O
may	DT	O
be	JJ	O
a	NN	O
polypeptide	VBN	O
that	IN	O
is	DT	O
produced	NN	O
and	IN	O
secreted	DT	O
by	NN	O
a	NN	O
cancer	CC	O
cell.	MD	O
Preferred	VB	O
growth	DT	O
inhibitory	NN	O
anti-PRO227,	WDT	O
anti-PRO233,	VBZ	O
anti-PRO238,	VBN	O
anti-PRO1328,	CC	O
anti-PRO4342,	VBN	O
anti-PRO7423,	IN	O
anti-PRO10096,	DT	O
anti-PRO21384,	NN	O
anti-PRO353	.	O
or	NNP	O
anti-PRO1885	NN	O
antibodies,	NN	O
oligopeptides	,	O
or	,	O
organic	,	O
molecules	,	O
inhibit	,	O
growth	,	O
of	,	O
PRO227-,	,	O
PRO233-,	JJ	O
PRO238-,	CC	O
PRO1328-,	JJ	O
PRO4342-,	,	O
PRO7423-,	NNS	O
PRO10096-,	CC	O
PRO21384-,	JJ	O
PRO353-	NNS	O
or	VBP	O
PRO1885-expressing	NN	O
tumor	IN	O
cells	,	O
by	,	O
or	,	O
by	,	O
greater	,	O
than	,	O
20%,	,	O
preferably	,	O
from	NNP	O
about	CC	O
20%	NNP	O
to	NN	O
about	NNS	O
50%,	IN	O
and	CC	O
even	IN	O
more	JJR	O
preferably,	IN	O
by	,	O
or	RB	O
by	IN	O
greater	IN	O
than	NN	O
50%	TO	O
(e.g.,	RB	O
from	,	O
about	CC	O
50%	RB	O
to	RBR	O
about	,	O
100%)	IN	O
as	CC	O
compared	IN	O
to	JJR	O
the	IN	O
appropriate	NN	O
control,	,	O
the	IN	O
control	IN	O
typically	NN	O
being	TO	O
tumor	RB	O
cells	)	O
not	IN	O
treated	VBN	O
with	TO	O
the	DT	O
antibody,	JJ	O
oligopeptide	,	O
or	DT	O
other	NN	O
organic	RB	O
molecule	VBG	O
being	NN	O
tested.	NNS	O
Growth	RB	O
inhibition	VBN	O
can	IN	O
be	DT	O
measured	,	O
at	RB	O
an	CC	O
antibody	JJ	O
concentration	JJ	O
of	NN	O
about	VBG	O
0.1	.	O
to	NNP	O
30	NN	O
μg/ml	MD	O
or	VB	O
about	VBN	O
0.5	IN	O
nM	DT	O
to	NN	O
200	NN	O
nM	IN	O
in	RB	O
cell	CD	O
culture,	TO	O
where	CD	O
the	NNS	O
growth	CC	O
inhibition	IN	O
is	CD	O
determined	NNS	O
1-10	TO	O
days	CD	O
after	NNS	O
exposure	IN	O
of	NN	O
the	,	O
tumor	WRB	O
cells	DT	O
to	NN	O
the	NN	O
antibody.	VBZ	O
Growth	VBN	O
inhibition	JJ	O
of	NNS	O
tumor	IN	O
cells	NN	O
in	IN	O
vivo	DT	O
can	NN	O
be	NNS	O
determined	TO	O
in	DT	O
various	.	O
ways.	NNP	O
The	NN	O
antibody	IN	O
is	NN	O
growth	NNS	O
inhibitory	IN	O
in	NN	O
vivo	MD	O
if	VB	O
administration	VBN	O
of	IN	O
the	JJ	O
anti-PRO227,	.	O
anti-PRO233,	DT	O
anti-PRO238,	NN	O
anti-PRO1328,	VBZ	O
anti-PRO4342,	NN	O
anti-PRO7423,	NN	O
anti-PRO10096,	IN	O
anti-PRO21384,	NN	O
anti-PRO353	IN	O
or	NN	O
anti-PRO1885	IN	O
antibody	DT	O
at	,	O
about	,	O
1	,	O
μg/kg	,	O
to	,	O
about	,	O
100	,	O
mg/kg	,	O
body	JJ	O
weight	CC	O
results	JJ	O
in	NN	O
reduction	IN	O
in	IN	O
tumor	CD	O
size	NNS	O
or	TO	O
tumor	IN	O
cell	CD	O
proliferation	NNS	O
within	NN	O
about	JJ	O
5	NNS	O
days	IN	O
to	NN	O
3	IN	O
months	NN	O
from	NN	O
the	CC	O
first	NN	O
administration	NN	O
of	NN	O
the	IN	O
antibody,	IN	O
preferably	CD	O
within	NNS	O
about	TO	O
5	CD	O
to	NNS	O
30	IN	O
days.	DT	O
An	JJ	O
antibody,	NN	O
oligopeptide	IN	O
or	DT	O
other	,	O
organic	RB	O
molecule	IN	O
which	RB	O
“induces	CD	O
apoptosis”	TO	O
is	CD	O
one	.	O
which	DT	O
induces	,	O
programmed	RB	O
cell	CC	O
death	JJ	O
as	JJ	O
determined	NN	O
by	WDT	O
binding	VBZ	O
of	NN	O
annexin	VBZ	O
V,	CD	O
fragmentation	WDT	O
of	VBZ	O
DNA,	VBN	O
cell	RB	O
shrinkage,	NN	O
dilation	IN	O
of	VBN	O
endoplasmic	IN	O
reticulum,	VBG	O
cell	IN	O
fragmentation,	NN	O
and/or	,	O
formation	NN	O
of	IN	O
membrane	,	O
vesicles	NN	O
(called	,	O
apoptotic	NN	O
bodies).	IN	O
The	JJ	O
cell	,	O
is	NN	O
usually	,	O
one	JJ	O
which	NN	O
overexpresses	IN	O
a	NN	O
PRO227,	NNS	O
PRO233,	VBN	O
PRO238,	JJ	O
PRO1328,	.	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	VBZ	O
PRO21384,	RB	O
PRO353	CD	O
or	WDT	O
PRO1885	VBZ	O
polypeptide.	DT	O
Preferably	,	O
the	,	O
cell	,	O
is	,	O
a	,	O
tumor	,	O
cell,	,	O
e.g.,	,	O
a	NNP	O
prostate,	CC	O
breast,	NNP	O
ovarian,	.	O
stomach,	RB	O
endometrial,	DT	O
lung,	NN	O
kidney,	VBZ	O
colon,	DT	O
bladder	NN	O
cell.	,	O
Various	,	O
methods	DT	O
are	,	O
available	,	O
for	,	O
evaluating	,	O
the	,	O
cellular	,	O
events	,	O
associated	,	O
with	NN	O
apoptosis.	.	O
For	JJ	O
example,	NNS	O
phosphatidyl	VBP	O
serine	JJ	O
(PS)	IN	O
translocation	VBG	O
can	DT	O
be	JJ	O
measured	NNS	O
by	VBN	O
annexin	IN	O
binding;	.	O
DNA	IN	O
fragmentation	,	O
can	FW	O
be	NN	O
evaluated	)	O
through	NN	O
DNA	MD	O
laddering;	VB	O
and	VBN	O
nuclear/chromatin	IN	O
condensation	NN	O
along	:	O
with	NNP	O
DNA	NN	O
fragmentation	MD	O
can	VB	O
be	VBN	O
evaluated	IN	O
by	NNP	O
any	:	O
increase	CC	O
in	DT	O
hypodiploid	NN	O
cells.	IN	O
Preferably,	IN	O
the	NNP	O
antibody,	NN	O
oligopeptide	MD	O
or	VB	O
other	VBN	O
organic	IN	O
molecule	DT	O
which	NN	O
induces	IN	O
apoptosis	JJ	O
is	.	O
one	,	O
which	DT	O
results	,	O
in	RB	O
or	CC	O
in	JJ	O
about	JJ	O
2	NN	O
to	WDT	O
50	VBZ	O
fold,	NN	O
preferably	VBZ	O
in	CD	O
or	WDT	O
in	NNS	O
about	IN	O
5	CC	O
to	IN	O
50	RB	O
fold,	CD	O
and	TO	O
most	CD	O
preferably	,	O
in	RB	O
or	IN	O
in	CC	O
about	IN	O
10	RB	O
to	CD	O
50	TO	O
fold,	CD	O
induction	,	O
of	CC	O
annexin	JJS	O
binding	RB	O
relative	IN	O
to	CC	O
untreated	IN	O
cell	RB	O
in	CD	O
an	TO	O
annexin	CD	O
binding	,	O
assay.	NN	O
Antibody	IN	O
“effector	NN	O
functions”	VBG	O
refer	JJ	O
to	TO	O
those	JJ	O
biological	NN	O
activities	IN	O
attributable	DT	O
to	NN	O
the	VBG	O
Fc	.	O
region	NNP	O
(a	NNP	O
native	VBD	O
sequence	NN	O
Fc	TO	O
region	DT	O
or	JJ	O
amino	NNS	O
acid	JJ	O
sequence	TO	O
variant	DT	O
Fc	NNP	O
region)	NN	O
of	DT	O
an	JJ	O
antibody,	NN	O
and	NNP	O
vary	NN	O
with	CC	O
the	NN	O
antibody	JJ	O
isotype.	NN	O
Examples	NN	O
of	NNP	O
antibody	)	O
effector	IN	O
functions	DT	O
include:	,	O
C1q	CC	O
binding	JJ	O
and	IN	O
complement	DT	O
dependent	NN	O
cytotoxicity;	.	O
Fc	NNS	O
receptor	IN	O
binding;	NN	O
antibody-dependent	NN	O
cell-mediated	NNS	O
cytotoxicity	:	O
(ADCC);	NNP	O
phagocytosis;	NN	O
down	CC	O
regulation	NN	O
of	JJ	O
cell	:	O
surface	NNP	O
receptors	NN	O
(e.g.,	:	O
B	JJ	O
cell	JJ	O
receptor);	NN	O
and	:	O
B	:	O
cell	IN	O
activation.	NN	O
“Antibody-dependent	IN	O
cell-mediated	NN	O
cytotoxicity”	NN	O
or	NNS	O
“ADCC”	,	O
refers	NNP	O
to	NN	O
a	:	O
form	CC	O
of	NNP	O
cytotoxicity	NN	O
in	.	O
which	JJ	O
secreted	JJ	O
Ig	NN	O
bound	CC	O
onto	JJ	O
Fc	NNS	O
receptors	TO	O
(FcRs)	DT	O
present	NN	O
on	IN	O
certain	NN	O
cytotoxic	IN	O
cells	WDT	O
(e.g.,	VBD	O
Natural	NNP	O
Killer	IN	O
(NK)	IN	O
cells,	NNP	O
neutrophils,	NNS	O
and	)	O
macrophages)	NN	O
enable	IN	O
these	JJ	O
cytotoxic	NN	O
effector	NNS	O
cells	,	O
to	NNP	O
bind	NNP	O
specifically	)	O
to	,	O
an	,	O
antigen-bearing	CC	O
target	)	O
cell	VBP	O
and	DT	O
subsequently	NNS	O
kill	VBP	O
the	NNS	O
target	TO	O
cell	VB	O
with	RB	O
cytotoxins.	TO	O
The	DT	O
antibodies	JJ	O
“arm”	NN	O
the	NN	O
cytotoxic	CC	O
cells	RB	O
and	VB	O
are	DT	O
absolutely	NN	O
required	NN	O
for	IN	O
such	.	O
killing.	DT	O
The	NNS	O
primary	VBP	O
cells	DT	O
for	NN	O
mediating	NNS	O
ADCC,	CC	O
NK	VBP	O
cells,	RB	O
express	VBN	O
FcγRIII	IN	O
only,	JJ	O
whereas	.	O
monocytes	DT	O
express	JJ	O
FcγRI,	NNS	O
FcγRII	IN	O
and	VBG	O
FcγRIII.	,	O
FcR	NNP	O
expression	,	O
on	NN	O
hematopoietic	NNP	O
cells	,	O
is	JJ	O
summarized	NNS	O
in	JJ	O
Table	,	O
3	NNP	O
on	CC	O
page	.	O
464	NNP	O
of	NN	O
Ravetch	IN	B
and	JJ	I
Kinet,	NNS	I
Annu.	VBZ	I
Rev.	VBN	I
Immunol.	IN	I
9:457-92	JJ	I
(1991).	CD	I
To	IN	O
assess	NN	O
ADCC	CD	O
activity	IN	O
of	NNP	O
a	CC	O
molecule	,	O
of	.	O
interest,	.	O
an	.	O
in	CD	O
vitro	.	O
ADCC	TO	O
assay,	VB	O
such	NNP	O
as	NN	O
that	IN	O
described	DT	O
in	NN	O
U.S.	IN	O
Pat.	,	O
No.	DT	O
5,500,362	IN	O
or	NN	O
5,821,337	NNP	O
may	,	O
be	JJ	O
performed.	IN	O
Useful	DT	O
effector	VBD	O
cells	IN	O
for	NNP	O
such	.	O
assays	.	O
include	CD	O
peripheral	CC	O
blood	CD	O
mononuclear	MD	O
cells	VB	O
(PBMC)	.	O
and	JJ	O
Natural	NN	O
Killer	NNS	O
(NK)	IN	O
cells.	JJ	O
Alternatively,	NNS	O
or	VBP	O
additionally,	JJ	O
ADCC	NN	O
activity	NN	O
of	NNS	O
the	)	O
molecule	CC	O
of	NNP	O
interest	NNP	O
may	)	O
be	.	O
assessed	,	O
in	CC	O
vivo,	,	O
e.g.,	NNP	O
in	NN	O
a	IN	O
animal	DT	O
model	NN	O
such	IN	O
as	NN	O
that	MD	O
disclosed	VB	O
in	VBN	O
Clynes	IN	B
et	,	I
al.	,	I
Proc.	IN	I
Natl.	DT	I
Acad.	JJ	I
Sci.	NN	I
U.S.A.	JJ	I
95:652-656	IN	I
(1998).
“Fc	DT	O
receptor”	VBD	O
or	IN	O
“FcR”	NNP	O
describes	CC	O
a	.	O
receptor	.	O
that	.	O
binds	.	O
to	.	O
the	NNP	O
Fc	CD	O
region	.	O
of	JJ	O
an	NN	O
antibody.	CC	O
The	VB	O
preferred	VBZ	O
FcR	DT	O
is	NN	O
a	WDT	O
native	VBZ	O
sequence	TO	O
human	DT	O
FcR.	NNP	O
Moreover,	NN	O
a	IN	O
preferred	DT	O
FcR	.	O
is	DT	O
one	JJ	O
which	NNP	O
binds	VBZ	O
an	DT	O
IgG	JJ	O
antibody	NN	O
(a	JJ	O
gamma	.	O
receptor)	,	O
and	DT	O
includes	JJ	O
receptors	NNP	O
of	VBZ	O
the	CD	O
FcγRI,	WDT	O
FcγRII	VBZ	O
and	DT	O
FcγRIII	NNP	O
subclasses,	NN	O
including	DT	O
allelic	NN	O
variants	)	O
and	CC	O
alternatively	VBZ	O
spliced	NNS	O
forms	IN	O
of	DT	O
these	,	O
receptors.	NNP	O
FcγRII	CC	O
receptors	NNP	O
include	,	O
FcγRIIA	VBG	O
(an	JJ	O
“activating	NNS	O
receptor”)	CC	O
and	RB	O
FcγRIIB	VBD	O
(an	NNS	O
“inhibiting	IN	O
receptor”),	DT	O
which	.	O
have	NNP	O
similar	NNS	O
amino	VBP	O
acid	NNP	O
sequences	DT	O
that	VBG	O
differ	)	O
primarily	CC	O
in	NNP	O
the	DT	O
cytoplasmic	VBG	O
domains	,	O
thereof.	WDT	O
Activating	VBP	O
receptor	JJ	O
FcγRIIA	NN	O
contains	NN	O
an	NNS	O
immunoreceptor	WDT	O
tyrosine-based	VBP	O
activation	RB	O
motif	IN	O
(ITAM)	DT	O
in	JJ	O
its	NNS	O
cytoplasmic	.	O
domain.	VBG	O
Inhibiting	NN	O
receptor	NNP	O
FcγRIIB	VBZ	O
contains	DT	O
an	NN	O
immunoreceptor	JJ	O
tyrosine-based	NN	O
inhibition	NN	O
motif	)	O
(ITIM)	IN	O
in	PRP$	O
its	JJ	O
cytoplasmic	.	O
domain.	VBG	O
(see	NN	O
review	NNP	O
M.	VBZ	B
in	DT	I
Daëron,	NN	I
Annu.	JJ	I
Rev.	NN	I
Immunol.	NN	I
15:203-234	)	I
(1997)).FcRs	IN	O
are	PRP$	O
reviewed	JJ	O
in	.	O
Ravetch	VB	O
and	NN	O
Kinet,	NNP	B
Annu.	IN	I
Rev.	,	I
Immunol.	.	I
9:457-492	.	I
(1991);	.	I
Capel	CD	B
et	.	I
al.,	NNS	I
Immunomethods	VBP	I
4:25-34	VBN	I
(1994);	IN	I
and	NNP	O
de	CC	B
Haas	,	I
et	.	I
al.,	.	I
J.	.	I
Lab.	CD	I
Clin.	:	I
Med.	NNP	I
126:330-41	FW	I
(1995).	,	I
Other	NNP	O
FcRs,	CD	O
including	:	O
those	CC	O
to	VB	O
be	NNP	O
identified	CC	O
in	,	O
the	.	O
future,	.	O
are	.	O
encompassed	.	O
by	CD	O
the	.	O
term	JJ	O
“FcR”	,	O
herein.	VBG	O
The	DT	O
term	TO	O
also	VB	O
includes	VBN	O
the	IN	O
neonatal	DT	O
receptor,	,	O
FcRn,	VBP	O
which	VBN	O
is	IN	O
responsible	DT	O
for	NN	O
the	NNP	O
transfer	.	O
of	DT	O
maternal	NN	O
IgGs	RB	O
to	VBZ	O
the	DT	O
fetus	JJ	O
Guyer	,	B
et	,	I
al.,	WDT	I
J.	VBZ	I
Immunol.	JJ	I
117:587	IN	I
(1976)	DT	I
a(nd	NN	O
Kim	IN	B
et	JJ	I
al.,	NNP	I
J.	TO	I
Immunol.	DT	I
24:249	NN	I
(1994)).“Human	NNP	O
effector	RB	O
cells”	,	O
are	NNP	O
leukocytes	.	O
which	CD	O
express	)	O
one	CC	O
or	NNP	O
more	NNP	O
FcRs	,	O
and	NNP	O
perform	.	O
effector	CD	O
functions.	.	O
Preferably,	JJ	O
the	NN	O
cells	NN	O
express	VBP	O
at	VBZ	O
least	WDT	O
FcγRIII	VBP	O
and	CD	O
perform	CC	O
ADCC	JJR	O
effector	NNS	O
function.	CC	O
Examples	VB	O
of	NN	O
human	.	O
leukocytes	,	O
which	DT	O
mediate	NNS	O
ADCC	NN	O
include	IN	O
peripheral	JJS	O
blood	NNP	O
mononuclear	CC	O
cells	VB	O
(PBMC),	NNP	O
natural	NN	O
killer	.	O
(NK)	NNS	O
cells,	IN	O
monocytes,	NN	O
cytotoxic	NNS	O
T	WDT	O
cells	VBP	O
and	NNP	O
neutrophils;	VBP	O
with	JJ	O
PBMCs	NN	O
and	NN	O
NK	NNS	O
cells	,	O
being	JJ	O
preferred.	NN	O
The	)	O
effector	,	O
cells	,	O
may	NN	O
be	NNP	O
isolated	NNS	O
from	CC	O
a	:	O
native	IN	O
source,	NNP	O
e.g.,	CC	O
from	NNP	O
blood.	NNS	O
“Complement	VBG	O
dependent	.	O
cytotoxicity”	DT	O
or	NN	O
“CDC”	NNS	O
refers	MD	O
to	VB	O
the	VBN	O
lysis	IN	O
of	DT	O
a	JJ	O
target	,	O
cell	,	O
in	IN	O
the	.	O
presence	JJ	O
of	JJ	O
complement.	NN	O
Activation	CC	O
of	JJ	O
the	NNS	O
classical	TO	O
complement	DT	O
pathway	NN	O
is	IN	O
initiated	DT	O
by	NN	O
the	NN	O
binding	IN	O
of	DT	O
the	NN	O
first	IN	O
component	.	O
of	NN	O
the	IN	O
complement	DT	O
system	JJ	O
(C1q)	NN	O
to	NN	O
antibodies	VBZ	O
(of	VBN	O
the	IN	O
appropriate	DT	O
subclass)	NN	O
which	IN	O
are	DT	O
bound	JJ	O
to	NN	O
their	IN	O
cognate	DT	O
antigen.	NN	O
To	NN	O
assess	)	O
complement	TO	O
activation,	NNS	O
a	IN	O
CDC	DT	O
assay,	JJ	O
e.g.,	)	O
as	WDT	O
described	VBP	O
in	VBN	O
Gazzano-Santoro	TO	B
et	PRP$	I
al.,	NN	I
J.	.	I
Immunol.	TO	I
Methods	VB	I
202:163	JJ	I
(1996),	,	I
may	DT	O
be	NNP	O
performed.	,	O
The	,	O
terms	IN	O
“cancer”	VBN	O
and	IN	O
“cancerous”	NNP	O
refer	NN	O
to	,	O
or	NNP	O
describe	.	O
the	NNS	O
physiological	CD	O
condition	,	O
in	MD	O
mammals	VB	O
that	.	O
is	DT	O
typically	NNS	O
characterized	VBP	O
by	CC	O
unregulated	VBP	O
cell	VBP	O
growth.	TO	O
Examples	CC	O
of	VB	O
cancer	DT	O
include	JJ	O
but	NN	O
are	IN	O
not	NNS	O
limited	WDT	O
to,	VBZ	O
carcinoma,	RB	O
lymphoma,	VBN	O
blastoma,	IN	O
sarcoma,	JJ	O
and	NN	O
leukemia.	.	O
More	NNS	O
particular	IN	O
examples	NN	O
of	VBP	O
such	CC	O
cancers	VBP	O
include	RB	O
squamous	VBN	O
cell	,	O
cancer,	,	O
lung	,	O
cancer	,	O
(including	,	O
small-cell	CC	O
lung	.	O
cancer,	JJR	O
non-small	JJ	O
cell	NNS	O
lung	IN	O
cancer,	JJ	O
adenocarcinoma	NNS	O
of	VBP	O
the	JJ	O
lung,	NN	O
and	,	O
squamous	NN	O
carcinoma	NN	O
of	VBG	O
the	NN	O
lung),	NN	O
cancer	,	O
of	JJ	O
the	NN	O
peritoneum,	NN	O
hepatocellular	,	O
cancer,	NN	O
gastric	IN	O
or	DT	O
stomach	,	O
cancer	CC	O
(including	JJ	O
gastrointestinal	NN	O
cancer),	IN	O
pancreatic	DT	O
cancer,	,	O
glioblastoma,	NN	O
cervical	IN	O
cancer,	DT	O
ovarian	,	O
cancer,	JJ	O
liver	,	O
cancer,	JJ	O
bladder	CC	O
cancer,	JJ	O
hepatoma,	NN	O
breast	VBG	O
cancer,	JJ	O
colon	,	O
cancer,	JJ	O
colorectal	,	O
cancer,	,	O
endometrial	JJ	O
or	,	O
uterine	JJ	O
carcinoma,	,	O
salivary	RB	O
gland	,	O
carcinoma,	NN	O
kidney	,	O
or	,	O
renal	NN	O
cancer,	,	O
liver	NN	O
cancer,	,	O
prostate	JJ	O
cancer,	,	O
vulval	JJ	O
cancer,	CC	O
thyroid	JJ	O
cancer,	,	O
hepatic	JJ	O
carcinoma	NN	O
and	,	O
various	NN	O
types	CC	O
of	JJ	O
head	,	O
and	RB	O
neck	,	O
cancer,	NN	O
as	,	O
well	JJ	O
as	,	O
B-cell	JJ	O
lymphoma	,	O
(including	JJ	O
low	NN	O
grade/follicular	CC	O
non-Hodgkin's	JJ	O
lymphoma	NNS	O
(NHL);	IN	O
small	NN	O
lymphocytic	CC	O
(SL)	NN	O
NHL;	,	O
intermediate	RB	O
grade/follicular	RB	O
NHL;	IN	O
intermediate	NNP	O
grade	NN	O
diffuse	VBG	O
NHL;	JJ	O
high	JJ	O
grade	POS	O
immunoblastic	NN	O
NHL;	:	O
high	JJ	O
grade	JJ	O
lymphoblastic	)	O
NHL;	:	O
high	JJ	O
grade	JJ	O
small	:	O
non-cleaved	JJ	O
cell	NN	O
NHL;	NN	O
bulky	:	O
disease	JJ	O
NHL;	NN	O
mantle	JJ	O
cell	:	O
lymphoma;	JJ	O
AIDS-related	NN	O
lymphoma;	JJ	O
and	:	O
Waldenstrom's	JJ	O
Macroglobulinemia);	NN	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(CLL);	:	O
acute	JJ	O
lymphoblastic	NN	O
leukemia	:	O
(ALL);	CC	O
Hairy	NN	O
cell	:	O
leukemia;	JJ	O
chronic	:	O
myeloblastic	CC	O
leukemia;	POS	O
and	:	O
post-transplant	JJ	O
lymphoproliferative	JJ	O
disorder	NN	O
(PTLD).	:	O
Preferably,	JJ	O
the	JJ	O
cancer	NN	O
comprises	:	O
a	NNP	O
tumor	NN	O
that	:	O
expresses	JJ	O
an	JJ	O
IGF	:	O
receptor,	CC	O
more	JJ	O
preferably	JJ	O
breast	NN	O
cancer,	.	O
lung	,	O
cancer,	DT	O
colorectal	NN	O
cancer,	VBZ	O
or	DT	O
prostate	NN	O
cancer,	WDT	O
and	VBZ	O
most	DT	O
preferably	NNP	O
breast	,	O
or	JJR	O
prostate	RB	O
cancer.	NN	O
A	,	O
“chemotherapeutic	NN	O
agent”	,	O
is	JJ	O
a	,	O
chemical	CC	O
compound	NN	O
useful	,	O
in	CC	O
the	JJS	O
treatment	RB	O
of	NN	O
cancer.	CC	O
Examples	NN	O
of	.	O
chemotherapeutic	DT	O
agents	JJ	O
include	NN	O
alkylating	VBZ	O
agents	DT	O
such	NN	O
as	NN	O
thiotepa	JJ	O
and	IN	O
CYTOXAN®	DT	O
cyclosphosphamide;	NN	O
alkyl	IN	O
sulfonates	.	O
such	NNS	O
as	IN	O
busulfan,	JJ	O
improsulfan	NNS	O
and	VBP	O
piposulfan;	VBG	O
aziridines	NNS	O
such	JJ	O
as	IN	O
benzodopa,	NN	O
carboquone,	CC	O
meturedopa,	NNP	O
and	:	O
uredopa;	VB	O
ethylenimines	NNS	O
and	JJ	O
methylamelamines	IN	O
including	,	O
altretamine,	NN	O
triethylenemelamine,	CC	O
trietylenephosphoramide,	:	O
triethiylenethiophosphoramide	NNS	O
and	JJ	O
trimethylolomelamine;	IN	O
acetogenins	,	O
(especially	,	O
bullatacin	,	O
and	CC	O
bullatacinone);	:	O
a	NNS	O
camptothecin	CC	O
(including	NNS	O
the	VBG	O
synthetic	,	O
analogue	,	O
topotecan);	,	O
bryostatin;	NN	O
callystatin;	CC	O
CC-1065	:	O
(including	NNS	O
its	RB	O
adozelesin,	VBN	O
carzelesin	CC	O
and	:	O
bizelesin	DT	O
synthetic	NN	O
analogues);	VBG	O
cryptophycins	DT	O
(particularly	JJ	O
cryptophycin	NN	O
1	:	O
and	:	O
cryptophycin	:	O
8);	NNP	O
dolastatin;	VBG	O
duocarmycin	PRP$	O
(including	,	O
the	NN	O
synthetic	CC	O
analogues,	NN	O
KW-2189	JJ	O
and	:	O
CB1-TM1);	NNS	O
eleutherobin;	RB	O
pancratistatin;	VBP	O
a	CD	O
sarcodictyin;	CC	O
spongistatin;	VB	O
nitrogen	:	O
mustards	:	O
such	NN	O
as	VBG	O
chlorambucil,	DT	O
chlornaphazine,	JJ	O
cholophosphamide,	,	O
estramustine,	NNP	O
ifosfamide,	CC	O
mechlorethamine,	:	O
mechlorethamine	:	O
oxide	:	O
hydrochloride,	DT	O
melphalan,	:	O
novembichin,	:	O
phenesterine,	CC	O
prednimustine,	NNS	O
trofosfamide,	JJ	O
uracil	IN	O
mustard;	,	O
nitrosureas	,	O
such	,	O
as	,	O
carmustine,	,	O
chlorozotocin,	,	O
fotemustine,	JJ	O
lomustine,	IN	O
nimustine,	,	O
and	,	O
ranimnustine;	,	O
antibiotics	,	O
such	,	O
as	,	O
the	JJ	O
enediyne	:	O
antibiotics	NNS	O
(e.g.,	JJ	O
calicheamicin,	IN	O
especially	,	O
calicheamicin	,	O
gamma1I	,	O
and	,	O
calicheamicin	,	O
omegaI1	CC	O
(see,	:	O
e.g.,	NNS	O
Agnew,	JJ	B
Chem.	IN	I
Intl.	DT	I
Ed.	NN	I
Engl.,	NNS	I
33:	,	I
183-186	,	I
(1994));dynemicin,	RB	O
including	JJ	O
dynemicin	NN	O
A;	CC	O
bisphosphonates,	NN	O
such	NN	O
as	,	O
clodronate;	,	O
an	,	O
esperamicin;	.	O
as	.	O
well	.	O
as	,	O
neocarzinostatin	:	O
chromophore	CD	O
and	:	O
related	,	O
chromoprotein	VBG	O
enediyne	NN	O
antibiotic	:	O
chromophores),	,	O
aclacinomysins,	JJ	O
actinomycin,	IN	O
authramycin,	:	O
azaserine,	DT	O
bleomycins,	:	O
cactinomycin,	RB	O
carabicin,	RB	O
caminomycin,	IN	O
carzinophilin,	NN	O
chromomycinis,	NN	O
dactinomycin,	CC	O
daunorubicin,	JJ	O
detorubicin,	NN	O
6-diazo-5-oxo-L-norleucine,	VBZ	O
ADRIAMYCIN®	JJ	O
doxorubicin	,	O
(including	,	O
morpholino-doxorubicin,	,	O
cyanomorpholino-doxorubicin,	,	O
2-pyrrolino-doxorubicin	,	O
and	,	O
deoxydoxorubicin),	,	O
epirubicin,	,	O
esorubicin,	,	O
idarubicin,	,	O
marcellomycin,	,	O
mitomycins	,	O
such	,	O
as	,	O
mitomycin	,	O
C,	NNP	O
mycophenolic	NN	O
acid,	VBG	O
nogalamycin,	,	O
olivomycins,	,	O
peplomycin,	JJ	O
potfiromycin,	CC	O
puromycin,	,	O
quelamycin,	,	O
rodorubicin,	,	O
streptonigrin,	,	O
streptozocin,	,	O
tubercidin,	NNS	O
ubenimex,	JJ	O
zinostatin,	IN	O
zorubicin;	NN	O
anti-metabolites	,	O
such	JJ	O
as	,	O
methotrexate	,	O
and	,	O
5-fluorouracil	,	O
(5-FU);	,	O
folic	,	O
acid	,	O
analogues	,	O
such	,	O
as	,	O
denopterin,	,	O
methotrexate,	,	O
pteropterin,	,	O
trimetrexate;	:	O
purine	NNS	O
analogs	JJ	O
such	IN	O
as	NN	O
fludarabine,	CC	O
6-mercaptopurine,	JJ	O
thiamiprine,	:	O
thioguanine;	JJ	O
pyrimidine	NN	O
analogs	NNS	O
such	JJ	O
as	IN	O
ancitabine,	,	O
azacitidine,	,	O
6-azauridine,	,	O
carmofur,	:	O
cytarabine,	JJ	O
dideoxyuridine,	NNS	O
doxifluridine,	JJ	O
enocitabine,	IN	O
floxuridine;	,	O
androgens	,	O
such	,	O
as	:	O
calusterone,	JJ	O
dromostanolone	NNS	O
propionate,	JJ	O
epitiostanol,	IN	O
mepitiostane,	,	O
testolactone;	,	O
anti-adrenals	,	O
such	,	O
as	,	O
aminoglutethimide,	,	O
mitotane,	,	O
trilostane;	,	O
folic	:	O
acid	NNS	O
replenisher	JJ	O
such	IN	O
as	,	O
frolinic	NN	O
acid;	,	O
aceglatone;	,	O
aldophosphamide	,	O
glycoside;	:	O
aminolevulinic	NNS	O
acid;	JJ	O
eniluracil;	IN	O
amsacrine;	,	O
bestrabucil;	,	O
bisantrene;	:	O
edatraxate;	JJ	O
defofamine;	VBP	O
demecolcine;	RB	O
diaziquone;	JJ	O
elformithine;	IN	O
elliptinium	JJ	O
acetate;	:	O
an	:	O
epothilone;	JJ	O
etoglucid;	:	O
gallium	JJ	O
nitrate;	:	O
hydroxyurea;	:	O
lentinan;	:	O
lonidainine;	:	O
maytansinoids	:	O
such	:	O
as	:	O
maytansine	:	O
and	:	O
ansamitocins;	:	O
mitoguazone;	JJ	O
mitoxantrone;	:	O
mopidanmol;	DT	O
nitraerine;	:	O
pentostatin;	:	O
phenamet;	NN	O
pirarubicin;	:	O
losoxantrone;	:	O
podophyllinic	:	O
acid;	:	O
2-ethylhydrazide;	NNS	O
procarbazine;	JJ	O
PSK®	IN	O
polysaccharide	NN	O
complex	CC	O
(JHS	:	O
Natural	:	O
Products,	:	O
Eugene,	:	O
Oreg.);	:	O
razoxane;	:	O
rhizoxin;	:	O
sizofuran;	:	O
spirogermanium;	:	O
tenuazonic	JJ	O
acid;	:	O
triaziquone;	:	O
2,2′,2″-trichlorotriethylamine;	:	O
trichothecenes	NNP	O
(especially	NN	O
T-2	NN	O
toxin,	NNP	O
verracurin	NNP	O
A,	,	O
roridin	,	O
A	:	O
and	:	O
anguidine);	:	O
urethan;	:	O
vindesine;	:	O
dacarbazine;	JJ	O
mannomustine;	:	O
mitobronitol;	:	O
mitolactol;	:	O
pipobroman;	NNS	O
gacytosine;	RB	O
arabinoside	NNP	O
(“Ara-C”);	,	O
cyclophosphamide;	FW	O
thiotepa;	,	O
taxoids,	VBZ	O
e.g.,	NNP	O
TAXOL®	CC	O
paclitaxel	:	O
(Bristol-Myers	:	O
Squibb	:	O
Oncology,	:	O
Princeton,	:	O
N.J.),	:	O
ABRAXANE™	:	O
Cremophor-free,	:	O
albumin-engineered	:	O
nanoparticle	RB	O
formulation	:	O
of	:	O
paclitaxel	:	O
(American	,	O
Pharmaceutical	,	O
Partners,	NNP	O
Schaumberg,	NN	O
Ill.),	NNP	O
and	NNP	O
TAXOTERE®	,	O
doxetaxel	,	O
(Rhône-Poulenc	,	O
Rorer,	NNP	O
Antony,	,	O
France);	JJ	O
chloranbucil;	NN	O
GEMZAR®	NN	O
gemcitabine;	IN	O
6-thioguanine;	NN	O
mercaptopurine;	JJ	O
methotrexate;	NNP	O
platinum	,	O
analogs	,	O
such	,	O
as	CC	O
cisplatin	NNP	O
and	NN	O
carboplatin;	JJ	O
vinblastine;	,	O
platinum;	,	O
etoposide	:	O
(VP-16);	:	O
ifosfamide;	NNP	O
mitoxantrone;	:	O
vincristine;	:	O
NAVELBINE®	:	O
vinorelbine;	:	O
novantrone;	CC	O
teniposide;	NNS	O
edatrexate;	JJ	O
daunomycin;	IN	O
aminopterin;	NN	O
xeloda;	CC	O
ibandronate;	:	O
CPT-11;	:	O
topoisomerase	:	O
inhibitor	CC	O
RFS	:	O
2000;	:	O
difluoromethylornithine	:	O
(DMFO);	:	O
retinoids	NNP	O
such	:	O
as	:	O
retinoic	:	O
acid;	:	O
capecitabine;	:	O
and	:	O
pharmaceutically	:	O
acceptable	:	O
salts,	:	O
acids	NN	O
or	NN	O
derivatives	NNP	O
of	:	O
any	NN	O
of	:	O
the	NNS	O
above.	JJ	O
Also	IN	O
included	JJ	O
in	:	O
this	:	O
definition	CC	O
are	RB	O
anti-hormonal	JJ	O
agents	,	O
that	NNS	O
act	CC	O
to	NNS	O
regulate	IN	O
or	DT	O
inhibit	IN	O
hormone	DT	O
action	.	O
on	RB	O
tumors	VBN	O
such	IN	O
as	DT	O
anti-estrogens	NN	O
and	VBP	O
selective	JJ	O
estrogen	NNS	O
receptor	WDT	O
modulators	VBP	O
(SERMs),	TO	O
including,	VB	O
for	CC	O
example,	VB	O
tamoxifen	JJ	O
(including	NN	O
NOLVADEX®	IN	O
tamoxifen),	NNS	O
raloxifene,	JJ	O
droloxifene,	IN	O
4-hydroxytamoxifen,	NNS	O
trioxifene,	CC	O
keoxifene,	JJ	O
LY117018,	NN	O
onapristone,	NN	O
and	NNS	O
FARESTON•toremifene;	,	O
aromatase	,	O
inhibitors	IN	O
that	,	O
inhibit	NN	O
the	VBG	O
enzyme	NNP	O
aromatase,	,	O
which	,	O
regulates	,	O
estrogen	,	O
production	,	O
in	,	O
the	,	O
adrenal	,	O
glands,	CC	O
such	:	O
as,	NN	O
for	NNS	O
example,	WDT	O
4(5)-imidazoles,	VBP	O
aminoglutethimide,	DT	O
MEGASE®	NN	O
megestrol	,	O
acetate,	WDT	O
AROMASIN®	VBZ	O
exemestane,	NN	O
formestanie,	NN	O
fadrozole,	IN	O
RIVISOR®	DT	O
vorozole,	JJ	O
FEMARA®	,	O
letrozole,	JJ	O
and	,	O
ARIMIDEX®	IN	O
anastrozole;	,	O
and	,	O
anti-androgens	,	O
such	NNP	O
as	NN	O
flutamide,	,	O
nilutamide,	NNP	O
bicalutamide,	,	O
leuprolide,	,	O
and	,	O
goserelin;	NNP	O
as	,	O
well	NNP	O
as	,	O
troxacitabine	CC	O
(a	NNP	O
1,3-dioxolane	:	O
nucleoside	CC	O
cytosine	NNS	O
analog);	JJ	O
antisense	IN	O
oligonucleotides,	,	O
particularly	,	O
those	,	O
which	,	O
inhibit	CC	O
expression	:	O
of	RB	O
genes	RB	O
in	IN	O
signaling	NN	O
pathways	DT	O
implicated	JJ	O
in	JJ	O
abherant	NN	O
cell	:	O
proliferation,	JJ	O
such	,	O
as,	RB	O
for	DT	O
example,	WDT	O
PKC-alpha,	VBP	O
Ralf	NN	O
and	IN	O
H-Ras;	NNS	O
ribozymes	IN	O
such	VBG	O
as	NNS	O
a	VBN	O
VEGF	IN	O
expression	JJ	O
inhibitor	NN	O
(e.g.,	,	O
ANGIOZYME®	JJ	O
ribozyme)	,	O
and	IN	O
a	,	O
HER2	,	O
expression	NNP	O
inhibitor;	CC	O
vaccines	:	O
such	NNS	O
as	JJ	O
gene	IN	O
therapy	DT	O
vaccines,	NNP	O
for	NN	O
example,	NN	O
ALLOVECTIN®	,	O
vaccine,	NNP	O
LEUVECTIN®	)	O
vaccine,	CC	O
and	DT	O
VAXID®	NNP	O
vaccine;	NN	O
PROLEUKIN®	:	O
rIL-2;	NNS	O
LURTOTECAN®	JJ	O
topoisomerase	IN	O
1	NN	O
inhibitor;	NN	O
ABARELIX®	,	O
rmRH;	IN	O
and	,	O
pharmaceutically	NNP	O
acceptable	,	O
salts,	NNP	O
acids	,	O
or	CC	O
derivatives	NNP	O
of	:	O
any	NNP	O
of	:	O
the	NNP	O
above.	VBD	O
The	CD	O
terms	:	O
“cell	NNP	O
proliferative	:	O
disorder”	CC	O
and	RB	O
“proliferative	JJ	O
disorder”	,	O
refer	NNS	O
to	CC	O
disorders	NNS	O
that	IN	O
are	DT	O
associated	IN	O
with	DT	O
some	.	O
degree	DT	O
of	NNS	O
abnormal	VBP	O
cell	JJ	O
proliferation.	NN	O
In	CC	O
one	JJ	O
aspect	NN	O
of	NN	O
the	TO	O
invention,	NNS	O
the	WDT	O
cell	VBP	O
proliferative	VBN	O
disorder	IN	O
is	DT	O
cancer.	NN	O
“Tumor”,	IN	O
as	JJ	O
used	NN	O
herein,	.	O
refers	IN	O
to	CD	O
all	NN	O
neoplastic	IN	O
cell	DT	O
growth	,	O
and	DT	O
proliferation,	NN	O
whether	JJ	O
malignant	NN	O
or	VBZ	O
benign,	.	O
and	,	O
all	IN	O
pre-cancerous	VBN	O
and	,	O
cancerous	NNS	O
cells	TO	O
and	DT	O
tissues.	JJ	O
An	NN	O
antibody,	NN	O
oligopeptide	CC	O
or	,	O
other	IN	O
organic	JJ	O
molecule	CC	O
which	,	O
“induces	CC	O
cell	DT	O
death”	JJ	O
is	CC	O
one	JJ	O
which	NNS	O
causes	CC	O
a	.	O
viable	DT	O
cell	,	O
to	RB	O
become	CC	O
nonviable.	JJ	O
The	JJ	O
cell	NN	O
is	WDT	O
one	VBZ	O
which	NN	O
expresses	NN	O
a	VBZ	O
PRO227,	CD	O
PRO233,	WDT	O
PRO238,	VBZ	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	TO	O
PRO21384,	VB	O
PRO353	.	O
or	DT	O
PRO1885	NN	O
polypeptide,	VBZ	O
preferably	CD	O
a	WDT	O
cell	VBZ	O
that	DT	O
overexpresses	,	O
a	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	,	O
PRO1885	RB	O
polypeptide	DT	O
as	NN	O
compared	WDT	O
to	VBZ	O
a	DT	O
normal	,	O
cell	,	O
of	,	O
the	,	O
same	,	O
tissue	,	O
type.	,	O
The	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	RB	O
PRO4342,	RB	O
PRO7423,	VBN	O
PRO10096,	TO	O
PRO21384,	DT	O
PRO353	JJ	O
or	NN	O
PRO1885	IN	O
polypeptide	DT	O
may	JJ	O
be	NN	O
a	.	O
transmembrane	DT	O
polypeptide	,	O
expressed	,	O
on	,	O
the	,	O
surface	,	O
of	,	O
a	,	O
cancer	,	O
cell	NNP	O
or	CC	O
may	NNP	O
be	NN	O
a	MD	O
polypeptide	VB	O
that	DT	O
is	JJ	O
produced	NN	O
and	VBN	O
secreted	IN	O
by	DT	O
a	NN	O
cancer	IN	O
cell.	DT	O
Preferably,	NN	O
the	NN	O
cell	CC	O
is	MD	O
a	VB	O
cancer	DT	O
cell,	NN	O
e.g.,	WDT	O
a	VBZ	O
breast,	VBN	O
ovarian,	CC	O
stomach,	VBN	O
endometrial,	IN	O
salivary	DT	O
gland,	NN	O
lung,	.	O
kidney,	,	O
colon,	DT	O
thyroid,	NN	O
pancreatic	VBZ	O
or	DT	O
bladder	NN	O
cell.	,	O
Cell	,	O
death	DT	O
in	,	O
vitro	,	O
may	,	O
be	,	O
determined	JJ	O
in	,	O
the	,	O
absence	,	O
of	,	O
complement	,	O
and	JJ	O
immune	CC	O
effector	NN	O
cells	.	O
to	NNP	O
distinguish	NN	O
cell	IN	O
death	NN	O
induced	MD	O
by	VB	O
antibody-dependent	VBN	O
cell-mediated	IN	O
cytotoxicity	DT	O
(ADCC)	NN	O
or	IN	O
complement	NN	O
dependent	CC	O
cytotoxicity	JJ	O
(CDC).	NN	O
Thus,	NNS	O
the	TO	O
assay	VB	O
for	NN	O
cell	NN	O
death	VBN	O
may	IN	O
be	JJ	O
performed	JJ	O
using	NN	O
heat	)	O
inactivated	CC	O
serum	JJ	O
(i.e.,	JJ	O
in	NN	O
the	.	O
absence	,	O
of	DT	O
complement)	NN	O
and	IN	O
in	NN	O
the	NN	O
absence	MD	O
of	VB	O
immune	VBN	O
effector	VBG	O
cells.	NN	O
To	VBN	O
determine	NN	O
whether	,	O
the	IN	O
antibody,	DT	O
oligopeptide	NN	O
or	IN	O
other	)	O
organic	CC	O
molecule	IN	O
is	DT	O
able	NN	O
to	IN	O
induce	JJ	O
cell	NN	O
death,	.	O
loss	TO	O
of	VB	O
membrane	IN	O
integrity	DT	O
as	,	O
evaluated	RB	O
by	CC	O
uptake	JJ	O
of	JJ	O
propidium	NN	O
iodide	VBZ	O
(PI),	JJ	O
trypan	TO	O
blue	VB	O
(see	NN	O
Moore	,	B
et	NN	I
al.	IN	I
Cytotechnology	JJ	I
17:1-11	NN	I
(1995))	IN	I
or	VBN	O
7AAD	IN	O
can	NN	O
be	IN	O
assessed	NN	O
relative	NN	O
to	,	O
untreated	JJ	O
cells.	NN	O
Preferred	VB	O
cell	NNP	O
death-inducing	FW	O
antibodies,	.	O
oligopeptides	NNP	O
or	CD	O
other	)	O
organic	CC	O
molecules	CD	O
are	MD	O
those	VB	O
which	VBN	O
induce	JJ	O
PI	TO	O
uptake	JJ	O
in	.	O
the	VBN	O
PI	NN	O
uptake	JJ	O
assay	,	O
in	NNS	O
BT474	CC	O
cells.	JJ	O
As	JJ	O
used	NNS	O
herein,	VBP	O
the	DT	O
term	WDT	O
“immunoadhesion”	VBP	O
designates	NNP	O
antibody-like	NN	O
molecules	IN	O
which	DT	O
combine	NNP	O
the	JJ	O
binding	NN	O
specificity	IN	O
of	NNP	O
a	.	O
heterologous	IN	O
protein	VBN	O
(an	,	O
“adhesion”)	DT	O
with	NN	O
the	NNP	O
effector	VBZ	O
functions	JJ	O
of	NNS	O
immunoglobulin	WDT	O
constant	VBP	O
domains.	DT	O
Structurally,	NN	O
the	NN	O
immunoadhesions	IN	O
comprise	DT	O
a	JJ	O
fusion	NN	O
of	DT	O
an	)	O
amino	IN	O
acid	DT	O
sequence	NN	O
with	NNS	O
the	IN	O
desired	NN	O
binding	JJ	O
specificity	.	O
which	,	O
is	DT	O
other	NNS	O
than	VBP	O
the	DT	O
antigen	NN	O
recognition	IN	O
and	DT	O
binding	NN	O
site	NN	O
of	NN	O
an	IN	O
antibody	DT	O
(i.e.,	JJ	O
is	NN	O
“heterologous”),	NN	O
and	WDT	O
an	VBZ	O
immunoglobulin	JJ	O
constant	IN	O
domain	DT	O
sequence.	NN	O
The	NN	O
adhesion	CC	O
part	VBG	O
of	NN	O
an	IN	O
immunoadhesion	DT	O
molecule	NN	O
typically	,	O
is	VBZ	O
a	,	O
contiguous	CC	O
amino	DT	O
acid	NN	O
sequence	JJ	O
comprising	NN	O
at	.	O
least	DT	O
the	NN	O
binding	NN	O
site	IN	O
of	DT	O
a	NN	O
receptor	NN	O
or	RB	O
a	VBZ	O
ligand.	DT	O
The	JJ	O
immunoglobulin	NN	O
constant	NN	O
domain	NN	O
sequence	VBG	O
in	IN	O
the	JJS	O
immunoadhesion	DT	O
may	VBG	O
be	NN	O
obtained	IN	O
from	DT	O
any	NN	O
immunoglobulin,	CC	O
such	DT	O
as	.	O
IgG-1,	DT	O
IgG-2,	NN	O
IgG-3,	JJ	O
or	NN	O
IgG-4	NN	O
subtypes,	IN	O
IgA	DT	O
(including	NN	O
IgA-1	MD	O
and	VB	O
IgA-2),	VBN	O
IgE,	IN	O
IgD	DT	O
or	,	O
IgM.	JJ	O
The	IN	O
word	,	O
“label”	,	O
when	,	O
used	CC	O
herein	NNP	O
refers	,	O
to	NNP	O
a	VBG	O
detectable	NNP	O
compound	CC	O
or	,	O
composition	,	O
which	NNP	O
is	CC	O
conjugated	.	O
directly	DT	O
or	NN	O
indirectly	NN	O
to	WRB	O
the	VBN	O
antibody	NN	O
so	NNS	O
as	TO	O
to	DT	O
generate	JJ	O
a	NN	O
“labeled”	CC	O
antibody.	NN	O
The	WDT	O
label	VBZ	O
may	VBN	O
be	RB	O
detectable	CC	O
by	RB	O
itself	TO	O
(e.g.	DT	O
radioisotope	NN	O
labels	RB	O
or	IN	O
fluorescent	TO	O
labels)	VB	O
or,	DT	O
in	NN	O
the	.	O
case	DT	O
of	NN	O
an	MD	O
enzymatic	VB	O
label,	JJ	O
may	IN	O
catalyze	PRP	O
chemical	.	O
alteration	NN	O
of	NNS	O
a	CC	O
substrate	JJ	O
compound	)	O
or	,	O
composition	IN	O
which	DT	O
is	NN	O
detectable.	IN	O
“Replication-preventing	DT	O
agent”	JJ	O
is	,	O
an	MD	O
agent	VB	O
wherein	JJ	O
replication,	NN	O
function,	IN	O
and/or	DT	O
growth	NN	O
of	NN	O
the	CC	O
cells	NN	O
is	WDT	O
inhibited	VBZ	O
or	.	O
prevented,	JJ	O
or	NN	O
cells	VBZ	O
are	DT	O
destroyed,	JJ	O
no	NN	O
matter	,	O
what	,	O
the	JJ	O
mechanism,	NN	O
such	IN	O
as	DT	O
by	NNS	O
apoptosis,	VBZ	O
angiostasis,	VBN	O
cytosis,	CC	O
tumoricide,	,	O
mytosis	CC	O
inhibition,	NNS	O
blocking	VBP	O
cell	,	O
cycle	DT	O
progression,	NN	O
arresting	WP	O
cell	DT	O
growth,	,	O
binding	JJ	O
to	IN	O
tumors,	IN	O
acting	,	O
as	,	O
cellular	,	O
mediators,	,	O
etc.	NN	O
Such	,	O
agents	VBG	O
include	NN	O
a	NN	O
chemotherapeutic	,	O
agent,	VBG	O
cytotoxic	NN	O
agent,	,	O
cytokine,	VBG	O
growth-inhibitory	TO	O
agent,	,	O
or	VBG	O
anti-hormonal	IN	O
agent,	JJ	O
e.g.,	,	O
an	.	O
anti-estrogen	JJ	O
compound	NNS	O
such	VBP	O
as	DT	O
tamoxifen,	JJ	O
an	,	O
anti-progesterone	NN	O
such	,	O
as	,	O
onapristone	JJ	O
(see,	,	O
EP	CC	O
616	JJ	O
812);	,	O
or	,	O
an	DT	O
anti-androgen	JJ	O
such	NN	O
as	JJ	O
flutamide,	IN	O
as	,	O
well	DT	O
as	NN	O
aromidase	JJ	O
inhibitors,	IN	O
or	NN	O
a	,	O
hormonal	NNP	O
agent	CD	O
such	:	O
as	CC	O
an	DT	O
androgen.	JJ	O
The	JJ	O
term	IN	O
“cytotoxic	,	O
agent”	RB	O
as	RB	O
used	IN	O
herein	NN	O
refers	,	O
to	CC	O
a	DT	O
substance	JJ	O
that	NN	O
inhibits	JJ	O
or	IN	O
prevents	DT	O
the	.	O
function	DT	O
of	NN	O
cells	NNP	O
and/or	NN	O
causes	IN	O
destruction	VBN	O
of	NN	O
cells.	NNS	O
The	TO	O
term	DT	O
is	NN	O
intended	WDT	O
to	VBZ	O
include	CC	O
radioactive	VBZ	O
isotopes	DT	O
(e.g.,	NN	O
At211,	IN	O
I131,	NNS	O
I125,	JJ	O
Y90,	NNS	O
Re186,	NN	O
Re188,	IN	O
Sm153,	.	O
Bi212,	DT	O
P32	NN	O
and	VBZ	O
radioactive	VBN	O
isotopes	TO	O
of	VB	O
Lu),	JJ	O
chemotherapeutic	NNS	O
agents	,	O
e.g.	,	O
methotrexate,	,	O
adriamicin,	,	O
vinca	,	O
alkaloids	,	O
(vincristine,	,	O
vinblastine,	,	O
etoposide),	,	O
doxorubicin,	NNP	O
melphalan,	CC	O
mitomycin	JJ	O
C,	NNS	O
chlorambucil,	IN	O
daunorubicin	,	O
or	JJ	O
other	NNS	O
intercalating	.	O
agents,	,	O
enzymes	,	O
and	JJ	O
fragments	NNS	O
thereof	,	O
such	,	O
as	,	O
nucleolytic	,	O
enzymes,	,	O
antibiotics,	FW	O
and	,	O
toxins	,	O
such	NN	O
as	CC	O
small	JJ	O
molecule	VBG	O
toxins	,	O
or	NNS	O
enzymatically	CC	O
active	NNS	O
toxins	VBP	O
of	JJ	O
bacterial,	IN	O
fungal,	JJ	O
plant	,	O
or	,	O
animal	CC	O
origin,	NNS	O
including	JJ	O
fragments	IN	O
and/or	JJ	O
variants	NN	O
thereof,	NNS	O
and	CC	O
the	RB	O
various	JJ	O
antitumor	NNS	O
or	IN	O
anticancer	,	O
agents	,	O
disclosed	NN	O
below.	CC	O
Other	NN	O
cytotoxic	,	O
agents	VBG	O
are	NNS	O
described	JJ	O
below.	NNS	O
A	,	O
tumoricidal	CC	O
agent	DT	O
causes	JJ	O
destruction	NN	O
of	CC	O
tumor	NN	O
cells.	NNS	O
Preferred	VBN	O
cytotoxic	.	O
agents	JJ	O
herein	NN	O
for	NNS	O
the	VBP	O
specific	VBN	O
tumor	.	O
types	DT	O
to	JJ	O
use	NN	O
in	VBZ	O
combination	NN	O
with	IN	O
the	NN	O
antagonists	.	O
herein	NNP	O
are	NN	O
as	NNS	O
follows:	VBP	O
1.	IN	O
Prostate	DT	O
cancer:	JJ	O
androgens,	NN	O
docetaxel,	NNS	O
paclitaxel,	TO	O
estramustine,	VB	O
doxorubicin,	IN	O
mitoxantrone,	NN	O
antibodies	IN	O
to	DT	O
ErbB2	NNS	O
domain(s)	VBP	O
such	VBP	O
as	IN	O
2C4	:	O
(WO	.	O
01/00245;	NNP	O
hybridoma	:	O
ATCC	,	O
HB-12697),	,	O
which	,	O
binds	,	O
to	,	O
a	,	O
region	NNS	O
in	TO	O
the	NNP	O
extracellular	)	O
domain	JJ	O
of	IN	O
ErbB2	CD	O
(e.g.,	NNP	O
any	:	O
one	NN	O
or	NNP	O
more	,	O
residues	WDT	O
in	VBZ	O
the	TO	O
region	DT	O
from	NN	O
about	IN	O
residue	DT	O
22	JJ	O
to	NN	O
about	IN	O
residue	NNP	O
584	,	O
of	DT	O
ErbB2,	CD	O
inclusive),	CC	O
AVASTIN™	JJR	O
anti-vascular	NNS	O
endothelial	IN	O
growth	DT	O
factor	NN	O
(VEGF),	IN	O
TARCEVA™	IN	O
OSI-774	JJ	O
(erlotinib)	CD	O
(Genenetech	TO	O
and	IN	O
OSI	JJ	O
Pharmaceuticals),	CD	O
or	IN	O
other	,	O
epidermal	,	O
growth	NNP	O
factor	JJ	O
receptor	JJ	O
tyrosine	NN	O
kinase	NN	O
inhibitors	,	O
(EGFR	NNP	O
TKI's).2.	NNP	O
Stomach	)	O
cancer:	NNP	O
5-fluorouracil	CC	O
(5FU),	NNP	O
XELODA™	,	O
capecitabine,	CC	O
methotrexate,	JJ	O
etoposide,	JJ	O
cisplatin/carboplatin,	NN	O
paclitaxel,	NN	O
docetaxel,	NN	O
gemcitabine,	NN	O
doxorubicin,	NN	O
and	NNS	O
CPT-11	NNP	O
(camptothcin-11;	.	O
irinotecan,	NN	O
USA	:	O
Brand	JJ	O
Name:	,	O
CAMPTOSAR®).3.	NNP	O
Pancreatic	,	O
cancer:	,	O
gemcitabine,	,	O
5FU,	,	O
XELODA™	,	O
capecitabine,	,	O
CPT-11,	,	O
docetaxel,	,	O
paclitaxel,	CC	O
cisplatin,	NNP	O
carboplatin,	:	O
TARCEVA™	,	O
erlotinib,	NNP	O
and	NNP	O
other	:	O
EGFR	.	O
TKI's.4.	JJ	O
Colorectal	:	O
cancer:	,	O
5FU,	,	O
XELODA™	NNP	O
capecitabine,	,	O
CPT-11,	,	O
oxaliplatin,	,	O
AVASTIN™	,	O
anti-VEGF,	,	O
TARCEVA™	,	O
erlotinib	NNP	O
and	,	O
other	CC	O
EGFR	JJ	O
TKI's,	NNP	O
and	.	O
ERBITUXT™	JJ	O
(formerly	:	O
known	,	O
as	NNP	O
IMC-C225)	,	O
human:murine-chimerized	,	O
monoclonal	,	O
antibody	NNP	O
that	,	O
binds	NNP	O
to	NN	O
EGFR	CC	O
and	JJ	O
blocks	NNP	O
the	,	O
ability	CC	O
of	NNP	O
EGF	RB	O
to	VBN	O
initiate	IN	O
receptor	)	O
activation	JJ	O
and	JJ	O
signaling	NN	O
to	WDT	O
the	VBZ	O
tumor.5.	TO	O
Renal	NNP	O
cancer:	CC	O
IL-2,	VBZ	O
interferon	DT	O
alpha,	NN	O
AVASTIN™	IN	O
anti-VEGF,	NNP	O
MEGACE™	TO	O
(Megestrol	VB	O
acetate)	NN	O
progestin,	NN	O
vinblastine,	CC	O
TARCEVA™	VBG	O
erlotinib,	TO	O
and	DT	O
other	.	O
EGFR	JJ	O
TKI's.	:	O
A	,	O
“growth	JJ	O
inhibitory	,	O
agent”	NNP	O
when	,	O
used	NNP	O
herein	NNP	O
refers	)	O
to	,	O
a	,	O
compound	NNP	O
or	,	O
composition	CC	O
which	JJ	O
inhibits	NNP	O
growth	.	O
of	DT	O
a	NN	O
cell,	NN	O
especially	NN	O
a	WRB	O
PRO227-,	VBN	O
PRO233-,	NN	O
PRO238-,	NNS	O
PRO1328-,	TO	O
PRO4342-,	DT	O
PRO7423-;	NN	O
PRO10096-;	CC	O
PRO21384-;	NN	O
PRO353-	WDT	O
or	VBZ	O
PRO1885-expressing	NN	O
cancer	IN	O
cell,	DT	O
either	,	O
in	RB	O
vitro	DT	O
or	,	O
in	,	O
vivo.	,	O
Thus,	,	O
the	,	O
growth	:	O
inhibitory	:	O
agent	:	O
may	NNP	O
be	CC	O
one	NNP	O
which	NN	O
significantly	,	O
reduces	RB	O
the	IN	O
percentage	NN	O
of	CC	O
PRO227-,	IN	O
PRO233-,	.	O
PRO238-,	,	O
PRO1328-,	DT	O
PRO4342-,	NN	O
PRO7423-,	JJ	O
PRO10096-,	NN	O
PRO21384-,	MD	O
PRO353-	VB	O
or	CD	O
PRO1885-expressing	WDT	O
cells	RB	O
in	VBZ	O
S	DT	O
phase.	NN	O
Examples	IN	O
of	,	O
growth	,	O
inhibitory	,	O
agents	,	O
include	,	O
agents	,	O
that	,	O
block	,	O
cell	NNP	O
cycle	CC	O
progression	NNP	O
(at	NNS	O
a	IN	O
place	NNP	O
other	.	O
than	NNS	O
S	IN	O
phase),	NN	O
such	JJ	O
as	NNS	O
agents	VBP	O
that	NNS	O
induce	WDT	O
G1	VBP	O
arrest	NN	O
and	NN	O
M-phase	NN	O
arrest.	IN	O
Classical	DT	O
M-phase	NN	O
blockers	JJ	O
include	IN	O
the	NNP	O
vincas	,	O
(vincristine	JJ	O
and	IN	O
vinblastine),	NNS	O
taxanes,	WDT	O
and	VBP	O
topoisomerase	NNP	O
II	NN	O
inhibitors	CC	O
such	NNP	O
as	.	O
doxorubicin,	JJ	O
epirubicin,	NNP	O
daunorubicin,	NNS	O
etoposide,	VBP	O
and	DT	O
bleomycin.	NN	O
Those	NN	O
agents	CC	O
that	,	O
arrest	,	O
G1	CC	O
also	NN	O
spill	NNP	O
over	NNS	O
into	JJ	O
S-phase	IN	O
arrest,	,	O
for	,	O
example,	,	O
DNA	,	O
alkylating	CC	O
agents	.	O
such	DT	O
as	NNS	O
tamoxifen,	WDT	O
prednisone,	VBP	O
dacarbazine,	NNP	O
mechlorethamine,	RB	O
cisplatin,	VBZ	O
methotrexate,	RP	O
5-fluorouracil,	IN	O
and	NNP	O
ara-C.	,	O
Further	IN	O
information	,	O
can	NNP	O
be	VBG	O
found	NNS	O
in	JJ	O
The	IN	O
Molecular	,	O
Basis	,	O
of	,	O
Cancer,	,	O
Mendelsohn	,	O
and	,	O
Israel,	,	O
eds.,	CC	O
Chapter	JJ	O
1,	NNP	O
entitled	NN	O
“Cell	MD	O
cycle	VB	O
regulation,	VBN	O
oncogenes,	IN	O
and	DT	O
antineoplastic	JJ	O
drugs”	NNP	O
by	IN	O
Murakami	,	B
et	NNP	I
al.	CC	I
(WB	,	I
Saunders:	,	I
Philadelphia,	NNP	I
1995),	,	I
especially	VBN	O
p.	NNP	O
13.	NN	O
The	,	O
taxanes	,	O
(paclitaxel	CC	O
and	JJ	O
docetaxel)	NN	O
are	IN	O
anticancer	NNP	O
drugs	CC	O
both	.	O
derived	JJ	O
from	:	O
the	,	O
yew	,	O
tree.	RB	O
Docetaxel	JJ	O
(TAXOTERE®,	.	O
Rhone-Poulenc	DT	O
Rorer),	NNS	O
derived	NN	O
from	CC	O
the	)	O
European	VBP	O
yew,	JJ	O
is	NNS	O
a	DT	O
semisynthetic	VBN	O
analogue	IN	O
of	DT	O
paclitaxel	NN	O
(TAXOL®,	.	O
Bristol-Myers	NNP	O
Squibb).	,	O
Paclitaxel	NNP	O
and	,	O
docetaxel	VBN	O
promote	IN	O
the	DT	O
assembly	NNP	O
of	,	O
microtubules	VBZ	O
from	DT	O
tubulin	JJ	O
dimers	NN	O
and	IN	O
stabilize	NN	O
microtubules	,	O
by	NNP	O
preventing	.	O
depolymerization,	NNP	O
which	CC	O
results	JJ	O
in	VBP	O
the	DT	O
inhibition	NN	O
of	IN	O
mitosis	NNS	O
in	IN	O
cells.	NN	O
“Doxorubicin”	NNS	O
is	CC	O
an	VB	O
anthracycline	NNS	O
antibiotic.	IN	O
The	VBG	O
full	,	O
chemical	WDT	O
name	NNS	O
of	IN	O
doxorubicin	DT	O
is	NN	O
(8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexapyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,1	IN	O
1-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione.	NN	O
The	IN	O
term	.	O
“cytokine”	NN	O
is	VBZ	O
a	DT	O
generic	JJ	O
term	.	O
for	DT	O
proteins	JJ	O
released	NN	O
by	NN	O
one	IN	O
cell	NN	O
population	VBZ	O
which	JJ	O
act	.	O
on	DT	O
another	NN	O
cell	NNP	O
as	VBZ	O
intercellular	DT	O
mediators.	JJ	O
Examples	NN	O
of	IN	O
such	NNS	O
cytokines	VBN	O
are	IN	O
lymphokines,	CD	O
monokines,	NN	O
and	NN	O
traditional	WDT	O
polypeptide	NN	O
hormones.	IN	O
Included	DT	O
among	NN	O
the	IN	O
cytokines	JJ	O
are	.	O
growth	NNS	O
hormone	IN	O
such	JJ	O
as	NNS	O
human	VBP	O
growth	,	O
hormone,	,	O
N-methionyl	CC	O
human	JJ	O
growth	NN	O
hormone,	.	O
and	VBN	O
bovine	IN	O
growth	DT	O
hormone;	NNS	O
parathyroid	VBP	O
hormone;	NN	O
thyroxine;	NN	O
insulin;	JJ	O
proinsulin;	IN	O
relaxin;	JJ	O
prorelaxin;	NN	O
glycoprotein	,	O
hormones	NNP	O
such	JJ	O
as	NN	O
follicle	,	O
stimulating	CC	O
hormone	VB	O
(FSH),	NN	O
thyroid	:	O
stimulating	CC	O
hormone	:	O
(TSH),	:	O
and	:	O
luteinizing	:	O
hormone	:	O
(LH);	:	O
hepatic	CC	O
growth	NNS	O
factor;	JJ	O
fibroblast	IN	O
growth	NN	O
factor;	VBG	O
prolactin;	NN	O
placental	,	O
lactogen;	JJ	O
tumor	VBG	O
necrosis	NN	O
factor-α	,	O
and	CC	O
-β;	VBG	O
mullerian-inhibiting	NN	O
substance;	:	O
mouse	JJ	O
gonadotropin-associated	NN	O
peptide;	:	O
inhibin;	JJ	O
activin;	NN	O
vascular	:	O
endothelial	:	O
growth	JJ	O
factor;	:	O
integrin;	CC	O
thrombopoietin	IN	O
(TPO);	JJ	O
nerve	CC	O
growth	:	O
factors	JJ	O
such	:	O
as	CC	O
NGF-β;	JJ	O
platelet-growth	:	O
factor;	:	O
transforming	:	O
growth	JJ	O
factors	JJ	O
(TGFs)	NN	O
such	:	O
as	:	O
TGF-α	NN	O
and	:	O
TGF-β;	CC	O
insulin-like	NN	O
growth	NNS	O
factor-I	JJ	O
and	IN	O
-II;	:	O
erythropoietin	JJ	O
(EPO);	:	O
osteoinductive	VBG	O
factors;	NN	O
interferons	NNS	O
such	)	O
as	JJ	O
interferon-α,	IN	O
-β,	NNP	O
and	CC	O
-γ;	:	O
colony	JJ	O
stimulating	NN	O
factors	JJ	O
(CSFs)	CC	O
such	:	O
as	NN	O
macrophage-CSF	:	O
(M-CSF);	JJ	O
granulocyte-macrophage-CSF	:	O
(GM-CSF);	NNS	O
and	JJ	O
granulocyte-CSF	IN	O
(G-CSF);	,	O
interleukins	,	O
(ILs)	CC	O
such	:	O
as	NN	O
IL-1,	NN	O
IL-1a,	NNS	O
IL-2,	)	O
IL-3,	JJ	O
IL-4,	IN	O
IL-5,	NN	O
IL-6,	:	O
IL-7,	JJ	O
IL-8,	:	O
IL-9,	CC	O
IL-11,	NNS	O
IL-12;	:	O
a	NNS	O
tumor	)	O
necrosis	JJ	O
factor	IN	O
such	,	O
as	,	O
TNF-α	,	O
or	,	O
TNF-β;	,	O
and	,	O
other	,	O
polypeptide	,	O
factors	,	O
including	,	O
LIF	,	O
and	:	O
kit	DT	O
ligand	NN	O
(KL).	NN	O
As	NN	O
used	JJ	O
herein,	IN	O
the	NNP	O
term	CC	O
cytokine	:	O
includes	CC	O
proteins	JJ	O
from	JJ	O
natural	NNS	O
sources	VBG	O
or	NNP	O
from	CC	O
recombinant	VB	O
cell	NN	O
culture	.	O
and	IN	O
biologically	VBN	O
active	,	O
equivalents	DT	O
of	NN	O
the	NN	O
native	VBZ	O
sequence	NNS	O
cytokines.	IN	O
The	JJ	O
term	NNS	O
“package	CC	O
insert”	IN	O
is	JJ	O
used	NN	O
to	NN	O
refer	CC	O
to	RB	O
instructions	JJ	O
customarily	NNS	O
included	IN	O
in	DT	O
commercial	JJ	O
packages	NN	O
of	.	O
therapeutic	DT	O
products,	NN	O
that	NN	O
contain	NN	O
information	VBZ	O
about	VBN	O
the	TO	O
indications,	VB	O
usage,	TO	O
dosage,	NNS	O
administration,	RB	O
contraindications	VBN	O
and/or	IN	O
warnings	JJ	O
concerning	NNS	O
the	IN	O
use	JJ	O
of	,	O
such	WDT	O
therapeutic	VBP	O
products.	NN	O
The	IN	O
term	DT	O
“gene”	,	O
refers	,	O
to	,	O
(a)	,	O
a	NNS	O
gene	VBP	O
containing	NNS	O
at	VBG	O
least	DT	O
one	NN	O
of	IN	O
the	JJ	O
DNA	JJ	O
sequences	.	O
disclosed	DT	O
herein;	NN	O
(b)	VBZ	O
any	NNS	O
DNA	TO	O
sequence	)	O
that	DT	O
encodes	NN	O
the	VBG	O
amino	IN	O
acid	JJS	O
sequence	CD	O
encoded	IN	O
by	DT	O
the	NN	O
DNA	NNS	O
sequences	VBD	O
disclosed	:	O
herein	)	O
and/or;	DT	O
(c)	NN	O
any	NN	O
DNA	WDT	O
sequence	VBZ	O
that	DT	O
hybridizes	NN	O
to	JJ	O
the	NN	O
complement	VBN	O
of	IN	O
the	DT	O
coding	NN	O
sequences	NNS	O
disclosed	VBD	O
herein.	JJ	O
Preferably,	:	O
the	)	O
term	DT	O
includes	NN	O
coding	NN	O
as	WDT	O
well	VBZ	O
as	TO	O
noncoding	DT	O
regions,	NN	O
and	IN	O
preferably	DT	O
includes	NN	O
all	NNS	O
sequences	VBD	O
necessary	.	O
for	,	O
normal	DT	O
gene	NN	O
expression.	VBZ	O
The	NN	O
term	RB	O
“gene	RB	O
targeting”	IN	O
refers	VBG	O
to	,	O
a	CC	O
type	RB	O
of	VBZ	O
homologous	DT	O
recombination	NNS	O
that	JJ	O
occurs	IN	O
when	JJ	O
a	NN	O
fragment	.	O
of	DT	O
genomic	NN	O
DNA	NNP	O
is	NN	O
introduced	NNS	O
into	TO	O
a	DT	O
mammalian	NN	O
cell	IN	O
and	JJ	O
that	NN	O
fragment	WDT	O
locates	VBZ	O
and	WRB	O
recombines	DT	O
with	NN	O
endogenous	IN	O
homologous	JJ	O
sequences.	NNP	O
Gene	VBZ	O
targeting	VBN	O
by	IN	O
homologous	DT	O
recombination	JJ	O
employs	NN	O
recombinant	CC	O
DNA	DT	O
technologies	NN	O
to	VBZ	O
replace	CC	O
specific	NNS	O
genomic	IN	O
sequences	JJ	O
with	JJ	O
exogenous	.	O
DNA	NNP	O
of	VBG	O
particular	IN	O
design.	JJ	O
The	NN	O
term	VBZ	O
“homologous	JJ	O
recombination”	NNP	O
refers	NNS	O
to	TO	O
the	VB	O
exchange	JJ	O
of	JJ	O
DNA	NNS	O
fragments	IN	O
between	JJ	O
two	NN	O
DNA	IN	O
molecules	JJ	O
or	.	O
chromatids	DT	O
at	NN	O
the	JJ	O
site	NN	O
of	NNS	O
homologous	TO	O
nucleotide	DT	O
sequences.	NN	O
The	IN	O
term	NNP	O
“target	NNS	O
gene”	IN	O
(alternatively	CD	O
referred	NNP	O
to	NNS	O
as	CC	O
“target	NNS	O
gene	IN	O
sequence”	DT	O
or	NN	O
“target	IN	O
DNA	JJ	O
sequence”)	JJ	O
refers	.	O
to	DT	O
any	NN	O
nucleic	NNP	O
acid	NN	O
molecule,	RB	O
polynucleotide,	VBN	O
or	TO	O
gene	IN	O
to	NNP	O
be	NN	O
modified	NN	O
by	CC	O
homologous	VB	O
recombination.	NNP	O
The	)	O
target	NNS	O
sequence	TO	O
includes	DT	O
an	JJ	O
intact	NN	O
gene,	,	O
an	,	O
exon	CC	O
or	NN	O
intron,	TO	O
a	VB	O
regulatory	VBN	O
sequence	IN	O
or	JJ	O
any	.	O
region	DT	O
between	NN	O
genes.	NN	O
The	VBZ	O
target	DT	O
gene	JJ	O
my	,	O
comprise	DT	O
a	NN	O
portion	CC	O
of	,	O
a	DT	O
particular	JJ	O
gene	NN	O
or	CC	O
genetic	DT	O
locus	NN	O
in	IN	O
the	.	O
individual's	DT	O
genomic	NN	O
DNA.	NN	O
“Disruption”	PRP$	O
of	NN	O
a	DT	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	CC	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	IN	O
or	DT	O
PRO1885	POS	O
gene	JJ	O
occurs	.	O
when	NN	O
a	IN	O
fragment	DT	O
of	,	O
genomic	,	O
DNA	,	O
locates	,	O
and	,	O
recombines	,	O
with	,	O
an	,	O
endogenous	NNP	O
homologous	CC	O
sequence	NNP	O
wherein	NN	O
the	VBZ	O
disruption	WRB	O
is	DT	O
a	NN	O
deletion	IN	O
of	JJ	O
the	NNP	O
native	NNS	O
gene	CC	O
or	NNS	O
a	IN	O
portion	DT	O
thereof,	JJ	O
or	JJ	O
a	NN	O
mutation	VBD	O
in	DT	O
the	NN	O
native	VBZ	O
gene	DT	O
or	NN	O
wherein	IN	O
the	DT	O
disruption	JJ	O
is	NN	O
the	CC	O
functional	DT	O
inactivation	NN	O
of	,	O
the	CC	O
native	DT	O
gene.	NN	O
Alternatively,	IN	O
sequence	DT	O
disruptions	JJ	O
may	NN	O
be	CC	O
generated	VB	O
by	DT	O
nonspecific	NN	O
insertional	VBZ	O
inactivation	DT	O
using	JJ	O
a	NN	O
gene	IN	O
trap	DT	O
vector	JJ	O
(i.e.	.	O
non-human	,	O
transgenic	NN	O
animals	NNS	O
containing	MD	O
and	VB	O
expressing	VBN	O
a	IN	O
randomly	JJ	O
inserted	JJ	O
transgene;	NN	O
see	VBG	O
for	DT	O
example	NN	O
U.S.	NN	O
Pat.	NN	O
No.	.	O
6,436,707	JJ	O
issued	JJ	O
Aug.	NNS	O
20,	VBG	O
2002).	CC	O
These	VBG	O
sequence	DT	O
disruptions	RB	O
or	VBN	O
modifications	:	O
may	VB	O
include	IN	O
insertions,	NN	O
missense,	NNP	O
frameshift,	.	O
deletion,	.	O
or	CD	O
substitutions,	VBN	O
or	NNP	O
replacements	,	O
of	.	O
DNA	DT	O
sequence,	NN	O
or	NNS	O
any	CC	O
combination	NNS	O
thereof.	MD	O
Insertions	VB	O
include	,	O
the	,	O
insertion	,	O
of	,	O
entire	CC	O
genes,	,	O
which	CC	O
may	NNS	O
be	IN	O
of	NNP	O
animal,	,	O
plant,	CC	O
fungal,	DT	O
insect,	NN	O
prokaryotic,	.	O
or	NNS	O
viral	VBP	O
origin.	DT	O
Disruption,	NN	O
for	IN	O
example,	JJ	O
can	,	O
alter	WDT	O
the	MD	O
normal	VB	O
gene	IN	O
product	,	O
by	,	O
inhibiting	,	O
its	,	O
production	,	O
partially	CC	O
or	JJ	O
completely	.	O
or	,	O
by	IN	O
enhancing	,	O
the	MD	O
normal	VB	O
gene	DT	O
product's	JJ	O
activity.	NN	O
Preferably,	NN	O
the	IN	O
disruption	VBG	O
is	PRP$	O
a	NN	O
null	RB	O
disruption,	CC	O
wherein	RB	O
there	CC	O
is	IN	O
no	VBG	O
significant	DT	O
expression	JJ	O
of	NN	O
the	POS	O
PRO227,	.	O
PRO233,	,	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	,	O
PRO353	NN	O
or	EX	O
PRO1885	VBZ	O
gene.	DT	O
The	JJ	O
term	NN	O
“native	IN	O
expression”	DT	O
refers	,	O
to	,	O
the	,	O
expression	,	O
of	,	O
the	,	O
full-length	,	O
polypeptide	,	O
encoded	NNP	O
by	CC	O
the	NNP	O
PRO227,	.	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	NNS	O
PRO10096,	TO	O
PRO21384,	DT	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
gene,	JJ	O
at	NN	O
expression	VBN	O
levels	IN	O
present	DT	O
in	,	O
the	,	O
wild-type	,	O
mouse.	,	O
Thus,	,	O
a	,	O
disruption	,	O
in	,	O
which	NNP	O
there	CC	O
is	NNP	O
“no	,	O
native	IN	O
expression”	NN	O
of	NNS	O
the	VBP	O
endogenous	IN	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	.	O
PRO1328,	,	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	WDT	O
PRO353	EX	O
or	VBZ	O
PRO1885	JJ	O
gene	JJ	O
refers	NN	O
to	IN	O
a	DT	O
partial	JJ	O
or	,	O
complete	,	O
reduction	,	O
of	,	O
the	,	O
expression	,	O
of	,	O
at	,	O
least	NNP	O
a	CC	O
portion	NNP	O
of	NN	O
a	NNS	O
polypeptide	TO	O
encoded	DT	O
by	JJ	O
an	CC	O
endogenous	JJ	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	IN	O
PRO10096,	JJS	O
PRO21384,	DT	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
gene	NN	O
of	VBN	O
a	IN	O
single	DT	O
cell,	JJ	O
selected	,	O
cells,	,	O
or	,	O
all	,	O
of	,	O
the	,	O
cells	,	O
of	,	O
a	NNP	O
mammal.	CC	O
The	NNP	O
term	NN	O
“knockout”	IN	O
refers	DT	O
to	JJ	O
the	,	O
disruption	VBN	O
of	,	O
a	CC	O
PRO227,	DT	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	.	O
PRO21384,	DT	O
PRO353	NN	O
or	VBZ	O
PRO1885	NNS	O
gene	TO	O
wherein	DT	O
the	NN	O
disruption	IN	O
results	DT	O
in:	,	O
the	,	O
functional	,	O
inactivation	,	O
of	,	O
the	,	O
native	,	O
gene;	,	O
the	NNP	O
deletion	CC	O
of	NNP	O
the	NN	O
native	VBD	O
gene	DT	O
or	NN	O
a	NNS	O
portion	:	O
thereof;	DT	O
or	JJ	O
a	NN	O
mutation	IN	O
in	DT	O
the	JJ	O
native	:	O
gene.	DT	O
The	NN	O
term	IN	O
“knock-in”	DT	O
refers	JJ	O
to	NN	O
the	CC	O
replacement	DT	O
of	NN	O
the	:	O
mouse	CC	O
ortholog	DT	O
(or	NN	O
other	IN	O
mouse	DT	O
gene)	JJ	O
with	.	O
a	DT	O
human	NN	O
cDNA	JJ	O
encoding	NNS	O
any	TO	O
of	DT	O
the	NN	O
specific	IN	O
human	DT	O
PRO227-,	NN	O
PRO233-,	NN	O
PRO238-,	CC	O
PRO1328-,	JJ	O
PRO4342-,	NN	O
PRO7423-,	)	O
PRO10096-,	IN	O
PRO21384-,	DT	O
PRO353-	JJ	O
or	NN	O
PRO1885-encoding	VBG	O
genes	DT	O
or	IN	O
variants	DT	O
thereof	JJ	O
(ie.	JJ	O
the	,	O
disruption	,	O
results	,	O
in	,	O
a	,	O
replacement	,	O
of	,	O
a	,	O
native	NNP	O
mouse	CC	O
gene	NNP	O
with	NNS	O
a	CC	O
native	NNS	O
human	VBP	O
gene).	.	O
The	DT	O
term	NN	O
“construct”	NNS	O
or	IN	O
“targeting	DT	O
construct”	NN	O
refers	IN	O
to	DT	O
an	JJ	O
artificially	NN	O
assembled	NN	O
DNA	IN	O
segment	DT	O
to	JJ	O
be	JJ	O
transferred	.	O
into	DT	O
a	NN	O
target	NN	O
tissue,	CC	O
cell	VBG	O
line	JJ	O
or	NNS	O
animal.	TO	O
Typically,	DT	O
the	RB	O
targeting	JJ	O
construct	NNP	O
will	NN	O
include	TO	O
a	VB	O
gene	VBN	O
or	IN	O
a	DT	O
nucleic	NN	O
acid	,	O
sequence	NN	O
of	NN	O
particular	CC	O
interest,	.	O
a	,	O
marker	DT	O
gene	VBG	O
and	NN	O
appropriate	MD	O
control	VB	O
sequences.	DT	O
As	NN	O
provided	CC	O
herein,	DT	O
the	JJ	O
targeting	JJ	O
construct	NN	O
comprises	IN	O
a	JJ	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	.	O
PRO353	IN	O
or	VBN	O
PRO1885	,	O
targeting	DT	O
construct.	VBG	O
A	NN	O
“PRO227,	VBZ	O
PRO233,	DT	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
targeting	CC	O
construct”	NNP	O
includes	VBG	O
a	.	O
DNA	DT	O
sequence	,	O
homologous	,	O
to	,	O
at	,	O
least	,	O
one	,	O
portion	,	O
of	,	O
a	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	VBG	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	NN	O
PRO353	JJ	O
or	TO	O
PRO1885	IN	O
gene	JJS	O
and	CD	O
is	NN	O
capable	IN	O
of	DT	O
producing	,	O
a	,	O
disruption	,	O
in	,	O
a	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	CC	O
PRO7423,	NNP	O
PRO10096,	NN	O
PRO21384,	CC	O
PRO353	VBZ	O
or	JJ	O
PRO1885	IN	O
gene	VBG	O
in	DT	O
a	NN	O
host	IN	O
cell.	DT	O
The	,	O
term	,	O
“transgenic	,	O
cell”	,	O
refers	,	O
to	,	O
a	,	O
cell	,	O
containing	NNP	O
within	CC	O
its	NNP	O
genome	NN	O
a	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	.	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	NNP	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	TO	O
or	DT	O
PRO1885	NN	O
gene	VBG	O
that	IN	O
has	PRP$	O
been	NN	O
disrupted,	DT	O
modified,	,	O
altered,	,	O
or	,	O
replaced	,	O
completely	,	O
or	,	O
partially	,	O
by	,	O
the	NNP	O
method	CC	O
of	NNP	O
gene	NN	O
targeting.	WDT	O
The	VBZ	O
term	VBN	O
“transgenic	,	O
animal”	,	O
refers	,	O
to	CC	O
an	VBD	O
animal	RB	O
that	CC	O
contains	RB	O
within	IN	O
its	DT	O
genome	NN	O
a	IN	O
specific	NN	O
gene	.	O
that	DT	O
has	NN	O
been	NNP	O
disrupted	NN	O
or	NNS	O
otherwise	TO	O
modified	DT	O
or	NN	O
mutated	WDT	O
by	VBZ	O
the	IN	O
methods	PRP$	O
described	NN	O
herein	DT	O
or	JJ	O
methods	NN	O
otherwise	WDT	O
well	VBZ	O
known	VBN	O
in	VBN	O
the	CC	O
art.	RB	O
Preferably	VBN	O
the	CC	O
non-human	VBN	O
transgenic	IN	O
animal	DT	O
is	NNS	O
a	VBD	O
mammal.	NN	O
More	CC	O
preferably,	NNS	O
the	RB	O
mammal	RB	O
is	VBN	O
a	IN	O
rodent	DT	O
such	.	O
as	RB	O
a	DT	O
rat	JJ	O
or	JJ	O
mouse.	NN	O
In	VBZ	O
addition,	DT	O
a	.	O
“transgenic	RBR	O
animal”	,	O
may	DT	O
be	NN	O
a	VBZ	O
heterozygous	DT	O
animal	NN	O
(i.e.,	JJ	O
one	IN	O
defective	DT	O
allele	NN	O
and	CC	O
one	.	O
wild-type	IN	O
allele)	,	O
or	DT	O
a	JJ	O
homozygous	NN	O
animal	MD	O
(i.e.,	VB	O
two	DT	O
defective	JJ	O
alleles).	NN	O
An	,	O
embryo	CD	O
is	JJ	O
considered	NN	O
to	CC	O
fall	CD	O
within	JJ	O
the	)	O
definition	CC	O
of	DT	O
an	JJ	O
animal.	NN	O
The	,	O
provision	CD	O
of	JJ	O
an	.	O
animal	DT	O
includes	NN	O
the	VBZ	O
provision	VBN	O
of	TO	O
an	VB	O
embryo	IN	O
or	DT	O
foetus	NN	O
in	IN	O
utero,	DT	O
whether	.	O
by	DT	O
mating	NN	O
or	IN	O
otherwise,	DT	O
and	NN	O
whether	VBZ	O
or	DT	O
not	NN	O
the	IN	O
embryo	DT	O
goes	NN	O
to	CC	O
term.	NN	O
As	IN	O
used	,	O
herein,	IN	O
the	IN	O
terms	VBG	O
“selective	CC	O
marker”	,	O
and	CC	O
position	IN	O
selection	CC	O
marker”	RB	O
refer	DT	O
to	NN	O
a	VBZ	O
gene	TO	O
encoding	.	O
a	IN	O
product	VBN	O
that	,	O
enables	DT	O
only	NNS	O
the	VBP	O
cells	NN	O
that	CC	O
carry	NN	O
the	NN	O
gene	NN	O
to	VBP	O
survive	TO	O
and/or	DT	O
grow	NN	O
under	VBG	O
certain	DT	O
conditions.	NN	O
For	WDT	O
example,	VBZ	O
plant	RB	O
and	DT	O
animal	NNS	O
cells	WDT	O
that	VBP	O
express	DT	O
the	NN	O
introduced	TO	O
neomycin	VB	O
resistance	JJ	O
(Neor)	NNS	O
gene	IN	O
are	JJ	O
resistant	.	O
to	IN	O
the	,	O
compound	NN	O
G418.	CC	O
Cells	NN	O
that	NNS	O
do	WDT	O
not	VBP	O
carry	DT	O
the	JJ	O
Neor	NN	O
gene	NN	O
marker	)	O
are	NN	O
killed	VBP	O
by	JJ	O
G418.	TO	O
Other	DT	O
positive	NN	O
selection	.	O
markers	NNS	O
are	WDT	O
known	VBP	O
to,	RB	O
or	VB	O
are	DT	O
within	NNP	O
the	NN	O
purview	NN	O
of,	VBP	O
those	VBN	O
of	IN	O
ordinary	.	O
skill	JJ	O
in	JJ	O
the	NN	O
art.	NNS	O
The	VBP	O
term	VBN	O
“modulates”	,	O
or	CC	O
“modulation”	VBP	O
as	IN	O
used	DT	O
herein	NN	O
refers	,	O
to	DT	O
the	IN	O
decrease,	JJ	O
inhibition,	NN	O
reduction,	IN	O
amelioration,	DT	O
increase	.	O
or	DT	O
enhancement	NN	O
of	NN	O
a	CC	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	VBN	O
PRO1328,	NN	O
PRO4342,	NNS	O
PRO7423,	TO	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene	NN	O
function,	CC	O
expression,	NN	O
activity,	IN	O
or	DT	O
alternatively	,	O
a	,	O
phenotype	,	O
associated	,	O
with	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	CC	O
PRO7423,	NNP	O
PRO10096,	NN	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	CC	O
gene.	RB	O
The	DT	O
term	NN	O
“ameliorates”	VBN	O
or	IN	O
“amelioration”	,	O
as	,	O
used	,	O
herein	,	O
refers	,	O
to	,	O
a	,	O
decrease,	,	O
reduction	NNP	O
or	CC	O
elimination	NNP	O
of	.	O
a	DT	O
condition,	NN	O
disease,	NN	O
disorder,	CC	O
or	NN	O
phenotype,	IN	O
including	VBN	O
an	NN	O
abnormality	NNS	O
or	TO	O
symptom.	DT	O
The	,	O
term	NN	O
“abnormality”	CC	O
refers	NN	O
to	IN	O
any	DT	O
disease,	,	O
disorder,	,	O
condition,	,	O
or	CC	O
phenotype	,	O
in	VBG	O
which	DT	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	.	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	VBZ	O
PRO10096,	NNS	O
PRO21384,	TO	O
PRO353	DT	O
or	,	O
PRO1885	,	O
is	,	O
implicated,	CC	O
including	NN	O
pathological	IN	O
conditions	WDT	O
and	,	O
behavioral	,	O
observations.	,	O
II.	,	O
Compositions	,	O
and	,	O
Methods	,	O
of	,	O
the	NNP	O
Invention	CC	O
A.	NNP	O
Full-Length	VBZ	O
PRO227,	,	O
PRO233,	VBG	O
PRO238,	JJ	O
PRO1328,	NNS	O
PRO4342,	CC	O
PRO7423;	JJ	O
PRO10096;	.	O
PRO21384;	.	O
PRO353	NNS	O
or	CC	O
PRO1885	NNS	O
Polypeptides	IN	O
The	DT	O
present	NNP	O
invention	NN	O
provides	NNP	O
newly	,	O
identified	,	O
and	,	O
isolated	,	O
nucleotide	,	O
sequences	:	O
encoding	:	O
polypeptides	:	O
referred	NNP	O
to	CC	O
in	NNP	O
the	NNP	O
present	DT	O
application	JJ	O
as	NN	O
PRO227,	VBZ	O
PRO233,	RB	O
PRO238,	VBN	O
PRO1328,	CC	O
PRO4342,	VBN	O
PRO7423,	JJ	O
PRO10096,	NNS	O
PRO21384,	VBG	O
PRO353	NNS	O
or	VBD	O
PRO1885	TO	O
polypeptides.	IN	O
In	DT	O
particular,	JJ	O
cDNAs	NN	O
encoding	IN	O
various	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	.	O
polypeptides	IN	O
have	,	O
been	JJ	O
identified	VBG	O
and	JJ	O
isolated,	,	O
as	,	O
disclosed	,	O
in	,	O
further	,	O
detail	,	O
in	,	O
the	,	O
Examples	NNP	O
below.	CC	O
It	NNP	O
is	NNS	O
noted	VBP	O
that	VBN	O
proteins	VBN	O
produced	CC	O
in	,	O
separate	IN	O
expression	VBN	O
rounds	IN	O
may	JJ	O
be	NN	O
given	IN	O
different	DT	O
PRO	NNP	O
numbers	.	O
but	PRP	O
the	VBZ	O
UNQ	VBN	O
number	IN	O
is	NNS	O
unique	VBN	O
for	IN	O
any	JJ	O
given	NN	O
DNA	NNS	O
and	MD	O
the	VB	O
encoded	VBN	O
protein,	JJ	O
and	NNP	O
will	NNS	O
not	CC	O
be	DT	O
changed.	NNP	O
However,	NN	O
for	VBZ	O
sake	JJ	O
of	IN	O
simplicity,	DT	O
in	VBN	O
the	NN	O
present	CC	O
specification	DT	O
the	JJ	O
protein	,	O
encoded	CC	O
by	MD	O
the	RB	O
full	VB	O
length	.	O
native	,	O
nucleic	IN	O
acid	NN	O
molecules	IN	O
disclosed	,	O
herein	IN	O
as	DT	O
well	JJ	O
as	NN	O
all	DT	O
further	NN	O
native	VBN	O
homologues	IN	O
and	DT	O
variants	JJ	O
included	NN	O
in	JJ	O
the	JJ	O
foregoing	NN	O
definition	NNS	O
of	VBD	O
PRO,	NN	O
will	RB	O
be	RB	O
referred	IN	O
to	DT	O
as	JJ	O
“PRO/number”,	JJ	O
regardless	NNS	O
of	CC	O
their	NNS	O
origin	VBN	O
or	IN	O
mode	DT	O
of	JJ	O
preparation.	NN	O
As	IN	O
disclosed	,	O
in	MD	O
the	VB	O
Examples	VBN	O
below,	TO	O
various	IN	O
cDNA	,	O
clones	RB	O
have	IN	O
been	PRP$	O
deposited	NN	O
with	CC	O
the	NN	O
ATCC.	IN	O
The	.	O
actual	IN	O
nucleotide	VBN	O
sequences	IN	O
of	DT	O
those	NNP	O
clones	,	O
can	JJ	O
readily	NN	O
be	NNS	O
determined	VBP	O
by	VBN	O
the	VBN	O
skilled	IN	O
artisan	DT	O
by	.	O
sequencing	DT	O
of	JJ	O
the	JJ	O
deposited	NNS	O
clone	IN	O
using	DT	O
routine	NNS	O
methods	MD	O
in	RB	O
the	VB	O
art.	VBN	O
The	IN	O
predicted	DT	O
amino	VBN	O
acid	NN	O
sequence	IN	O
can	VBG	O
be	IN	O
determined	DT	O
from	JJ	O
the	NN	O
nucleotide	VBG	O
sequence	JJ	O
using	NNS	O
routine	IN	O
skill.	DT	O
For	.	O
the	DT	O
PRO227,	VBN	O
PRO233,	NN	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	MD	O
PRO7423,	VB	O
PRO10096,	VBN	O
PRO21384,	IN	O
PRO353	DT	O
or	JJ	O
PRO1885	NN	O
polypeptides	VBG	O
and	JJ	O
encoding	.	O
nucleic	IN	O
acids	DT	O
described	,	O
herein,	,	O
Applicants	,	O
have	,	O
identified	,	O
what	,	O
is	,	O
believed	,	O
to	NNP	O
be	CC	O
the	NNP	O
reading	NNS	O
frame	CC	O
best	VBG	O
identifiable	JJ	O
with	NNS	O
the	VBD	O
sequence	,	O
information	NNS	O
available	VBP	O
at	VBN	O
the	WP	O
time.	VBZ	O
B.	VBN	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	RBS	O
PRO10096,	JJ	O
PRO21384,	IN	O
PRO353	DT	O
or	NN	O
PRO1885	NN	O
Polypeptide	JJ	O
Variants	IN	O
In	DT	O
addition	.	O
to	NNP	O
the	,	O
full-length	,	O
native	,	O
sequence	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	NNP	O
or	IN	O
PRO1885	NN	O
polypeptides	TO	O
described	DT	O
herein,	JJ	O
it	JJ	O
is	NN	O
contemplated	,	O
that	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	NNS	O
PRO1885	VBD	O
variants	,	O
can	PRP	O
be	VBZ	O
prepared.	VBN	O
PRO227,	IN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
variants	NNP	O
can	NNS	O
be	MD	O
prepared	VB	O
by	.	O
introducing	,	O
appropriate	,	O
nucleotide	,	O
changes	,	O
into	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	NNS	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	VBN	O
or	IN	O
PRO1885	VBG	O
DNA,	JJ	O
and/or	JJ	O
by	NNS	O
synthesis	IN	O
of	DT	O
the	,	O
desired	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	,	O
PRO1885	NN	O
polypeptide.	IN	O
Those	NN	O
skilled	IN	O
in	DT	O
the	JJ	O
art	,	O
will	,	O
appreciate	,	O
that	,	O
amino	,	O
acid	,	O
changes	,	O
may	,	O
alter	NNP	O
post-translational	CC	O
processes	NNP	O
of	.	O
the	DT	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	MD	O
PRO7423,	VB	O
PRO10096,	IN	O
PRO21384,	NN	O
PRO353	NNS	O
or	NNS	O
PRO1885	MD	O
polypeptide,	VB	O
such	JJ	O
as	NNS	O
changing	IN	O
the	DT	O
number	,	O
or	,	O
position	,	O
of	,	O
glycosylation	,	O
sites	,	O
or	,	O
altering	,	O
the	NNP	O
membrane	CC	O
anchoring	NNP	O
characteristics.	,	O
Variations	JJ	O
in	IN	O
the	VBG	O
native	DT	O
full-length	NN	O
sequence	CC	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	NN	O
PRO1328,	NNS	O
PRO4342,	CC	O
PRO7423,	VBG	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	VBG	O
or	.	O
PRO1885	NNS	O
polypeptide	IN	O
or	DT	O
in	JJ	O
various	JJ	O
domains	NN	O
of	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	NN	O
PRO1885	CC	O
polypeptide	IN	O
described	JJ	O
herein,	NNS	O
can	IN	O
be	DT	O
made,	,	O
for	,	O
example,	,	O
using	,	O
any	,	O
of	,	O
the	,	O
techniques	,	O
and	NNP	O
guidelines	CC	O
for	NNP	O
conservative	RB	O
and	VBD	O
non-conservative	,	O
mutations	MD	O
set	VB	O
forth,	,	O
for	IN	O
instance,	,	O
in	VBG	O
U.S.	DT	O
Pat.	IN	O
No.	DT	O
5,364,934.	NNS	O
Variations	CC	O
may	NNS	O
be	IN	O
a	JJ	O
substitution,	CC	O
deletion	JJ	O
or	NNS	O
insertion	VBD	O
of	,	O
one	IN	O
or	,	O
more	IN	O
codons	NNP	O
encoding	.	O
the	.	O
PRO227,	.	O
PRO233,	NNS	O
PRO238,	MD	O
PRO1328,	VB	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	NN	O
PRO21384,	CC	O
PRO353	NN	O
or	IN	O
PRO1885	CD	O
polypeptide	CC	O
that	JJR	O
results	NNS	O
in	VBG	O
a	DT	O
change	,	O
in	,	O
the	,	O
amino	,	O
acid	,	O
sequence	,	O
of	,	O
the	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
polypeptide	NN	O
as	JJ	O
compared	NN	O
with	IN	O
the	DT	O
native	,	O
sequence	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	RB	O
PRO1885	IN	O
polypeptide.	VBN	O
Optionally	IN	O
the	DT	O
variation	JJ	O
is	NN	O
by	,	O
substitution	,	O
of	,	O
at	,	O
least	,	O
one	,	O
amino	,	O
acid	,	O
with	NNP	O
any	CC	O
other	NNP	O
amino	.	O
acid	RB	O
in	DT	O
one	NN	O
or	VBZ	O
more	IN	O
of	NN	O
the	IN	O
domains	IN	O
of	JJS	O
the	CD	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	CD	O
or	CC	O
PRO1885	JJR	O
polypeptide.	IN	O
Guidance	DT	O
in	NNS	O
determining	IN	O
which	DT	O
amino	,	O
acid	,	O
residue	,	O
may	,	O
be	,	O
inserted,	,	O
substituted	,	O
or	,	O
deleted	NNP	O
without	CC	O
adversely	NNP	O
affecting	.	O
the	NN	O
desired	IN	O
activity	VBG	O
may	WDT	O
be	NN	O
found	NNS	O
by	VBP	O
comparing	MD	O
the	VB	O
sequence	,	O
of	VBD	O
the	CC	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	RB	O
PRO1328,	VBG	O
PRO4342,	DT	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	MD	O
PRO353	VB	O
or	VBN	O
PRO1885	IN	O
polypeptide	VBG	O
with	DT	O
that	NN	O
of	IN	O
homologous	DT	O
known	,	O
protein	,	O
molecules	,	O
and	,	O
minimizing	,	O
the	,	O
number	,	O
of	,	O
amino	NNP	O
acid	CC	O
sequence	NNP	O
changes	IN	O
made	IN	O
in	DT	O
regions	IN	O
of	JJ	O
high	VBN	O
homology.	NN	O
Amino	NNS	O
acid	CC	O
substitutions	VBG	O
can	DT	O
be	NN	O
the	IN	O
result	JJ	O
of	JJ	O
replacing	NN	O
one	NNS	O
amino	VBN	O
acid	IN	O
with	NNS	O
another	IN	O
amino	JJ	O
acid	.	O
having	NNP	O
similar	JJ	O
structural	NNS	O
and/or	MD	O
chemical	VB	O
properties,	DT	O
such	NN	O
as	IN	O
the	VBG	O
replacement	CD	O
of	NN	O
a	NN	O
leucine	IN	O
with	DT	O
a	NN	O
serine,	NN	O
i.e.,	VBG	O
conservative	JJ	O
amino	JJ	O
acid	NN	O
replacements.	NN	O
Insertions	,	O
or	JJ	O
deletions	IN	O
may	DT	O
optionally	NN	O
be	IN	O
in	DT	O
the	NN	O
range	IN	O
of	DT	O
about	,	O
1	,	O
to	JJ	O
5	NN	O
amino	NN	O
acids.	.	O
The	NNS	O
variation	CC	O
allowed	NNS	O
may	MD	O
be	RB	O
determined	VB	O
by	IN	O
systematically	DT	O
making	NN	O
insertions,	IN	O
deletions	RB	O
or	CD	O
substitutions	TO	O
of	CD	O
amino	NN	O
acids	.	O
in	DT	O
the	NN	O
sequence	VBD	O
and	MD	O
testing	VB	O
the	VBN	O
resulting	IN	O
variants	RB	O
for	VBG	O
activity	,	O
exhibited	NNS	O
by	CC	O
the	NNS	O
full-length	IN	O
or	JJ	O
mature	NNS	O
native	IN	O
sequence.	DT	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	VBG	O
PRO1328,	DT	O
PRO4342,	VBG	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	NN	O
PRO353	VBN	O
or	IN	O
PRO1885	DT	O
polypeptide	NN	O
fragments	CC	O
are	NN	O
provided	JJ	O
herein.	.	O
Such	,	O
fragments	,	O
may	,	O
be	,	O
truncated	,	O
at	,	O
the	,	O
N-terminus	,	O
or	NNP	O
C-terminus,	CC	O
or	NNP	O
may	IN	O
lack	NNS	O
internal	VBP	O
residues,	VBN	O
for	.	O
example,	JJ	O
when	NNS	O
compared	MD	O
with	VB	O
a	VBN	O
full	IN	O
length	DT	O
native	NNP	O
protein.	CC	O
Certain	,	O
fragments	CC	O
lack	MD	O
amino	VB	O
acid	JJ	O
residues	,	O
that	IN	O
are	,	O
not	WRB	O
essential	VBN	O
for	IN	O
a	DT	O
desired	JJ	O
biological	NN	O
activity	JJ	O
of	.	O
the	NN	O
PRO227,	NNS	O
PRO233,	VBP	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	NNS	O
PRO7423,	WDT	O
PRO10096,	VBP	O
PRO21384,	RB	O
PRO353	JJ	O
or	IN	O
PRO1885	DT	O
polypeptide.	JJ	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
fragments	,	O
may	NNP	O
be	CC	O
prepared	NNP	O
by	.	O
any	,	O
of	,	O
a	,	O
number	,	O
of	,	O
conventional	,	O
techniques.	,	O
Desired	,	O
peptide	NNP	O
fragments	CC	O
may	NNP	O
be	NNS	O
chemically	MD	O
synthesized.	VB	O
An	VBN	O
alternative	IN	O
approach	DT	O
involves	IN	O
generating	DT	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	JJ	O
PRO1328,	.	O
PRO4342,	NNP	O
PRO7423,	NN	O
PRO10096,	NNS	O
PRO21384,	MD	O
PRO353	VB	O
or	RB	O
PRO1885	.	O
fragments	DT	O
by	JJ	O
enzymatic	NN	O
digestion,	VBZ	O
e.g.,	VBG	O
by	,	O
treating	,	O
the	,	O
protein	,	O
with	,	O
an	,	O
enzyme	,	O
known	,	O
to	NNP	O
cleave	CC	O
proteins	NNP	O
at	NNS	O
sites	IN	O
defined	JJ	O
by	,	O
particular	,	O
amino	IN	O
acid	VBG	O
residues,	DT	O
or	NN	O
by	IN	O
digesting	DT	O
the	NN	O
DNA	VBN	O
with	TO	O
suitable	VB	O
restriction	NNS	O
enzymes	IN	O
and	NNS	O
isolating	VBN	O
the	IN	O
desired	JJ	O
fragment.	NN	O
Yet	NN	O
another	,	O
suitable	CC	O
technique	IN	O
involves	VBG	O
isolating	DT	O
and	NN	O
amplifying	IN	O
a	JJ	O
DNA	NN	O
fragment	NNS	O
encoding	CC	O
a	VBG	O
desired	DT	O
polypeptide	JJ	O
fragment,	.	O
by	RB	O
polymerase	DT	O
chain	JJ	O
reaction	NN	O
(PCR).	VBZ	O
Oligonucleotides	VBG	O
that	CC	O
define	VBG	O
the	DT	O
desired	NN	O
termini	NN	O
of	VBG	O
the	DT	O
DNA	JJ	O
fragment	NN	O
are	,	O
employed	IN	O
at	NN	O
the	NN	O
5′	NN	O
and	.	O
3′	NNS	O
primers	WDT	O
in	VBP	O
the	DT	O
PCR.	JJ	O
Preferably,	NN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NNP	O
PRO1328,	NN	O
PRO4342,	VBP	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	CD	O
or	CC	O
PRO1885	CD	O
polypeptide	NNS	O
fragments	IN	O
share	DT	O
at	.	O
least	,	O
one	,	O
biological	,	O
and/or	,	O
immunological	,	O
activity	,	O
with	,	O
the	,	O
native	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	IN	O
PRO4342,	NNS	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	JJS	O
PRO353	CD	O
or	JJ	O
PRO1885	JJ	O
polypeptide	JJ	O
disclosed	NN	O
herein.	IN	O
Conservative	DT	O
substitutions	JJ	O
of	,	O
interest	,	O
are	,	O
shown	,	O
in	,	O
Table	,	O
6	,	O
under	,	O
the	NNP	O
heading	CC	O
of	NNP	O
preferred	RB	O
substitutions.	VBD	O
If	.	O
such	JJ	O
substitutions	NNS	O
result	IN	O
in	NN	O
a	VBP	O
change	VBN	O
in	IN	O
biological	JJ	O
activity,	CD	O
then	IN	O
more	DT	O
substantial	NN	O
changes,	IN	O
denominated	JJ	O
exemplary	.	O
substitutions	IN	O
in	JJ	O
Table	NNS	O
6,	VBP	O
or	IN	O
as	DT	O
further	NN	O
described	IN	O
below	JJ	O
in	,	O
reference	RB	O
to	RBR	O
amino	JJ	O
acid	,	O
classes,	VBD	O
are	JJ	O
preferably	NNS	O
introduced	IN	O
and	JJ	O
the	,	O
products	CC	O
screened.	IN	O
Substantial	JJ	O
modifications	VBD	O
in	IN	O
function	IN	O
or	NN	O
immunological	TO	O
identity	VB	O
of	JJ	O
the	,	O
PRO227,	VBP	O
PRO233,	RB	O
PRO238,	VBN	O
PRO1328,	CC	O
PRO4342,	DT	O
PRO7423,	NNS	O
PRO10096,	.	O
PRO21384,	JJ	O
PRO353	NNS	O
or	IN	O
PRO1885	NN	O
polypeptide	CC	O
are	JJ	O
accomplished	NN	O
by	IN	O
selecting	DT	O
substitutions	,	O
that	,	O
differ	,	O
significantly	,	O
in	,	O
their	,	O
effect	,	O
on	,	O
maintaining	NNP	O
(a)	CC	O
the	NNP	O
structure	NN	O
of	VBP	O
the	VBN	O
polypeptide	IN	O
backbone	VBG	O
in	NNS	O
the	WDT	O
area	VBP	O
of	RB	O
the	IN	O
substitution,	PRP$	O
for	NN	O
example,	IN	O
as	NN	O
a	)	O
sheet	DT	O
or	NN	O
helical	IN	O
conformation,	DT	O
(b)	NN	O
the	NN	O
charge	IN	O
or	DT	O
hydrophobicity	NN	O
of	IN	O
the	DT	O
molecule	,	O
at	IN	O
the	,	O
target	IN	O
site,	DT	O
or	NN	O
(c)	CC	O
the	JJ	O
bulk	,	O
of	)	O
the	DT	O
side	NN	O
chain.	CC	O
Naturally	NN	O
occurring	IN	O
residues	DT	O
are	NN	O
divided	IN	O
into	DT	O
groups	NN	O
based	,	O
on	CC	O
common	)	O
side-chain	DT	O
properties:	NN	O
Amino	IN	O
acids	DT	O
may	NN	O
be	.	O
grouped	RB	O
according	VBG	O
to	NNS	O
similarities	VBP	O
in	VBN	O
the	IN	O
properties	NNS	O
of	VBN	O
their	IN	O
side	JJ	O
chains	JJ	O
(in	:	O
A.	NNP	O
L.	NNS	O
Lehninger,	MD	O
in	VB	O
Biochemistry,	VBN	O
second	VBG	O
ed.,	TO	O
pp.	NNS	O
73-75,	IN	O
Worth	DT	O
Publishers,	NNS	O
New	IN	O
York	PRP$	O
(1975)):	NN	O
(1)	NNS	O
non-polar:	IN	O
Ala	NNP	O
(A),	NNP	O
Val	,	O
(V),	IN	O
Leu	,	O
(L),	JJ	O
Ile	,	O
(I),	.	O
Pro	,	O
(P),	JJ	O
Phe	,	O
(F),	NNP	O
Trp	NNP	O
(W),	:	O
Met	)	O
(M)	:	O
(2)	NNP	O
uncharged	,	O
polar:	NNP	O
Gly	,	O
(G),	NNP	O
Ser	,	O
(S),	NNP	O
Thr	,	O
(T),	NNP	O
Cys©),	,	O
Tyr	NNP	O
(Y),	,	O
Asn	NNP	O
(N),	,	O
Gln	NNP	O
(Q)	)	O
(3)	)	O
acidic:	VBD	O
Asp	:	O
(D),	NNP	O
Glu	,	O
(E)	NNP	O
(4)	,	O
basic:	NNP	O
Lys	,	O
(K),	,	O
Arg®),	NNP	O
His	,	O
(H)	NNP	O
Alternatively,	,	O
naturally	NNP	O
occurring	)	O
residues	)	O
may	:	O
be	NNP	O
divided	,	O
into	NNP	O
groups	)	O
based	)	O
on	:	O
common	NNP	O
side-chain	,	O
properties:	,	O
(1)	PRP$	O
hydrophobic:	)	O
Norleucine,	,	O
Met,	RB	O
Ala,	VBG	O
Val,	NNS	O
Leu,	MD	O
Ile;	VB	O
(2)	VBN	O
neutral	IN	O
hydrophilic:	NNS	O
Cys,	VBN	O
Ser,	IN	O
Thr,	JJ	O
Asn,	JJ	O
Gln;	:	O
(3)	)	O
acidic:	:	O
Asp,	,	O
Glu;	,	O
(4)	,	O
basic:	,	O
His,	,	O
Lys,	:	O
Arg;	)	O
(5)	JJ	O
residues	:	O
that	,	O
influence	,	O
chain	,	O
orientation:	,	O
Gly,	:	O
Pro;	)	O
(6)	:	O
aromatic:	,	O
Trp,	:	O
Tyr,	)	O
Phe.	:	O
Non-conservative	,	O
substitutions	,	O
will	:	O
entail	)	O
exchanging	NNS	O
a	WDT	O
member	NN	O
of	NN	O
one	:	O
of	,	O
these	:	O
classes	)	O
for	:	O
another	,	O
class.	,	O
Such	.	O
substituted	JJ	O
residues	NNS	O
also	MD	O
may	VB	O
be	VBG	O
introduced	DT	O
into	NN	O
the	IN	O
conservative	CD	O
substitution	IN	O
sites	DT	O
or,	NNS	O
more	IN	O
preferably,	DT	O
into	.	O
the	JJ	O
remaining	VBN	O
(non-conserved)	NNS	O
sites.	RB	O
The	MD	O
variations	VB	O
can	VBN	O
be	IN	O
made	DT	O
using	JJ	O
methods	NN	O
known	NNS	O
in	,	O
the	JJR	O
art	,	O
such	IN	O
as	DT	O
oligonucleotide-mediated	VBG	O
(site-directed)	)	O
mutagenesis,	.	O
alanine	DT	O
scanning,	NNS	O
and	MD	O
PCR	VB	O
mutagenesis.	VBN	O
Site-directed	VBG	O
mutagenesis	NNS	O
Carter	VBN	B
et	IN	I
al.,	DT	I
Nucl.	NN	I
Acids	JJ	I
Res.,	IN	I
13:4331	JJ	I
(1986);	)	I
Zoller	,	B
et	NN	I
al.,	,	I
Nucl.	CC	I
Acids	NNP	I
Res.,	.	I
10:6487	JJ	I
(1987)],[	NN	O
cassette	NNP	O
mutagenesis	FW	O
Wells	,	B
et	.	I
al.,	NNP	I
Gene,	,	I
34:315	CD	I
(1985)],[	:	O
restriction	NNP	O
selection	FW	O
mutagenesis	,	O
Wells	.	B
et	NNP	I
al.,	,	I
Philos.	CD	I
Trans.	,	I
R.	NN	I
Soc.	NN	I
London	NNP	I
SerA,	FW	I
317:415	,	I
(1986)]	,	I
[or	CD	O
other	,	O
known	NN	O
techniques	NN	O
can	NN	O
be	NNP	O
performed	FW	O
on	,	O
the	.	O
cloned	.	O
DNA	NNP	O
to	.	O
produce	NNP	O
the	,	O
PRO227,	CD	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	JJ	O
PRO4342,	VBN	O
PRO7423,	NNS	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	VBN	O
or	IN	O
PRO1885	DT	O
variant	VBN	O
DNA.	NN	O
Scanning	TO	O
amino	VB	O
acid	DT	O
analysis	,	O
can	,	O
also	,	O
be	,	O
employed	,	O
to	,	O
identify	,	O
one	,	O
or	NNP	O
more	CC	O
amino	NNP	O
acids	JJ	O
along	.	O
a	VBG	O
contiguous	NN	O
sequence.	JJ	O
Among	NN	O
the	MD	O
preferred	RB	O
scanning	VB	O
amino	VBN	O
acids	TO	O
are	VB	O
relatively	CD	O
small,	CC	O
neutral	JJR	O
amino	JJ	O
acids.	NNS	O
Such	IN	O
amino	DT	O
acids	JJ	O
include	.	O
alanine,	IN	O
glycine,	DT	O
serine,	JJ	O
and	NN	O
cysteine.	NN	O
Alanine	NNS	O
is	VBP	O
typically	RB	O
a	,	O
preferred	JJ	O
scanning	NN	O
amino	.	O
acid	JJ	O
among	JJ	O
this	NNS	O
group	VBP	O
because	,	O
it	,	O
eliminates	,	O
the	CC	O
side-chain	.	O
beyond	NNP	O
the	VBZ	O
beta-carbon	RB	O
and	DT	O
is	JJ	O
less	NN	O
likely	NN	O
to	NN	O
alter	IN	O
the	DT	O
main-chain	NN	O
conformation	IN	O
of	PRP	O
the	VBZ	O
variant	DT	O
Cunningham	JJ	B
and	IN	I
Wells,	DT	I
Science,	NN	I
244:	CC	I
1081-1085	VBZ	I
(1989)].[	RBR	O
Alanine	JJ	O
is	TO	O
also	VB	O
typically	DT	O
preferred	JJ	O
because	NN	O
it	IN	O
is	DT	O
the	JJ	O
most	NNP	O
common	CC	O
amino	,	O
acid.	,	O
Further,	:	O
it	CD	O
is	.	O
frequently	NNP	O
found	VBZ	O
in	RB	O
both	RB	O
buried	JJ	O
and	IN	O
exposed	PRP	O
positions	VBZ	O
Creighton,	DT	B
The	RBS	I
Proteins,	JJ	I
(W.H.	NN	I
Freeman	.	I
&	,	I
Co.,	PRP	I
N.Y.);	VBZ	I
Chothia,	RB	B
J.	VBN	I
Mol.	IN	I
Biol.,	DT	I
150:1	VBN	I
(1976)].[	CC	O
If	VBN	O
alanine	NNS	O
substitution	,	O
does	DT	O
not	,	O
yield	.	O
adequate	NNP	O
amounts	CC	O
of	,	O
variant,	:	O
an	,	O
isoteric	NNP	O
amino	.	O
acid	,	O
can	CD	O
be	.	O
used.	IN	O
C.	JJ	O
Modifications	NN	O
of	VBZ	O
PRO227,	RB	O
PRO233,	VB	O
PRO238,	JJ	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	,	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	NN	O
or	NN	O
PRO1885	MD	O
Covalent	VB	O
modifications	.	O
of	NNP	O
PRO227,	NNP	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
polypeptides	CC	O
are	NNP	O
included	NNP	O
within	NNS	O
the	IN	O
scope	,	O
of	,	O
this	,	O
invention.	,	O
One	,	O
type	,	O
of	,	O
covalent	,	O
modification	NNP	O
includes	CC	O
reacting	NNP	O
targeted	NNS	O
amino	VBP	O
acid	VBN	O
residues	IN	O
of	DT	O
a	NN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	.	O
PRO1328,	CD	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	VBZ	O
or	VBG	O
PRO1885	VBN	O
polypeptide	JJ	O
with	JJ	O
an	NNS	O
organic	IN	O
derivatizing	DT	O
agent	,	O
that	,	O
is	,	O
capable	,	O
of	,	O
reacting	,	O
with	,	O
selected	,	O
side	NNP	O
chains	CC	O
or	NNP	O
the	IN	O
N-	IN	O
or	DT	O
C-terminal	JJ	O
residues	NN	O
of	NN	O
the	WDT	O
PRO227,	VBZ	O
PRO233,	JJ	O
PRO238,	IN	O
PRO1328,	VBG	O
PRO4342,	IN	O
PRO7423,	VBN	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	CC	O
or	DT	O
PRO1885	JJ	O
polypeptide.	CC	O
Derivatization	JJ	O
with	NNS	O
bifunctional	IN	O
agents	DT	O
is	,	O
useful,	,	O
for	,	O
instance,	,	O
for	,	O
crosslinking	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	.	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	JJ	O
or	NNS	O
PRO1885	VBZ	O
polypeptides	,	O
to	IN	O
a	,	O
water-insoluble	IN	O
support	VBG	O
matrix	,	O
or	,	O
surface	,	O
for	,	O
use	,	O
in	,	O
the	,	O
method	,	O
for	NNP	O
purifying	CC	O
anti-PRO227,	NNP	O
anti-PRO233,	NNS	O
anti-PRO238,	TO	O
anti-PRO1328,	DT	O
anti-PRO4342,	JJ	O
anti-PRO7423,	NN	O
anti-PRO10096,	NN	O
anti-PRO21384,	CC	O
anti-PRO353	NN	O
or	IN	O
anti-PRO1885	NN	O
antibodies,	IN	O
and	DT	O
vice-versa.	NN	O
Commonly	IN	O
used	VBG	O
crosslinking	,	O
agents	,	O
include,	,	O
e.g.,	,	O
1,1-bis(diazoacetyl)-2-phenylethane,	,	O
glutaraldehyde,	,	O
N-hydroxysuccinimide	,	O
esters,	,	O
for	JJ	O
example,	CC	O
esters	JJ	O
with	,	O
4-azidosalicylic	CC	O
acid,	.	O
homobifunctional	RB	O
imidoesters,	VBN	O
including	VBG	O
disuccinimidyl	NNS	O
esters	,	O
such	,	O
as	,	O
3,3′-dithiobis(succinimidylpropionate),	,	O
bifunctionalmaleimides	JJ	O
such	,	O
as	IN	O
bis-N-maleimido-1,8-octane	,	O
and	NNS	O
agents	IN	O
such	JJ	O
as	,	O
ethyl-3-[(p-azidophenyl)dithio]propioimidate.	JJ	O
Other	,	O
modifications	VBG	O
include	JJ	O
deamidation	NNS	O
of	JJ	O
glutaminyl	IN	O
and	,	O
asparaginyl	NNS	O
residues	JJ	O
to	IN	O
the	NN	O
corresponding	CC	O
glutamyl	NNS	O
and	JJ	O
aspartyl	IN	O
residues,	.	O
respectively,	JJ	O
hydroxylation	NNS	O
of	VBP	O
proline	NN	O
and	IN	O
lysine,	NN	O
phosphorylation	CC	O
of	NN	O
hydroxyl	NNS	O
groups	TO	O
of	DT	O
seryl	JJ	O
or	NN	O
threonyl	CC	O
residues,	NN	O
methylation	,	O
of	,	O
the	NN	O
α-amino	IN	O
groups	NN	O
of	CC	O
lysine,	,	O
arginine,	NN	O
and	IN	O
histidine	NN	O
side	NNS	O
chains	IN	O
T.E.	NN	B
Creighton,	CC	I
Proteins:	NN	I
Structure	,	I
and	NN	I
Molecular	IN	I
Properties,	DT	I
W.H.	JJ	I
Freeman	NNS	I
&	IN	I
Co.,	,	I
San	,	I
Francisco,	CC	I
pp.	JJ	I
79-86	NN	I
(1983)],[	NNS	O
acetylation	.	O
of	,	O
the	:	O
N-terminal	NN	O
amine,	CC	O
and	NNP	O
amidation	,	O
of	.	O
any	NNP	O
C-terminal	CC	O
carboxyl	,	O
group.	NNP	O
Another	,	O
type	.	O
of	CD	O
covalent	,	O
modification	NN	O
of	IN	O
the	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	CC	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	.	O
or	DT	O
PRO1885	NN	O
polypeptide	IN	O
included	JJ	O
within	NN	O
the	IN	O
scope	DT	O
of	,	O
this	,	O
invention	,	O
comprises	,	O
altering	,	O
the	,	O
native	,	O
glycosylation	,	O
pattern	NNP	O
of	CC	O
the	NNP	O
polypeptide.	NN	O
“Altering	VBD	O
the	IN	O
native	DT	O
glycosylation	NN	O
pattern”	IN	O
is	DT	O
intended	NN	O
for	VBZ	O
purposes	VBG	O
herein	DT	O
to	JJ	O
mean	NN	O
deleting	NN	O
one	IN	O
or	DT	O
more	.	O
carbohydrate	VBG	O
moieties	DT	O
found	JJ	O
in	NN	O
native	NN	O
sequence	VBZ	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	NNS	O
PRO1328,	VBP	O
PRO4342,	TO	O
PRO7423,	VB	O
PRO10096,	VBG	O
PRO21384,	CD	O
PRO353	CC	O
or	JJR	O
PRO1885	JJ	O
polypeptides	NNS	O
(either	VBN	O
by	IN	O
removing	JJ	O
the	NN	O
underlying	,	O
glycosylation	,	O
site	,	O
or	,	O
by	,	O
deleting	,	O
the	,	O
glycosylation	,	O
by	NNP	O
chemical	CC	O
and/or	NNP	O
enzymatic	NNS	O
means),	CC	O
and/or	IN	O
adding	VBG	O
one	DT	O
or	JJ	O
more	NN	O
glycosylation	NN	O
sites	CC	O
that	IN	O
are	VBG	O
not	DT	O
present	NN	O
in	IN	O
the	NN	O
native	NN	O
sequence	JJ	O
PRO227,	,	O
PRO233,	JJ	O
PRO238,	VBG	O
PRO1328,	CD	O
PRO4342,	CC	O
PRO7423,	JJR	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	WDT	O
or	VBP	O
PRO1885	RB	O
polypeptide.	JJ	O
In	IN	O
addition,	DT	O
the	JJ	O
phrase	NN	O
includes	,	O
qualitative	,	O
changes	,	O
in	,	O
the	,	O
glycosylation	,	O
of	,	O
the	,	O
native	NNP	O
proteins,	CC	O
involving	NNP	O
a	.	O
change	IN	O
in	,	O
the	DT	O
nature	NN	O
and	VBZ	O
proportions	JJ	O
of	NNS	O
the	IN	O
various	DT	O
carbohydrate	NN	O
moieties	IN	O
present.	DT	O
Addition	JJ	O
of	,	O
glycosylation	VBG	O
sites	DT	O
to	NN	O
the	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	NNS	O
or	.	O
PRO1885	NN	O
polypeptide	IN	O
may	NN	O
be	NNS	O
accomplished	TO	O
by	DT	O
altering	,	O
the	,	O
amino	,	O
acid	,	O
sequence.	,	O
The	,	O
alteration	,	O
may	,	O
be	NNP	O
made,	CC	O
for	NNP	O
example,	NN	O
by	MD	O
the	VB	O
addition	VBN	O
of,	IN	O
or	VBG	O
substitution	DT	O
by,	NN	O
one	JJ	O
or	.	O
more	DT	O
serine	NN	O
or	MD	O
threonine	VB	O
residues	,	O
to	IN	O
the	,	O
native	IN	O
sequence	DT	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	CC	O
PRO1328,	NN	O
PRO4342,	,	O
PRO7423,	CD	O
PRO10096,	CC	O
PRO21384,	JJR	O
PRO353	NN	O
or	CC	O
PRO1885	NN	O
(for	NNS	O
O-linked	TO	O
glycosylation	DT	O
sites).	JJ	O
The	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
amino	IN	O
acid	NNP	O
sequence	NN	O
may	.	O
optionally	DT	O
be	,	O
altered	,	O
through	,	O
changes	,	O
at	,	O
the	,	O
DNA	,	O
level,	,	O
particularly	NNP	O
by	CC	O
mutating	NNP	O
the	VBP	O
DNA	JJ	O
encoding	NN	O
the	MD	O
PRO227,	RB	O
PRO233,	VB	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NNP	O
PRO353	,	O
or	RB	O
PRO1885	IN	O
polypeptide	VBG	O
at	DT	O
preselected	NN	O
bases	VBG	O
such	DT	O
that	,	O
codons	,	O
are	,	O
generated	,	O
that	,	O
will	,	O
translate	,	O
into	,	O
the	NNP	O
desired	CC	O
amino	NNP	O
acids.	VBP	O
Another	IN	O
means	VBN	O
of	NNS	O
increasing	JJ	O
the	IN	O
number	NNS	O
of	VBP	O
carbohydrate	VBN	O
moieties	IN	O
on	MD	O
the	VB	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	VBN	O
PRO1328,	NN	O
PRO4342,	.	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	VBG	O
or	DT	O
PRO1885	NN	O
polypeptide	IN	O
is	JJ	O
by	NNS	O
chemical	IN	O
or	DT	O
enzymatic	,	O
coupling	,	O
of	,	O
glycosides	,	O
to	,	O
the	,	O
polypeptide.	,	O
Such	,	O
methods	NNP	O
are	CC	O
described	NNP	O
in	NN	O
the	VBZ	O
art,	IN	O
e.g.,	NN	O
in	CC	O
WO	JJ	O
87/05330	NN	O
published	IN	O
11	NNS	O
Sep.	TO	O
1987,	DT	O
and	.	O
in	JJ	O
Aplin	NNS	B
and	VBP	I
Wriston,	VBN	I
CRC	IN	I
Crit.	DT	I
Rev.	,	I
Biochem.,	,	I
pp.	IN	I
259-306	NNP	I
(1981).
Removal	CD	O
of	VBD	O
carbohydrate	CD	O
moieties	NNP	O
present	,	O
on	CC	O
the	IN	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	.	O
PRO7423,	.	O
PRO10096,	,	O
PRO21384,	.	O
PRO353	CD	O
or	.	O
PRO1885	NN	O
polypeptide	IN	O
may	NN	O
be	NNS	O
accomplished	VBP	O
chemically	IN	O
or	DT	O
enzymatically	,	O
or	,	O
by	,	O
mutational	,	O
substitution	,	O
of	,	O
codons	,	O
encoding	,	O
for	NNP	O
amino	CC	O
acid	NNP	O
residues	NN	O
that	MD	O
serve	VB	O
as	VBN	O
targets	RB	O
for	CC	O
glycosylation.	RB	O
Chemical	CC	O
deglycosylation	IN	O
techniques	JJ	O
are	NN	O
known	IN	O
in	NNS	O
the	VBG	O
art	IN	O
and	NN	O
described,	NN	O
for	NNS	O
instance,	WDT	O
by	VBP	O
Hakimuddin,	IN	B
et	NNS	I
al.,	IN	I
Arch.	.	I
Biochem.	NNP	I
Biophys.,	NN	I
259:52	NNS	I
(1987)	VBP	I
and	VBN	O
by	IN	O
Edge	DT	B
et	NN	I
al.,	CC	I
Anal.	,	I
Biochem.,	IN	I
118:131	,	I
(1981).	IN	I
Enzymatic	,	O
cleavage	FW	O
of	,	O
carbohydrate	.	O
moieties	.	O
on	,	O
polypeptides	CD	O
can	)	O
be	CC	O
achieved	IN	O
by	NNP	O
the	FW	O
use	,	O
of	.	O
a	,	O
variety	CD	O
of	.	O
endo-	JJ	O
and	NN	O
exo-glycosidases	IN	O
as	NN	O
described	NNS	O
by	IN	O
Thotakura	NNS	B
et	MD	I
al.,	VB	I
Meth.	VBN	I
Enzymol.,	IN	I
138:350	DT	I
(1987).
Another	NN	O
type	IN	O
of	DT	O
covalent	NN	O
modification	IN	O
of	JJ	O
PRO227,	CC	O
PRO233,	NNS	O
PRO238,	IN	O
PRO1328,	VBN	O
PRO4342,	IN	O
PRO7423,	NNP	O
PRO10096,	FW	O
PRO21384,	,	O
PRO353	.	O
or	,	O
PRO1885	CD	O
polypeptides	.	O
comprises	DT	O
linking	NN	O
the	IN	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	NNP	O
to	CC	O
one	NNP	O
of	NNS	O
a	VBZ	O
variety	VBG	O
of	DT	O
nonproteinaceous	,	O
polymers,	,	O
e.g.,	,	O
polyethylene	,	O
glycol	,	O
(PEG),	,	O
polypropylene	,	O
glycol,	,	O
or	NNP	O
polyoxyalkylenes,	CC	O
in	NNP	O
the	IN	O
manner	TO	O
set	CD	O
forth	IN	O
in	DT	O
U.S.	NN	O
Pat.	IN	O
Nos.	JJ	O
4,640,835;	,	O
4,496,689;	,	O
4,301,144;	NN	O
4,670,417;	NN	O
4,791,192	,	O
or	JJ	O
4,179,337.	,	O
The	CC	O
PRO227,	,	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBN	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	NNP	O
PRO353	.	O
or	.	O
PRO1885	:	O
polypeptides	:	O
of	:	O
the	:	O
present	CD	O
invention	CC	O
may	.	O
also	DT	O
be	,	O
modified	,	O
in	,	O
a	,	O
way	,	O
to	,	O
form	,	O
a	,	O
chimeric	NNP	O
molecule	CC	O
comprising	NNP	O
the	NNS	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	MD	O
PRO7423,	RB	O
PRO10096,	VB	O
PRO21384,	VBN	O
PRO353	IN	O
or	DT	O
PRO1885	NN	O
polypeptide	TO	O
fused	VB	O
to	DT	O
another,	JJ	O
heterologous	NN	O
polypeptide	VBG	O
or	DT	O
amino	,	O
acid	,	O
sequence.	,	O
Such	,	O
a	,	O
chimeric	,	O
molecule	,	O
comprises	,	O
a	NNP	O
fusion	CC	O
of	NNP	O
the	RB	O
PRO227,	VBD	O
PRO233,	TO	O
PRO238,	,	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	CC	O
PRO10096,	NN	O
PRO21384,	JJ	O
PRO353	.	O
or	JJ	O
PRO1885	DT	O
polypeptide	JJ	O
with	NN	O
a	VBZ	O
tag	DT	O
polypeptide	NN	O
which	IN	O
provides	DT	O
an	,	O
epitope	,	O
to	,	O
which	,	O
an	,	O
anti-tag	,	O
antibody	,	O
can	,	O
selectively	NNP	O
bind.	CC	O
The	NNP	O
epitope	IN	O
tag	IN	O
is	DT	O
generally	NN	O
placed	NN	O
at	WDT	O
the	VBZ	O
amino-	DT	O
or	NN	O
carboxyl-terminus	TO	O
of	WDT	O
the	DT	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	MD	O
PRO1328,	RB	O
PRO4342,	.	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	NN	O
PRO353	VBZ	O
or	RB	O
PRO1885	VBN	O
polypeptide.	IN	O
The	DT	O
presence	JJ	O
of	CC	O
such	NN	O
epitope-tagged	IN	O
forms	DT	O
of	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	.	O
PRO1885	DT	O
polypeptide	NN	O
can	IN	O
be	JJ	O
detected	JJ	O
using	NNS	O
an	IN	O
antibody	DT	O
against	,	O
the	,	O
tag	,	O
polypeptide.	,	O
Also,	,	O
provision	,	O
of	,	O
the	,	O
epitope	NNP	O
tag	CC	O
enables	NNP	O
the	NN	O
PRO227,	MD	O
PRO233,	VB	O
PRO238,	VBN	O
PRO1328,	VBG	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	JJ	O
or	.	O
PRO1885	,	O
polypeptide	NN	O
to	IN	O
be	DT	O
readily	NN	O
purified	NN	O
by	VBZ	O
affinity	DT	O
purification	,	O
using	,	O
an	,	O
anti-tag	,	O
antibody	,	O
or	,	O
another	,	O
type	,	O
of	NNP	O
affinity	CC	O
matrix	NNP	O
that	NN	O
binds	TO	O
to	VB	O
the	RB	O
epitope	VBN	O
tag.	IN	O
Various	NN	O
tag	NN	O
polypeptides	VBG	O
and	DT	O
their	JJ	O
respective	NN	O
antibodies	CC	O
are	DT	O
well	NN	O
known	IN	O
in	NN	O
the	NN	O
art.	WDT	O
Examples	VBZ	O
include	TO	O
poly-histidine	DT	O
(poly-his)	NN	O
or	.	O
poly-histidine-glycine	JJ	O
(poly-his-gly)	NN	O
tags;	NNS	O
the	CC	O
flu	PRP$	O
HA	JJ	O
tag	NNS	O
polypeptide	VBP	O
and	RB	O
its	VBN	O
antibody	IN	O
12CA5	DT	O
Field	.	B
et	NNS	I
al.,	VBP	I
Mol.	JJ	I
Cell.	)	I
Biol.,	CC	I
8:2159-2165	JJ	I
(1988)];[	)	O
the	:	O
c-myc	DT	O
tag	NN	O
and	NNP	O
the	NN	O
8F9,	NN	O
3C7,	CC	O
6E10,	PRP$	O
G4,	NN	O
B7	CD	O
and	NNP	O
9E10	NN	O
antibodies	,	O
thereto	.	O
Evan	.	B
et	,	I
al.,	CD	I
Molecular	:	I
and	DT	I
Cellular	JJ	I
Biology,	NN	I
5:3610-3616	CC	I
(1985)];[	DT	O
and	,	O
the	,	O
Herpes	,	O
Simplex	,	O
virus	NNP	O
glycoprotein	CC	O
D	CD	O
(gD)	NNS	O
tag	VBP	O
and	NNP	O
its	NN	O
antibody	,	O
Paborsky	NNP	B
et	CC	I
al.,	NNP	I
Protein	,	I
Engineering,	NNP	I
3(6):547-553	:	I
(1990)].[	CC	O
Other	DT	O
tag	NNP	O
polypeptides	NNP	O
include	NN	O
the	NN	O
Flag-peptide	NNP	O
Hopp	)	B
et	NN	I
al.,	CC	I
BioTechnology,	PRP$	I
6:1204-1210	NN	I
(1988)];[	NNP	O
the	FW	O
KT3	,	O
epitope	NNP	O
peptide	,	O
Martin	NN	B
et	.	I
al.,	JJ	I
Science,	NN	I
255:192-194	NNS	I
(1992)];[	VBP	O
an	DT	O
α-tubulin	NNP	O
epitope	NNP	O
peptide	FW	O
Skinner	,	B
et	,	I
al.,	NNP	I
J.	:	I
Biol.	DT	I
Chem.,	NNP	I
266:15163-15166	NN	I
(1991)];[	NN	O
and	NNP	O
the	FW	O
T7	,	O
gene	,	O
10	CD	O
protein	:	O
peptide	DT	O
tag	JJ	O
Lutz-Freyermuth	NN	B
et	IN	I
al.,	NNP	I
Proc.	FW	I
Natl.	,	I
Acad.	NNP	I
Sci.	.	I
USA,	,	I
87:6393-6397	CD	I
(1990)].[	:	O
The	CC	O
chimeric	DT	O
molecule	NNP	O
may	NN	O
comprise	CD	O
a	NN	O
fusion	NN	O
of	NN	O
the	NNP	O
PRO227,	NN	O
PRO233,	,	O
PRO238,	.	O
PRO1328,	.	O
PRO4342,	.	O
PRO7423,	.	O
PRO10096,	,	O
PRO21384,	CD	O
PRO353	.	O
or	DT	O
PRO1885	JJ	O
polypeptide	NN	O
with	MD	O
an	VB	O
immunoglobulin	DT	O
or	NN	O
a	IN	O
particular	DT	O
region	,	O
of	,	O
an	,	O
immunoglobulin.	,	O
For	,	O
a	,	O
bivalent	,	O
form	,	O
of	NNP	O
the	CC	O
chimeric	NNP	O
molecule	IN	O
(also	IN	O
referred	DT	O
to	NN	O
as	CC	O
an	DT	O
“immunoadhesin”),	JJ	O
such	NN	O
a	IN	O
fusion	DT	O
could	.	O
be	IN	O
to	DT	O
the	JJ	O
Fc	NN	O
region	IN	O
of	DT	O
an	JJ	O
IgG	NN	O
molecule.	RB	O
The	VBN	O
Ig	TO	O
fusions	IN	O
preferably	DT	O
include	,	O
the	PDT	O
substitution	DT	O
of	NN	O
a	MD	O
soluble	VB	O
(transmembrane	TO	O
domain	DT	O
deleted	NNP	O
or	NN	O
inactivated)	IN	O
form	DT	O
of	NNP	O
a	.	O
PRO227,	DT	O
PRO233,	NNP	O
PRO238,	NNS	O
PRO1328,	RB	O
PRO4342,	VBP	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	DT	O
or	JJ	O
PRO1885	JJ	O
polypeptide	NN	O
in	VBD	O
place	CC	O
of	)	O
at	NN	O
least	IN	O
one	DT	O
variable	,	O
region	,	O
within	,	O
an	,	O
Ig	,	O
molecule.	,	O
In	,	O
a	,	O
particularly	NNP	O
preferred	CC	O
aspect	NNP	O
of	VBP	O
the	IN	O
invention,	NN	O
the	IN	O
immunoglobulin	IN	O
fusion	JJS	O
includes	CD	O
the	JJ	O
hinge,	NN	O
CH2	IN	O
and	DT	O
CH3,	NNP	O
or	.	O
the	IN	O
hinge,	DT	O
CH1,	RB	O
CH2	JJ	O
and	NN	O
CH3	IN	O
regions	DT	O
of	,	O
an	DT	O
IgG1	JJ	O
molecule.	NN	O
For	VBZ	O
the	DT	O
production	,	O
of	NNP	O
immunoglobulin	CC	O
fusions	,	O
see	CC	O
also	DT	O
U.S.	,	O
Pat.	,	O
No.	NNP	O
5,428,130	CC	O
issued	NNP	O
Jun.	NNS	O
27,	IN	O
1995.	DT	O
D.	NNP	O
Preparation	.	O
of	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	JJ	O
PRO4342,	NNS	O
PRO7423,	VBP	O
PRO10096,	RB	O
PRO21384,	NNP	O
PRO353	.	O
or	.	O
PRO1885	CD	O
Polypeptides	VBN	O
The	.	O
description	,	O
below	.	O
relates	NNP	O
primarily	NNP	O
to	IN	O
production	,	O
of	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	NNP	O
PRO1885	DT	O
polypeptides	NN	O
by	IN	O
culturing	NNS	O
cells	RB	O
transformed	TO	O
or	NN	O
transfected	IN	O
with	,	O
a	,	O
vector	,	O
containing	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NNS	O
PRO353	IN	O
or	VBG	O
PRO1885	NNS	O
nucleic	VBD	O
acid.	CC	O
It	VBN	O
is,	IN	O
of	DT	O
course,	NN	O
contemplated	VBG	O
that	,	O
alternative	,	O
methods,	,	O
which	,	O
are	,	O
well	,	O
known	,	O
in	,	O
the	NNP	O
art,	CC	O
may	NNP	O
be	JJ	O
employed	.	O
to	PRP	O
prepare	,	O
PRO227,	IN	O
PRO233,	,	O
PRO238,	VBD	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	,	O
PRO10096,	WDT	O
PRO21384,	VBP	O
PRO353	RB	O
or	VBN	O
PRO1885	IN	O
polypeptides.	DT	O
For	,	O
instance,	MD	O
the	VB	O
PRO227,	VBN	O
PRO233,	TO	O
PRO238,	VB	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
sequence,	NNP	O
or	CC	O
portions	NNP	O
thereof,	.	O
may	IN	O
be	,	O
produced	DT	O
by	,	O
direct	,	O
peptide	,	O
synthesis	,	O
using	,	O
solid-phase	,	O
techniques	,	O
[see,	,	O
e.g.,	NNP	O
Stewart	CC	B
et	NNP	I
al.,	,	I
Solid-Phase	CC	I
Peptide	NNS	I
Synthesis,	,	I
W.H.	MD	I
Freeman	VB	I
Co.,	VBN	I
San	IN	I
Francisco,	JJ	I
Calif.	NN	I
(1969);	NN	I
Merrifield,	VBG	B
J.	JJ	I
Am.	NNS	I
Chem.	,	I
Soc.,	,	I
85:2149-2154	NNP	I
(1963)].In	VBZ	O
vitro	,	O
protein	NNP	O
synthesis	NNP	O
may	,	O
be	.	O
performed	NNP	O
using	,	O
manual	NNP	O
techniques	,	O
or	NNP	O
by	:	O
automation.	,	O
Automated	.	O
synthesis	.	O
may	.	O
be	,	O
accomplished,	CD	O
for	.	O
instance,	IN	O
using	JJ	O
an	JJ	O
Applied	NN	O
Biosystems	MD	O
Peptide	VB	O
Synthesizer	VBN	O
(Foster	VBG	O
City,	JJ	O
Calif.)	NNS	O
using	CC	O
manufacturer's	IN	O
instructions.	.	O
Various	VBN	O
portions	NN	O
of	MD	O
the	VB	O
PRO227,	,	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	VBG	O
PRO4342,	DT	O
PRO7423,	NNP	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	NNP	O
or	NNP	O
PRO1885	,	O
polypeptide	)	O
may	VBG	O
be	POS	O
chemically	.	O
synthesized	JJ	O
separately	NNS	O
and	IN	O
combined	DT	O
using	,	O
chemical	,	O
or	,	O
enzymatic	,	O
methods	,	O
to	,	O
produce	,	O
the	,	O
full-length	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NN	O
PRO1328,	MD	O
PRO4342,	VB	O
PRO7423,	RB	O
PRO10096,	VBN	O
PRO21384,	RB	O
PRO353	CC	O
or	VBN	O
PRO1885	VBG	O
polypeptide.	NN	O
1.	CC	O
Isolation	JJ	O
of	NNS	O
DNA	TO	O
Encoding	VB	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	NNP	O
Polypeptides	CC	O
DNA	NNP	O
encoding	.	O
PRO227,	.	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	NNP	O
PRO4342,	NNP	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
may	,	O
be	NNP	O
obtained	CC	O
from	NNP	O
a	NNP	O
cDNA	NNP	O
library	VBG	O
prepared	,	O
from	,	O
tissue	,	O
believed	,	O
to	,	O
possess	,	O
the	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	NNS	O
PRO7423,	MD	O
PRO10096,	VB	O
PRO21384,	VBN	O
PRO353	IN	O
or	DT	O
PRO1885	NN	O
mRNA	NN	O
and	VBD	O
to	IN	O
express	NN	O
it	VBN	O
at	TO	O
a	VB	O
detectable	DT	O
level.	,	O
Accordingly,	,	O
human	,	O
PRO227-,	,	O
PRO233-,	,	O
PRO238-,	,	O
PRO1328-,	,	O
PRO4342-,	,	O
PRO7423-,	NNP	O
PRO10096-,	CC	O
PRO21384-,	NNP	O
PRO353-	NN	O
or	CC	O
PRO1885-DNA	TO	O
can	VB	O
be	PRP	O
conveniently	IN	O
obtained	DT	O
from	JJ	O
a	.	O
cDNA	,	O
library	JJ	O
prepared	,	O
from	,	O
human	,	O
tissue,	,	O
such	,	O
as	,	O
described	,	O
in	,	O
the	NNP	O
Examples.	CC	O
The	NNP	O
PRO227-,	MD	O
PRO233-,	VB	O
PRO238-,	RB	O
PRO1328-,	VBN	O
PRO4342-,	IN	O
PRO7423-,	DT	O
PRO10096-,	NN	O
PRO21384-,	NN	O
PRO353-	VBD	O
or	IN	O
PRO1885-encoding	JJ	O
gene	,	O
may	JJ	O
also	IN	O
be	VBN	O
obtained	IN	O
from	DT	O
a	.	O
genomic	DT	O
library	,	O
or	,	O
by	,	O
known	,	O
synthetic	,	O
procedures	,	O
(e.g.,	,	O
automated	,	O
nucleic	NNP	O
acid	CC	O
synthesis).	NNP	O
Libraries	NN	O
can	MD	O
be	RB	O
screened	VB	O
with	VBN	O
probes	IN	O
(such	DT	O
as	JJ	O
antibodies	NN	O
to	CC	O
the	IN	O
PRO227,	VBN	O
PRO233,	JJ	O
PRO238,	NNS	O
PRO1328,	,	O
PRO4342,	VBD	O
PRO7423,	JJ	O
PRO10096,	JJ	O
PRO21384,	.	O
PRO353	NNS	O
or	MD	O
PRO1885	VB	O
polypeptide	VBN	O
or	IN	O
oligonucleotides	NNS	O
of	JJ	O
at	IN	O
least	NNS	O
about	TO	O
20-80	DT	O
bases)	,	O
designed	,	O
to	,	O
identify	,	O
the	,	O
gene	,	O
of	,	O
interest	,	O
or	NNP	O
the	CC	O
protein	NNP	O
encoded	NN	O
by	CC	O
it.	NNS	O
Screening	IN	O
the	IN	O
cDNA	JJS	O
or	IN	O
genomic	JJ	O
library	)	O
with	VBN	O
the	TO	O
selected	VB	O
probe	DT	O
may	NN	O
be	IN	O
conducted	NN	O
using	CC	O
standard	DT	O
procedures,	NN	O
such	VBN	O
as	IN	O
described	.	O
in	VBG	O
Sambrook	DT	B
et	NN	I
al.,	CC	I
Molecular	JJ	I
Cloning:	NN	I
A	IN	I
Laboratory	DT	I
Manual	VBN	I
(New	NN	I
York:	MD	I
Cold	VB	I
Spring	VBN	I
Harbor	VBG	I
Laboratory	JJ	I
Press,	,	I
1989).An	JJ	O
alternative	IN	O
means	NNS	O
to	IN	O
isolate	NNP	O
the	CC	O
gene	,	O
encoding	JJ	O
PRO227,	:	O
PRO233,	DT	O
PRO238,	NNP	O
PRO1328,	NNP	O
PRO4342,	NNP	O
PRO7423,	:	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	NNP	O
or	NNP	O
PRO1885	,	O
is	.	O
to	DT	O
use	JJ	O
PCR	NNS	O
methodology	TO	O
Sambrook	VB	B
et	DT	I
al.,	NN	I
supra;	VBG	I
Dieffenbach	,	B
et	,	I
al.,	,	I
PCR	,	I
Primer:	,	I
A	,	I
Laboratory	,	I
Manual	,	I
(Cold	NNP	I
Spring	CC	I
Harbor	NNP	I
Laboratory	VBZ	I
Press,	TO	I
1995)].
[	VB	O
The	NNP	O
Examples	NN	O
below	NNP	O
describe	FW	O
techniques	,	O
for	:	O
screening	NNP	O
a	FW	O
cDNA	,	O
library.	NNP	O
The	:	O
oligonucleotide	DT	O
sequences	NNP	O
selected	NNP	O
as	NNP	O
probes	NNP	O
should	NNP	O
be	NNP	O
of	,	O
sufficient	.	O
length	DT	O
and	NNP	O
sufficiently	IN	O
unambiguous	NN	O
that	NNS	O
false	IN	O
positives	VBG	O
are	DT	O
minimized.	NN	O
The	.	O
oligonucleotide	DT	O
is	JJ	O
preferably	NNS	O
labeled	VBN	O
such	IN	O
that	NNS	O
it	MD	O
can	VB	O
be	IN	O
detected	JJ	O
upon	NN	O
hybridization	CC	O
to	RB	O
DNA	JJ	O
in	IN	O
the	JJ	O
library	NNS	O
being	VBP	O
screened.	.	O
Methods	DT	O
of	NN	O
labeling	VBZ	O
are	RB	O
well	VBN	O
known	JJ	O
in	IN	O
the	PRP	O
art,	MD	O
and	VB	O
include	VBN	O
the	IN	O
use	NN	O
of	TO	O
radiolabels	NNP	O
like	IN	O
32P-labeled	DT	O
ATP,	JJ	O
biotinylation	VBG	O
or	.	O
enzyme	NNS	O
labeling.	IN	O
Hybridization	VBG	O
conditions,	VBP	O
including	RB	O
moderate	VBN	O
stringency	IN	O
and	DT	O
high	,	O
stringency,	CC	O
are	VBP	O
provided	DT	O
in	NN	O
Sambrook	IN	B
et	NNS	I
al.,	IN	I
supra.
Sequences	JJ	O
identified	,	O
in	NN	O
such	CC	O
library	NN	O
screening	.	O
methods	NN	O
can	,	O
be	VBG	O
compared	JJ	O
and	NN	O
aligned	CC	O
to	JJ	O
other	,	O
known	VBP	O
sequences	VBN	O
deposited	IN	O
and	NNP	O
available	CC	O
in	,	O
public	.	O
databases	NNS	O
such	VBN	O
as	IN	O
GenBank	JJ	O
or	JJ	O
other	VBG	O
private	NNS	O
sequence	MD	O
databases.	VB	O
Sequence	VBN	O
identity	CC	O
(at	VBN	O
either	TO	O
the	JJ	O
amino	JJ	O
acid	NNS	O
or	VBD	O
nucleotide	CC	O
level)	JJ	O
within	IN	O
defined	JJ	O
regions	NNS	O
of	JJ	O
the	IN	O
molecule	NNP	O
or	CC	O
across	JJ	O
the	JJ	O
full-length	NN	O
sequence	.	O
can	NN	O
be	NN	O
determined	IN	O
using	CC	O
methods	DT	O
known	NN	O
in	NN	O
the	CC	O
art	JJ	O
and	)	O
as	IN	O
described	VBN	O
herein.	NNS	O
Nucleic	IN	O
acid	DT	O
having	NN	O
protein	CC	O
coding	IN	O
sequence	DT	O
may	JJ	O
be	NN	O
obtained	MD	O
by	VB	O
screening	VBN	O
selected	VBG	O
cDNA	NNS	O
or	VBN	O
genomic	IN	O
libraries	DT	O
using	NN	O
the	CC	O
deduced	IN	O
amino	JJ	O
acid	.	O
sequence	NNP	O
disclosed	NN	O
herein	VBG	O
for	NN	O
the	VBG	O
first	NN	O
time,	MD	O
and,	VB	O
if	VBN	O
necessary,	IN	O
using	VBG	O
conventional	VBN	O
primer	NN	O
extension	CC	O
procedures	JJ	O
as	NNS	O
described	VBG	O
in	DT	O
Sambrook	JJ	O
et	NN	O
al.,	NN	O
supra,	NN	O
to	VBD	O
detect	NN	O
precursors	IN	O
and	DT	O
processing	JJ	O
intermediates	,	O
of	,	O
mRNA	IN	O
that	,	O
may	VBG	O
not	JJ	O
have	JJ	O
been	NN	O
reverse-transcribed	NNS	O
into	IN	O
cDNA.	VBN	O
2.	IN	O
Selection	NNP	O
and	CC	O
Transformation	,	O
of	,	O
Host	TO	O
Cells	VB	O
Host	NNS	O
cells	CC	O
are	VBG	O
transfected	NNS	O
or	IN	O
transformed	NN	O
with	WDT	O
expression	MD	O
or	RB	O
cloning	VB	O
vectors	VBN	O
described	JJ	O
herein	IN	O
for	.	O
PRO227,	.	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	IN	O
PRO7423,	NNP	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	NNS	O
or	VBP	O
PRO1885	VBN	O
polypeptide	CC	O
production	VBN	O
and	IN	O
cultured	NN	O
in	CC	O
conventional	VBG	O
nutrient	NNS	O
media	VBD	O
modified	NN	O
as	IN	O
appropriate	,	O
for	,	O
inducing	,	O
promoters,	,	O
selecting	,	O
transformants,	,	O
or	,	O
amplifying	,	O
the	NNP	O
genes	CC	O
encoding	NNP	O
the	IN	O
desired	NN	O
sequences.	CC	O
The	VBN	O
culture	IN	O
conditions,	JJ	O
such	JJ	O
as	NNS	O
media,	VBD	O
temperature,	IN	O
pH	NN	O
and	IN	O
the	VBG	O
like,	,	O
can	VBG	O
be	,	O
selected	CC	O
by	VBG	O
the	DT	O
skilled	NNS	O
artisan	VBG	O
without	DT	O
undue	JJ	O
experimentation.	.	O
In	DT	O
general,	NN	O
principles,	,	O
protocols,	JJ	O
and	IN	O
practical	,	O
techniques	,	O
for	NN	O
maximizing	CC	O
the	DT	O
productivity	,	O
of	MD	O
cell	VB	O
cultures	VBN	O
can	IN	O
be	DT	O
found	JJ	O
in	NN	O
Mammalian	IN	O
Cell	JJ	O
Biotechnology:	.	O
a	IN	B
Practical	,	I
Approach,	,	I
M.	,	I
Butler,	CC	I
ed.	JJ	I
(IRL	NNS	I
Press,	IN	I
1991)	VBG	I
and	DT	O
Sambrook	NN	B
et	IN	I
al.,	NN	I
supra.
Methods	NNS	O
of	MD	O
eukaryotic	VB	O
cell	VBN	O
transfection	IN	O
and	NNP	O
prokaryotic	NNP	O
cell	:	O
transformation	DT	O
are	NNP	O
known	,	O
to	NNP	O
the	,	O
ordinarily	.	O
skilled	NNP	O
artisan,	,	O
for	)	O
example,	CC	O
CaCl2,	NNP	O
CaPO4,	VBP	O
liposome-mediated	,	O
and	.	O
electroporation.	NNS	O
Depending	IN	O
on	JJ	O
the	NN	O
host	NN	O
cell	CC	O
used,	JJ	O
transformation	NN	O
is	NN	O
performed	VBP	O
using	VBN	O
standard	TO	O
techniques	DT	O
appropriate	RB	O
to	VBN	O
such	,	O
cells.	IN	O
The	,	O
calcium	,	O
treatment	,	O
employing	JJ	O
calcium	CC	O
chloride,	.	O
as	VBG	O
described	IN	O
in	DT	O
Sambrook	NN	O
et	NN	O
al.,	,	O
supra,	NN	O
or	VBZ	O
electroporation	VBN	O
is	VBG	O
generally	JJ	O
used	NNS	O
for	VBP	O
prokaryotes.	TO	O
Infection	JJ	O
with	.	O
Agrobacterium	DT	O
tumefaciens	NN	O
is	NN	O
used	VBG	O
for	NN	O
transformation	,	O
of	IN	O
certain	VBN	O
plant	IN	O
cells,	NNP	O
as	CC	O
described	,	O
by	,	O
Shaw	CC	B
et	NN	I
al.,	VBZ	I
Gene,	RB	I
23:315	VBN	I
(1983)	IN	I
and	.	O
WO	NN	O
89/05859	IN	O
published	NNP	O
29	NNS	O
Jun.	VBZ	O
1989.	VBN	O
For	IN	O
mammalian	NN	O
cells	IN	O
without	JJ	O
such	NN	O
cell	,	O
walls,	IN	O
the	VBN	O
calcium	IN	O
phosphate	NNP	O
precipitation	FW	O
method	,	O
of	,	O
Graham	CD	B
and	)	I
van	CC	I
der	$	I
Eb,	CD	I
Virology,	VBN	I
52:456-457	CD	I
(1978)	.	I
can	.	O
be	IN	O
employed.	JJ	O
General	NNS	O
aspects	IN	O
of	JJ	O
mammalian	NN	O
cell	,	O
host	DT	O
system	NN	O
transfections	NN	O
have	NN	O
been	NN	O
described	IN	O
in	NNP	O
U.S.	CC	O
Pat.	JJ	O
No.	NN	O
4,399,216.	,	O
Transformations	,	O
into	NNP	O
yeast	)	O
are	MD	O
typically	VB	O
carried	.	O
out	NNP	O
according	NNS	O
to	IN	O
the	JJ	O
method	NN	O
of	NN	O
Van	NN	B
Solingen	NNS	I
et	VBP	I
al.,	VBN	I
J.	VBN	I
Bact.,	IN	I
130:946	NNP	I
(1977)	.	I
and	.	O
Hsiao	.	B
et	NNS	I
al.,	IN	I
Proc.	NN	I
Natl.	VBP	I
Acad.	RB	I
Sci.	VBN	I
(USA),	RP	I
76:3829	VBG	I
(1979).	TO	I
However,	DT	O
other	NN	O
methods	IN	O
for	NNP	O
introducing	NNP	O
DNA	FW	O
into	,	O
cells,	.	O
such	,	O
as	CD	O
by	)	O
nuclear	CC	O
microinjection,	NNP	O
electroporation,	VBP	O
bacterial	,	O
protoplast	.	O
fusion	.	O
with	.	O
intact	.	O
cells,	,	O
or	CD	O
polycations,	.	O
e.g.,	,	O
polybrene,	JJ	O
polyornithine,	NNS	O
may	IN	O
also	VBG	O
be	NNP	O
used.	IN	O
For	,	O
various	JJ	O
techniques	IN	O
for	IN	O
transforming	JJ	O
mammalian	,	O
cells,	,	O
see	JJ	O
Keown	NN	B
et	NN	I
al.,	IN	I
Methods	JJ	I
in	,	I
Enzymology,	CC	I
185:527-537	,	I
(1990)	,	I
and	,	O
Mansour	,	B
et	MD	I
al.,	RB	I
Nature,	VB	I
336:348-352	.	I
(1988).
Suitable	IN	O
host	JJ	O
cells	NNS	O
for	IN	O
cloning	VBG	O
or	JJ	O
expressing	,	O
the	VBP	O
DNA	NNP	O
in	FW	O
the	,	O
vectors	NNP	O
herein	IN	O
include	,	O
prokaryote,	CD	O
yeast,	)	O
or	CC	O
higher	NNP	O
eukaryote	CC	O
cells.	,	O
Suitable	,	O
prokaryotes	CD	O
include	.	O
but	JJ	O
are	NN	O
not	NNS	O
limited	IN	O
to	VBG	O
eubacteria,	CC	O
such	VBG	O
as	DT	O
Gram-negative	NN	O
or	IN	O
Gram-positive	DT	O
organisms,	NNS	O
for	VBP	O
example,	VBP	O
Enterobacteriaceae	,	O
such	,	O
as	CC	O
E.	JJR	O
coli.	NN	O
Various	.	O
E.	JJ	O
coli	NNS	O
strains	VBP	O
are	CC	O
publicly	VBP	O
available,	RB	O
such	VBN	O
as	TO	O
E.	,	O
coli	JJ	O
K12	IN	O
strain	JJ	O
MM294	CC	O
(ATCC	JJ	O
31,446);	,	O
E.	IN	O
coli	,	O
X1776	NNP	O
(ATCC	JJ	O
31,537);	IN	O
E.	NNP	O
coli	.	O
strain	NNP	O
W3110	NNP	O
(ATCC	NNS	O
27,325)	NNS	O
and	VBP	O
K5	RB	O
772	,	O
(ATCC	JJ	O
53,635).	IN	O
Other	NNP	O
suitable	VBP	O
prokaryotic	NNP	O
host	NN	O
cells	NNP	O
include	NNP	O
Enterobacteriaceae	:	O
such	NNP	O
as	NNS	O
Escherichia,	NNP	O
e.g.,	NNP	O
E.	:	O
coli,	NNP	O
Enterobacter,	NNS	O
Erwinia,	VBP	O
Klebsiella,	NNP	O
Proteus,	NNP	O
Salmonella,	)	O
e.g.,	CC	O
Salmonella	$	O
typhimurium,	CD	O
Serratia,	NNP	O
e.g.,	.	O
Serratia	JJ	O
marcescans,	JJ	O
and	JJ	O
Shigella,	NN	O
as	NNS	O
well	VBP	O
as	NNP	O
Bacilli	JJ	O
such	IN	O
as	,	O
B.	,	O
subtilis	NNP	O
and	,	O
B.	,	O
licheniformis	,	O
(e.g.,	,	O
B.	,	O
licheniformis	,	O
41P	,	O
disclosed	NNP	O
in	,	O
DD	,	O
266,710	,	O
published	NNP	O
12	,	O
Apr.	CC	O
1989),	,	O
Pseudomonas	RB	O
such	RB	O
as	IN	O
P.	NNP	O
aeruginosa,	JJ	O
and	IN	O
Streptomyces.	NNP	O
These	NNS	O
examples	CC	O
are	NNP	O
illustrative	NNP	O
rather	,	O
than	NNP	O
limiting.	VBZ	O
Strain	CD	O
W3110	VBN	O
is	IN	O
one	NNP	O
particularly	CD	O
preferred	VBD	O
host	CD	O
or	.	O
parent	,	O
host	NNP	O
because	JJ	O
it	IN	O
is	NNP	O
a	,	O
common	CC	O
host	.	O
strain	DT	O
for	NNS	O
recombinant	VBP	O
DNA	JJ	O
product	RB	O
fermentations.	IN	O
Preferably,	.	O
the	NNP	O
host	NNP	O
cell	VBZ	O
secretes	CD	O
minimal	RB	O
amounts	JJ	O
of	NN	O
proteolytic	CC	O
enzymes.	NN	O
For	NN	O
example,	IN	O
strain	PRP	O
W3110	VBZ	O
may	DT	O
be	JJ	O
modified	NN	O
to	NN	O
effect	IN	O
a	JJ	O
genetic	NNP	O
mutation	NN	O
in	.	O
the	,	O
genes	DT	O
encoding	NN	O
proteins	NN	O
endogenous	VBZ	O
to	JJ	O
the	NNS	O
host,	IN	O
with	JJ	O
examples	.	O
of	IN	O
such	,	O
hosts	VBP	O
including	NNP	O
E.	MD	O
coli	VB	O
W3110	VBN	O
strain	TO	O
1A2,	NN	O
which	DT	O
has	JJ	O
the	NN	O
complete	IN	O
genotype	DT	O
tonA;	NNS	O
E.	VBG	O
coli	NNS	O
W3110	JJ	O
strain	TO	O
9E4,	DT	O
which	,	O
has	IN	O
the	NNS	O
complete	IN	O
genotype	JJ	O
tonA	NNS	O
ptr3;	VBG	O
E.	NNP	O
coli	NNS	O
W3110	NNP	O
strain	NN	O
27C7	,	O
(ATCC	WDT	O
55,244),	VBZ	O
which	DT	O
has	JJ	O
the	NN	O
complete	:	O
genotype	NNP	O
tonA	NNS	O
ptr3	NNP	O
phoA	NN	O
E15	,	O
(argF-lac)	WDT	O
169	VBZ	O
degP	DT	O
ompT	JJ	O
kanr	NN	O
;	NN	O
E.	:	O
coli	NNP	O
W3110	NNS	O
strain	NNP	O
37D6,	VBP	O
which	CD	O
has	NNP	O
the	,	O
complete	WDT	O
genotype	VBZ	O
tonA	DT	O
ptr3	JJ	O
phoA	NN	O
E15	NN	O
(argF-lac)	NN	O
169	NN	O
degP	NNP	O
ompT	)	O
rbs7	CD	O
ilvG	JJ	O
kanr	JJ	O
;	NN	O
E.	:	O
coli	NNP	O
W3110	NNS	O
strain	NNP	O
40B4,	NN	O
which	,	O
is	WDT	O
strain	VBZ	O
37D6	DT	O
with	JJ	O
a	NN	O
non-kanamycin	NN	O
resistant	NN	O
degP	NN	O
deletion	NNP	O
mutation;	)	O
and	CD	O
an	JJ	O
E.	NN	O
coli	NN	O
strain	NN	O
having	NN	O
mutant	:	O
periplasmic	NNP	O
protease	NNS	O
disclosed	NNP	O
in	NN	O
U.S.	,	O
Pat.	WDT	O
No.	VBZ	O
4,946,783	JJ	O
issued	CD	O
7	IN	O
Aug.	DT	O
1990.	JJ	O
Alternatively,	NN	O
in	NN	O
vitro	NN	O
methods	:	O
of	CC	O
cloning,	DT	O
e.g.,	NNP	O
PCR	NNS	O
or	VBP	O
other	VBG	O
nucleic	JJ	O
acid	JJ	O
polymerase	NN	O
reactions,	VBN	O
are	IN	O
suitable.	NNP	O
In	.	O
addition	.	O
to	CD	O
prokaryotes,	VBD	O
eukaryotic	CD	O
microbes	NNP	O
such	.	O
as	,	O
filamentous	IN	O
fungi	JJ	O
or	NNS	O
yeast	IN	O
are	,	O
suitable	,	O
cloning	NNP	O
or	CC	O
expression	JJ	O
hosts	JJ	O
for	JJ	O
PRO227-,	NN	O
PRO233-,	,	O
PRO238-,	VBP	O
PRO1328-,	.	O
PRO4342-,	IN	O
PRO7423-,	NN	O
PRO10096-,	TO	O
PRO21384-,	,	O
PRO353-	JJ	O
or	NNS	O
PRO1885-encoding	JJ	O
vectors.	IN	O
Saccharomyces	JJ	O
cerevisiae	NNS	O
is	CC	O
a	NN	O
commonly	VBP	O
used	JJ	O
lower	NN	O
eukaryotic	CC	O
host	NN	O
microorganism.	NNS	O
Others	IN	O
include	,	O
Schizosaccharomyces	,	O
pombe	,	O
Beach	,	B
and	,	I
Nurse,	,	I
Nature,	,	I
290:	,	I
140	NNP	I
[1981];	CC	I
EP	JJ	I
139,383	.	I
published	NNS	I
2	NN	I
May	VBZ	I
1985);(	DT	O
Kluyveromyces	RB	O
hosts	VBN	O
(U.S.	JJR	O
Pat.	JJ	O
No.	NN	O
4,943,529;	.	O
Fleer	NNS	B
et	VBP	I
al.,	NNS	I
Bio/Technology,	VBP	I
9:968-975	NNP	I
(1991))	CC	I
such	,	O
as,	,	O
e.g.,	:	O
K.	CD	O
lactis	:	O
(MW98-8C,	NNP	O
CBS683,	CD	O
CBS4574;	VBD	O
Louvencourt	CD	B
et	NNP	I
al.,	:	I
J.	NNS	I
Bacteriol.,	NNS	I
154(2):737-742	NNP	I
[1983]),K.	.	O
fragilis	.	O
(ATCC	:	O
12,424),	NNP	O
K.	FW	O
bulgaricus	,	O
(ATCC	,	O
16,045),	CD	O
K.	)	O
wickeramii	JJ	O
(ATCC	,	O
24,178),	,	O
K.	NNP	O
waltii	NN	O
(ATCC	,	O
56,500),	,	O
K.	:	O
drosophilarum	NNP	O
(ATCC	FW	O
36,906;	,	O
Van	.	B
den	,	I
Berg	CD	I
et	,	I
al.,	NNP	I
Bio/Technology,	NN	I
8:135	NNP	I
(1990)),K.	,	O
thermotolerans,	NNP	O
and	NN	O
K.	NNP	O
marxianus;	,	O
yarrowia	NNP	O
(EP	NN	O
402,226);	NNP	O
Pichia	,	O
pastoris	NNP	O
(EP	NN	O
183,070;	NNP	O
Sreekrishna	,	B
et	NNP	I
al.,	NN	I
J.	NNP	I
Basic	:	I
Microbiol.,	NNP	I
28:265-278	VBZ	I
[1988]);Candida;	NNP	O
Trichoderma	NN	O
reesia	,	O
(EP	,	O
244,234);	CD	O
Neurospora	,	O
crassa	NNP	O
Case	,	B
et	CC	I
al.,	NNP	I
Proc.	:	I
Natl.	CC	I
Acad.	NNP	I
Sci.	:	I
USA,	NNP	I
76:5259-5263	NN	I
[1979]);(	NNP	O
Schwanniomyces	:	O
such	NNP	O
as	FW	O
Schwanniomyces	,	O
occidentalis	.	O
(EP	NNP	O
394,538	,	O
published	JJ	O
31	:	O
Oct.	:	O
1990);	NNP	O
and	NN	O
filamentous	NNP	O
fungi	:	O
such	NNP	O
as,	NN	O
e.g.,	NNP	O
Neurospora,	VBZ	O
Penicillium,	,	O
Tolypocladium	.	O
(WO	.	O
91/00357	.	O
published	.	O
10	,	O
Jan.	JJ	O
1991),	:	O
and	NNS	O
Aspergillus	JJ	O
hosts	IN	O
such	NNS	O
as	VBP	O
A.	NNP	O
nidulans	CD	O
Ballance	VBD	B
et	CD	I
al.,	NNP	I
Biochem.	:	I
Biophys.	CC	I
Res.	JJ	I
Commun.,	NNS	I
112:284-289	JJ	I
[1983];	,	I
Tilburn	,	B
et	,	I
al.,	,	I
Gene,	NNP	I
26:205-221	NNP	I
[1983];	CD	I
Yelton	VBD	B
et	CD	I
al.,	NNP	I
Proc.	,	I
Natl.	CC	I
Acad.	NNP	I
Sci.	NNS	I
USA,	JJ	I
81:	IN	I
1470-1474	NN	I
[1984])	NNS	I
(and	NNP	O
A.	RB	B
niger	,	I
(Kelly	.	I
and	.	I
Hynes,	.	I
EMBO	,	I
J.,	JJ	I
4:475-479	:	I
[1985]).Methylotropic	NNP	O
yeasts	FW	O
are	,	O
suitable	,	O
herein	JJ	O
and	:	O
include,	NNP	O
but	FW	O
are	,	O
not	.	O
limited	.	O
to,	.	O
yeast	.	O
capable	,	O
of	:	O
growth	JJ	O
on	)	O
methanol	CC	O
selected	NNP	O
from	NNP	O
the	NNP	O
genera	CC	O
consisting	,	O
of	NNP	O
Hansenula,	,	O
Candida,	JJ	O
Kloeckera,	.	O
Pichia,	NNP	O
Saccharomyces,	NNS	O
Torulopsis,	VBP	O
and	JJ	O
Rhodotorula.	NN	O
A	CC	O
list	,	O
of	CC	O
specific	VBP	O
species	RB	O
that	VBN	O
are	,	O
exemplary	RB	O
of	JJ	O
this	IN	O
class	NN	O
of	IN	O
yeasts	NN	O
may	VBN	O
be	IN	O
found	DT	O
in	NN	O
C.	NN	B
Anthony,	IN	I
The	,	I
Biochemistry	,	I
of	,	I
Methylotrophs,	,	I
269	,	I
(1982).
Suitable	,	O
host	CC	O
cells	.	O
for	DT	O
the	NN	O
expression	IN	O
of	JJ	O
glycosylated	NNS	O
PRO227,	WDT	O
PRO233,	VBP	O
PRO238,	JJ	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	NNS	O
PRO353	MD	O
or	VB	O
PRO1885	VBN	O
polypeptides	IN	O
are	NNP	O
derived	,	O
from	DT	O
multicellular	NNP	O
organisms.	IN	O
Examples	,	O
of	CD	O
invertebrate	.	O
cells	JJ	O
include	NN	O
insect	NNS	O
cells	IN	O
such	DT	O
as	NN	O
Drosophila	IN	O
S2	JJ	O
and	,	O
Spodoptera	,	O
Sf9,	,	O
as	,	O
well	,	O
as	,	O
plant	,	O
cells.	,	O
Examples	NNP	O
of	CC	O
useful	NNP	O
mammalian	NNS	O
host	VBP	O
cell	VBN	O
lines	IN	O
include	JJ	O
Chinese	.	O
hamster	NNS	O
ovary	IN	O
(CHO)	JJ	O
and	NNS	O
COS	VBP	O
cells.	JJ	O
More	NNS	O
specific	JJ	O
examples	IN	O
include	NNP	O
monkey	NNP	O
kidney	CC	O
CV1	NNP	O
line	,	O
transformed	RB	O
by	RB	O
SV40	IN	O
(COS-7,	NN	O
ATCC	.	O
CRL	NNS	O
1651);	IN	O
human	JJ	O
embryonic	JJ	O
kidney	NN	O
line	NN	O
(293	NNS	O
or	VBP	O
293	JJ	O
cells	NN	O
subcloned	JJ	O
for	)	O
growth	CC	O
in	NNP	O
suspension	.	O
culture,	RBR	O
Graham	JJ	B
et	NNS	I
al.,	VBP	I
J.	JJ	I
Gen	NNP	I
Virol.,	NNP	I
36:59	NN	I
(1977));Chinese	VBN	O
hamster	IN	O
ovary	NNP	O
cells/−DHFR	,	O
CHO,	NNP	B
Urlaub	NNP	I
and	:	I
Chasin,	JJ	I
Proc.	JJ	I
Natl.	NN	I
Acad.	NN	I
Sci.	CD	I
USA,	CC	I
77:4216	CD	I
(1980));(	NNS	O
mouse	VBN	O
sertoli	IN	O
cells	NN	O
(TM4,	IN	O
Mather,	NN	O
Biol.	,	O
Reprod.,	NNP	O
23:243-251	FW	O
(1980));	,	O
human	NNP	O
lung	NNP	O
cells	,	O
(W138,	CD	O
ATCC	:	O
CCL	JJ	O
75);	NN	O
human	JJ	O
liver	NN	O
cells	,	O
(Hep	NNP	O
G2,	CC	O
HB	,	O
8065);	.	O
and	.	O
mouse	.	O
mammary	.	O
tumor	,	O
(MMT	CD	O
060562,	:	O
ATCC	CC	O
CCL51).	JJ	O
The	NNS	O
selection	,	O
of	,	O
the	.	O
appropriate	,	O
host	CD	O
cell	:	O
is	JJ	O
deemed	NN	O
to	NNS	O
be	,	O
within	NNP	O
the	NNP	O
skill	:	O
in	JJ	O
the	NN	O
art.	NNS	O
3.	NNP	O
Selection	,	O
and	NNP	O
Use	:	O
of	CC	O
a	VB	O
Replicable	JJ	O
Vector	NN	O
The	NNP	O
nucleic	,	O
acid	NNP	O
(e.g.,	.	O
cDNA	DT	O
or	NN	O
genomic	IN	O
DNA)	DT	O
encoding	JJ	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	VBZ	O
PRO1328,	VBN	O
PRO4342,	TO	O
PRO7423,	VB	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
polypeptides	.	O
may	.	O
be	NN	O
inserted	CC	O
into	NNP	O
a	IN	O
replicable	DT	O
vector	JJ	O
for	NNP	O
cloning	DT	O
(amplification	JJ	O
of	NN	O
the	,	O
DNA)	NN	O
or	CC	O
for	JJ	O
expression.	)	O
Various	VBG	O
vectors	,	O
are	,	O
publicly	,	O
available.	,	O
The	,	O
vector	,	O
may,	,	O
for	,	O
example,	NNP	O
be	CC	O
in	NNP	O
the	NNS	O
form	MD	O
of	VB	O
a	VBN	O
plasmid,	IN	O
cosmid,	DT	O
viral	JJ	O
particle,	NN	O
or	IN	O
phage.	VBG	O
The	NN	O
appropriate	IN	O
nucleic	DT	O
acid	)	O
sequence	CC	O
may	IN	O
be	.	O
inserted	JJ	O
into	NNS	O
the	VBP	O
vector	RB	O
by	.	O
a	DT	O
variety	NN	O
of	,	O
procedures.	IN	O
In	,	O
general,	VB	O
DNA	IN	O
is	DT	O
inserted	NN	O
into	IN	O
an	DT	O
appropriate	,	O
restriction	,	O
endonuclease	JJ	O
site(s)	,	O
using	CC	O
techniques	.	O
known	DT	O
in	JJ	O
the	JJ	O
art.	NN	O
Vector	NN	O
components	MD	O
generally	VB	O
include,	VBN	O
but	IN	O
are	DT	O
not	NN	O
limited	IN	O
to,	DT	O
one	NN	O
or	IN	O
more	.	O
of	IN	O
a	,	O
signal	NNP	O
sequence,	VBZ	O
an	VBN	O
origin	IN	O
of	DT	O
replication,	JJ	O
one	NN	O
or	NN	O
more	)	O
marker	VBG	O
genes,	NNS	O
an	VBN	O
enhancer	IN	O
element,	DT	O
a	.	O
promoter,	NN	O
and	NNS	O
a	RB	O
transcription	,	O
termination	CC	O
sequence.	VBP	O
Construction	RB	O
of	VBN	O
suitable	,	O
vectors	CD	O
containing	CC	O
one	JJR	O
or	IN	O
more	DT	O
of	JJ	O
these	,	O
components	DT	O
employs	NN	O
standard	IN	O
ligation	,	O
techniques	CD	O
which	CC	O
are	JJR	O
known	NN	O
to	,	O
the	DT	O
skilled	NN	O
artisan.	,	O
The	DT	O
PRO227,	,	O
PRO233,	CC	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	.	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	JJ	O
or	NNS	O
PRO1885	VBG	O
polypeptide	CD	O
may	CC	O
be	JJR	O
produced	IN	O
recombinantly	DT	O
not	NNS	O
only	VBZ	O
directly,	JJ	O
but	NN	O
also	NNS	O
as	WDT	O
a	VBP	O
fusion	VBN	O
polypeptide	TO	O
with	DT	O
a	VBN	O
heterologous	.	O
polypeptide,	DT	O
which	,	O
may	,	O
be	,	O
a	,	O
signal	,	O
sequence	,	O
or	,	O
other	,	O
polypeptide	NNP	O
having	CC	O
a	NNP	O
specific	NN	O
cleavage	MD	O
site	VB	O
at	VBN	O
the	RB	O
N-terminus	RB	O
of	RB	O
the	,	O
mature	CC	O
protein	RB	O
or	IN	O
polypeptide.	DT	O
In	NN	O
general,	NN	O
the	IN	O
signal	DT	O
sequence	JJ	O
may	,	O
be	WDT	O
a	MD	O
component	VB	O
of	DT	O
the	JJ	O
vector,	NN	O
or	CC	O
it	JJ	O
may	NN	O
be	VBG	O
a	DT	O
part	JJ	O
of	NN	O
the	NN	O
PRO227-,	IN	O
PRO233-,	DT	O
PRO238-,	NNP	O
PRO1328-,	IN	O
PRO4342-,	DT	O
PRO7423-,	NN	O
PRO10096-,	NN	O
PRO21384-,	CC	O
PRO353-	.	O
or	IN	O
PRO1885-encoding	,	O
DNA	DT	O
that	JJ	O
is	NN	O
inserted	MD	O
into	VB	O
the	DT	O
vector.	NN	O
The	IN	O
signal	DT	O
sequence	,	O
may	CC	O
be	PRP	O
a	MD	O
prokaryotic	VB	O
signal	DT	O
sequence	NN	O
selected,	IN	O
for	DT	O
example,	,	O
from	,	O
the	,	O
group	,	O
of	,	O
the	,	O
alkaline	,	O
phosphatase,	,	O
penicillinase,	NNP	O
1	CC	O
pp,	NNP	O
or	NNP	O
heat-stable	WDT	O
enterotoxin	VBZ	O
II	VBN	O
leaders.	IN	O
For	DT	O
yeast	.	O
secretion	DT	O
the	JJ	O
signal	NN	O
sequence	MD	O
may	VB	O
be,	DT	O
e.g.,	JJ	O
the	NN	O
yeast	NN	O
invertase	,	O
leader,	IN	O
alpha	,	O
factor	IN	O
leader	DT	O
(including	NN	O
Saccharomyces	IN	O
and	DT	O
Kluyveromyces	JJ	O
α-factor	,	O
leaders,	,	O
the	CD	O
latter	,	O
described	CC	O
in	JJ	O
U.S.	NN	O
Pat.	NNP	O
No.	.	O
5,010,182),	IN	O
or	JJ	O
acid	NN	O
phosphatase	DT	O
leader,	JJ	O
the	NN	O
C.	MD	O
albicans	,	O
glucoamylase	,	O
leader	DT	O
(EP	NN	O
362,179	NN	O
published	,	O
4	JJ	O
Apr.	NN	O
1990),	NN	O
or	VBG	O
the	NNS	O
signal	CC	O
described	NNP	O
in	NN	O
WO	,	O
90/13646	DT	O
published	JJ	O
15	VBN	O
Nov.	IN	O
1990.	NNP	O
In	.	O
mammalian	.	O
cell	,	O
expression,	CC	O
mammalian	JJ	O
signal	NN	O
sequences	,	O
may	DT	O
be	NNP	O
used	NNS	O
to	JJ	O
direct	NN	O
secretion	NNP	O
of	CD	O
the	VBD	O
protein,	CD	O
such	.	O
as	,	O
signal	CC	O
sequences	DT	O
from	JJ	O
secreted	NN	O
polypeptides	IN	O
of	NNP	O
the	CD	O
same	VBD	O
or	CD	O
related	NNP	O
species,	.	O
as	IN	O
well	JJ	O
as	NN	O
viral	,	O
secretory	JJ	O
leaders.	NN	O
Both	NNS	O
expression	MD	O
and	VB	O
cloning	VBN	O
vectors	TO	O
contain	JJ	O
a	NN	O
nucleic	IN	O
acid	DT	O
sequence	,	O
that	JJ	O
enables	IN	O
the	JJ	O
vector	NNS	O
to	IN	O
replicate	VBN	O
in	NNS	O
one	IN	O
or	DT	O
more	JJ	O
selected	CC	O
host	JJ	O
cells.	,	O
Such	RB	O
sequences	RB	O
are	IN	O
well	JJ	O
known	NN	O
for	.	O
a	DT	O
variety	NN	O
of	CC	O
bacteria,	VBG	O
yeast,	NNS	O
and	VBP	O
viruses.	DT	O
The	JJ	O
origin	NN	O
of	NN	O
replication	WDT	O
from	VBZ	O
the	DT	O
plasmid	NN	O
pBR322	TO	O
is	VB	O
suitable	IN	O
for	CD	O
most	CC	O
Gram-negative	JJR	O
bacteria,	VBN	O
the	NN	O
2μ	.	O
plasmid	JJ	O
origin	NNS	O
is	VBP	O
suitable	RB	O
for	VBN	O
yeast,	IN	O
and	DT	O
various	NN	O
viral	IN	O
origins	,	O
(SV40,	,	O
polyoma,	CC	O
adenovirus,	.	O
VSV	DT	O
or	NN	O
BPV)	IN	O
are	NN	O
useful	IN	O
for	DT	O
cloning	NN	O
vectors	NN	O
in	VBZ	O
mammalian	JJ	O
cells.	IN	O
Expression	JJS	O
and	JJ	O
cloning	,	O
vectors	DT	O
will	CD	O
typically	NN	O
contain	NN	O
a	VBZ	O
selection	JJ	O
gene,	IN	O
also	,	O
termed	CC	O
a	JJ	O
selectable	JJ	O
marker.	NNS	O
Typical	,	O
selection	,	O
genes	,	O
encode	NNP	O
proteins	CC	O
that	)	O
(a)	VBP	O
confer	JJ	O
resistance	IN	O
to	VBG	O
antibiotics	NNS	O
or	IN	O
other	JJ	O
toxins,	.	O
e.g.,	NN	O
ampicillin,	CC	O
neomycin,	VBG	O
methotrexate,	NNS	O
or	MD	O
tetracycline,	RB	O
(b)	VB	O
complement	DT	O
auxotrophic	NN	O
deficiencies,	,	O
or	RB	O
(c)	VBD	O
supply	DT	O
critical	JJ	O
nutrients	.	O
not	JJ	O
available	NN	O
from	NNS	O
complex	VBP	O
media,	NNS	O
e.g.,	WDT	O
the	)	O
gene	NN	O
encoding	NN	O
D-alanine	TO	O
racemase	NNS	O
for	CC	O
Bacilli.	JJ	O
An	,	O
example	,	O
of	,	O
suitable	,	O
selectable	,	O
markers	CC	O
for	,	O
mammalian	)	O
cells	NN	O
are	JJ	O
those	,	O
that	CC	O
enable	)	O
the	NN	O
identification	JJ	O
of	NNS	O
cells	RB	O
competent	JJ	O
to	IN	O
take	JJ	O
up	,	O
the	,	O
PRO227-,	DT	O
PRO233-,	NN	O
PRO238-,	VBG	O
PRO1328-,	NNP	O
PRO4342-,	NN	O
PRO7423-,	IN	O
PRO10096-,	.	O
PRO21384-,	DT	O
PRO353-	NN	O
or	IN	O
PRO1885-encoding	JJ	O
nucleic	JJ	O
acid,	NNS	O
such	IN	O
as	JJ	O
DHFR	NNS	O
or	VBP	O
thymidine	DT	O
kinase.	IN	O
An	VBP	O
appropriate	DT	O
host	NN	O
cell	IN	O
when	NNS	O
wild-type	JJ	O
DHFR	TO	O
is	VB	O
employed	RP	O
is	DT	O
the	,	O
CHO	,	O
cell	,	O
line	,	O
deficient	,	O
in	,	O
DHFR	,	O
activity,	,	O
prepared	NNP	O
and	CC	O
propagated	NNP	O
as	JJ	O
described	,	O
by	JJ	O
Urlaub	IN	B
et	NNP	I
al.,	CC	I
Proc.	JJ	I
Natl.	.	I
Acad.	DT	I
Sci.	JJ	I
USA,	NN	I
77:4216	NN	I
(1980).	WRB	I
A	NN	O
suitable	NNP	O
selection	VBZ	O
gene	VBN	O
for	VBZ	O
use	DT	O
in	NNP	O
yeast	NN	O
is	NN	O
the	NN	O
trp1	IN	O
gene	NNP	O
present	,	O
in	JJ	O
the	CC	O
yeast	VBD	O
plasmid	IN	O
YRp7	VBN	O
Stinchcomb	IN	B
et	NNP	I
al.,	FW	I
Nature,	,	I
282:39	.	I
(1979);	.	I
Kingsman	.	B
et	.	I
al.,	,	I
Gene,	CD	I
7:141	.	I
(1979);	DT	I
Tschemper	JJ	B
et	NN	I
al.,	NN	I
Gene,	IN	I
10:157	NN	I
(1980)].[	IN	O
The	NN	O
trp1	VBZ	O
gene	DT	O
provides	JJ	O
a	NN	O
selection	NN	O
marker	IN	O
for	DT	O
a	NN	O
mutant	NN	O
strain	NNP	O
of	NNP	O
yeast	FW	O
lacking	,	O
the	,	O
ability	CD	O
to	:	O
grow	NNP	O
in	VBZ	O
tryptophan,	,	O
for	,	O
example,	CD	O
ATCC	:	O
No.	NNP	O
44076	FW	O
or	,	O
PEP4-1	,	O
Jones,	CD	B
Genetics,	.	I
85:12	DT	I
(1977)].[	JJ	O
Expression	NN	O
and	VBZ	O
cloning	DT	O
vectors	NN	O
usually	NN	O
contain	IN	O
a	DT	O
promoter	JJ	O
operably	NN	O
linked	IN	O
to	NN	O
the	VBG	O
PRO227-,	DT	O
PRO233-,	NN	O
PRO238-,	TO	O
PRO1328-,	VB	O
PRO4342-,	IN	O
PRO7423-,	,	O
PRO10096-,	IN	O
PRO21384-,	,	O
PRO353-	NNP	O
or	.	O
PRO1885-encoding	CD	O
nucleic	CC	O
acid	NNP	O
sequence	,	O
to	,	O
direct	CD	O
mRNA	.	O
synthesis.	NN	O
Promoters	CC	O
recognized	VBG	O
by	NNS	O
a	RB	O
variety	VBP	O
of	DT	O
potential	NN	O
host	RB	O
cells	VBD	O
are	TO	O
well	DT	O
known.	,	O
Promoters	,	O
suitable	,	O
for	,	O
use	,	O
with	,	O
prokaryotic	,	O
hosts	,	O
include	NNP	O
the	CC	O
β-lactamase	NNP	O
and	JJ	O
lactose	NN	O
promoter	NN	O
systems	TO	O
Chang	VB	B
et	JJ	I
al.,	.	I
Nature,	NNS	I
275:615	VBN	I
(1978);	IN	I
Goeddel	DT	B
et	NN	I
al.,	IN	I
Nature,	JJ	I
281:544	NN	I
(1979)],[	NNS	O
alkaline	VBP	O
phosphatase,	RB	O
a	.	O
tryptophan	NNS	O
(tip)	JJ	O
promoter	IN	O
system	NN	O
Goeddel,	IN	B
Nucleic	JJ	I
Acids	NNS	I
Res.,	VBP	I
8:4057	DT	I
(1980);	JJ	I
[EP	CC	O
36,776],	JJ	O
and	NN	O
hybrid	NNS	O
promoters	NNP	O
such	FW	O
as	,	O
the	,	O
tac	CD	O
promoter	:	O
deBoer	NNP	B
et	FW	I
al.,	,	I
Proc.	,	I
Natl.	CD	I
Acad.	,	I
Sci.	JJ	I
USA,	,	I
80:21-25	DT	I
(1983)].[	NN	O
Promoters	)	O
for	NN	O
use	NN	O
in	,	O
bacterial	NNP	O
systems	NNP	O
also	,	O
will	CD	O
contain	:	O
a	$	O
Shine-Dalgarno	,	O
(S.D.)	CC	O
sequence	JJ	O
operably	NNS	O
linked	JJ	O
to	IN	O
the	DT	O
DNA	NN	O
encoding	NN	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	,	O
PRO1328,	.	O
PRO4342,	.	O
PRO7423,	.	O
PRO10096,	.	O
PRO21384,	,	O
PRO353	CD	O
or	.	O
PRO1885	NNS	O
polypeptides.	IN	O
Examples	NN	O
of	IN	O
suitable	JJ	O
promoting	NNS	O
sequences	RB	O
for	MD	O
use	VB	O
with	DT	O
yeast	NNP	O
hosts	)	O
include	NN	O
the	RB	O
promoters	VBD	O
for	TO	O
3-phosphoglycerate	DT	O
kinase	NNP	O
Hitzeman	VBG	B
et	,	I
al.,	,	I
J.	,	I
Biol.	,	I
Chem.,	,	I
255:2073	,	I
(1980)]	,	I
[or	,	O
other	NNP	O
glycolytic	CC	O
enzymes	NNP	O
Hess	.	B
et	NNS	I
al.,	IN	I
J.	JJ	I
Adv.	NN	I
Enzyme	NNS	I
Reg.,	IN	I
7:149	NN	I
(1968);	IN	I
Holland,	JJ	B
Biochemistry,	NNS	I
17:4900	VBP	I
(1978)],[	DT	O
such	NNS	O
as	IN	O
enolase,	JJ	O
glyceraldehyde-3-phosphate	NN	O
dehydrogenase,	NNP	O
hexokinase,	VBZ	O
pyruvate	,	O
decarboxylase,	NNP	O
phosphofructokinase,	.	O
glucose-6-phosphate	,	O
isomerase,	CD	O
3-phosphoglycerate	NN	O
mutase,	CC	O
pyruvate	JJ	O
kinase,	JJ	O
triosephosphate	NNS	O
isomerase,	NNP	O
phosphoglucose	CC	O
isomerase,	,	O
and	NNP	O
glucokinase.	.	O
Other	NNP	O
yeast	,	O
promoters,	CD	O
which	:	O
are	,	O
inducible	,	O
promoters	CD	O
having	,	O
the	JJ	O
additional	IN	O
advantage	,	O
of	JJ	O
transcription	,	O
controlled	,	O
by	JJ	O
growth	,	O
conditions,	,	O
are	JJ	O
the	,	O
promoter	JJ	O
regions	,	O
for	JJ	O
alcohol	,	O
dehydrogenase	JJ	O
2,	,	O
isocytochrome	JJ	O
C,	,	O
acid	CC	O
phosphatase,	.	O
degradative	JJ	O
enzymes	NN	O
associated	,	O
with	WDT	O
nitrogen	VBP	O
metabolism,	JJ	O
metallothionein,	NNS	O
glyceraldehyde-3-phosphate	VBG	O
dehydrogenase,	DT	O
and	JJ	O
enzymes	NN	O
responsible	IN	O
for	NN	O
maltose	VBN	O
and	IN	O
galactose	NN	O
utilization.	,	O
Suitable	VBP	O
vectors	DT	O
and	NN	O
promoters	NNS	O
for	IN	O
use	NN	O
in	NN	O
yeast	,	O
expression	JJ	O
are	,	O
further	JJ	O
described	,	O
in	JJ	O
EP	NNS	O
73,657.	VBN	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	JJ	O
PRO7423,	,	O
PRO10096,	CC	O
PRO21384,	VBZ	O
PRO353	JJ	O
or	IN	O
PRO1885	JJ	O
transcription	CC	O
from	JJ	O
vectors	.	O
in	JJ	O
mammalian	NNS	O
host	CC	O
cells	NNS	O
is	IN	O
controlled,	NN	O
for	IN	O
example,	JJ	O
by	NN	O
promoters	VBP	O
obtained	JJ	O
from	VBN	O
the	IN	O
genomes	NNP	O
of	.	O
viruses	,	O
such	,	O
as	,	O
polyoma	,	O
virus,	,	O
fowlpox	,	O
virus	,	O
(UK	,	O
2,211,504	NNP	O
published	CC	O
5	NNP	O
Jul.	NN	O
1989),	IN	O
adenovirus	NNS	O
(such	IN	O
as	JJ	O
Adenovirus	NN	O
2),	NNS	O
bovine	VBZ	O
papilloma	,	O
virus,	IN	O
avian	,	O
sarcoma	IN	O
virus,	NNS	O
cytomegalovirus,	VBN	O
a	IN	O
retrovirus,	DT	O
hepatitis-B	NNS	O
virus	IN	O
and	NNS	O
Simian	JJ	O
Virus	IN	O
40	NN	O
(SV40),	,	O
from	JJ	O
heterologous	NN	O
mammalian	NNP	O
promoters,	CD	O
e.g.,	VBD	O
the	CD	O
actin	.	O
promoter	,	O
or	RB	O
an	JJ	O
immunoglobulin	IN	O
promoter,	NNP	O
and	,	O
from	JJ	O
heat-shock	NN	O
promoters,	,	O
provided	JJ	O
such	NN	O
promoters	,	O
are	,	O
compatible	DT	O
with	,	O
the	JJ	O
host	NN	O
cell	CC	O
systems.	JJ	O
Transcription	NNP	O
of	CD	O
a	,	O
DNA	IN	O
encoding	JJ	O
the	JJ	O
PRO227,	,	O
PRO233,	,	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	CC	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	,	O
or	CC	O
PRO1885	IN	O
polypeptide	JJ	O
by	,	O
higher	VBD	O
eukaryotes	JJ	O
may	NNS	O
be	VBP	O
increased	JJ	O
by	IN	O
inserting	DT	O
an	NN	O
enhancer	NN	O
sequence	.	O
into	NN	O
the	IN	O
vector.	DT	O
Enhancers	NN	O
are	VBG	O
cis-acting	DT	O
elements	,	O
of	,	O
DNA,	,	O
usually	,	O
about	,	O
from	,	O
10	,	O
to	,	O
300	NNP	O
bp,	CC	O
that	NNP	O
act	RB	O
on	IN	O
a	JJR	O
promoter	NNS	O
to	MD	O
increase	VB	O
its	VBN	O
transcription.	IN	O
Many	VBG	O
enhancer	DT	O
sequences	NN	O
are	NN	O
now	IN	O
known	DT	O
from	.	O
mammalian	NNS	O
genes	VBP	O
(globin,	JJ	O
elastase,	NNS	O
albumin,	IN	O
α-fetoprotein,	,	O
and	RB	O
insulin).	IN	O
Typically,	IN	O
however,	CD	O
one	TO	O
will	CD	O
use	,	O
an	WDT	O
enhancer	VBP	O
from	IN	O
a	DT	O
eukaryotic	NN	O
cell	TO	O
virus.	VB	O
Examples	PRP$	O
include	.	O
the	JJ	O
SV40	NN	O
enhancer	NNS	O
on	VBP	O
the	RB	O
late	VBN	O
side	IN	O
of	JJ	O
the	NNS	O
replication	,	O
origin	,	O
(bp	,	O
100-270),	,	O
the	CC	O
cytomegalovirus	.	O
early	,	O
promoter	,	O
enhancer,	CD	O
the	MD	O
polyoma	VB	O
enhancer	DT	O
on	NN	O
the	IN	O
late	DT	O
side	JJ	O
of	NN	O
the	.	O
replication	NNS	O
origin,	VBP	O
and	DT	O
adenovirus	NNP	O
enhancers.	NN	O
The	IN	O
enhancer	DT	O
may	JJ	O
be	NN	O
spliced	IN	O
into	DT	O
the	NN	O
vector	NN	O
at	IN	O
a	,	O
position	DT	O
5′	NN	O
or	JJ	O
3′	NN	O
to	,	O
the	DT	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	NN	O
or	,	O
PRO1885	CC	O
coding	NN	O
sequence,	.	O
but	DT	O
is	NN	O
preferably	MD	O
located	VB	O
at	VBN	O
a	IN	O
site	DT	O
5′	NN	O
from	IN	O
the	DT	O
promoter.	NN	O
Expression	CD	O
vectors	CC	O
used	CD	O
in	TO	O
eukaryotic	DT	O
host	,	O
cells	,	O
(yeast,	,	O
fungi,	,	O
insect,	,	O
plant,	,	O
animal,	,	O
human,	,	O
or	NNP	O
nucleated	CC	O
cells	NNP	O
from	VBG	O
other	,	O
multicellular	CC	O
organisms)	VBZ	O
will	RB	O
also	VBN	O
contain	IN	O
sequences	DT	O
necessary	NN	O
for	CD	O
the	IN	O
termination	DT	O
of	.	O
transcription	NN	O
and	NNS	O
for	VBN	O
stabilizing	IN	O
the	JJ	O
mRNA.	NN	O
Such	NNS	O
sequences	,	O
are	,	O
commonly	,	O
available	,	O
from	,	O
the	,	O
5′	CC	O
and,	JJ	O
occasionally	NNS	O
3′,	IN	O
untranslated	JJ	O
regions	JJ	O
of	)	O
eukaryotic	MD	O
or	RB	O
viral	VB	O
DNAs	NNS	O
or	JJ	O
cDNAs.	IN	O
These	DT	O
regions	NN	O
contain	IN	O
nucleotide	NN	O
segments	CC	O
transcribed	IN	O
as	VBG	O
polyadenylated	DT	O
fragments	.	O
in	JJ	O
the	NNS	O
untranslated	VBP	O
portion	RB	O
of	JJ	O
the	IN	O
mRNA	DT	O
encoding	CD	O
PRO227,	,	O
PRO233,	RB	O
PRO238,	,	O
PRO1328,	JJ	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	CC	O
PRO353	JJ	O
or	NNP	O
PRO1885	CC	O
polypeptides.	.	O
Still	DT	O
other	NNS	O
methods,	VBP	O
vectors,	JJ	O
and	NNS	O
host	VBD	O
cells	IN	O
suitable	JJ	O
for	NNS	O
adaptation	IN	O
to	DT	O
the	JJ	O
synthesis	NN	O
of	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	VBG	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	NNP	O
in	CC	O
recombinant	NNP	O
vertebrate	.	O
cell	RB	O
culture	JJ	O
are	,	O
described	,	O
in	CC	O
Gething	NN	B
et	NNS	I
al.,	JJ	I
Nature,	IN	I
293:620-625	NN	I
(1981);	TO	I
Mantei	DT	B
et	NN	I
al.,	IN	I
Nature,	,	I
281:40-46	,	I
(1979);	,	I
EP	,	O
117,060;	,	O
and	,	O
EP	,	O
117,058.	,	O
4.	NNP	O
Detecting	CC	O
Gene	NNP	O
Amplification/Expression	NNS	O
Gene	IN	O
amplification	JJ	O
and/or	NN	O
expression	NN	O
may	NN	O
be	VBP	O
measured	VBN	O
in	IN	O
a	VBG	O
sample	NN	O
directly,	,	O
for	,	O
example,	CD	O
by	:	O
conventional	NNP	O
Southern	FW	O
blotting,	,	O
Northern	,	O
blotting	CD	O
to	:	O
quantitate	NNP	O
the	:	O
transcription	CC	O
of	NNP	O
mRNA	.	O
Thomas,	.	B
Proc.	VBG	I
Natl.	NNP	I
Acad.	NNP	I
Sci.	NNP	I
USA,	NN	I
77:5201-5205	NNS	I
(1980)],[	NN	O
dot	MD	O
blotting	VB	O
(DNA	VBN	O
analysis),	IN	O
or	DT	O
in	NN	O
situ	,	O
hybridization,	IN	O
using	,	O
an	IN	O
appropriately	JJ	O
labeled	NNP	O
probe,	,	O
based	NNP	O
on	VBG	O
the	TO	O
sequences	VB	O
provided	DT	O
herein.	NN	O
Alternatively,	IN	O
antibodies	NN	O
may	,	O
be	.	O
employed	.	O
that	.	O
can	.	O
recognize	,	O
specific	NNP	O
duplexes,	,	O
including	NN	O
DNA	NN	O
duplexes,	NNP	O
RNA	,	O
duplexes,	CC	O
and	IN	O
DNA-RNA	JJ	O
hybrid	,	O
duplexes	VBG	O
or	DT	O
DNA-protein	RB	O
duplexes.	JJ	O
The	,	O
antibodies	VBN	O
in	IN	O
turn	DT	O
may	NNS	O
be	VBD	O
labeled	.	O
and	,	O
the	NNS	O
assay	MD	O
may	VB	O
be	VBN	O
carried	IN	O
out	MD	O
where	VB	O
the	JJ	O
duplex	,	O
is	VBG	O
bound	NN	O
to	,	O
a	NNP	O
surface,	,	O
so	CC	O
that	NNP	O
upon	JJ	O
the	NNS	O
formation	CC	O
of	NNP	O
duplex	.	O
on	DT	O
the	NNS	O
surface,	IN	O
the	NN	O
presence	MD	O
of	VB	O
antibody	VBN	O
bound	CC	O
to	DT	O
the	NN	O
duplex	MD	O
can	VB	O
be	VBN	O
detected.	IN	O
Gene	WRB	O
expression,	DT	O
alternatively,	NN	O
may	VBZ	O
be	VBN	O
measured	TO	O
by	DT	O
immunological	,	O
methods,	IN	O
such	DT	O
as	IN	O
immunohistochemical	DT	O
staining	NN	O
of	IN	O
cells	NN	O
or	IN	O
tissue	DT	O
sections	,	O
and	DT	O
assay	NN	O
of	IN	O
cell	NN	O
culture	NN	O
or	TO	O
body	DT	O
fluids,	NN	O
to	MD	O
quantitate	VB	O
directly	.	O
the	NNP	O
expression	,	O
of	,	O
gene	MD	O
product.	VB	O
Antibodies	VBN	O
useful	IN	O
for	JJ	O
immunohistochemical	,	O
staining	JJ	O
and/or	IN	O
assay	JJ	O
of	NN	O
sample	IN	O
fluids	NNS	O
may	CC	O
be	NN	O
either	NNS	O
monoclonal	CC	O
or	NN	O
polyclonal,	IN	O
and	NN	O
may	NN	O
be	CC	O
prepared	NN	O
in	,	O
any	TO	O
mammal.	VB	O
Conveniently,	RB	O
the	DT	O
antibodies	NN	O
may	IN	O
be	NN	O
prepared	.	O
against	NNS	O
a	JJ	O
native	IN	O
sequence	JJ	O
PRO227,	NN	O
PRO233,	NNS	O
PRO238,	VBP	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	NNS	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	CC	O
or	JJ	O
PRO1885	CC	O
polypeptide	,	O
or	CC	O
against	MD	O
a	VB	O
synthetic	VBN	O
peptide	IN	O
based	DT	O
on	.	O
the	,	O
DNA	DT	O
sequences	NNS	O
provided	MD	O
herein	VB	O
or	VBN	O
against	IN	O
exogenous	DT	O
sequence	JJ	O
fused	NN	O
to	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	VBP	O
DNA	CC	O
and	IN	O
encoding	DT	O
a	JJ	O
specific	NN	O
antibody	VBN	O
epitope.	IN	O
5.	DT	O
Purification	NN	O
of	NNS	O
Polypeptide	VBD	O
Forms	NN	O
of	CC	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	VBD	O
PRO4342,	TO	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
may	,	O
be	NNP	O
recovered	CC	O
from	NNP	O
culture	NNP	O
medium	CC	O
or	VBG	O
from	DT	O
host	JJ	O
cell	NN	O
lysates.	.	O
If	.	O
membrane-bound,	NN	O
it	IN	O
can	NNP	O
be	NNP	O
released	IN	O
from	,	O
the	,	O
membrane	,	O
using	,	O
a	,	O
suitable	,	O
detergent	,	O
solution	,	O
(e.g.	NNP	O
Triton-X	CC	O
100)	NNP	O
or	NNS	O
by	MD	O
enzymatic	VB	O
cleavage.	VBN	O
Cells	IN	O
employed	NN	O
in	NN	O
expression	CC	O
of	IN	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	.	O
PRO1328,	IN	O
PRO4342,	,	O
PRO7423,	PRP	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	VBN	O
or	IN	O
PRO1885	DT	O
polypeptides	NN	O
can	VBG	O
be	DT	O
disrupted	JJ	O
by	NN	O
various	NN	O
physical	.	O
or	NNP	O
chemical	)	O
means,	CC	O
such	IN	O
as	JJ	O
freeze-thaw	.	O
cycling,	NNS	O
sonication,	VBN	O
mechanical	IN	O
disruption,	NN	O
or	IN	O
cell	,	O
lysing	,	O
agents.	,	O
It	,	O
may	,	O
be	,	O
desired	,	O
to	,	O
purify	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NNS	O
PRO1328,	MD	O
PRO4342,	VB	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	JJ	O
PRO353	JJ	O
or	CC	O
PRO1885	NN	O
polypeptides	,	O
from	JJ	O
recombinant	IN	O
cell	JJ	O
proteins	,	O
or	,	O
polypeptides.	JJ	O
The	,	O
following	CC	O
procedures	NN	O
are	VBG	O
exemplary	.	O
of	PRP	O
suitable	MD	O
purification	VB	O
procedures:	VBN	O
by	TO	O
fractionation	VB	O
on	,	O
an	,	O
ion-exchange	,	O
column;	,	O
ethanol	,	O
precipitation;	,	O
reverse	,	O
phase	,	O
HPLC;	NNP	O
chromatography	CC	O
on	NNP	O
silica	NNS	O
or	IN	O
on	NN	O
a	NN	O
cation-exchange	VBZ	O
resin	CC	O
such	.	O
as	DT	O
DEAE;	JJ	O
chromatofocusing;	NNS	O
SDS-PAGE;	VBP	O
ammonium	JJ	O
sulfate	IN	O
precipitation;	JJ	O
gel	NN	O
filtration	:	O
using,	IN	O
for	NN	O
example,	IN	O
Sephadex	DT	O
G-75;	JJ	O
protein	:	O
A	CC	O
Sepharose	:	O
columns	VB	O
to	NN	O
remove	:	O
contaminants	NN	O
such	IN	O
as	NN	O
IgG;	CC	O
and	IN	O
metal	DT	O
chelating	JJ	O
columns	NN	O
to	JJ	O
bind	IN	O
epitope-tagged	:	O
forms	:	O
of	:	O
the	NN	O
PRO227,	NN	O
PRO233,	:	O
PRO238,	CC	O
PRO1328,	NN	O
PRO4342,	,	O
PRO7423,	IN	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	:	O
or	VBZ	O
PRO1885	DT	O
polypeptide.	NNP	O
Various	NN	O
methods	TO	O
of	VB	O
protein	NNS	O
purification	JJ	O
may	IN	O
be	:	O
employed	CC	O
and	NN	O
such	VBG	O
methods	NN	O
are	TO	O
known	VB	O
in	JJ	O
the	NNS	O
art	IN	O
and	DT	O
described	,	O
for	,	O
example	,	O
in	,	O
Deutscher,	,	O
Methods	,	O
in	,	O
Enzymology,	,	O
182	NNP	O
(1990);	CC	O
Scopes,	NNP	O
Protein	.	O
Purification:	JJ	O
Principles	NNS	O
and	IN	O
Practice,	JJ	O
Springer-Verlag,	NN	O
New	MD	O
York	VB	O
(1982).	VBN	O
The	CC	O
purification	JJ	O
step(s)	NNS	O
selected	VBP	O
will	VBN	O
depend,	IN	O
for	DT	O
example,	NN	O
on	CC	O
the	NN	O
nature	IN	O
of	NN	O
the	IN	O
production	,	O
process	NNP	O
used	IN	O
and	,	O
the	CD	O
particular	:	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	:	O
PRO1328,	NNS	O
PRO4342,	CC	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	NNP	O
or	.	O
PRO1885	DT	O
polypeptide	NN	O
produced.	)	O
E.	VBN	O
Uses	MD	O
for	,	O
PRO227,	IN	O
PRO233,	,	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423;	IN	O
PRO10096;	DT	O
PRO21384;	NN	O
PRO353	NN	O
or	VBN	O
PRO1885	CC	O
Polypeptides	DT	O
Nucleotide	JJ	O
sequences	,	O
(or	,	O
their	,	O
complement)	,	O
encoding	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	CC	O
PRO7423,	NNP	O
PRO10096,	RB	O
PRO21384,	.	O
PRO353	NNP	O
or	VBZ	O
PRO1885	IN	O
polypeptides	,	O
have	,	O
various	,	O
applications	,	O
in	,	O
the	:	O
art	:	O
of	:	O
molecular	NNP	O
biology,	CC	O
including	NNP	O
uses	NNP	O
as	NNP	O
hybridization	NNS	O
probes,	CC	O
in	PRP$	O
chromosome	)	O
and	VBG	O
gene	,	O
mapping	,	O
and	,	O
in	,	O
the	,	O
generation	,	O
of	,	O
anti-sense	,	O
RNA	NNP	O
and	CC	O
DNA.	NNP	O
PRO227,	NNS	O
PRO233,	VBP	O
PRO238,	JJ	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	JJ	O
or	,	O
PRO1885	VBG	O
nucleic	NNS	O
acid	IN	O
will	NN	O
also	,	O
be	IN	O
useful	NN	O
for	CC	O
the	NN	O
preparation	NN	O
of	CC	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	.	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
by	,	O
the	,	O
recombinant	,	O
techniques	,	O
described	NNP	O
herein.	CC	O
The	NNP	O
full-length	JJ	O
native	NN	O
sequence	MD	O
PRO227,	RB	O
PRO233,	VB	O
PRO238,	JJ	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene,	,	O
or	,	O
portions	,	O
thereof,	,	O
may	NNP	O
be	CC	O
used	NNP	O
as	NNS	O
hybridization	IN	O
probes	DT	O
for	NN	O
a	NNS	O
cDNA	VBN	O
library	.	O
to	DT	O
isolate	JJ	O
the	JJ	O
full-length	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
cDNA	,	O
or	CC	O
to	NNS	O
isolate	,	O
still	MD	O
other	VB	O
cDNAs	VBN	O
(for	IN	O
instance,	NN	O
those	NNS	O
encoding	IN	O
naturally-occurring	DT	O
variants	NN	O
of	NN	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	DT	O
PRO1328,	JJ	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
or	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NN	O
PRO1328,	CC	O
PRO4342,	TO	O
PRO7423,	VB	O
PRO10096,	RB	O
PRO21384,	JJ	O
PRO353	NN	O
or	IN	O
PRO1885	,	O
polypeptides	DT	O
from	VBG	O
other	JJ	O
species)	NNS	O
which	IN	O
have	,	O
a	,	O
desired	,	O
sequence	,	O
identity	,	O
to	,	O
the	,	O
native	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	NNS	O
PRO4342,	CC	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
sequence	,	O
disclosed	,	O
herein.	NNP	O
Optionally,	CC	O
the	NNP	O
length	NNS	O
of	IN	O
the	JJ	O
probes	)	O
will	WDT	O
be	VBP	O
about	DT	O
20	VBN	O
to	NN	O
about	NN	O
50	TO	O
bases.	DT	O
The	JJ	O
hybridization	,	O
probes	,	O
may	,	O
be	,	O
derived	,	O
from	,	O
at	,	O
least	,	O
partially	NNP	O
novel	CC	O
regions	NNP	O
of	NN	O
the	VBD	O
full	.	O
length	,	O
native	DT	O
nucleotide	NN	O
sequence	IN	O
wherein	DT	O
those	NNS	O
regions	MD	O
may	VB	O
be	RB	O
determined	CD	O
without	TO	O
undue	IN	O
experimentation	CD	O
or	.	O
from	DT	O
genomic	NN	O
sequences	NNS	O
including	MD	O
promoters,	VB	O
enhancer	VBN	O
elements	IN	O
and	IN	O
introns	JJS	O
of	RB	O
native	JJ	O
sequence	NNS	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	JJ	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	VBD	O
PRO353	DT	O
or	NNS	O
PRO1885.	MD	O
By	VB	O
way	VBN	O
of	IN	O
example,	JJ	O
a	NN	O
screening	CC	O
method	IN	O
will	JJ	O
comprise	NNS	O
isolating	VBG	O
the	,	O
coding	JJ	O
region	NNS	O
of	CC	O
the	NNS	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene	NNP	O
using	CC	O
the	.	O
known	IN	O
DNA	NN	O
sequence	IN	O
to	,	O
synthesize	DT	O
a	NN	O
selected	NN	O
probe	MD	O
of	VB	O
about	VBG	O
40	DT	O
bases.	VBG	O
Hybridization	NN	O
probes	IN	O
may	DT	O
be	,	O
labeled	,	O
by	,	O
a	,	O
variety	,	O
of	,	O
labels,	,	O
including	,	O
radionucleotides	NNP	O
such	CC	O
as	NNP	O
32P	NN	O
or	VBG	O
35S,	DT	O
or	VBN	O
enzymatic	NNP	O
labels	NN	O
such	TO	O
as	VB	O
alkaline	DT	O
phosphatase	JJ	O
coupled	NN	O
to	IN	O
the	IN	O
probe	CD	O
via	.	O
avidin/biotin	NNP	O
coupling	NNS	O
systems.	MD	O
Labeled	VB	O
probes	VBN	O
having	IN	O
a	DT	O
sequence	NN	O
complementary	IN	O
to	,	O
that	VBG	O
of	NNS	O
the	JJ	O
PRO227,	IN	O
PRO233,	CD	O
PRO238,	CC	O
PRO1328,	,	O
PRO4342,	CC	O
PRO7423,	JJ	O
PRO10096,	NNS	O
PRO21384,	JJ	O
PRO353	IN	O
or	JJ	O
PRO1885	NN	O
gene	VBN	O
of	TO	O
the	DT	O
present	NN	O
invention	IN	O
can	JJ	O
be	VBG	O
used	.	O
to	VBN	O
screen	NNS	O
libraries	VBG	O
of	DT	O
human	NN	O
cDNA,	NN	O
genomic	TO	O
DNA	DT	O
or	IN	O
mRNA	DT	O
to	,	O
determine	,	O
which	,	O
members	,	O
of	,	O
such	,	O
libraries	,	O
the	,	O
probe	NNP	O
hybridizes	CC	O
to.	NNP	O
Hybridization	NN	O
techniques	IN	O
are	DT	O
described	JJ	O
in	NN	O
further	MD	O
detail	VB	O
in	VBN	O
the	TO	O
Examples	JJ	O
below.	NNS	O
Any	IN	O
EST	JJ	O
sequences	,	O
disclosed	JJ	O
in	NN	O
the	CC	O
present	NN	O
application	TO	O
may	VB	O
similarly	WDT	O
be	NNS	O
employed	IN	O
as	JJ	O
probes,	NNS	O
using	DT	O
the	NN	O
methods	VBZ	O
disclosed	.	O
herein.	NN	O
Other	NNS	O
useful	VBP	O
fragments	VBN	O
of	IN	O
the	JJ	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NNP	O
PRO4342,	.	O
PRO7423,	DT	O
PRO10096,	NNP	O
PRO21384,	NNS	O
PRO353	VBD	O
or	IN	O
PRO1885	DT	O
nucleic	JJ	O
acids	NN	O
include	MD	O
antisense	RB	O
or	VB	O
sense	VBN	O
oligonucleotides	IN	O
comprising	,	O
a	VBG	O
singe-stranded	DT	O
nucleic	NNS	O
acid	VBD	O
sequence	.	O
(either	JJ	O
RNA	JJ	O
or	NNS	O
DNA)	IN	O
capable	DT	O
of	,	O
binding	,	O
to	,	O
target	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	JJ	O
PRO353	NNS	O
or	VBP	O
PRO1885	NN	O
mRNA	CC	O
(sense)	NN	O
or	NNS	O
PRO227,	VBG	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	NN	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	CC	O
or	)	O
PRO1885	NN	O
DNA	IN	O
(antisense)	VBG	O
sequences.	TO	O
Antisense	VB	O
or	,	O
sense	,	O
oligonucleotides,	,	O
according	,	O
to	,	O
the	,	O
present	,	O
invention,	,	O
comprise	NNP	O
a	CC	O
fragment	NNP	O
of	NN	O
the	)	O
coding	CC	O
region	,	O
of	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	NNP	O
PRO1885	)	O
DNA.	.	O
Such	NNP	O
a	CC	O
fragment	NN	O
generally	,	O
comprises	VBG	O
at	TO	O
least	DT	O
about	JJ	O
14	,	O
nucleotides,	VB	O
preferably	DT	O
from	NN	O
about	IN	O
14	DT	O
to	VBG	O
30	NN	O
nucleotides.	IN	O
The	,	O
ability	,	O
to	,	O
derive	,	O
an	,	O
antisense	,	O
or	,	O
a	,	O
sense	NNP	O
oligonucleotide,	CC	O
based	NNP	O
upon	.	O
a	JJ	O
cDNA	DT	O
sequence	NN	O
encoding	RB	O
a	VBZ	O
given	IN	O
protein	JJS	O
is	IN	O
described	CD	O
in,	,	O
for	RB	O
example,	IN	O
Stein	RB	B
and	CD	I
Cohen	TO	I
(Cancer	CD	I
Res.	.	I
48:2659,	DT	I
1988)	NN	I
and	TO	O
van	VB	B
der	DT	I
Krol	NN	I
et	CC	I
al.	DT	I
(BioTechniques	NN	I
6:958,	,	I
1988).
Binding	VBN	O
of	IN	O
antisense	DT	O
or	NN	O
sense	NN	O
oligonucleotides	VBG	O
to	DT	O
target	VBN	O
nucleic	NN	O
acid	VBZ	O
sequences	VBN	O
results	,	O
in	IN	O
the	,	O
formation	NNP	O
of	CC	O
duplexes	NNP	O
that	NNP	O
block	.	O
transcription	,	O
or	)	O
translation	CC	O
of	JJ	O
the	NN	O
target	NNP	O
sequence	VBZ	O
by	.	O
one	NNS	O
of	,	O
several	.	O
means,	NNP	O
including	IN	O
enhanced	NN	O
degradation	CC	O
of	NN	O
the	NNS	O
duplexes,	TO	O
premature	VB	O
termination	JJ	O
of	JJ	O
transcription	NNS	O
or	NNS	O
translation,	IN	O
or	DT	O
by	NN	O
other	IN	O
means.	NNS	O
The	WDT	O
antisense	VBP	O
oligonucleotides	NN	O
thus	CC	O
may	NN	O
be	IN	O
used	DT	O
to	NN	O
block	NN	O
expression	IN	O
of	CD	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	,	O
PRO1328,	VBG	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	,	O
or	JJ	O
PRO1885.	NN	O
Antisense	IN	O
or	NN	O
sense	CC	O
oligonucleotides	,	O
further	CC	O
comprise	IN	O
oligonucleotides	JJ	O
having	.	O
modified	DT	O
sugar-phosphodiester	NN	O
backbones	VBZ	O
(or	RB	O
other	MD	O
sugar	VB	O
linkages,	VBN	O
such	TO	O
as	VB	O
those	NN	O
described	IN	O
in	,	O
WO	,	O
91/06629)	,	O
and	,	O
wherein	,	O
such	,	O
sugar	,	O
linkages	,	O
are	NNP	O
resistant	CC	O
to	.	O
endogenous	NNP	O
nucleases.	CC	O
Such	NN	O
oligonucleotides	IN	O
with	JJ	O
resistant	NN	O
sugar	NNS	O
linkages	VBG	O
are	VBN	O
stable	JJ	O
in	NNS	O
vivo	CC	O
(i.e.,	JJ	O
capable	NN	O
of	,	O
resisting	JJ	O
enzymatic	IN	O
degradation)	DT	O
but	VBN	O
retain	IN	O
sequence	NNP	O
specificity	)	O
to	CC	O
be	$	O
able	JJ	O
to	NN	O
bind	NNS	O
to	VBP	O
target	JJ	O
nucleotide	TO	O
sequences.	JJ	O
Other	.	O
examples	JJ	O
of	NNS	O
sense	IN	O
or	JJ	O
antisense	NN	O
oligonucleotides	NNS	O
include	VBP	O
those	JJ	O
oligonucleotides	IN	O
which	NN	O
are	,	O
covalently	JJ	O
linked	IN	O
to	VBG	O
organic	JJ	O
moieties,	)	O
such	CC	O
as	VBP	O
those	JJ	O
described	NN	O
in	TO	O
WO	VB	O
90/10048,	JJ	O
and	TO	O
other	VB	O
moieties	TO	O
that	VB	O
increases	JJ	O
affinity	.	O
of	JJ	O
the	NNS	O
oligonucleotide	IN	O
for	NN	O
a	CC	O
target	NN	O
nucleic	NNS	O
acid	VBP	O
sequence,	DT	O
such	NNS	O
as	WDT	O
poly-(L-lysine).	VBP	O
Further	RB	O
still,	VBN	O
intercalating	TO	O
agents,	JJ	O
such	,	O
as	JJ	O
ellipticine,	IN	O
and	DT	O
alkylating	VBN	O
agents	IN	O
or	NNP	O
metal	,	O
complexes	CC	O
may	JJ	O
be	NNS	O
attached	WDT	O
to	VBZ	O
sense	NN	O
or	IN	O
antisense	DT	O
oligonucleotides	NN	O
to	IN	O
modify	DT	O
binding	NN	O
specificities	JJ	O
of	JJ	O
the	,	O
antisense	JJ	O
or	IN	O
sense	.	O
oligonucleotide	RB	O
for	,	O
the	VBG	O
target	,	O
nucleotide	JJ	O
sequence.	IN	O
Antisense	,	O
or	CC	O
sense	VBG	O
oligonucleotides	NNS	O
may	CC	O
be	NN	O
introduced	NNS	O
into	MD	O
a	VB	O
cell	VBN	O
containing	TO	O
the	VB	O
target	CC	O
nucleic	VB	O
acid	NNS	O
sequence	TO	O
by	VB	O
any	VBG	O
gene	NNS	O
transfer	IN	O
method,	DT	O
including,	NN	O
for	CC	O
example,	NN	O
CaPO4-mediated	NN	O
DNA	IN	O
transfection,	DT	O
electroporation,	NN	O
or	JJ	O
by	.	O
using	NNP	O
gene	CC	O
transfer	NN	O
vectors	NNS	O
such	MD	O
as	VB	O
Epstein-Barr	VBN	O
virus.	IN	O
In	DT	O
a	NN	O
preferred	VBG	O
procedure,	DT	O
an	NN	O
antisense	JJ	O
or	JJ	O
sense	NN	O
oligonucleotide	IN	O
is	DT	O
inserted	NN	O
into	NN	O
a	,	O
suitable	,	O
retroviral	IN	O
vector.	,	O
A	JJ	O
cell	NNP	O
containing	,	O
the	,	O
target	CC	O
nucleic	IN	O
acid	VBG	O
sequence	NN	O
is	NN	O
contacted	NNS	O
with	JJ	O
the	IN	O
recombinant	NNP	O
retroviral	.	O
vector,	IN	O
either	DT	O
in	JJ	O
vivo	,	O
or	DT	O
ex	NN	O
vivo.	CC	O
Suitable	NN	O
retroviral	NN	O
vectors	VBZ	O
include,	VBN	O
but	IN	O
are	DT	O
not	JJ	O
limited	JJ	O
to,	.	O
those	DT	O
derived	NN	O
from	VBG	O
the	DT	O
murine	NN	O
retrovirus	JJ	O
M-MuLV,	JJ	O
N2	NN	O
(a	VBZ	O
retrovirus	VBN	O
derived	IN	O
from	DT	O
M-MuLV),	JJ	O
or	JJ	O
the	,	O
double	RB	O
copy	IN	O
vectors	NN	O
designated	CC	O
DCT5A,	NN	O
DCT5B	.	O
and	JJ	O
DCT5C	JJ	O
(see	NNS	O
WO	,	O
90/13641).	CC	O
Sense	VBP	O
or	RB	O
antisense	VBN	O
oligonucleotides	,	O
also	DT	O
may	VBN	O
be	IN	O
introduced	DT	O
into	NN	O
a	NN	O
cell	,	O
containing	NNP	O
the	DT	O
target	NN	O
nucleotide	VBN	O
sequence	IN	O
by	,	O
formation	CC	O
of	DT	O
a	JJ	O
conjugate	NN	O
with	NNS	O
a	VBD	O
ligand	,	O
binding	NNP	O
molecule,	CC	O
as	NNP	O
described	VB	O
in	NNP	O
WO	.	O
91/04753.	NN	O
Suitable	CC	O
ligand	NN	O
binding	NNS	O
molecules	RB	O
include,	MD	O
but	VB	O
are	VBN	O
not	IN	O
limited	DT	O
to,	NN	O
cell	VBG	O
surface	DT	O
receptors,	NN	O
growth	JJ	O
factors,	NN	O
other	IN	O
cytokines,	NN	O
or	IN	O
other	DT	O
ligands	NN	O
that	IN	O
bind	DT	O
to	NN	O
cell	NN	O
surface	,	O
receptors.	IN	O
Preferably,	VBN	O
conjugation	IN	O
of	NNP	O
the	.	O
ligand	JJ	O
binding	NN	O
molecule	VBG	O
does	NNS	O
not	,	O
substantially	CC	O
interfere	VBP	O
with	RB	O
the	VBN	O
ability	,	O
of	VB	O
the	NN	O
ligand	,	O
binding	NN	O
molecule	,	O
to	JJ	O
bind	,	O
to	CC	O
its	JJ	O
corresponding	NNS	O
molecule	WDT	O
or	VBP	O
receptor,	TO	O
or	VB	O
block	NN	O
entry	.	O
of	,	O
the	NN	O
sense	IN	O
or	DT	O
antisense	NN	O
oligonucleotide	VBG	O
or	NN	O
its	VBZ	O
conjugated	RB	O
version	RB	O
into	VB	O
the	IN	O
cell.	DT	O
Alternatively,	NN	O
a	IN	O
sense	DT	O
or	NN	O
an	VBG	O
antisense	NN	O
oligonucleotide	TO	O
may	VB	O
be	TO	O
introduced	PRP$	O
into	VBG	O
a	NN	O
cell	CC	O
containing	,	O
the	CC	O
target	VB	O
nucleic	NN	O
acid	IN	O
sequence	DT	O
by	NN	O
formation	CC	O
of	JJ	O
an	NN	O
oligonucleotide-lipid	CC	O
complex,	PRP$	O
as	JJ	O
described	NN	O
in	IN	O
WO	DT	O
90/10448.	.	O
The	,	O
sense	DT	O
or	NN	O
antisense	CC	O
oligonucleotide-lipid	DT	O
complex	JJ	O
is	NN	O
preferably	MD	O
dissociated	VB	O
within	VBN	O
the	IN	O
cell	DT	O
by	NN	O
an	VBG	O
endogenous	DT	O
lipase.	NN	O
Antisense	JJ	O
or	JJ	O
sense	NN	O
RNA	IN	O
or	NN	O
DNA	IN	O
molecules	DT	O
are	JJ	O
generally	,	O
at	IN	O
least	VBN	O
about	IN	O
5	NNP	O
bases	.	O
in	DT	O
length,	NN	O
about	CC	O
10	JJ	O
bases	JJ	O
in	NN	O
length,	VBZ	O
about	RB	O
15	VBN	O
bases	IN	O
in	DT	O
length,	NN	O
about	IN	O
20	DT	O
bases	JJ	O
in	.	O
length,	NNP	O
about	CC	O
25	NN	O
bases	NNPS	O
in	CC	O
length,	NNP	O
about	NNS	O
30	VBP	O
bases	RB	O
in	IN	O
length,	JJS	O
about	IN	O
35	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
40	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
45	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
50	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
55	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
60	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
65	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
70	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
75	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
80	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
85	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
90	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
95	CD	O
bases	NNS	O
in	IN	O
length,	,	O
about	RB	O
100	CD	O
bases	NNS	O
in	IN	O
length,	,	O
or	RB	O
more.	CD	O
The	NNS	O
probes	IN	O
may	,	O
also	RB	O
be	CD	O
employed	NNS	O
in	IN	O
PCR	,	O
techniques	RB	O
to	CD	O
generate	NNS	O
a	IN	O
pool	,	O
of	RB	O
sequences	CD	O
for	NNS	O
identification	IN	O
of	,	O
closely	RB	O
related	CD	O
PRO227,	NNS	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	RB	O
PRO4342,	CD	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	CC	O
or	.	O
PRO1885	DT	O
coding	NNS	O
sequences.	MD	O
Nucleotide	RB	O
sequences	VB	O
encoding	VBN	O
a	IN	O
PRO227,	NNP	O
PRO233,	NNS	O
PRO238,	TO	O
PRO1328,	VB	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	NNS	O
PRO353	IN	O
or	NN	O
PRO1885	IN	O
polypeptide	RB	O
can	JJ	O
also	,	O
be	,	O
used	,	O
to	,	O
construct	,	O
hybridization	,	O
probes	,	O
for	,	O
mapping	NNP	O
the	CC	O
gene	NNP	O
which	VBG	O
encodes	.	O
that	NNP	O
PRO227,	VBZ	O
PRO233,	VBG	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	NNP	O
and	CC	O
for	NNP	O
the	NN	O
genetic	MD	O
analysis	RB	O
of	VB	O
individuals	VBN	O
with	TO	O
genetic	VB	O
disorders.	NN	O
The	NNS	O
nucleotide	IN	O
sequences	VBG	O
provided	DT	O
herein	NN	O
may	WDT	O
be	VBZ	O
mapped	IN	O
to	,	O
a	,	O
chromosome	,	O
and	,	O
specific	,	O
regions	,	O
of	,	O
a	,	O
chromosome	NNP	O
using	CC	O
known	NNP	O
techniques,	NN	O
such	CC	O
as	IN	O
in	DT	O
situ	JJ	O
hybridization,	NN	O
linkage	IN	O
analysis	NNS	O
against	IN	O
known	JJ	O
chromosomal	.	O
markers,	DT	O
and	JJ	O
hybridization	NNS	O
screening	VBD	O
with	NN	O
libraries.	MD	O
When	VB	O
the	VBN	O
coding	TO	O
sequences	DT	O
for	NN	O
PRO227,	CC	O
PRO233,	JJ	O
PRO238,	NNS	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	VBG	O
PRO21384,	VBN	O
PRO353	,	O
or	JJ	O
PRO1885	IN	O
encode	IN	O
a	JJ	O
protein	,	O
which	NN	O
binds	NN	O
to	IN	O
another	VBN	O
protein	JJ	O
(for	,	O
example,	CC	O
where	NN	O
the	VBG	O
PRO227,	IN	O
PRO233,	.	O
PRO238,	WRB	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
is	,	O
a	,	O
receptor),	,	O
the	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	VBP	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	WDT	O
PRO21384,	VBZ	O
PRO353	TO	O
or	DT	O
PRO1885	NN	O
polypeptide	IN	O
can	,	O
be	WRB	O
used	DT	O
in	,	O
assays	,	O
to	,	O
identify	,	O
the	,	O
other	,	O
proteins	,	O
or	,	O
molecules	NNP	O
involved	CC	O
in	NNP	O
the	VBZ	O
binding	DT	O
interaction.	,	O
By	DT	O
such	,	O
methods,	,	O
inhibitors	,	O
of	,	O
the	,	O
receptor/ligand	,	O
binding	,	O
interaction	,	O
can	NNP	O
be	CC	O
identified.	NNP	O
Proteins	NN	O
involved	MD	O
in	VB	O
such	VBN	O
binding	IN	O
interactions	NNS	O
can	TO	O
also	VB	O
be	DT	O
used	JJ	O
to	NNS	O
screen	CC	O
for	NNS	O
peptide	VBN	O
or	IN	O
small	DT	O
molecule	NN	O
inhibitors	.	O
or	IN	O
agonists	JJ	O
of	,	O
the	NNS	O
binding	IN	O
interaction.	DT	O
Also,	NN	O
the	VBG	O
receptor	NN	O
PRO227,	MD	O
PRO233,	VB	O
PRO238,	.	O
PRO1328,	NNS	O
PRO4342,	VBN	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	JJ	O
PRO353	NNS	O
or	MD	O
PRO1885	RB	O
can	VB	O
be	VBN	O
used	TO	O
to	VB	O
isolate	IN	O
correlative	NN	O
ligand(s).	CC	O
Screening	JJ	O
assays	NN	O
can	NNS	O
be	CC	O
designed	NNS	O
to	IN	O
find	DT	O
lead	NN	O
compounds	.	O
that	,	O
mimic	DT	O
the	NN	O
biological	,	O
activity	,	O
of	,	O
a	,	O
native	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	CC	O
PRO7423,	NNP	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	VBN	O
or	TO	O
PRO1885	VB	O
polypeptide	JJ	O
or	.	O
a	VBG	O
receptor	NNS	O
for	MD	O
PRO227,	VB	O
PRO233,	VBN	O
PRO238,	TO	O
PRO1328,	VB	O
PRO4342,	JJ	O
PRO7423,	NNS	O
PRO10096,	WDT	O
PRO21384,	VBP	O
PRO353	DT	O
or	JJ	O
PRO1885	NN	O
polypeptides.	IN	O
Such	DT	O
screening	JJ	O
assays	,	O
will	,	O
include	,	O
assays	,	O
amenable	,	O
to	,	O
high-throughput	,	O
screening	,	O
of	NNP	O
chemical	CC	O
libraries,	NNP	O
making	VBP	O
them	CC	O
particularly	DT	O
suitable	NN	O
for	IN	O
identifying	,	O
small	,	O
molecule	,	O
drug	,	O
candidates.	,	O
Small	,	O
molecules	,	O
contemplated	,	O
include	NNP	O
synthetic	CC	O
organic	NNP	O
or	.	O
inorganic	JJ	O
compounds.	NN	O
The	NNS	O
assays	MD	O
can	VB	O
be	NNS	O
performed	JJ	O
in	TO	O
a	JJ	O
variety	NN	O
of	IN	O
formats,	NN	O
including	,	O
protein-protein	VBG	O
binding	PRP	O
assays,	RB	O
biochemical	JJ	O
screening	IN	O
assays,	VBG	O
immunoassays	JJ	O
and	JJ	O
cell	NN	O
based	.	O
assays,	JJ	O
which	NNS	O
are	VBN	O
well	VBP	O
characterized	JJ	O
in	JJ	O
the	CC	O
art.	JJ	O
Nucleic	.	O
acids	DT	O
which	NNS	O
encode	MD	O
PRO227,	VB	O
PRO233,	VBN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	,	O
PRO21384,	VBG	O
PRO353	JJ	O
or	NN	O
PRO1885	,	O
polypeptides	JJ	O
or	NN	O
its	,	O
modified	NNS	O
forms	CC	O
can	NN	O
also	VBN	O
be	,	O
used	WDT	O
to	VBP	O
generate	RB	O
either	VBN	O
transgenic	IN	O
animals	DT	O
or	.	O
“knock	NNP	O
out”	NNS	O
animals	WDT	O
which,	VBP	O
in	,	O
turn,	,	O
are	,	O
useful	,	O
in	,	O
the	,	O
development	,	O
and	,	O
screening	NNP	O
of	CC	O
therapeutically	NNP	O
useful	NNS	O
reagents.	CC	O
A	PRP$	O
transgenic	JJ	O
animal	NNS	O
(e.g.,	MD	O
a	RB	O
mouse	VB	O
or	VBN	O
rat)	TO	O
is	VB	O
an	DT	O
animal	JJ	O
having	NNS	O
cells	CC	O
that	NNP	O
contain	NN	O
a	NNS	O
transgene,	,	O
which	IN	O
transgene	,	O
was	VBP	O
introduced	JJ	O
into	IN	O
the	DT	O
animal	NN	O
or	CC	O
an	NN	O
ancestor	IN	O
of	RB	O
the	JJ	O
animal	.	O
at	DT	O
a	JJ	O
prenatal,	NN	O
e.g.,	,	O
an	DT	O
embryonic	NN	O
stage.	CC	O
A	)	O
transgene	VBZ	O
is	DT	O
a	JJ	O
DNA	VBG	O
which	NNS	O
is	WDT	O
integrated	VBP	O
into	DT	O
the	,	O
genome	WDT	O
of	NN	O
a	VBD	O
cell	VBN	O
from	IN	O
which	DT	O
a	NN	O
transgenic	CC	O
animal	DT	O
develops.	NN	O
The	IN	O
invention	DT	O
provides	NN	O
cDNA	IN	O
encoding	DT	O
a	,	O
PRO227,	,	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	.	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	VBZ	O
PRO21384,	DT	O
PRO353	NN	O
or	WDT	O
PRO1885	VBZ	O
polypeptide	VBN	O
which	IN	O
can	DT	O
be	NN	O
used	IN	O
to	DT	O
clone	NN	O
genomic	IN	O
DNA	WDT	O
encoding	DT	O
a	NN	O
PRO227,	NN	O
PRO233,	.	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	NN	O
PRO10096,	VBG	O
PRO21384,	DT	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
in	,	O
accordance	,	O
with	,	O
established	,	O
techniques	NNP	O
and	CC	O
the	NNP	O
genomic	IN	O
sequences	WDT	O
used	MD	O
to	VB	O
generate	VBN	O
transgenic	TO	O
animals	VB	O
that	JJ	O
contain	NNP	O
cells	VBG	O
which	DT	O
express	,	O
DNA	,	O
encoding	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	VBP	O
or	IN	O
PRO1885	NN	O
polypeptides.	IN	O
Any	VBN	O
technique	NNS	O
known	CC	O
in	DT	O
the	JJ	O
art	NNS	O
may	VBN	O
be	TO	O
used	VB	O
to	JJ	O
introduce	NNS	O
a	WDT	O
target	VBP	O
gene	NNS	O
transgene	WDT	O
into	VBP	O
animals	NNP	O
to	VBG	O
produce	,	O
the	,	O
founder	,	O
lines	,	O
of	,	O
transgenic	,	O
animals.	,	O
Such	,	O
techniques	NNP	O
include,	CC	O
but	NNP	O
are	.	O
not	DT	O
limited	NN	O
to	VBN	O
pronuclear	IN	O
microinjection	DT	O
(U.S.	NN	O
Pat.	MD	O
Nos.	VB	O
4,873,191,	VBN	O
4,736,866	TO	O
and	VB	O
4,870,009);	DT	O
retrovirus	NN	O
mediated	NN	O
gene	NN	O
transfer	IN	O
into	NNS	O
germ	TO	O
lines	VB	O
Van	DT	B
der	NN	I
Putten,	NNS	I
et	IN	I
al.,	JJ	I
Proc.	.	I
Natl.	JJ	I
Acad.	NNS	I
Sci.,	,	I
USA,	CC	I
82:6148-6152	VBP	I
(1985));(	RB	O
gene	VBN	O
targeting	TO	O
in	VB	O
embryonic	NN	O
stem	NNP	O
cells	.	O
Thompson,	.	B
et	,	I
al.,	CD	I
Cell,	CC	I
56:313-321	:	I
(1989));(	NN	O
nonspecific	VBD	O
insertional	NN	O
inactivation	NN	O
using	IN	O
a	JJ	O
gene	NNS	O
trap	NNP	O
vector	NN	O
(U.S.	,	O
Pat.	FW	O
No.	,	O
6,436,707);	.	O
electroporation	.	O
of	.	O
embryos	,	O
Lo,	,	B
Mol.	CD	I
Cell.	:	I
Biol.,	NN	I
3:1803-1814	VBG	I
(1983));(	IN	O
and	JJ	O
sperm-mediated	NN	O
gene	NNS	O
transfer	,	O
Lavitrano,	FW	B
et	,	I
al.,	,	I
Cell,	NNP	I
57:717-723	:	I
(1989));(	JJ	O
etc.	JJ	O
Typically,	NN	O
particular	VBG	O
cells	DT	O
would	NN	O
be	NN	O
targeted	NN	O
for	NNP	O
a	.	O
PRO227,	.	O
PRO233,	:	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	NN	O
PRO7423,	,	O
PRO10096,	.	O
PRO21384,	.	O
PRO353	,	O
or	NNP	O
PRO1885	:	O
transgene	CC	O
incorporation	JJ	O
with	NN	O
tissue-specific	NN	O
enhancers.	,	O
Transgenic	FW	O
animals	,	O
that	,	O
include	NNP	O
a	:	O
copy	.	O
of	,	O
a	JJ	O
transgene	NNS	O
encoding	MD	O
a	VB	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	NNP	O
introduced	CC	O
into	NNP	O
the	JJ	O
germ	NN	O
line	IN	O
of	JJ	O
the	.	O
animal	JJ	O
at	NNS	O
an	WDT	O
embryonic	VBP	O
stage	DT	O
can	NN	O
be	IN	O
used	DT	O
to	NN	O
examine	VBG	O
the	DT	O
effect	,	O
of	,	O
increased	,	O
expression	,	O
of	,	O
DNA	,	O
encoding	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	RB	O
PRO7423,	VBD	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	JJ	O
or	NN	O
PRO1885	IN	O
polypeptides.	DT	O
Such	NN	O
animals	IN	O
can	DT	O
be	JJ	O
used	NN	O
as	MD	O
tester	VB	O
animals	VBN	O
for	TO	O
reagents	VB	O
thought	DT	O
to	NN	O
confer	IN	O
protection	JJ	O
from,	NN	O
for	IN	O
example,	NNP	O
pathological	VBG	O
conditions	,	O
associated	,	O
with	,	O
its	,	O
overexpression.	,	O
In	,	O
accordance	,	O
with	,	O
this	NNP	O
facet	CC	O
of	NNP	O
the	.	O
invention,	JJ	O
an	NNS	O
animal	MD	O
is	VB	O
treated	VBN	O
with	IN	O
the	NN	O
reagent	NNS	O
and	IN	O
a	NNS	O
reduced	VBN	O
incidence	TO	O
of	VB	O
the	NN	O
pathological	,	O
condition,	IN	O
compared	,	O
to	JJ	O
untreated	NNS	O
animals	VBN	O
bearing	IN	O
the	PRP$	O
transgene,	.	O
would	IN	O
indicate	NN	O
a	IN	O
potential	DT	O
therapeutic	NN	O
intervention	IN	O
for	DT	O
the	,	O
pathological	DT	O
condition.	NN	O
Alternatively,	VBZ	O
non-human	VBN	O
homologues	IN	O
of	DT	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	DT	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	,	O
or	VBN	O
PRO1885	TO	O
polypeptides	JJ	O
can	NNS	O
be	VBG	O
used	DT	O
to	,	O
construct	MD	O
a	VB	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	.	O
PRO353	,	O
or	JJ	O
PRO1885	NNS	O
“knock	IN	O
out”	,	O
animal	,	O
which	,	O
has	,	O
a	,	O
defective	,	O
or	,	O
altered	,	O
gene	NNP	O
encoding	CC	O
PRO227,	NNP	O
PRO233,	NNS	O
PRO238,	MD	O
PRO1328,	VB	O
PRO4342,	VBN	O
PRO7423,	TO	O
PRO10096,	VB	O
PRO21384,	DT	O
PRO353	,	O
or	,	O
PRO1885	,	O
proteins	,	O
as	,	O
a	,	O
result	,	O
of	,	O
homologous	NNP	O
recombination	CC	O
between	NNP	O
the	NNP	O
endogenous	NNP	O
gene	NN	O
encoding	WDT	O
PRO227,	VBZ	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	CC	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	VBG	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
and	,	O
altered	,	O
genomic	,	O
DNA	NNP	O
encoding	CC	O
PRO227,	NNP	O
PRO233,	VBZ	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	IN	O
or	DT	O
PRO1885	JJ	O
polypeptides	NN	O
introduced	VBG	O
into	,	O
an	,	O
embryonic	,	O
stem	,	O
cell	,	O
of	,	O
the	,	O
animal.	,	O
Preferably	NNP	O
the	CC	O
knock	NNP	O
out	NNS	O
animal	CC	O
is	JJ	O
a	JJ	O
mammal.	NN	O
More	VBG	O
preferably,	,	O
the	,	O
mammal	,	O
is	,	O
a	,	O
rodent	,	O
such	,	O
as	,	O
a	NNP	O
rat	CC	O
or	NNP	O
mouse.	NNS	O
For	VBD	O
example,	IN	O
cDNA	DT	O
encoding	JJ	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	.	O
PRO7423,	RB	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	RP	O
or	NN	O
PRO1885	VBZ	O
polypeptides	DT	O
can	.	O
be	RBR	O
used	,	O
to	DT	O
clone	NN	O
genomic	VBZ	O
DNA	DT	O
encoding	NN	O
PRO227,	JJ	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	.	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	NN	O
or	VBG	O
PRO1885	,	O
polypeptides	,	O
in	,	O
accordance	,	O
with	,	O
established	,	O
techniques.	,	O
A	,	O
portion	NNP	O
of	CC	O
the	NNP	O
genomic	NNS	O
DNA	MD	O
encoding	VB	O
the	VBN	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	JJ	O
PRO1328,	NNP	O
PRO4342,	VBG	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
can	,	O
be	NNP	O
deleted	CC	O
or	NNP	O
replaced	NNS	O
with	IN	O
another	NN	O
gene,	IN	O
such	VBN	O
as	.	O
a	DT	O
gene	NN	O
encoding	IN	O
a	DT	O
selectable	JJ	O
marker	NNP	O
which	VBG	O
can	DT	O
be	,	O
used	,	O
to	,	O
monitor	,	O
integration.	,	O
Typically,	,	O
several	,	O
kilobases	,	O
of	NNP	O
unaltered	CC	O
flanking	NNP	O
DNA	NN	O
(both	MD	O
at	VB	O
the	VBN	O
5′	CC	O
and	VBN	O
3′	IN	O
ends)	DT	O
are	,	O
included	JJ	O
in	IN	O
the	DT	O
vector	NN	O
[see	VBG	O
e.g.,	DT	O
Thomas	JJ	B
and	NN	I
Capecchi,	WDT	I
Cell,	MD	I
51:503	VB	I
(1987)	VBN	I
for	TO	O
a	VB	O
description	.	O
of	,	O
homologous	JJ	O
recombination	NNS	O
vectors].	IN	O
The	JJ	O
vector	NN	O
is	NN	O
introduced	DT	O
into	IN	O
an	DT	O
embryonic	CD	O
stem	CC	O
cell	CD	O
line	)	O
(e.g.,	VBP	O
by	VBN	O
electroporation)	IN	O
and	DT	O
cells	NN	O
in	NN	O
which	,	O
the	NNP	O
introduced	CC	O
DNA	,	O
has	,	O
homologously	CD	O
recombined	)	O
with	IN	O
the	DT	O
endogenous	NN	O
DNA	IN	O
are	JJ	O
selected	NN	O
[see	.	O
e.g.,	DT	O
Li	NN	B
et	VBZ	I
al.,	VBN	I
Cell,	IN	I
69:915	DT	I
(1992)].The	JJ	O
selected	NN	O
cells	NN	O
are	NN	O
then	,	O
injected	IN	O
into	)	O
a	CC	O
blastocyst	NNS	O
of	IN	O
an	WDT	O
animal	DT	O
(e.g.,	VBN	O
a	NNP	O
mouse	VBZ	O
or	RB	O
rat)	VBN	O
to	IN	O
form	DT	O
aggregation	JJ	O
chimeras	NN	O
[see	VBP	O
e.g.,	VBN	O
Bradley,	VBP	B
in	,	I
Teratocarcinomas	NNP	I
and	FW	I
Embryonic	,	I
Stem	,	I
Cells:	CD	I
A	.	I
Practical	DT	I
Approach,	VBN	I
E.	NNS	I
J.	VBP	I
Robertson,	RB	I
ed.	VBN	I
(IRL,	IN	I
Oxford,	DT	I
1987),	NN	I
pp.	IN	I
113-152].A	DT	O
chimeric	NN	O
embryo	,	O
can	DT	O
then	NN	O
be	CC	O
implanted	)	O
into	TO	O
a	VB	O
suitable	NN	O
pseudopregnant	NNS	O
female	VB	O
foster	,	O
animal	,	O
and	IN	O
the	NNP	O
embryo	CC	O
brought	NNP	O
to	NNP	O
term	:	O
to	DT	O
create	NNP	O
a	,	O
“knock	NNP	O
out”	NNP	O
animal.	,	O
Progeny	.	O
harboring	,	O
the	,	O
homologously	,	O
recombined	.	O
DNA	.	O
in	DT	O
their	JJ	O
germ	NN	O
cells	MD	O
can	RB	O
be	VB	O
identified	VBN	O
by	IN	O
standard	DT	O
techniques	JJ	O
and	JJ	O
used	NN	O
to	NN	O
breed	NN	O
animals	CC	O
in	DT	O
which	NN	O
all	VBD	O
cells	TO	O
of	NN	O
the	TO	O
animal	VB	O
contain	DT	O
the	NN	O
homologously	NN	O
recombined	.	O
DNA.	NNP	O
Knockout	VBG	O
animals	DT	O
can	RB	O
be	VBN	O
characterized	NNP	O
for	IN	O
instance,	PRP$	O
for	JJ	O
their	NNS	O
ability	MD	O
to	VB	O
defend	VBN	O
against	IN	O
certain	JJ	O
pathological	NNS	O
conditions	CC	O
and	VBN	O
for	TO	O
their	VB	O
development	NNS	O
of	IN	O
pathological	WDT	O
conditions	DT	O
due	NNS	O
to	IN	O
absence	DT	O
of	NN	O
the	VBP	O
gene	DT	O
encoding	RB	O
the	VBN	O
PRO227,	.	O
PRO233,	IN	O
PRO238,	NNS	O
PRO1328,	MD	O
PRO4342,	VB	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	IN	O
or	PRP$	O
PRO1885	NN	O
polypeptide.	TO	O
In	VB	O
addition,	IN	O
knockout	JJ	O
mice	JJ	O
can	NNS	O
be	CC	O
highly	IN	O
informative	PRP$	O
in	NN	O
the	IN	O
discovery	JJ	O
of	NNS	O
gene	JJ	O
function	TO	O
and	NN	O
pharmaceutical	IN	O
utility	DT	O
for	NN	O
a	VBG	O
drug	DT	O
target,	,	O
as	,	O
well	,	O
as	,	O
in	,	O
the	,	O
determination	,	O
of	,	O
the	NNP	O
potential	CC	O
on-target	NNP	O
side	.	O
effects	IN	O
associated	,	O
with	IN	O
a	NNS	O
given	MD	O
target.	VB	O
Gene	RB	O
function	JJ	O
and	IN	O
physiology	DT	O
are	NN	O
so	IN	O
well	NN	O
conserved	NN	O
between	CC	O
mice	JJ	O
and	NN	O
humans.,	IN	O
since	DT	O
they	NN	O
are	,	O
both	RB	O
mammals	RB	O
and	IN	O
contain	IN	O
similar	DT	O
numbers	NN	O
of	IN	O
genes,	DT	O
which	JJ	O
are	JJ	O
highly	NN	O
conserved	NNS	O
between	VBN	O
the	IN	O
species.	DT	O
It	VBN	O
has	.	O
recently	NNP	O
been	NN	O
well	CC	O
documented,	NN	O
for	VBP	O
example,	RB	O
that	RB	O
98%	VBN	O
of	IN	O
genes	NNS	O
on	CC	O
mouse	,	O
chromosome	IN	O
16	PRP	O
have	VBP	O
a	DT	O
human	NNS	O
ortholog	CC	O
Mural	VB	B
et	JJ	I
al.,	NNS	I
Science	IN	I
296:1661-71	,	I
(2002)).(	WDT	O
Although	VBP	O
gene	RB	O
targeting	VBN	O
in	IN	O
embryonic	DT	O
stem	.	O
(ES)	PRP	O
cells	VBZ	O
has	RB	O
enabled	VBN	O
the	RB	O
construction	,	O
of	IN	O
mice	,	O
with	IN	O
null	NN	O
mutations	IN	O
in	NNS	O
many	IN	O
genes	NN	O
associated	NN	O
with	CD	O
human	VBP	O
disease,	DT	O
not	JJ	O
all	NN	O
genetic	NNP	O
diseases	RB	O
are	,	O
attributable	NNP	O
to	CD	O
null	.	O
mutations.	IN	O
One	NN	O
can	VBG	O
design	IN	O
valuable	JJ	O
mouse	NN	O
models	)	O
of	NNS	O
human	VBZ	O
diseases	VBN	O
by	DT	O
establishing	NN	O
a	IN	O
method	NN	O
for	IN	O
gene	JJ	O
replacement	NNS	O
(knock-in)	IN	O
which	JJ	O
will	NNS	O
disrupt	VBN	O
the	IN	O
mouse	JJ	O
locus	,	O
and	RB	O
introduce	DT	O
a	JJ	O
human	NNS	O
counterpart	VBP	O
with	JJ	O
mutation,	TO	O
Subsequently	JJ	O
one	.	O
can	CD	O
conduct	MD	O
in	VB	O
vivo	JJ	O
drug	NN	O
studies	NNS	O
targeting	IN	O
the	JJ	O
human	NNS	O
protein	IN	O
Kitamoto	VBG	B
et.	DT	I
Al.,	NN	I
Biochemical	IN	I
and	NN	I
Biophysical	NN	I
Res.	)	I
Commun.,	WDT	I
222:742-47	MD	I
(1996)).(	VB	O
Nucleic	DT	O
acid	NN	O
encoding	NN	O
the	CC	O
PRO227,	VB	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	,	O
PRO10096,	RB	O
PRO21384,	CD	O
PRO353	MD	O
or	VB	O
PRO1885	IN	O
polypeptides	JJ	O
may	NN	O
also	NNS	O
be	VBG	O
used	DT	O
in	JJ	O
gene	NN	O
therapy.	NNP	O
In	.	O
gene	,	O
therapy	NNP	O
applications,	CC	O
genes	NNP	O
are	.	O
introduced	,	O
into	CD	O
cells	.	O
in	NNP	O
order	NN	O
to	VBG	O
achieve	DT	O
in	,	O
vivo	,	O
synthesis	,	O
of	,	O
a	,	O
therapeutically	,	O
effective	,	O
genetic	,	O
product,	NNP	O
for	CC	O
example	NNP	O
for	NNS	O
replacement	MD	O
of	RB	O
a	VB	O
defective	VBN	O
gene.	IN	O
“Gene	NN	O
therapy”	.	O
includes	IN	O
both	NN	O
conventional	NN	O
gene	,	O
therapy	NNS	O
where	VBP	O
a	VBN	O
lasting	IN	O
effect	NNS	O
is	IN	O
achieved	NN	O
by	TO	O
a	VB	O
single	IN	O
treatment,	JJ	O
and	NN	O
the	IN	O
administration	DT	O
of	RB	O
gene	JJ	O
therapeutic	JJ	O
agents,	,	O
which	IN	O
involves	NN	O
the	IN	O
one	NN	O
time	IN	O
or	DT	O
repeated	JJ	O
administration	.	O
of	JJ	O
a	NN	O
therapeutically	VBZ	O
effective	DT	O
DNA	JJ	O
or	NN	O
mRNA.	NN	O
Antisense	WRB	O
RNAs	DT	O
and	JJ	O
DNAs	NN	O
can	VBZ	O
be	VBN	O
used	IN	O
as	DT	O
therapeutic	JJ	O
agents	,	O
for	CC	O
blocking	DT	O
the	NN	O
expression	IN	O
of	NN	O
certain	JJ	O
genes	,	O
in	WDT	O
vivo.	VBZ	O
It	DT	O
has	CD	O
already	NN	O
been	CC	O
shown	VBN	O
that	NN	O
short	IN	O
antisense	DT	O
oligonucleotides	RB	O
can	JJ	O
be	NNP	O
imported	CC	O
into	.	O
cells	NNP	O
where	NNP	O
they	CC	O
act	NNP	O
as	MD	O
inhibitors,	VB	O
despite	VBN	O
their	IN	O
low	JJ	O
intracellular	NNS	O
concentrations	IN	O
caused	VBG	O
by	DT	O
their	NN	O
restricted	IN	O
uptake	JJ	O
by	NNS	O
the	IN	O
cell	.	O
membrane.	PRP	O
Zamecnik	VBZ	B
et	RB	I
al.,	VBN	I
Proc.	VBN	I
Natl.	IN	I
Acad.	JJ	I
Sci.	NN	I
USA	NNS	I
83:4143-4146	MD	I
[1986]).(	VB	O
The	VBN	O
oligonucleotides	IN	O
can	NNS	O
be	WRB	O
modified	PRP	O
to	VBP	O
enhance	IN	O
their	,	O
uptake,	IN	O
e.g.	PRP$	O
by	JJ	O
substituting	JJ	O
their	NNS	O
negatively	VBN	O
charged	IN	O
phosphodiester	PRP$	O
groups	VBN	O
by	NN	O
uncharged	IN	O
groups.	DT	O
There	NN	O
are	.	O
a	NNP	O
variety	RB	O
of	,	O
techniques	.	O
available	.	O
for	.	O
introducing	.	O
nucleic	NNP	O
acids	CD	O
into	.	O
viable	DT	O
cells.	NNS	O
The	MD	O
techniques	VB	O
vary	VBN	O
depending	TO	O
upon	VB	O
whether	PRP$	O
the	,	O
nucleic	.	O
acid	IN	O
is	VBG	O
transferred	PRP$	O
into	RB	O
cultured	VBN	O
cells	NN	O
in	NNS	O
vitro,	IN	O
or	JJ	O
in	.	O
vivo	EX	O
in	VBP	O
the	DT	O
cells	NN	O
of	IN	O
the	NNS	O
intended	JJ	O
host.	IN	O
Techniques	VBG	O
suitable	JJ	O
for	NNS	O
the	IN	O
transfer	JJ	O
of	.	O
nucleic	DT	O
acid	NNS	O
into	VBP	O
mammalian	VBG	O
cells	IN	O
in	IN	O
vitro	DT	O
include	JJ	O
the	NN	O
use	VBZ	O
of	VBN	O
liposomes,	IN	O
electroporation,	JJ	O
microinjection,	NNS	O
cell	IN	O
fusion,	,	O
DEAE-dextran,	CC	O
the	IN	O
calcium	NN	O
phosphate	IN	O
precipitation	DT	O
method,	NNS	O
etc.	IN	O
The	DT	O
currently	JJ	O
preferred	.	O
in	NNS	O
vivo	JJ	O
gene	IN	O
transfer	DT	O
techniques	NN	O
include	IN	O
transfection	JJ	O
with	NN	O
viral	IN	O
(typically	JJ	O
retroviral)	NNS	O
vectors	IN	O
and	JJ	O
viral	VBP	O
coat	DT	O
protein-liposome	NN	O
mediated	IN	O
transfection	,	O
Dzau	,	B
et	,	I
al.,	NN	I
Trends	,	I
in	,	I
Biotechnology	DT	I
11,	NN	I
205-210	NN	I
[1993]).(	NN	O
In	,	O
some	.	O
situations	DT	O
it	RB	O
is	VBN	O
desirable	IN	O
to	NN	O
provide	NN	O
the	NN	O
nucleic	NNS	O
acid	VBP	O
source	NN	O
with	IN	O
an	JJ	O
agent	RB	O
that	)	O
targets	NNS	O
the	CC	O
target	JJ	O
cells,	NN	O
such	NN	O
as	VBN	O
an	NN	O
antibody	NNP	O
specific	RB	O
for	,	O
a	NNS	O
cell	IN	O
surface	NNP	O
membrane	,	O
protein	CD	O
or	.	O
the	IN	O
target	DT	O
cell,	NNS	O
a	PRP	O
ligand	VBZ	O
for	JJ	O
a	TO	O
receptor	VB	O
on	DT	O
the	JJ	O
target	NN	O
cell,	NN	O
etc.	IN	O
Where	DT	O
liposomes	NN	O
are	WDT	O
employed,	VBZ	O
proteins	DT	O
which	NN	O
bind	,	O
to	JJ	O
a	IN	O
cell	DT	O
surface	NN	O
membrane	NN	O
protein	IN	O
associated	DT	O
with	NN	O
endocytosis	NN	O
may	NN	O
be	NN	O
used	CC	O
for	DT	O
targeting	NN	O
and/or	,	O
to	DT	O
facilitate	NN	O
uptake,	IN	O
e.g.	DT	O
capsid	NN	O
proteins	IN	O
or	DT	O
fragments	NN	O
thereof	,	O
tropic	.	O
for	WRB	O
a	NNS	O
particular	VBP	O
cell	,	O
type,	VBZ	O
antibodies	WDT	O
for	NN	O
proteins	TO	O
which	DT	O
undergo	NN	O
internalization	NN	O
in	NN	O
cycling,	NN	O
proteins	VBN	O
that	IN	O
target	NN	O
intracellular	MD	O
localization	VB	O
and	VBN	O
enhance	IN	O
intracellular	VBG	O
half-life.	NN	O
The	TO	O
technique	VB	O
of	,	O
receptor-mediated	.	O
endocytosis	NN	O
is	NNS	O
described,	CC	O
for	NNS	O
example,	VBP	O
by	NN	O
Wu	IN	B
et	DT	I
al.,	JJ	I
J.	NN	I
Biol.	,	I
Chem.	NNS	I
262,	IN	I
4429-4432	NNS	I
(1987);	WDT	I
and	VBP	O
Wagner	NN	B
et	IN	I
al.,	,	I
Proc.	VBZ	I
Natl.	IN	I
Acad.	NN	I
Sci.	JJ	I
USA	NN	I
87,	CC	I
3410-3414	VB	I
(1990).	JJ	I
For	.	O
review	DT	O
of	NN	O
gene	IN	O
marking	JJ	O
and	NN	O
gene	VBZ	O
therapy	,	O
protocols	IN	O
see	,	O
Anderson	IN	B
et	NNP	I
al.,	FW	I
Science	,	I
256,	NNP	I
808-813	.	I
(1992).
The	.	O
PRO227,	,	O
PRO233,	CD	O
PRO238,	:	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	VBP	O
PRO10096,	,	O
PRO21384,	.	O
PRO353	.	O
or	.	O
PRO1885	.	O
polypeptides	NNP	O
described	,	O
herein	CD	O
may	.	O
also	IN	O
be	NN	O
employed	IN	O
as	NN	O
molecular	NN	O
weight	CC	O
markers	NN	O
for	NN	O
protein	NNS	O
electrophoresis	VBP	O
purposes	NNP	O
and	FW	O
the	,	O
isolated	NNP	O
nucleic	,	O
acid	CD	O
sequences	.	O
may	DT	O
be	,	O
used	,	O
for	,	O
recombinantly	,	O
expressing	,	O
those	,	O
markers.	,	O
The	,	O
nucleic	NNP	O
acid	CC	O
molecules	NNP	O
encoding	NNS	O
the	VBD	O
PRO227,	NN	O
PRO233,	MD	O
PRO238,	RB	O
PRO1328,	VB	O
PRO4342,	VBN	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	NNS	O
or	IN	O
PRO1885	JJ	O
polypeptides	NN	O
or	NNS	O
fragments	CC	O
thereof	DT	O
described	JJ	O
herein	JJ	O
are	JJ	O
useful	NNS	O
for	MD	O
chromosome	VB	O
identification.	VBN	O
In	IN	O
this	RB	O
regard,	VBG	O
there	DT	O
exists	.	O
an	DT	O
ongoing	JJ	O
need	NN	O
to	NNS	O
identify	VBG	O
new	DT	O
chromosome	,	O
markers,	,	O
since	,	O
relatively	,	O
few	,	O
chromosome	,	O
marking	,	O
reagents,	,	O
based	NNP	O
upon	CC	O
actual	NNP	O
sequence	NNS	O
data	CC	O
are	NNS	O
presently	JJ	O
available.	VBN	O
Each	NNS	O
PRO227,	VBP	O
PRO233,	JJ	O
PRO238,	IN	O
PRO1328,	NN	O
PRO4342,	.	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	EX	O
or	VBZ	O
PRO1885	DT	O
nucleic	VBG	O
acid	NN	O
molecule	TO	O
of	VB	O
the	JJ	O
present	NN	O
invention	,	O
can	IN	O
be	RB	O
used	JJ	O
as	NN	O
a	VBG	O
chromosome	,	O
marker.	VBN	O
The	IN	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	NNS	O
PRO1328,	VBP	O
PRO4342,	RB	O
PRO7423,	.	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	,	O
and	,	O
nucleic	,	O
acid	,	O
molecules	NNP	O
of	CC	O
the	NNP	O
present	JJ	O
invention	NN	O
may	NN	O
also	IN	O
be	DT	O
used	JJ	O
diagnostically	NN	O
for	MD	O
tissue	VB	O
typing,	VBN	O
wherein	IN	O
the	DT	O
PRO227,	NN	O
PRO233,	.	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	NNP	O
of	CC	O
the	NNP	O
present	NNS	O
invention	CC	O
may	JJ	O
be	NN	O
differentially	NNS	O
expressed	IN	O
in	DT	O
one	JJ	O
tissue	NN	O
as	MD	O
compared	RB	O
to	VB	O
another,	VBN	O
preferably	RB	O
in	IN	O
a	NN	O
diseased	,	O
tissue	VBP	O
as	DT	O
compared	,	O
to	,	O
a	,	O
normal	,	O
tissue	,	O
of	,	O
the	,	O
same	,	O
tissue	NNP	O
type.	CC	O
PRO227,	NNP	O
PRO233,	NNS	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	RB	O
or	VBN	O
PRO1885	IN	O
nucleic	CD	O
acid	NN	O
molecules	IN	O
will	VBN	O
find	TO	O
use	,	O
for	RB	O
generating	IN	O
probes	DT	O
for	JJ	O
PCR,	NN	O
Northern	IN	O
analysis,	VBN	O
Southern	TO	O
analysis	DT	O
and	JJ	O
Western	NN	O
analysis.	IN	O
The	DT	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	.	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	NNP	O
described	CC	O
herein	NNP	O
may	JJ	O
also	NN	O
be	NNS	O
employed	MD	O
as	VB	O
therapeutic	NN	O
agents.	IN	O
The	VBG	O
PRO227,	NNS	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	,	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	CC	O
PRO353	JJ	O
or	.	O
PRO1885	DT	O
polypeptides	,	O
of	,	O
the	,	O
present	,	O
invention	,	O
can	,	O
be	,	O
formulated	,	O
according	NNP	O
to	CC	O
known	NNP	O
methods	NNS	O
to	VBD	O
prepare	NN	O
pharmaceutically	MD	O
useful	RB	O
compositions,	VB	O
whereby	VBN	O
the	IN	O
PRO227,	JJ	O
PRO233,	.	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
product	NNP	O
hereof	CC	O
is	NNP	O
combined	NNS	O
in	IN	O
admixture	DT	O
with	JJ	O
a	NN	O
pharmaceutically	MD	O
acceptable	VB	O
carrier	VBN	O
vehicle.	VBG	O
Therapeutic	TO	O
formulations	VBN	O
are	NNS	O
prepared	TO	O
for	VB	O
storage	RB	O
by	JJ	O
mixing	,	O
the	VBP	O
active	DT	O
ingredient	,	O
having	,	O
the	,	O
desired	,	O
degree	,	O
of	,	O
purity	,	O
with	,	O
optional	NNP	O
physiologically	CC	O
acceptable	NNP	O
carriers,	NN	O
excipients	NN	O
or	VBZ	O
stabilizers	VBN	O
Remington's	IN	B
Pharmaceutical	NN	I
Sciences	IN	I
16th	DT	I
edition,	RB	I
Osol,	JJ	I
A.	NN	I
Ed.	.	I
(1980)),(	JJ	O
in	NNS	O
the	VBP	O
form	JJ	O
of	IN	O
lyophilized	NN	O
formulations	IN	O
or	VBG	O
aqueous	DT	O
solutions.	JJ	O
Acceptable	NN	O
carriers,	VBG	O
excipients	DT	O
or	JJ	O
stabilizers	NN	O
are	IN	O
nontoxic	NN	O
to	IN	O
recipients	JJ	O
at	RB	O
the	JJ	O
dosages	,	O
and	NNS	O
concentrations	CC	O
employed,	NNS	O
and	POS	O
include	NNP	O
buffers	NNPS	O
such	CD	O
as	,	O
phosphate,	,	O
citrate	NNP	O
and	.	O
other	,	O
organic	IN	O
acids;	DT	O
antioxidants	NN	O
including	IN	O
ascorbic	JJ	O
acid;	NNS	O
low	CC	O
molecular	JJ	O
weight	.	O
(less	JJ	O
than	,	O
about	NNS	O
10	CC	O
residues)	NNS	O
polypeptides;	VBP	O
proteins,	JJ	O
such	TO	O
as	NNS	O
serum	IN	O
albumin,	DT	O
gelatin	NNS	O
or	CC	O
immunoglobulins;	NNS	O
hydrophilic	,	O
polymers	CC	O
such	VBP	O
as	NNS	O
polyvinylpyrrolidone,	JJ	O
amino	IN	O
acids	,	O
such	NN	O
as	CC	O
glycine,	JJ	O
glutamine,	JJ	O
asparagine,	:	O
arginine	NNS	O
or	VBG	O
lysine;	JJ	O
monosaccharides,	:	O
disaccharides	JJ	O
and	JJ	O
other	NN	O
carbohydrates	JJR	O
including	IN	O
glucose,	RB	O
mannose,	CD	O
or	)	O
dextrins;	:	O
chelating	,	O
agents	JJ	O
such	IN	O
as	NN	O
EDTA;	,	O
sugar	NN	O
alcohols	CC	O
such	:	O
as	JJ	O
mannitol	NNS	O
or	JJ	O
sorbitol;	IN	O
salt-forming	,	O
counterions	JJ	O
such	NNS	O
as	JJ	O
sodium;	IN	O
and/or	,	O
nonionic	,	O
surfactants	,	O
such	NN	O
as	CC	O
TWEEN™,	:	O
PLURONICS™	,	O
or	NNS	O
PEG.	CC	O
The	JJ	O
formulations	NNS	O
to	VBG	O
be	,	O
used	,	O
for	CC	O
in	:	O
vivo	VBG	O
administration	NNS	O
must	JJ	O
be	IN	O
sterile.	:	O
This	NN	O
is	NNS	O
readily	JJ	O
accomplished	IN	O
by	NN	O
filtration	CC	O
through	:	O
sterile	JJ	O
filtration	NNS	O
membranes,	JJ	O
prior	IN	O
to	:	O
or	CC	O
following	JJ	O
lyophilization	NNS	O
and	JJ	O
reconstitution.	IN	O
Therapeutic	,	O
compositions	NNP	O
herein	CC	O
generally	.	O
are	DT	O
placed	NNS	O
into	TO	O
a	VB	O
container	VBN	O
having	IN	O
a	IN	O
sterile	JJ	O
access	NN	O
port,	MD	O
for	VB	O
example,	.	O
an	DT	O
intravenous	VBZ	O
solution	RB	O
bag	VBN	O
or	IN	O
vial	NN	O
having	IN	O
a	JJ	O
stopper	NN	O
pierceable	,	O
by	RB	O
a	TO	O
hypodermic	CC	O
injection	VBG	O
needle.	NN	O
The	CC	O
route	.	O
of	JJ	O
administration	NNS	O
is	VBP	O
in	RB	O
accord	VBP	O
with	VBN	O
known	IN	O
methods,	DT	O
e.g.	NN	O
injection	VBG	O
or	DT	O
infusion	JJ	O
by	NN	O
intravenous,	,	O
intraperitoneal,	IN	O
intracerebral,	,	O
intramuscular,	DT	O
intraocular,	JJ	O
intraarterial	NN	O
or	NN	O
intralesional	CC	O
routes,	JJ	O
topical	VBG	O
administration,	DT	O
or	NN	O
by	NN	O
sustained	IN	O
release	DT	O
systems.	JJ	O
Dosages	NN	O
and	.	O
desired	DT	O
drug	NN	O
concentrations	IN	O
of	NN	O
pharmaceutical	VBZ	O
compositions	IN	O
of	NN	O
the	IN	O
present	VBN	O
invention	,	O
may	.	O
vary	NN	O
depending	CC	O
on	NN	O
the	IN	O
particular	,	O
use	,	O
envisioned.	,	O
The	,	O
determination	,	O
of	JJ	O
the	CC	O
appropriate	JJ	O
dosage	,	O
or	JJ	O
route	,	O
of	CC	O
administration	IN	O
is	JJ	O
well	NN	O
within	.	O
the	NNS	O
skill	CC	O
of	VBN	O
an	NN	O
ordinary	NNS	O
physician.	IN	O
Animal	JJ	O
experiments	NNS	O
provide	IN	O
reliable	DT	O
guidance	JJ	O
for	NN	O
the	MD	O
determination	VB	O
of	VBG	O
effective	IN	O
doses	DT	O
for	JJ	O
human	NN	O
therapy.	.	O
Interspecies	DT	O
scaling	NN	O
of	IN	O
effective	DT	O
doses	JJ	O
can	NN	O
be	CC	O
performed	NN	O
following	IN	O
the	NN	O
principles	VBZ	O
laid	RB	O
down	IN	O
by	DT	O
Mordenti,	NN	B
J.	IN	I
and	DT	I
Chappell,	JJ	I
W.	.	I
“The	JJ	I
use	NNS	I
of	VBP	I
interspecies	JJ	I
scaling	NN	I
in	IN	I
toxicokinetics”	DT	I
In	NN	I
Toxicokinetics	IN	I
and	JJ	I
New	NNS	I
Drug	IN	I
Development,	JJ	I
Yacobi	.	I
et	NNS	I
al.,	VBG	I
Eds.,	IN	I
Pergamon	JJ	I
Press,	NNS	I
New	MD	I
York	VB	I
1989,	VBN	I
pp.	VBG	I
42-96.
When	DT	O
in	NNS	O
vivo	VBD	O
administration	RB	O
of	IN	O
a	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	,	O
PRO1328,	NNP	O
PRO4342,	NNP	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	NNS	O
PRO353	VBG	O
or	IN	O
PRO1885	NN	O
polypeptide	IN	O
or	NNP	O
agonist	CC	O
or	NNP	O
antagonist	NNP	O
thereof	,	O
is	NNP	O
employed,	FW	O
normal	,	O
dosage	,	O
amounts	NNP	O
may	,	O
vary	NNP	O
from	NNP	O
about	,	O
10	.	O
ng/kg	.	O
to	WRB	O
up	IN	O
to	JJ	O
100	NN	O
mg/kg	IN	O
of	DT	O
mammal	,	O
body	,	O
weight	,	O
or	,	O
more	,	O
per	,	O
day,	,	O
preferably	,	O
about	NNP	O
1	CC	O
μg/kg/day	NNP	O
to	NN	O
10	CC	O
mg/kg/day,	NN	O
depending	CC	O
upon	NN	O
the	NN	O
route	VBZ	O
of	,	O
administration.	JJ	O
Guidance	NN	O
as	NNS	O
to	MD	O
particular	VB	O
dosages	IN	O
and	RB	O
methods	CD	O
of	NNS	O
delivery	TO	O
is	RB	O
provided	TO	O
in	CD	O
the	NN	O
literature;	IN	O
see,	JJ	O
for	NN	O
example,	VBD	O
U.S.	CC	O
Pat.	JJR	O
Nos.	IN	O
4,657,760;	,	O
5,206,344;	RB	O
or	IN	O
5,225,212.	CD	O
It	NN	O
is	TO	O
anticipated	CD	O
that	,	O
different	VBG	O
formulations	IN	O
will	DT	O
be	NN	O
effective	IN	O
for	.	O
different	NN	O
treatment	IN	O
compounds	TO	O
and	JJ	O
different	NNS	O
disorders,	CC	O
that	NNS	O
administration	IN	O
targeting	NN	O
one	VBZ	O
organ	VBN	O
or	IN	O
tissue,	DT	O
for	:	O
example,	,	O
may	IN	O
necessitate	,	O
delivery	NNP	O
in	.	O
a	.	O
manner	:	O
different	:	O
from	CC	O
that	.	O
to	PRP	O
another	VBZ	O
organ	VBN	O
or	IN	O
tissue.	JJ	O
Where	NNS	O
sustained-release	MD	O
administration	VB	O
of	JJ	O
a	IN	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	NNS	O
PRO1328,	CC	O
PRO4342,	JJ	O
PRO7423,	,	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	VBG	O
or	CD	O
PRO1885	NN	O
polypeptide	CC	O
is	,	O
desired	IN	O
in	,	O
a	MD	O
formulation	VB	O
with	NN	O
release	IN	O
characteristics	DT	O
suitable	NN	O
for	JJ	O
the	IN	O
treatment	DT	O
of	TO	O
any	DT	O
disease	NN	O
or	CC	O
disorder	.	O
requiring	WRB	O
administration	JJ	O
of	NN	O
the	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
microencapsulation	NN	O
of	VBZ	O
the	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	NN	O
PRO7423,	NNS	O
PRO10096,	JJ	O
PRO21384,	IN	O
PRO353	DT	O
or	NN	O
PRO1885	IN	O
polypeptide	DT	O
is	NN	O
contemplated.	CC	O
Microencapsulation	NN	O
of	VBG	O
recombinant	NN	O
proteins	IN	O
for	DT	O
sustained	,	O
release	,	O
has	,	O
been	,	O
successfully	,	O
performed	,	O
with	,	O
human	,	O
growth	NNP	O
hormone	CC	O
(rhGH),	NNP	O
interferon-(rhIFN-),	,	O
interleukin-2,	NN	O
and	IN	O
MN	DT	O
rgp120.	,	O
Johnson	,	B
et	,	I
al.,	,	I
Nat.	,	I
Med.,	,	I
2:795-799	,	I
(1996);	,	I
Yasuda,	NNP	B
Biomed.	CC	I
Ther.,	NNP	I
27:1221-1223	NN	I
(1993);	VBZ	I
Hora	.	B
et	NN	I
al.,	IN	I
Bio/Technology,	JJ	I
8:755-758	NNS	I
(1990);	IN	I
Cleland,	JJ	B
“Design	NN	I
and	VBZ	I
Production	VBN	I
of	RB	I
Single	VBN	I
Immunization	IN	I
Vaccines	JJ	I
Using	NN	I
Polylactide	NN	I
Polyglycolide	,	I
Microsphere	,	I
Systems,”	,	I
in	CC	I
Vaccine	NNP	I
Design:	.	I
The	NNP	I
Subunit	CC	I
and	,	I
Adjuvant	.	I
Approach,	,	I
Powell	CD	I
and	:	I
Newman,	,	I
eds,	.	I
(Plenum	,	I
Press:	CD	I
New	:	I
York,	NNP	I
1995),	FW	I
pp.	,	I
439-462;	,	I
WO	CD	O
97/03692,	:	O
WO	,	O
96/40072,	NN	O
WO	CC	O
96/07399;	NN	O
and	IN	O
U.S.	NNP	O
Pat.	NNP	O
No.	NNP	O
5,654,010.	NNP	O
The	NNP	O
sustained-release	NNP	O
formulations	NNP	O
of	NNP	O
these	IN	O
proteins	NNP	O
were	:	O
developed	DT	O
using	NNP	O
poly-lactic-coglycolic	CC	O
acid	NNP	O
(PLGA)	,	O
polymer	NNP	O
due	CC	O
to	,	O
its	,	O
biocompatibility	NNP	O
and	:	O
wide	NNP	O
range	,	O
of	,	O
biodegradable	.	O
properties.	:	O
The	NNP	O
degradation	,	O
products	NNP	O
of	,	O
PLGA,	NNP	O
lactic	:	O
and	CC	O
glycolic	NNP	O
acids,	.	O
can	.	O
be	.	O
cleared	DT	O
quickly	JJ	O
within	NNS	O
the	IN	O
human	DT	O
body.	NNS	O
Moreover,	VBD	O
the	VBN	O
degradability	VBG	O
of	JJ	O
this	NN	O
polymer	)	O
can	NN	O
be	JJ	O
adjusted	TO	O
from	PRP$	O
months	NN	O
to	CC	O
years	JJ	O
depending	NN	O
on	IN	O
its	JJ	O
molecular	.	O
weight	DT	O
and	NN	O
composition.	NNS	O
Lewis,	IN	B
“Controlled	,	I
release	JJ	I
of	CC	I
bioactive	JJ	I
agents	,	I
from	MD	I
lactide/glycolide	VB	I
polymer,”	VBN	I
in:	RB	I
M.	IN	I
Chasin	DT	I
and	JJ	I
R.	.	I
Langer	,	I
(Eds.),	DT	I
Biodegradable	NN	I
Polymers	IN	I
as	DT	I
Drug	NN	I
Delivery	MD	I
Systems	VB	I
(Marcel	VBN	I
Dekker:	IN	I
New	NNS	I
York,	TO	I
1990),	NNS	I
pp.	VBG	I
1-41.
This	IN	O
invention	PRP$	O
encompasses	JJ	O
methods	NN	O
of	CC	O
screening	.	O
compounds	,	O
to	VBD	O
identify	NN	O
those	IN	O
that	JJ	O
mimic	NNS	O
the	IN	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	:	O
PRO1328,	NNP	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	,	O
or	JJ	O
PRO1885	NNPS	O
polypeptide	IN	O
(agonists)	NNP	O
or	NNP	O
prevent	NNP	O
the	NNP	O
effect	:	O
of	NNP	O
the	,	O
PRO227,	,	O
PRO233,	.	O
PRO238,	.	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	VBZ	O
PRO10096,	NNS	O
PRO21384,	IN	O
PRO353	VBG	O
or	NNS	O
PRO1885	TO	O
polypeptide	VB	O
(antagonists).	DT	O
Agonists	WDT	O
that	VBP	O
mimic	DT	O
a	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	NN	O
polypeptide	)	O
would	CC	O
be	VB	O
especially	DT	O
valuable	NN	O
therapeutically	IN	O
in	DT	O
those	,	O
instances	,	O
where	,	O
a	,	O
negative	,	O
phenotype	,	O
is	,	O
observed	,	O
based	NNP	O
on	CC	O
findings	NNP	O
with	NN	O
the	.	O
non-human	NNS	O
transgenic	WDT	O
animal	VBP	O
whose	DT	O
genome	,	O
comprises	,	O
a	,	O
disruption	,	O
of	,	O
the	,	O
gene	,	O
which	,	O
encodes	NNP	O
for	CC	O
the	NNP	O
PRO227,	NN	O
PRO233,	MD	O
PRO238,	VB	O
PRO1328,	RB	O
PRO4342,	JJ	O
PRO7423,	RB	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	NNS	O
or	WRB	O
PRO1885	DT	O
polypeptide.	JJ	O
Antagonists	NN	O
that	VBZ	O
prevent	VBN	O
the	VBN	O
effects	IN	O
of	NNS	O
a	IN	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	WP$	O
PRO7423,	JJ	O
PRO10096,	VBZ	O
PRO21384,	DT	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
polypeptide	NN	O
would	WDT	O
be	VBZ	O
especially	IN	O
valuable	DT	O
therapeutically	,	O
in	,	O
those	,	O
instances	,	O
where	,	O
a	,	O
positive	,	O
phenotype	,	O
is	NNP	O
observed	CC	O
based	NNP	O
upon	.	O
observations	NNS	O
with	WDT	O
the	VBP	O
non-human	DT	O
transgenic	NNS	O
knockout	IN	O
animal.	DT	O
Screening	,	O
assays	,	O
for	,	O
antagonist	,	O
drug	,	O
candidates	,	O
are	,	O
designed	,	O
to	NNP	O
identify	CC	O
compounds	NNP	O
that	NN	O
bind	MD	O
or	VB	O
complex	RB	O
with	JJ	O
the	RB	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NNS	O
PRO1328,	WRB	O
PRO4342,	DT	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	VBZ	O
PRO353	VBN	O
or	VBN	O
PRO1885	IN	O
polypeptide	NNS	O
encoded	IN	O
by	DT	O
the	JJ	O
genes	NN	O
identified	NN	O
herein,	.	O
or	VBG	O
otherwise	NNS	O
interfere	IN	O
with	JJ	O
the	NN	O
interaction	NNS	O
of	VBP	O
the	VBN	O
encoded	TO	O
polypeptide	VB	O
with	NNS	O
other	WDT	O
cellular	VBP	O
proteins.	CC	O
Such	JJ	O
screening	IN	O
assays	DT	O
will	,	O
include	,	O
assays	,	O
amenable	,	O
to	,	O
high-throughput	,	O
screening	,	O
of	,	O
chemical	NNP	O
libraries,	CC	O
making	NNP	O
them	RB	O
particularly	VBD	O
suitable	IN	O
for	DT	O
identifying	NNS	O
small	VBN	O
molecule	,	O
drug	CC	O
candidates.	RB	O
The	RB	O
assays	IN	O
can	DT	O
be	NN	O
performed	IN	O
in	DT	O
a	JJ	O
variety	NN	O
of	IN	O
formats,	JJ	O
including	JJ	O
protein-protein	.	O
binding	JJ	O
assays,	NN	O
biochemical	NNS	O
screening	MD	O
assays,	VB	O
immunoassays,	NNS	O
and	JJ	O
cell-based	TO	O
assays,	JJ	O
which	NN	O
are	IN	O
well	NN	O
characterized	,	O
in	VBG	O
the	PRP	O
art.	RB	O
All	JJ	O
assays	IN	O
for	VBG	O
antagonists	JJ	O
are	JJ	O
common	NN	O
in	.	O
that	DT	O
they	NNS	O
call	MD	O
for	VB	O
contacting	VBN	O
the	IN	O
drug	DT	O
candidate	NN	O
with	IN	O
a	,	O
PRO227,	VBG	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	,	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	CC	O
or	JJ	O
PRO1885	,	O
polypeptide	WDT	O
encoded	VBP	O
by	RB	O
a	VBN	O
nucleic	IN	O
acid	DT	O
identified	.	O
herein	DT	O
under	NNS	O
conditions	IN	O
and	NNS	O
for	VBP	O
a	JJ	O
time	IN	O
sufficient	DT	O
to	PRP	O
allow	VBP	O
these	IN	O
two	VBG	O
components	DT	O
to	NN	O
interact.	NN	O
In	IN	O
binding	DT	O
assays,	,	O
the	,	O
interaction	,	O
is	,	O
binding	,	O
and	,	O
the	,	O
complex	,	O
formed	NNP	O
can	CC	O
be	NNP	O
isolated	RB	O
or	VBD	O
detected	IN	O
in	DT	O
the	JJ	O
reaction	NN	O
mixture.	VBN	O
The	JJ	O
PRO227,	IN	O
PRO233,	NNS	O
PRO238,	CC	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	NN	O
PRO21384,	TO	O
PRO353	VB	O
or	DT	O
PRO1885	CD	O
polypeptide	NNS	O
encoded	TO	O
by	.	O
the	IN	O
gene	VBG	O
identified	,	O
herein	DT	O
or	NN	O
the	VBZ	O
drug	VBG	O
candidate	CC	O
is	DT	O
immobilized	NN	O
on	VBD	O
a	MD	O
solid	VB	O
phase,	VBN	O
e.g.,	CC	O
on	VBN	O
a	IN	O
microtiter	DT	O
plate,	NN	O
by	.	O
covalent	DT	O
or	,	O
non-covalent	,	O
attachments.	,	O
Non-covalent	,	O
attachment	,	O
generally	,	O
is	,	O
accomplished	,	O
by	NNP	O
coating	CC	O
the	NNP	O
solid	RB	O
surface	VBD	O
with	IN	O
a	DT	O
solution	NN	O
of	VBD	O
the	CD	O
PRO227,	CC	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	JJ	O
or	,	O
PRO1885	,	O
polypeptide	IN	O
and	DT	O
drying.	NN	O
Alternatively,	,	O
an	IN	O
immobilized	NN	O
antibody,	CC	O
e.g.,	JJ	O
a	.	O
monoclonal	JJ	O
antibody,	NN	O
specific	RB	O
for	VBZ	O
the	VBN	O
PRO227,	IN	O
PRO233,	VBG	O
PRO238,	DT	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	IN	O
or	DT	O
PRO1885	,	O
polypeptide	,	O
to	,	O
be	,	O
immobilized	,	O
can	,	O
be	,	O
used	,	O
to	NNP	O
anchor	CC	O
it	NNP	O
to	NN	O
a	CC	O
solid	.	O
surface.	,	O
The	DT	O
assay	JJ	O
is	,	O
performed	,	O
by	DT	O
adding	JJ	O
the	,	O
non-immobilized	NN	O
component,	IN	O
which	DT	O
may	,	O
be	,	O
labeled	,	O
by	,	O
a	,	O
detectable	,	O
label,	,	O
to	,	O
the	NNP	O
immobilized	CC	O
component,	NNP	O
e.g.,	NN	O
the	TO	O
coated	VB	O
surface	VBN	O
containing	MD	O
the	VB	O
anchored	VBN	O
component.	TO	O
When	VB	O
the	PRP	O
reaction	TO	O
is	DT	O
complete,	JJ	O
the	.	O
non-reacted	DT	O
components	NN	O
are	VBZ	O
removed,	VBN	O
e.g.,	IN	O
by	VBG	O
washing,	DT	O
and	JJ	O
complexes	,	O
anchored	WDT	O
on	MD	O
the	VB	O
solid	VBN	O
surface	IN	O
are	DT	O
detected.	JJ	O
When	,	O
the	TO	O
originally	DT	O
non-immobilized	JJ	O
component	,	O
carries	,	O
a	DT	O
detectable	JJ	O
label,	NN	O
the	VBG	O
detection	DT	O
of	JJ	O
label	.	O
immobilized	WRB	O
on	DT	O
the	NN	O
surface	VBZ	O
indicates	,	O
that	DT	O
complexing	JJ	O
occurred.	NNS	O
Where	VBP	O
the	,	O
originally	,	O
non-immobilized	IN	O
component	,	O
does	CC	O
not	NNS	O
carry	VBN	O
a	IN	O
label,	DT	O
complexing	JJ	O
can	NN	O
be	VBP	O
detected,	.	O
for	WRB	O
example,	DT	O
by	RB	O
using	JJ	O
a	NN	O
labeled	VBZ	O
antibody	DT	O
specifically	JJ	O
binding	,	O
the	DT	O
immobilized	NN	O
complex.	IN	O
If	NN	O
the	VBN	O
candidate	IN	O
compound	DT	O
interacts	NN	O
with	VBZ	O
but	IN	O
does	VBG	O
not	.	O
bind	WRB	O
to	DT	O
a	RB	O
particular	JJ	O
PRO227,	NN	O
PRO233,	VBZ	O
PRO238,	RB	O
PRO1328,	VB	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	VBG	O
PRO21384,	MD	O
PRO353	VB	O
or	,	O
PRO1885	IN	O
polypeptide	,	O
encoded	IN	O
by	VBG	O
a	DT	O
gene	VBN	O
identified	NN	O
herein,	RB	O
its	VBG	O
interaction	DT	O
with	JJ	O
that	.	O
polypeptide	IN	O
can	DT	O
be	NN	O
assayed	NN	O
by	VBZ	O
methods	IN	O
well	CC	O
known	VBZ	O
for	RB	O
detecting	VB	O
protein-protein	TO	O
interactions.	DT	O
Such	JJ	O
assays	,	O
include	,	O
traditional	,	O
approaches,	,	O
such	,	O
as,	,	O
e.g.,	,	O
cross-linking,	,	O
co-immunoprecipitation,	NNP	O
and	CC	O
co-purification	NNP	O
through	RB	O
gradients	VBD	O
or	IN	O
chromatographic	DT	O
columns.	NN	O
In	VBN	O
addition,	,	O
protein-protein	PRP$	O
interactions	NN	O
can	IN	O
be	DT	O
monitored	NN	O
by	MD	O
using	VB	O
a	VBN	O
yeast-based	IN	O
genetic	NNS	O
system	RB	O
described	VBN	O
by	IN	O
Fields	VBG	B
and	JJ	I
co-workers	.	I
(Fields	JJ	I
and	NNS	I
Song,	VBP	I
Nature	JJ	I
(London),	,	I
340:245-246	JJ	I
(1989);	,	I
Chien	,	B
et	,	I
al.,	,	I
Proc.	CC	I
Natl.	NN	I
Acad.	IN	I
Sci.	NNS	I
USA,	CC	I
88:9578-9582	JJ	I
(1991))	.	I
as	IN	O
disclosed	,	O
by	JJ	O
Chevray	NNS	B
and	MD	I
Nathans,	VB	I
Proc.	VBN	I
Natl.	IN	I
Acad.	VBG	I
Sci.	DT	I
USA,	JJ	I
89:	JJ	I
5789-5793	NN	I
(1991).	VBN	I
Many	IN	O
transcriptional	NNS	O
activators,	CC	O
such	NNS	O
as	NNS	O
yeast	CC	O
GAL4,	,	O
consist	NNP	O
of	,	O
two	JJ	O
physically	:	O
discrete	NNP	O
modular	FW	O
domains,	,	O
one	.	O
acting	.	O
as	.	O
the	.	O
DNA-binding	,	O
domain,	CD	O
the	)	O
other	IN	O
one	VBN	O
functioning	IN	O
as	NNP	O
the	CC	O
transcription-activation	,	O
domain.	.	O
The	.	O
yeast	.	O
expression	.	O
system	,	O
described	:	O
in	JJ	O
the	.	O
foregoing	JJ	O
publications	JJ	O
(generally	,	O
referred	JJ	O
to	IN	O
as	NN	O
the	,	O
“two-hybrid	NN	O
system”)	IN	O
takes	CD	O
advantage	RB	O
of	JJ	O
this	NN	O
property,	,	O
and	CD	O
employs	NN	O
two	IN	O
hybrid	DT	O
proteins,	NNP	O
one	,	O
in	DT	O
which	JJ	O
the	CD	O
target	NN	O
protein	IN	O
is	DT	O
fused	NN	O
to	.	O
the	DT	O
DNA-binding	JJS	O
domain	NN	O
of	NN	O
GAL4,	VBN	O
and	IN	O
another,	DT	O
in	NN	O
which	NNS	O
candidate	RB	O
activating	VBN	O
proteins	TO	O
are	IN	O
fused	DT	O
to	JJ	O
the	)	O
activation	VBZ	O
domain.	NN	O
The	IN	O
expression	DT	O
of	,	O
a	CC	O
GAL1-lacZ	VBZ	O
reporter	CD	O
gene	JJ	O
under	,	O
control	CD	O
of	IN	O
a	WDT	O
GAL4-activated	DT	O
promoter	NN	O
depends	NN	O
on	VBZ	O
reconstitution	VBN	O
of	TO	O
GAL4	DT	O
activity	NNP	O
via	NN	O
protein-protein	IN	O
interaction.	,	O
Colonies	CC	O
containing	,	O
interacting	IN	O
polypeptides	WDT	O
are	NN	O
detected	NN	O
with	NNS	O
a	VBP	O
chromogenic	VBN	O
substrate	TO	O
for	DT	O
β-galactosidase.	NN	O
A	.	O
complete	DT	O
kit	NN	O
(MATCHMAKER™)	IN	O
for	DT	O
identifying	NNP	O
protein-protein	NN	O
interactions	NN	O
between	IN	O
two	NN	O
specific	IN	O
proteins	DT	O
using	JJ	O
the	NN	O
two-hybrid	VBZ	O
technique	IN	O
is	NN	O
commercially	IN	O
available	NNP	O
from	NN	O
Clontech.	IN	O
This	JJ	O
system	.	O
can	NNS	O
also	VBG	O
be	VBG	O
extended	NNS	O
to	VBP	O
map	VBN	O
protein	IN	O
domains	DT	O
involved	JJ	O
in	NN	O
specific	IN	O
protein	.	O
interactions	DT	O
as	JJ	O
well	NN	O
as	)	O
to	IN	O
pinpoint	VBG	O
amino	JJ	O
acid	NNS	O
residues	IN	O
that	CD	O
are	JJ	O
crucial	NNS	O
for	VBG	O
these	DT	O
interactions.	JJ	O
Compounds	NN	O
that	VBZ	O
interfere	RB	O
with	JJ	O
the	IN	O
interaction	.	O
of	DT	O
a	NN	O
gene	MD	O
encoding	RB	O
a	VB	O
PRO227,	VBN	O
PRO233,	TO	O
PRO238,	VB	O
PRO1328,	NN	O
PRO4342,	NNS	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	JJ	O
PRO353	NN	O
or	NNS	O
PRO1885	RB	O
polypeptide	RB	O
identified	IN	O
herein	TO	O
and	VB	O
other	NN	O
intra-	NN	O
or	NNS	O
extracellular	WDT	O
components	VBP	O
can	JJ	O
be	IN	O
tested	DT	O
as	.	O
follows:	NNS	O
usually	WDT	O
a	VBP	O
reaction	IN	O
mixture	DT	O
is	NN	O
prepared	IN	O
containing	DT	O
the	NN	O
product	VBG	O
of	DT	O
the	,	O
gene	,	O
and	,	O
the	,	O
intra-	,	O
or	,	O
extracellular	,	O
component	,	O
under	NNP	O
conditions	CC	O
and	NNP	O
for	RB	O
a	VBD	O
time	NN	O
allowing	CC	O
for	JJ	O
the	JJ	O
interaction	CC	O
and	JJ	O
binding	NNS	O
of	MD	O
the	VB	O
two	VBN	O
products.	IN	O
To	:	O
test	RB	O
the	DT	O
ability	NN	O
of	NN	O
a	VBZ	O
candidate	JJ	O
compound	VBG	O
to	DT	O
inhibit	NN	O
binding,	IN	O
the	DT	O
reaction	NN	O
is	CC	O
run	DT	O
in	JJ	O
the	CC	O
absence	JJ	O
and	NN	O
in	IN	O
the	NNS	O
presence	CC	O
of	IN	O
the	DT	O
test	NN	O
compound.	VBG	O
In	IN	O
addition,	DT	O
a	NN	O
placebo	CC	O
may	NN	O
be	IN	O
added	DT	O
to	CD	O
a	.	O
third	TO	O
reaction	VB	O
mixture,	DT	O
to	NN	O
serve	IN	O
as	DT	O
positive	NN	O
control.	NN	O
The	TO	O
binding	VB	O
(complex	,	O
formation)	DT	O
between	NN	O
the	VBZ	O
test	VBN	O
compound	IN	O
and	DT	O
the	NN	O
intra-	CC	O
or	IN	O
extracellular	DT	O
component	NN	O
present	IN	O
in	DT	O
the	NN	O
mixture	.	O
is	IN	O
monitored	,	O
as	DT	O
described	NN	O
hereinabove.	MD	O
The	VB	O
formation	VBN	O
of	TO	O
a	DT	O
complex	JJ	O
in	NN	O
the	,	O
control	TO	O
reaction(s)	VB	O
but	IN	O
not	JJ	O
in	.	O
the	DT	O
reaction	NN	O
mixture	JJ	O
containing	)	O
the	IN	O
test	DT	O
compound	NN	O
indicates	NN	O
that	CC	O
the	DT	O
test	JJ	O
compound	CC	O
interferes	JJ	O
with	NN	O
the	NN	O
interaction	IN	O
of	DT	O
the	NN	O
test	VBZ	O
compound	VBN	O
and	IN	O
its	JJ	O
reaction	.	O
partner.	DT	O
To	NN	O
assay	IN	O
for	DT	O
antagonists,	NN	O
the	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	)	O
PRO1328,	CC	O
PRO4342,	RB	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	NN	O
or	VBG	O
PRO1885	DT	O
polypeptide	NN	O
may	NN	O
be	VBZ	O
added	IN	O
to	DT	O
a	NN	O
cell	NN	O
along	VBZ	O
with	IN	O
the	DT	O
compound	NN	O
to	IN	O
be	DT	O
screened	NN	O
for	NN	O
a	CC	O
particular	PRP$	O
activity	NN	O
and	.	O
the	TO	O
ability	VB	O
of	IN	O
the	,	O
compound	DT	O
to	,	O
inhibit	,	O
the	,	O
activity	,	O
of	,	O
interest	,	O
in	,	O
the	,	O
presence	NNP	O
of	CC	O
the	NNP	O
PRO227,	NN	O
PRO233,	MD	O
PRO238,	VB	O
PRO1328,	VBN	O
PRO4342,	TO	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	IN	O
or	DT	O
PRO1885	NN	O
polypeptide	TO	O
indicates	VB	O
that	VBN	O
the	IN	O
compound	DT	O
is	JJ	O
an	NN	O
antagonist	CC	O
to	DT	O
the	NN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	TO	O
PRO4342,	VB	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
polypeptide.	NN	O
Alternatively,	IN	O
antagonists	DT	O
may	,	O
be	,	O
detected	,	O
by	,	O
combining	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	VBP	O
PRO10096,	VBZ	O
PRO21384,	IN	O
PRO353	DT	O
or	NN	O
PRO1885	VBZ	O
polypeptide	DT	O
and	NN	O
a	TO	O
potential	DT	O
antagonist	,	O
with	,	O
membrane-bound	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	.	O
or	,	O
PRO1885	NNS	O
polypeptide	MD	O
receptors	VB	O
or	VBN	O
recombinant	IN	O
receptors	VBG	O
under	DT	O
appropriate	,	O
conditions	,	O
for	,	O
a	,	O
competitive	,	O
inhibition	,	O
assay.	,	O
The	,	O
PRO227,	NNP	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	IN	O
or	JJ	O
PRO1885	,	O
polypeptide	,	O
can	,	O
be	,	O
labeled,	,	O
such	,	O
as	,	O
by	,	O
radioactivity,	NNP	O
such	CC	O
that	NNP	O
the	JJ	O
number	NNS	O
of	CC	O
PRO227,	JJ	O
PRO233,	NNS	O
PRO238,	IN	O
PRO1328,	JJ	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	NN	O
or	.	O
PRO1885	DT	O
polypeptide	,	O
molecules	,	O
bound	,	O
to	,	O
the	,	O
receptor	,	O
can	,	O
be	,	O
used	NNP	O
to	CC	O
determine	NNP	O
the	NN	O
effectiveness	MD	O
of	VB	O
the	,	O
potential	JJ	O
antagonist.	IN	O
The	IN	O
gene	,	O
encoding	JJ	O
the	IN	O
receptor	DT	O
can	NN	O
be	IN	O
identified	,	O
by	,	O
numerous	,	O
methods	,	O
known	,	O
to	,	O
those	,	O
of	,	O
skill	NNP	O
in	CC	O
the	NNP	O
art,	IN	O
for	NNS	O
example,	IN	O
ligand	TO	O
panning	DT	O
and	NN	O
FACS	MD	O
sorting.	VB	O
Coligan	VBN	B
et	TO	I
al.,	VB	I
Current	DT	I
Protocols	NN	I
in	IN	I
Immun.,	DT	I
1(2):	JJ	I
Chapter	.	I
5	DT	I
(1991).	NN	I
Preferably,	VBG	O
expression	DT	O
cloning	NN	O
is	MD	O
employed	VB	O
wherein	VBN	O
polyadenylated	IN	O
RNA	JJ	O
is	NNS	O
prepared	VBN	O
from	TO	O
a	DT	O
cell	IN	O
responsive	NN	O
to	IN	O
the	DT	O
PRO227,	,	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	VBP	O
PRO4342,	VBG	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	.	O
PRO353	NNP	O
or	CC	O
PRO1885	,	O
polypeptide	NNP	O
and	NNP	O
a	IN	O
cDNA	,	O
library	:	O
created	NN	O
from	CD	O
this	.	O
RNA	,	O
is	NN	O
divided	NN	O
into	VBZ	O
pools	VBN	O
and	RB	O
used	JJ	O
to	NNP	O
transfect	VBZ	O
COS	VBN	O
cells	IN	O
or	DT	O
other	NN	O
cells	NN	O
that	TO	O
are	DT	O
not	,	O
responsive	,	O
to	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NN	O
PRO353	CC	O
or	DT	O
PRO1885	NN	O
polypeptide.	NN	O
Transfected	VBD	O
cells	IN	O
that	DT	O
are	NNP	O
grown	VBZ	O
on	VBN	O
glass	IN	O
slides	NNS	O
are	CC	O
exposed	VBN	O
to	TO	O
labeled	VB	O
PRO227,	NNP	O
PRO233,	NNS	O
PRO238,	CC	O
PRO1328,	JJ	O
PRO4342,	NNS	O
PRO7423,	WDT	O
PRO10096,	VBP	O
PRO21384,	RB	O
PRO353	JJ	O
or	TO	O
PRO1885	DT	O
polypeptide.	,	O
The	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	.	O
PRO1885	VBN	O
polypeptide	NNS	O
can	WDT	O
be	VBP	O
labeled	VBN	O
by	IN	O
a	NN	O
variety	NNS	O
of	VBP	O
means	VBN	O
including	TO	O
iodination	VBN	O
or	,	O
inclusion	,	O
of	,	O
a	,	O
recognition	,	O
site	,	O
for	,	O
a	,	O
site-specific	NNP	O
protein	CC	O
kinase.	NNP	O
Following	.	O
fixation	DT	O
and	,	O
incubation,	,	O
the	,	O
slides	,	O
are	,	O
subjected	,	O
to	,	O
autoradiographic	,	O
analysis.	NNP	O
Positive	CC	O
pools	NNP	O
are	NN	O
identified	MD	O
and	VB	O
sub-pools	VBN	O
are	IN	O
prepared	DT	O
and	NN	O
re-transfected	IN	O
using	NNS	O
an	VBG	O
interactive	NN	O
sub-pooling	CC	O
and	NN	O
re-screening	IN	O
process,	DT	O
eventually	NN	O
yielding	NN	O
a	IN	O
single	DT	O
clone	JJ	O
that	NN	O
encodes	.	O
the	VBG	O
putative	NN	O
receptor.	CC	O
As	,	O
an	DT	O
alternative	NNS	O
approach	VBP	O
for	VBN	O
receptor	TO	O
identification,	JJ	O
the	.	O
labeled	JJ	O
PRO227,	NNS	O
PRO233,	VBP	O
PRO238,	VBN	O
PRO1328,	CC	O
PRO4342,	NNS	O
PRO7423,	VBP	O
PRO10096,	JJ	O
PRO21384,	CC	O
PRO353	JJ	O
or	VBG	O
PRO1885	DT	O
polypeptide	JJ	O
can	NN	O
be	CC	O
photoaffinity-linked	JJ	O
with	,	O
cell	RB	O
membrane	VBG	O
or	DT	O
extract	JJ	O
preparations	NN	O
that	WDT	O
express	VBZ	O
the	DT	O
receptor	JJ	O
molecule.	.	O
Cross-linked	IN	O
material	DT	O
is	JJ	O
resolved	NN	O
by	IN	O
PAGE	NN	O
and	,	O
exposed	DT	O
to	JJ	O
X-ray	,	O
film.	,	O
The	,	O
labeled	,	O
complex	,	O
containing	,	O
the	,	O
receptor	,	O
can	NNP	O
be	CC	O
excised,	NNP	O
resolved	NN	O
into	MD	O
peptide	VB	O
fragments,	JJ	O
and	IN	O
subjected	NN	O
to	NN	O
protein	CC	O
micro-sequencing.	JJ	O
The	NNS	O
amino	WDT	O
acid	VBP	O
sequence	DT	O
obtained	NN	O
from	.	O
micro-sequencing	JJ	O
would	NN	O
be	VBZ	O
used	VBN	O
to	IN	O
design	NNP	O
a	CC	O
set	VBN	O
of	TO	O
degenerate	JJ	O
oligonucleotide	.	O
probes	DT	O
to	VBN	O
screen	NN	O
a	VBG	O
cDNA	DT	O
library	NN	O
to	MD	O
identify	VB	O
the	,	O
gene	VBN	O
encoding	IN	O
the	NN	O
putative	,	O
receptor.	CC	O
Another	VBN	O
approach	TO	O
in	VB	O
assessing	.	O
the	DT	O
effect	NN	O
of	JJ	O
an	NN	O
antagonist	VBN	O
to	IN	O
a	NN	O
PRO227,	MD	O
PRO233,	VB	O
PRO238,	VBN	O
PRO1328,	TO	O
PRO4342,	VB	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	JJ	O
or	NN	O
PRO1885	NNS	O
polypeptide,	TO	O
would	VB	O
be	DT	O
administering	NN	O
a	NN	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBG	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	.	O
PRO353	DT	O
or	NN	O
PRO1885	IN	O
antagonist	VBG	O
to	DT	O
a	NN	O
wild-type	IN	O
mouse	DT	O
in	NN	O
order	TO	O
to	DT	O
mimic	,	O
a	,	O
known	,	O
knockout	,	O
phenotype.	,	O
Thus,	,	O
one	,	O
would	,	O
initially	NNP	O
knockout	CC	O
the	NNP	O
PRO227,	,	O
PRO233,	MD	O
PRO238,	VB	O
PRO1328,	VBG	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene	,	O
of	,	O
interest	NNP	O
and	CC	O
observe	NNP	O
the	VBP	O
resultant	TO	O
phenotype	DT	O
as	JJ	O
a	NN	O
consequence	IN	O
of	NN	O
knocking	TO	O
out	VB	O
or	DT	O
disrupting	VBN	O
the	NN	O
PRO227,	.	O
PRO233,	,	O
PRO238,	CD	O
PRO1328,	MD	O
PRO4342,	RB	O
PRO7423,	VB	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene.	,	O
Subsequently,	,	O
one	,	O
could	,	O
then	NNP	O
assess	CC	O
the	NNP	O
effectiveness	NN	O
of	IN	O
an	NN	O
antagonist	CC	O
to	VB	O
the	DT	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	VBG	O
PRO21384,	RP	O
PRO353	CC	O
or	VBG	O
PRO1885	DT	O
polypeptide	,	O
by	,	O
administering	,	O
an	,	O
antagonist	,	O
to	,	O
the	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	.	O
PRO7423,	,	O
PRO10096,	CD	O
PRO21384,	MD	O
PRO353	RB	O
or	VB	O
PRO1885	DT	O
polypeptide	NN	O
to	IN	O
a	DT	O
wild-type	NN	O
mouse.	TO	O
An	DT	O
effective	,	O
antagonist	,	O
would	,	O
be	,	O
expected	,	O
to	,	O
mimic	,	O
the	,	O
phenotypic	NNP	O
effect	CC	O
that	NNP	O
was	NN	O
initially	IN	O
observed	VBG	O
in	DT	O
the	NN	O
knockout	TO	O
animal.	DT	O
Likewise,	,	O
one	,	O
could	,	O
assess	,	O
the	,	O
effect	,	O
of	,	O
an	,	O
agonist	NNP	O
to	CC	O
a	NNP	O
PRO227,	VBP	O
PRO233,	TO	O
PRO238,	DT	O
PRO1328,	JJ	O
PRO4342,	.	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	MD	O
or	VB	O
PRO1885	VBN	O
polypeptide,	TO	O
by	VB	O
administering	DT	O
a	NN	O
PRO227,	NN	O
PRO233,	WDT	O
PRO238,	VBD	O
PRO1328,	RB	O
PRO4342,	VBN	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	.	O
or	,	O
PRO1885	CD	O
agonist	MD	O
to	VB	O
a	DT	O
non-human	NN	O
transgenic	IN	O
mouse	DT	O
in	NN	O
order	TO	O
to	DT	O
ameliorate	,	O
a	,	O
known	,	O
negative	,	O
knockout	,	O
phenotype.	,	O
Thus,	,	O
one	,	O
would	NNP	O
initially	CC	O
knockout	NNP	O
the	,	O
PRO227,	IN	O
PRO233,	VBG	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene	NNP	O
of	CC	O
interest	NNP	O
and	VBP	O
observe	TO	O
the	DT	O
resultant	JJ	O
phenotype	NN	O
as	NN	O
a	IN	O
consequence	NN	O
of	TO	O
knocking	VB	O
out	DT	O
or	JJ	O
disrupting	JJ	O
the	NN	O
PRO227,	.	O
PRO233,	,	O
PRO238,	CD	O
PRO1328,	MD	O
PRO4342,	RB	O
PRO7423,	VB	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
gene.	,	O
Subsequently,	,	O
one	,	O
could	,	O
then	NNP	O
assess	CC	O
the	NNP	O
effectiveness	NN	O
of	IN	O
an	NN	O
agonist	CC	O
to	VB	O
the	DT	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	VBG	O
PRO21384,	RP	O
PRO353	CC	O
or	VBG	O
PRO1885	DT	O
polypeptide	,	O
by	,	O
administering	,	O
an	,	O
agonist	,	O
to	,	O
the	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	.	O
PRO7423,	,	O
PRO10096,	CD	O
PRO21384,	MD	O
PRO353	RB	O
or	VB	O
PRO1885	DT	O
polypeptide	NN	O
to	IN	O
a	DT	O
the	NN	O
non-human	TO	O
transgenic	DT	O
mouse.	,	O
An	,	O
effective	,	O
agonist	,	O
would	,	O
be	,	O
expected	,	O
to	,	O
ameliorate	NNP	O
the	CC	O
negative	NNP	O
phenotypic	NN	O
effect	IN	O
that	VBG	O
was	DT	O
initially	NN	O
observed	TO	O
in	DT	O
the	,	O
knockout	,	O
animal	,	O
In	,	O
another	,	O
assay	,	O
for	,	O
antagonists,	,	O
mammalian	NNP	O
cells	CC	O
or	NNP	O
a	VBP	O
membrane	TO	O
preparation	DT	O
expressing	DT	O
the	JJ	O
receptor	JJ	O
would	.	O
be	DT	O
incubated	JJ	O
with	NN	O
a	MD	O
labeled	VB	O
PRO227,	VBN	O
PRO233,	TO	O
PRO238,	VB	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	NN	O
PRO21384,	WDT	O
PRO353	VBD	O
or	RB	O
PRO1885	VBN	O
polypeptide	IN	O
in	DT	O
the	NN	O
presence	NN	O
of	IN	O
the	DT	O
candidate	NN	O
compound.	IN	O
The	,	O
ability	JJ	O
of	NNS	O
the	CC	O
compound	DT	O
to	JJ	O
enhance	NN	O
or	VBG	O
block	DT	O
this	NN	O
interaction	MD	O
could	VB	O
then	VBN	O
be	IN	O
measured.	DT	O
More	JJ	O
specific	,	O
examples	,	O
of	,	O
potential	,	O
antagonists	,	O
include	,	O
an	,	O
oligonucleotide	,	O
that	NNP	O
binds	CC	O
to	NNP	O
the	NN	O
fusions	IN	O
of	DT	O
immunoglobulin	NN	O
with	IN	O
the	DT	O
PRO227,	NN	O
PRO233,	.	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	TO	O
PRO353	VB	O
or	CC	O
PRO1885	VB	O
polypeptide,	DT	O
and,	NN	O
in	MD	O
particular,	RB	O
antibodies	VB	O
including,	.	O
without	RBR	O
limitation,	JJ	O
poly-	NNS	O
and	IN	O
monoclonal	JJ	O
antibodies	NNS	O
and	VBP	O
antibody	DT	O
fragments,	NN	O
single-chain	WDT	O
antibodies,	VBZ	O
anti-idiotypic	TO	O
antibodies,	DT	O
and	NNS	O
chimeric	IN	O
or	NN	O
humanized	IN	O
versions	DT	O
of	,	O
such	,	O
antibodies	,	O
or	,	O
fragments,	,	O
as	,	O
well	,	O
as	,	O
human	NNP	O
antibodies	CC	O
and	NNP	O
antibody	,	O
fragments.	,	O
Alternatively,	IN	O
a	,	O
potential	NNS	O
antagonist	,	O
may	IN	O
be	,	O
a	JJ	O
closely	CC	O
related	JJ	O
protein,	NNS	O
for	CC	O
example,	NN	O
a	,	O
mutated	JJ	O
form	,	O
of	JJ	O
the	,	O
PRO227,	CC	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	JJ	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NNS	O
PRO353	CC	O
or	,	O
PRO1885	RB	O
polypeptide	RB	O
that	IN	O
recognizes	JJ	O
the	NNS	O
receptor	CC	O
but	NN	O
imparts	.	O
no	,	O
effect,	DT	O
thereby	JJ	O
competitively	NN	O
inhibiting	MD	O
the	VB	O
action	DT	O
of	RB	O
the	JJ	O
PRO227,	,	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide.	,	O
Another	,	O
potential	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	IN	O
PRO10096,	WDT	O
PRO21384,	VBZ	O
PRO353	DT	O
or	NN	O
PRO1885	CC	O
polypeptide	VBZ	O
antagonist	DT	O
is	,	O
an	RB	O
antisense	RB	O
RNA	VBG	O
or	DT	O
DNA	NN	O
construct	IN	O
prepared	DT	O
using	,	O
antisense	,	O
technology,	,	O
where,	,	O
e.g.,	,	O
an	,	O
antisense	,	O
RNA	,	O
or	NNP	O
DNA	CC	O
molecule	NNP	O
acts	.	O
to	DT	O
block	JJ	O
directly	,	O
the	,	O
translation	,	O
of	,	O
mRNA	,	O
by	,	O
hybridizing	,	O
to	,	O
targeted	NNP	O
mRNA	CC	O
and	NNP	O
preventing	IN	O
protein	NN	O
translation.	VBZ	O
Antisense	DT	O
technology	JJ	O
can	NNP	O
be	CC	O
used	NNP	O
to	NN	O
control	VBD	O
gene	VBG	O
expression	JJ	O
through	,	O
triple-helix	,	O
formation	,	O
or	DT	O
antisense	JJ	O
DNA	NNP	O
or	CC	O
RNA,	NNP	O
both	NN	O
of	NNS	O
which	TO	O
methods	VB	O
are	RB	O
based	DT	O
on	NN	O
binding	IN	O
of	NN	O
a	IN	O
polynucleotide	VBG	O
to	TO	O
DNA	VBN	O
or	NN	O
RNA.	CC	O
For	VBG	O
example,	JJ	O
the	.	O
5′	NNP	O
coding	NN	O
portion	MD	O
of	VB	O
the	VBN	O
polynucleotide	TO	O
sequence,	VB	O
which	NN	O
encodes	NN	O
the	IN	O
mature	JJ	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	,	O
PRO10096,	DT	O
PRO21384,	IN	O
PRO353	WDT	O
or	NNS	O
PRO1885	VBP	O
polypeptides	VBN	O
herein,	IN	O
is	NN	O
used	IN	O
to	DT	O
design	NN	O
an	TO	O
antisense	NNP	O
RNA	CC	O
oligonucleotide	.	O
of	IN	O
from	,	O
about	DT	O
10	CD	O
to	VBG	O
40	NN	O
base	IN	O
pairs	DT	O
in	NN	O
length.	,	O
A	WDT	O
DNA	VBZ	O
oligonucleotide	DT	O
is	NN	O
designed	,	O
to	,	O
be	,	O
complementary	,	O
to	,	O
a	,	O
region	,	O
of	,	O
the	NNP	O
gene	CC	O
involved	NNP	O
in	NNS	O
transcription	,	O
(triple	VBZ	O
helix—see	VBN	O
Lee	TO	B
et	VB	I
al.,	DT	I
Nucl.	NN	I
Acids	NNP	I
Res.,	NN	I
6:3073	IN	I
(1979);	IN	I
Cooney	IN	B
et	CD	I
al.,	TO	I
Science,	CD	I
241:	NN	I
456	NNS	I
(1988);	IN	I
Dervan	.	B
et	DT	I
al.,	NNP	I
Science,	NN	I
251:1360	VBZ	I
(1991)),thereby	VBN	O
preventing	TO	O
transcription	VB	O
and	JJ	O
the	TO	O
production	DT	O
of	NN	O
the	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	NN	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	NNP	O
PRO353	CC	O
or	,	O
PRO1885	.	O
polypeptide.	NNP	O
The	,	O
antisense	CD	O
RNA	:	O
oligonucleotide	NNP	O
hybridizes	FW	O
to	,	O
the	,	O
mRNA	:	O
in	CD	O
vivo	:	O
and	NNP	O
blocks	FW	O
translation	,	O
of	,	O
the	CD	O
mRNA	,	O
molecule	RB	O
into	VBG	O
the	NN	O
PRO227,	CC	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
Okano,	,	B
Neurochem.,	NNP	I
56:560	CC	I
(1991);	NNP	I
(antisense—Oligodeoxynucleotides	.	O
as	DT	O
Antisense	NN	O
Inhibitors	NNP	O
of	RB	O
Gene	VBZ	O
Expression	TO	O
(CRC	DT	O
Press:	NN	O
Boca	IN	O
Raton,	NN	O
Fla.,	CC	O
1988).	NNS	O
The	NN	O
oligonucleotides	IN	O
described	DT	O
above	NN	O
can	NN	O
also	IN	O
be	DT	O
delivered	,	O
to	,	O
cells	,	O
such	,	O
that	,	O
the	,	O
antisense	,	O
RNA	,	O
or	NNP	O
DNA	CC	O
may	NNP	O
be	NN	O
expressed	,	O
in	,	O
vivo	CD	O
to	:	O
inhibit	CC	O
production	IN	O
of	NNP	O
the	NNP	O
PRO227,	IN	O
PRO233,	NNP	O
PRO238,	NNP	O
PRO1328,	NNP	O
PRO4342,	:	O
PRO7423,	NNP	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	.	O
or	DT	O
PRO1885	NNS	O
polypeptide.	VBN	O
When	IN	O
antisense	MD	O
DNA	RB	O
is	VB	O
used,	VBN	O
oligodeoxyribonucleotides	TO	O
derived	NNS	O
from	JJ	O
the	IN	O
translation-initiation	DT	O
site,	NN	O
e.g.,	NNP	O
between	CC	O
about	NNP	O
−10	MD	O
and	VB	O
+10	VBN	O
positions	IN	O
of	NN	O
the	TO	O
target	VB	O
gene	NN	O
nucleotide	IN	O
sequence,	DT	O
are	,	O
preferred.	,	O
Potential	,	O
antagonists	,	O
include	,	O
small	,	O
molecules	,	O
that	,	O
bind	NNP	O
to	CC	O
the	NNP	O
active	.	O
site,	WRB	O
the	NN	O
receptor	NN	O
binding	VBZ	O
site,	,	O
or	VBZ	O
growth	VBN	O
factor	IN	O
or	DT	O
other	NN	O
relevant	,	O
binding	,	O
site	IN	O
of	IN	O
the	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NNS	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	NN	O
PRO21384,	JJ	O
PRO353	,	O
or	VBP	O
PRO1885	.	O
polypeptide,	JJ	O
thereby	NNS	O
blocking	VBP	O
the	JJ	O
normal	NNS	O
biological	WDT	O
activity	VBP	O
of	TO	O
the	DT	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBG	O
PRO7423,	,	O
PRO10096,	CC	O
PRO21384,	NN	O
PRO353	NN	O
or	CC	O
PRO1885	JJ	O
polypeptide.	JJ	O
Examples	VBG	O
of	NN	O
small	IN	O
molecules	DT	O
include,	,	O
but	,	O
are	,	O
not	,	O
limited	,	O
to,	,	O
small	,	O
peptides	,	O
or	NNP	O
peptide-like	CC	O
molecules,	NNP	O
preferably	,	O
soluble	RB	O
peptides,	VBG	O
and	DT	O
synthetic	JJ	O
non-peptidyl	JJ	O
organic	NN	O
or	IN	O
inorganic	DT	O
compounds.	,	O
Ribozymes	,	O
are	,	O
enzymatic	,	O
RNA	,	O
molecules	,	O
capable	,	O
of	,	O
catalyzing	NNP	O
the	CC	O
specific	NNP	O
cleavage	.	O
of	NNS	O
RNA.	IN	O
Ribozymes	JJ	O
act	NNS	O
by	,	O
sequence-specific	CC	O
hybridization	VBP	O
to	RB	O
the	VBN	O
complementary	,	O
target	JJ	O
RNA,	NNS	O
followed	CC	O
by	JJ	O
endonucleolytic	,	O
cleavage.	RB	O
Specific	JJ	O
ribozyme	,	O
cleavage	CC	O
sites	JJ	O
within	JJ	O
a	NN	O
potential	CC	O
RNA	JJ	O
target	.	O
can	NNS	O
be	VBP	O
identified	JJ	O
by	NNP	O
known	NNS	O
techniques.	JJ	O
For	IN	O
further	VBG	O
details	DT	O
see,	JJ	O
e.g.,	NN	O
Rossi,	IN	B
Current	.	I
Biology,	NNP	I
4:469-471	NN	I
(1994),	IN	I
and	JJ	O
PCT	NN	O
publication	TO	O
No.	DT	O
WO	JJ	O
97/33551	NN	O
(published	,	O
Sep.	VBN	O
18,	IN	O
1997).	JJ	O
Nucleic	.	O
acid	JJ	O
molecules	NN	O
in	NN	O
triple-helix	NNS	O
formation	IN	O
used	DT	O
to	JJ	O
inhibit	NNP	O
transcription	NN	O
should	MD	O
be	VB	O
single-stranded	VBN	O
and	IN	O
composed	VBN	O
of	.	O
deoxynucleotides.	IN	O
The	JJ	O
base	NNS	O
composition	,	O
of	,	O
these	,	O
oligonucleotides	NNP	O
is	,	O
designed	CD	O
such	,	O
that	CC	O
it	NNP	O
promotes	NN	O
triple-helix	.	O
formation	$	O
via	CD	O
Hoogsteen	VBN	O
base-pairing	NNP	O
rules,	,	O
which	.	O
generally	NNP	O
require	NN	O
sizeable	NNS	O
stretches	IN	O
of	JJ	O
purines	NN	O
or	VBN	O
pyrimidines	TO	O
on	VB	O
one	NN	O
strand	MD	O
of	VB	O
a	JJ	O
duplex.	CC	O
For	VBN	O
further	IN	O
details	.	O
see,	DT	O
e.g.,	JJ	O
PCT	NN	O
publication	IN	O
No.	DT	O
WO	NNS	O
97/33551,	VBZ	O
supra.	VBN	O
These	JJ	O
small	IN	O
molecules	PRP	O
can	VBZ	O
be	JJ	O
identified	NN	O
by	IN	O
any	NNP	O
one	NN	O
or	,	O
more	WDT	O
of	RB	O
the	VBP	O
screening	JJ	O
assays	NNS	O
discussed	IN	O
hereinabove	NNS	O
and/or	CC	O
by	NNS	O
any	IN	O
other	CD	O
screening	NN	O
techniques	IN	O
well	DT	O
known	.	O
for	IN	O
those	JJ	O
skilled	NNS	O
in	,	O
the	,	O
art.	NNP	O
Diagnostic	NN	O
and	.	O
therapeutic	NNP	O
uses	,	O
of	.	O
the	DT	O
herein	JJ	O
disclosed	NNS	O
molecules	MD	O
may	VB	O
also	VBN	O
be	IN	O
based	DT	O
upon	CD	O
the	CC	O
positive	JJR	O
functional	IN	O
assay	DT	O
hits	NN	O
disclosed	NNS	O
and	VBN	O
described	VB	O
below.	NN	O
F.	IN	O
Anti-PRO227,	DT	O
Anti-PRO233,	JJ	O
Anti-PRO238,	NN	O
Anti-PRO1328,	NNS	O
Anti-PRO4342,	RB	O
Anti-PRO7423;	VBN	O
Anti-PRO10096;	IN	O
Anti-PRO21384;	DT	O
Anti-PRO353	VBN	O
or	IN	O
Anti-PRO1885	DT	O
Antibodies	.	O
The	JJ	O
present	CC	O
invention	JJ	O
provides	NNS	O
anti-PRO227,	IN	O
anti-PRO233,	DT	O
anti-PRO238,	NN	O
anti-PRO1328,	VBD	O
anti-PRO4342,	NNS	O
anti-PRO7423,	MD	O
anti-PRO10096,	RB	O
anti-PRO21384,	VB	O
anti-PRO353	VBN	O
or	IN	O
anti-PRO1885	DT	O
antibodies	JJ	O
which	JJ	O
may	NN	O
find	NNS	O
use	VBN	O
herein	CC	O
as	VBN	O
therapeutic	.	O
and/or	NNP	O
diagnostic	,	O
agents.	,	O
Exemplary	,	O
antibodies	,	O
include	,	O
polyclonal,	:	O
monoclonal,	:	O
humanized,	:	O
bispecific,	NNP	O
and	CC	O
heteroconjugate	NNP	O
antibodies.	NNPS	O
1.	DT	O
Polyclonal	JJ	O
Antibodies	NN	O
Polyclonal	VBZ	O
antibodies	,	O
are	,	O
preferably	,	O
raised	,	O
in	,	O
animals	,	O
by	,	O
multiple	,	O
subcutaneous	JJ	O
(sc)	CC	O
or	JJ	O
intraperitoneal	NNS	O
(ip)	WDT	O
injections	MD	O
of	VB	O
the	NN	O
relevant	NN	O
antigen	IN	O
and	JJ	O
an	NN	O
adjuvant.	JJ	O
It	.	O
may	JJ	O
be	NNS	O
useful	VBP	O
to	,	O
conjugate	,	O
the	,	O
relevant	,	O
antigen	CC	O
(especially	NN	O
when	.	O
synthetic	.	O
peptides	JJ	O
are	NNP	O
used)	NNP	O
to	NNS	O
a	VBP	O
protein	RB	O
that	VBN	O
is	IN	O
immunogenic	NNS	O
in	IN	O
the	JJ	O
species	JJ	O
to	)	O
be	CC	O
immunized.	NN	O
For	)	O
example,	NNS	O
the	IN	O
antigen	DT	O
can	JJ	O
be	NN	O
conjugated	CC	O
to	DT	O
keyhole	.	O
limpet	PRP	O
hemocyanin	MD	O
(KLH),	VB	O
serum	JJ	O
albumin,	TO	O
bovine	VB	O
thyroglobulin,	DT	O
or	JJ	O
soybean	NN	O
trypsin	RB	O
inhibitor,	WRB	O
using	JJ	O
a	NNS	O
bifunctional	VBP	O
or	)	O
derivatizing	TO	O
agent,	DT	O
e.g.,	NN	O
maleimidobenzoyl	WDT	O
sulfosuccinimide	VBZ	O
ester	JJ	O
(conjugation	IN	O
through	DT	O
cysteine	NNS	O
residues),	TO	O
N-hydroxysuccinimide	VB	O
(through	.	O
lysine	IN	O
residues),	,	O
glutaraldehyde,	DT	O
succinic	NN	O
anhydride,	MD	O
SOCl2,	VB	O
or	VBN	O
R1N═C═NR,	TO	O
where	VB	O
R	NN	O
and	NN	O
R1	,	O
are	JJ	O
different	,	O
alkyl	NN	O
groups.	,	O
Animals	CC	O
are	NN	O
immunized	NN	O
against	,	O
the	VBG	O
antigen,	DT	O
immunogenic	JJ	O
conjugates,	CC	O
or	VBG	O
derivatives	,	O
by	,	O
combining,	JJ	O
e.g.,	NN	O
100	NN	O
μg	NN	O
or	IN	O
5	NN	O
μg	,	O
of	NNP	O
the	IN	O
protein	NN	O
or	,	O
conjugate	,	O
(for	JJ	O
rabbits	,	O
or	,	O
mice,	CC	O
respectively)	,	O
with	WRB	O
3	NNP	O
volumes	CC	O
of	NNP	O
Freund's	VBP	O
complete	JJ	O
adjuvant	JJ	O
and	.	O
injecting	NNS	O
the	VBP	O
solution	VBN	O
intradermally	IN	O
at	DT	O
multiple	,	O
sites.	JJ	O
One	,	O
month	CC	O
later,	NNS	O
the	IN	O
animals	,	O
are	,	O
boosted	CD	O
with	NN	O
⅕	CC	O
to	CD	O
1/10	NN	O
the	IN	O
original	DT	O
amount	NN	O
of	CC	O
peptide	NN	O
or	IN	O
conjugate	NNS	O
in	CC	O
Freund's	,	O
complete	)	O
adjuvant	IN	O
by	CD	O
subcutaneous	NNS	O
injection	IN	O
at	POS	O
multiple	JJ	O
sites.	NN	O
Seven	CC	O
to	VBG	O
14	DT	O
days	NN	O
later,	RB	O
the	IN	O
animals	JJ	O
are	.	O
bled	CD	O
and	NN	O
the	,	O
serum	DT	O
is	NNS	O
assayed	VBP	O
for	VBN	O
antibody	IN	O
titer.	NN	O
Animals	TO	O
are	CD	O
boosted	DT	O
until	JJ	O
the	NN	O
titer	IN	O
plateaus.	NN	O
Conjugates	CC	O
also	NN	O
can	IN	O
be	POS	O
made	JJ	O
in	NN	O
recombinant	IN	O
cell	JJ	O
culture	NN	O
as	IN	O
protein	JJ	O
fusions.	.	O
Also,	RB	O
aggregating	TO	O
agents	CD	O
such	NNS	O
as	,	O
alum	DT	O
are	NNS	O
suitably	VBP	O
used	VBN	O
to	CC	O
enhance	DT	O
the	NN	O
immune	VBZ	O
response.	VBN	O
2.	IN	O
Monoclonal	NN	O
Antibodies	.	O
Monoclonal	NNS	O
antibodies	VBP	O
may	VBN	O
be	IN	O
made	DT	O
using	NN	O
the	.	O
hybridoma	NNS	O
method	RB	O
first	MD	O
described	VB	O
by	VBN	O
Kohler	IN	B
et	JJ	I
al.,	NN	I
Nature,	NN	I
256:495	IN	I
(1975),	NN	I
or	.	O
may	,	O
be	VBG	O
made	NNS	O
by	JJ	O
recombinant	IN	O
DNA	NN	O
methods	VBP	O
(U.S.	RB	O
Pat.	VBN	O
No.	TO	O
4,816,567).	VB	O
In	DT	O
the	JJ	O
hybridoma	.	O
method,	.	O
a	JJ	O
mouse	NNP	O
or	NNP	O
other	NNS	O
appropriate	MD	O
host	VB	O
animal,	VBN	O
such	VBG	O
as	DT	O
a	NN	O
hamster,	NN	O
is	RB	O
immunized	VBN	O
as	IN	O
described	NNP	O
above	FW	O
to	,	O
elicit	,	O
lymphocytes	CD	O
that	,	O
produce	CC	O
or	MD	O
are	VB	O
capable	VBN	O
of	IN	O
producing	JJ	O
antibodies	NNP	O
that	NNS	O
will	NNP	O
specifically	.	O
bind	.	O
to	.	O
the	IN	O
protein	DT	O
used	NN	O
for	,	O
immunization.	DT	O
Alternatively,	NN	O
lymphocytes	CC	O
may	JJ	O
be	JJ	O
immunized	NN	O
in	,	O
vitro.	JJ	O
After	IN	O
immunization,	DT	O
lymphocytes	,	O
are	VBZ	O
isolated	VBN	O
and	IN	O
then	VBN	O
fused	IN	O
with	TO	O
a	VB	O
myeloma	NNS	O
cell	IN	O
line	VBP	O
using	CC	O
a	VBP	O
suitable	JJ	O
fusing	IN	O
agent,	VBG	O
such	NNS	O
as	WDT	O
polyethylene	MD	O
glycol,	RB	O
to	VB	O
form	TO	O
a	DT	O
hybridoma	NN	O
cell	VBN	O
Goding,	IN	B
Monoclonal	.	I
Antibodies:	,	I
Principles	NNS	I
and	MD	I
Practice,	VB	I
pp.	VBN	I
59-103	IN	I
(Academic	.	I
Press,	IN	I
1986)).(	,	O
The	NNS	O
hybridoma	VBP	O
cells	VBN	O
thus	CC	O
prepared	RB	O
are	VBD	O
seeded	IN	O
and	DT	O
grown	NN	O
in	NN	O
a	NN	O
suitable	VBG	O
culture	DT	O
medium	JJ	O
which	NN	O
medium	,	O
preferably	JJ	O
contains	IN	O
one	NN	O
or	,	O
more	TO	O
substances	VB	O
that	DT	O
inhibit	NN	O
the	NN	O
growth	,	O
or	NNP	O
survival	:	O
of	NNS	O
the	CC	O
unfused,	,	O
parental	.	O
myeloma	JJ	O
cells	NNP	O
(also	,	O
referred	.	O
to	DT	O
as	NN	O
fusion	NNS	O
partner).	RB	O
For	VBN	O
example,	VBP	O
if	VBN	O
the	CC	O
parental	VBN	O
myeloma	IN	O
cells	DT	O
lack	JJ	O
the	NN	O
enzyme	NN	O
hypoxanthine	WDT	O
guanine	NN	O
phosphoribosyl	RB	O
transferase	VBZ	O
(HGPRT	CD	O
or	CC	O
HPRT),	JJR	O
the	NNS	O
selective	WDT	O
culture	VBP	O
medium	DT	O
for	NN	O
the	CC	O
hybridomas	NN	O
typically	IN	O
will	DT	O
include	,	O
hypoxanthine,	JJ	O
aminopterin,	NN	O
and	NNS	O
thymidine	RB	O
(HAT	VBN	O
medium),	TO	O
which	IN	O
substances	NN	O
prevent	.	O
the	IN	O
growth	,	O
of	IN	O
HGPRT-deficient	DT	O
cells.	JJ	O
Preferred	NN	O
fusion	NNS	O
partner	VBP	O
myeloma	DT	O
cells	NN	O
are	NN	O
those	NN	O
that	NN	O
fuse	NN	O
efficiently,	NNP	O
support	CC	O
stable	,	O
high-level	DT	O
production	JJ	O
of	NN	O
antibody	NN	O
by	IN	O
the	DT	O
selected	NN	O
antibody-producing	RB	O
cells,	MD	O
and	VB	O
are	,	O
sensitive	,	O
to	CC	O
a	NN	O
selective	NNP	O
medium	,	O
that	WDT	O
selects	VBZ	O
against	VBP	O
the	DT	O
unfused	NN	O
parental	IN	O
cells.	NNP	O
Preferred	.	O
myeloma	JJ	O
cell	NN	O
lines	NN	O
are	NN	O
murine	NNS	O
myeloma	VBP	O
lines,	DT	O
such	IN	O
as	VBP	O
those	,	O
derived	NN	O
from	JJ	O
MOPC-21	JJ	O
and	NN	O
MPC-11	IN	O
mouse	NN	O
tumors	IN	O
available	DT	O
from	VBN	O
the	NN	O
Salk	,	O
Institute	CC	O
Cell	VBP	O
Distribution	JJ	O
Center,	TO	O
San	DT	O
Diego,	JJ	O
Calif.	NN	O
USA,	WDT	O
and	VBZ	O
SP-2	IN	O
and	DT	O
derivatives	JJ	O
e.g.,	JJ	O
X63-Ag8-653	.	O
cells	NNP	O
available	NN	O
from	NN	O
the	NNS	O
American	VBP	O
Type	JJ	O
Culture	NN	O
Collection,	,	O
Manassas,	JJ	O
Va.,	IN	O
USA.	DT	O
Human	VBN	O
myeloma	IN	O
and	NNP	O
mouse-human	CC	O
heteromyeloma	NNP	O
cell	NN	O
lines	NNS	O
also	JJ	O
have	IN	O
been	DT	O
described	NNP	O
for	NNP	O
the	NNP	O
production	NNP	O
of	,	O
human	NNP	O
monoclonal	,	O
antibodies	NNP	O
Kozbor,	,	B
J.	CC	I
Immunol.,	NNP	I
133:3001	CC	I
(1984);	NNS	I
(and	,	O
Brodeur	JJ	B
et	NNS	I
al.,	JJ	I
Monoclonal	IN	I
Antibody	DT	I
Production	JJ	I
Techniques	NNP	I
and	NNP	I
Applications,	,	I
pp.	,	I
51-63	,	I
(Marcel	.	I
Dekker,	NNP	I
Inc.,	NN	I
New	CC	I
York,	JJ	I
1987)).Culture	NN	O
medium	NN	O
in	NNS	O
which	RB	O
hybridoma	VBP	O
cells	VBN	O
are	VBN	O
growing	IN	O
is	DT	O
assayed	NN	O
for	IN	O
production	JJ	O
of	JJ	O
monoclonal	NNS	O
antibodies	,	O
directed	.	O
against	,	O
the	CD	O
antigen.	:	O
Preferably,	CC	O
the	NNP	O
binding	FW	O
specificity	,	O
of	NNP	O
monoclonal	NNP	O
antibodies	NNP	O
produced	NNP	O
by	CC	O
hybridoma	,	O
cells	.	O
is	JJ	O
determined	NNP	O
by	,	O
immunoprecipitation	,	O
or	NNP	O
by	,	O
an	.	O
in	NN	O
vitro	NN	O
binding	IN	O
assay,	WDT	O
such	NN	O
as	NNS	O
radioimmunoassay	VBP	O
(RIA)	VBG	O
or	VBZ	O
enzyme-linked	VBN	O
immunosorbent	IN	O
assay	NN	O
(ELISA).	IN	O
The	JJ	O
binding	NNS	O
affinity	VBN	O
of	IN	O
the	DT	O
monoclonal	.	O
antibody	,	O
can,	DT	O
for	VBG	O
example,	NN	O
be	IN	O
determined	JJ	O
by	NNS	O
the	VBN	O
Scatchard	IN	O
analysis	NN	O
described	NNS	O
in	VBZ	O
Munson	VBN	B
et	IN	I
al.,	NN	I
Anal.	CC	I
Biochem.,	IN	I
107:220	DT	I
(1980).
Once	IN	O
hybridoma	NN	O
cells	NN	O
that	,	O
produce	JJ	O
antibodies	IN	O
of	NN	O
the	)	O
desired	CC	O
specificity,	JJ	O
affinity,	NN	O
and/or	NN	O
activity	.	O
are	DT	O
identified,	VBG	O
the	NN	O
clones	IN	O
may	DT	O
be	JJ	O
subcloned	NN	O
by	,	O
limiting	IN	O
dilution	,	O
procedures	VB	O
and	VBN	O
grown	IN	O
by	DT	O
standard	NNP	O
methods	NN	O
Goding,	VBN	B
Monoclonal	IN	I
Antibodies:	NNP	I
Principles	CC	I
and	,	I
Practice,	.	I
pp.	,	I
59-103	CD	I
(Academic	.	I
Press,	RB	I
1986)).(	JJ	O
Suitable	NNS	O
culture	WDT	O
media	VBP	O
for	NNS	O
this	IN	O
purpose	DT	O
include,	JJ	O
for	,	O
example,	,	O
D-MEM	JJ	O
or	NN	O
RPMI-1640	VBP	O
medium.	,	O
In	DT	O
addition,	NNS	O
the	MD	O
hybridoma	VB	O
cells	VBN	O
may	IN	O
be	VBG	O
grown	NN	O
in	NNS	O
vivo	CC	O
as	VBN	O
ascites	IN	O
tumors	JJ	O
in	NNS	O
an	,	O
animal	JJ	O
e.g.	:	O
by	NNS	O
i.p.	CC	O
injection	,	O
of	.	O
the	JJ	O
cells	NNP	O
into	,	O
mice.	.	O
The	JJ	O
monoclonal	NN	O
antibodies	NNS	O
secreted	IN	O
by	DT	O
the	JJ	O
subclones	,	O
are	IN	O
suitably	,	O
separated	NNP	O
from	CC	O
the	NNP	O
culture	.	O
medium,	IN	O
ascites	,	O
fluid,	DT	O
or	NN	O
serum	NNS	O
by	MD	O
conventional	VB	O
antibody	VBN	O
purification	IN	O
procedures	NN	O
such	IN	O
as,	NNS	O
for	NNS	O
example,	IN	O
affinity	DT	O
chromatography	JJ	O
(e.g.,	.	O
using	IN	O
protein	.	O
A	NN	O
or	IN	O
protein	DT	O
G-Sepharose)	NNS	O
or	IN	O
ion-exchange	.	O
chromatography,	DT	O
hydroxylapatite	JJ	O
chromatography,	NNS	O
gel	VBN	O
electrophoresis,	IN	O
dialysis,	DT	O
etc.	NNS	O
DNA	VBP	O
encoding	RB	O
the	VBN	O
monoclonal	IN	O
antibodies	DT	O
is	NN	O
readily	,	O
isolated	VBZ	O
and	,	O
sequenced	CC	O
using	NN	O
conventional	IN	O
procedures	JJ	O
(e.g.,	NN	O
by	NN	O
using	NNS	O
oligonucleotide	JJ	O
probes	,	O
that	IN	O
are	,	O
capable	NN	O
of	NN	O
binding	,	O
specifically	VBG	O
to	RP	O
genes	DT	O
encoding	CC	O
the	JJ	O
heavy	)	O
and	CC	O
light	JJ	O
chains	,	O
of	JJ	O
murine	,	O
antibodies).	JJ	O
The	,	O
hybridoma	,	O
cells	.	O
serve	NN	O
as	VBG	O
a	DT	O
preferred	JJ	O
source	NNS	O
of	VBZ	O
such	RB	O
DNA.	VBN	O
Once	CC	O
isolated,	VBN	O
the	VBG	O
DNA	JJ	O
may	NNS	O
be	,	O
placed	IN	O
into	VBG	O
expression	JJ	O
vectors,	NNS	O
which	WDT	O
are	VBP	O
then	JJ	O
transfected	IN	O
into	VBG	O
host	RB	O
cells	TO	O
such	NNS	O
as	VBG	O
E.	DT	O
coli	JJ	O
cells,	CC	O
simian	JJ	O
COS	NNS	O
cells,	IN	O
Chinese	NN	O
Hamster	.	O
Ovary	DT	O
(CHO)	NN	O
cells,	NNS	O
or	VBP	O
myeloma	IN	O
cells	DT	O
that	JJ	O
do	NN	O
not	IN	O
otherwise	JJ	O
produce	.	O
antibody	RB	O
protein,	,	O
to	DT	O
obtain	NN	O
the	MD	O
synthesis	VB	O
of	VBN	O
monoclonal	IN	O
antibodies	NN	O
in	,	O
the	WDT	O
recombinant	VBP	O
host	RB	O
cells.	VBN	O
Review	IN	O
articles	NN	O
on	NNS	O
recombinant	JJ	O
expression	IN	O
in	NNP	O
bacteria	VBP	O
of	,	O
DNA	JJ	O
encoding	NNP	O
the	,	O
antibody	JJ	O
include	NNP	O
Skerra	NNP	B
et	)	I
al.,	,	I
Curr.	CC	I
Opinion	NN	I
in	NNS	I
Immunol.,	WDT	I
5:256-262	VBP	I
(1993)	RB	I
and	RB	O
Plückthun,	VB	B
Immunol.	NN	I
Revs.	,	I
130:151-188	TO	I
(1992).
Monoclonal	VB	O
antibodies	DT	O
or	NN	O
antibody	IN	O
fragments	JJ	O
can	NNS	O
be	IN	O
isolated	DT	O
from	NN	O
antibody	NN	O
phage	.	O
libraries	NNP	O
generated	NNS	O
using	IN	O
the	JJ	O
techniques	NN	O
described	IN	O
in	NNS	O
McCafferty	IN	B
et	NNP	I
al.,	VBG	I
Nature,	DT	I
348:552-554	NN	I
(1990).	VBP	I
Clackson	NNP	B
et	FW	I
al.,	,	I
Nature,	.	I
352:624-628	NN	I
(1991)	IN	I
and	,	O
Marks	NNP	B
et	)	I
al.,	CC	I
J.	,	I
Mol.	.	I
Biol.,	.	I
222:581-597	CD	I
(1991)	.	I
describe	JJ	O
the	NNS	O
isolation	CC	O
of	NN	O
murine	NNS	O
and	MD	O
human	VB	O
antibodies,	VBN	O
respectively,	IN	O
using	JJ	O
phage	NN	O
libraries.	NNS	O
Subsequent	VBD	O
publications	VBG	O
describe	DT	O
the	NNS	O
production	VBN	O
of	IN	O
high	NNP	O
affinity	CC	O
(nM	,	O
range)	,	O
human	NNP	O
antibodies	.	O
by	NNP	O
chain	CC	O
shuffling	,	O
Marks	,	B
et	NNP	I
al.,	)	I
Bio/Technology,	CC	I
10:779-783	NNP	I
(1992)),(	VBP	O
as	,	O
well	NNP	O
as	.	O
combinatorial	,	O
infection	CD	O
and	)	O
in	VB	O
vivo	DT	O
recombination	NN	O
as	IN	O
a	NN	O
strategy	CC	O
for	JJ	O
constructing	,	O
very	,	O
large	VBG	O
phage	NN	O
libraries	.	O
Waterhouse	JJ	B
et	NNS	I
al.,	VBP	I
Nuc.	DT	I
Acids.	NN	I
Res.	IN	I
21:2265-2266	JJ	I
(1993)).(	NN	O
Thus,	JJ	O
these	)	O
techniques	NN	O
are	NNS	O
viable	IN	O
alternatives	NN	O
to	NN	O
traditional	NNP	O
monoclonal	RB	O
antibody	,	O
hybridoma	,	O
techniques	CD	O
for	,	O
isolation	RB	O
of	RB	O
monoclonal	IN	O
antibodies.	JJ	O
The	NN	O
DNA	CC	O
that	IN	O
encodes	JJ	O
the	NN	O
antibody	IN	O
may	DT	O
be	NN	O
modified	IN	O
to	VBG	O
produce	RB	O
chimeric	JJ	O
or	NN	O
fusion	NNS	O
antibody	NNP	O
polypeptides,	VBZ	O
for	,	O
example,	.	O
by	.	O
substituting	.	O
human	CD	O
heavy	.	O
chain	,	O
and	DT	O
light	NNS	O
chain	VBP	O
constant	JJ	O
domain	NNS	O
(CH	TO	O
and	JJ	O
CL)	JJ	O
sequences	NN	O
for	NN	O
the	NNS	O
homologous	IN	O
murine	NN	O
sequences	IN	O
(U.S.	JJ	O
Pat.	.	O
No.	DT	O
4,816,567;	NN	O
and	WDT	O
Morrison,	VBZ	B
et	DT	I
al.,	NN	I
Proc.	MD	I
Natl.	VB	I
Acad.	VBN	I
Sci.	TO	I
USA,	VB	I
81:6851	JJ	I
(1984)),or	CC	O
by	NN	O
fusing	NN	O
the	,	O
immunoglobulin	IN	O
coding	,	O
sequence	IN	O
with	VBG	O
all	JJ	O
or	JJ	O
part	NN	O
of	CC	O
the	NN	O
coding	NN	O
sequence	JJ	O
for	NN	O
a	NNP	O
non-immunoglobulin	CC	O
polypeptide	)	O
(heterologous	NNS	O
polypeptide).	IN	O
The	DT	O
non-immunoglobulin	JJ	O
polypeptide	NN	O
sequences	NNS	O
can	NNP	O
substitute	.	O
for	.	O
the	:	O
constant	CC	O
domains	,	O
of	FW	O
an	,	O
antibody,	.	O
or	.	O
they	.	O
are	.	O
substituted	,	O
for	CD	O
the	,	O
variable	CC	O
domains	IN	O
of	VBG	O
one	DT	O
antigen-combining	NN	O
site	VBG	O
of	NN	O
an	IN	O
antibody	DT	O
to	CC	O
create	NN	O
a	IN	O
chimeric	DT	O
bivalent	NN	O
antibody	NN	O
comprising	IN	O
one	DT	O
antigen-combining	JJ	O
site	NN	O
having	JJ	O
specificity	.	O
for	DT	O
an	JJ	O
antigen	NN	O
and	NNS	O
another	MD	O
antigen-combining	VB	O
site	IN	O
having	DT	O
specificity	JJ	O
for	NNS	O
a	IN	O
different	DT	O
antigen.	,	O
3.	CC	O
Human	PRP	O
and	VBP	O
Humanized	VBN	O
Antibodies	IN	O
The	DT	O
anti-PRO227,	JJ	O
anti-PRO233,	NNS	O
anti-PRO238,	IN	O
anti-PRO1328,	CD	O
anti-PRO4342,	JJ	O
anti-PRO7423,	NN	O
anti-PRO10096,	IN	O
anti-PRO21384,	DT	O
anti-PRO353	NN	O
or	TO	O
anti-PRO1885	VB	O
antibodies	DT	O
of	JJ	O
the	NN	O
invention	NN	O
may	VBG	O
further	CD	O
comprise	JJ	O
humanized	NN	O
antibodies	VBG	O
or	NN	O
human	IN	O
antibodies.	DT	O
Humanized	NN	O
forms	CC	O
of	DT	O
non-human	JJ	O
(e.g.,	NN	O
murine)	VBG	O
antibodies	NN	O
are	IN	O
chimeric	DT	O
immunoglobulins,	JJ	O
immunoglobulin	.	O
chains	.	O
or	NNP	O
fragments	CC	O
thereof	NNP	O
(such	NNPS	O
as	DT	O
Fv,	,	O
Fab,	,	O
Fab′,	,	O
F(ab′)2	,	O
or	,	O
other	,	O
antigen-binding	,	O
subsequences	,	O
of	JJ	O
antibodies)	CC	O
which	JJ	O
contain	NNS	O
minimal	IN	O
sequence	DT	O
derived	NN	O
from	MD	O
non-human	RB	O
immunoglobulin.	VB	O
Humanized	JJ	O
antibodies	NNS	O
include	CC	O
human	JJ	O
immunoglobulins	.	O
(recipient	VBN	O
antibody)	NNS	O
in	IN	O
which	JJ	O
residues	,	O
from	)	O
a	NNS	O
complementary	VBP	O
determining	JJ	O
region	,	O
(CDR)	NN	O
of	NNS	O
the	CC	O
recipient	NNS	O
are	JJ	O
replaced	JJ	O
by	IN	O
residues	,	O
from	,	O
a	,	O
CDR	CD	O
of	CC	O
a	JJ	O
non-human	JJ	O
species	NNS	O
(donor	IN	O
antibody)	)	O
such	WDT	O
as	VBP	O
mouse,	JJ	O
rat	NN	O
or	VBN	O
rabbit	IN	O
having	JJ	O
the	.	O
desired	VBN	O
specificity,	NNS	O
affinity	VBP	O
and	JJ	O
capacity.	NNS	O
In	VB	O
some	)	O
instances,	IN	O
Fv	WDT	O
framework	VBP	O
residues	IN	O
of	DT	O
the	JJ	O
human	NN	O
immunoglobulin	NN	O
are	)	O
replaced	IN	O
by	DT	O
corresponding	NN	O
non-human	VBP	O
residues.	VBN	O
Humanized	IN	O
antibodies	NNS	O
may	IN	O
also	DT	O
comprise	NNP	O
residues	IN	O
which	DT	O
are	JJ	O
found	NNS	O
neither	VB	O
in	)	O
the	JJ	O
recipient	IN	O
antibody	,	O
nor	NN	O
in	CC	O
the	NN	O
imported	VBG	O
CDR	DT	O
or	JJ	O
framework	,	O
sequences.	NN	O
In	CC	O
general,	.	O
the	IN	O
humanized	DT	O
antibody	,	O
will	NNP	O
comprise	NN	O
substantially	NNS	O
all	IN	O
of	DT	O
at	JJ	O
least	NN	O
one,	VBP	O
and	VBN	O
typically	IN	O
two,	VBG	O
variable	JJ	O
domains,	.	O
in	VBN	O
which	NNS	O
all	MD	O
or	RB	O
substantially	VB	O
all	NNS	O
of	WDT	O
the	VBP	O
CDR	VBN	O
regions	RB	O
correspond	IN	O
to	DT	O
those	NN	O
of	NN	O
a	CC	O
non-human	IN	O
immunoglobulin	DT	O
and	JJ	O
all	NNP	O
or	CC	O
substantially	NN	O
all	.	O
of	IN	O
the	,	O
FR	DT	O
regions	VBN	O
are	NN	O
those	MD	O
of	VB	O
a	RB	O
human	DT	O
immunoglobulin	IN	O
consensus	IN	O
sequence.	JJS	O
The	,	O
humanized	CC	O
antibody	RB	O
optimally	,	O
also	JJ	O
will	,	O
comprise	IN	O
at	WDT	O
least	DT	O
a	CC	O
portion	RB	O
of	DT	O
an	IN	O
immunoglobulin	DT	O
constant	NNP	O
region	NNS	O
(Fc),	NN	O
typically	TO	O
that	DT	O
of	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
Jones	CC	B
et	DT	I
al.,	CC	I
Nature,	RB	I
321:522-525	DT	I
(1986);	IN	I
Riechmann	DT	B
et	NNP	I
al.,	NNS	I
Nature,	VBP	I
332:323-329	DT	I
(1988);	IN	I
[and	DT	O
Presta,	JJ	B
Curr.	NN	I
Op.	NN	I
Struct.	.	I
Biol.,	DT	I
2:593-596	VBN	I
(1992)].Methods	NN	O
for	RB	O
humanizing	RB	O
non-human	MD	O
antibodies	VB	O
are	IN	O
well	JJS	O
known	DT	O
in	NN	O
the	IN	O
art.	DT	O
Generally,	NN	O
a	JJ	O
humanized	NN	O
antibody	,	O
has	RB	O
one	IN	O
or	IN	O
more	DT	O
amino	JJ	O
acid	NN	O
residues	NNP	O
introduced	FW	O
into	,	O
it	,	O
from	NNP	O
a	:	O
source	NNP	O
which	FW	O
is	,	O
non-human.	,	O
These	NNP	O
non-human	:	O
amino	CC	O
acid	,	O
residues	.	O
are	.	O
often	.	O
referred	,	O
to	CD	O
as	.	O
“import”	NNS	O
residues,	IN	O
which	VBG	O
are	JJ	O
typically	NNS	O
taken	VBP	O
from	RB	O
an	VBN	O
“import”	IN	O
variable	DT	O
domain.	.	O
Humanization	,	O
can	DT	O
be	VBN	O
essentially	NN	O
performed	VBZ	O
following	CD	O
the	CC	O
method	JJR	O
of	JJ	O
Winter	NN	O
and	NNS	O
co-workers	VBN	O
Jones	IN	B
et	PRP	I
al.,	IN	I
Nature,	DT	I
321:522-525	NN	I
(1986);	WDT	I
Riechmann	VBZ	B
et	.	I
al.,	DT	I
Nature,	JJ	I
332:323-327	NN	I
(1988);	NN	I
Verhoeyen	NNS	B
et	VBP	I
al.,	RB	I
Science,	VBN	I
239:1534-1536	TO	I
(1988)],[	IN	O
by	NNP	O
substituting	,	O
rodent	WDT	O
CDRs	VBP	O
or	RB	O
CDR	VBN	O
sequences	IN	O
for	DT	O
the	NN	O
corresponding	JJ	O
sequences	.	O
of	NN	O
a	MD	O
human	VB	O
antibody.	RB	O
Accordingly,	VBN	O
such	VBG	O
“humanized”	DT	O
antibodies	NN	O
are	IN	O
chimeric	NNP	O
antibodies	CC	O
(U.S.	NNS	O
Pat.	NNP	O
No.	FW	O
4,816,567),	,	O
wherein	,	O
substantially	NNP	O
less	:	O
than	NNP	O
an	FW	O
intact	,	O
human	,	O
variable	NNP	O
domain	:	O
has	NNP	O
been	FW	O
substituted	,	O
by	,	O
the	CD	O
corresponding	,	O
sequence	IN	O
from	VBG	O
a	NN	O
non-human	NNP	O
species.	CC	O
In	NNP	O
practice,	NNS	O
humanized	IN	O
antibodies	DT	O
are	JJ	O
typically	NNS	O
human	IN	O
antibodies	DT	O
in	JJ	O
which	.	O
some	,	O
CDR	JJ	O
residues	JJ	O
and	NNS	O
possibly	VBP	O
some	JJ	O
FR	NNS	O
residues	NNP	O
are	.	O
substituted	.	O
by	,	O
residues	WP	O
from	RB	O
analogous	JJR	O
sites	IN	O
in	DT	O
rodent	JJ	O
antibodies.	JJ	O
The	NN	O
choice	NN	O
of	VBZ	O
human	VBN	O
variable	VBN	O
domains,	IN	O
both	DT	O
light	JJ	O
and	NN	O
heavy,	IN	O
to	DT	O
be	JJ	O
used	.	O
in	IN	O
making	,	O
the	VBN	O
humanized	NNS	O
antibodies	VBP	O
is	RB	O
very	JJ	O
important	NNS	O
to	IN	O
reduce	WDT	O
antigenicity	DT	O
and	NNP	O
HAMA	NNS	O
response	CC	O
(human	RB	O
anti-mouse	DT	O
antibody)	NNP	O
when	NNS	O
the	VBP	O
antibody	VBN	O
is	IN	O
intended	NNS	O
for	IN	O
human	JJ	O
therapeutic	NNS	O
use.	IN	O
According	JJ	O
to	.	O
the	DT	O
so-called	NN	O
“best-fit”	IN	O
method,	JJ	O
the	JJ	O
sequence	,	O
of	DT	O
the	JJ	O
variable	CC	O
domain	,	O
of	TO	O
a	VB	O
rodent	VBN	O
antibody	IN	O
is	VBG	O
screened	DT	O
against	JJ	O
the	NNS	O
entire	VBZ	O
library	RB	O
of	JJ	O
known	TO	O
human	VB	O
variable	NN	O
domain	CC	O
sequences.	NNP	O
The	NN	O
human	JJ	O
V	NN	O
domain	)	O
sequence	WRB	O
which	DT	O
is	NN	O
closest	VBZ	O
to	VBN	O
that	IN	O
of	JJ	O
the	JJ	O
rodent	.	O
is	VBG	O
identified	TO	O
and	DT	O
the	JJ	O
human	JJ	O
framework	,	O
region	DT	O
(FR)	NN	O
within	IN	O
it	DT	O
accepted	JJ	O
for	NN	O
the	IN	O
humanized	DT	O
antibody	NN	O
Sims	NN	B
et	VBZ	I
al.,	VBN	I
J.	IN	I
Immunol.	DT	I
151:2296	JJ	I
(1993);	NN	I
Chothia	IN	B
et	VBN	I
al.,	JJ	I
J.	JJ	I
Mol.	NN	I
Biol.,	.	I
196:901	DT	I
(1987)).(	JJ	O
Another	NNP	O
method	NN	O
uses	NN	O
a	WDT	O
particular	VBZ	O
framework	JJS	O
region	TO	O
derived	DT	O
from	IN	O
the	DT	O
consensus	NN	O
sequence	VBZ	O
of	VBN	O
all	CC	O
human	DT	O
antibodies	JJ	O
of	NN	O
a	NN	O
particular	)	O
subgroup	IN	O
of	PRP	O
light	VBD	O
or	IN	O
heavy	DT	O
chains.	VBN	O
The	NN	O
same	NNP	O
framework	RB	O
may	,	O
be	NNP	O
used	.	O
for	CD	O
several	:	O
different	NNP	O
humanized	FW	O
antibodies	,	O
Carter	NNP	B
et	.	I
al.,	,	I
Proc.	CD	I
Natl.	.	I
Acad.	DT	I
Sci.	NN	I
USA,	VBZ	I
89:4285	DT	I
(1992);	JJ	I
Presta	NN	B
et	NN	I
al.,	VBN	I
J.	IN	I
Immunol.	DT	I
151:2623	NN	I
(1993)).(	NN	O
It	IN	O
is	DT	O
further	JJ	O
important	NNS	O
that	IN	O
antibodies	DT	O
be	JJ	O
humanized	NN	O
with	IN	O
retention	NN	O
of	CC	O
high	JJ	O
binding	.	O
affinity	DT	O
for	JJ	O
the	NN	O
antigen	MD	O
and	VB	O
other	VBN	O
favorable	IN	O
biological	JJ	O
properties.	JJ	O
To	VBN	O
achieve	NNS	O
this	NNP	O
goal,	RB	O
according	,	O
to	.	O
a	.	O
preferred	.	O
method,	.	O
humanized	,	O
antibodies	CD	O
are	:	O
prepared	NNP	O
by	FW	O
a	,	O
process	NNP	O
of	.	O
analysis	CD	O
of	.	O
the	PRP	O
parental	VBZ	O
sequences	RBR	O
and	JJ	O
various	IN	O
conceptual	NNS	O
humanized	VB	O
products	VBN	O
using	IN	O
three-dimensional	NN	O
models	IN	O
of	JJ	O
the	NN	O
parental	NN	O
and	IN	O
humanized	DT	O
sequences.	NN	O
Three-dimensional	CC	O
immunoglobulin	JJ	O
models	JJ	O
are	JJ	O
commonly	.	O
available	TO	O
and	VB	O
are	DT	O
familiar	,	O
to	VBG	O
those	TO	O
skilled	DT	O
in	JJ	O
the	,	O
art.	VBN	O
Computer	NNS	O
programs	VBP	O
are	VBN	O
available	IN	O
which	DT	O
illustrate	NN	O
and	IN	O
display	NN	O
probable	IN	O
three-dimensional	DT	O
conformational	JJ	O
structures	NNS	O
of	CC	O
selected	JJ	O
candidate	JJ	O
immunoglobulin	VBN	O
sequences.	NNS	O
Inspection	VBG	O
of	JJ	O
these	NNS	O
displays	IN	O
permits	DT	O
analysis	NN	O
of	CC	O
the	JJ	O
likely	.	O
role	JJ	O
of	NN	O
the	NNS	O
residues	VBP	O
in	RB	O
the	JJ	O
functioning	CC	O
of	VBP	O
the	JJ	O
candidate	TO	O
immunoglobulin	DT	O
sequence,	VBN	O
i.e.,	IN	O
the	DT	O
analysis	.	O
of	NNP	O
residues	NNS	O
that	VBP	O
influence	JJ	O
the	WDT	O
ability	NN	O
of	CC	O
the	NN	O
candidate	JJ	O
immunoglobulin	JJ	O
to	JJ	O
bind	NNS	O
its	IN	O
antigen.	VBN	O
In	NN	O
this	NN	O
way,	.	O
FR	NN	O
residues	IN	O
can	DT	O
be	NNS	O
selected	VBP	O
and	NN	O
combined	IN	O
from	DT	O
the	JJ	O
recipient	NN	O
and	IN	O
import	DT	O
sequences	NNS	O
so	IN	O
that	DT	O
the	NN	O
desired	IN	O
antibody	DT	O
characteristic,	NN	O
such	NN	O
as	,	O
increased	,	O
affinity	DT	O
for	NN	O
the	IN	O
target	NNS	O
antigen(s),	WDT	O
is	VBP	O
achieved.	DT	O
In	NN	O
general,	IN	O
the	DT	O
hypervariable	NN	O
region	NN	O
residues	TO	O
are	VB	O
directly	PRP$	O
and	.	O
most	IN	O
substantially	DT	O
involved	,	O
in	NNP	O
influencing	NNS	O
antigen	MD	O
binding.	VB	O
Various	VBN	O
forms	CC	O
of	VBN	O
a	IN	O
humanized	DT	O
anti-PRO227,	NN	O
anti-PRO233,	CC	O
anti-PRO238,	NN	O
anti-PRO1328,	NNS	O
anti-PRO4342,	RB	O
anti-PRO7423,	IN	O
anti-PRO10096,	DT	O
anti-PRO21384,	VBN	O
anti-PRO353	NN	O
or	,	O
anti-PRO1885	JJ	O
antibody	IN	O
are	JJ	O
contemplated.	NN	O
For	IN	O
example,	DT	O
the	NN	O
humanized	,	O
antibody	VBZ	O
may	.	O
be	IN	O
an	,	O
antibody	DT	O
fragment,	JJ	O
such	NN	O
as	NNS	O
a	VBP	O
Fab,	RB	O
which	CC	O
is	JJS	O
optionally	RB	O
conjugated	VBN	O
with	IN	O
one	VBG	O
or	NN	O
more	.	O
cytotoxic	JJ	O
agent(s)	NNS	O
in	IN	O
order	DT	O
to	JJ	O
generate	,	O
an	,	O
immunoconjugate.	,	O
Alternatively,	,	O
the	,	O
humanized	,	O
antibody	,	O
may	,	O
be	JJ	O
an	CC	O
intact	JJ	O
antibody,	NN	O
such	VBP	O
as	.	O
an	IN	O
intact	,	O
IgG1	DT	O
antibody.	VBN	O
As	NN	O
an	MD	O
alternative	VB	O
to	DT	O
humanization,	NN	O
human	,	O
antibodies	JJ	O
can	IN	O
be	DT	O
generated.	,	O
For	WDT	O
example,	VBZ	O
it	RB	O
is	VBN	O
now	IN	O
possible	CD	O
to	CC	O
produce	JJR	O
transgenic	JJ	O
animals	)	O
(e.g.,	IN	O
mice)	NN	O
that	TO	O
are	VB	O
capable,	DT	O
upon	.	O
immunization,	,	O
of	DT	O
producing	VBN	O
a	NN	O
full	MD	O
repertoire	VB	O
of	DT	O
human	JJ	O
antibodies	,	O
in	JJ	O
the	IN	O
absence	DT	O
of	JJ	O
endogenous	NNP	O
immunoglobulin	.	O
production.	IN	O
For	DT	O
example,	NN	O
it	TO	O
has	,	O
been	JJ	O
described	NNS	O
that	MD	O
the	VB	O
homozygous	.	O
deletion	IN	O
of	,	O
the	PRP	O
antibody	VBZ	O
heavy-chain	RB	O
joining	JJ	O
region	TO	O
(JH)	VB	O
gene	JJ	O
in	NNS	O
chimeric	,	O
and	)	O
germ-line	WDT	O
mutant	VBP	O
mice	,	O
results	JJ	O
in	,	O
complete	IN	O
inhibition	VBG	O
of	DT	O
endogenous	JJ	O
antibody	NN	O
production.	IN	O
Transfer	JJ	O
of	NNS	O
the	IN	O
human	DT	O
germ-line	NN	O
immunoglobulin	IN	O
gene	JJ	O
array	NN	O
into	.	O
such	IN	O
germ-line	,	O
mutant	PRP	O
mice	VBZ	O
will	VBN	O
result	VBN	O
in	IN	O
the	DT	O
production	JJ	O
of	NN	O
human	IN	O
antibodies	DT	O
upon	NN	O
antigen	JJ	O
challenge.	NN	O
See,	NN	O
e.g.,	)	O
Jakobovits	NN	B
et	IN	I
al.,	JJ	I
Proc.	CC	I
Natl.	JJ	I
Acad.	JJ	I
Sci.	NN	I
USA,	NNS	I
90:2551	IN	I
(1993);	JJ	I
Jakobovits	NN	B
et	IN	I
al.,	JJ	I
Nature,	NN	I
362:255-258	.	I
(1993);	NN	I
Bruggemann	IN	B
et	DT	I
al.,	JJ	I
Year	JJ	I
in	NN	I
Immuno.	NN	I
7:33	NN	I
(1993);	IN	I
U.S.	JJ	O
Pat.	JJ	O
Nos.	NN	O
5,545,806,	NN	O
5,569,825,	MD	O
5,591,669	VB	O
(all	IN	O
of	DT	O
GenPharm);	NN	O
5,545,807;	IN	O
and	JJ	O
WO	NNS	O
97/17852.	IN	O
Alternatively,	NN	O
phage	.	O
display	,	O
technology	,	O
McCafferty	NNP	B
et	CC	I
al.,	,	I
Nature	.	I
348:552-553	.	I
[1990])	.	I
(can	.	O
be	,	O
used	CD	O
to	:	O
produce	NNP	O
human	FW	O
antibodies	,	O
and	,	O
antibody	NNP	O
fragments	:	O
in	NNP	O
vitro,	FW	O
from	,	O
immunoglobulin	NN	O
variable	IN	O
(V)	.	O
domain	CD	O
gene	:	O
repertoires	NNP	O
from	.	O
unimmunized	.	O
donors.	,	O
According	,	O
to	CD	O
this	DT	O
technique,	IN	O
antibody	:	O
V	:	O
domain	CC	O
genes	NNP	O
are	.	O
cloned	,	O
in-frame	NN	O
into	NN	O
either	NN	O
a	NNP	O
major	RB	O
or	,	O
minor	NNP	O
coat	CD	O
protein	)	O
gene	MD	O
of	VB	O
a	VBN	O
filamentous	TO	O
bacteriophage,	VB	O
such	JJ	O
as	NNS	O
M13	CC	O
or	NN	O
fd,	NNS	O
and	IN	O
displayed	,	O
as	IN	O
functional	NN	O
antibody	NN	O
fragments	)	O
on	VBP	O
the	NN	O
surface	NNS	O
of	IN	O
the	JJ	O
phage	.	O
particle.	VBG	O
Because	TO	O
the	DT	O
filamentous	,	O
particle	NN	O
contains	NNP	O
a	NN	O
single-stranded	NNS	O
DNA	VBP	O
copy	VBN	O
of	JJ	O
the	IN	O
phage	CC	O
genome,	DT	O
selections	JJ	O
based	CC	O
on	JJ	O
the	NN	O
functional	NN	O
properties	NN	O
of	IN	O
the	DT	O
antibody	JJ	O
also	,	O
result	JJ	O
in	IN	O
selection	NNP	O
of	CC	O
the	,	O
gene	CC	O
encoding	VBD	O
the	IN	O
antibody	JJ	O
exhibiting	NN	O
those	NNS	O
properties.	IN	O
Thus,	DT	O
the	NN	O
phage	IN	O
mimics	DT	O
some	NN	O
of	.	O
the	IN	O
properties	DT	O
of	JJ	O
the	NN	O
B-cell.	VBZ	O
Phage	DT	O
display	JJ	O
can	NNP	O
be	NN	O
performed	IN	O
in	DT	O
a	NN	O
variety	,	O
of	NNS	O
formats,	VBN	O
reviewed	IN	O
in,	DT	O
e.g.,	JJ	O
Johnson,	NNS	B
Kevin	IN	I
S,	DT	I
and	NN	I
Chiswell,	RB	I
David	NN	I
J.,	IN	I
Current	NN	I
Opinion	IN	I
in	DT	I
Structural	NN	I
Biology	VBG	I
3:564-571	DT	I
(1993).	NN	I
Several	VBG	O
sources	DT	O
of	.	O
V-gene	,	O
segments	DT	O
can	NN	O
be	VBD	O
used	DT	O
for	IN	O
phage	DT	O
display.	NNS	O
Clackson	IN	B
et	DT	I
al.,	.	I
Nature,	NN	I
352:624-628	NN	I
(1991)	MD	I
isolated	VB	O
a	VBN	O
diverse	IN	O
array	DT	O
of	NN	O
anti-oxazolone	IN	O
antibodies	,	O
from	VBN	O
a	,	O
small	,	O
random	,	O
combinatorial	NNP	O
library	,	O
of	CC	O
V	,	O
genes	NNP	O
derived	,	O
from	NNP	O
the	NNP	O
spleens	IN	O
of	NNP	O
immunized	NNP	O
mice.	CD	O
A	.	O
repertoire	JJ	O
of	NNS	O
V	IN	O
genes	NNP	O
from	NNS	O
unimmunized	MD	O
human	VB	O
donors	VBN	O
can	IN	O
be	NN	O
constructed	.	O
and	NNP	O
antibodies	CC	O
to	,	O
a	,	O
diverse	NNP	O
array	)	O
of	VBD	O
antigens	DT	O
(including	JJ	O
self-antigens)	NN	O
can	IN	O
be	JJ	O
isolated	NNS	O
essentially	IN	O
following	DT	O
the	JJ	O
techniques	JJ	O
described	JJ	O
by	NN	O
Marks	IN	B
et	NNP	I
al.,	NNS	I
J.	VBN	I
Mol.	IN	I
Biol.	DT	I
222:581-597	NNS	I
(1991),	IN	I
or	JJ	O
Griffith	.	B
et	DT	I
al.,	NN	I
EMBO	IN	I
J.	NNP	I
12:725-734	NNS	I
(1993).	IN	I
See,	JJ	O
also,	JJ	O
U.S.	NNS	O
Pat.	MD	O
Nos.	VB	O
5,565,332	VBN	O
and	CC	O
5,573,905.	NNS	O
As	TO	O
discussed	DT	O
above,	JJ	O
human	NN	O
antibodies	IN	O
may	NNS	O
also	VBG	O
be	)	O
generated	MD	O
by	VB	O
in	VBN	O
vitro	RB	O
activated	VBG	O
B	DT	O
cells	NNS	O
(see	VBN	O
U.S.	IN	O
Pat.	NNP	O
Nos.	FW	O
5,567,610	,	O
and	NNP	O
5,229,275).	.	O
4.	.	O
Antibody	CD	O
Fragments	,	O
In	CC	O
certain	NNP	O
circumstances	CC	O
there	,	O
are	NNP	O
advantages	.	O
of	CD	O
using	.	O
antibody	,	O
fragments,	,	O
rather	NNP	O
than	.	O
whole	.	O
antibodies.	CD	O
The	CC	O
smaller	.	O
size	IN	O
of	VBN	O
the	,	O
fragments	JJ	O
allows	NNS	O
for	MD	O
rapid	RB	O
clearance,	VB	O
and	VBN	O
may	IN	O
lead	IN	O
to	NN	O
improved	VBN	O
access	NNP	O
to	NNS	O
solid	VB	O
tumors.	NNP	O
Various	.	O
techniques	.	O
have	CD	O
been	CC	O
developed	.	O
for	.	O
the	NN	O
production	NNS	O
of	IN	O
antibody	JJ	O
fragments.	NNS	O
Traditionally,	EX	O
these	VBP	O
fragments	NNS	O
were	IN	O
derived	VBG	O
via	NN	O
proteolytic	,	O
digestion	RB	O
of	IN	O
intact	JJ	O
antibodies	.	O
(see,	DT	O
e.g.,	JJR	O
Morimoto	NN	B
et	IN	I
al.,	DT	I
Journal	NNS	I
of	VBZ	I
Biochemical	IN	I
and	JJ	I
Biophysical	,	I
Methods	CC	I
24:107-117	MD	I
(1992);	VB	I
and	TO	O
Brennan	JJ	B
et	NN	I
al.,	TO	I
Science,	JJ	I
229:81	.	I
(1985)).However,	JJ	O
these	NNS	O
fragments	VBP	O
can	VBN	O
now	VBN	O
be	IN	O
produced	DT	O
directly	NN	O
by	IN	O
recombinant	NN	O
host	.	O
cells.	,	O
Fab,	DT	O
Fv	NNS	O
and	VBD	O
ScFv	VBN	O
antibody	IN	O
fragments	JJ	O
can	NN	O
all	IN	O
be	JJ	O
expressed	NNS	O
in	,	O
and	,	O
secreted	NNP	O
from	FW	O
E.	,	O
coli,	NNP	O
thus	IN	O
allowing	NNP	O
the	CC	O
facile	NNP	O
production	NNP	O
of	CD	O
large	:	O
amounts	CC	O
of	NNP	O
these	VBP	O
fragments.	,	O
Antibody	,	O
fragments	CD	O
can	.	O
be	,	O
isolated	DT	O
from	NNS	O
the	MD	O
antibody	RB	O
phage	VB	O
libraries	VBN	O
discussed	RB	O
above.	IN	O
Alternatively,	JJ	O
Fab′-SH	NN	O
fragments	.	O
can	,	O
be	NNP	O
directly	CC	O
recovered	NNP	O
from	NN	O
E.	NNS	O
coli	MD	O
and	DT	O
chemically	VB	O
coupled	VBN	O
to	IN	O
form	CC	O
F(ab′)2	VBD	O
fragments	IN	O
Carter	NNP	B
et	,	I
al.,	RB	I
Bio/Technology	VBG	I
10:163-167	DT	I
(1992)).(	JJ	O
According	NN	O
to	IN	O
another	JJ	O
approach,	NNS	O
F(ab′)2	IN	O
fragments	DT	O
can	.	O
be	NN	O
isolated	NNS	O
directly	MD	O
from	VB	O
recombinant	VBN	O
host	IN	O
cell	DT	O
culture.	NN	O
Fab	NN	O
and	NNS	O
F(ab′)2	VBN	O
fragment	.	O
with	,	O
increased	JJ	O
in	NNS	O
vivo	MD	O
half-life	VB	O
comprising	RB	O
a	VBN	O
salvage	IN	O
receptor	NNP	O
binding	NNS	O
epitope	CC	O
residues	RB	O
are	VBN	O
described	TO	O
in	VB	O
U.S.	CD	O
Pat.	NNS	O
No.	NNP	O
5,869,046.	RB	O
Other	,	O
techniques	NNP	O
for	CD	O
the	.	O
production	VBG	O
of	TO	O
antibody	DT	O
fragments	,	O
will	CD	O
be	NNS	O
apparent	MD	O
to	VB	O
the	VBN	O
skilled	RB	O
practitioner.	IN	O
The	JJ	O
antibody	NN	O
of	NN	O
choice	.	O
is	NNP	O
a	CC	O
single	CD	O
chain	JJ	O
Fv	IN	O
fragment	VBN	O
(scFv).	IN	O
See	JJ	O
WO	JJ	O
93/16185;	VBG	O
U.S.	DT	O
Pat.	NN	O
No.	NN	O
5,571,894;	VBG	O
and	NN	O
U.S.	NNS	O
Pat.	VBP	O
No.	VBN	O
5,587,458.	IN	O
Fv	NNP	O
and	.	O
sFv	.	O
are	.	O
the	JJ	O
only	NNS	O
species	IN	O
with	DT	O
intact	NN	O
combining	IN	O
sites	NN	O
that	NNS	O
are	MD	O
devoid	VB	O
of	JJ	O
constant	TO	O
regions;	DT	O
thus,	JJ	O
they	.	O
are	DT	O
suitable	NN	O
for	IN	O
reduced	NN	O
nonspecific	VBZ	O
binding	DT	O
during	JJ	O
in	NN	O
vivo	NNP	O
use.	NN	O
sFv	.	O
fusion	NNP	O
proteins	NNP	O
may	:	O
be	NNP	O
constructed	.	O
to	.	O
yield	:	O
fusion	CC	O
of	NNP	O
an	.	O
effector	.	O
protein	.	O
at	NNP	O
either	CC	O
the	NN	O
amino	VBP	O
or	DT	O
the	JJ	O
carboxy	NNS	O
terminus	IN	O
of	JJ	O
an	VBG	O
sFv.	NNS	O
See	WDT	O
Antibody	VBP	O
Engineering,	JJ	O
ed.	IN	O
Borrebaeck,	JJ	O
supra.	:	O
The	,	O
antibody	PRP	O
fragment	VBP	O
may	JJ	O
also	IN	O
be	JJ	O
a	JJ	O
“linear	NN	O
antibody”,	IN	O
e.g.,	IN	O
as	NN	O
described	.	O
in	JJ	O
U.S.	NN	O
Pat.	NNS	O
No.	MD	O
5,641,870	VB	O
for	VBN	O
example.	TO	O
Such	VB	O
linear	NN	O
antibody	IN	O
fragments	DT	O
may	NN	O
be	NN	O
monospecific	IN	O
or	CC	O
bispecific.	DT	O
5.	NN	O
Bispecific	CC	O
Antibodies	DT	O
Bispecific	JJ	O
antibodies	NN	O
are	IN	O
antibodies	DT	O
that	.	O
have	VB	O
binding	NNP	O
specificities	,	O
for	.	O
at	,	O
least	.	O
two	DT	O
different	NN	O
epitopes.	NN	O
Exemplary	MD	O
bispecific	RB	O
antibodies	VB	O
may	DT	O
bind	JJ	O
to	,	O
two	,	O
different	IN	O
epitopes	VBN	O
of	IN	O
a	NNP	O
PRO227,	.	O
PRO233,	.	O
PRO238,	CD	O
PRO1328,	IN	O
PRO4342,	.	O
PRO7423,	JJ	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	NNS	O
or	MD	O
PRO1885	VB	O
protein	JJ	O
as	CC	O
described	.	O
herein.	.	O
Other	NNP	O
such	NNP	O
antibodies	NNP	O
may	NNS	O
combine	VBP	O
a	NNS	O
PRO227,	WDT	O
PRO233,	VBP	O
PRO238,	VBG	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	IN	O
PRO10096,	JJS	O
PRO21384,	CD	O
PRO353	JJ	O
or	.	O
PRO1885	NNP	O
binding	NN	O
site	NNS	O
with	MD	O
a	VB	O
binding	TO	O
site	CD	O
for	JJ	O
another	NNS	O
protein.	IN	O
Alternatively,	DT	O
an	,	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	NNP	O
anti-PRO353	CC	O
or	NNP	O
anti-PRO1885	CC	O
arm	IN	O
may	JJ	O
be	.	O
combined	JJ	O
with	JJ	O
an	NNS	O
arm	MD	O
which	VB	O
binds	DT	O
to	,	O
a	,	O
triggering	,	O
molecule	,	O
on	,	O
a	,	O
leukocyte	,	O
such	,	O
as	NNP	O
a	CC	O
T-cell	NNP	O
receptor	VBG	O
molecule	NN	O
(e.g.	IN	O
CD3),	DT	O
or	NN	O
Fc	NN	O
receptors	IN	O
for	DT	O
IgG	.	O
(FcγR),	,	O
such	DT	O
as	,	O
FcγRI	,	O
(CD64),	,	O
FcγRII	,	O
(CD32)	,	O
and	,	O
FcγRIII	,	O
(CD16),	,	O
so	JJ	O
as	CC	O
to	JJ	O
focus	NN	O
and	MD	O
localize	VB	O
cellular	VBN	O
defense	IN	O
mechanisms	DT	O
to	NN	O
the	WDT	O
PRO227-,	VBZ	O
PRO233-,	TO	O
PRO238-,	DT	O
PRO1328-,	VBG	O
PRO4342-,	NN	O
PRO7423-,	IN	O
PRO10096-,	DT	O
PRO21384-,	NN	O
PRO353-	JJ	O
or	IN	O
PRO1885-expressing	DT	O
cell.	NNP	O
Bispecific	NN	O
antibodies	NN	O
may	.	O
also	,	O
be	CC	O
used	NNP	O
to	NNS	O
localize	IN	O
cytotoxic	NNP	O
agents	,	O
to	JJ	O
cells	IN	O
which	NNP	O
express	,	O
a	NNP	O
PRO227,	)	O
PRO233,	CC	O
PRO238,	NNP	O
PRO1328,	,	O
PRO4342,	RB	O
PRO7423,	IN	O
PRO10096,	TO	O
PRO21384,	VB	O
PRO353	CC	O
or	VB	O
PRO1885	JJ	O
polypeptide.	NN	O
These	NN	O
antibodies	TO	O
possess	DT	O
a	,	O
PRO227-,	,	O
PRO233-,	,	O
PRO238-,	,	O
PRO1328-,	,	O
PRO4342-,	,	O
PRO7423-,	,	O
PRO10096-,	,	O
PRO21384-,	NNP	O
PRO353-	CC	O
or	NNP	O
PRO1885-binding	.	O
arm	NNP	O
and	NNS	O
an	MD	O
arm	RB	O
which	VB	O
binds	VBN	O
the	TO	O
cytotoxic	VB	O
agent	JJ	O
(e.g.,	NNS	O
saporin,	TO	O
anti-interferon-α,	NNS	O
vinca	WDT	O
alkaloid,	VBP	O
ricin	DT	O
A	,	O
chain,	,	O
methotrexate	,	O
or	,	O
radioactive	,	O
isotope	,	O
hapten).	,	O
Bispecific	,	O
antibodies	NNP	O
can	CC	O
be	NNP	O
prepared	.	O
as	DT	O
full	NNS	O
length	VBP	O
antibodies	DT	O
or	,	O
antibody	,	O
fragments	,	O
(e.g.,	,	O
F(ab′)2	,	O
bispecific	,	O
antibodies).	,	O
WO	,	O
96/16673	NNP	O
describes	CC	O
a	NNP	O
bispecific	NN	O
anti-ErbB2/anti-FcγRIII	CC	O
antibody	DT	O
and	NN	O
U.S.	WDT	O
Pat.	VBZ	O
No.	DT	O
5,837,234	NN	O
discloses	NN	O
a	,	O
bispecific	,	O
anti-ErbB2/anti-FcγRI	,	O
antibody.	JJ	O
A	,	O
bispecific	VB	O
anti-ErbB2/Fcα	NNP	O
antibody	,	O
is	NN	O
shown	CC	O
in	JJ	O
WO98/02463.	NN	O
U.S.	.	O
Pat.	NNP	O
No.	NNS	O
5,821,337	MD	O
teaches	VB	O
a	VBN	O
bispecific	IN	O
anti-ErbB2/anti-CD3	JJ	O
antibody.	NN	O
Methods	NNS	O
for	CC	O
making	NN	O
bispecific	NNS	O
antibodies	,	O
are	CD	O
known	JJ	O
in	.	O
the	$	O
art.	CD	O
Traditional	VBZ	O
production	DT	O
of	JJ	O
full	JJ	O
length	NN	O
bispecific	CC	O
antibodies	NNP	O
is	.	O
based	.	O
on	CD	O
the	VBZ	O
co-expression	DT	O
of	JJ	O
two	JJ	O
immunoglobulin	.	O
heavy	DT	O
chain-light	JJ	O
chain	JJ	O
pairs,	NN	O
where	VBZ	O
the	VBN	O
two	IN	O
chains	.	O
have	NNP	O
different	.	O
specificities	.	O
Millstein	CD	B
et	NNS	I
al.,	DT	I
Nature	JJ	I
305:537-539	JJ	I
(1983)).(	.	O
Because	NNS	O
of	IN	O
the	VBG	O
random	JJ	O
assortment	NNS	O
of	VBP	O
immunoglobulin	VBN	O
heavy	IN	O
and	DT	O
light	.	O
chains,	JJ	O
these	NN	O
hybridomas	IN	O
(quadromas)	JJ	O
produce	NN	O
a	NN	O
potential	NNS	O
mixture	VBZ	O
of	VBN	O
10	IN	O
different	DT	O
antibody	NN	O
molecules,	IN	O
of	CD	O
which	JJ	O
only	JJ	O
one	NN	O
has	NN	O
the	,	O
correct	WRB	O
bispecific	DT	O
structure.	CD	O
Purification	NNS	O
of	VBP	O
the	JJ	O
correct	NNS	O
molecule,	NNP	O
which	VBZ	O
is	,	O
usually	NNP	O
done	CD	O
by	.	O
affinity	IN	O
chromatography	IN	O
steps,	DT	O
is	JJ	O
rather	NN	O
cumbersome,	IN	O
and	NN	O
the	JJ	O
product	CC	O
yields	JJ	O
are	,	O
low.	DT	O
Similar	NNS	O
procedures	)	O
are	VBP	O
disclosed	DT	O
in	JJ	O
WO	NN	O
93/08829,	IN	O
and	CD	O
in	JJ	O
Traunecker	NN	B
et	,	I
al.,	IN	I
EMBO	WDT	I
J.	RB	I
10:3655-3659	CD	I
(1991).
According	VBZ	O
to	DT	O
a	JJ	O
different	NN	O
approach,	.	O
antibody	NN	O
variable	IN	O
domains	DT	O
with	JJ	O
the	,	O
desired	WDT	O
binding	VBZ	O
specificity	RB	O
(antibody-antigen	VBN	O
combining	IN	O
sites)	NN	O
are	NN	O
fused	,	O
to	VBZ	O
immunoglobulin	RB	O
constant	,	O
domain	CC	O
sequences.	DT	O
Preferably,	NN	O
the	NNS	O
fusion	VBP	O
is	.	O
with	JJ	O
an	NNS	O
Ig	VBP	O
heavy	VBN	O
chain	IN	O
constant	NNP	O
domain,	,	O
comprising	CC	O
at	IN	O
least	NNP	O
part	CC	O
of	,	O
the	NNP	O
hinge,	.	O
CH2,	CD	O
and	.	O
CH3	VBG	O
regions.	TO	O
It	DT	O
is	JJ	O
preferred	,	O
to	NN	O
have	JJ	O
the	NNS	O
first	IN	O
heavy-chain	DT	O
constant	JJ	O
region	NN	O
(CH1)	NN	O
containing	JJ	O
the	NN	O
site	)	O
necessary	VBP	O
for	VBN	O
light	TO	O
chain	VB	O
bonding,	JJ	O
present	NN	O
in	.	O
at	,	O
least	DT	O
one	NN	O
of	VBZ	O
the	IN	O
fusions.	DT	O
DNAs	NNP	O
encoding	NN	O
the	NN	O
immunoglobulin	JJ	O
heavy	,	O
chain	VBG	O
fusions	IN	O
and,	JJS	O
if	NN	O
desired,	IN	O
the	DT	O
immunoglobulin	,	O
light	,	O
chain,	CC	O
are	NNP	O
inserted	.	O
into	PRP	O
separate	VBZ	O
expression	VBN	O
vectors,	TO	O
and	VB	O
are	DT	O
co-transfected	JJ	O
into	NN	O
a	JJ	O
suitable	NN	O
host	)	O
cell.	VBG	O
This	DT	O
provides	NN	O
for	JJ	O
greater	IN	O
flexibility	NN	O
in	NN	O
adjusting	,	O
the	JJ	O
mutual	IN	O
proportions	IN	O
of	JJS	O
the	CD	O
three	IN	O
polypeptide	DT	O
fragments	.	O
when	NNP	O
unequal	VBG	O
ratios	DT	O
of	NN	O
the	NN	O
three	NN	O
polypeptide	NNS	O
chains	,	O
used	IN	O
in	,	O
the	DT	O
construction	NN	O
provide	NN	O
the	,	O
optimum	VBP	O
yield	VBN	O
of	IN	O
the	JJ	O
desired	NN	O
bispecific	,	O
antibody.	CC	O
It	VBP	O
is,	VBN	O
however,	IN	O
possible	DT	O
to	JJ	O
insert	NN	O
the	.	O
coding	DT	O
sequences	VBZ	O
for	IN	O
two	JJR	O
or	NN	O
all	IN	O
three	VBG	O
polypeptide	DT	O
chains	JJ	O
into	NNS	O
a	IN	O
single	DT	O
expression	CD	O
vector	NN	O
when	NNS	O
the	WRB	O
expression	JJ	O
of	NNS	O
at	IN	O
least	DT	O
two	CD	O
polypeptide	NN	O
chains	NNS	O
in	VBN	O
equal	IN	O
ratios	DT	O
results	NN	O
in	IN	O
high	DT	O
yields	JJ	O
or	NN	O
when	IN	O
the	DT	O
ratios	VBN	O
have	NN	O
no	.	O
significant	PRP	O
affect	,	O
on	,	O
the	JJ	O
yield	TO	O
of	VB	O
the	DT	O
desired	NN	O
chain	NNS	O
combination.	IN	O
The	CD	O
invention	CC	O
provides	DT	O
bispecific	CD	O
antibodies	NN	O
which	NNS	O
are	IN	O
composed	DT	O
of	JJ	O
a	NN	O
hybrid	NN	O
immunoglobulin	WRB	O
heavy	DT	O
chain	NN	O
with	IN	O
a	IN	O
first	JJS	O
binding	CD	O
specificity	NN	O
in	NNS	O
one	IN	O
arm,	JJ	O
and	NNS	O
a	NNS	O
hybrid	IN	O
immunoglobulin	JJ	O
heavy	NNS	O
chain-light	CC	O
chain	WRB	O
pair	DT	O
(providing	NNS	O
a	VBP	O
second	DT	O
binding	JJ	O
specificity)	NN	O
in	IN	O
the	DT	O
other	NN	O
arm.	IN	O
It	DT	O
was	VBN	O
found	NN	O
that	.	O
this	DT	O
asymmetric	NN	O
structure	VBZ	O
facilitates	JJ	O
the	NNS	O
separation	WDT	O
of	VBP	O
the	VBN	O
desired	IN	O
bispecific	DT	O
compound	JJ	O
from	NN	O
unwanted	NN	O
immunoglobulin	NN	O
chain	IN	O
combinations,	DT	O
as	JJ	O
the	NN	O
presence	NN	O
of	IN	O
an	CD	O
immunoglobulin	,	O
light	CC	O
chain	DT	O
in	JJ	O
only	JJ	O
one	JJ	O
half	NN	O
of	NN	O
the	NN	O
bispecific	VBG	O
molecule	DT	O
provides	JJ	O
for	NN	O
a	)	O
facile	IN	O
way	DT	O
of	JJ	O
separation.	.	O
This	PRP	O
approach	VBD	O
is	VBN	O
disclosed	IN	O
in	DT	O
WO	JJ	O
94/04690.	NN	O
For	VBZ	O
further	DT	O
details	NN	O
of	IN	O
generating	DT	O
bispecific	VBN	O
antibodies	NN	O
see,	NN	O
for	IN	O
example,	JJ	O
Suresh	NN	B
et	NN	I
al.,	,	I
Methods	IN	I
in	DT	I
Enzymology	NN	I
121:210	IN	I
(1986).
According	DT	O
to	NN	O
another	NN	O
approach	NN	O
described	IN	O
in	RB	O
U.S.	CD	O
Pat.	NN	O
No.	IN	O
5,731,168,	DT	O
the	JJ	O
interface	NN	O
between	VBZ	O
a	IN	O
pair	DT	O
of	JJ	O
antibody	NN	O
molecules	IN	O
can	.	O
be	DT	O
engineered	NN	O
to	VBZ	O
maximize	VBN	O
the	IN	O
percentage	NNP	O
of	.	O
heterodimers	IN	O
which	JJ	O
are	NNS	O
recovered	IN	O
from	VBG	O
recombinant	JJ	O
cell	NNS	O
culture.	,	O
The	IN	O
preferred	,	O
interface	NNP	O
comprises	FW	O
at	,	O
least	NNP	O
a	IN	O
part	NNP	O
of	CD	O
the	.	O
CH3	VBG	O
domain.	TO	O
In	DT	O
this	NN	O
method,	VBN	O
one	IN	O
or	NNP	O
more	.	O
small	.	O
amino	,	O
acid	DT	O
side	NN	O
chains	IN	O
from	DT	O
the	NN	O
interface	IN	O
of	NN	O
the	NNS	O
first	MD	O
antibody	VB	O
molecule	VBN	O
are	TO	O
replaced	VB	O
with	DT	O
larger	NN	O
side	IN	O
chains	NNS	O
(e.g.,	WDT	O
tyrosine	VBP	O
or	VBN	O
tryptophan).	IN	O
Compensatory	NN	O
“cavities”	NN	O
of	.	O
identical	DT	O
or	JJ	O
similar	NN	O
size	NNS	O
to	IN	O
the	JJS	O
large	DT	O
side	NN	O
chain(s)	IN	O
are	DT	O
created	NNP	O
on	.	O
the	IN	O
interface	DT	O
of	,	O
the	CD	O
second	CC	O
antibody	JJR	O
molecule	JJ	O
by	NN	O
replacing	JJ	O
large	NN	O
amino	NNS	O
acid	IN	O
side	DT	O
chains	NN	O
with	IN	O
smaller	DT	O
ones	JJ	O
(e.g.,	NN	O
alanine	NN	O
or	VBP	O
threonine).	VBN	O
This	IN	O
provides	JJR	O
a	NN	O
mechanism	NNS	O
for	,	O
increasing	NN	O
the	CC	O
yield	.	O
of	NNP	O
the	NNP	O
heterodimer	IN	O
over	JJ	O
other	CC	O
unwanted	JJ	O
end-products	NN	O
such	TO	O
as	DT	O
homodimers.	JJ	O
Bispecific	NN	O
antibodies	)	O
include	VBP	O
cross-linked	VBN	O
or	IN	O
“heteroconjugate”	DT	O
antibodies.	NN	O
For	IN	O
example,	DT	O
one	JJ	O
of	NN	O
the	NN	O
antibodies	IN	O
in	VBG	O
the	JJ	O
heteroconjugate	NN	O
can	JJ	O
be	NN	O
coupled	NNS	O
to	IN	O
avidin,	JJR	O
the	NNS	O
other	,	O
to	NN	O
biotin.	CC	O
Such	.	O
antibodies	DT	O
have,	VBZ	O
for	DT	O
example,	NN	O
been	IN	O
proposed	VBG	O
to	DT	O
target	NN	O
immune	IN	O
system	DT	O
cells	NN	O
to	IN	O
unwanted	JJ	O
cells	JJ	O
(U.S.	NNS	O
Pat.	JJ	O
No.	IN	O
4,676,980),	.	O
and	NNP	O
for	NNS	O
treatment	VBP	O
of	JJ	O
HIV	CC	O
infection	JJ	O
(WO	.	O
91/00360,	IN	O
WO	,	O
92/200373,	CD	O
and	IN	O
EP	DT	O
03089).	NNS	O
Heteroconjugate	IN	O
antibodies	DT	O
may	NN	O
be	MD	O
made	VB	O
using	VBN	O
any	TO	O
convenient	,	O
cross-linking	DT	O
methods.	JJ	O
Suitable	TO	O
cross-linking	.	O
agents	JJ	O
are	NNS	O
well	,	O
known	IN	O
in	,	O
the	VBN	O
art,	VBN	O
and	TO	O
are	VB	O
disclosed	JJ	O
in	NN	O
U.S.	NNS	O
Pat.	TO	O
No.	JJ	O
4,676,980,	NNS	O
along	NNP	O
with	.	O
a	.	O
number	,	O
of	CC	O
cross-linking	IN	O
techniques.	NN	O
Techniques	IN	O
for	NNP	O
generating	NN	O
bispecific	NNP	O
antibodies	,	O
from	NNP	O
antibody	,	O
fragments	CC	O
have	NNP	O
also	.	O
been	NNP	O
described	NNS	O
in	MD	O
the	VB	O
literature.	VBN	O
For	VBG	O
example,	DT	O
bispecific	JJ	O
antibodies	JJ	O
can	.	O
be	JJ	O
prepared	JJ	O
using	NNS	O
chemical	VBP	O
linkage.	RB	O
Brennan	VBN	B
et	IN	I
al.,	DT	I
Science	,	I
229:81	CC	I
(1985)	VBP	I
describe	VBN	O
a	IN	O
procedure	NNP	O
wherein	.	O
intact	.	O
antibodies	,	O
are	IN	O
proteolytically	IN	O
cleaved	DT	O
to	NN	O
generate	IN	O
F(ab′)2	JJ	O
fragments.	.	O
These	NNS	O
fragments	IN	O
are	VBG	O
reduced	JJ	O
in	NNS	O
the	IN	O
presence	NN	O
of	NNS	O
the	VBP	O
dithiol	RB	O
complexing	VBN	O
agent,	VBN	O
sodium	IN	O
arsenite,	DT	O
to	.	O
stabilize	IN	O
vicinal	,	O
dithiols	JJ	O
and	NNS	O
prevent	MD	O
intermolecular	VB	O
disulfide	VBN	O
formation.	VBG	O
The	JJ	O
Fab′	.	O
fragments	NNP	O
generated	CC	O
are	,	O
then	NNP	O
converted	CD	O
to	)	O
thionitrobenzoate	VB	O
(TNB)	DT	O
derivatives.	NN	O
One	NN	O
of	JJ	O
the	NNS	O
Fab′-TNB	VBP	O
derivatives	RB	O
is	VBN	O
then	TO	O
reconverted	VB	O
to	CD	O
the	.	O
Fab′-thiol	DT	O
by	NNS	O
reduction	VBP	O
with	VBN	O
mercaptoethylamine	IN	O
and	DT	O
is	NN	O
mixed	IN	O
with	DT	O
an	NN	O
equimolar	VBG	O
amount	,	O
of	NN	O
the	,	O
other	TO	O
Fab′-TNB	VB	O
derivative	JJ	O
to	NNS	O
form	CC	O
the	NN	O
bispecific	JJ	O
antibody.	NN	O
The	.	O
bispecific	DT	O
antibodies	NNP	O
produced	NNS	O
can	VBD	O
be	VBP	O
used	RB	O
as	VBN	O
agents	TO	O
for	VB	O
the	)	O
selective	.	O
immobilization	CD	O
of	IN	O
enzymes.	DT	O
Recent	NNP	O
progress	NNS	O
has	VBZ	O
facilitated	RB	O
the	VBN	O
direct	TO	O
recovery	DT	O
of	NNP	O
Fab′-SH	IN	O
fragments	NN	O
from	IN	O
E.	NN	O
coli,	CC	O
which	VBZ	O
can	JJ	O
be	IN	O
chemically	DT	O
coupled	JJ	O
to	NN	O
form	IN	O
bispecific	DT	O
antibodies.	JJ	O
Shalaby	NNP	B
et	NN	I
al.,	TO	I
J.	VB	I
Exp.	DT	I
Med.	NN	I
175:	.	I
217-225	DT	I
(1992)	NN	I
describe	NNS	O
the	VBD	O
production	MD	O
of	VB	O
a	VBN	O
fully	IN	O
humanized	NNS	O
bispecific	IN	O
antibody	DT	O
F(ab′)2	JJ	O
molecule.	NN	O
Each	IN	O
Fab′	.	O
fragment	JJ	O
was	NN	O
separately	VBZ	O
secreted	VBN	O
from	DT	O
E.	JJ	O
coli	NN	O
and	IN	O
subjected	NNP	O
to	NNS	O
directed	IN	O
chemical	NNP	O
coupling	,	O
in	WDT	O
vitro	MD	O
to	VB	O
form	RB	O
the	VBN	O
bispecific	TO	O
antibody.	VB	O
The	JJ	O
bispecific	.	O
antibody	NNP	O
thus	CC	O
formed	,	O
was	NNP	O
able	.	O
to	.	O
bind	:	O
to	CD	O
cells	)	O
overexpressing	VB	O
the	DT	O
ErbB2	NN	O
receptor	IN	O
and	DT	O
normal	RB	O
human	VBN	O
T	NN	O
cells,	NN	O
as	CD	O
well	.	O
as	DT	O
trigger	NNP	O
the	NN	O
lytic	VBD	O
activity	RB	O
of	VBN	O
human	IN	O
cytotoxic	NNP	O
lymphocytes	NNS	O
against	CC	O
human	VBN	O
breast	TO	O
tumor	VB	O
targets.	NN	O
Various	NN	O
techniques	IN	O
for	NN	O
making	TO	O
and	VB	O
isolating	DT	O
bispecific	NN	O
antibody	.	O
fragments	DT	O
directly	NN	O
from	NN	O
recombinant	RB	O
cell	VBN	O
culture	VBD	O
have	JJ	O
also	TO	O
been	VB	O
described.	TO	O
For	NNS	O
example,	VBG	O
bispecific	DT	O
antibodies	NNP	O
have	NN	O
been	CC	O
produced	JJ	O
using	JJ	O
leucine	NNP	O
zippers.	,	O
Kostelny	RB	B
et	RB	I
al.,	IN	I
J.	NN	I
Immunol.	DT	I
148(5):1547-1553	JJ	I
(1992).	NN	I
The	IN	O
leucine	JJ	O
zipper	NN	O
peptides	NNS	O
from	IN	O
the	JJ	O
Fos	NN	O
and	NN	O
Jun	.	O
proteins	JJ	O
were	NNS	O
linked	IN	O
to	VBG	O
the	CC	O
Fab′	VBG	O
portions	NN	O
of	NN	O
two	NNS	O
different	RB	O
antibodies	IN	O
by	NN	O
gene	NN	O
fusion.	NN	O
The	VBP	O
antibody	RB	O
homodimers	VBN	O
were	.	O
reduced	IN	O
at	,	O
the	NN	O
hinge	NNS	O
region	VBP	O
to	VBN	O
form	VBN	O
monomers	VBG	O
and	JJ	O
then	.	O
re-oxidized	NNP	O
to	CC	O
form	,	O
the	NNP	O
antibody	.	O
heterodimers.	NN	O
This	.	O
method	DT	O
can	JJ	O
also	NN	O
be	NNS	O
utilized	IN	O
for	DT	O
the	NNP	O
production	CC	O
of	NNP	O
antibody	NNS	O
homodimers.	VBD	O
The	VBN	O
“diabody”	TO	O
technology	DT	O
described	NNP	O
by	NNS	O
Hollinger	IN	B
et	CD	I
al.,	JJ	I
Proc.	NNS	I
Natl.	IN	I
Acad.	NN	I
Sci.	.	I
USA	DT	I
90:6444-6448	NN	I
(1993)	NNS	I
has	VBD	O
provided	VBN	O
an	IN	O
alternative	DT	O
mechanism	NN	O
for	NN	O
making	TO	O
bispecific	VB	O
antibody	NNS	O
fragments.	CC	O
The	RB	O
fragments	JJ	O
comprise	TO	O
a	VB	O
VH	DT	O
connected	NN	O
to	.	O
a	DT	O
VL	NN	O
by	MD	O
a	RB	O
linker	VB	O
which	VBN	O
is	IN	O
too	DT	O
short	NN	O
to	IN	O
allow	NN	O
pairing	.	O
between	DT	O
the	NNP	O
two	NN	O
domains	VBN	O
on	IN	O
the	NNP	O
same	FW	O
chain.	,	O
Accordingly,	.	O
the	.	O
VH	.	O
and	.	O
VL	NNP	O
domains	CD	O
of	)	O
one	VBZ	O
fragment	VBN	O
are	DT	O
forced	JJ	O
to	NN	O
pair	IN	O
with	VBG	O
the	JJ	O
complementary	NN	O
VL	.	O
and	DT	O
VH	NNS	O
domains	VBP	O
of	DT	O
another	NNP	O
fragment,	VBN	O
thereby	TO	O
forming	DT	O
two	NNP	O
antigen-binding	IN	O
sites.	DT	O
Another	NN	O
strategy	WDT	O
for	VBZ	O
making	RB	O
bispecific	JJ	O
antibody	TO	O
fragments	VB	O
by	VBG	O
the	IN	O
use	DT	O
of	CD	O
single-chain	NNS	O
Fv	IN	O
(sFv)	DT	O
dimers	JJ	O
has	.	O
also	,	O
been	DT	O
reported.	NNP	O
See	CC	O
Gruber	NNP	B
et	NNS	I
al.,	IN	I
J.	CD	I
Immunol.,	NN	I
152:5368	VBP	I
(1994).
Antibodies	VBN	O
with	TO	O
more	VB	O
than	IN	O
two	DT	O
valencies	JJ	O
are	NNP	O
contemplated.	CC	O
For	NNP	O
example,	NNS	O
trispecific	IN	O
antibodies	DT	O
can	,	O
be	RB	O
prepared.	VBG	O
Tutt	CD	B
et	JJ	I
al.,	.	I
J.	DT	I
Immunol.	NN	I
147:60	IN	I
(1991).
6.	VBG	O
Heteroconjugate	JJ	O
Antibodies	NN	O
Heteroconjugate	NNS	O
antibodies	IN	O
are	DT	O
also	NN	O
within	IN	O
the	JJ	O
scope	NNP	O
of	)	O
the	NNS	O
present	VBZ	O
invention.	RB	O
Heteroconjugate	VBN	O
antibodies	.	O
are	VB	O
composed	NNP	O
of	FW	O
two	,	O
covalently	.	O
joined	,	O
antibodies.	CD	O
Such	.	O
antibodies	NNS	O
have,	IN	O
for	JJR	O
example,	IN	O
been	CD	O
proposed	NNS	O
to	VBP	O
target	.	O
immune	IN	O
system	,	O
cells	JJ	O
to	NNS	O
unwanted	MD	O
cells	VB	O
[U.S.	.	O
Pat.	NNP	O
No.	CC	O
4,676,980],	,	O
and	NNP	O
for	.	O
treatment	CD	O
of	.	O
HIV	.	O
infection	NNP	O
[WO	NNP	O
91/00360;	NNP	O
WO	NNS	O
92/200373;	VBP	O
EP	RB	O
03089].	IN	O
It	DT	O
is	NN	O
contemplated	IN	O
that	DT	O
the	JJ	O
antibodies	.	O
may	NNP	O
be	NNS	O
prepared	VBP	O
in	VBN	O
vitro	IN	O
using	CD	O
known	RB	O
methods	VBD	O
in	.	O
synthetic	JJ	O
protein	NNS	O
chemistry,	,	O
including	IN	O
those	,	O
involving	VBN	O
crosslinking	VBN	O
agents.	TO	O
For	VB	O
example,	JJ	O
immunotoxins	NN	O
may	NNS	O
be	TO	O
constructed	JJ	O
using	NNS	O
a	NNP	O
disulfide	.	O
exchange	.	O
reaction	,	O
or	CC	O
by	IN	O
forming	NN	O
a	IN	O
thioether	NNP	O
bond.	NN	O
Examples	NNP	O
of	:	O
suitable	NNP	O
reagents	:	O
for	NNP	O
this	.	O
purpose	PRP	O
include	VBZ	O
iminothiolate	VBN	O
and	IN	O
methyl-4-mercaptobutyrimidate	DT	O
and	NNS	O
those	MD	O
disclosed,	VB	O
for	VBN	O
example,	IN	O
in	JJ	O
U.S.	VBG	O
Pat.	VBN	O
No.	NNS	O
4,676,980.	IN	O
7.	JJ	O
Multivalent	NN	O
Antibodies	,	O
A	VBG	O
multivalent	DT	O
antibody	VBG	O
may	VBG	O
be	.	O
internalized	IN	O
(and/or	,	O
catabolized)	NNS	O
faster	MD	O
than	VB	O
a	VBN	O
bivalent	VBG	O
antibody	DT	O
by	JJ	O
a	NN	O
cell	NN	O
expressing	CC	O
an	IN	O
antigen	VBG	O
to	DT	O
which	NN	O
the	.	O
antibodies	NNS	O
bind.	IN	O
The	JJ	O
antibodies	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	VBP	O
can	JJ	O
be	CC	O
multivalent	JJ	O
antibodies	CC	O
(which	DT	O
are	,	O
other	IN	O
than	,	O
of	IN	O
the	NNP	O
IgM	.	O
class)	.	O
with	.	O
three	.	O
or	NNP	O
more	VBZ	O
antigen	NNP	O
binding	NN	O
sites	NN	O
(e.g.	MD	O
tetravalent	VB	O
antibodies),	VBN	O
which	JJ	O
can	)	O
be	RBR	O
readily	IN	O
produced	DT	O
by	NN	O
recombinant	NN	O
expression	IN	O
of	DT	O
nucleic	NN	O
acid	VBG	O
encoding	DT	O
the	NN	O
polypeptide	TO	O
chains	WDT	O
of	DT	O
the	NNS	O
antibody.	.	O
The	DT	O
multivalent	NNS	O
antibody	IN	O
can	DT	O
comprise	JJ	O
a	NN	O
dimerization	MD	O
domain	VB	O
and	JJ	O
three	NNS	O
or	WDT	O
more	VBP	O
antigen	JJ	O
binding	IN	O
sites.	IN	O
The	DT	O
preferred	NNP	O
dimerization	)	O
domain	IN	O
comprises	CD	O
(or	CC	O
consists	JJR	O
of)	JJ	O
an	NN	O
Fc	NNS	O
region	.	O
or	JJ	O
a	,	O
hinge	WDT	O
region.	MD	O
In	VB	O
this	RB	O
scenario,	VBN	O
the	IN	O
antibody	JJ	O
will	NN	O
comprise	IN	O
an	JJ	O
Fc	NN	O
region	VBG	O
and	DT	O
three	NN	O
or	NNS	O
more	IN	O
antigen	DT	O
binding	.	O
sites	DT	O
amino-terminal	NN	O
to	NN	O
the	MD	O
Fc	VB	O
region.	DT	O
The	NN	O
preferred	NN	O
multivalent	CC	O
antibody	CD	O
herein	CC	O
comprises	JJR	O
(or	JJ	O
consists	NN	O
of)	.	O
three	DT	O
to	JJ	O
about	NN	O
eight,	NN	O
but	NNS	O
preferably	CC	O
four,	VBZ	O
antigen	)	O
binding	DT	O
sites.	JJ	O
The	NN	O
multivalent	CC	O
antibody	DT	O
comprises	JJ	O
at	.	O
least	IN	O
one	DT	O
polypeptide	,	O
chain	DT	O
(and	NN	O
preferably	MD	O
two	VB	O
polypeptide	DT	O
chains),	NNP	O
wherein	NN	O
the	CC	O
polypeptide	CD	O
chain(s)	CC	O
comprise	JJR	O
two	JJ	O
or	NN	O
more	VBZ	O
variable	JJ	O
domains.	TO	O
For	DT	O
instance,	NNP	O
the	.	O
polypeptide	DT	O
chain(s)	JJ	O
may	NN	O
comprise	NN	O
VD1-(X1)n-VD2-(X2)n-Fc,	NN	O
wherein	VBZ	O
VD1	CC	O
is	VBZ	O
a	)	O
first	CD	O
variable	TO	O
domain,	IN	O
VD2	,	O
is	CC	O
a	RB	O
second	,	O
variable	NN	O
domain,	NN	O
Fc	.	O
is	DT	O
one	NN	O
polypeptide	NN	O
chain	VBZ	O
of	IN	O
an	JJS	O
Fc	CD	O
region,	NN	O
X1	NN	O
and	CC	O
X2	RB	O
represent	CD	O
an	NN	O
amino	,	O
acid	VBD	O
or	DT	O
polypeptide,	NN	O
and	)	O
n	VBP	O
is	CD	O
0	CC	O
or	JJR	O
1.	JJ	O
For	.	O
instance,	IN	O
the	,	O
polypeptide	DT	O
chain(s)	NN	O
may	)	O
comprise:	MD	O
VH-CH1-flexible	VB	O
linker-VH-CH1-Fc	,	O
region	NN	O
chain;	NNP	O
or	VBZ	O
VH-CH1-VH-CH1-Fc	DT	O
region	JJ	O
chain.	JJ	O
The	,	O
multivalent	NNP	O
antibody	VBZ	O
herein	DT	O
preferably	JJ	O
further	JJ	O
comprises	,	O
at	NNP	O
least	VBZ	O
two	CD	O
(and	NN	O
preferably	NN	O
four)	IN	O
light	DT	O
chain	NNP	O
variable	,	O
domain	NNP	O
polypeptides.	CC	O
The	NNP	O
multivalent	VBP	O
antibody	DT	O
herein	NN	O
may,	NN	O
for	CC	O
instance,	,	O
comprise	CC	O
from	NN	O
about	VBZ	O
two	CD	O
to	CC	O
about	.	O
eight	IN	O
light	,	O
chain	DT	O
variable	NN	O
domain	)	O
polypeptides.	MD	O
The	:	O
light	JJ	O
chain	JJ	O
variable	NN	O
domain	:	O
polypeptides	CC	O
contemplated	JJ	O
here	NN	O
comprise	.	O
a	DT	O
light	NN	O
chain	NN	O
variable	NN	O
domain	RB	O
and,	JJ	O
optionally,	NNS	O
further	IN	O
comprise	JJS	O
a	CD	O
CL	CC	O
domain.	RB	O
8.	)	O
Effector	NN	O
Function	NN	O
Engineering	JJ	O
It	NN	O
may	.	O
be	DT	O
desirable	NN	O
to	NN	O
modify	NN	O
the	,	O
antibody	IN	O
of	,	O
the	NN	O
invention	IN	O
with	RB	O
respect	CD	O
to	TO	O
effector	IN	O
function,	CD	O
e.g.,	NN	O
so	NN	O
as	JJ	O
to	NN	O
enhance	.	O
antigen-dependent	DT	O
cell-mediated	NN	O
cyotoxicity	NN	O
(ADCC)	JJ	O
and/or	NN	O
complement	NNS	O
dependent	VBD	O
cytotoxicity	RB	O
(CDC)	VB	O
of	DT	O
the	NN	O
antibody.	NN	O
This	JJ	O
may	NN	O
be	,	O
achieved	,	O
by	JJ	O
introducing	NN	O
one	DT	O
or	NNP	O
more	.	O
amino	.	O
acid	NNP	O
substitutions	NNP	O
in	NNP	O
an	PRP	O
Fc	MD	O
region	VB	O
of	JJ	O
the	TO	O
antibody.	VB	O
Alternatively	DT	O
or	NN	O
additionally,	IN	O
cysteine	DT	O
residue(s)	NN	O
may	IN	O
be	NN	O
introduced	TO	O
in	VB	O
the	,	O
Fc	,	O
region,	RB	O
thereby	IN	O
allowing	TO	O
interchain	VB	O
disulfide	JJ	O
bond	JJ	O
formation	NN	O
in	)	O
this	VBP	O
region.	JJ	O
The	JJ	O
homodimeric	NN	O
antibody	)	O
thus	IN	O
generated	DT	O
may	.	O
have	DT	O
improved	MD	O
internalization	VB	O
capability	VBN	O
and/or	IN	O
increased	VBG	O
complement-mediated	CD	O
cell	CC	O
killing	JJR	O
and	JJ	O
antibody-dependent	NN	O
cellular	NNS	O
cytotoxicity	IN	O
(ADCC).	DT	O
See	NNP	O
Caron	NN	B
et	IN	I
al.,	DT	I
J.	.	I
Exp	RB	I
Med.	CC	I
176:1191-1195	,	I
(1992)	NN	I
and	)	O
Shopes,	MD	B
B.	VB	I
J.	VBN	I
Immunol.	IN	I
148:2918-2922	DT	I
(1992).	NNP	I
Homodimeric	,	O
antibodies	RB	O
with	VBG	O
enhanced	JJ	O
anti-tumor	JJ	O
activity	NN	O
may	NN	O
also	IN	O
be	DT	O
prepared	.	O
using	DT	O
heterobifunctional	JJ	O
cross-linkers	NN	O
as	RB	O
described	VBD	O
in	MD	O
Wolff	VB	B
et	VBN	I
al.,	NN	I
Cancer	NN	I
Research	NN	I
53:2560-2565	VBD	I
(1993).	JJ	I
Alternatively,	NN	O
an	VBG	O
antibody	CC	O
can	JJ	O
be	JJ	O
engineered	NN	O
which	.	O
has	VB	O
dual	NNP	O
Fc	FW	O
regions	,	O
and	NNP	O
may	NNP	O
thereby	.	O
have	CD	O
enhanced	)	O
complement	CC	O
lysis	,	O
and	NNP	O
ADCC	NNP	O
capabilities.	.	O
See	CD	O
Stevenson	.	B
et	JJ	I
al.,	NNS	I
Anti-Cancer	IN	I
Drug	JJ	I
Design	JJ	I
3:219-230	NN	I
(1989).	MD	I
To	RB	O
increase	VB	O
the	VBN	O
serum	VBG	O
half	JJ	O
life	NNS	O
of	IN	O
the	VBN	O
antibody,	IN	O
one	NNP	O
may	CC	O
incorporate	,	O
a	NNP	O
salvage	NNP	O
receptor	CD	O
binding	.	O
epitope	,	O
into	DT	O
the	NN	O
antibody	MD	O
(especially	VB	O
an	VBN	O
antibody	WDT	O
fragment)	VBZ	O
as	JJ	O
described	NNP	O
in	NNS	O
U.S.	CC	O
Pat.	MD	O
No.	RB	O
5,739,277,	VB	O
for	VBN	O
example.	JJ	O
As	NN	O
used	CC	O
herein,	NNP	O
the	.	O
term	VB	O
“salvage	NNP	O
receptor	FW	O
binding	,	O
epitope”	NNP	O
refers	NNP	O
to	NNP	O
an	CD	O
epitope	.	O
of	TO	O
the	VB	O
Fc	DT	O
region	NN	O
of	JJ	O
an	NN	O
IgG	IN	O
molecule	DT	O
(e.g.,	,	O
IgG1,	CD	O
IgG2,	MD	O
IgG3,	VB	O
or	DT	O
IgG4)	NN	O
that	NN	O
is	VBG	O
responsible	NN	O
for	IN	O
increasing	DT	O
the	NN	O
in	RB	O
vivo	DT	O
serum	NN	O
half-life	)	O
of	IN	O
the	VBN	O
IgG	IN	O
molecule.	NNP	O
9.	.	O
Immunoconjugates	.	O
The	,	O
invention	IN	O
also	.	O
pertains	IN	O
to	VBN	O
immunoconjugates	,	O
comprising	DT	O
an	NN	O
antibody	NN	O
conjugated	NN	O
to	VBG	O
a	JJ	O
cytotoxic	NNS	O
agent	TO	O
such	DT	O
as	NN	O
a	IN	O
chemotherapeutic	DT	O
agent,	NNP	O
a	NN	O
growth	IN	O
inhibitory	DT	O
agent,	NNP	O
a	NN	O
toxin	,	O
(e.g.,	,	O
an	,	O
enzymatically	,	O
active	CC	O
toxin	)	O
of	WDT	O
bacterial,	VBZ	O
fungal,	JJ	O
plant,	IN	O
or	VBG	O
animal	DT	O
origin,	IN	O
or	JJ	O
fragments	JJ	O
thereof),	NN	O
or	IN	O
a	DT	O
radioactive	NNP	O
isotope	.	O
(i.e.,	.	O
a	VBZ	O
radioconjugate).	DT	O
Chemotherapeutic	NN	O
agents	RB	O
useful	VBZ	O
in	TO	O
the	VB	O
generation	VBG	O
of	DT	O
such	NN	O
immunoconjugates	VBD	O
have	TO	O
been	DT	O
described	JJ	O
above.	NN	O
Enzymatically	JJ	O
active	IN	O
toxins	DT	O
and	JJ	O
fragments	,	O
thereof	DT	O
that	NN	O
can	NN	O
be	,	O
used	DT	O
include	NN	O
diphtheria	,	O
A	DT	O
chain,	RB	O
nonbinding	JJ	O
active	NN	O
fragments	IN	O
of	,	O
diphtheria	,	O
toxin,	,	O
exotoxin	CC	O
A	JJ	O
chain	,	O
(from	CC	O
Pseudomonas	NNS	O
aeruginosa),	,	O
ricin	CC	O
A	DT	O
chain,	JJ	O
abrin	NN	O
A	,	O
chain,	DT	O
modeccin	.	O
A	JJ	O
chain,	NNS	O
alpha-sarcin,	JJ	O
Aleurites	IN	O
fordii	DT	O
proteins,	NN	O
dianthin	IN	O
proteins,	JJ	O
Phytolaca	NNS	O
americana	VBP	O
proteins	VBN	O
(PAPI,	VBN	O
PAPII,	.	O
and	RB	O
PAP-S),	JJ	O
momordica	NNS	O
charantia	CC	O
inhibitor,	NNS	O
curcin,	VBP	O
crotin,	IN	O
sapaonaria	MD	O
officinalis	VB	O
inhibitor,	VBN	O
gelonin,	VBP	O
mitogellin,	NNS	O
restrictocin,	NNP	O
phenomycin,	,	O
enomycin,	VBG	O
and	JJ	O
the	NNS	O
tricothecenes.	IN	O
A	NN	O
variety	,	O
of	VBZ	O
radionuclides	NNP	O
are	NN	O
available	IN	O
for	NNP	O
the	,	O
production	VBZ	O
of	NNP	O
radioconjugated	,	O
antibodies.	VBZ	O
Examples	NNP	O
include	,	O
212Bi,	VBZ	O
131I,	NNP	O
131In,	,	O
90Y,	,	O
and	NNP	O
186Re.	VBP	O
Conjugates	,	O
of	JJ	O
the	,	O
antibody	NNP	O
and	NN	O
cytotoxic	NNS	O
agent	,	O
are	,	O
made	CC	O
using	,	O
a	JJ	O
variety	NN	O
of	,	O
bifunctional	,	O
protein-coupling	,	O
agents	NN	O
such	NN	O
as	,	O
N-succinimidyl-3-(2-pyridyldithiol)	,	O
propionate	,	O
(SPDP),	,	O
iminothiolane	,	O
(TT),	,	O
bifunctional	CC	O
derivatives	DT	O
of	.	O
imidoesters	DT	O
(such	NN	O
as	IN	O
dimethyl	NNS	O
adipimidate	VBP	O
HCL),	JJ	O
active	IN	O
esters	DT	O
(such	NN	O
as	IN	O
disuccinimidyl	JJ	O
suberate),	.	O
aldehydes	NNS	O
(such	VBP	O
as	,	O
glutareldehyde),	,	O
bis-azido	,	O
compounds	,	O
(such	CC	O
as	.	O
bis(p-azidobenzoyl)hexanediamine),	NNS	O
bis-diazonium	IN	O
derivatives	DT	O
(such	NN	O
as	CC	O
bis-(p-diazoniumbenzoyl)-ethylenediamine),	NN	O
diisocyanates	NN	O
(such	VBP	O
as	VBN	O
tolyene	VBG	O
2,6-diisocyanate),	DT	O
and	NN	O
bis-active	IN	O
fluorine	JJ	O
compounds	JJ	O
(such	NNS	O
as	JJ	O
1,5-difluoro-2,4-dinitrobenzene).	IN	O
For	)	O
example,	NN	O
a	,	O
ricin	NN	O
immunotoxin	,	O
can	JJ	O
be	NNS	O
prepared	IN	O
as	NNS	O
described	JJ	O
in	IN	O
Vitetta	JJ	B
et	NN	I
al.,	,	I
Science,	JJ	I
238:	NNS	I
1098	JJ	I
(1987).	IN	I
Carbon-14-labeled	JJ	O
1-isothiocyanatobenzyl-3-methyldiethylene	,	O
triaminepentaacetic	NNS	O
acid	JJ	O
(MX-DTPA)	IN	O
is	,	O
an	JJ	O
exemplary	NNS	O
chelating	JJ	O
agent	IN	O
for	,	O
conjugation	JJ	O
of	NNS	O
radionucleotide	JJ	O
to	IN	O
the	,	O
antibody.	VBZ	O
See	JJ	O
WO94/11026.	IN	O
Conjugates	JJ	O
of	,	O
an	CC	O
antibody	JJ	O
and	NN	O
one	NNS	O
or	JJ	O
more	IN	O
small	.	O
molecule	IN	O
toxins,	,	O
such	DT	O
as	NN	O
a	NN	O
calicheamicin,	MD	O
maytansinoids,	VB	O
a	VBN	O
trichothene,	IN	O
and	VBN	O
CC1065,	IN	O
and	NNP	O
the	CC	O
derivatives	,	O
of	,	O
these	:	O
toxins	CD	O
that	.	O
have	JJ	O
toxin	JJ	O
activity,	JJ	O
are	NN	O
also	)	O
contemplated	VBZ	O
herein.	DT	O
Maytansine	JJ	O
and	NN	O
Maytansinoids	NN	O
The	IN	O
invention	NN	O
provides	IN	O
an	NN	O
anti-PRO227,	TO	O
anti-PRO233,	DT	O
anti-PRO238,	.	O
anti-PRO1328,	VB	O
anti-PRO4342,	.	O
anti-PRO7423,	NNS	O
anti-PRO10096,	IN	O
anti-PRO21384,	DT	O
anti-PRO353	NN	O
or	CC	O
anti-PRO1885	CD	O
antibody	CC	O
(full	JJR	O
length	JJ	O
or	NN	O
fragments)	,	O
which	JJ	O
is	IN	O
conjugated	DT	O
to	,	O
one	,	O
or	DT	O
more	,	O
maytansinoid	CC	O
molecules.	,	O
Maytansinoids	CC	O
are	DT	O
mitototic	NNS	O
inhibitors	IN	O
which	DT	O
act	NNS	O
by	WDT	O
inhibiting	VBP	O
tubulin	VBN	O
polymerization.	,	O
Maytansine	VBP	O
was	RB	O
first	VBN	O
isolated	.	O
from	NNP	O
the	CC	O
east	NNP	O
African	DT	O
shrub	NN	O
Maytenus	VBZ	O
serrata	DT	O
(U.S.	,	O
Pat.	,	O
No.	,	O
3,896,111).	,	O
Subsequently,	,	O
it	,	O
was	,	O
discovered	,	O
that	JJ	O
certain	CC	O
microbes	JJ	O
also	NN	O
produce	JJ	O
maytansinoids,	NN	O
such	CC	O
as	)	O
maytansinol	WDT	O
and	VBZ	O
C-3	VBN	O
maytansinol	TO	O
esters	CD	O
(U.S.	CC	O
Pat.	JJR	O
No.	JJ	O
4,151,042).	.	O
Synthetic	NNS	O
maytansinol	VBP	O
and	JJ	O
derivatives	NNS	O
and	WDT	O
analogues	VBP	O
thereof	IN	O
are	VBG	O
disclosed,	JJ	O
for	.	O
example,	NNP	O
in	VBD	O
U.S.	RB	O
Pat.	VBN	O
Nos.	IN	O
4,137,230;	DT	O
4,248,870;	JJ	O
4,256,746;	JJ	O
4,260,608;	NN	O
4,265,814;	NNP	O
4,294,757;	NN	O
4,307,016;	NNP	O
4,308,268;	.	O
4,308,269;	.	O
4,309,428;	.	O
4,313,946;	,	O
4,315,929;	PRP	O
4,317,821;	VBD	O
4,322,348;	VBN	O
4,331,598;	IN	O
4,361,650;	JJ	O
4,364,866;	NNS	O
4,424,219;	RB	O
4,450,254;	VBP	O
4,362,663;	,	O
and	JJ	O
4,371,533,	IN	O
the	NNS	O
disclosures	CC	O
of	NNP	O
which	NN	O
are	NNS	O
hereby	NNP	O
expressly	.	O
incorporated	.	O
by	.	O
reference.	JJ	O
Maytansinoid-Antibody	NN	O
Conjugates	CC	O
In	NNS	O
an	CC	O
attempt	NNS	O
to	NNS	O
improve	VBP	O
their	,	O
therapeutic	IN	O
index,	,	O
maytansine	IN	O
and	NNP	O
maytansinoids	.	O
have	.	O
been	:	O
conjugated	:	O
to	:	O
antibodies	:	O
specifically	:	O
binding	:	O
to	:	O
tumor	:	O
cell	:	O
antigens.	:	O
Immunoconjugates	:	O
containing	:	O
maytansinoids	:	O
and	:	O
their	:	O
therapeutic	:	O
use	:	O
are	:	O
disclosed,	:	O
for	:	O
example,	CC	O
in	,	O
U.S.	DT	O
Pat.	NNS	O
Nos.	IN	O
5,208,020,	WDT	O
5,416,064	VBP	O
and	RB	O
European	RB	O
Patent	VBN	O
EP	IN	O
0	.	O
425	NN	O
235	NNS	O
B1,	IN	O
the	DT	O
disclosures	NN	O
of	TO	O
which	VB	O
are	PRP$	O
hereby	JJ	O
expressly	,	O
incorporated	NN	O
by	CC	O
reference.	NNS	O
Liu	VBP	B
et	VBN	I
al.,	VBN	I
Proc.	TO	I
Natl.	NNS	I
Acad.	RB	I
Sci.	VBG	I
USA	TO	I
93:8618-8623	VB	I
(1996)	NN	I
described	.	O
immunoconjugates	NNS	O
comprising	VBG	O
a	NNS	O
maytansinoid	CC	O
designated	PRP$	O
DM1	JJ	O
linked	NN	O
to	VBP	O
the	,	O
monoclonal	IN	O
antibody	,	O
C242	IN	O
directed	NNP	O
against	.	O
human	.	O
colorectal	,	O
cancer.	CD	O
The	CC	O
conjugate	JJ	O
was	NNP	O
found	NNP	O
to	CD	O
be	CD	O
highly	CD	O
cytotoxic	,	O
towards	DT	O
cultured	NNS	O
colon	IN	O
cancer	WDT	O
cells,	VBP	O
and	RB	O
showed	RB	O
antitumor	VBN	O
activity	IN	O
in	.	O
an	NNP	O
in	CC	O
vivo	,	O
tumor	.	O
growth	.	O
assay.	.	O
Chari	.	B
et	NNP	I
al.,	CD	I
Cancer	)	I
Research	VBN	I
52:127-131	VBZ	I
(1992)	VBG	I
describe	DT	O
immunoconjugates	NN	O
in	VBN	O
which	NNP	O
a	VBD	O
maytansinoid	TO	O
was	DT	O
conjugated	JJ	O
via	NN	O
a	NNP	O
disulfide	VBD	O
linker	IN	O
to	JJ	O
the	JJ	O
murine	.	O
antibody	DT	O
A7	NN	O
binding	VBD	O
to	VBN	O
an	TO	O
antigen	VB	O
on	RB	O
human	JJ	O
colon	NNS	O
cancer	VBN	O
cell	NN	O
lines,	NN	O
or	,	O
to	CC	O
another	VBD	O
murine	NN	O
monoclonal	NN	O
antibody	IN	O
TA.1	DT	O
that	IN	O
binds	JJ	O
the	NN	O
HER-2/neu	NN	O
oncogene.	.	O
The	NNP	O
cytotoxicity	CC	O
of	,	O
the	NNP	O
TA.1-maytansonoid	NNP	O
conjugate	CD	O
was	)	O
tested	NN	O
in	NNS	O
vitro	IN	O
on	WDT	O
the	DT	O
human	NN	O
breast	VBD	O
cancer	VBN	O
cell	IN	O
line	DT	O
SK-BR-3,	JJ	O
which	NN	O
expresses	TO	O
3×105	DT	O
HER-2	NN	O
surface	NN	O
antigens	NNP	O
per	NN	O
cell.	TO	O
The	DT	O
drug	NN	O
conjugate	IN	O
achieved	JJ	O
a	NN	O
degree	NN	O
of	NN	O
cytotoxicity	,	O
similar	CC	O
to	TO	O
the	DT	O
free	NN	O
maytansonid	NN	O
drug,	NN	O
which	NNP	O
could	WDT	O
be	VBZ	O
increased	DT	O
by	NNP	O
increasing	.	O
the	DT	O
number	NN	O
of	IN	O
maytansinoid	DT	O
molecules	JJ	O
per	NN	O
antibody	VBD	O
molecule.	VBN	O
The	IN	O
A7-maytansinoid	NN	O
conjugate	IN	O
showed	DT	O
low	JJ	O
systemic	NN	O
cytotoxicity	NN	O
in	NN	O
mice.	NN	O
Anti-PRO227,	,	O
Anti-PRO233,	WDT	O
Anti-PRO238,	VBZ	O
Anti-PRO1328,	CD	O
Anti-PRO4342,	JJ	O
Anti-PRO7423,	NN	O
anti-PRO10096,	NNS	O
anti-PRO21384,	IN	O
anti-PRO353	.	O
or	DT	O
Anti-PRO1885	NN	O
Antibody-Maytansinoid	NN	O
Conjugates	VBD	O
(Immunoconjugates)	DT	O
Anti-PRO227,	NN	O
anti-PRO233,	IN	O
anti-PRO238,	NN	O
anti-PRO1328,	JJ	O
anti-PRO4342,	TO	O
anti-PRO7423,	DT	O
anti-PRO10096,	JJ	O
anti-PRO21384,	NN	O
anti-PRO353	,	O
or	WDT	O
anti-PRO1885	MD	O
antibody-maytansinoid	VB	O
conjugates	VBN	O
are	IN	O
prepared	VBG	O
by	DT	O
chemically	NN	O
linking	IN	O
an	JJ	O
anti-PRO227,	NNS	O
anti-PRO233,	IN	O
anti-PRO238,	NN	O
anti-PRO1328,	.	O
anti-PRO4342,	DT	O
anti-PRO7423,	JJ	O
anti-PRO10096,	NN	O
anti-PRO21384,	VBD	O
anti-PRO353	JJ	O
or	JJ	O
anti-PRO1885	NN	O
antibody	IN	O
to	.	O
a	,	O
maytansinoid	,	O
molecule	,	O
without	,	O
significantly	,	O
diminishing	,	O
the	,	O
biological	,	O
activity	JJ	O
of	CC	O
either	JJ	O
the	JJ	O
antibody	NNP	O
or	)	O
the	,	O
maytansinoid	,	O
molecule.	,	O
An	,	O
average	,	O
of	,	O
3-4	,	O
maytansinoid	,	O
molecules	JJ	O
conjugated	CC	O
per	JJ	O
antibody	JJ	O
molecule	NNS	O
has	VBP	O
shown	VBN	O
efficacy	IN	O
in	RB	O
enhancing	VBG	O
cytotoxicity	DT	O
of	,	O
target	,	O
cells	,	O
without	,	O
negatively	,	O
affecting	,	O
the	,	O
function	,	O
or	JJ	O
solubility	CC	O
of	JJ	O
the	NN	O
antibody,	TO	O
although	DT	O
even	NN	O
one	NN	O
molecule	IN	O
of	RB	O
toxin/antibody	VBG	O
would	DT	O
be	JJ	O
expected	NN	O
to	IN	O
enhance	CC	O
cytotoxicity	DT	O
over	NN	O
the	CC	O
use	DT	O
of	JJ	O
naked	.	O
antibody.	DT	O
Maytansinoids	NN	O
are	IN	O
well	JJ	O
known	NN	O
in	NNS	O
the	VBN	O
art	IN	O
and	NN	O
can	NN	O
be	VBZ	O
synthesized	VBN	O
by	NN	O
known	IN	O
techniques	VBG	O
or	NN	O
isolated	IN	O
from	NN	O
natural	NNS	O
sources.	IN	O
Suitable	RB	O
maytansinoids	VBG	O
are	DT	O
disclosed,	NN	O
for	CC	O
example,	NN	O
in	IN	O
U.S.	DT	O
Pat.	,	O
No.	IN	O
5,208,020	RB	O
and	CD	O
in	NN	O
the	IN	O
other	NN	O
patents	MD	O
and	VB	O
nonpatent	VBN	O
publications	TO	O
referred	VB	O
to	NN	O
hereinabove.	IN	O
Preferred	DT	O
maytansinoids	NN	O
are	IN	O
maytansinol	JJ	O
and	.	O
maytansinol	NNS	O
analogues	VBP	O
modified	RB	O
in	VBN	O
the	IN	O
aromatic	DT	O
ring	NN	O
or	CC	O
at	MD	O
other	VB	O
positions	VBN	O
of	IN	O
the	VBN	O
maytansinol	NNS	O
molecule,	CC	O
such	VBN	O
as	IN	O
various	JJ	O
maytansinol	.	O
esters.	JJ	O
There	NNS	O
are	VBP	O
many	,	O
linking	IN	O
groups	,	O
known	IN	O
in	NNP	O
the	.	O
art	.	O
for	CD	O
making	CC	O
antibody-maytansinoid	IN	O
conjugates,	DT	O
including,	JJ	O
for	NNS	O
example,	CC	O
those	JJ	O
disclosed	NNS	O
in	VBD	O
U.S.	TO	O
Pat.	.	O
No.	JJ	O
5,208,020	NNS	O
or	VBP	O
EP	JJ	O
Patent	CC	O
0	JJ	O
425	NNS	O
235	VBN	O
B1,	IN	O
and	DT	O
Chari	JJ	B
et	NN	I
al.,	CC	I
Cancer	IN	I
Research	JJ	I
52:127-131	NNS	I
(1992).	IN	I
The	DT	O
linking	NN	O
groups	,	O
include	JJ	O
disulfide	IN	O
groups,	JJ	O
thioether	NN	O
groups,	.	O
acid	EX	O
labile	VBP	O
groups,	JJ	O
photolabile	VBG	O
groups,	NNS	O
peptidase	VBN	O
labile	IN	O
groups,	DT	O
or	NN	O
esterase	IN	O
labile	VBG	O
groups,	JJ	O
as	,	O
disclosed	,	O
in	IN	O
the	,	O
above-identified	DT	O
patents,	VBN	O
disulfide	IN	O
and	NNP	O
thioether	.	O
groups	.	O
being	CD	O
preferred.	CC	O
Conjugates	NNP	O
of	NNP	O
the	CD	O
antibody	CD	O
and	CD	O
maytansinoid	,	O
may	CC	O
be	NNP	O
made	VBP	O
using	,	O
a	NNP	O
variety	NNP	O
of	CD	O
bifunctional	.	O
protein	DT	O
coupling	VBG	O
agents	NNS	O
such	VBP	O
as	JJ	O
N-succinimidyl-3-(2-pyridyldithio)propionate	,	O
(SPDP),	RB	O
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,	,	O
iminothiolane	VBP	O
(IT),	JJ	O
bifunctional	,	O
derivatives	NN	O
of	,	O
imidoesters	NN	O
(such	NN	O
as	,	O
dimethyl	CC	O
adipimidate	VB	O
HCL),	JJ	O
active	,	O
esters	IN	O
(such	VBN	O
as	IN	O
disuccinimidyl	DT	O
suberate),	JJ	O
aldehydes	,	O
(such	NN	O
as	CC	O
glutareldehyde),	NN	O
bis-azido	NNS	O
compounds	VBG	O
(such	.	O
as	NNS	O
bis(p-azidobenzoyl)hexanediamine),	IN	O
bis-diazonium	DT	O
derivatives	NN	O
(such	CC	O
as	NN	O
bis-(p-diazoniumbenzoyl)-ethylenediamine),	MD	O
diisocyanates	VB	O
(such	VBN	O
as	VBG	O
toluene	DT	O
2,6-diisocyanate),	NN	O
and	IN	O
bis-active	JJ	O
fluorine	NN	O
compounds	VBG	O
(such	NNS	O
as	JJ	O
1,5-difluoro-2,4-dinitrobenzene).	IN	O
Particularly	NN	O
preferred	,	O
coupling	,	O
agents	NN	O
include	,	O
N-succinimidyl-3-(2-pyridyldithio)propionate	JJ	O
(SPDP)	NNS	O
Carlsson	IN	B
et	NNS	I
al.,	JJ	I
Biochem.	IN	I
J.	JJ	I
173:723-737	NN	I
[1978])	,	I
(and	JJ	O
N-succinimidyl-4-(2-pyridylthio)pentanoate	NNS	O
(SPP)	JJ	O
to	IN	O
provide	JJ	O
for	,	O
a	NNS	O
disulfide	JJ	O
linkage.	IN	O
The	,	O
linker	JJ	O
may	NNS	O
be	JJ	O
attached	IN	O
to	,	O
the	JJ	O
maytansinoid	NNS	O
molecule	JJ	O
at	IN	O
various	,	O
positions,	VBZ	O
depending	JJ	O
on	IN	O
the	JJ	O
type	,	O
of	CC	O
the	JJ	O
link.	NN	O
For	NNS	O
example,	JJ	O
an	IN	O
ester	.	O
linkage	RB	O
may	JJ	O
be	VBG	O
formed	NNS	O
by	VBP	O
reaction	NN	O
with	)	O
a	NNP	O
hydroxyl	RB	O
group	,	O
using	.	O
conventional	.	O
coupling	CD	O
techniques.	)	O
The	CC	O
reaction	NN	O
may	)	O
occur	TO	O
at	VB	O
the	IN	O
C-3	DT	O
position	JJ	O
having	.	O
a	DT	O
hydroxyl	NN	O
group,	MD	O
the	VB	O
C-14	VBN	O
position	TO	O
modified	DT	O
with	NN	O
hyrdoxymethyl,	NN	O
the	IN	O
C-15	JJ	O
position	,	O
modified	VBG	O
with	IN	O
a	DT	O
hydroxyl	NN	O
group,	IN	O
and	DT	O
the	.	O
C-20	IN	O
position	,	O
having	DT	O
a	JJ	O
hydroxyl	NN	O
group.	MD	O
The	VB	O
linkage	VBN	O
is	IN	O
formed	NN	O
at	IN	O
the	DT	O
C-3	NN	O
position	NN	O
of	VBG	O
maytansinol	JJ	O
or	NN	O
a	.	O
maytansinol	DT	O
analogue.	NN	O
Calicheamicin	MD	O
Another	VB	O
immunoconjugate	IN	O
of	DT	O
interest	NNP	O
comprises	NN	O
an	VBG	O
anti-PRO227,	DT	O
anti-PRO233,	NN	O
anti-PRO238,	,	O
anti-PRO1328,	DT	O
anti-PRO4342,	NNP	O
anti-PRO7423,	NN	O
anti-PRO10096,	VBD	O
anti-PRO21384,	IN	O
anti-PRO353	,	O
or	DT	O
anti-PRO1885	NNP	O
antibody	NN	O
conjugated	VBD	O
to	IN	O
one	DT	O
or	NN	O
more	,	O
calicheamicin	CC	O
molecules.	DT	O
The	NNP	O
calicheamicin	NN	O
family	VBG	O
of	DT	O
antibiotics	NN	O
are	.	O
capable	DT	O
of	NN	O
producing	VBZ	O
double-stranded	VBN	O
DNA	IN	O
breaks	DT	O
at	NNP	O
sub-picomolar	NN	O
concentrations.	IN	O
For	NN	O
the	CC	O
preparation	DT	O
of	JJ	O
conjugates	.	O
of	NNP	O
the	DT	O
calicheamicin	NN	O
family,	IN	O
see	NN	O
U.S.	NNS	O
Pat.	DT	O
Nos.	,	O
5,712,374,	,	O
5,714,586,	,	O
5,739,116,	,	O
5,767,285,	,	O
5,770,701,	,	O
5,770,710,	,	O
5,773,001,	,	O
5,877,296	JJ	O
(all	CC	O
to	JJ	O
American	NN	O
Cyanamid	VBD	O
Company).	TO	O
Structural	CD	O
analogues	CC	O
of	JJR	O
calicheamicin	JJ	O
which	.	O
may	DT	O
be	JJ	O
used	NN	O
include,	IN	O
but	NNS	O
are	VBP	O
not	JJ	O
limited	IN	O
to,	VBG	O
γ1	JJ	O
I,	NNP	O
α2	NNS	O
I,	IN	O
α3	JJ	O
I,	.	O
N-acetyl-γ1	IN	O
I,	DT	O
PSAG	NN	O
and	IN	O
θI	NNS	O
1	IN	O
Hinman	DT	B
et	NN	I
al.,	,	I
Cancer	VBP	I
Research	NNP	I
53:3336-3342	.	I
(1993),	.	I
Lode	,	B
et	,	I
al.,	,	I
Cancer	,	I
Research	,	I
58:2925-2928	,	I
(1998)	,	I
a(nd	CD	O
the	DT	O
aforementioned	TO	O
U.S.	NNP	O
patents	NNP	O
to	.	O
American	JJ	O
Cyanamid).	NNS	O
Another	IN	O
anti-tumor	NN	O
drug	WDT	O
that	MD	O
the	VB	O
antibody	VBN	O
can	,	O
be	CC	O
conjugated	VBP	O
is	RB	O
QFA	VBN	O
which	,	O
is	NNP	O
an	,	O
antifolate.	''	O
Both	,	O
calicheamicin	''	O
and	,	O
QFA	NNP	O
have	,	O
intracellular	NNP	O
sites	CC	O
of	$	O
action	CD	O
and	NNP	O
do	VBZ	O
not	,	O
readily	NNP	O
cross	NNP	O
the	CD	O
plasma	,	O
membrane.	NNP	O
Therefore,	FW	O
cellular	,	O
uptake	NNP	O
of	NNP	O
these	CD	O
agents	)	O
through	CC	O
antibody	DT	O
mediated	JJ	O
internalization	NNP	O
greatly	NNS	O
enhances	TO	O
their	NNP	O
cytotoxic	.	O
effects.	DT	O
Other	JJ	O
Cytotoxic	NN	O
Agents	IN	O
Other	DT	O
antitumor	NN	O
agents	MD	O
that	VB	O
can	VBN	O
be	VBZ	O
conjugated	NNP	O
to	WDT	O
the	VBZ	O
anti-PRO227,	DT	O
anti-PRO233,	.	O
anti-PRO238,	DT	O
anti-PRO1328,	NN	O
anti-PRO4342,	CC	O
anti-PRO7423,	NNP	O
anti-PRO10096,	VBP	O
anti-PRO21384,	JJ	O
anti-PRO353	NNS	O
or	IN	O
anti-PRO1885	NN	O
antibodies	CC	O
of	VBP	O
the	RB	O
invention	RB	O
include	VB	O
BCNU,	DT	O
streptozoicin,	NN	O
vincristine	.	O
and	,	O
5-fluorouracil,	JJ	O
the	NN	O
family	IN	O
of	DT	O
agents	NNS	O
known	IN	O
collectively	NN	O
LL-E33288	VBN	O
complex	NN	O
described	RB	O
in	VBZ	O
U.S.	PRP$	O
Pat.	JJ	O
Nos.	.	O
5,053,394,	JJ	O
5,770,710,	NNP	O
as	NNP	O
well	JJ	O
as	NN	O
esperamicins	NNS	O
(U.S.	WDT	O
Pat.	MD	O
No.	VB	O
5,877,296).	VBN	O
Enzymatically	TO	O
active	DT	O
toxins	,	O
and	,	O
fragments	,	O
thereof	,	O
which	,	O
can	,	O
be	,	O
used	,	O
include	JJ	O
diphtheria	CC	O
A	JJ	O
chain,	NNS	O
nonbinding	IN	O
active	DT	O
fragments	NN	O
of	VBP	O
diphtheria	,	O
toxin,	,	O
exotoxin	NN	O
A	CC	O
chain	,	O
(from	DT	O
Pseudomonas	NN	O
aeruginosa),	IN	O
ricin	NNS	O
A	VBN	O
chain,	RB	O
abrin	NNP	O
A	JJ	O
chain,	VBN	O
modeccin	IN	O
A	NNP	O
chain,	.	O
alpha-sarcin,	.	O
Aleurites	,	O
fordii	,	O
proteins,	RB	O
dianthin	RB	O
proteins,	IN	O
Phytolaca	NNS	O
americana	NNP	O
proteins	.	O
(PAPI,	.	O
PAPII,	.	O
and	RB	O
PAP-S),	JJ	O
momordica	NNS	O
charantia	CC	O
inhibitor,	NNS	O
curcin,	IN	O
crotin,	WDT	O
sapaonaria	MD	O
officinalis	VB	O
inhibitor,	VBN	O
gelonin,	VBP	O
mitogellin,	NNS	O
restrictocin,	NNP	O
phenomycin,	,	O
enomycin	VBG	O
and	JJ	O
the	NNS	O
tricothecenes.	IN	O
See,	NN	O
for	,	O
example,	VBZ	O
WO	NNP	O
93/21232	NN	O
published	IN	O
Oct.	NNP	O
28,	,	O
1993.	VBZ	O
The	NNP	O
present	,	O
invention	VBZ	O
further	NNP	O
contemplates	,	O
an	VBZ	O
immunoconjugate	NNP	O
formed	,	O
between	,	O
an	NNP	O
antibody	VBP	O
and	,	O
a	JJ	O
compound	,	O
with	NNP	O
nucleolytic	NN	O
activity	NNS	O
(e.g.,	,	O
a	,	O
ribonuclease	CC	O
or	,	O
a	JJ	O
DNA	NN	O
endonuclease	,	O
such	,	O
as	,	O
a	NN	O
deoxyribonuclease;	NN	O
DNase).	,	O
For	,	O
selective	,	O
destruction	,	O
of	,	O
the	NN	O
tumor,	CC	O
the	DT	O
antibody	.	O
may	,	O
comprise	IN	O
a	,	O
highly	NNP	O
radioactive	CD	O
atom.	VBN	O
A	NNP	O
variety	,	O
of	.	O
radioactive	DT	O
isotopes	JJ	O
are	NN	O
available	RBR	O
for	VBZ	O
the	DT	O
production	NN	O
of	VBD	O
radioconjugated	IN	O
anti-PRO227,	DT	O
anti-PRO233,	NN	O
anti-PRO238,	CC	O
anti-PRO1328,	DT	O
anti-PRO4342,	NN	O
anti-PRO7423,	IN	O
anti-PRO10096,	JJ	O
anti-PRO21384,	NN	O
anti-PRO353	,	O
or	DT	O
anti-PRO1885	NN	O
antibodies.	CC	O
Examples	DT	O
include	JJ	O
At211,	NN	O
I131,	JJ	O
I125,	IN	O
Y90,	DT	O
Re186,	:	O
Re188,	.	O
Sm153,	IN	O
Bi212,	JJ	O
P32,	NN	O
Pb212	IN	O
and	DT	O
radioactive	,	O
isotopes	DT	O
of	NN	O
Lu.	MD	O
When	VB	O
the	DT	O
conjugate	RB	O
is	JJ	O
used	.	O
for	DT	O
diagnosis,	NN	O
it	IN	O
may	JJ	O
comprise	NNS	O
a	VBP	O
radioactive	JJ	O
atom	IN	O
for	DT	O
scintigraphic	NN	O
studies,	IN	O
for	JJ	O
example	,	O
tc99m	,	O
or	,	O
I123,	,	O
or	,	O
a	,	O
spin	,	O
label	,	O
for	JJ	O
nuclear	CC	O
magnetic	JJ	O
resonance	.	O
(NMR)	NNS	O
imaging	VBP	O
(also	,	O
known	,	O
as	,	O
magnetic	,	O
resonance	,	O
imaging,	,	O
mri),	,	O
such	,	O
as	,	O
iodine-123	NNP	O
again,	CC	O
iodine-131,	JJ	O
indium-111,	NNS	O
fluorine-19,	IN	O
carbon-13,	.	O
nitrogen-15,	WRB	O
oxygen-17,	DT	O
gadolinium,	NN	O
manganese	VBZ	O
or	VBN	O
iron.	IN	O
The	,	O
radio-	PRP	O
or	MD	O
other	VB	O
labels	DT	O
may	JJ	O
be	NN	O
incorporated	IN	O
in	JJ	O
the	,	O
conjugate	IN	O
in	NN	O
known	NN	O
ways.	CC	O
For	,	O
example,	CC	O
the	DT	O
peptide	JJ	O
may	NN	O
be	IN	O
biosynthesized	JJ	O
or	JJ	O
may	NN	O
be	)	O
synthesized	NN	O
by	RB	O
chemical	VBN	O
amino	IN	O
acid	JJ	O
synthesis	NN	O
using	,	O
suitable	,	O
amino	JJ	O
acid	IN	O
precursors	NN	O
involving,	,	O
for	,	O
example,	,	O
fluorine-19	,	O
in	,	O
place	,	O
of	,	O
hydrogen.	,	O
Labels	JJ	O
such	CC	O
as	.	O
tc99m	DT	O
or	NN	O
I123,	CC	O
Re186,	JJ	O
Re188	NNS	O
and	MD	O
In111	VB	O
can	VBN	O
be	IN	O
attached	DT	O
via	NN	O
a	IN	O
cysteine	JJ	O
residue	.	O
in	IN	O
the	,	O
peptide.	DT	O
Yttrium-90	NN	O
can	MD	O
be	VB	O
attached	VBN	O
via	CC	O
a	MD	O
lysine	VB	O
residue.	VBN	O
The	IN	O
IODOGEN	NN	O
method	NN	O
(Fraker	JJ	B
et	NN	I
al	VBG	I
(1978)	JJ	I
Biochem.	NN	I
Biophys.	NN	I
Res.	NNS	I
Commun.	,	I
80:	IN	I
49-57	,	I
can	NN	O
be	IN	O
used	NN	O
to	IN	O
incorporate	.	O
iodine-123.	NNS	O
“Monoclonal	JJ	B
Antibodies	IN	I
in	NN	I
Immunoscintigraphy”	CC	I
(Chatal,	,	I
CRC	,	I
Press	NNP	I
1989)	CC	I
describes	NNP	O
other	MD	O
methods	VB	O
in	VBN	O
detail.	IN	O
Conjugates	DT	O
of	NN	O
the	NN	O
antibody	IN	O
and	DT	O
cytotoxic	.	O
agent	NN	O
may	MD	O
be	VB	O
made	VBN	O
using	IN	O
a	DT	O
variety	NN	O
of	.	O
bifunctional	DT	O
protein	NNP	O
coupling	NN	O
agents	NNP	O
such	VBZ	O
as	NN	O
N-succinimidyl-3-(2-pyridyldithio)propionate	)	O
(SPDP),	.	O
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,	.	O
iminothiolane	.	O
(IT),	.	O
bifunctional	:	O
derivatives	JJ	O
of	MD	O
imidoesters	VB	O
(such	VBN	O
as	TO	O
dimethyl	VB	O
adipimidate	.	O
HCL),	JJ	O
active	NNS	O
esters	IN	O
(such	NNP	O
as	,	O
disuccinimidyl	NNP	O
suberate),	NNP	O
aldehydes	)	O
(such	VBZ	O
as	JJ	O
glutareldehyde),	NNS	O
bis-azido	IN	O
compounds	.	O
(such	NNS	O
as	IN	O
bis(p-azidobenzoyl)hexanediamine),	DT	O
bis-diazonium	NN	O
derivatives	CC	O
(such	JJ	O
as	NN	O
bis-(p-diazoniumbenzoyl)-ethylenediamine),	MD	O
diisocyanates	VB	O
(such	VBN	O
as	VBG	O
tolyene	DT	O
2,6-diisocyanate),	NN	O
and	IN	O
bis-active	JJ	O
fluorine	NN	O
compounds	VBG	O
(such	NNS	O
as	JJ	O
1,5-difluoro-2,4-dinitrobenzene).	IN	O
For	NN	O
example,	,	O
a	,	O
ricin	NN	O
immunotoxin	,	O
can	JJ	O
be	NNS	O
prepared	IN	O
as	NNS	O
described	JJ	O
in	IN	O
Vitetta	JJ	B
et	NN	I
al.,	,	I
Science	JJ	I
238:1098	NNS	I
(1987).	JJ	I
Carbon-14-labeled	IN	O
1-isothiocyanatobenzyl-3-methyldiethylene	JJ	O
triaminepentaacetic	,	O
acid	NNS	O
(MX-DTPA)	JJ	O
is	IN	O
an	,	O
exemplary	JJ	O
chelating	NNS	O
agent	JJ	O
for	IN	O
conjugation	,	O
of	JJ	O
radionucleotide	NNS	O
to	JJ	O
the	IN	O
antibody.	,	O
See	VBZ	O
WO94/11026.	JJ	O
The	IN	O
linker	JJ	O
may	,	O
be	CC	O
a	JJ	O
“cleavable	NN	O
linker”	NNS	O
facilitating	JJ	O
release	IN	O
of	.	O
the	IN	O
cytotoxic	,	O
drug	DT	O
in	NN	O
the	NN	O
cell.	MD	O
For	VB	O
example,	VBN	O
an	IN	O
acid-labile	VBN	O
linker,	IN	O
peptidase-sensitive	NNP	O
linker,	CC	O
photolabile	,	O
linker,	NNP	O
dimethyl	CD	O
linker	.	O
or	JJ	O
disulfide-containing	JJ	O
linker	JJ	O
Chari	NN	B
et	)	I
al.,	VBZ	I
Cancer	DT	I
Research	JJ	I
52:127-131	NN	I
(1992);	NN	I
(U.S.	IN	O
Pat.	NN	O
No.	IN	O
5,208,020)	NN	O
may	TO	O
be	DT	O
used.	.	O
Alternatively,	VB	O
a	.	O
fusion	DT	O
protein	NN	O
comprising	MD	O
the	VB	O
anti-PRO227,	DT	O
anti-PRO233,	JJ	O
anti-PRO238,	NN	O
anti-PRO1328,	VBG	O
anti-PRO4342,	NN	O
anti-PRO7423,	IN	O
anti-PRO10096,	DT	O
anti-PRO21384,	JJ	O
anti-PRO353	NN	O
or	IN	O
anti-PRO1885	DT	O
antibody	.	O
and	IN	O
cytotoxic	,	O
agent	DT	O
may	JJ	O
be	,	O
made,	JJ	O
e.g.,	,	O
by	NN	O
recombinant	,	O
techniques	JJ	O
or	NN	O
peptide	CC	O
synthesis.	JJ	O
The	NN	O
length	NNP	O
of	RB	O
DNA	,	O
may	NNP	O
comprise	NNP	O
respective	CD	O
regions	:	O
encoding	NNP	O
the	.	O
two	.	O
portions	)	O
of	MD	O
the	VB	O
conjugate	.	O
either	,	O
adjacent	DT	O
one	NN	O
another	NN	O
or	VBG	O
separated	DT	O
by	,	O
a	,	O
region	,	O
encoding	,	O
a	,	O
linker	,	O
peptide	,	O
which	,	O
does	JJ	O
not	CC	O
destroy	JJ	O
the	NN	O
desired	CC	O
properties	JJ	O
of	NN	O
the	MD	O
conjugate.	VB	O
The	,	O
invention	,	O
provides	IN	O
that	JJ	O
the	NNS	O
antibody	CC	O
may	JJ	O
be	.	O
conjugated	DT	O
to	NN	O
a	IN	O
“receptor”	NNP	O
(such	MD	O
streptavidin)	VB	O
for	JJ	O
utilization	NNS	O
in	VBG	O
tumor	DT	O
pre-targeting	CD	O
wherein	NNS	O
the	IN	O
antibody-receptor	DT	O
conjugate	NN	O
is	CC	O
administered	JJ	O
to	CD	O
the	DT	O
patient,	CC	O
followed	VBN	O
by	IN	O
removal	DT	O
of	NN	O
unbound	VBG	O
conjugate	DT	O
from	NN	O
the	NN	O
circulation	WDT	O
using	VBZ	O
a	RB	O
clearing	VB	O
agent	DT	O
and	JJ	O
then	NNS	O
administration	IN	O
of	DT	O
a	.	O
“ligand”	DT	O
(e.g.,	NN	O
avidin)	VBZ	O
which	IN	O
is	DT	O
conjugated	NN	O
to	MD	O
a	VB	O
cytotoxic	VBN	O
agent	TO	O
(e.g.,	DT	O
a	NN	O
radionucleotide).	JJ	O
10.	)	O
Immunoliposomes	IN	O
The	NN	O
anti-PRO227,	IN	O
anti-PRO233,	NN	O
anti-PRO238,	NN	O
anti-PRO1328,	IN	O
anti-PRO4342,	DT	O
anti-PRO7423,	JJ	O
anti-PRO10096,	NN	O
anti-PRO21384,	VBZ	O
anti-PRO353	VBN	O
or	TO	O
anti-PRO1885	DT	O
antibodies	,	O
disclosed	VBN	O
herein	IN	O
may	NN	O
also	IN	O
be	JJ	O
formulated	NN	O
as	IN	O
immunoliposomes.	DT	O
A	NN	O
“liposome”	VBG	O
is	DT	O
a	NN	O
small	NN	O
vesicle	CC	O
composed	RB	O
of	NN	O
various	IN	O
types	DT	O
of	NN	O
lipids,	,	O
phospholipids	)	O
and/or	WDT	O
surfactant	VBZ	O
which	VBN	O
is	TO	O
useful	DT	O
for	NN	O
delivery	NN	O
of	,	O
a	DT	O
drug	.	O
to	.	O
a	VBZ	O
mammal.	DT	O
The	,	O
components	,	O
of	,	O
the	,	O
liposome	,	O
are	,	O
commonly	,	O
arranged	,	O
in	JJ	O
a	CC	O
bilayer	JJ	O
formation,	NNS	O
similar	VBN	O
to	NN	O
the	MD	O
lipid	RB	O
arrangement	VB	O
of	VBN	O
biological	IN	O
membranes.	.	O
Liposomes	DT	O
containing	NN	O
the	VBZ	O
antibody	DT	O
are	JJ	O
prepared	NN	O
by	VBN	O
methods	IN	O
known	JJ	O
in	NNS	O
the	IN	O
art,	,	O
such	NNS	O
as	VBP	O
described	JJ	O
in	WDT	O
Epstein	VBZ	B
et	JJ	I
al.,	IN	I
Proc.	NN	I
Natl.	IN	I
Acad.	DT	I
Sci.	NN	I
USA	TO	I
82:3688	DT	I
(1985);	.	I
Hwang	DT	B
et	NNS	I
al.,	IN	I
Proc.	DT	I
Natl.	NN	I
Acad.	VBP	I
Sci.	RB	I
USA	VBN	I
77:4030	IN	I
(1980);	DT	I
U.S.	NN	O
Pat.	,	O
Nos.	JJ	O
4,485,045	TO	O
and	DT	O
4,544,545;	JJ	O
and	NN	O
WO97/38731	IN	O
published	JJ	O
Oct.	.	O
23,	NNS	O
1997.	VBG	O
Liposomes	DT	O
with	NN	O
enhanced	VBP	O
circulation	VBN	O
time	IN	O
are	NNS	O
disclosed	VBN	O
in	IN	O
U.S.	DT	O
Pat.	,	O
No.	JJ	O
5,013,556.	IN	O
Particularly	NNS	O
useful	IN	O
liposomes	NNP	O
can	CC	O
be	,	O
generated	.	O
by	.	O
the	.	O
reverse	.	O
phase	NNP	O
evaporation	CD	O
method	:	O
with	NNP	O
a	FW	O
lipid	,	O
composition	.	O
comprising	.	O
phosphatidylcholine,	.	O
cholesterol	.	O
and	NNP	O
PEG-derivatized	CD	O
phosphatidylethanolamine	:	O
(PEG-PE).	NNP	O
Liposomes	.	O
are	.	O
extruded	CD	O
through	CC	O
filters	:	O
of	CC	O
defined	NNP	O
pore	VBD	O
size	NNP	O
to	,	O
yield	.	O
liposomes	NNS	O
with	IN	O
the	JJ	O
desired	NN	O
diameter.	NN	O
Fab′	VBP	O
fragments	VBN	O
of	IN	O
the	NNP	O
antibody	.	O
of	.	O
the	.	O
present	RB	O
invention	JJ	O
can	NNS	O
be	MD	O
conjugated	VB	O
to	VBN	O
the	IN	O
liposomes	DT	O
as	NN	O
described	NN	O
in	NN	O
Martin	NN	B
et	IN	I
al.,	DT	I
J.	JJ	I
Biol.	NN	I
Chem.	VBG	I
257:286-288	,	I
(1982)	NN	I
via	CC	O
a	JJ	O
disulfide	NN	O
interchange	.	O
reaction.	NNS	O
A	VBP	O
chemotherapeutic	VBN	O
agent	IN	O
is	NNS	O
optionally	IN	O
contained	VBN	O
within	NN	O
the	NN	O
liposome.	TO	O
See	VB	O
Gabizon	RB	B
et	IN	I
al.,	DT	I
J.	JJ	I
National	.	I
Cancer	NNP	I
Inst.	NNS	I
81(19):1484	IN	I
(1989).
11.	DT	O
Pharmaceutical	NN	O
Compositions	IN	O
of	DT	O
Antibodies	JJ	O
Antibodies	NN	O
specifically	MD	O
binding	VB	O
a	VBN	O
PRO227,	TO	O
PRO233,	DT	O
PRO238,	NNS	O
PRO1328,	IN	O
PRO4342,	VBN	O
PRO7423,	IN	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	,	O
or	NNP	O
PRO1885	.	O
polypeptide	.	O
identified	CD	O
herein,	)	O
as	IN	O
well	DT	O
as	JJ	O
other	NN	O
molecules	.	O
identified	DT	O
by	JJ	O
the	NN	O
screening	VBZ	O
assays	RB	O
disclosed	VBN	O
hereinbefore,	IN	O
can	DT	O
be	.	O
administered	VB	O
for	NNP	O
the	FW	O
treatment	,	O
of	.	O
various	NNP	O
disorders	NNP	O
in	.	O
the	NN	O
form	.	O
of	.	O
pharmaceutical	JJ	O
compositions.	NNS	O
If	IN	O
the	NNP	O
PRO227,	NNP	O
PRO233,	RB	O
PRO238,	VBG	O
PRO1328,	DT	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
is	NNP	O
intracellular	CC	O
and	NNP	O
whole	RB	O
antibodies	VBD	O
are	,	O
used	RB	O
as	RB	O
inhibitors,	IN	O
internalizing	JJ	O
antibodies	NNS	O
are	VBN	O
preferred.	IN	O
However,	DT	O
lipofections	NN	O
or	NNS	O
liposomes	VBD	O
can	,	O
also	MD	O
be	VB	O
used	VBN	O
to	IN	O
deliver	DT	O
the	NN	O
antibody,	IN	O
or	JJ	O
an	NNS	O
antibody	IN	O
fragment,	DT	O
into	NN	O
cells.	IN	O
Where	JJ	O
antibody	.	O
fragments	IN	O
are	DT	O
used,	,	O
the	,	O
smallest	,	O
inhibitory	,	O
fragment	,	O
that	,	O
specifically	,	O
binds	,	O
to	NNP	O
the	CC	O
binding	NNP	O
domain	NN	O
of	VBZ	O
the	JJ	O
target	CC	O
protein	JJ	O
is	NNS	O
preferred.	VBP	O
For	VBN	O
example,	IN	O
based	,	O
upon	VBG	O
the	NNS	O
variable-region	VBP	O
sequences	.	O
of	,	O
an	NNS	O
antibody,	CC	O
peptide	NNS	O
molecules	MD	O
can	RB	O
be	VB	O
designed	VBN	O
that	TO	O
retain	VB	O
the	DT	O
ability	,	O
to	CC	O
bind	DT	O
the	NN	O
target	,	O
protein	IN	O
sequence.	.	O
Such	WRB	O
peptides	NN	O
can	NNS	O
be	VBP	O
synthesized	,	O
chemically	DT	O
and/or	JJS	O
produced	JJ	O
by	NN	O
recombinant	WDT	O
DNA	RB	O
technology.	VBZ	O
See,	TO	O
e.g.,	DT	O
Marasco	VBG	B
et	NN	I
al.,	IN	I
Proc.	DT	I
Natl.	NN	I
Acad.	NN	I
Sci.	VBZ	I
USA,	.	I
90:	IN	I
7889-7893	,	I
(1993).	VBN	I
The	IN	O
formulation	DT	O
herein	NN	O
may	NNS	O
also	IN	O
contain	DT	O
more	,	O
than	IN	O
one	NNS	O
active	MD	O
compound	VB	O
as	VBN	O
necessary	IN	O
for	VBP	O
the	DT	O
particular	NN	O
indication	TO	O
being	VB	O
treated,	DT	O
preferably	NN	O
those	NN	O
with	.	O
complementary	JJ	O
activities	NNS	O
that	MD	O
do	VB	O
not	VBN	O
adversely	RB	O
affect	RB	O
each	VBN	O
other.	IN	O
Alternatively,	JJ	O
or	NNP	O
in	.	O
addition,	,	O
the	,	O
composition	NNP	O
may	FW	O
comprise	,	O
an	.	O
agent	.	O
that	.	O
enhances	.	O
its	,	O
function,	:	O
such	CD	O
as,	.	O
for	DT	O
example,	NN	O
a	NN	O
cytotoxic	MD	O
agent,	RB	O
cytokine,	VB	O
chemotherapeutic	JJR	O
agent,	IN	O
or	CD	O
growth-inhibitory	JJ	O
agent.	NN	O
Such	IN	O
molecules	JJ	O
are	IN	O
suitably	DT	O
present	JJ	O
in	NN	O
combination	VBG	O
in	,	O
amounts	RB	O
that	DT	O
are	IN	O
effective	JJ	O
for	NNS	O
the	WDT	O
purpose	VBP	O
intended.	RB	O
The	RB	O
active	JJ	O
ingredients	DT	O
may	.	O
also	,	O
be	CC	O
entrapped	IN	O
in	,	O
microcapsules	DT	O
prepared,	NN	O
for	MD	O
example,	VB	O
by	DT	O
coacervation	NN	O
techniques	WDT	O
or	VBZ	O
by	PRP$	O
interfacial	,	O
polymerization,	JJ	O
for	,	O
example,	IN	O
hydroxymethylcellulose	,	O
or	DT	O
gelatin-microcapsules	NN	O
and	,	O
poly-(methylmethacylate)	,	O
microcapsules,	JJ	O
respectively,	,	O
in	CC	O
colloidal	JJ	O
drug	.	O
delivery	JJ	O
systems	NNS	O
(for	VBP	O
example,	RB	O
liposomes,	JJ	O
albumin	IN	O
microspheres,	NN	O
microemulsions,	IN	O
nano-particles,	NNS	O
and	WDT	O
nanocapsules)	VBP	O
or	JJ	O
in	IN	O
macroemulsions.	DT	O
Such	NN	O
techniques	.	O
are	DT	O
disclosed	JJ	O
in	NNS	O
Remington's	MD	O
Pharmaceutical	RB	O
Sciences,	VB	O
supra.	VBN	O
The	IN	O
formulations	NNS	O
to	,	O
be	IN	O
used	,	O
for	IN	O
in	NN	O
vivo	NNS	O
administration	CC	O
must	IN	O
be	JJ	O
sterile.	,	O
This	IN	O
is	,	O
readily	VB	O
accomplished	CC	O
by	NNS	O
filtration	CC	O
through	)	O
sterile	,	O
filtration	,	O
membranes.	IN	O
Sustained-release	JJ	O
preparations	NN	O
may	NN	O
be	NNS	O
prepared.	IN	O
Suitable	,	O
examples	,	O
of	JJ	O
sustained-release	,	O
preparations	,	O
include	,	O
semipermeable	CC	O
matrices	)	O
of	CC	O
solid	IN	O
hydrophobic	.	O
polymers	JJ	O
containing	NNS	O
the	VBP	O
antibody,	VBN	O
which	IN	O
matrices	POS	O
are	NNP	O
in	,	O
the	.	O
form	DT	O
of	NNS	O
shaped	TO	O
articles,	VB	O
e.g.,	VBN	O
films,	IN	O
or	IN	O
microcapsules.	JJ	O
Examples	NN	O
of	MD	O
sustained-release	VB	O
matrices	.	O
include	DT	O
polyesters,	VBZ	O
hydrogels	RB	O
(for	VBN	O
example,	IN	O
poly(2-hydroxyethyl-methacrylate),	NN	O
or	IN	O
poly(vinylalcohol)),	JJ	O
polylactides	NN	O
(U.S.	.	O
Pat.	JJ	O
No.	NNS	O
3,773,919),	MD	O
copolymers	VB	O
of	.	O
L-glutamic	JJ	O
acid	NNS	O
and	IN	O
γ	JJ	O
ethyl-L-glutamate,	NNS	O
non-degradable	VBP	O
ethylene-vinyl	JJ	O
acetate,	NNS	O
degradable	IN	O
lactic	JJ	O
acid-glycolic	NN	O
acid	NNS	O
copolymers	VBG	O
such	DT	O
as	,	O
the	WDT	O
LUPRON	NNS	O
DEPOT™	VBP	O
(injectable	IN	O
microspheres	DT	O
composed	NN	O
of	IN	O
lactic	JJ	O
acid-glycolic	,	O
acid	,	O
copolymer	,	O
and	CC	O
leuprolide	.	O
acetate),	NNS	O
and	IN	O
poly-D-(−)-3-hydroxybutyric	JJ	O
acid.	NNS	O
While	VBP	O
polymers	,	O
such	NNS	O
as	IN	O
ethylene-vinyl	,	O
acetate	,	O
and	CC	O
lactic	,	O
acid-glycolic	NNS	O
acid	NNP	O
enable	.	O
release	.	O
of	,	O
molecules	NNS	O
for	IN	O
over	NNP	O
100	NN	O
days,	CC	O
certain	JJ	O
hydrogels	,	O
release	JJ	O
proteins	JJ	O
for	,	O
shorter	JJ	O
time	JJ	O
periods.	JJ	O
When	NN	O
encapsulated	NNS	O
antibodies	JJ	O
remain	IN	O
in	DT	O
the	NNP	O
body	NNP	O
for	JJ	O
a	NNS	O
long	VBN	O
time,	IN	O
they	JJ	O
may	JJ	O
denature	NN	O
or	NN	O
aggregate	CC	O
as	JJ	O
a	,	O
result	CC	O
of	JJ	O
exposure	.	O
to	IN	O
moisture	NNS	O
at	JJ	O
37°	IN	O
C.,	JJ	O
resulting	NN	O
in	CC	O
a	JJ	O
loss	JJ	O
of	NN	O
biological	JJ	O
activity	NN	O
and	IN	O
possible	NNS	O
changes	IN	O
in	IN	O
immunogenicity.	CD	O
Rational	,	O
strategies	JJ	O
can	NNS	O
be	VBP	O
devised	NNS	O
for	IN	O
stabilization	JJR	O
depending	NN	O
on	.	O
the	WRB	O
mechanism	JJ	O
involved.	NNS	O
For	VBP	O
example,	IN	O
if	DT	O
the	NN	O
aggregation	IN	O
mechanism	DT	O
is	JJ	O
discovered	,	O
to	PRP	O
be	MD	O
intermolecular	VB	O
S—S	CC	O
bond	VB	O
formation	IN	O
through	DT	O
thio-disulfide	NN	O
interchange,	IN	O
stabilization	NN	O
may	TO	O
be	VB	O
achieved	IN	O
by	CD	O
modifying	,	O
sulfhydryl	VBG	O
residues,	IN	O
lyophilizing	DT	O
from	NN	O
acidic	IN	O
solutions,	JJ	O
controlling	NN	O
moisture	CC	O
content,	JJ	O
using	NNS	O
appropriate	IN	O
additives,	.	O
and	JJ	O
developing	NNS	O
specific	MD	O
polymer	VB	O
matrix	VBN	O
compositions.	IN	O
G.	NN	O
Uses	VBG	O
for	IN	O
Anti-PRO227,	DT	O
Anti-PRO233,	NN	O
Anti-PRO238,	.	O
Anti-PRO1328,	IN	O
Anti-PRO4342,	,	O
Anti-PRO7423;	IN	O
Anti-PRO10096;	DT	O
Anti-PRO21384;	NN	O
Anti-PRO353	NN	O
or	VBZ	O
Anti-PRO1885	VBN	O
Antibodies	TO	O
The	VB	O
anti-PRO227,	JJ	O
anti-PRO233,	NNP	O
anti-PRO238,	NN	O
anti-PRO1328,	NN	O
anti-PRO4342,	IN	O
anti-PRO7423,	JJ	O
anti-PRO10096,	,	O
anti-PRO21384,	NN	O
anti-PRO353	MD	O
or	VB	O
anti-PRO1885	VBN	O
antibodies	IN	O
of	VBG	O
the	NN	O
invention	,	O
have	VBG	O
various	IN	O
therapeutic	JJ	O
and/or	,	O
diagnostic	VBG	O
utilities	NN	O
for	,	O
a	VBG	O
neurological	JJ	O
disorder;	,	O
a	CC	O
cardiovascular,	VBG	O
endothelial	JJ	O
or	NN	O
angiogenic	NN	O
disorder;	.	O
an	NNP	O
immunological	VBZ	O
disorder;	IN	O
an	,	O
oncological	,	O
disorder;	,	O
an	,	O
embryonic	,	O
developmental	:	O
disorder	:	O
or	:	O
lethality,	NNP	O
or	CC	O
a	NNP	O
metabolic	NNPS	O
abnormality.	DT	O
For	,	O
example,	,	O
anti-PRO227,	,	O
anti-PRO233,	,	O
anti-PRO238,	,	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	JJ	O
anti-PRO21384,	CC	O
anti-PRO353	JJ	O
or	NNS	O
anti-PRO1885	IN	O
antibodies	DT	O
may	NN	O
be	VBP	O
used	JJ	O
in	JJ	O
diagnostic	NN	O
assays	JJ	O
for	NNS	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	:	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	JJ	O
PRO21384,	CC	O
PRO353	JJ	O
or	:	O
PRO1885,	DT	O
e.g.,	JJ	O
detecting	:	O
its	DT	O
expression	JJ	O
(and	:	O
in	DT	O
some	JJ	O
cases,	NN	O
differential	NN	O
expression)	CC	O
in	,	O
specific	CC	O
cells,	DT	O
tissues,	JJ	O
or	.	O
serum.	IN	O
Various	,	O
diagnostic	,	O
assay	,	O
techniques	,	O
known	,	O
in	,	O
the	,	O
art	,	O
may	,	O
be	JJ	O
used,	CC	O
such	JJ	O
as	NNS	O
competitive	MD	O
binding	VB	O
assays,	VBN	O
direct	IN	O
or	JJ	O
indirect	NNS	O
sandwich	IN	O
assays	,	O
and	,	O
immunoprecipitation	,	O
assays	,	O
conducted	,	O
in	,	O
either	,	O
heterogeneous	,	O
or	NNP	O
homogeneous	CC	O
phases	,	O
Zola,	,	B
Monoclonal	VBG	I
Antibodies:	PRP$	I
A	NN	I
Manual	CC	I
of	IN	I
Techniques,	DT	I
CRC	,	I
Press,	JJ	I
Inc.	)	I
(1987)	IN	I
pp.	JJ	I
147-158].[	,	O
The	,	O
antibodies	CC	O
used	.	O
in	JJ	O
the	JJ	O
diagnostic	NN	O
assays	NNS	O
can	VBN	O
be	IN	O
labeled	DT	O
with	NN	O
a	MD	O
detectable	VB	O
moiety.	,	O
The	JJ	O
detectable	IN	O
moiety	JJ	O
should	NN	O
be	,	O
capable	JJ	O
of	CC	O
producing,	JJ	O
either	NN	O
directly	NNS	O
or	CC	O
indirectly,	NN	O
a	NNS	O
detectable	VBN	O
signal.	IN	O
For	DT	O
example,	JJ	O
the	CC	O
detectable	JJ	O
moiety	NNS	O
may	,	O
be	NNP	O
a	:	O
radioisotope,	DT	O
such	NNP	O
as	IN	O
3H,	,	O
14C,	NNP	O
32P,	,	O
35S,	NNP	O
or	)	O
125I,	.	O
a	.	O
fluorescent	DT	O
or	NNS	O
chemiluminescent	VBN	O
compound,	IN	O
such	DT	O
as	JJ	O
fluorescein	NNS	O
isothiocyanate,	MD	O
rhodamine,	VB	O
or	VBN	O
luciferin,	IN	O
or	DT	O
an	JJ	O
enzyme,	.	O
such	DT	O
as	JJ	O
alkaline	NN	O
phosphatase,	MD	O
beta-galactosidase	VB	O
or	JJ	O
horseradish	IN	O
peroxidase.	,	O
Any	DT	O
method	RB	O
known	CC	O
in	,	O
the	DT	O
art	JJ	O
for	.	O
conjugating	IN	O
the	,	O
antibody	DT	O
to	JJ	O
the	NN	O
detectable	MD	O
moiety	VB	O
may	DT	O
be	,	O
employed,	JJ	O
including	IN	O
those	,	O
methods	,	O
described	,	O
by	,	O
Hunter	CC	B
et	,	I
al.,	DT	I
Nature,	NN	I
144:945	CC	I
(1962);	NN	I
David	,	B
et	JJ	I
al.,	IN	I
Biochemistry,	JJ	I
13:1014	,	I
(1974);	,	I
Pain	CC	B
et	,	I
al.,	CC	I
J.	DT	I
Immunol.	,	I
Meth.,	JJ	I
40:219	IN	I
(1981);	JJ	I
and	,	O
Nygren,	NN	B
J.	CC	I
Histochem.	JJ	I
and	.	I
Cytochem.,	DT	I
30:407	NN	I
(1982).
Anti-PRO227,	VBN	O
anti-PRO233,	IN	O
anti-PRO238,	DT	O
anti-PRO1328,	NN	O
anti-PRO4342,	IN	O
anti-PRO7423,	VBG	O
anti-PRO10096,	DT	O
anti-PRO21384,	NN	O
anti-PRO353	TO	O
or	DT	O
anti-PRO1885	JJ	O
antibodies	NN	O
also	MD	O
are	VB	O
useful	,	O
for	VBG	O
the	DT	O
affinity	NNS	O
purification	VBN	O
of	IN	O
PRO227,	NNP	O
PRO233,	FW	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	CD	O
PRO7423,	:	O
PRO10096,	NNP	O
PRO21384,	FW	O
PRO353	,	O
or	,	O
PRO1885	CD	O
polypeptides	:	O
from	NNP	O
recombinant	FW	O
cell	,	O
culture	NNP	O
or	.	O
natural	,	O
sources.	CD	O
In	:	O
this	CC	O
process,	,	O
the	NNP	O
antibodies	.	O
against	CC	O
PRO227,	,	O
PRO233,	CD	O
PRO238,	.	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptides	JJ	O
are	CC	O
immobilized	JJ	O
on	NNS	O
a	RB	O
suitable	VBP	O
support,	JJ	O
such	IN	O
a	DT	O
Sephadex	NN	O
resin	NN	O
or	IN	O
filter	,	O
paper,	,	O
using	,	O
methods	,	O
well	,	O
known	,	O
in	,	O
the	,	O
art.	NNP	O
The	CC	O
immobilized	NNP	O
antibody	NNS	O
then	IN	O
is	NN	O
contacted	NN	O
with	NN	O
a	CC	O
sample	JJ	O
containing	.	O
the	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	DT	O
PRO1328,	NNS	O
PRO4342,	IN	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
to	,	O
be	NNP	O
purified,	CC	O
and	NNP	O
thereafter	NNS	O
the	VBP	O
support	VBN	O
is	IN	O
washed	DT	O
with	JJ	O
a	,	O
suitable	PDT	O
solvent	DT	O
that	NNP	O
will	NN	O
remove	CC	O
substantially	JJ	O
all	,	O
the	VBG	O
material	NNS	O
in	RB	O
the	VBN	O
sample	IN	O
except	DT	O
the	.	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	RB	O
PRO4342,	VBZ	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	NN	O
or	VBG	O
PRO1885	DT	O
polypeptide,	,	O
which	,	O
is	,	O
bound	,	O
to	,	O
the	,	O
immobilized	,	O
antibody.	,	O
Finally,	NNP	O
the	CC	O
support	NNP	O
is	NN	O
washed	TO	O
with	VB	O
another	,	O
suitable	CC	O
solvent	RB	O
that	DT	O
will	NN	O
release	VBZ	O
the	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	WDT	O
PRO7423,	MD	O
PRO10096,	VB	O
PRO21384,	RB	O
PRO353	PDT	O
or	DT	O
PRO1885	NN	O
polypeptide	IN	O
from	DT	O
the	NN	O
antibody.	IN	O
The	DT	O
following	,	O
examples	,	O
are	,	O
offered	,	O
for	,	O
illustrative	,	O
purposes	,	O
only,	,	O
and	NNP	O
are	CC	O
not	NNP	O
intended	,	O
to	WDT	O
limit	VBZ	O
the	VBN	O
scope	TO	O
of	DT	O
the	VBN	O
present	.	O
invention	,	O
in	DT	O
any	NN	O
way.	VBZ	O
All	VBN	O
patent	IN	O
and	DT	O
literature	JJ	O
references	NN	O
cited	WDT	O
in	MD	O
the	VB	O
present	DT	O
specification	,	O
are	,	O
hereby	,	O
incorporated	,	O
by	,	O
reference	,	O
in	,	O
their	,	O
entirety.	NNP	O
EXAMPLES	CC	O
Commercially	NNP	O
available	IN	O
reagents	IN	O
referred	DT	O
to	.	O
in	DT	O
the	JJ	O
examples	NNS	O
were	VBP	O
used	VBN	O
according	IN	O
to	JJ	O
manufacturer's	NNS	O
instructions	,	O
unless	CC	O
otherwise	VBP	O
indicated.	RB	O
The	VBN	O
source	TO	O
of	VB	O
those	DT	O
cells	NN	O
identified	IN	O
in	DT	O
the	JJ	O
following	NN	O
examples,	IN	O
and	DT	O
throughout	.	O
the	DT	O
specification,	NN	O
by	CC	O
ATCC	NN	O
accession	NNS	O
numbers	VBD	O
is	IN	O
the	DT	O
American	JJ	O
Type	NN	O
Culture	VBP	O
Collection,	RB	O
Manassas,	VBN	O
Va.	IN	O
Example	NN	O
1	IN	O
Extracellular	PRP$	O
Domain	.	O
Homology	NNP	O
Screening	NNP	O
to	JJ	O
Identify	NNS	O
Novel	VBD	O
Polypeptides	TO	O
and	IN	O
cDNA	DT	O
Encoding	NNS	O
Therefor	VBD	O
The	VBN	O
extracellular	VBG	O
domain	TO	O
(ECD)	POS	O
sequences	NNS	O
(including	IN	O
the	RB	O
secretion	.	O
signal	DT	O
sequence,	NN	O
if	IN	O
any)	DT	O
from	NNS	O
about	VBN	O
950	IN	O
known	DT	O
secreted	JJ	O
proteins	,	O
from	CC	O
the	IN	O
Swiss-Prot	DT	O
public	,	O
database	IN	O
were	NNP	O
used	NN	O
to	NNS	O
search	VBZ	O
EST	DT	O
databases.	JJ	O
The	NNP	O
EST	NNP	O
databases	,	O
included	,	O
public	.	O
databases	RB	O
(e.g.,	CD	O
Dayhoff,	JJ	O
GenBank),	NNP	O
and	NNP	O
proprietary	NNP	O
databases	TO	O
(e.g.	NNP	O
LIFESEQ™,	NNP	O
Incyte	NNP	O
Pharmaceuticals,	CC	O
Palo	NN	O
Alto,	NNP	O
Calif.).	NNP	O
The	DT	O
search	JJ	O
was	NN	O
performed	)	O
using	NNS	O
the	VBG	O
computer	DT	O
program	NN	O
BLAST	JJ	O
or	,	O
BLAST-2	IN	O
Altschul	)	B
et	IN	I
al.,	IN	I
Methods	CD	I
in	NNS	I
Enzymology,	VBD	I
266:460-480	NNS	I
(1996))	IN	I
(as	DT	O
a	NNP	O
comparison	JJ	O
of	NN	O
the	VBD	O
ECD	VBN	O
protein	TO	O
sequences	VB	O
to	NNP	O
a	.	O
6	DT	O
frame	NNP	O
translation	NNS	O
of	VBD	O
the	JJ	O
EST	NNS	O
sequences.	,	O
Those	,	O
comparisons	,	O
with	CC	O
a	JJ	O
BLAST	NNS	O
score	.	O
of	,	O
70	NNP	O
(or	,	O
in	NNP	O
some	,	O
cases	.	O
90)	DT	O
or	NN	O
greater	VBD	O
that	VBN	O
did	VBG	O
not	DT	O
encode	NN	O
known	NN	O
proteins	NNP	O
were	CC	O
clustered	NNP	O
and	NNP	O
assembled	RB	O
into	,	O
consensus	NNS	O
DNA	IN	O
sequences	,	O
with	CD	O
the	)	O
program	IN	O
“phrap”	DT	O
(Phil	NN	O
Green,	IN	O
University	DT	O
of	NNP	O
Washington,	NN	O
Seattle,	NNS	O
Wash.).	TO	O
Using	DT	O
this	CD	O
extracellular	NN	O
domain	NN	O
homology	IN	O
screen,	DT	O
consensus	NNP	O
DNA	.	O
sequences	DT	O
were	NNS	O
assembled	IN	O
relative	DT	O
to	NNP	O
the	NN	O
other	IN	O
identified	CD	O
EST	CC	O
sequences	IN	O
using	DT	O
phrap.	NNS	O
In	)	O
addition,	CC	O
the	JJR	O
consensus	WDT	O
DNA	VBD	O
sequences	RB	O
obtained	VB	O
were	JJ	O
often	NNS	O
(but	VBD	O
not	VBN	O
always)	CC	O
extended	VBN	O
using	IN	O
repeated	NN	O
cycles	NNP	O
of	VBZ	O
BLAST	IN	O
or	DT	O
BLAST-2	NN	O
and	NNP	O
phrap	NNP	O
to	,	O
extend	NNP	O
the	IN	O
consensus	,	O
sequence	,	O
as	.	O
far	VBG	O
as	DT	O
possible	JJ	O
using	NN	O
the	NN	O
sources	,	O
of	NN	O
EST	NN	O
sequences	NNS	O
discussed	VBD	O
above.	VBN	O
Based	JJ	O
upon	TO	O
the	DT	O
consensus	JJ	O
sequences	JJ	O
obtained	NNP	O
as	NNS	O
described	VBG	O
above,	.	O
oligonucleotides	IN	O
were	,	O
then	DT	O
synthesized	NN	O
and	NNP	O
used	NNS	O
to	VBN	O
identify	VBD	O
by	RB	O
PCR	CC	O
a	RB	O
cDNA	)	O
library	VBD	O
that	VBG	O
contained	JJ	O
the	NNS	O
sequence	IN	O
of	NNP	O
interest	CC	O
and	NNP	O
for	CC	O
use	NN	O
as	TO	O
probes	VB	O
to	DT	O
isolate	NN	O
a	NN	O
clone	RB	O
of	RB	O
the	IN	O
full-length	JJ	O
coding	VBG	O
sequence	DT	O
for	NNS	O
a	IN	O
PRO	NNP	O
polypeptide.	NNS	O
Forward	VBN	O
and	.	O
reverse	VBN	O
PCR	IN	O
primers	DT	O
generally	NN	O
range	NNS	O
from	VBD	O
20	IN	O
to	VBN	O
30	,	O
nucleotides	NNS	O
and	VBD	O
are	RB	O
often	VBN	O
designed	CC	O
to	VBN	O
give	TO	O
a	VB	O
PCR	IN	O
product	NNP	O
of	DT	O
about	NN	O
100-1000	NN	O
bp	WDT	O
in	VBD	O
length.	DT	O
The	NN	O
probe	IN	O
sequences	NN	O
are	CC	O
typically	IN	O
40-55	NN	O
bp	IN	O
in	NNS	O
length.	TO	O
In	VB	O
some	DT	O
cases,	NN	O
additional	IN	O
oligonucleotides	DT	O
are	JJ	O
synthesized	NN	O
when	NN	O
the	IN	O
consensus	DT	O
sequence	NNP	O
is	.	O
greater	NNP	O
than	CC	O
about	VB	O
1-1.5	NNP	O
kbp.	NNS	O
In	RB	O
order	VBP	O
to	IN	O
screen	CD	O
several	TO	O
libraries	CD	O
for	NNS	O
a	CC	O
full-length	VBP	O
clone,	RB	O
DNA	VBN	O
from	TO	O
the	VB	O
libraries	DT	O
was	NNP	O
screened	NN	O
by	IN	O
PCR	IN	O
amplification,	CD	O
as	NN	O
per	IN	O
Ausubel	.	O
et	DT	O
al.,	NN	O
Current	NNS	O
Protocols	VBP	O
in	RB	O
Molecular	JJ	O
Biology,	NN	O
with	IN	O
the	.	O
PCR	IN	O
primer	DT	O
pair.	,	O
A	JJ	O
positive	NNS	O
library	VBP	O
was	VBN	O
then	WRB	O
used	DT	O
to	NN	O
isolate	NN	O
clones	VBZ	O
encoding	JJR	O
the	IN	O
gene	IN	O
of	JJ	O
interest	.	O
using	IN	O
the	NN	O
probe	TO	O
oligonucleotide	VB	O
and	JJ	O
one	NNS	O
of	IN	O
the	DT	O
primer	JJ	O
pairs.	,	O
The	NN	O
cDNA	IN	O
libraries	DT	O
used	NNS	O
to	VBD	O
isolate	VBN	O
the	IN	O
cDNA	NNP	O
clones	,	O
were	IN	O
constructed	IN	O
by	NNP	O
standard	FW	O
methods	,	O
using	NNP	O
commercially	NNP	O
available	IN	O
reagents	NNP	O
such	,	O
as	IN	O
those	DT	O
from	NNP	O
Invitrogen,	NN	O
San	.	O
Diego,	DT	O
Calif.	JJ	O
The	NN	O
cDNA	VBD	O
was	RB	O
primed	VBN	O
with	TO	O
oligo	VB	O
dT	NNS	O
containing	VBG	O
a	DT	O
NotI	NN	O
site,	IN	O
linked	NN	O
with	VBG	O
blunt	DT	O
to	NN	O
SalI	NN	O
hemikinased	CC	O
adaptors,	CD	O
cleaved	IN	O
with	DT	O
NotI,	NN	O
sized	.	O
appropriately	DT	O
by	NN	O
gel	NNS	O
electrophoresis,	VBN	O
and	TO	O
cloned	VB	O
in	DT	O
a	NN	O
defined	NNS	O
orientation	VBD	O
into	VBN	O
a	IN	O
suitable	JJ	O
cloning	NNS	O
vector	VBG	O
(such	RB	O
as	JJ	O
pRKB	NNS	O
or	JJ	O
pRKD;	IN	O
pRK5B	DT	O
is	IN	O
a	,	O
precursor	NNP	O
of	,	O
pRK5D	.	O
that	DT	O
does	NN	O
not	VBD	O
contain	VBN	O
the	IN	O
SfiI	JJ	O
site;	NN	O
see,	VBG	O
Holmes	DT	B
et	NNP	I
al.,	,	I
Science,	VBN	I
253:1278-1280	IN	I
(1991))	NN	I
in	TO	O
the	NNP	O
unique	VBD	O
XhoI	,	O
and	VBN	O
NotI	IN	O
sites.	,	O
Example	VBD	O
2	RB	O
Isolation	IN	O
of	JJ	O
cDNA	,	O
Clones	CC	O
by	VBD	O
Amylase	IN	O
Screening	DT	O
1.	JJ	O
Preparation	NN	O
of	IN	O
Oligo	DT	O
dT	JJ	O
Primed	NN	O
cDNA	NN	O
Library	JJ	O
mRNA	IN	O
was	NN	O
isolated	CC	O
from	:	O
a	NN	O
human	VBZ	O
tissue	DT	O
of	NN	O
interest	IN	O
using	NN	O
reagents	WDT	O
and	VBZ	O
protocols	RB	O
from	VB	O
Invitrogen,	DT	O
San	NNP	O
Diego,	:	O
Calif.	,	O
(Fast	NNP	O
Track	FW	O
2).	,	O
This	,	O
RNA	CD	O
was	)	O
used	IN	O
to	DT	O
generate	JJ	O
an	NNP	O
oligo	CC	O
dT	NNP	O
primed	.	O
cDNA	RB	O
library	CD	O
in	NNP	O
the	IN	O
vector	NN	O
pRK5D	NNS	O
using	IN	O
reagents	NNP	O
and	NNP	O
protocols	.	O
from	NN	O
Life	IN	O
Technologies,	NNP	O
Gaithersburg,	NN	O
Md.	NNP	O
(Super	NN	O
Script	NNP	O
Plasmid	NN	O
System).	VBD	O
In	VBN	O
this	IN	O
procedure,	DT	O
the	JJ	O
double	NN	O
stranded	IN	O
cDNA	NN	O
was	VBG	O
sized	NNS	O
to	CC	O
greater	NNS	O
than	IN	O
1000	,	O
bp	NNP	O
and	,	O
the	NNP	O
SalI/NotI	NNP	O
linkered	NNP	O
cDNA	.	O
was	DT	O
cloned	NNP	O
into	VBD	O
XhoI/NotI	VBN	O
cleaved	TO	O
vector.	VB	O
pRK5D	DT	O
is	JJ	O
a	NN	O
cloning	VBD	O
vector	JJ	O
that	NN	O
has	IN	O
an	DT	O
sp6	NN	O
transcription	NN	O
initiation	VBG	O
site	NNS	O
followed	CC	O
by	NNS	O
an	IN	O
SfiI	NNP	O
restriction	,	O
enzyme	,	O
site	.	O
preceding	NNP	O
the	NNP	O
XhoI/NotI	NNP	O
cDNA	.	O
cloning	IN	O
sites.	DT	O
2.	,	O
Preparation	DT	O
of	NN	O
Random	VBD	O
Primed	NN	O
cDNA	VBD	O
Library	VBN	O
A	TO	O
secondary	JJR	O
cDNA	IN	O
library	CD	O
was	NN	O
generated	CC	O
in	DT	O
order	NNP	O
to	VBD	O
preferentially	NN	O
represent	VBD	O
the	VBN	O
5′	IN	O
ends	NNP	O
of	VBD	O
the	.	O
primary	NN	O
cDNA	VBZ	O
clones.	DT	O
Sp6	VBG	O
RNA	NN	O
was	WDT	O
generated	VBZ	O
from	DT	O
the	JJ	O
primary	NN	O
library	NN	O
(described	NN	O
above),	VBN	O
and	IN	O
this	DT	O
RNA	NNP	O
was	NN	O
used	NN	O
to	NN	O
generate	VBG	O
a	DT	O
random	NNP	O
primed	NN	O
cDNA	VBG	O
library	.	O
in	.	O
the	NN	O
vector	IN	O
pSST-AMY.0	NNP	O
using	NNP	O
reagents	NN	O
and	NNP	O
protocols	NNP	O
from	JJ	O
Life	NN	O
Technologies	NN	O
(Super	VBD	O
Script	VBN	O
Plasmid	IN	O
System,	NN	O
referenced	TO	O
above).	RB	O
In	VB	O
this	DT	O
procedure	CD	O
the	NNS	O
double	IN	O
stranded	DT	O
cDNA	JJ	O
was	NN	O
sized	.	O
to	NNP	O
500-1000	NNP	O
bp,	VBD	O
linkered	VBN	O
with	IN	O
blunt	DT	O
to	JJ	O
NotI	NN	O
adaptors,	VBN	O
cleaved	,	O
with	CC	O
SfiI,	DT	O
and	NNP	O
cloned	VBD	O
into	VBN	O
SfiI/NotI	TO	O
cleaved	VB	O
vector.	DT	O
pSST-AMY.0	NN	O
is	VBN	O
a	JJ	O
cloning	NN	O
vector	IN	O
that	DT	O
has	NN	O
a	JJ	O
yeast	VBG	O
alcohol	NNS	O
dehydrogenase	CC	O
promoter	NNS	O
preceding	IN	O
the	NNP	O
cDNA	NNPS	O
cloning	NNP	O
sites	NNP	O
and	NNP	O
the	,	O
mouse	VBN	O
amylase	.	O
sequence	IN	O
(the	DT	O
mature	NN	O
sequence	DT	O
without	NN	O
the	VBD	O
secretion	NN	O
signal)	VBD	O
followed	VBN	O
by	TO	O
the	CD	O
yeast	,	O
alcohol	VBN	O
dehydrogenase	IN	O
terminator,	NN	O
after	TO	O
the	NNP	O
cloning	,	O
sites.	VBN	O
Thus,	IN	O
cDNAs	,	O
cloned	CC	O
into	VBD	O
this	IN	O
vector	NNP	O
that	VBD	O
are	.	O
fused	NN	O
in	VBZ	O
frame	DT	O
with	VBG	O
amylase	NN	O
sequence	WDT	O
will	VBZ	O
lead	DT	O
to	NN	O
the	NN	O
secretion	NN	O
of	NN	O
amylase	VBG	O
from	DT	O
appropriately	NN	O
transfected	VBG	O
yeast	NNS	O
colonies.	CC	O
3.	DT	O
Transformation	NN	O
and	NN	O
Detection	NN	O
DNA	DT	O
from	NN	O
the	NN	O
library	IN	O
described	DT	O
in	NN	O
paragraph	)	O
2	VBN	O
above	IN	O
was	DT	O
chilled	NN	O
on	NN	O
ice	NN	O
to	,	O
which	IN	O
was	DT	O
added	NN	O
electrocompetent	.	O
DH10B	,	O
bacteria	NN	O
(Life	VBD	O
Technologies,	IN	O
20	DT	O
ml).	NN	O
The	WDT	O
bacteria	VBP	O
and	VBN	O
vector	IN	O
mixture	NN	O
was	IN	O
then	JJ	O
electroporated	NN	O
as	MD	O
recommended	VB	O
by	TO	O
the	DT	O
manufacturer.	NN	O
Subsequently,	IN	O
SOC	NN	O
media	IN	O
(Life	RB	O
Technologies,	VBN	O
1	NN	O
ml)	.	O
was	.	O
added	NN	O
and	CC	O
the	NNP	O
mixture	NNP	O
was	IN	O
incubated	DT	O
at	JJ	O
37°	NN	O
C.	IN	O
for	NN	O
30	CD	O
minutes.	NN	O
The	VBD	O
transformants	VBN	O
were	IN	O
then	NN	O
plated	TO	O
onto	WDT	O
20	VBD	O
standard	VBN	O
150	JJ	O
mm	NNP	O
LB	NN	O
plates	NNP	O
containing	,	O
ampicillin	CD	O
and	.	O
incubated	DT	O
for	NN	O
16	CC	O
hours	NN	O
(37°	NN	O
C.).	VBD	O
Positive	RB	O
colonies	VBN	O
were	IN	O
scraped	VBN	O
off	IN	O
the	DT	O
plates	.	O
and	,	O
the	NNP	O
DNA	NNS	O
was	NNP	O
isolated	,	O
from	CD	O
the	)	O
bacterial	VBD	O
pellet	VBN	O
using	CC	O
standard	DT	O
protocols,	NN	O
e.g.	VBD	O
CsCl-gradient.	VBN	O
The	IN	O
purified	CD	O
DNA	NNP	O
was	IN	O
then	CD	O
carried	.	O
on	DT	O
to	NNS	O
the	VBD	O
yeast	RB	O
protocols	VBN	O
below.	IN	O
The	CD	O
yeast	JJ	O
methods	CD	O
were	NN	O
divided	NNP	O
into	VBZ	O
three	VBG	O
categories:	NN	O
(1)	CC	O
Transformation	VBN	O
of	IN	O
yeast	CD	O
with	NNS	O
the	CD	O
plasmid/cDNA	.	O
combined	JJ	O
vector;	NNS	O
(2)	VBD	O
Detection	VBN	O
and	RP	O
isolation	DT	O
of	NNS	O
yeast	CC	O
clones	DT	O
secreting	NN	O
amylase;	VBD	O
and	VBN	O
(3)	IN	O
PCR	DT	O
amplification	JJ	O
of	NN	O
the	VBG	O
insert	JJ	O
directly	,	O
from	.	O
the	.	O
yeast	DT	O
colony	JJ	O
and	NN	O
purification	VBD	O
of	RB	O
the	VBN	O
DNA	IN	O
for	TO	O
sequencing	DT	O
and	NN	O
further	NNS	O
analysis.	.	O
The	DT	O
yeast	NN	O
strain	NNS	O
used	VBD	O
was	VBN	O
HD56-5A	IN	O
(ATCC-90785).	CD	O
This	:	O
strain	)	O
has	NN	O
the	IN	O
following	NN	O
genotype:	IN	O
MAT	DT	O
alpha,	NN	O
ura3-52,	VBD	O
leu2-3,	:	O
leu2-112,	)	O
his3-11,	NN	O
his3-15,	CC	O
MAL+,	NN	O
SUC+,	IN	O
GAL+.	NN	O
Preferably,	NNS	O
yeast	VBG	O
mutants	:	O
can	CC	O
be	)	O
employed	NNP	O
that	NN	O
have	IN	O
deficient	DT	O
post-translational	NN	O
pathways.	RB	O
Such	IN	O
mutants	DT	O
may	NN	O
have	NN	O
translocation	CC	O
deficient	NN	O
alleles	IN	O
in	DT	O
sec71,	NN	O
sec72,	IN	O
sec62,	VBG	O
with	CC	O
truncated	JJ	O
sec71	.	O
being	DT	O
most	NN	O
preferred.	NN	O
Alternatively,	VBN	O
antagonists	VBD	O
(including	NNP	O
antisense	.	O
nucleotides	DT	O
and/or	NN	O
ligands)	VBZ	O
which	DT	O
interfere	JJ	O
with	:	O
the	NNP	O
normal	,	O
operation	,	O
of	,	O
these	,	O
genes,	,	O
other	,	O
proteins	,	O
implicated	,	O
in	.	O
this	,	O
post	JJ	O
translation	NNS	O
pathway	MD	O
(e.g.,	VB	O
SEC61p,	VBN	O
SEC72p,	DT	O
SEC62p,	VBP	O
SEC63p,	JJ	O
TDJ1p	JJ	O
or	.	O
SSA1p-4p)	JJ	O
or	NNS	O
the	MD	O
complex	VB	O
formation	NN	O
of	NN	O
these	NNS	O
proteins	IN	O
may	,	O
also	,	O
be	,	O
preferably	IN	O
employed	JJ	O
in	NN	O
combination	VBG	O
with	JJS	O
the	.	O
amylase-expressing	,	O
yeast.	NNS	O
Transformation	VBG	O
was	NN	O
performed	NNS	O
based	VBP	O
on	)	O
the	WDT	O
protocol	RB	O
outlined	IN	O
by	DT	O
Gietz	JJ	B
et	NN	I
al.,	IN	I
Nucl.	DT	I
Acid.	,	I
Res.,	JJ	I
20:1425	NNS	I
(1992).	VBN	I
Transformed	IN	O
cells	DT	O
were	NN	O
then	NN	O
inoculated	NN	O
from	,	O
agar	,	O
into	,	O
YEPD	,	O
complex	,	O
media	NNP	O
broth	CC	O
(100	)	O
ml)	CC	O
and	DT	O
grown	JJ	O
overnight	NN	O
at	IN	O
30°	DT	O
C.	NNS	O
The	MD	O
YEPD	RB	O
broth	VB	O
was	RB	O
prepared	VBN	O
as	IN	O
described	NN	O
in	IN	O
Kaiser	DT	B
et	JJ	I
al.,	.	I
Methods	NN	I
in	VBD	I
Yeast	VBN	I
Genetics,	VBN	I
Cold	IN	I
Spring	DT	I
Harbor	NN	I
Press,	VBN	I
Cold	IN	I
Spring	NNP	I
Harbor,	FW	I
N.Y.,	,	I
p.	.	I
207	.	I
(1994).	,	I
The	CD	O
overnight	.	O
culture	NNP	O
was	NNS	O
then	VBD	O
diluted	RB	O
to	VBN	O
about	IN	O
2×106	NN	O
cells/ml	IN	O
(approx.	NNP	O
OD600=0.1)	JJ	O
into	NNS	O
fresh	NN	O
YEPD	CD	O
broth	)	O
(500	CC	O
ml)	JJ	O
and	NN	O
regrown	IN	O
to	CD	O
1×107	NNP	O
cells/ml	DT	O
(approx.	NNP	O
OD600=0.4-0.5).	NN	O
The	VBD	O
cells	VBN	O
were	IN	O
then	VBN	O
harvested	IN	O
and	NNP	O
prepared	CC	O
for	,	O
transformation	NNP	O
by	IN	O
transfer	NNP	O
into	,	O
GS3	NNP	O
rotor	NNP	O
bottles	NNP	O
in	,	O
a	NNP	O
Sorval	NNP	O
GS3	,	O
rotor	,	O
at	VBZ	O
5,000	CD	O
rpm	.	O
for	DT	O
5	JJ	O
minutes,	NN	O
the	VBD	O
supernatant	RB	O
discarded,	VBN	O
and	TO	O
then	IN	O
resuspended	CD	O
into	NN	O
sterile	.	O
water,	)	O
and	IN	O
centrifuged	JJ	O
again	NNP	O
in	NN	O
50	CD	O
ml	)	O
falcon	CC	O
tubes	VBN	O
at	TO	O
3,500	CD	O
rpm	NN	O
in	.	O
a	.	O
Beckman	DT	O
GS-6KR	NNS	O
centrifuge.	VBD	O
The	RB	O
supernatant	VBN	O
was	CC	O
discarded	VBN	O
and	IN	O
the	NN	O
cells	IN	O
were	NN	O
subsequently	IN	O
washed	NNP	O
with	NN	O
LiAc/TE	NNS	O
(10	IN	O
ml,	DT	O
10	NNP	O
mM	NNP	O
Tris-HCl,	NN	O
1	IN	O
mM	CD	O
EDTA	NN	O
pH	IN	O
7.5,	CD	O
100	,	O
mM	DT	O
Li2OOCCH3),	NN	O
and	,	O
resuspended	CC	O
into	RB	O
LiAc/TE	VBD	O
(2.5	IN	O
ml).	JJ	O
Transformation	,	O
took	CC	O
place	VBD	O
by	RB	O
mixing	IN	O
the	CD	O
prepared	JJ	O
cells	NN	O
(100	NNS	O
μl)	IN	O
with	CD	O
freshly	NN	O
denatured	IN	O
single	DT	O
stranded	NNP	O
salmon	NNP	O
testes	.	O
DNA	DT	O
(Lofstrand	NN	O
Labs,	VBD	O
Gaithersburg,	VBN	O
Md.)	CC	O
and	DT	O
transforming	NNS	O
DNA	VBD	O
(1	RB	O
μg,	VBN	O
vol.	IN	O
<10	NNP	O
μl)	CD	O
in	,	O
microfuge	CD	O
tubes.	NN	O
The	,	O
mixture	CD	O
was	NN	O
mixed	NNP	O
briefly	NN	O
by	,	O
vortexing,	CD	O
then	NN	O
40%	,	O
PEG/TE	CC	O
(600	VBD	O
μl,	IN	O
40%	NNP	O
polyethylene	CD	O
glycol-4000,	.	O
10	NN	O
mM	VBD	O
Tris-HCl,	NN	O
1	IN	O
mM	VBG	O
EDTA,	DT	O
100	JJ	O
mM	NNS	O
Li2OOCCH3,	CD	O
pH	)	O
7.5)	IN	O
was	RB	O
added.	VBN	O
This	JJ	O
mixture	VBD	O
was	JJ	O
gently	NNS	O
mixed	NNP	O
and	NNP	O
incubated	,	O
at	,	O
30°	)	O
C.	CC	O
while	VBG	O
agitating	NNP	O
for	CD	O
30	,	O
minutes.	.	O
The	CD	O
cells	)	O
were	IN	O
then	NN	O
heat	.	O
shocked	DT	O
at	NN	O
42°	VBD	O
C.	JJ	O
for	NN	O
15	IN	O
minutes,	,	O
and	RB	O
the	NN	O
reaction	NNP	O
vessel	CD	O
centrifuged	,	O
in	NN	O
a	JJ	O
microfuge	,	O
at	CD	O
12,000	NN	O
rpm	,	O
for	CD	O
5-10	NN	O
seconds,	,	O
decanted	CD	O
and	NN	O
resuspended	,	O
into	RB	O
TE	)	O
(500	VBD	O
μl,	.	O
10	DT	O
mM	NN	O
Tris-HCl,	VBD	O
1	RB	O
mM	JJ	O
EDTA	CC	O
pH	VBN	O
7.5)	IN	O
followed	CD	O
by	NNP	O
recentrifugation.	IN	O
The	VBG	O
cells	IN	O
were	CD	O
then	.	O
diluted	DT	O
into	NNS	O
TE	VBD	O
(1	RB	O
ml)	NN	O
and	VBD	O
aliquots	IN	O
(200	CD	O
μl)	NNP	O
were	IN	O
spread	CD	O
onto	,	O
the	CC	O
selective	DT	O
media	NN	O
previously	NN	O
prepared	VBN	O
in	IN	O
150	DT	O
mm	NN	O
growth	IN	O
plates	CD	O
(VWR).	NN	O
Alternatively,	IN	O
instead	JJ	O
of	,	O
multiple	VBN	O
small	CC	O
reactions,	VBN	O
the	IN	O
transformation	NNP	O
was	CD	O
performed	,	O
using	CD	O
a	NN	O
single,	,	O
large	CD	O
scale	NN	O
reaction,	NNP	O
wherein	VBZ	O
reagent	)	O
amounts	VBN	O
were	IN	O
scaled	.	O
up	DT	O
accordingly.	NNS	O
The	VBD	O
selective	RB	O
media	VBN	O
used	IN	O
was	NNP	O
a	CD	O
synthetic	)	O
complete	CC	O
dextrose	NNS	O
agar	CD	O
lacking	)	O
uracil	VBD	O
(SCD-Ura)	VBN	O
prepared	IN	O
as	DT	O
described	JJ	O
in	NNS	O
Kaiser	RB	B
et	VBN	I
al.,	IN	I
Methods	CD	I
in	JJ	I
Yeast	NN	I
Genetics,	NNS	I
Cold	.	I
Spring	,	I
Harbor	RB	I
Press,	IN	I
Cold	JJ	I
Spring	JJ	I
Harbor,	,	I
N.Y.,	DT	I
p.	NN	I
208-210	VBD	I
(1994).	VBN	I
Transformants	VBG	O
were	DT	O
grown	,	O
at	JJ	O
30°	NN	O
C.	,	O
for	JJ	O
2-3	NN	O
days.	NNS	O
The	VBD	O
detection	VBN	O
of	RP	O
colonies	.	O
secreting	DT	O
amylase	JJ	O
was	NNS	O
performed	VBN	O
by	VBD	O
including	DT	O
red	JJ	O
starch	JJ	O
in	NN	O
the	NN	O
selective	VBG	O
growth	JJ	O
media.	)	O
Starch	VBD	O
was	IN	O
coupled	VBN	O
to	IN	O
the	NNP	O
red	CC	O
dye	,	O
(Reactive	NNP	O
Red-120,	IN	O
Sigma)	NNP	O
as	,	O
per	NNP	O
the	NNP	O
procedure	NNP	O
described	,	O
by	NNP	O
Biely	NNP	B
et	,	I
al.,	,	I
Anal.	VBZ	I
Biochem.,	CD	I
172:176-179	.	I
(1988).	NNS	I
The	VBD	O
coupled	VBN	O
starch	IN	O
was	CD	O
incorporated	NNP	O
into	IN	O
the	JJ	O
SCD-Ura	.	O
agar	DT	O
plates	NN	O
at	IN	O
a	NNS	O
final	VBG	O
concentration	NN	O
of	VBD	O
0.15%	VBN	O
(w/v),	IN	O
and	VBG	O
was	JJ	O
buffered	NN	O
with	IN	O
potassium	DT	O
phosphate	JJ	O
to	NN	O
a	.	O
pH	NN	O
of	VBD	O
7.0	VBN	O
(50-100	TO	O
mM	DT	O
final	JJ	O
concentration).	NN	O
The	JJ	O
positive	,	O
colonies	)	O
were	IN	O
picked	IN	O
and	DT	O
streaked	NN	O
across	VBN	O
fresh	IN	O
selective	NNP	O
media	FW	O
(onto	,	O
150	.	O
mm	,	O
plates)	CD	O
in	.	O
order	DT	O
to	VBN	O
obtain	NN	O
well	VBD	O
isolated	VBN	O
and	IN	O
identifiable	DT	O
single	NNP	O
colonies.	NN	O
Well	NNS	O
isolated	IN	O
single	DT	O
colonies	JJ	O
positive	NN	O
for	IN	O
amylase	NN	O
secretion	,	O
were	CC	O
detected	VBD	O
by	VBN	O
direct	IN	O
incorporation	NN	O
of	NN	O
red	TO	O
starch	DT	O
into	NN	O
buffered	IN	O
SCD-Ura	CD	O
agar.	JJ	O
Positive	NN	O
colonies	JJ	O
were	.	O
determined	DT	O
by	JJ	O
their	NNS	O
ability	VBD	O
to	VBN	O
break	CC	O
down	VBN	O
starch	IN	O
resulting	JJ	O
in	JJ	O
a	NNS	O
clear	IN	O
halo	CD	O
around	NNS	O
the	)	O
positive	IN	O
colony	NN	O
visualized	TO	O
directly.	VB	O
4.	RB	O
Isolation	JJ	O
of	CC	O
DNA	JJ	O
by	JJ	O
PCR	.	O
Amplification	RB	O
When	JJ	O
a	JJ	O
positive	NNS	O
colony	JJ	O
was	IN	O
isolated,	JJ	O
a	NN	O
portion	VBD	O
of	VBN	O
it	IN	O
was	JJ	O
picked	NN	O
by	IN	O
a	JJ	O
toothpick	NN	O
and	IN	O
diluted	VBN	O
into	NNP	O
sterile	.	O
water	JJ	O
(30	NNS	O
μl)	VBD	O
in	VBN	O
a	IN	O
96	PRP$	O
well	NN	O
plate.	TO	O
At	VB	O
this	RP	O
time,	NN	O
the	VBG	O
positive	IN	O
colonies	DT	O
were	JJ	O
either	NN	O
frozen	IN	O
and	DT	O
stored	JJ	O
for	NN	O
subsequent	VBN	O
analysis	.	O
or	.	O
immediately	NN	O
amplified.	IN	O
An	NN	O
aliquot	IN	O
of	NNP	O
cells	NNP	O
(5	WRB	O
μl)	DT	O
was	JJ	O
used	NN	O
as	VBD	O
a	,	O
template	DT	O
for	NN	O
the	IN	O
PCR	PRP	O
reaction	VBD	O
in	VBN	O
a	IN	O
25	DT	O
μl	NN	O
volume	CC	O
containing	VBD	O
0.5	IN	O
μl	JJ	O
Klentaq	NN	O
(Clontech,	CD	O
Palo	)	O
Alto,	IN	O
Calif.);	DT	O
4.0	CD	O
μl	RB	O
10	.	O
mM	IN	O
dNTP's	DT	O
(Perkin	,	O
Elmer-Cetus);	DT	O
2.5	JJ	O
μl	NNS	O
Kentaq	VBD	O
buffer	RB	O
(Clontech);	JJ	O
0.25	CC	O
μl	VBD	O
forward	IN	O
oligo	JJ	O
1;	NN	O
0.25	CC	O
μl	RB	O
reverse	.	O
oligo	DT	O
2;	NN	O
12.5	IN	O
μl	NNS	O
distilled	CD	O
water.	)	O
The	VBD	O
sequence	VBN	O
of	IN	O
the	DT	O
forward	NN	O
oligonucleotide	IN	O
1	DT	O
was:	NNP	O
The	NN	O
sequence	IN	O
of	DT	O
reverse	CD	O
oligonucleotide	NN	O
2	NN	O
was:	VBG	O
PCR	CD	O
was	JJ	O
then	NNP	O
performed	,	O
as	NNP	O
follows:	,	O
The	:	O
underlined	CD	O
regions	$	O
of	CD	O
the	NN	O
oligonucleotides	POS	O
annealed	NNP	O
to	:	O
the	CD	O
ADH	NN	O
promoter	NNP	O
region	NN	O
and	:	O
the	CD	O
amylase	FW	O
region,	RB	O
respectively,	VBZ	O
and	:	O
amplified	CD	O
a	JJ	O
307	NN	O
bp	NN	O
region	:	O
from	CD	O
vector	NN	O
pSST-AMY.0	JJ	O
when	.	O
no	DT	O
insert	NN	O
was	IN	O
present.	DT	O
Typically,	NN	O
the	IN	O
first	CD	O
18	:	O
nucleotides	DT	O
of	NN	O
the	IN	O
5′	JJ	O
end	IN	O
of	CD	O
these	:	O
oligonucleotides	NN	O
contained	VBD	O
annealing	RB	O
sites	VBN	O
for	IN	O
the	:	O
sequencing	DT	O
primers.	JJ	O
Thus,	NNS	O
the	IN	O
total	DT	O
product	NNS	O
of	VBD	O
the	TO	O
PCR	DT	O
reaction	NNP	O
from	NN	O
an	NN	O
empty	CC	O
vector	DT	O
was	JJ	O
343	,	O
bp.	,	O
However,	CC	O
signal	VBD	O
sequence-fused	DT	O
cDNA	CD	O
resulted	JJ	O
in	NN	O
considerably	IN	O
longer	NN	O
nucleotide	NN	O
sequences.	WRB	O
Following	DT	O
the	NN	O
PCR,	VBD	O
an	.	O
aliquot	,	O
of	DT	O
the	JJ	O
reaction	CD	O
(5	NNS	O
μl)	IN	O
was	DT	O
examined	CD	O
by	NN	O
agarose	IN	O
gel	DT	O
electrophoresis	NNS	O
in	VBD	O
a	VBG	O
1%	NNS	O
agarose	IN	O
gel	DT	O
using	NN	O
a	.	O
Tris-Borate-EDTA	,	O
(TBE)	DT	O
buffering	JJ	O
system	NN	O
as	IN	O
described	DT	O
by	NNP	O
Sambrook	NN	O
et	IN	O
al.,	DT	O
supra.	JJ	O
Clones	NN	O
resulting	VBD	O
in	CD	O
a	.	O
single	,	O
strong	JJ	O
PCR	JJ	O
product	NN	O
larger	VBD	O
than	IN	O
400	RB	O
bp	RBR	O
were	JJ	O
further	.	O
analyzed	VBG	O
by	DT	O
DNA	,	O
sequencing	DT	O
after	NN	O
purification	IN	O
with	DT	O
a	NN	O
96	CD	O
Qiaquick	)	O
PCR	VBD	O
clean-up	VBN	O
column	IN	O
(Qiagen	JJ	O
Inc.,	JJ	O
Chatsworth,	NN	O
Calif.).	IN	O
Example	DT	O
3	NN	O
Isolation	JJ	O
of	NN	O
cDNA	VBG	O
Clones	DT	O
Using	NNP	O
Signal	)	O
Algorithm	VBG	O
Analysis	NN	O
Various	IN	O
polypeptide-encoding	VBN	O
nucleic	IN	O
acid	NNP	O
sequences	FW	O
were	,	O
identified	.	O
by	NNS	O
applying	VBG	O
a	IN	O
proprietary	DT	O
signal	JJ	O
sequence	JJ	O
finding	NNP	O
algorithm	NN	O
developed	JJR	O
by	IN	O
Genentech,	CD	O
Inc.	NNS	O
(South	VBD	O
San	RB	O
Francisco,	VBN	O
Calif.)	IN	O
upon	NNP	O
ESTs	VBG	O
as	IN	O
well	NN	O
as	IN	O
clustered	DT	O
and	CD	O
assembled	NNP	O
EST	NNP	O
fragments	JJ	O
from	NN	O
public	NNP	O
(e.g.,	,	O
GenBank)	,	O
and/or	.	O
private	RB	O
(LIFESEQ®,	CD	O
Incyte	NNP	O
Pharmaceuticals,	IN	O
Inc.,	NN	O
Palo	NNP	O
Alto,	NNP	O
Calif.)	NNP	O
databases.	NNP	O
The	NNP	O
signal	NNP	O
sequence	JJ	O
algorithm	JJ	O
computes	NN	O
a	NNS	O
secretion	VBD	O
signal	VBN	O
score	IN	O
based	VBG	O
on	DT	O
the	JJ	O
character	NN	O
of	NN	O
the	VBG	O
DNA	NNS	O
nucleotides	VBN	O
surrounding	IN	O
the	,	O
first	NNP	O
and	NNP	O
optionally	NNP	O
the	,	O
second	)	O
methionine	NN	O
codon(s)	NNP	O
(ATG)	RB	O
at	RB	O
the	IN	O
5′-end	VBN	O
of	CC	O
the	VBN	O
sequence	NN	O
or	NNS	O
sequence	IN	O
fragment	JJ	O
under	,	O
consideration.	)	O
The	VBP	O
nucleotides	JJ	O
following	,	O
the	NNP	O
first	,	O
ATG	,	O
must	NNP	O
code	,	O
for	)	O
at	.	O
least	DT	O
35	JJ	O
unambiguous	NN	O
amino	NN	O
acids	VBZ	O
without	DT	O
any	NN	O
stop	NN	O
codons.	NN	O
If	VBN	O
the	IN	O
first	DT	O
ATG	NN	O
has	IN	O
the	DT	O
required	NNP	O
amino	NNS	O
acids,	VBG	O
the	DT	O
second	JJ	O
is	CC	O
not	RB	O
examined.	DT	O
If	JJ	O
neither	NN	O
meets	)	O
the	)	O
requirement,	IN	O
the	DT	O
candidate	NN	O
sequence	IN	O
is	DT	O
not	NN	O
scored.	CC	O
In	NN	O
order	NN	O
to	IN	O
determine	.	O
whether	DT	O
the	NNS	O
EST	VBG	O
sequence	DT	O
contains	JJ	O
an	NNP	O
authentic	MD	O
signal	VB	O
sequence,	IN	O
the	IN	O
DNA	JJS	O
and	CD	O
corresponding	JJ	O
amino	NN	O
acid	NNS	O
sequences	IN	O
surrounding	DT	O
the	JJ	O
ATG	.	O
codon	IN	O
are	DT	O
scored	JJ	O
using	NNP	O
a	VBZ	O
set	DT	O
of	VBN	O
seven	NN	O
sensors	,	O
(evaluation	DT	O
parameters)	NN	O
known	VBZ	O
to	RB	O
be	.	O
associated	IN	O
with	DT	O
secretion	VBZ	O
signals.	DT	O
Use	,	O
of	DT	O
this	NN	O
algorithm	NN	O
resulted	VBZ	O
in	RB	O
the	.	O
identification	IN	O
of	NN	O
numerous	TO	O
polypeptide-encoding	VB	O
nucleic	IN	O
acid	DT	O
sequences.	NNP	O
Using	NN	O
the	VBZ	O
techniques	DT	O
described	JJ	O
in	NN	O
Examples	,	O
1	DT	O
to	NN	O
3	CC	O
above,	VBG	O
numerous	NN	O
full-length	NN	O
cDNA	NNS	O
clones	VBG	O
were	DT	O
identified	NNP	O
as	NN	O
encoding	VBP	O
PRO227,	VBN	O
PRO233,	VBG	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	CD	O
PRO10096,	NNS	O
PRO21384,	NN	O
PRO353	)	O
or	VBN	O
PRO1885	TO	O
polypeptides	VB	O
as	VBN	O
disclosed	IN	O
herein.	NN	O
These	.	O
cDNAs	NN	O
were	IN	O
then	DT	O
deposited	NN	O
under	VBD	O
the	IN	O
terms	DT	O
of	NN	O
the	IN	O
Budapest	JJ	O
Treaty	JJ	O
with	JJ	O
the	NN	O
American	.	O
Type	VBG	O
Culture	DT	O
Collection,	NNS	O
10801	VBN	O
University	IN	O
Blvd.,	NNP	O
Manassas,	CD	O
Va.	TO	O
20110-2209,	CD	O
USA	,	O
(ATCC)	JJ	O
as	JJ	O
shown	NN	O
in	NNS	O
Table	VBD	O
7	VBN	O
below.	IN	O
In	VBG	O
addition,	,	O
the	,	O
coding	,	O
sequence	,	O
of	,	O
DNA108809	,	O
(UNQ2964),	,	O
was	,	O
identified	NNP	O
from	CC	O
GenBank	NNP	O
accession	NNS	O
no.:	IN	O
AJ010588.	JJ	O
These	.	O
deposits	DT	O
were	NNS	O
made	VBD	O
under	RB	O
the	VBN	O
provisions	IN	O
of	DT	O
the	NNS	O
Budapest	IN	O
Treaty	DT	O
on	NNP	O
the	NN	O
International	IN	O
Recognition	DT	O
of	JJ	O
the	NNP	O
Deposit	NNP	O
of	,	O
Microorganisms	CD	O
for	NNP	O
the	,	O
Purpose	,	O
of	NNP	O
Patent	,	O
Procedure	NNP	O
and	)	O
the	IN	O
Regulations	VBN	O
thereunder	IN	O
(Budapest	JJ	O
Treaty).	CD	O
This	.	O
assures	IN	O
maintenance	,	O
of	DT	O
a	VBG	O
viable	NN	O
culture	IN	O
of	NNP	O
the	,	O
deposit	VBD	O
for	VBN	O
30	IN	O
years	NNP	O
from	NN	O
the	:	O
date	.	O
of	DT	O
deposit.	NNS	O
The	VBD	O
deposits	VBN	O
will	IN	O
be	DT	O
made	NNS	O
available	IN	O
by	DT	O
ATCC	NNP	O
under	NNP	O
the	IN	O
terms	DT	O
of	NNP	O
the	NNP	O
Budapest	IN	O
Treaty,	DT	O
and	NNP	O
subject	IN	O
to	NNP	O
an	IN	O
agreement	DT	O
between	NNP	O
Genentech,	IN	O
Inc.	NNP	O
and	NNP	O
ATCC,	CC	O
which	DT	O
assures	NNPS	O
permanent	NN	O
and	NNP	O
unrestricted	.	O
availability	DT	O
of	VBZ	O
the	NN	O
progeny	IN	O
of	DT	O
the	JJ	O
culture	NN	O
of	IN	O
the	DT	O
deposit	NN	O
to	IN	O
the	CD	O
public	NNS	O
upon	IN	O
issuance	DT	O
of	NN	O
the	IN	O
pertinent	.	O
U.S.	DT	O
patent	NNS	O
or	MD	O
upon	VB	O
laying	VBN	O
open	JJ	O
to	IN	O
the	NNP	O
public	IN	O
of	DT	O
any	NNS	O
U.S.	IN	O
or	DT	O
foreign	NNP	O
patent	,	O
application,	CC	O
whichever	JJ	O
comes	TO	O
first,	DT	O
and	NN	O
assures	IN	O
availability	,	O
of	NNP	O
the	CC	O
progeny	,	O
to	WDT	O
one	VBZ	O
determined	JJ	O
by	CC	O
the	JJ	O
U.S.	NN	O
Commissioner	IN	O
of	DT	O
Patents	NN	O
and	IN	O
Trademarks	DT	O
to	NN	O
be	IN	O
entitled	DT	O
thereto	NN	O
according	TO	O
to	DT	O
35	JJ	O
USC	JJ	O
§122	NN	O
and	IN	O
the	DT	O
Commissioner's	JJ	O
rules	NNP	O
pursuant	NN	O
thereto	CC	O
(including	IN	O
37	VBG	O
CFR	JJ	O
§1.14	TO	O
with	DT	O
particular	NN	O
reference	IN	O
to	DT	O
886	NNP	O
OG	CC	O
638).	JJ	O
The	NN	O
assignee	,	O
of	WDT	O
the	VBZ	O
present	,	O
application	CC	O
has	VBZ	O
agreed	NN	O
that	IN	O
if	DT	O
a	NN	O
culture	TO	O
of	CD	O
the	VBN	O
materials	IN	O
on	DT	O
deposit	NNP	O
should	NNP	O
die	IN	O
or	NNP	O
be	CC	O
lost	NNP	O
or	TO	O
destroyed	VB	O
when	VBN	O
cultivated	RB	O
under	VBG	O
suitable	TO	O
conditions,	CD	O
the	NNP	O
materials	NN	O
will	CC	O
be	DT	O
promptly	POS	O
replaced	NNS	O
on	VBP	O
notification	NN	O
with	VBG	O
another	CD	O
of	NNP	O
the	NN	O
same.	IN	O
Availability	JJ	O
of	NN	O
the	TO	O
deposited	CD	O
material	NNP	O
is	.	O
not	DT	O
to	NN	O
be	IN	O
construed	DT	O
as	JJ	O
a	NN	O
license	VBZ	O
to	VBN	O
practice	IN	O
the	IN	O
invention	DT	O
in	NN	O
contravention	IN	O
of	DT	O
the	NNS	O
rights	IN	O
granted	NN	O
under	MD	O
the	VB	O
authority	CC	O
of	VB	O
any	VBN	O
government	CC	O
in	VBN	O
accordance	WRB	O
with	VBN	O
its	IN	O
patent	JJ	O
laws.	,	O
Example	DT	O
4	NNS	O
Isolation	MD	O
of	VB	O
cDNA	RB	O
Clones	VBN	O
Encoding	IN	O
Human	NN	O
PRO227	IN	O
Polypeptides	DT	O
(UNQ201)	IN	O
The	DT	O
extracellular	.	O
domain	NN	O
(ECD)	IN	O
sequences	DT	O
(including	JJ	O
the	NN	O
secretion	VBZ	O
signal,	RB	O
if	TO	O
any)	VB	O
of	VBN	O
from	IN	O
about	DT	O
950	NN	O
known	TO	O
secreted	NN	O
proteins	DT	O
from	NN	O
the	IN	O
Swiss-Prot	NN	O
public	IN	O
protein	DT	O
database	NNS	O
were	VBN	O
used	IN	O
to	DT	O
search	NN	O
expressed	IN	O
sequence	DT	O
tag	NN	O
(EST)	IN	O
databases.	NN	O
The	IN	O
EST	PRP$	O
databases	NN	O
included	.	O
public	RB	O
EST	CD	O
databases	NNP	O
(e.g.,	IN	O
GenBank)	NN	O
and	NNP	O
a	NNP	O
proprietary	NNP	O
EST	NNP	O
DNA	NNP	O
database	)	O
(LIFESEQ®,	DT	O
Incyte	JJ	O
Pharmaceuticals,	NN	O
Palo	)	O
Alto,	NNS	O
Calif.).	VBG	O
The	DT	O
search	NN	O
was	,	O
performed	IN	O
using	)	O
the	IN	O
computer	IN	O
program	IN	O
BLAST	CD	O
or	NNS	O
BLAST2	VBD	O
Altshul	NNS	B
et	IN	I
al.,	DT	I
Methods	NNP	I
in	JJ	I
Enzymology	NN	I
266:460-480	NN	I
(1996))	VBD	I
(as	VBN	O
a	TO	O
comparison	VB	O
of	JJ	O
the	NN	O
ECD	NN	O
protein	)	O
sequences	.	O
to	DT	O
a	NNP	O
6	NNS	O
frame	VBD	O
translation	JJ	O
of	NNP	O
the	NNS	O
EST	,	O
sequence.	)	O
Those	CC	O
comparisons	DT	O
resulting	JJ	O
in	NNP	O
a	NN	O
BLAST	NN	O
score	,	O
of	NNP	O
70	,	O
(or	NNP	O
in	,	O
some	.	O
cases	DT	O
90)	NN	O
or	VBD	O
greater	VBN	O
that	VBG	O
did	DT	O
not	NN	O
encode	NN	O
known	NNP	O
proteins	CC	O
were	NNP	O
clustered	NNP	O
and	RB	O
assembled	,	O
into	NNS	O
consensus	IN	O
DNA	NNP	O
sequences	CD	O
with	)	O
the	IN	O
program	DT	O
“phrap”	NN	O
(Phil	IN	O
Green,	DT	O
University	NNP	O
of	NN	O
Washington,	NNS	O
Seattle,	TO	O
Wash.).	DT	O
A	CD	O
consensus	NN	O
DNA	NN	O
sequence	IN	O
encoding	DT	O
PRO227	NNP	O
was	.	O
assembled	DT	O
relative	NNS	O
to	VBG	O
the	IN	O
other	DT	O
identified	NNP	O
EST	NN	O
sequences,	IN	O
wherein	CD	O
the	CC	O
consensus	IN	O
sequence	DT	O
was	NNS	O
designated	)	O
herein	CC	O
as	JJR	O
DNA28740.	WDT	O
Based	VBD	O
on	RB	O
the	VB	O
DNA28740	JJ	O
consensus	NNS	O
sequence,	VBD	O
oligonucleotides	VBN	O
were	CC	O
synthesized	VBN	O
to	IN	O
identify	NN	O
by	NNP	O
PCR	VBZ	O
a	IN	O
cDNA	DT	O
library	NN	O
that	NNP	O
contained	NNP	O
the	,	O
sequence	NNP	O
of	IN	O
interest	,	O
and	,	O
for	.	O
use	DT	O
as	NN	O
probes	NNP	O
to	NN	O
isolate	VBG	O
a	NNP	O
clone	VBD	O
of	VBN	O
the	JJ	O
full-length	TO	O
coding	DT	O
sequence	JJ	O
for	JJ	O
PRO227.	NNP	O
A	,	O
pair	VBP	O
of	DT	O
PCR	NN	O
primers	NN	O
(forward	VBD	O
and	VBN	O
reverse)	RB	O
were	IN	O
synthesized:	.	O
Additionally,	VBN	O
a	IN	O
synthetic	DT	O
oligonucleotide	NNP	O
hybridization	NN	O
probe	,	O
was	NNS	O
constructed	VBD	O
from	VBN	O
the	TO	O
consensus	VB	O
DNA28740	IN	O
sequence	NNP	O
which	DT	O
had	NN	O
the	NN	O
following	WDT	O
nucleotide	VBD	O
sequence:	DT	O
In	NN	O
order	IN	O
to	NN	O
screen	CC	O
several	IN	O
libraries	NN	O
for	IN	O
a	NNS	O
source	TO	O
of	VB	O
a	DT	O
full-length	NN	O
clone,	IN	O
DNA	DT	O
from	JJ	O
the	NN	O
libraries	NN	O
was	IN	O
screened	.	O
by	DT	O
PCR	NN	O
amplification	IN	O
with	NNP	O
the	NNS	O
PCR	RB	O
primer	CC	O
pair	)	O
identified	VBD	O
above.	:	O
A	,	O
positive	DT	O
library	JJ	O
was	NN	O
then	NN	O
used	NN	O
to	VBD	O
isolate	VBN	O
clones	IN	O
encoding	DT	O
the	NN	O
PRO227	NNP	O
gene	NN	O
using	WDT	O
the	VBD	O
probe	DT	O
oligonucleotide	JJ	O
and	JJ	O
one	:	O
of	IN	O
the	NN	O
PCR	TO	O
primers.	VB	O
RNA	JJ	O
for	NNS	O
construction	IN	O
of	DT	O
the	NN	O
cDNA	IN	O
libraries	DT	O
was	JJ	O
isolated	,	O
from	NN	O
human	IN	O
fetal	DT	O
lung	NNS	O
tissue.	VBD	O
The	VBN	O
cDNA	IN	O
libraries	NNP	O
used	NN	O
to	IN	O
isolate	DT	O
the	NNP	O
cDNA	NN	O
clones	NN	O
were	VBN	O
constructed	.	O
by	DT	O
standard	JJ	O
methods	NN	O
using	VBD	O
commercially	RB	O
available	VBN	O
reagents	TO	O
such	VB	O
as	NNS	O
those	VBG	O
from	DT	O
Invitrogen,	NNP	O
San	NN	O
Diego,	VBG	O
Calif.	DT	O
The	NN	O
cDNA	NN	O
was	CC	O
primed	CD	O
with	IN	O
oligo	DT	O
dT	NNP	O
containing	.	O
a	NNP	O
NotI	IN	O
site,	NN	O
linked	IN	O
with	DT	O
blunt	NN	O
to	NNS	O
SalI	VBD	O
hemikinased	VBN	O
adaptors,	IN	O
cleaved	JJ	O
with	JJ	O
NotI,	NN	O
sized	.	O
appropriately	DT	O
by	NN	O
gel	NNS	O
electrophoresis,	VBN	O
and	TO	O
cloned	VB	O
in	DT	O
a	NN	O
defined	NNS	O
orientation	VBD	O
into	VBN	O
a	IN	O
suitable	JJ	O
cloning	NNS	O
vector	VBG	O
(such	RB	O
as	JJ	O
pRKB	NNS	O
or	JJ	O
pRKD;	IN	O
pRK5B	DT	O
is	IN	O
a	,	O
precursor	NNP	O
of	,	O
pRK5D	.	O
that	DT	O
does	NN	O
not	VBD	O
contain	VBN	O
the	IN	O
SfiI	JJ	O
site;	NN	O
see,	VBG	O
Holmes	DT	B
et	NNP	I
al.,	,	I
Science,	VBN	I
253:1278-1280	IN	I
(1991))	NN	I
in	TO	O
the	NNP	O
unique	VBD	O
XhoI	,	O
and	VBN	O
NotI	IN	O
sites.	,	O
DNA	VBD	O
sequencing	RB	O
of	IN	O
the	JJ	O
clones	,	O
isolated	CC	O
as	VBD	O
described	IN	O
above	DT	O
gave	JJ	O
the	NN	O
full-length	IN	O
DNA	DT	O
sequence	JJ	O
for	NN	O
PRO227	NN	O
[herein	JJ	O
designated	IN	O
as	NN	O
UNQ201	CC	O
(DNA33786-1132)	:	O
and	NN	O
the	VBZ	O
derived	DT	O
protein	NN	O
sequence	IN	O
for	NN	O
PRO227.	WDT	O
The	VBZ	O
entire	RB	O
nucleotide	VB	O
sequence	DT	O
of	NNP	O
UNQ201	:	O
(DNA33786-1132)	,	O
is	NNP	O
shown	FW	O
in	,	O
FIG.	,	O
1	CD	O
(SEQ	)	O
ID	IN	O
NO:1).	DT	O
Clone	JJ	O
UNQ201	NNP	O
(DNA33786-1132)	CC	O
contains	NNP	O
a	.	O
single	NN	O
open	NN	O
reading	IN	O
frame	DT	O
with	NNS	O
an	VBD	O
apparent	IN	O
translational	VBN	O
initiation	IN	O
site	VBD	O
at	DT	O
nucleotide	JJ	O
positions	NNP	O
117-119	NN	O
and	IN	O
ending	NNP	O
at	RB	O
the	VBD	O
stop	IN	O
codon	NNP	O
at	)	O
nucleotide	CC	O
positions	DT	O
1989-1991	JJ	O
(FIG.	NN	O
1,	NN	O
the	IN	O
initiation	.	O
and	DT	O
stop	JJ	O
codons	JJ	O
are	NN	O
bold	IN	O
and	NNP	O
underlined).	)	O
The	VBZ	O
predicted	VBN	O
polypeptide	IN	O
precursor	.	O
is	CD	O
620	NNP	O
amino	NNP	O
acids	.	O
long	NN	O
(FIG.	NNP	O
2;	)	O
SEQ	VBZ	O
ID	DT	O
NO:2).	JJ	O
Clone	JJ	O
UNQ201	NN	O
(DNA33786-1132)	NN	O
has	IN	O
been	DT	O
deposited	JJ	O
with	JJ	O
ATCC	NN	O
on	NN	O
Sep.	IN	O
16,	JJ	O
1997	NNS	O
and	JJ	O
is	CC	O
assigned	VBG	O
ATCC	IN	O
deposit	DT	O
no.	NN	O
209253.	NN	O
Example	IN	O
5	JJ	O
Isolation	NNS	O
of	JJ	O
cDNA	.	O
Clones	,	O
Encoding	DT	O
Human	NN	O
PRO233	CC	O
Polypeptides	VB	O
(UNQ207)	NNS	O
The	VBP	O
extracellular	JJ	O
domain	CC	O
(ECD)	.	O
sequences	DT	O
(including	JJ	O
the	NN	O
secretion	NN	O
signal,	VBZ	O
if	CD	O
any)	JJ	O
of	NNS	O
from	RB	O
about	.	O
950	:	O
known	NNP	O
secreted	NNP	O
proteins	.	O
from	NN	O
the	NNP	O
Swiss-Prot	)	O
public	VBZ	O
protein	VBN	O
database	VBN	O
were	IN	O
used	NNP	O
to	IN	O
search	NNP	O
expressed	,	O
sequence	CD	O
tag	CC	O
(EST)	VBZ	O
databases.	VBN	O
The	NNP	O
EST	NN	O
databases	.	O
included	.	O
public	RB	O
EST	CD	O
databases	NNP	O
(e.g.,	IN	O
GenBank)	NN	O
and	NNP	O
a	NNP	O
proprietary	NNP	O
EST	NNP	O
DNA	NNP	O
database	)	O
(LIFESEQ®,	DT	O
Incyte	JJ	O
Pharmaceuticals,	NN	O
Palo	)	O
Alto,	NNS	O
Calif.).	VBG	O
The	DT	O
search	NN	O
was	,	O
performed	IN	O
using	)	O
the	IN	O
computer	IN	O
program	IN	O
BLAST	CD	O
or	NNS	O
BLAST2	VBD	O
Altshul	NNS	B
et	IN	I
al.,	DT	I
Methods	NNP	I
in	JJ	I
Enzymology	NN	I
266:460-480	NN	I
(1996))	VBD	I
(as	VBN	O
a	TO	O
comparison	VB	O
of	JJ	O
the	NN	O
ECD	NN	O
protein	)	O
sequences	.	O
to	DT	O
a	NNP	O
6	NNS	O
frame	VBD	O
translation	JJ	O
of	NNP	O
the	NNS	O
EST	,	O
sequence.	)	O
Those	CC	O
comparisons	DT	O
resulting	JJ	O
in	NNP	O
a	NN	O
BLAST	NN	O
score	,	O
of	NNP	O
70	,	O
(or	NNP	O
in	,	O
some	.	O
cases	DT	O
90)	NN	O
or	VBD	O
greater	VBN	O
that	VBG	O
did	DT	O
not	NN	O
encode	NN	O
known	NNP	O
proteins	CC	O
were	NNP	O
clustered	NNP	O
and	RB	O
assembled	,	O
into	NNS	O
consensus	IN	O
DNA	NNP	O
sequences.	CD	O
An	)	O
expressed	IN	O
sequence	DT	O
tag	NN	O
(EST)	IN	O
was	DT	O
identified	NNP	O
by	NN	O
the	NNS	O
EST	TO	O
database	DT	O
search	CD	O
and	NN	O
a	NN	O
consensus	IN	O
DNA	DT	O
sequence	NNP	O
was	.	O
assembled	DT	O
relative	NNS	O
to	VBG	O
other	IN	O
EST	DT	O
sequences	NNP	O
using	NN	O
phrap	IN	O
(Phil	CD	O
Green,	CC	O
University	IN	O
of	DT	O
Washington,	NNS	O
Seattle,	)	O
Wash.).	CC	O
This	JJR	O
consensus	WDT	O
sequence	VBD	O
is	RB	O
herein	VB	O
designated	JJ	O
“Consen0821”,	NNS	O
which	VBD	O
was	VBN	O
used	CC	O
to	VBN	O
derive	IN	O
the	NN	O
final	NNP	O
consensus	.	O
sequence,	DT	O
“DNA30945”.	JJ	O
Based	NN	O
on	NN	O
the	)	O
DNA30945	VBD	O
consensus	VBN	O
sequence,	IN	O
oligonucleotides	DT	O
were	NNP	O
synthesized:	NN	O
1)	NN	O
to	CC	O
identify	DT	O
by	NN	O
PCR	NNP	O
a	NN	O
cDNA	VBD	O
library	VBN	O
that	JJ	O
contained	TO	O
the	JJ	O
sequence	NNP	O
of	NNS	O
interest,	VBG	O
and	NN	O
2)	NNP	O
for	,	O
use	NNP	O
as	IN	O
probes	,	O
to	,	O
isolate	.	O
a	DT	O
clone	NN	O
of	NN	O
the	VBZ	O
full-length	RB	O
coding	VBN	O
sequence	,	O
for	WDT	O
PRO233.	VBD	O
Forward	VBN	O
and	TO	O
reverse	VB	O
PCR	DT	O
primers	JJ	O
generally	NN	O
range	,	O
from	.	O
20	VBN	O
to	IN	O
30	DT	O
nucleotides	NNP	O
and	NN	O
are	,	O
often	NNS	O
designed	VBD	O
to	:	O
give	)	O
a	TO	O
PCR	VB	O
product	IN	O
of	NNP	O
about	DT	O
100-1000	NN	O
bp	NN	O
in	WDT	O
length.	VBD	O
The	DT	O
probe	NN	O
sequences	IN	O
are	,	O
typically	CC	O
40-55	)	O
bp	IN	O
in	NN	O
length.	IN	O
In	NNS	O
some	TO	O
cases,	VB	O
additional	DT	O
oligonucleotides	NN	O
are	IN	O
synthesized	DT	O
when	JJ	O
the	NN	O
consensus	NN	O
sequence	IN	O
is	.	O
greater	NNP	O
than	CC	O
about	VB	O
1-1.5	NNP	O
kbp.	NNS	O
In	RB	O
order	VBP	O
to	IN	O
screen	CD	O
several	TO	O
libraries	CD	O
for	NNS	O
a	CC	O
full-length	VBP	O
clone,	RB	O
DNA	VBN	O
from	TO	O
the	VB	O
libraries	DT	O
was	NNP	O
screened	NN	O
by	IN	O
PCR	IN	O
amplification,	CD	O
as	NN	O
ber	IN	O
Ausubel	.	O
et	DT	O
al.,	NN	O
Current	NNS	O
Protocols	VBP	O
in	RB	O
Molecular	JJ	O
Biology,	NN	O
with	IN	O
the	.	O
PCR	IN	O
primer	DT	O
pair.	,	O
A	JJ	O
positive	NNS	O
library	VBP	O
was	VBN	O
then	WRB	O
used	DT	O
to	NN	O
isolate	NN	O
clones	VBZ	O
encoding	JJR	O
the	IN	O
gene	IN	O
of	JJ	O
interest	.	O
by	IN	O
the	NN	O
in	TO	O
vivo	VB	O
cloning	JJ	O
procedure	NNS	O
using	IN	O
the	DT	O
probe	JJ	O
oligonucleotide	,	O
and	NN	O
one	IN	O
of	DT	O
the	NNS	O
primer	VBD	O
pairs.	VBN	O
Forward	IN	O
and	NNP	O
reverse	,	O
PCR	IN	O
primers	NN	O
were	NNP	O
synthesized:	CC	O
Additionally,	,	O
a	NNP	O
synthetic	NNP	O
oligonucleotide	IN	O
hybridization	NNP	O
probe	,	O
was	IN	O
constructed	DT	O
from	NNP	O
the	NN	O
consensus	.	O
DNA30945	DT	O
sequence	JJ	O
which	NN	O
had	VBD	O
the	RB	O
following	VBN	O
nucleotide	TO	O
sequence:	VB	O
In	NNS	O
order	VBG	O
to	DT	O
screen	NN	O
several	IN	O
libraries	NN	O
for	IN	O
a	DT	O
source	IN	O
of	NN	O
a	NN	O
full-length	NN	O
clone,	VBG	O
DNA	DT	O
from	NN	O
the	NN	O
libraries	CC	O
was	CD	O
screened	IN	O
by	DT	O
PCR	NN	O
amplification	.	O
with	NNP	O
the	CC	O
PCR	VB	O
primer	NNP	O
pair	NNS	O
identified	VBD	O
above.	:	O
A	,	O
positive	DT	O
library	JJ	O
was	NN	O
then	NN	O
used	NN	O
to	VBD	O
isolate	VBN	O
clones	IN	O
encoding	DT	O
the	NN	O
PRO233	NNP	O
gene	NN	O
using	WDT	O
the	VBD	O
probe	DT	O
oligonucleotide.	JJ	O
RNA	JJ	O
for	:	O
construction	IN	O
of	NN	O
the	TO	O
cDNA	VB	O
libraries	JJ	O
was	NNS	O
isolated	IN	O
from	DT	O
human	NN	O
fetal	IN	O
brain	DT	O
tissue.	JJ	O
The	,	O
cDNA	NN	O
libraries	IN	O
used	DT	O
to	NNS	O
isolate	VBD	O
the	VBN	O
cDNA	IN	O
clones	NNP	O
were	NN	O
constructed	IN	O
by	DT	O
standard	NNP	O
methods	NN	O
using	NN	O
commercially	VBN	O
available	.	O
reagents	DT	O
such	JJ	O
as	NN	O
those	VBD	O
from	RB	O
Invitrogen,	VBN	O
San	TO	O
Diego,	VB	O
Calif.	NNS	O
The	VBG	O
cDNA	DT	O
was	NNP	O
primed	NN	O
with	VBG	O
oligo	DT	O
dT	NN	O
containing	.	O
a	NNP	O
NotI	IN	O
site,	NN	O
linked	IN	O
with	DT	O
blunt	NN	O
to	NNS	O
SalI	VBD	O
hemikinased	VBN	O
adaptors,	IN	O
cleaved	JJ	O
with	JJ	O
NotI,	NN	O
sized	.	O
appropriately	DT	O
by	NN	O
gel	NNS	O
electrophoresis,	VBN	O
and	TO	O
cloned	VB	O
in	DT	O
a	NN	O
defined	NNS	O
orientation	VBD	O
into	VBN	O
a	IN	O
suitable	JJ	O
cloning	NNS	O
vector	VBG	O
(such	RB	O
as	JJ	O
pRKB	NNS	O
or	JJ	O
pRKD;	IN	O
pRK5B	DT	O
is	IN	O
a	,	O
precursor	NNP	O
of	,	O
pRK5D	.	O
that	DT	O
does	NN	O
not	VBD	O
contain	VBN	O
the	IN	O
SfiI	JJ	O
site;	NN	O
see,	VBG	O
Holmes	DT	B
et	NNP	I
al.,	,	I
Science,	VBN	I
253:1278-1280	IN	I
(1991))	NN	I
in	TO	O
the	NNP	O
unique	VBD	O
XhoI	,	O
and	VBN	O
NotI	IN	O
sites.	,	O
DNA	VBD	O
sequencing	RB	O
of	IN	O
the	JJ	O
clones	,	O
isolated	CC	O
as	VBD	O
described	IN	O
above	DT	O
gave	JJ	O
the	NN	O
full-length	IN	O
DNA	DT	O
sequence	JJ	O
for	NN	O
PRO233	NN	O
[herein	JJ	O
designated	IN	O
as	NN	O
UNQ207	CC	O
(DNA34436-1238)]	:	O
(SEQ	NN	O
ID	VBZ	O
NO:3)	DT	O
and	NN	O
the	IN	O
derived	NN	O
protein	WDT	O
sequence	VBZ	O
for	RB	O
PRO233	VB	O
(SEQ	DT	O
ID	NNP	O
NO:4).	:	O
The	,	O
entire	NNP	O
nucleotide	FW	O
sequence	,	O
of	,	O
UNQ207	CD	O
(DNA34436-1238)	)	O
is	IN	O
shown	DT	O
in	JJ	O
FIG.	NNP	O
3	CC	O
(SEQ	NNP	O
ID	.	O
NO:3).	NN	O
Clone	NN	O
UNQ207	IN	O
(DNA34436-1238)	DT	O
contains	NNS	O
a	VBD	O
single	IN	O
open	VBN	O
reading	IN	O
frame	VBD	O
with	DT	O
an	JJ	O
apparent	NNP	O
translational	NN	O
initiation	IN	O
site	NNP	O
at	RB	O
nucleotide	VBD	O
positions	IN	O
101-103	NNP	O
and	NN	O
ending	NNP	O
at	NNP	O
the	)	O
stop	CC	O
codon	DT	O
at	JJ	O
nucleotide	NN	O
positions	NN	O
1001-1003	IN	O
(FIG.	NNP	O
3).	NNP	O
The	NNP	O
predicted	.	O
polypeptide	DT	O
precursor	JJ	O
is	JJ	O
300	NN	O
amino	IN	O
acids	NNP	O
long	)	O
(FIG.	VBZ	O
4;	VBN	O
SEQ	IN	O
ID	.	O
NO:4).	CD	O
The	NNP	O
full-length	NNP	O
PRO233	.	O
protein	NN	O
shown	NNP	O
in	)	O
FIG.	VBZ	O
4	DT	O
has	JJ	O
an	JJ	O
estimated	NN	O
molecular	NN	O
weight	IN	O
of	DT	O
about	JJ	O
32964	JJ	O
and	NN	O
a	NN	O
pI	IN	O
of	JJ	O
about	NNS	O
9.52.	JJ	O
In	CC	O
addition,	VBG	O
regions	IN	O
of	DT	O
interest	NN	O
including	NN	O
the	IN	O
signal	JJ	O
peptide	NNS	O
and	JJ	O
a	.	O
putative	.	O
oxidoreductase	DT	O
active	JJ	O
site,	NN	O
are	NN	O
designated	VBZ	O
in	CD	O
FIG.	JJ	O
4.	NNS	O
Clone	RB	O
UNQ207	.	O
(DNA34436-1238)	:	O
has	NNP	O
been	NNP	O
deposited	.	O
with	DT	O
ATCC	JJ	O
on	NNP	O
Dec.	NN	O
10,	VBN	O
1997	IN	O
and	.	O
is	CD	O
assigned	VBZ	O
ATCC	DT	O
deposit	VBN	O
no.	JJ	O
209523.	NN	O
Analysis	IN	O
of	IN	O
the	CD	O
amino	CC	O
acid	DT	O
sequence	NN	O
of	IN	O
the	IN	O
full-length	.	O
PRO233	IN	O
polypeptide	,	O
suggests	NNS	O
that	IN	O
portions	NN	O
of	VBG	O
it	DT	O
possess	JJ	O
significant	NN	O
homology	CC	O
to	DT	O
reductase	JJ	O
proteins,	NN	O
thereby	JJ	O
indicating	,	O
that	VBP	O
PRO233	VBN	O
may	IN	O
be	.	O
a	.	O
novel	NN	O
reductase.	NNP	O
Example	)	O
6	VBZ	O
Isolation	VBN	O
of	VBN	O
cDNA	IN	O
Clones	NNP	O
Encoding	IN	O
Human	NNP	O
PRO238	,	O
Polypeptides	CD	O
(UNQ212)	CC	O
A	VBZ	O
consensus	VBN	O
DNA	NNP	O
sequence	NN	O
was	.	O
assembled	.	O
relative	NN	O
to	IN	O
other	DT	O
EST	NN	O
sequences	JJ	O
using	NN	O
phrap	IN	O
as	DT	O
described	JJ	O
above	NNP	O
in	NN	O
Example	VBZ	O
1.	IN	O
This	NNS	O
consensus	IN	O
sequence	PRP	O
is	JJ	O
herein	JJ	O
designated	NN	O
DNA30908.	TO	O
Based	VB	O
on	,	O
the	RB	O
DNA30908	VBG	O
consensus	IN	O
sequence,	NNP	O
oligonucleotides	MD	O
were	VB	O
synthesized:	DT	O
1)	JJ	O
to	.	O
identify	RB	O
by	CD	O
PCR	NNP	O
a	IN	O
cDNA	NN	O
library	NNP	O
that	NNP	O
contained	NNP	O
the	NNP	O
sequence	NNP	O
of	)	O
interest,	NNP	O
and	NN	O
2)	NNP	O
for	NN	O
use	VBD	O
as	VBN	O
probes	JJ	O
to	TO	O
isolate	JJ	O
a	NNP	O
clone	NNS	O
of	VBG	O
the	NN	O
full-length	IN	O
coding	VBN	O
sequence	IN	O
for	IN	O
PRO238.	NNP	O
PCR	.	O
primers	DT	O
(forward	NN	O
and	NN	O
reverse)	VBZ	O
were	RB	O
synthesized:	VBN	O
Additionally,	.	O
a	VBN	O
synthetic	IN	O
oligonucleotide	DT	O
hybridization	NNP	O
probe	NN	O
was	,	O
constructed	NNS	O
from	VBD	O
the	:	O
consensus	)	O
DNA30908	TO	O
sequence	VB	O
which	IN	O
had	NNP	O
the	DT	O
following	NN	O
nucleotide	NN	O
sequence	WDT	O
In	VBD	O
order	DT	O
to	NN	O
screen	IN	O
several	,	O
libraries	CC	O
for	)	O
a	IN	O
source	NN	O
of	IN	O
a	NNS	O
full-length	TO	O
clone,	VB	O
DNA	DT	O
from	NN	O
the	IN	O
libraries	DT	O
was	JJ	O
screened	NN	O
by	NN	O
PCR	IN	O
amplification	.	O
with	NNP	O
the	NNS	O
PCR	RB	O
primer	CC	O
pair	)	O
identified	VBD	O
above.	:	O
A	,	O
positive	DT	O
library	JJ	O
was	NN	O
then	NN	O
used	NN	O
to	VBD	O
isolate	VBN	O
clones	IN	O
encoding	DT	O
the	NN	O
PRO238	NNP	O
gene	NN	O
using	WDT	O
the	VBD	O
probe	DT	O
oligonucleotide	JJ	O
and	JJ	O
one	NN	O
of	IN	O
the	NN	O
PCR	TO	O
primers.	VB	O
RNA	JJ	O
for	NNS	O
construction	IN	O
of	DT	O
the	NN	O
cDNA	IN	O
libraries	DT	O
was	JJ	O
isolated	,	O
from	NN	O
human	IN	O
fetal	DT	O
liver	NNS	O
tissue.	VBD	O
DNA	VBN	O
sequencing	IN	O
of	NNP	O
the	NN	O
clones	IN	O
isolated	DT	O
as	NNP	O
described	NN	O
above	NN	O
gave	VBN	O
the	.	O
full-length	DT	O
DNA	JJ	O
sequence	NN	O
for	VBD	O
DNA35600-1162	RB	O
and	VBN	O
the	TO	O
derived	VB	O
protein	NNS	O
sequence	VBG	O
for	DT	O
PRO238.	NNP	O
The	NN	O
entire	VBG	O
nucleotide	DT	O
sequence	NN	O
of	NN	O
DNA35600-1162	CC	O
(UNQ212)	CD	O
is	IN	O
shown	DT	O
in	NNP	O
FIG.	.	O
5	NNP	O
(SEQ	IN	O
ID	NN	O
NO:5).	IN	O
Clone	DT	O
DNA35600-1162	NN	O
contains	NNS	O
a	VBD	O
single	VBN	O
open	IN	O
reading	JJ	O
frame	JJ	O
with	NN	O
an	.	O
apparent	NN	O
translational	NN	O
initiation	IN	O
site	DT	O
at	NNS	O
nucleotide	VBD	O
positions	IN	O
134-136	VBN	O
and	IN	O
ending	VBD	O
prior	DT	O
to	JJ	O
the	NNP	O
stop	NN	O
codon	IN	O
at	NNP	O
nucleotide	CC	O
positions	DT	O
1064-1066	JJ	O
(FIG.	NN	O
5).	NN	O
The	IN	O
predicted	.	O
polypeptide	DT	O
precursor	JJ	O
is	JJ	O
310	NN	O
amino	IN	O
acids	NNP	O
long	)	O
(FIG.	VBZ	O
6;	VBN	O
SEQ	IN	O
ID	.	O
NO:6).	CD	O
Clone	NNP	O
DNA35600-1162	NNP	O
has	.	O
been	NNP	O
deposited	NNP	O
with	VBZ	O
ATCC	DT	O
on	JJ	O
Oct.	JJ	O
16,	NN	O
1997	NN	O
and	IN	O
is	DT	O
assigned	JJ	O
ATCC	JJ	O
deposit	NN	O
no.	NN	O
ATCC	IN	O
209370.	JJ	O
Analysis	NNS	O
of	JJ	O
the	CC	O
amino	VBG	O
acid	RB	O
sequence	TO	O
of	DT	O
the	NN	O
full-length	NN	O
PRO238	IN	O
polypeptide	JJ	O
suggests	NNS	O
that	JJ	O
portions	.	O
of	.	O
it	DT	O
possess	JJ	O
significant	NN	O
homology	NN	O
to	VBZ	O
reductase,	CD	O
particularly	JJ	O
oxidoreductase,	NNS	O
thereby	RB	O
indicating	.	O
that	:	O
PRO238	NNP	O
may	NNP	O
be	.	O
a	NNP	O
novel	NNP	O
reductase.	VBZ	O
Example	VBN	O
7	VBN	O
Isolation	IN	O
of	NNP	O
cDNA	IN	O
Clones	NNP	O
Encoding	,	O
Human	CD	O
PRO1328	CC	O
Polypeptides	VBZ	O
(UNQ688)	VBN	O
DNA66658-1584	NNP	O
was	NN	O
identified	.	O
by	$	O
applying	.	O
a	NN	O
proprietary	IN	O
signal	DT	O
sequence	NN	O
finding	JJ	O
algorithm	NN	O
developed	IN	O
by	DT	O
Genentech,	JJ	O
Inc.	NNP	O
(South	NN	O
San	VBZ	O
Francisco,	IN	O
Calif.)	NNS	O
upon	IN	O
ESTs	PRP	O
as	JJ	O
well	JJ	O
as	NN	O
clustered	TO	O
and	,	O
assembled	RB	O
EST	,	O
fragments	RB	O
from	VBG	O
public	IN	O
(e.g.,	NNP	O
GenBank)	MD	O
and/or	VB	O
private	DT	O
(LIFESEQ®,	JJ	O
Incyte	.	O
Pharmaceuticals,	RB	O
Inc.,	CD	O
Palo	NNP	O
Alto,	IN	O
Calif.)	NN	O
databases.	NNP	O
The	NNP	O
signal	NNP	O
sequence	NNP	O
algorithm	NNP	O
computes	)	O
a	NNP	O
secretion	VBD	O
signal	VBN	O
score	IN	O
based	VBG	O
on	DT	O
the	JJ	O
character	NN	O
of	NN	O
the	VBG	O
DNA	NNS	O
nucleotides	VBN	O
surrounding	IN	O
the	,	O
first	NNP	O
and	NNP	O
optionally	NNP	O
the	,	O
second	)	O
methionine	NN	O
codon(s)	NNP	O
(ATG)	RB	O
at	RB	O
the	IN	O
5′-end	VBN	O
of	CC	O
the	VBN	O
sequence	NN	O
or	NNS	O
sequence	IN	O
fragment	JJ	O
under	,	O
consideration.	)	O
The	VBP	O
nucleotides	JJ	O
following	,	O
the	NNP	O
first	,	O
ATG	,	O
must	NNP	O
code	,	O
for	)	O
at	.	O
least	DT	O
35	JJ	O
unambiguous	NN	O
amino	NN	O
acids	VBZ	O
without	DT	O
any	NN	O
stop	NN	O
codons.	NN	O
If	VBN	O
the	IN	O
first	DT	O
ATG	NN	O
has	IN	O
the	DT	O
required	NNP	O
amino	NNS	O
acids,	VBG	O
the	DT	O
second	JJ	O
is	CC	O
not	RB	O
examined.	DT	O
If	JJ	O
neither	NN	O
meets	)	O
the	)	O
requirement,	IN	O
the	DT	O
candidate	NN	O
sequence	IN	O
is	DT	O
not	NN	O
scored.	CC	O
In	NN	O
order	NN	O
to	IN	O
determine	.	O
whether	DT	O
the	NNS	O
EST	VBG	O
sequence	DT	O
contains	JJ	O
an	NNP	O
authentic	MD	O
signal	VB	O
sequence,	IN	O
the	IN	O
DNA	JJS	O
and	CD	O
corresponding	JJ	O
amino	NN	O
acid	NNS	O
sequences	IN	O
surrounding	DT	O
the	JJ	O
ATG	.	O
codon	IN	O
are	DT	O
scored	JJ	O
using	NNP	O
a	VBZ	O
set	DT	O
of	VBN	O
seven	NN	O
sensors	,	O
(evaluation	DT	O
parameters)	NN	O
known	VBZ	O
to	RB	O
be	.	O
associated	IN	O
with	DT	O
secretion	VBZ	O
signals.	DT	O
Use	,	O
of	DT	O
the	NN	O
above	NN	O
described	VBZ	O
signal	RB	O
sequence	.	O
algorithm	IN	O
allowed	NN	O
identification	TO	O
of	VB	O
an	IN	O
EST	DT	O
cluster	NNP	O
sequence	NN	O
from	VBZ	O
the	DT	O
Incyte	JJ	O
database,	NN	O
designated	,	O
Incyte	DT	O
EST	NN	O
cluster	CC	O
sequence	VBG	O
no.	NN	O
40671.	NN	O
This	NNS	O
EST	VBG	O
cluster	DT	O
sequence	NNP	O
was	NN	O
then	VBP	O
compared	VBN	O
to	VBG	O
a	DT	O
variety	NN	O
of	IN	O
expressed	CD	O
sequence	NNS	O
tag	NN	O
(EST)	)	O
databases	VBN	O
which	TO	O
included	VB	O
public	VBN	O
EST	IN	O
databases	NN	O
(e.g.,	.	O
GenBank)	NNP	O
and	IN	O
a	DT	O
proprietary	JJ	O
EST	VBD	O
DNA	JJ	O
database	NN	O
(Lifeseq®,	NN	O
Incyte	VBD	O
Pharmaceuticals,	NN	O
Palo	IN	O
Alto,	DT	O
Calif.)	NNP	O
to	NN	O
identify	NN	O
existing	IN	O
homologies.	DT	O
The	NNP	O
homology	,	O
search	VBN	O
was	NNP	O
performed	NNP	O
using	NN	O
the	NN	O
computer	.	O
program	.	O
BLAST	DT	O
or	NNP	O
BLAST2	NN	O
Altshul	NN	B
et	VBD	I
al.,	RB	I
Methods	VBN	I
in	TO	I
Enzymology	DT	I
266:460-480	NN	I
(1996)).(	IN	O
Those	JJ	O
comparisons	NN	O
resulting	NN	O
in	)	O
a	VBZ	O
BLAST	WDT	O
score	VBD	O
of	JJ	O
70	NNP	O
(or	NNS	O
in	,	O
some	)	O
cases	CC	O
90)	DT	O
or	JJ	O
greater	NNP	O
that	NN	O
did	NN	O
not	,	O
encode	NNP	O
known	,	O
proteins	NNP	O
were	,	O
clustered	)	O
and	TO	O
assembled	VB	O
into	VBG	O
a	.	O
consensus	DT	O
DNA	NN	O
sequence	NN	O
with	VBD	O
the	VBN	O
program	VBG	O
“phrap”	DT	O
(Phil	NN	O
Green,	NN	O
University	NNP	O
of	CC	O
Washington,	NNP	O
Seattle,	NNP	O
Wash.).	RB	O
The	,	O
consensus	NNS	O
sequence	IN	O
is	NNP	O
herein	CD	O
designated	.	O
DNA56749.	DT	O
Proprietary	NNS	O
Genentech	VBG	O
EST	IN	O
sequences	DT	O
were	NNP	O
used	NN	O
in	IN	O
the	CD	O
assembly.	CC	O
In	IN	O
light	DT	O
of	NNS	O
the	)	O
sequence	CC	O
homology	JJR	O
between	WDT	O
the	VBD	O
DNA56749	RB	O
sequence	VB	O
and	JJ	O
the	NNS	O
Incyte	VBD	O
EST	VBN	O
clone	CC	O
no.	VBN	O
4111192,	IN	O
the	DT	O
Incyte	NN	O
EST	NNP	O
clone	NN	O
no.	IN	O
4111192	DT	O
was	NN	O
purchased	NNP	O
and	NNP	O
the	,	O
cDNA	NNP	O
insert	IN	O
was	,	O
obtained	,	O
and	.	O
sequenced.	DT	O
The	NN	O
sequence	NN	O
of	VBZ	O
this	RB	O
cDNA	VBN	O
insert	.	O
is	JJ	O
shown	NNP	O
in	NNP	O
FIG.	NNS	O
7	VBD	O
(SEQ	VBN	O
ID	IN	O
NO:7)	DT	O
and	.	O
is	IN	O
herein	NN	O
designated	IN	O
as	DT	O
DNA66658-1584.	NN	O
Clone	NN	O
UNQ688	IN	O
(DNA66658-1584)	DT	O
contains	NNP	O
a	NN	O
single	CC	O
open	DT	O
reading	NNP	O
frame	NNP	O
with	NN	O
an	.	O
apparent	,	O
translational	DT	O
initiation	NNP	O
site	NNP	O
at	NN	O
nucleotide	.	O
positions	CD	O
9-11	VBD	O
and	VBN	O
ending	CC	O
at	DT	O
the	NN	O
stop	NN	O
codon	VBD	O
at	VBN	O
nucleotide	CC	O
positions	.	O
780-782	DT	O
(FIG.	NN	O
7;	IN	O
SEQ	DT	O
ID	NN	O
NO:7).	NN	O
The	VBZ	O
predicted	VBN	O
polypeptide	IN	O
precursor	.	O
is	CD	O
257	NNP	O
amino	NNP	O
acids	)	O
long	CC	O
(FIG.	VBZ	O
8;	RB	O
SEQ	VBN	O
ID	IN	O
NO:8).	.	O
The	NN	O
full-length	NNP	O
PRO1328	)	O
protein	VBZ	O
shown	DT	O
in	JJ	O
FIG.	JJ	O
8	NN	O
has	NN	O
an	IN	O
estimated	DT	O
molecular	JJ	O
weight	JJ	O
of	NN	O
about	NN	O
28,472	IN	O
daltons	JJ	O
and	NNS	O
a	CD	O
pI	CC	O
of	VBG	O
about	IN	O
9.33.	DT	O
Analysis	NN	O
of	NN	O
the	IN	O
full-length	JJ	O
PRO1328	NNS	O
sequence	JJ	O
shown	.	O
in	:	O
FIG.	NNP	O
8	NNP	O
(SEQ	.	O
ID	DT	O
NO:8)	JJ	O
evidences	NN	O
the	NN	O
presence	VBZ	O
of	CD	O
the	JJ	O
following:	NNS	O
a	RB	O
signal	.	O
peptide	:	O
from	NNP	O
about	NNP	O
amino	.	O
acid	DT	O
1	JJ	O
to	NNP	O
about	NN	O
amino	VBN	O
acid	IN	O
19,	.	O
transmembrane	CD	O
domains	VBZ	O
from	DT	O
about	VBN	O
amino	JJ	O
acid	NN	O
32	IN	O
to	IN	O
about	CD	O
amino	NNS	O
acid	CC	O
51,	DT	O
from	NN	O
about	IN	O
amino	IN	O
acid	.	O
119	NN	O
to	IN	O
about	DT	O
amino	JJ	O
acid	NNP	O
138,	NN	O
from	VBN	O
about	IN	O
amino	.	O
acid	CD	O
152	NNP	O
to	NNP	O
about	)	O
amino	VBZ	O
acid	DT	O
169	NN	O
and	IN	O
from	DT	O
about	:	O
amino	DT	O
acid	JJ	O
216	NN	O
to	IN	O
about	IN	O
amino	NN	O
acid	NN	O
235,	CD	O
a	TO	O
glycosaminoglycan	IN	O
attachment	NN	O
site	NN	O
from	,	O
about	NN	O
amino	NNS	O
acid	IN	O
120	IN	O
to	NN	O
about	NN	O
amino	CD	O
acid	TO	O
123	IN	O
and	NN	O
sodium/neurotransmitter	NN	O
symporter	,	O
family	IN	O
protein	IN	O
homology	NN	O
block	NN	O
from	CD	O
about	TO	O
amino	IN	O
acid	NN	O
31	NN	O
to	,	O
about	IN	O
amino	IN	O
acid	NN	O
65.	NN	O
Clone	CD	O
UNQ688	TO	O
(DNA66658-1584)	IN	O
has	NN	O
been	NN	O
deposited	CD	O
with	CC	O
ATCC	IN	O
on	IN	O
Sep.	NN	O
15,	NN	O
1998	CD	O
and	TO	O
is	IN	O
assigned	NN	O
ATCC	NN	O
deposit	,	O
no.	DT	O
203229.	JJ	O
An	NN	O
analysis	NN	O
of	IN	O
the	IN	O
Dayhoff	NN	O
database	NN	O
(version	CD	O
35.45	TO	O
SwissProt	IN	O
35),	NN	O
using	NN	O
a	CD	O
WU-BLAST2	CC	O
sequence	JJR	O
alignment	NN	O
analysis	NN	O
of	NN	O
the	NN	O
full-length	NN	O
PRO1328	IN	O
amino	IN	O
acid	NN	O
sequence	NN	O
shown	CD	O
in	TO	O
FIG.	IN	O
8	NN	O
(SEQ	NN	O
ID	.	O
NO:8),	NN	O
evidenced	NNP	O
significant	)	O
homology	VBZ	O
between	VBN	O
the	VBN	O
PRO1328	IN	O
amino	NNP	O
acid	IN	O
sequence	NNP	O
and	,	O
the	CD	O
following	CC	O
Dayhoff	VBZ	O
sequences:	VBN	O
CEVF36H2L—2,	NNP	O
TIP2_TOBAC,	NN	O
AB009466—16,	.	O
ATU39485—1,	.	O
P_R60153,	DT	O
P_R77082,	NN	O
S73351,	IN	O
C69392,	DT	O
LEU95008—1	NNP	O
and	NN	O
E64667.	NN	O
Example	CD	O
8	NNP	O
Isolation	,	O
of	VBG	O
cDNA	DT	O
Clones	JJ	O
Encoding	NN	O
Human	JJ	O
PRO4342	NN	O
Polypeptides	IN	O
(UNQ1896)	DT	O
A	JJ	O
expressed	NNP	O
sequence	NN	O
tag	NN	O
(EST)	NN	O
DNA	VBN	O
database	IN	O
(LIFESEQ®,	.	O
Incyte	CD	O
Pharmaceuticals,	NNP	O
Palo	NNP	O
Alto,	,	O
Calif.)	VBD	O
was	JJ	O
searched	NN	O
with	IN	O
human	DT	O
interleukin-1	NNP	O
receptor	NN	O
antagonist	NN	O
(hIL-1Ra)	NN	O
sequence,	CC	O
and	DT	O
the	JJ	O
EST,	NNP	O
designated	:	O
5120028	,	O
was	,	O
identified,	,	O
which	,	O
showed	,	O
homology	,	O
with	,	O
the	,	O
hIL-1Ra	NNP	O
known	CC	O
protein.	.	O
EST	RB	O
clone	CD	O
5120028	NNP	O
was	IN	O
purchased	NN	O
from	NNP	O
Incyte	NNP	O
Pharmaceuticals	NNP	O
(Palo	NNP	O
Alto,	NNP	O
Calif.)	)	O
and	NNP	O
the	VBN	O
cDNA	NN	O
insert	NN	O
was	)	O
obtained	NNP	O
and	NN	O
sequenced	,	O
in	NNP	O
its	,	O
entirety.	NNP	O
The	,	O
entire	)	O
nucleotide	VBD	O
sequence	VBN	O
of	IN	O
the	JJ	O
clone	JJ	O
5120028,	NN	O
designated	NN	O
UNQ1896	)	O
(DNA96787-2534-1),	,	O
is	CC	O
shown	DT	O
in	,	O
FIG.	VBD	O
9	CD	O
(SEQ	VBD	O
ID	,	O
NO:9).	WDT	O
Clone	VBD	O
UNQ1896	NN	O
(DNA96787-2534-1)	IN	O
contains	DT	O
a	JJ	O
single	JJ	O
open	.	O
reading	NNP	O
frame	NN	O
with	CD	O
an	VBD	O
apparent	VBN	O
translational	IN	O
initiation	NNP	O
site	NNP	O
at	NNP	O
nucleotide	,	O
positions	)	O
1-3,	CC	O
and	DT	O
a	NN	O
stop	NN	O
codon	VBD	O
at	VBN	O
nucleotide	CC	O
positions	VBN	O
466-468	IN	O
(FIG.	PRP$	O
9;	.	O
SEQ	DT	O
ID	JJ	O
NO:9).	JJ	O
The	NN	O
predicted	IN	O
polypeptide	DT	O
precursor	NN	O
(hIL-1Ra3)	,	O
is	VBN	O
155	NNP	O
amino	,	O
acids	VBZ	O
long	VBN	O
(FIG.	IN	O
10;	.	O
SEQ	CD	O
ID	NNP	O
NO:10).	NNP	O
The	.	O
putative	NN	O
signal	NNP	O
sequence	)	O
extends	VBZ	O
from	DT	O
amino	JJ	O
acid	JJ	O
positions	NN	O
1-33.	NN	O
Putative	IN	O
N-myristoylation	DT	O
sites	JJ	O
are	JJ	O
located	NN	O
at	NN	O
amino	IN	O
acid	JJ	O
positions	NNS	O
29-34,	,	O
60-65,	CC	O
63-68,	DT	O
73-78,	JJ	O
91-96	NN	O
and	IN	O
106-111.	JJ	O
An	NNS	O
interleukin-1-like	JJ	O
sequence	.	O
is	:	O
located	NNP	O
at	NNP	O
amino	.	O
acid	DT	O
positions	JJ	O
111-131.	NN	O
Clone	NN	O
DNA96787	)	O
(designated	VBZ	O
as	CD	O
DNA96787-2534-1)	JJ	O
was	NNS	O
deposited	RB	O
with	.	O
ATCC	:	O
on	NNP	O
Jan.	NNP	O
12,	.	O
1999	DT	O
and	JJ	O
was	NN	O
assigned	NN	O
ATCC	VBZ	O
deposit	IN	O
no.	JJ	O
203589.	JJ	O
The	NNS	O
full	.	O
length	JJ	O
hIL-1Ra3	NN	O
protein	NNS	O
shown	VBP	O
in	VBN	O
FIG.	IN	O
10	JJ	O
(SEQ	JJ	O
ID	NNS	O
NO:10)	,	O
has	,	O
an	,	O
estimated	,	O
molecular	JJ	O
weight	CC	O
of	.	O
about	DT	O
16,961	JJ	O
daltons	NN	O
and	VBZ	O
a	VBN	O
pI	IN	O
of	JJ	O
about	JJ	O
4.9.	NNS	O
Based	.	O
on	NN	O
a	NNP	O
BLAST	VBN	O
and	IN	O
FastA	)	O
sequence	VBD	O
alignment	VBN	O
analysis	IN	O
(using	NNP	O
the	IN	O
ALIGN	NNP	O
computer	,	O
program)	CD	O
of	CC	O
the	VBD	O
full-length	VBN	O
sequence,	NNP	O
hIL-1Ra3	NN	O
shows	.	O
significant	.	O
amino	DT	O
acid	JJ	O
sequence	NN	O
identity	JJ	O
to	NN	O
hicIL-1Ra	VBN	O
and	IN	O
hIL-1Ra	.	O
proteins.	CD	O
Example	NNP	O
9	NNP	O
Isolation	)	O
of	VBZ	O
cDNA	DT	O
Clones	VBN	O
Encoding	JJ	O
Human	NN	O
PRO10096	IN	O
Polypeptides	IN	O
(UNQ3099)	CD	O
DNA125185-2806	NNS	O
(UNQ3099)	CC	O
was	DT	O
identified	NN	O
by	IN	O
applying	IN	O
a	.	O
proprietary	VBN	O
signal	IN	O
sequence	DT	O
finding	NNP	O
algorithm	CC	O
developed	NNP	O
by	NN	O
Genentech,	NN	O
Inc.	NN	O
(South	VBG	O
San	DT	O
Francisco,	NNP	O
Calif.)	NN	O
upon	)	O
ESTs	IN	O
as	DT	O
well	JJ	O
as	,	O
clustered	JJ	O
and	NNS	O
assembled	JJ	O
EST	JJ	O
fragments	NN	O
from	NN	O
public	NN	O
(e.g.,	TO	O
GenBank)	JJ	O
and/or	CC	O
private	JJ	O
(LIFESEQ®,	.	O
Incyte	RB	O
Pharmaceuticals,	CD	O
Inc.,	NNP	O
Palo	IN	O
Alto,	NN	O
Calif.)	NNP	O
databases.	NNP	O
The	NNP	O
signal	NNP	O
sequence	NNP	O
algorithm	)	O
computes	NNP	O
a	)	O
secretion	VBD	O
signal	VBN	O
score	IN	O
based	VBG	O
on	DT	O
the	JJ	O
character	NN	O
of	NN	O
the	VBG	O
DNA	NNS	O
nucleotides	VBN	O
surrounding	IN	O
the	,	O
first	NNP	O
and	NNP	O
optionally	NNP	O
the	,	O
second	)	O
methionine	NN	O
codon(s)	NNP	O
(ATG)	RB	O
at	RB	O
the	IN	O
5′-end	VBN	O
of	CC	O
the	VBN	O
sequence	NN	O
or	NNS	O
sequence	IN	O
fragment	JJ	O
under	,	O
consideration.	)	O
The	VBP	O
nucleotides	JJ	O
following	,	O
the	NNP	O
first	,	O
ATG	,	O
must	NNP	O
code	,	O
for	)	O
at	.	O
least	DT	O
35	JJ	O
unambiguous	NN	O
amino	NN	O
acids	VBZ	O
without	DT	O
any	NN	O
stop	NN	O
codons.	NN	O
If	VBN	O
the	IN	O
first	DT	O
ATG	NN	O
has	IN	O
the	DT	O
required	NNP	O
amino	NNS	O
acids,	VBG	O
the	DT	O
second	JJ	O
is	CC	O
not	RB	O
examined.	DT	O
If	JJ	O
neither	NN	O
meets	)	O
the	)	O
requirement,	IN	O
the	DT	O
candidate	NN	O
sequence	IN	O
is	DT	O
not	NN	O
scored.	CC	O
In	NN	O
order	NN	O
to	IN	O
determine	.	O
whether	DT	O
the	NNS	O
EST	VBG	O
sequence	DT	O
contains	JJ	O
an	NNP	O
authentic	MD	O
signal	VB	O
sequence,	IN	O
the	IN	O
DNA	JJS	O
and	CD	O
corresponding	JJ	O
amino	NN	O
acid	NNS	O
sequences	IN	O
surrounding	DT	O
the	JJ	O
ATG	.	O
codon	IN	O
are	DT	O
scored	JJ	O
using	NNP	O
a	VBZ	O
set	DT	O
of	VBN	O
seven	NN	O
sensors	,	O
(evaluation	DT	O
parameters)	NN	O
known	VBZ	O
to	RB	O
be	.	O
associated	IN	O
with	DT	O
secretion	VBZ	O
signals.	DT	O
Use	,	O
of	DT	O
the	NN	O
above	NN	O
described	VBZ	O
signal	RB	O
sequence	.	O
algorithm	IN	O
allowed	NN	O
identification	TO	O
of	VB	O
an	IN	O
EST	DT	O
cluster	NNP	O
sequence	NN	O
from	VBZ	O
the	DT	O
Incyte	JJ	O
database,	NN	O
designated	,	O
herein	DT	O
as	NN	O
5086173H1.	CC	O
This	VBG	O
EST	NN	O
cluster	NN	O
sequence	NNS	O
was	VBG	O
then	DT	O
compared	NNP	O
to	NN	O
a	VBP	O
variety	VBN	O
of	VBG	O
expressed	DT	O
sequence	NN	O
tag	IN	O
(EST)	CD	O
databases	NNS	O
which	NN	O
included	)	O
public	VBN	O
EST	TO	O
databases	VB	O
(e.g.,	VBN	O
GenBank)	IN	O
and	NN	O
a	.	O
proprietary	NNP	O
EST	IN	O
DNA	DT	O
database	JJ	O
(LIFESEQ®,	VBD	O
Incyte	JJ	O
Pharmaceuticals,	NN	O
Palo	NN	O
Alto,	VBD	O
Calif.)	NN	O
to	IN	O
identify	DT	O
existing	NNP	O
homologies.	NN	O
The	NN	O
homology	IN	O
search	DT	O
was	NNP	O
performed	,	O
using	VBN	O
the	NN	O
computer	IN	O
program	.	O
BLAST	DT	O
or	NNP	O
BLAST2	NN	O
Altshul	NN	B
et	VBD	I
al.,	RB	I
Methods	VBN	I
in	TO	I
Enzymology	DT	I
266:460-480	NN	I
(1996)).(	IN	O
Those	JJ	O
comparisons	NN	O
resulting	NN	O
in	)	O
a	VBZ	O
BLAST	WDT	O
score	VBD	O
of	JJ	O
70	NNP	O
(or	NNS	O
in	,	O
some	)	O
cases	CC	O
90)	DT	O
or	JJ	O
greater	NNP	O
that	NN	O
did	NN	O
not	,	O
encode	NNP	O
known	,	O
proteins	NNP	O
were	,	O
clustered	)	O
and	TO	O
assembled	VB	O
into	VBG	O
a	.	O
consensus	DT	O
DNA	NN	O
sequence	NN	O
with	VBD	O
the	VBN	O
program	VBG	O
“phrap”	DT	O
(Phil	NN	O
Green,	NN	O
University	NNP	O
of	CC	O
Washington,	NNP	O
Seattle,	NNP	O
Wash.).	RB	O
The	,	O
consensus	NNS	O
sequence	IN	O
obtained	NNP	O
therefrom	CD	O
is	.	O
herein	DT	O
designated	NNS	O
DNA110880.	VBG	O
In	IN	O
light	DT	O
of	NNP	O
an	NN	O
observed	IN	O
sequence	CD	O
homology	CC	O
between	IN	O
the	DT	O
DNA110880	NNS	O
sequence	)	O
and	CC	O
an	JJR	O
EST	WDT	O
sequence	VBD	O
encompassed	RB	O
within	VB	O
clone	JJ	O
no.	NNS	O
5088384	VBD	O
from	VBN	O
the	CC	O
Incyte	VBN	O
database,	IN	O
clone	DT	O
no.	NN	O
5088384	NNP	O
was	NN	O
purchased	IN	O
and	DT	O
the	NN	O
cDNA	NNP	O
insert	NNP	O
was	,	O
obtained	NNP	O
and	IN	O
sequenced.	,	O
It	,	O
was	.	O
found	DT	O
herein	NN	O
that	NN	O
that	VBN	O
cDNA	NN	O
insert	VBZ	O
encoded	RB	O
a	VBN	O
full-length	.	O
protein.	IN	O
The	NN	O
sequence	IN	O
of	DT	O
this	JJ	O
cDNA	NN	O
insert	NN	O
is	IN	O
shown	DT	O
in	NNP	O
FIG.	NN	O
13	CC	O
(SEQ	DT	O
ID	NNP	O
NO:13)	NN	O
and	VBD	O
is	IN	O
herein	NN	O
designated	.	O
as	CD	O
DNA125185-2806.	IN	O
Clone	DT	O
DNA125185-2806	NNP	O
[UNQ3099]	,	O
contains	NN	O
a	.	O
single	CD	O
open	VBD	O
reading	VBN	O
frame	CC	O
with	DT	O
an	NN	O
apparent	NN	O
translational	VBD	O
initiation	VBN	O
site	CC	O
at	.	O
nucleotide	PRP	O
positions	VBD	O
58-60	VBN	O
and	NN	O
ending	IN	O
at	DT	O
the	NN	O
stop	NN	O
codon	VBD	O
at	DT	O
nucleotide	JJ	O
positions	.	O
595-597	DT	O
(FIG.	NN	O
13).	IN	O
The	DT	O
predicted	NN	O
polypeptide	NN	O
precursor	VBZ	O
is	VBN	O
179	IN	O
amino	.	O
acids	CD	O
long	NNP	O
(FIG.	NNP	O
14;	)	O
SEQ	CC	O
ID	VBZ	O
NO:14).	RB	O
The	VBN	O
full-length	IN	O
PRO10096	.	O
(SEQ	NNP	O
ID	NNP	O
NO:14)	NNP	O
protein	VBZ	O
shown	DT	O
in	JJ	O
FIG.	JJ	O
14	NN	O
has	NN	O
an	IN	O
estimated	DT	O
molecular	JJ	O
weight	JJ	O
of	NN	O
about	NN	O
20,011	IN	O
daltons	JJ	O
and	NNS	O
a	JJ	O
pI	CC	O
of	VBG	O
about	IN	O
8.10.	DT	O
Analysis	NN	O
of	NN	O
the	IN	O
full-length	JJ	O
PRO10096	NNS	O
sequence	JJ	O
shown	.	O
in	.	O
FIG.	DT	O
14	JJ	O
(SEQ	NN	O
ID	NN	O
NO:14)	VBZ	O
evidences	CD	O
the	JJ	O
presence	NNS	O
of	RB	O
a	.	O
variety	:	O
of	NNP	O
important	NNP	O
polypeptide	.	O
domains	DT	O
as	JJ	O
shown	NNP	O
in	NNP	O
FIG.	NNP	O
14,	)	O
wherein	VBP	O
the	VBN	O
locations	IN	O
given	.	O
for	CD	O
those	VBZ	O
important	DT	O
polypeptide	VBN	O
domains	JJ	O
are	NN	O
approximate	IN	O
as	IN	O
described	CD	O
above.	NNS	O
Clone	CC	O
DNA125185-2806	DT	O
has	NN	O
been	IN	O
deposited	IN	O
with	.	O
ATCC	NN	O
on	IN	O
Dec.	DT	O
7,	JJ	O
1999	NNP	O
and	NN	O
is	VBN	O
assigned	IN	O
ATCC	.	O
deposit	CD	O
no.	NNP	O
PTA-1031.	NNP	O
Example	)	O
10	VBZ	O
Isolation	DT	O
of	NN	O
cDNA	IN	O
Clones	DT	O
Encoding	NN	O
Human	IN	O
PRO21384	JJ	O
Polypeptides	NN	O
(UNQ6368)	NNS	O
The	IN	O
extracellular	VBN	O
domain	IN	O
(ECD)	.	O
sequences	,	O
(including	VBD	O
the	DT	O
secretion	NNS	O
signal,	VBN	O
if	IN	O
any)	DT	O
of	JJ	O
from	NN	O
about	NNS	O
950	VBP	O
known	JJ	O
secreted	IN	O
proteins	VBN	O
from	.	O
the	NNP	O
Swiss-Prot	NNP	O
public	VBZ	O
protein	VBN	O
database	VBN	O
were	IN	O
used	NNP	O
to	IN	O
search	NNP	O
expressed	,	O
sequence	CD	O
tag	CC	O
(EST)	VBZ	O
databases.	VBN	O
The	NNP	O
EST	NN	O
databases	.	O
included	.	O
public	RB	O
EST	CD	O
databases	NNP	O
(e.g.,	IN	O
GenBank)	NN	O
and	NNP	O
a	NNP	O
proprietary	NNP	O
EST	NNP	O
DNA	NNP	O
database	)	O
(LIFESEQ®,	DT	O
Incyte	JJ	O
Pharmaceuticals,	NN	O
Palo	)	O
Alto,	NNS	O
Calif.).	VBG	O
The	DT	O
search	NN	O
was	,	O
performed	IN	O
using	)	O
the	IN	O
computer	IN	O
program	IN	O
BLAST	CD	O
or	NNS	O
BLAST2	VBD	O
Altshul	NNS	B
et	IN	I
al.,	DT	I
Methods	NNP	I
in	JJ	I
Enzymology	NN	I
266:460-480	NN	I
(1996))	VBD	I
(as	VBN	O
a	TO	O
comparison	VB	O
of	JJ	O
the	NN	O
ECD	NN	O
protein	)	O
sequences	.	O
to	DT	O
a	NNP	O
6	NNS	O
frame	VBD	O
translation	JJ	O
of	NNP	O
the	NNS	O
EST	,	O
sequence.	)	O
Those	CC	O
comparisons	DT	O
resulting	JJ	O
in	NNP	O
a	NN	O
BLAST	NN	O
score	,	O
of	NNP	O
70	,	O
(or	NNP	O
in	,	O
some	.	O
cases	DT	O
90)	NN	O
or	VBD	O
greater	VBN	O
that	VBG	O
did	DT	O
not	NN	O
encode	NN	O
known	NNP	O
proteins	CC	O
were	NNP	O
clustered	NNP	O
and	RB	O
assembled	,	O
into	NNS	O
consensus	IN	O
DNA	NNP	O
sequences.	CD	O
An	)	O
expressed	IN	O
sequence	DT	O
tag	NN	O
(EST)	IN	O
was	DT	O
identified	NNP	O
by	NN	O
the	NNS	O
EST	TO	O
database	DT	O
search	CD	O
and	NN	O
a	NN	O
consensus	IN	O
DNA	DT	O
sequence	NNP	O
was	.	O
assembled	DT	O
relative	NNS	O
to	VBG	O
other	IN	O
EST	DT	O
sequences	NNP	O
using	NN	O
phrap	IN	O
(Phil	CD	O
Green,	CC	O
University	IN	O
of	DT	O
Washington,	NNS	O
Seattle,	)	O
Wash.).	CC	O
This	JJR	O
consensus	WDT	O
sequence	VBD	O
is	RB	O
herein	VB	O
designated	JJ	O
“Consen0821”,	NNS	O
which	VBD	O
was	VBN	O
used	CC	O
to	VBN	O
derive	IN	O
the	NN	O
final	NNP	O
consensus	.	O
sequence,	DT	O
“DNA172257”.	JJ	O
Based	NN	O
on	NN	O
the	)	O
DNA172257	VBD	O
consensus	VBN	O
sequence,	IN	O
oligonucleotides	DT	O
were	NNP	O
synthesized:	NN	O
1)	NN	O
to	CC	O
identify	DT	O
by	NN	O
PCR	NNP	O
a	NN	O
cDNA	VBD	O
library	VBN	O
that	JJ	O
contained	TO	O
the	JJ	O
sequence	NNP	O
of	NNS	O
interest,	VBG	O
and	NN	O
2)	NNP	O
for	,	O
use	NNP	O
as	IN	O
probes	,	O
to	,	O
isolate	.	O
a	DT	O
clone	NN	O
of	NN	O
the	VBZ	O
full-length	RB	O
coding	VBN	O
sequence	,	O
for	WDT	O
PRO233.	VBD	O
Forward	VBN	O
and	TO	O
reverse	VB	O
PCR	DT	O
primers	JJ	O
generally	NN	O
range	,	O
from	.	O
20	VBN	O
to	IN	O
30	DT	O
nucleotides	NNP	O
and	NN	O
are	,	O
often	NNS	O
designed	VBD	O
to	:	O
give	)	O
a	TO	O
PCR	VB	O
product	IN	O
of	NNP	O
about	DT	O
100-1000	NN	O
bp	NN	O
in	WDT	O
length.	VBD	O
The	DT	O
probe	NN	O
sequences	IN	O
are	,	O
typically	CC	O
40-55	)	O
bp	IN	O
in	NN	O
length.	IN	O
In	NNS	O
some	TO	O
cases,	VB	O
additional	DT	O
oligonucleotides	NN	O
are	IN	O
synthesized	DT	O
when	JJ	O
the	NN	O
consensus	NN	O
sequence	IN	O
is	.	O
greater	NNP	O
than	CC	O
about	VB	O
1-1.5	NNP	O
kbp.	NNS	O
In	RB	O
order	VBP	O
to	IN	O
screen	CD	O
several	TO	O
libraries	CD	O
for	NNS	O
a	CC	O
full-length	VBP	O
clone,	RB	O
DNA	VBN	O
from	TO	O
the	VB	O
libraries	DT	O
was	NNP	O
screened	NN	O
by	IN	O
PCR	IN	O
amplification,	CD	O
as	NN	O
ber	IN	O
Ausubel	.	O
et	DT	O
al.,	NN	O
Current	NNS	O
Protocols	VBP	O
in	RB	O
Molecular	JJ	O
Biology,	NN	O
with	IN	O
the	.	O
PCR	IN	O
primer	DT	O
pair.	,	O
A	JJ	O
positive	NNS	O
library	VBP	O
was	VBN	O
then	WRB	O
used	DT	O
to	NN	O
isolate	NN	O
clones	VBZ	O
encoding	JJR	O
the	IN	O
gene	IN	O
of	JJ	O
interest	.	O
by	IN	O
the	NN	O
in	TO	O
vivo	VB	O
cloning	JJ	O
procedure	NNS	O
using	IN	O
the	DT	O
probe	JJ	O
oligonucleotide	,	O
and	NN	O
one	IN	O
of	DT	O
the	NNS	O
primer	VBD	O
pairs.	VBN	O
Forward	IN	O
and	NNP	O
reverse	,	O
PCR	IN	O
primers	NN	O
were	NNP	O
synthesized:	CC	O
Additionally,	,	O
a	NNP	O
synthetic	NNP	O
oligonucleotide	IN	O
hybridization	NNP	O
probe	,	O
was	IN	O
constructed	DT	O
from	NNP	O
the	NN	O
consensus	.	O
DNA172257	DT	O
sequence	JJ	O
which	NN	O
had	VBD	O
the	RB	O
following	VBN	O
nucleotide	TO	O
sequence:	VB	O
In	NNS	O
order	VBG	O
to	DT	O
screen	NN	O
several	IN	O
libraries	NN	O
for	IN	O
a	DT	O
source	IN	O
of	NN	O
a	NN	O
full-length	NN	O
clone,	VBG	O
DNA	DT	O
from	NN	O
the	NN	O
libraries	CC	O
was	CD	O
screened	IN	O
by	DT	O
PCR	NN	O
amplification	.	O
with	NNP	O
the	CC	O
PCR	VB	O
primer	NNP	O
pair	NNS	O
identified	VBD	O
above.	:	O
A	,	O
positive	DT	O
library	JJ	O
was	NN	O
then	NN	O
used	NN	O
to	VBD	O
isolate	VBN	O
clones	IN	O
encoding	DT	O
the	NN	O
PRO21384	NNP	O
gene	NN	O
using	WDT	O
the	VBD	O
probe	DT	O
oligonucleotide.	JJ	O
RNA	JJ	O
for	:	O
construction	IN	O
of	NN	O
the	TO	O
cDNA	VB	O
libraries	JJ	O
was	NNS	O
isolated	IN	O
from	DT	O
a	NN	O
mixture	IN	O
of	DT	O
human	JJ	O
tissues.	,	O
The	NN	O
cDNA	IN	O
libraries	DT	O
used	NNS	O
to	VBD	O
isolate	VBN	O
the	IN	O
cDNA	NNP	O
clones	NN	O
were	IN	O
constructed	DT	O
by	NNP	O
standard	NN	O
methods	NN	O
using	VBN	O
commercially	.	O
available	DT	O
reagents	JJ	O
such	NN	O
as	VBD	O
those	RB	O
from	VBN	O
Invitrogen,	TO	O
San	VB	O
Diego,	NNS	O
Calif.	VBG	O
The	DT	O
cDNA	NNP	O
was	NN	O
primed	VBG	O
with	DT	O
oligo	NN	O
dT	.	O
containing	NNP	O
a	IN	O
NotI	NN	O
site,	IN	O
linked	DT	O
with	NN	O
blunt	NNS	O
to	VBD	O
SalI	VBN	O
hemikinased	IN	O
adaptors,	DT	O
cleaved	NN	O
with	IN	O
NotI,	JJ	O
sized	.	O
appropriately	DT	O
by	NN	O
gel	NNS	O
electrophoresis,	VBN	O
and	TO	O
cloned	VB	O
in	DT	O
a	NN	O
defined	NNS	O
orientation	VBD	O
into	VBN	O
a	IN	O
suitable	JJ	O
cloning	NNS	O
vector	VBG	O
(such	RB	O
as	JJ	O
pRKB	NNS	O
or	JJ	O
pRKD;	IN	O
pRK5B	DT	O
is	IN	O
a	,	O
precursor	NNP	O
of	,	O
pRK5D	.	O
that	DT	O
does	NN	O
not	VBD	O
contain	VBN	O
the	IN	O
SfiI	JJ	O
site;	NN	O
see,	VBG	O
Holmes	DT	B
et	NNP	I
al.,	,	I
Science,	VBN	I
253:1278-1280	IN	I
(1991))	NN	I
in	TO	O
the	NNP	O
unique	VBD	O
XhoI	,	O
and	VBN	O
NotI	IN	O
sites.	,	O
DNA	VBD	O
sequencing	RB	O
of	IN	O
the	JJ	O
clones	,	O
isolated	CC	O
as	VBD	O
described	IN	O
above	DT	O
gave	JJ	O
the	NN	O
full-length	IN	O
DNA	DT	O
sequence	JJ	O
of	NN	O
PRO21384	NN	O
[herein	JJ	O
designated	IN	O
as	NN	O
UNQ6368	CC	O
(DNA177313-2982)]	:	O
(SEQ	NN	O
ID	VBZ	O
NO:15)	DT	O
and	NN	O
the	IN	O
derived	NN	O
protein	WDT	O
sequence	VBZ	O
of	RB	O
PRO21384	VB	O
(SEQ	DT	O
ID	NNP	O
NO:16).	:	O
The	,	O
entire	NNP	O
nucleotide	FW	O
sequence	,	O
of	,	O
UNQ6368	CD	O
(DNA177313-2982)	)	O
is	IN	O
shown	DT	O
in	JJ	O
FIG.	NNP	O
15	CC	O
(SEQ	NNP	O
ID	.	O
NO:15).	NN	O
Clone	NN	O
UNQ6368	IN	O
(DNA177313-2982)	DT	O
contains	NNS	O
a	VBD	O
single	IN	O
open	VBN	O
reading	IN	O
frame	VBD	O
with	DT	O
an	JJ	O
apparent	NNP	O
translational	NN	O
initiation	IN	O
site	NNP	O
at	RB	O
nucleotide	VBD	O
positions	IN	O
93-95	NNP	O
and	NN	O
ending	NNP	O
at	NNP	O
the	)	O
stop	CC	O
codon	DT	O
at	JJ	O
nucleotide	NN	O
positions	NN	O
1939-1941	IN	O
(FIG.	NNP	O
15).	NNP	O
The	NNP	O
predicted	.	O
polypeptide	DT	O
precursor	JJ	O
is	JJ	O
582	NN	O
amino	IN	O
acids	NNP	O
long	)	O
(FIG.	VBZ	O
16;	VBN	O
SEQ	IN	O
ID	.	O
NO:16).	CD	O
The	NNP	O
full-length	NNP	O
PRO21384	.	O
protein	NN	O
shown	NNP	O
in	)	O
FIG.	VBZ	O
16	DT	O
has	JJ	O
an	JJ	O
estimated	NN	O
molecular	NN	O
weight	IN	O
of	DT	O
about	JJ	O
66605	JJ	O
daltons	NN	O
and	NN	O
a	IN	O
pI	JJ	O
of	NNS	O
about	CD	O
8.14.	CC	O
Clone	VBG	O
UNQ6368	IN	O
(DNA177313-2982)	DT	O
has	NN	O
been	NN	O
deposited	IN	O
with	JJ	O
ATCC	NNS	O
on	JJ	O
Jul.	.	O
19,	.	O
2000	DT	O
and	JJ	O
is	NN	O
assigned	NN	O
ATCC	VBZ	O
deposit	CD	O
no.	JJ	O
PTA-2251.	NNS	O
Analysis	RB	O
of	.	O
the	:	O
amino	NNP	O
acid	NNP	O
sequence	.	O
of	DT	O
the	JJ	O
full-length	NNP	O
PRO21384	NN	O
polypeptide	VBN	O
evidenced	IN	O
sequence	.	O
identity	CD	O
between	VBZ	O
the	DT	O
PRO21384	VBN	O
amino	JJ	O
acid	NN	O
sequence	IN	O
and	IN	O
the	CD	O
following	NNS	O
Dayhoff	CC	O
sequences:	DT	O
P_R10545,	NN	O
IL6B_MOUSE,	IN	O
GCSR_HUMAN,	IN	O
LIFR_HUMAN,	.	O
HSU64198—1,	NN	O
P_R85912,	NNP	O
P_W70848,	)	O
P_Y29779,	VBZ	O
P_Y17825	VBN	O
and	VBN	O
P_W70839.	IN	O
Example	NNP	O
11	IN	O
Isolation	.	O
of	,	O
cDNA	CD	O
Clones	CC	O
Encoding	VBZ	O
Human	VBN	O
PRO353	NNP	O
Polypeptides	NN	O
(UNQ310)	.	O
A	.	O
consensus	NN	O
DNA	IN	O
sequence	DT	O
was	NN	O
assembled	JJ	O
relative	NN	O
to	IN	O
other	DT	O
EST	JJ	O
sequences	NNP	O
using	NN	O
phrap	VBD	O
as	NN	O
described	NN	O
in	IN	O
Example	DT	O
1	NNP	O
above.	NN	O
This	NN	O
consensus	NN	O
sequences	CC	O
is	DT	O
herein	JJ	O
designated	NNP	O
DNA36363.	:	O
The	,	O
consensus	,	O
DNA	,	O
sequence	,	O
was	,	O
extended	,	O
using	,	O
repeated	,	O
cycles	NNP	O
of	CC	O
BLAST	.	O
and	RB	O
phrap	CD	O
to	NNP	O
extend	IN	O
the	NN	O
consensus	NNP	O
sequence	NNP	O
as	NNP	O
far	NNP	O
as	NNP	O
possible	)	O
using	NNP	O
the	NN	O
sources	NNP	O
of	NN	O
EST	VBD	O
sequences	VBN	O
discussed	JJ	O
above.	TO	O
Based	JJ	O
on	NNP	O
the	NNS	O
DNA36363	VBG	O
consensus	NN	O
sequence,	IN	O
oligonucleotides	VBN	O
were	IN	O
synthesized:	NNP	O
1)	CD	O
to	.	O
identify	DT	O
by	NN	O
PCR	VBZ	O
a	VBZ	O
cDNA	RB	O
library	VBN	O
that	.	O
contained	DT	O
the	NN	O
sequence	NNP	O
of	NN	O
interest,	VBD	O
and	VBN	O
2)	VBG	O
for	JJ	O
use	NNS	O
as	IN	O
probes	NNP	O
to	CC	O
isolate	NN	O
a	TO	O
clone	VB	O
of	DT	O
the	NN	O
full-length	NN	O
coding	RB	O
sequence	RB	O
for	IN	O
PRO353.	JJ	O
Based	VBG	O
on	DT	O
the	NNS	O
DNA36363	IN	O
consensus	NNP	O
sequence,	NNS	O
forward	VBN	O
and	.	O
reverse	VBN	O
PCR	IN	O
primers	DT	O
were	NNP	O
synthesized	NN	O
as	,	O
follows:	NNS	O
Additionally,	VBD	O
a	:	O
synthetic	)	O
oligonucleotide	TO	O
hybridization	VB	O
probe	IN	O
was	NNP	O
constructed	DT	O
from	NN	O
the	NN	O
DNA36363	WDT	O
consensus	VBD	O
sequence	DT	O
which	NN	O
had	IN	O
the	,	O
following	CC	O
nucleotide	)	O
sequence:	IN	O
In	NN	O
order	IN	O
to	NNS	O
screen	TO	O
several	VB	O
libraries	DT	O
for	NN	O
a	IN	O
source	DT	O
of	JJ	O
a	NN	O
full-length	NN	O
clone,	IN	O
DNA	.	O
from	VBN	O
the	IN	O
libraries	DT	O
was	NNP	O
screened	NN	O
by	,	O
PCR	RB	O
amplification	CC	O
with	VB	O
one	NNP	O
of	NNS	O
the	VBD	O
PCR	VBN	O
primer	IN	O
pairs	:	O
identified	,	O
above.	DT	O
A	JJ	O
positive	NN	O
library	NN	O
was	NN	O
then	VBD	O
used	VBN	O
to	IN	O
isolate	DT	O
clones	NNP	O
encoding	NN	O
the	NN	O
PRO353	WDT	O
gene	VBD	O
using	DT	O
the	JJ	O
probe	JJ	O
oligonucleotide	:	O
and	IN	O
one	NN	O
of	TO	O
the	VB	O
PCR	JJ	O
primers.	NNS	O
RNA	IN	O
for	DT	O
construction	NN	O
of	IN	O
the	DT	O
cDNA	JJ	O
libraries	,	O
was	NN	O
isolated	IN	O
from	DT	O
human	NNS	O
fetal	VBD	O
kidney	VBN	O
tissue.	IN	O
DNA	NNP	O
sequencing	NN	O
of	IN	O
the	CD	O
clones	IN	O
isolated	DT	O
as	NNP	O
described	NN	O
above	NNS	O
gave	VBN	O
the	.	O
full-length	DT	O
DNA	JJ	O
sequence	NN	O
for	VBD	O
PRO353	RB	O
[herein	VBN	O
designated	TO	O
as	VB	O
DNA41234-1242-1]	NNS	O
(SEQ	VBG	O
ID	DT	O
NO:17)	NNP	O
and	NN	O
the	VBG	O
derived	DT	O
protein	NN	O
sequence	NN	O
for	CC	O
PRO353	CD	O
(SEQ	IN	O
ID	DT	O
NO:18).	NNP	O
The	.	O
entire	NNP	O
nucleotide	IN	O
sequence	NN	O
of	IN	O
DNA41234-1242-1	DT	O
[UNQ310]	NN	O
is	NNS	O
shown	VBD	O
in	VBN	O
FIG.	IN	O
17	JJ	O
(SEQ	JJ	O
ID	NN	O
NO:17).	.	O
Clone	NN	O
DNA41234-1242-1	NN	O
contains	IN	O
a	DT	O
single	NNS	O
open	VBD	O
reading	IN	O
frame	VBN	O
with	IN	O
an	VBD	O
apparent	DT	O
translational	JJ	O
initiation	NNP	O
site	NN	O
at	IN	O
nucleotide	NNP	O
positions	RB	O
305-307	VBD	O
and	IN	O
ending	NNP	O
at	NNP	O
the	NNP	O
stop	)	O
codon	CC	O
at	DT	O
nucleotide	JJ	O
positions	NN	O
1148-1150	NN	O
(FIG.	IN	O
17).	NNP	O
The	NNP	O
predicted	NNP	O
polypeptide	.	O
precursor	DT	O
is	JJ	O
281	JJ	O
amino	NN	O
acids	IN	O
long	NNP	O
(FIG.	NNP	O
18;	VBZ	O
SEQ	VBN	O
ID	IN	O
NO:18).	.	O
Important	CD	O
regions	NNP	O
of	NNP	O
the	.	O
amino	NNP	O
acid	NNP	O
sequence	VBZ	O
encoded	DT	O
by	JJ	O
PRO353	JJ	O
include	NN	O
the	NN	O
signal	IN	O
peptide,	DT	O
corresponding	JJ	O
to	JJ	O
amino	NN	O
acids	NN	O
1-26,	IN	O
the	JJ	O
start	NNS	O
of	JJ	O
the	CC	O
mature	VBG	O
protein	IN	O
at	DT	O
amino	NN	O
acid	NN	O
position	IN	O
27,	JJ	O
a	NNS	O
potential	JJ	O
N-glycosylation	.	O
site,	.	O
corresponding	DT	O
to	JJ	O
amino	NN	O
acids	NN	O
93-98	VBZ	O
and	CD	O
a	JJ	O
region	NNS	O
which	RB	O
has	.	O
homology	:	O
to	NNP	O
a	NNP	O
30	.	O
kd	JJ	O
adipocyte	NNS	O
complement-related	IN	O
protein	DT	O
precursor,	NN	O
corresponding	JJ	O
to	NN	O
amino	VBN	O
acids	IN	O
99-281.	NNP	O
Clone	VBP	O
DNA41234-1242-1	DT	O
has	JJ	O
been	,	O
deposited	VBG	O
with	TO	O
the	VB	O
ATCC	NNS	O
and	,	O
is	DT	O
assigned	NN	O
ATCC	IN	O
deposit	DT	O
no.	NN	O
ATCC	NN	O
209618	IN	O
on	NN	O
Feb.	JJ	O
5,	NN	O
1998.	,	O
Analysis	DT	O
of	JJ	O
the	NN	O
amino	,	O
acid	VBG	O
sequence	TO	O
of	VB	O
the	NNS	O
full-length	CD	O
PRO353	CC	O
polypeptides	DT	O
suggests	NN	O
that	WDT	O
portions	VBZ	O
of	NN	O
them	TO	O
possess	DT	O
significant	CD	O
homology	NN	O
to	JJ	O
portions	JJ	O
of	NN	O
human	,	O
and	VBG	O
murine	TO	O
complement	VB	O
proteins,	JJ	O
thereby	.	O
indicating	NNP	O
that	NNP	O
PRO353	VBZ	O
may	VBN	O
be	VBN	O
a	IN	O
novel	DT	O
complement	NNP	O
protein.	CC	O
Example	VBZ	O
12	VBN	O
Isolation	NNP	O
of	NN	O
cDNA	.	O
Clones	$	O
Encoding	CD	O
Human	IN	O
PRO1885	NNP	O
Polypeptides	,	O
(UNQ868)	.	O
by	NN	O
Amylase	IN	O
Screening	DT	O
1.	NN	O
Preparation	JJ	O
of	NN	O
Oligo	IN	O
dT	DT	O
Primed	JJ	O
cDNA	NNP	O
Library	NNS	O
mRNA	VBZ	O
was	IN	O
isolated	NNS	O
from	IN	O
a	PRP	O
human	VBP	O
tissue	JJ	O
of	NN	O
interest	TO	O
using	NNS	O
reagents	IN	O
and	JJ	O
protocols	CC	O
from	JJ	O
Invitrogen,	NN	O
San	,	O
Diego,	RB	O
Calif.	VBG	O
(Fast	IN	O
Track	NNP	O
2).	MD	O
This	VB	O
RNA	DT	O
was	JJ	O
used	NN	O
to	.	O
generate	RB	O
an	CD	O
oligo	NNP	O
dT	IN	O
primed	NN	O
cDNA	NNP	O
library	NNP	O
in	NNP	O
the	NNP	O
vector	NNP	O
pRK5D	)	O
using	IN	O
reagents	NNP	O
and	NNP	O
protocols	.	O
from	NN	O
Life	IN	O
Technologies,	NNP	O
Gaithersburg,	NN	O
Md.	NNP	O
(Super	NN	O
Script	NNP	O
Plasmid	NN	O
System).	VBD	O
In	VBN	O
this	IN	O
procedure,	DT	O
the	JJ	O
double	NN	O
stranded	IN	O
cDNA	NN	O
was	VBG	O
sized	NNS	O
to	CC	O
greater	NNS	O
than	IN	O
1000	,	O
bp	NNP	O
and	,	O
the	NNP	O
SalI/NotI	NNP	O
linkered	NNP	O
cDNA	.	O
was	DT	O
cloned	NNP	O
into	VBD	O
XhoI/NotI	VBN	O
cleaved	TO	O
vector.	VB	O
pRK5D	DT	O
is	JJ	O
a	NN	O
cloning	VBD	O
vector	JJ	O
that	NN	O
has	IN	O
an	DT	O
sp6	NN	O
transcription	NN	O
initiation	VBG	O
site	NNS	O
followed	CC	O
by	NNS	O
an	IN	O
SfiI	NNP	O
restriction	,	O
enzyme	,	O
site	.	O
preceding	NNP	O
the	NNP	O
XhoI/NotI	NNP	O
cDNA	.	O
cloning	IN	O
sites.	DT	O
2.	,	O
Preparation	DT	O
of	NN	O
Random	VBD	O
Primed	NN	O
cDNA	VBD	O
Library	VBN	O
A	TO	O
secondary	JJR	O
cDNA	IN	O
library	CD	O
was	NN	O
generated	CC	O
in	DT	O
order	NNP	O
to	VBD	O
preferentially	NN	O
represent	VBD	O
the	VBN	O
5′	IN	O
ends	NNP	O
of	VBD	O
the	.	O
primary	NN	O
cDNA	VBZ	O
clones.	DT	O
Sp6	VBG	O
RNA	NN	O
was	WDT	O
generated	VBZ	O
from	DT	O
the	JJ	O
primary	NN	O
library	NN	O
(described	NN	O
above),	VBN	O
and	IN	O
this	DT	O
RNA	NNP	O
was	NN	O
used	NN	O
to	NN	O
generate	VBG	O
a	DT	O
random	NNP	O
primed	NN	O
cDNA	VBG	O
library	.	O
in	.	O
the	NN	O
vector	IN	O
pSST-AMY.0	NNP	O
using	NNP	O
reagents	NN	O
and	NNP	O
protocols	NNP	O
from	JJ	O
Life	NN	O
Technologies	NN	O
(Super	VBD	O
Script	VBN	O
Plasmid	IN	O
System,	NN	O
referenced	TO	O
above).	RB	O
In	VB	O
this	DT	O
procedure	CD	O
the	NNS	O
double	IN	O
stranded	DT	O
cDNA	JJ	O
was	NN	O
sized	.	O
to	NNP	O
500-1000	NNP	O
bp,	VBD	O
linkered	VBN	O
with	IN	O
blunt	DT	O
to	JJ	O
NotI	NN	O
adaptors,	VBN	O
cleaved	,	O
with	CC	O
SfiI,	DT	O
and	NNP	O
cloned	VBD	O
into	VBN	O
SfiI/NotI	TO	O
cleaved	VB	O
vector.	DT	O
pSST-AMY.0	NN	O
is	VBN	O
a	JJ	O
cloning	NN	O
vector	IN	O
that	DT	O
has	NN	O
a	JJ	O
yeast	VBG	O
alcohol	NNS	O
dehydrogenase	CC	O
promoter	NNS	O
preceding	IN	O
the	NNP	O
cDNA	NNPS	O
cloning	NNP	O
sites	NNP	O
and	NNP	O
the	,	O
mouse	VBN	O
amylase	.	O
sequence	IN	O
(the	DT	O
mature	NN	O
sequence	DT	O
without	NN	O
the	VBD	O
secretion	NN	O
signal)	VBD	O
followed	VBN	O
by	TO	O
the	CD	O
yeast	,	O
alcohol	VBN	O
dehydrogenase	IN	O
terminator,	NN	O
after	TO	O
the	NNP	O
cloning	,	O
sites.	VBN	O
Thus,	IN	O
cDNAs	,	O
cloned	CC	O
into	VBD	O
this	IN	O
vector	NNP	O
that	VBD	O
are	.	O
fused	NN	O
in	VBZ	O
frame	DT	O
with	VBG	O
amylase	NN	O
sequence	WDT	O
will	VBZ	O
lead	DT	O
to	NN	O
the	NN	O
secretion	NN	O
of	NN	O
amylase	VBG	O
from	DT	O
appropriately	NN	O
transfected	VBG	O
yeast	NNS	O
colonies.	CC	O
3.	DT	O
Transformation	NN	O
and	NN	O
Detection	NN	O
DNA	DT	O
from	NN	O
the	NN	O
library	IN	O
described	DT	O
in	NN	O
paragraph	)	O
2	VBN	O
above	IN	O
was	DT	O
chilled	NN	O
on	NN	O
ice	NN	O
to	,	O
which	IN	O
was	DT	O
added	NN	O
electrocompetent	.	O
DH10B	,	O
bacteria	NN	O
(Life	VBD	O
Technologies,	IN	O
20	DT	O
ml).	NN	O
The	WDT	O
bacteria	VBP	O
and	VBN	O
vector	IN	O
mixture	NN	O
was	IN	O
then	JJ	O
electroporated	NN	O
as	MD	O
recommended	VB	O
by	TO	O
the	DT	O
manufacturer.	NN	O
Subsequently,	IN	O
SOC	NN	O
media	IN	O
(Life	RB	O
Technologies,	VBN	O
1	NN	O
ml)	.	O
was	.	O
added	NN	O
and	CC	O
the	NNP	O
mixture	NNP	O
was	IN	O
incubated	DT	O
at	JJ	O
37°	NN	O
C.	IN	O
for	NN	O
30	CD	O
minutes.	NN	O
The	VBD	O
transformants	VBN	O
were	IN	O
then	NN	O
plated	TO	O
onto	WDT	O
20	VBD	O
standard	VBN	O
150	JJ	O
mm	NNP	O
LB	NN	O
plates	NNP	O
containing	,	O
ampicillin	CD	O
and	.	O
incubated	DT	O
for	NN	O
16	CC	O
hours	NN	O
(37°	NN	O
C.).	VBD	O
Positive	RB	O
colonies	VBN	O
were	IN	O
scraped	VBN	O
off	IN	O
the	DT	O
plates	.	O
and	,	O
the	NNP	O
DNA	NNS	O
was	NNP	O
isolated	,	O
from	CD	O
the	)	O
bacterial	VBD	O
pellet	VBN	O
using	CC	O
standard	DT	O
protocols,	NN	O
e.g.	VBD	O
CsCl-gradient.	VBN	O
The	IN	O
purified	CD	O
DNA	NNP	O
was	IN	O
then	CD	O
carried	.	O
on	DT	O
to	NNS	O
the	VBD	O
yeast	RB	O
protocols	VBN	O
below.	IN	O
The	CD	O
yeast	JJ	O
methods	CD	O
were	NN	O
divided	NNP	O
into	VBZ	O
three	VBG	O
categories:	NN	O
(1)	CC	O
Transformation	VBN	O
of	IN	O
yeast	CD	O
with	NNS	O
the	CD	O
plasmid/cDNA	.	O
combined	JJ	O
vector;	NNS	O
(2)	VBD	O
Detection	VBN	O
and	RP	O
isolation	DT	O
of	NNS	O
yeast	CC	O
clones	DT	O
secreting	NN	O
amylase;	VBD	O
and	VBN	O
(3)	IN	O
PCR	DT	O
amplification	JJ	O
of	NN	O
the	VBG	O
insert	JJ	O
directly	,	O
from	.	O
the	.	O
yeast	DT	O
colony	JJ	O
and	NN	O
purification	VBD	O
of	RB	O
the	VBN	O
DNA	IN	O
for	TO	O
sequencing	DT	O
and	NN	O
further	NNS	O
analysis.	.	O
The	DT	O
yeast	NN	O
strain	NNS	O
used	VBD	O
was	VBN	O
HD56-5A	IN	O
(ATCC-90785).	CD	O
This	:	O
strain	)	O
has	NN	O
the	IN	O
following	NN	O
genotype:	IN	O
MAT	DT	O
alpha,	NN	O
ura3-52,	VBD	O
leu2-3,	:	O
leu2-112,	)	O
his3-11,	NN	O
his3-15,	CC	O
MAL+,	NN	O
SUC+,	IN	O
GAL+.	NN	O
Preferably,	NNS	O
yeast	VBG	O
mutants	:	O
can	CC	O
be	)	O
employed	NNP	O
that	NN	O
have	IN	O
deficient	DT	O
post-translational	NN	O
pathways.	RB	O
Such	IN	O
mutants	DT	O
may	NN	O
have	NN	O
translocation	CC	O
deficient	NN	O
alleles	IN	O
in	DT	O
sec71,	NN	O
sec72,	IN	O
sec62,	VBG	O
with	CC	O
truncated	JJ	O
sec71	.	O
being	DT	O
most	NN	O
preferred.	NN	O
Alternatively,	VBN	O
antagonists	VBD	O
(including	NNP	O
antisense	.	O
nucleotides	DT	O
and/or	NN	O
ligands)	VBZ	O
which	DT	O
interfere	JJ	O
with	:	O
the	NNP	O
normal	,	O
operation	,	O
of	,	O
these	,	O
genes,	,	O
other	,	O
proteins	,	O
implicated	,	O
in	.	O
this	,	O
post	JJ	O
translation	NNS	O
pathway	MD	O
(e.g.,	VB	O
SEC61p,	VBN	O
SEC72p,	DT	O
SEC62p,	VBP	O
SEC63p,	JJ	O
TDJ1p	JJ	O
or	.	O
SSA1p-4p)	JJ	O
or	NNS	O
the	MD	O
complex	VB	O
formation	NN	O
of	NN	O
these	NNS	O
proteins	IN	O
may	,	O
also	,	O
be	,	O
preferably	IN	O
employed	JJ	O
in	NN	O
combination	VBG	O
with	JJS	O
the	.	O
amylase-expressing	,	O
yeast.	NNS	O
Transformation	VBG	O
was	NN	O
performed	NNS	O
based	VBP	O
on	)	O
the	WDT	O
protocol	RB	O
outlined	IN	O
by	DT	O
Gietz	JJ	B
et	NN	I
al.,	IN	I
Nucl.	DT	I
Acid.	,	I
Res.,	JJ	I
20:1425	NNS	I
(1992).	VBN	I
Transformed	IN	O
cells	DT	O
were	NN	O
then	NN	O
inoculated	NN	O
from	,	O
agar	,	O
into	,	O
YEPD	,	O
complex	,	O
media	NNP	O
broth	CC	O
(100	)	O
ml)	CC	O
and	DT	O
grown	JJ	O
overnight	NN	O
at	IN	O
30°	DT	O
C.	NNS	O
The	MD	O
YEPD	RB	O
broth	VB	O
was	RB	O
prepared	VBN	O
as	IN	O
described	NN	O
in	IN	O
Kaiser	DT	B
et	JJ	I
al.,	.	I
Methods	NN	I
in	VBD	I
Yeast	VBN	I
Genetics,	VBN	I
Cold	IN	I
Spring	DT	I
Harbor	NN	I
Press,	VBN	I
Cold	IN	I
Spring	NNP	I
Harbor,	FW	I
N.Y.,	,	I
p.	.	I
207	.	I
(1994).	,	I
The	CD	O
overnight	.	O
culture	NNP	O
was	NNS	O
then	VBD	O
diluted	RB	O
to	VBN	O
about	IN	O
2×106	NN	O
cells/ml	IN	O
(approx.	NNP	O
OD600=0.1)	JJ	O
into	NNS	O
fresh	NN	O
YEPD	CD	O
broth	)	O
(500	CC	O
ml)	JJ	O
and	NN	O
regrown	IN	O
to	CD	O
1×107	NNP	O
cells/ml	DT	O
(approx.	NNP	O
OD600=0.4-0.5).	NN	O
The	VBD	O
cells	VBN	O
were	IN	O
then	VBN	O
harvested	IN	O
and	NNP	O
prepared	CC	O
for	,	O
transformation	NNP	O
by	IN	O
transfer	NNP	O
into	,	O
GS3	NNP	O
rotor	NNP	O
bottles	NNP	O
in	,	O
a	NNP	O
Sorval	NNP	O
GS3	,	O
rotor	,	O
at	VBZ	O
5,000	CD	O
rpm	.	O
for	DT	O
5	JJ	O
minutes,	NN	O
the	VBD	O
supernatant	RB	O
discarded,	VBN	O
and	TO	O
then	IN	O
resuspended	CD	O
into	NN	O
sterile	.	O
water,	)	O
and	IN	O
centrifuged	JJ	O
again	NNP	O
in	NN	O
50	CD	O
ml	)	O
falcon	CC	O
tubes	VBN	O
at	TO	O
3,500	CD	O
rpm	NN	O
in	.	O
a	.	O
Beckman	DT	O
GS-6KR	NNS	O
centrifuge.	VBD	O
The	RB	O
supernatant	VBN	O
was	CC	O
discarded	VBN	O
and	IN	O
the	NN	O
cells	IN	O
were	NN	O
subsequently	IN	O
washed	NNP	O
with	NN	O
LiAc/TE	NNS	O
(10	IN	O
ml,	DT	O
10	NNP	O
mM	NNP	O
Tris-HCl,	NN	O
1	IN	O
mM	CD	O
EDTA	NN	O
pH	IN	O
7.5,	CD	O
100	,	O
mM	DT	O
Li2OOCCH3),	NN	O
and	,	O
resuspended	CC	O
into	RB	O
LiAc/TE	VBD	O
(2.5	IN	O
ml).	JJ	O
Transformation	,	O
took	CC	O
place	VBD	O
by	RB	O
mixing	IN	O
the	CD	O
prepared	JJ	O
cells	NN	O
(100	NNS	O
μl)	IN	O
with	CD	O
freshly	NN	O
denatured	IN	O
single	DT	O
stranded	NNP	O
salmon	NNP	O
testes	.	O
DNA	DT	O
(Lofstrand	NN	O
Labs,	VBD	O
Gaithersburg,	VBN	O
Md.)	CC	O
and	DT	O
transforming	NNS	O
DNA	VBD	O
(1	RB	O
μg,	VBN	O
vol.	IN	O
<10	NNP	O
μl)	CD	O
in	,	O
microfuge	CD	O
tubes.	NN	O
The	,	O
mixture	CD	O
was	NN	O
mixed	NNP	O
briefly	NN	O
by	,	O
vortexing,	CD	O
then	NN	O
40%	,	O
PEG/TE	CC	O
(600	VBD	O
μl,	IN	O
40%	NNP	O
polyethylene	CD	O
glycol-4000,	.	O
10	NN	O
mM	VBD	O
Tris-HCl,	NN	O
1	IN	O
mM	VBG	O
EDTA,	DT	O
100	JJ	O
mM	NNS	O
Li2OOCCH3,	CD	O
pH	)	O
7.5)	IN	O
was	RB	O
added.	VBN	O
This	JJ	O
mixture	VBD	O
was	JJ	O
gently	NNS	O
mixed	NNP	O
and	NNP	O
incubated	,	O
at	,	O
30°	)	O
C.	CC	O
while	VBG	O
agitating	NNP	O
for	CD	O
30	,	O
minutes.	.	O
The	CD	O
cells	)	O
were	IN	O
then	NN	O
heat	.	O
shocked	DT	O
at	NN	O
42°	VBD	O
C.	JJ	O
for	NN	O
15	IN	O
minutes,	,	O
and	RB	O
the	NN	O
reaction	NNP	O
vessel	CD	O
centrifuged	,	O
in	NN	O
a	JJ	O
microfuge	,	O
at	CD	O
12,000	NN	O
rpm	,	O
for	CD	O
5-10	NN	O
seconds,	,	O
decanted	CD	O
and	NN	O
resuspended	,	O
into	RB	O
TE	)	O
(500	VBD	O
μl,	.	O
10	DT	O
mM	NN	O
Tris-HCl,	VBD	O
1	RB	O
mM	JJ	O
EDTA	CC	O
pH	VBN	O
7.5)	IN	O
followed	CD	O
by	NNP	O
recentrifugation.	IN	O
The	VBG	O
cells	IN	O
were	CD	O
then	.	O
diluted	DT	O
into	NNS	O
TE	VBD	O
(1	RB	O
ml)	NN	O
and	VBD	O
aliquots	IN	O
(200	CD	O
μl)	NNP	O
were	IN	O
spread	CD	O
onto	,	O
the	CC	O
selective	DT	O
media	NN	O
previously	NN	O
prepared	VBN	O
in	IN	O
150	DT	O
mm	NN	O
growth	IN	O
plates	CD	O
(VWR).	NN	O
Alternatively,	IN	O
instead	JJ	O
of	,	O
multiple	VBN	O
small	CC	O
reactions,	VBN	O
the	IN	O
transformation	NNP	O
was	CD	O
performed	,	O
using	CD	O
a	NN	O
single,	,	O
large	CD	O
scale	NN	O
reaction,	NNP	O
wherein	VBZ	O
reagent	)	O
amounts	VBN	O
were	IN	O
scaled	.	O
up	DT	O
accordingly.	NNS	O
The	VBD	O
selective	RB	O
media	VBN	O
used	IN	O
was	NNP	O
a	CD	O
synthetic	)	O
complete	CC	O
dextrose	NNS	O
agar	CD	O
lacking	)	O
uracil	VBD	O
(SCD-Ura)	VBN	O
prepared	IN	O
as	DT	O
described	JJ	O
in	NNS	O
Kaiser	RB	B
et	VBN	I
al.,	IN	I
Methods	CD	I
in	JJ	I
Yeast	NN	I
Genetics,	NNS	I
Cold	.	I
Spring	,	I
Harbor	RB	I
Press,	IN	I
Cold	JJ	I
Spring	JJ	I
Harbor,	,	I
N.Y.,	DT	I
p.	NN	I
208-210	VBD	I
(1994).	VBN	I
Transformants	VBG	O
were	DT	O
grown	,	O
at	JJ	O
30°	NN	O
C.	,	O
for	JJ	O
2-3	NN	O
days.	NNS	O
The	VBD	O
detection	VBN	O
of	RP	O
colonies	.	O
secreting	DT	O
amylase	JJ	O
was	NNS	O
performed	VBN	O
by	VBD	O
including	DT	O
red	JJ	O
starch	JJ	O
in	NN	O
the	NN	O
selective	VBG	O
growth	JJ	O
media.	)	O
Starch	VBD	O
was	IN	O
coupled	VBN	O
to	IN	O
the	NNP	O
red	CC	O
dye	,	O
(Reactive	NNP	O
Red-120,	IN	O
Sigma)	NNP	O
as	,	O
per	NNP	O
the	NNP	O
procedure	NNP	O
described	,	O
by	NNP	O
Biely	NNP	B
et	,	I
al.,	,	I
Anal.	VBZ	I
Biochem.,	CD	I
172:176-179	.	I
(1988).	NNS	I
The	VBD	O
coupled	VBN	O
starch	IN	O
was	CD	O
incorporated	NNP	O
into	IN	O
the	JJ	O
SCD-Ura	.	O
agar	DT	O
plates	NN	O
at	IN	O
a	NNS	O
final	VBG	O
concentration	NN	O
of	VBD	O
0.15%	VBN	O
(w/v),	IN	O
and	VBG	O
was	JJ	O
buffered	NN	O
with	IN	O
potassium	DT	O
phosphate	JJ	O
to	NN	O
a	.	O
pH	NN	O
of	VBD	O
7.0	VBN	O
(50-100	TO	O
mM	DT	O
final	JJ	O
concentration).	NN	O
The	JJ	O
positive	,	O
colonies	)	O
were	IN	O
picked	IN	O
and	DT	O
streaked	NN	O
across	VBN	O
fresh	IN	O
selective	NNP	O
media	FW	O
(onto	,	O
150	.	O
mm	,	O
plates)	CD	O
in	.	O
order	DT	O
to	VBN	O
obtain	NN	O
well	VBD	O
isolated	VBN	O
and	IN	O
identifiable	DT	O
single	NNP	O
colonies.	NN	O
Well	NNS	O
isolated	IN	O
single	DT	O
colonies	JJ	O
positive	NN	O
for	IN	O
amylase	NN	O
secretion	,	O
were	CC	O
detected	VBD	O
by	VBN	O
direct	IN	O
incorporation	NN	O
of	NN	O
red	TO	O
starch	DT	O
into	NN	O
buffered	IN	O
SCD-Ura	CD	O
agar.	JJ	O
Positive	NN	O
colonies	JJ	O
were	.	O
determined	DT	O
by	JJ	O
their	NNS	O
ability	VBD	O
to	VBN	O
break	CC	O
down	VBN	O
starch	IN	O
resulting	JJ	O
in	JJ	O
a	NNS	O
clear	IN	O
halo	CD	O
around	NNS	O
the	)	O
positive	IN	O
colony	NN	O
visualized	TO	O
directly.	VB	O
4.	RB	O
Isolation	JJ	O
of	CC	O
DNA	JJ	O
by	JJ	O
PCR	.	O
Amplification	RB	O
When	JJ	O
a	JJ	O
positive	NNS	O
colony	JJ	O
was	IN	O
isolated,	JJ	O
a	NN	O
portion	VBD	O
of	VBN	O
it	IN	O
was	JJ	O
picked	NN	O
by	IN	O
a	JJ	O
toothpick	NN	O
and	IN	O
diluted	VBN	O
into	NNP	O
sterile	.	O
water	JJ	O
(30	NNS	O
μl)	VBD	O
in	VBN	O
a	IN	O
96	PRP$	O
well	NN	O
plate.	TO	O
At	VB	O
this	RP	O
time,	NN	O
the	VBG	O
positive	IN	O
colonies	DT	O
were	JJ	O
either	NN	O
frozen	IN	O
and	DT	O
stored	JJ	O
for	NN	O
subsequent	VBN	O
analysis	.	O
or	.	O
immediately	NN	O
amplified.	IN	O
An	NN	O
aliquot	IN	O
of	NNP	O
cells	NNP	O
(5	WRB	O
μl)	DT	O
was	JJ	O
used	NN	O
as	VBD	O
a	,	O
template	DT	O
for	NN	O
the	IN	O
PCR	PRP	O
reaction	VBD	O
in	VBN	O
a	IN	O
25	DT	O
μl	NN	O
volume	CC	O
containing	VBD	O
0.5	IN	O
μl	JJ	O
Klentaq	NN	O
(Clontech,	CD	O
Palo	)	O
Alto,	IN	O
Calif.);	DT	O
4.0	CD	O
μl	RB	O
10	.	O
mM	IN	O
dNTP's	DT	O
(Perkin	,	O
Elmer-Cetus);	DT	O
2.5	JJ	O
μl	NNS	O
Kentaq	VBD	O
buffer	RB	O
(Clontech);	JJ	O
0.25	CC	O
μl	VBD	O
forward	IN	O
oligo	JJ	O
1;	NN	O
0.25	CC	O
μl	RB	O
reverse	.	O
oligo	DT	O
2;	NN	O
12.5	IN	O
μl	NNS	O
distilled	CD	O
water.	)	O
The	VBD	O
sequence	VBN	O
of	IN	O
the	DT	O
forward	NN	O
oligonucleotide	IN	O
1	DT	O
was:	NNP	O
The	NN	O
sequence	IN	O
of	DT	O
reverse	CD	O
oligonucleotide	NN	O
2	NN	O
was:	VBG	O
PCR	CD	O
was	JJ	O
then	NNP	O
performed	,	O
as	NNP	O
follows:	,	O
The	:	O
underlined	CD	O
regions	$	O
of	CD	O
the	NN	O
oligonucleotides	POS	O
annealed	NNP	O
to	:	O
the	CD	O
ADH	NN	O
promoter	NNP	O
region	NN	O
and	:	O
the	CD	O
amylase	FW	O
region,	RB	O
respectively,	VBZ	O
and	:	O
amplified	CD	O
a	JJ	O
307	NN	O
bp	NN	O
region	:	O
from	CD	O
vector	NN	O
pSST-AMY.0	JJ	O
when	.	O
no	DT	O
insert	NN	O
was	IN	O
present.	DT	O
Typically,	NN	O
the	IN	O
first	CD	O
18	:	O
nucleotides	DT	O
of	NN	O
the	IN	O
5′	JJ	O
end	IN	O
of	CD	O
these	:	O
oligonucleotides	NN	O
contained	VBD	O
annealing	RB	O
sites	VBN	O
for	IN	O
the	:	O
sequencing	DT	O
primers.	JJ	O
Thus,	NNS	O
the	IN	O
total	DT	O
product	NNS	O
of	VBD	O
the	TO	O
PCR	DT	O
reaction	NNP	O
from	NN	O
an	NN	O
empty	CC	O
vector	DT	O
was	JJ	O
343	,	O
bp.	,	O
However,	CC	O
signal	VBD	O
sequence-fused	DT	O
cDNA	CD	O
resulted	JJ	O
in	NN	O
considerably	IN	O
longer	NN	O
nucleotide	NN	O
sequences.	WRB	O
Following	DT	O
the	NN	O
PCR,	VBD	O
an	.	O
aliquot	,	O
of	DT	O
the	JJ	O
reaction	CD	O
(5	NNS	O
μl)	IN	O
was	DT	O
examined	CD	O
by	NN	O
agarose	IN	O
gel	DT	O
electrophoresis	NNS	O
in	VBD	O
a	VBG	O
1%	NNS	O
agarose	IN	O
gel	DT	O
using	NN	O
a	.	O
Tris-Borate-EDTA	,	O
(TBE)	DT	O
buffering	JJ	O
system	NN	O
as	IN	O
described	DT	O
by	NNP	O
Sambrook	NN	O
et	IN	O
al.,	DT	O
supra.	JJ	O
Clones	NN	O
resulting	VBD	O
in	CD	O
a	.	O
single	,	O
strong	JJ	O
PCR	JJ	O
product	NN	O
larger	VBD	O
than	IN	O
400	RB	O
bp	RBR	O
were	JJ	O
further	.	O
analyzed	VBG	O
by	DT	O
DNA	,	O
sequencing	DT	O
after	NN	O
purification	IN	O
with	DT	O
a	NN	O
96	CD	O
Qiaquick	)	O
PCR	VBD	O
clean-up	VBN	O
column	IN	O
(Qiagen	JJ	O
Inc.,	JJ	O
Chatsworth,	NN	O
Calif.).	IN	O
5.	DT	O
Identification	NN	O
of	JJ	O
Full-Length	NN	O
Clone	VBG	O
A	DT	O
cDNA	NNP	O
sequence	)	O
was	VBG	O
isolated	NN	O
in	IN	O
the	VBN	O
above	IN	O
screen	NNP	O
and	FW	O
compared	,	O
to	.	O
a	NNS	O
variety	VBG	O
of	IN	O
expressed	DT	O
sequence	JJ	O
tag	JJ	O
(EST)	NNP	O
databases	NN	O
which	JJR	O
included	IN	O
public	CD	O
EST	NNS	O
databases	VBD	O
(e.g.,	RB	O
GenBank,	VBN	O
Merck/Wash.	IN	O
U.)	NNP	O
And	VBG	O
a	IN	O
proprietary	NN	O
EST	IN	O
DNA	DT	O
database	CD	O
(LIFESEQ®,	NNP	O
Incyte	NNP	O
Pharmaceuticals,	JJ	O
Palo	NN	O
Alto,	NNP	O
Calif.)	,	O
to	,	O
identify	.	O
existing	.	O
homologies.	NN	O
The	IN	O
homology	NNP	O
search	NNP	O
was	NNP	O
performed	NN	O
using	NN	O
the	VBD	O
computer	VBN	O
program	IN	O
BLAST	DT	O
or	JJ	O
BLAST2	NN	O
Altshul	CC	B
et	VBN	I
al.,	TO	I
Methods	DT	I
in	NN	I
Enzymology	IN	I
266:460-480	JJ	I
(1996)).(	NN	O
Those	NN	O
comparisons	)	O
resulting	VBZ	O
in	WDT	O
a	VBD	O
BLAST	JJ	O
score	NNP	O
of	NNS	O
70	,	O
(or	,	O
in	.	O
some	)	O
cases	CC	O
90)	DT	O
or	JJ	O
greater	NNP	O
that	NN	O
did	NN	O
not	,	O
encode	NNP	O
known	,	O
proteins	NNP	O
were	,	O
clustered	)	O
and	TO	O
assembled	VB	O
into	VBG	O
consensus	.	O
DNA	DT	O
sequences	NN	O
with	NN	O
the	VBD	O
program	VBN	O
“phrap”	VBG	O
(Phil	DT	O
Green,	NN	O
University	NN	O
of	NNP	O
Washington,	CC	O
Seattle	NNP	O
Wash.).	NNP	O
The	RB	O
consensus	,	O
sequence	NNS	O
obtained	IN	O
is	NNP	O
herein	CD	O
designated:	.	O
“DNA76621”.	DT	O
Based	NNS	O
on	VBG	O
the	IN	O
DNA76621	DT	O
sequence,	NNP	O
oligonucleotide	NN	O
probes	IN	O
were	CD	O
generated	CC	O
and	IN	O
used	DT	O
to	NNS	O
screen	)	O
a	CC	O
human	JJR	O
testis	WDT	O
library	VBD	O
prepared	RB	O
as	VB	O
described	JJ	O
in	NNS	O
paragraph	VBD	O
1	VBN	O
above.	CC	O
The	VBN	O
cloning	IN	O
vector	NN	O
was	NNP	O
pRK5B	VBZ	O
(pRK5B	IN	O
is	DT	O
a	NN	O
precursors	NNP	O
of	NNP	O
pRK5D	,	O
that	NNP	O
does	IN	O
not	,	O
contain	NNP	O
the	.	O
SfiI	DT	O
site;	NN	O
see	NN	O
Holmes	VBN	B
et	VBZ	I
al.,	JJ	I
Science	:	I
253:1278-1280	.	I
(1991)),and	VBN	O
the	IN	O
cDNA	DT	O
size	NNP	O
cut	,	O
was	IN	O
less	NNS	O
than	VBD	O
2800	VBN	O
bp.	CC	O
PCR	VBN	O
primers	TO	O
(forward	VB	O
and	DT	O
reverse)	JJ	O
were	NN	O
synthesized:	NN	O
Additionally,	VBD	O
a	IN	O
synthetic	VBN	O
oligonucleotide	IN	O
hybridization	NN	O
probe	CD	O
was	.	O
constructed	DT	O
fro	NN	O
the	NN	O
DNA76621	VBD	O
sequence	JJ	O
which	NN	O
had	VBZ	O
the	DT	O
following	NNS	O
nucleotide	IN	O
sequence:	NN	O
In	WDT	O
order	VBZ	O
to	RB	O
screen	VB	O
several	DT	O
libraries	NNP	O
for	:	O
a	VB	O
full-length	NNP	O
clone,	FW	O
DNA	,	O
from	NNP	O
the	CD	O
libraries	,	O
was	CC	O
screened	DT	O
by	NN	O
PCR	NN	O
amplification	NN	O
with	VBD	O
the	JJR	O
PCR	IN	O
primer	CD	O
pair	.	O
identified	NNP	O
above.	NNS	O
A	RB	O
positive	CC	O
library	)	O
was	VBD	O
then	:	O
used	,	O
to	DT	O
isolate	JJ	O
clones	NN	O
encoding	NN	O
the	NN	O
PRO1885	VBD	O
gene	VBN	O
using	PDT	O
the	DT	O
probe	NNP	O
oligonucleotide	NN	O
and	WDT	O
one	VBD	O
of	DT	O
the	JJ	O
PCR	JJ	O
primers.	:	O
A	IN	O
full-length	NN	O
clone	TO	O
was	VB	O
identified	JJ	O
(designated	NNS	O
DNA79302-2521)	IN	O
that	DT	O
contained	JJ	O
a	,	O
single	NN	O
open	IN	O
reading	DT	O
frame	NNS	O
with	VBD	O
an	VBN	O
apparent	IN	O
translational	NNP	O
initiation	NN	O
site	IN	O
at	DT	O
nucleotide	NNP	O
positions	NN	O
40-42,	NN	O
and	VBN	O
a	.	O
stop	DT	O
signal	JJ	O
at	NN	O
nucleotide	VBD	O
positions	RB	O
1705-1707	VBN	O
(FIG.	TO	O
19;	VB	O
SEQ	NNS	O
ID	VBG	O
NO:19).	DT	O
The	NNP	O
predicted	NN	O
polypeptide	VBG	O
precursor	DT	O
is	NN	O
555	NN	O
amino	CC	O
acids	CD	O
long	IN	O
(FIG.	DT	O
20;	NNP	O
SEQ	.	O
ID	DT	O
NO:20)	JJ	O
and	NN	O
has	VBD	O
a	VBN	O
calculated	VBN	O
molecular	)	O
weight	WDT	O
of	VBD	O
approximately	DT	O
63913	JJ	O
daltons	JJ	O
and	NN	O
an	NN	O
estimated	IN	O
pI	DT	O
of	JJ	O
approximately	JJ	O
4.99.	NN	O
Clone	NN	O
DNA79302-2521	IN	O
(UNQ868)	JJ	O
has	NNS	O
been	,	O
deposited	CC	O
with	DT	O
the	JJ	O
ATCC	NN	O
and	IN	O
is	JJ	O
assigned	NNS	O
ATCC	JJ	O
deposit	.	O
no.	:	O
203545	NNP	O
on	NNP	O
Dec.	.	O
22,	DT	O
1998.	JJ	O
An	NN	O
analysis	NN	O
of	VBZ	O
the	CD	O
Dayhoff	JJ	O
database	NNS	O
(version	RB	O
35.45	.	O
Swiss	:	O
Prot	NNP	O
35),	NNP	O
using	)	O
a	CC	O
WU-BLAST2	VBZ	O
sequence	DT	O
alignment	JJ	O
analysis	JJ	O
of	NN	O
the	IN	O
full-length	RB	O
sequence	CD	O
shown	NNS	O
in	CC	O
FIG.	DT	O
20	JJ	O
(SEQ	NN	O
ID	IN	O
NO:20);	RB	O
evidenced	.	O
sequence	CD	O
identity	NNP	O
between	)	O
the	VBZ	O
PRO1885	VBN	O
amino	VBN	O
acid	IN	O
sequence	DT	O
and	NNP	O
the	CC	O
following	VBZ	O
Dayhoff	VBN	O
sequences:	NNP	O
A31567—1,	NN	O
P_R10426,	.	O
ACE_HUMAN,	CD	O
P_R04111,	IN	O
A00914—1,	NNP	O
ACE_DROME,	,	O
P_R70013,	.	O
S81361—1,	DT	O
S57157	NN	O
and	IN	O
P_R65207.	DT	O
Example	NNP	O
13	NN	O
Generation	NN	O
and	CD	O
Analysis	JJ	O
of	NNP	O
Mice	,	O
Comprising	VBG	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	NN	O
or	VBN	O
PRO1885	IN	O
Gene	.	O
Disruptions	CD	O
To	NNP	O
investigate	NNP	O
the	:	O
role	VBN	O
of	NN	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NNP	O
PRO4342,	NN	O
PRO7423,	NN	O
PRO10096,	NN	O
PRO21384,	CC	O
PRO353	DT	O
or	JJ	O
PRO1885	NNP	O
polypeptides,	:	O
disruptions	,	O
in	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	.	O
or	RB	O
PRO1885	CD	O
genes	NNP	O
were	CC	O
produced	NNP	O
by	IN	O
homologous	NNP	O
recombination.	NNP	O
Specifically,	,	O
transgenic	,	O
mice	,	O
comprising	,	O
disruptions	,	O
in	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	NNP	O
PRO10096,	NNP	O
PRO21384,	TO	O
PRO353	VB	O
or	DT	O
PRO1885	NN	O
genes	IN	O
(i.e.,	,	O
knockout	,	O
mice)	,	O
were	,	O
created	,	O
by	,	O
either	,	O
gene	,	O
targeting	NNP	O
or	CC	O
gene	NNP	O
trapping.	,	O
Mutations	NNS	O
were	IN	O
confirmed	,	O
by	,	O
southern	,	O
blot	,	O
analysis	,	O
to	,	O
confirm	,	O
correct	,	O
targeting	NNP	O
on	CC	O
both	NNP	O
the	NNS	O
5′	VBD	O
and	VBN	O
3′	IN	O
ends.	JJ	O
Gene-specific	.	O
genotyping	,	O
was	JJ	O
also	NN	O
performed	VBG	O
by	NNS	O
genomic	IN	O
PCR	,	O
to	,	O
confirm	,	O
the	,	O
loss	,	O
of	,	O
the	,	O
endogenous	,	O
native	NNP	O
transcript	CC	O
as	NNP	O
demonstrated	NNS	O
by	,	O
RT-PCR	IN	O
using	)	O
primers	VBD	O
that	VBN	O
anneal	IN	O
to	DT	O
exons	NN	O
flanking	VBG	O
the	CC	O
site	NN	O
of	.	O
insertion.	NNS	O
Targeting	VBD	O
vectors	VBN	O
were	IN	O
electroporated	JJ	O
into	NN	O
129	NN	O
strain	TO	O
ES	VB	O
cells	JJ	O
and	VBG	O
targeted	IN	O
clones	CC	O
were	DT	O
identified.	CD	O
Targeted	CC	O
clones	CD	O
were	.	O
microinjected	JJ	O
into	NN	O
host	VBD	O
blastocysts	RB	O
to	VBN	O
produce	IN	O
chimeras.	JJ	O
Chimeras	NNP	O
were	TO	O
bred	VB	O
with	DT	O
C57	NN	O
animals	IN	O
to	DT	O
produce	JJ	O
F1	JJ	O
heterozygotes.	NN	O
Heterozygotes	IN	O
were	VBN	O
intercrossed	IN	O
to	NNP	O
produce	VBG	O
F2	NNS	O
wildtype,	WDT	O
heterozygote	VBP	O
and	TO	O
homozygote	NNS	O
cohorts	VBG	O
which	DT	O
were	NN	O
used	IN	O
for	.	O
phenotypic	VBG	O
analysis.	NNS	O
Rarely,	VBD	O
if	VBN	O
not	IN	O
enough	CD	O
F1	NN	O
heterozygotes	NNP	O
were	NNS	O
produced,	CC	O
the	VBN	O
F1	NNS	O
hets	VBD	O
were	.	O
bred	VBN	O
to	NNS	O
wildtype	VBD	O
C57	VBN	O
mice	IN	O
to	NN	O
produce	NNS	O
sufficient	TO	O
heterozygotes	VB	O
to	.	O
breed	NNS	O
for	VBD	O
cohorts	VBN	O
to	IN	O
be	NNP	O
analyzed	NNS	O
for	TO	O
a	VB	O
phenotype.	NNP	O
All	.	O
phenotypic	NNS	O
analysis	VBD	O
was	VBN	O
performed	TO	O
from	VB	O
12-16	NNP	O
weeks	,	O
after	NN	O
birth.	CC	O
Overall	NN	O
Summary	NNS	O
of	WDT	O
Results:	VBD	O
A.	VBN	O
Generation	IN	O
and	NN	O
Analysis	.	O
of	,	O
Mice	IN	O
Comprising	RB	O
DNA33786-1132	JJ	O
(UNQ201)	NNP	O
Gene	NNS	O
Disruptions	VBD	O
In	,	O
these	DT	O
knockout	NNP	O
experiments,	NNS	O
the	VBD	O
gene	VBN	O
encoding	TO	O
PRO227	VB	O
polypeptides	NNP	O
(designated	NN	O
as	TO	O
DNA33786-1132	VB	O
(UNQ201)	JJ	O
was	NNS	O
disrupted.	TO	O
The	VB	O
gene	IN	O
specific	NNS	O
information	TO	O
for	VB	O
these	VBN	O
studies	IN	O
is	DT	O
as	.	O
follows:	DT	O
the	NN	O
mutated	NN	O
mouse	VBD	O
gene	VBN	O
corresponds	IN	O
to	JJ	O
nucleotide	NNS	O
reference:	IN	O
NM—181074:	.	O
or	JJ	O
Mus	NNP	O
musculus	IN	O
RIKEN	:	O
cDNA	.	O
4930471K13	NN	O
gene	CC	O
(4930471K13Rik);	NNP	O
protein	IN	O
reference:	NNP	O
NP—851419	NNP	O
or	NNP	O
Mus	)	O
musculus	NNP	O
RIKEN	NNP	O
cDNA	IN	O
4930471K13;	DT	O
the	NN	O
human	,	O
gene	DT	O
sequence	NN	O
reference:	VBG	O
BC011057	NNP	O
or	NNS	O
homo	VBN	O
sapiens	IN	O
hypothetical	NNP	O
protein	)	O
FLJ14594	VBD	O
(cDNA	.	O
clone	DT	O
MGC:17422	NN	O
IMAGE:	JJ	O
4214343);	NN	O
the	IN	O
human	DT	O
protein	NNS	O
sequence	VBZ	O
corresponds	IN	O
to	:	O
reference:	DT	O
AAH11057	VBN	O
or	NN	O
Homo	NN	O
sapiens	NNS	O
hypothetical	TO	O
protein	JJ	O
FLJ14594.	:	O
Mutation	:	O
Specific	CC	O
Information	NNP	O
corresponds	CC	O
to	NNP	O
Homologous	VBP	O
Recombination	CD	O
(standard)	NN	O
wherein	:	O
Exon	JJ	O
2	:	O
was	NN	O
targeted	CC	O
(NM—181074).	NNP	O
The	CC	O
targeted	NNP	O
mouse	VBP	O
gene	:	O
is	DT	O
represented	JJ	O
by	NN	O
NCBI	NN	O
accession	:	O
NM—181074,	NNP	O
which	CC	O
is	NN	O
an	JJ	O
ortholog	JJ	O
of	NN	O
human	NNP	O
hypothetical	VB	O
protein	NN	O
FLJ14594.	NNP	O
FLJ14594	:	O
has	:	O
features	DT	O
consistent	JJ	O
with	NN	O
a	NN	O
type	NNS	O
I	TO	O
plasma	:	O
membrane	NNP	O
protein;	CC	O
contains	NNP	O
leucine-rich	JJ	O
repeats,	JJ	O
an	NN	O
immunoglobulin	.	O
(Ig)-like	NNP	O
domain,	NNP	O
a	NNP	O
transmembrane	VBZ	O
segment,	TO	O
and	NNP	O
possibly	NNP	O
a	)	O
short	NN	O
cytoplasmic	NNP	O
C	CD	O
terminus.	VBD	O
The	VBN	O
hypothetical	.	O
protein	DT	O
belongs	VBN	O
to	NN	O
a	NN	O
gene	VBZ	O
family	VBN	O
comprised	IN	O
of	NNP	O
three	NN	O
members,	,	O
all	WDT	O
having	VBZ	O
no	DT	O
known	NN	O
function	IN	O
(EnsEMBL	JJ	O
protein	JJ	O
family	NN	O
ENSF00000002632).	.	O
Both	NNP	O
leucine-rich	VBZ	O
repeats	NNS	O
and	JJ	O
Ig-like	IN	O
domains	DT	O
are	NN	O
usually	PRP	O
involved	VBP	O
in	JJ	O
protein-protein	:	O
interactions	VBZ	O
and	JJ	O
found	,	O
in	DT	O
a	NN	O
wide	NN	O
variety	,	O
of	DT	O
proteins	NN	O
(Pfam	,	O
PF00560	CC	O
and	RB	O
PF00047).	DT	O
The	JJ	O
domain	JJ	O
organization	NNP	O
and	.	O
predicted	DT	O
cell	JJ	O
location	NN	O
(plasma	NNS	O
membrane)	TO	O
of	DT	O
this	NN	O
hypothetical	NN	O
protein	VBN	O
suggests	IN	O
that	CD	O
it	,	O
may	DT	O
function	VBG	O
as	DT	O
a	VBN	O
cell	NN	O
adhesion	NNP	O
molecule,	VBP	O
receptor,	NN	O
or	.	O
ligand.	DT	O
Targeted	JJ	O
or	NNS	O
gene	CC	O
trap	JJ	O
mutations	NNS	O
were	VBP	O
generated	RB	O
in	VBN	O
strain	IN	O
129SvEvBrd-derived	JJ	O
embryonic	NNS	O
stem	CC	O
(ES)	VBN	O
cells.	IN	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	IN	O
bred	NNS	O
to	NNP	O
C57BL/6J	NNP	O
albino	CC	O
mice	.	O
to	DT	O
generate	NN	O
F1	NN	O
heterozygous	CC	O
animals.	VBD	O
These	NN	O
progeny	NN	O
were	JJ	O
intercrossed	)	O
to	IN	O
generate	DT	O
F2	JJ	O
wild	NN	O
type,	VBZ	O
heterozygous,	IN	O
and	PRP	O
homozygous	MD	O
mutant	VB	O
progeny.	IN	O
On	DT	O
rare	NN	O
occasions,	NN	O
for	,	O
example	,	O
when	CC	O
very	.	O
few	VBN	O
F1	CC	O
mice	NN	O
were	JJ	O
obtained	NNS	O
from	VBD	O
the	VBN	O
chimera,	IN	O
F1	JJ	O
heterozygous	JJ	O
mice	JJ	O
were	NN	O
crossed	)	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
Expression	VBD	O
of	VBN	O
the	TO	O
target	VB	O
gene	NNP	O
was	JJ	O
detected	,	O
in	,	O
embryonic	CC	O
stem	JJ	O
(ES)	NN	O
cells	.	O
and	IN	O
in	JJ	O
all	,	O
13	IN	O
adult	NN	O
tissue	WRB	O
samples	RB	O
tested	JJ	O
by	NNP	O
RT-PCR,	NN	O
except	VBD	O
bone,	VBN	O
small	IN	O
intestine	DT	O
and	,	O
colon,	NNP	O
and	JJ	O
adipose.	NNS	O
Disruption	VBD	O
of	VBN	O
the	TO	O
target	CD	O
gene	JJ	O
was	NN	O
confirmed	TO	O
by	VB	O
Southern	JJ	O
hybridization	JJ	O
analysis.	NNS	O
Phenotypic	IN	O
analysis	DT	O
was	NN	O
performed	TO	O
on	VB	O
mice	DT	O
from	NNP	O
this	.	O
generation	NN	O
as	IN	O
described	DT	O
below.	NN	O
1.	NN	O
Overall	VBD	O
Phenotypic	VBN	O
Analysis	IN	O
(for	JJ	O
Disrupted	NN	O
Gene:	)	O
DNA33786-1132	NNS	O
(UNQ201)	CC	O
(a)	IN	O
Overall	DT	O
Phenotypic	CD	O
Summary:	NNS	O
Mutation	NN	O
of	NNS	O
the	VBN	O
gene	IN	O
encoding	,	O
the	IN	O
ortholog	,	O
of	JJ	O
human	NN	O
hypothetical	CC	O
protein	,	O
FLJ14594	CC	O
(FLJ14594)	.	O
resulted	NN	O
in	IN	O
growth	DT	O
retardation	NN	O
in	NN	O
(−/−)	VBD	O
mice.	VBN	O
The	IN	O
homozygous	NNP	O
mutant	NN	O
mice	.	O
were	NNP	O
smaller	NN	O
than	VBD	O
their	VBN	O
wild-type	IN	O
littermates,	NN	O
exhibiting	IN	O
decreased	DT	O
mean	NN	O
body	IN	O
length,	VBN	O
total	.	O
tissue	.	O
mass,	JJ	O
and	NNP	O
lean	NNP	O
body	IN	O
mass.	VBN	O
The	:	O
(−/−)	NNP	O
mice	)	O
also	)	O
exhibited	JJ	O
a	NNP	O
decreased	:	O
bone	NN	O
mineral-related	IN	O
measurements.	DT	O
Both	NN	O
serum	VBG	O
cholesterol	DT	O
and	NN	O
triglycerides	IN	O
were	JJ	O
elevated	JJ	O
in	NN	O
(−/−)	NNP	O
mutant	)	O
mice.	VBD	O
Gene	IN	O
disruption	NN	O
was	NN	O
confirmed	IN	O
by	)	O
Southern	.	O
blot.	DT	O
(b)	JJ	O
Bone	JJ	O
Metabolism:	NN	O
Radiology	VBD	O
Phenotypic	JJR	O
Analysis	IN	O
In	PRP$	O
the	JJ	O
area	,	O
of	VBG	O
bone	VBN	O
metabolism,	JJ	O
targets	NN	O
were	,	O
identified	JJ	O
herein	NN	O
for	,	O
the	CC	O
treatment	JJ	O
of	NN	O
arthritis,	.	O
osteoporosis,	DT	O
osteopenia	)	O
and	NN	O
osteopetrosis	RB	O
as	VBD	O
well	DT	O
as	JJ	O
identifying	NN	O
targets	JJ	O
that	.	O
promote	DT	O
bone	JJ	O
healing.	NN	O
Tests	CC	O
included:	NNS	O
DEXA	VBD	O
for	VBN	O
measurement	IN	O
of	)	O
bone	NN	O
mineral	.	O
density	NNP	O
on	NN	O
femur	VBD	O
and	VBN	O
vertebra	IN	O
MicroCT	NNP	O
for	.	O
very	)	O
high	FW	O
resolution	:	O
and	NNP	O
very	NNP	O
high	NNP	O
sensitivity	IN	O
measurements	DT	O
of	NN	O
bone	IN	O
mineral	NN	O
density	,	O
for	NNS	O
both	VBD	O
trabecular	VBN	O
and	NN	O
cortical	IN	O
bone.	DT	O
Dexa	NN	O
Analysis—Test	IN	O
Description:	,	O
Procedure:	,	O
A	NN	O
cohort	CC	O
of	NN	O
4	RB	O
wild	RB	O
type,	IN	O
4	VBG	O
heterozygotes	NNS	O
and	WDT	O
8	VBP	O
homozygotes	NN	O
were	.	O
tested	NNS	O
in	:	O
this	NNP	O
assay.	IN	O
Dual	NN	O
Energy	IN	O
X-ray	JJ	O
Absorptiometry	JJ	O
(DEXA)	NN	O
has	IN	O
been	NN	O
used	CC	O
successfully	NN	O
to	NNP	O
identify	IN	O
changes	RB	O
in	JJ	O
bone.	NN	O
Anesthetized	CC	O
animals	RB	O
were	JJ	O
examined	NN	O
and	NNS	O
bone	IN	O
mineral	JJ	O
content	JJ	O
(BMC),	NN	O
BMC/LBM	IN	O
ratios,	DT	O
volumetric	JJ	O
bone	CC	O
mineral	JJ	O
density	.	O
(vBMD),	NNP	O
total	NNP	O
body	:	O
BMD,	:	O
femur	DT	O
BMD	NN	O
and	IN	O
vertebra	CD	O
BMD	JJ	O
were	,	O
measured.	CD	O
The	NNS	O
mouse	CC	O
was	CD	O
anesthetized	NNS	O
by	VBD	O
intraperitoneal	VBN	O
injection	IN	O
of	DT	O
Avertin	.	O
(1.25%	NNP	O
2,2,2,-tribromoethanol,	NNP	O
20	JJ	O
ml/kg	NNP	O
body	)	O
weight),	VBZ	O
body	VBN	O
length	VBN	O
and	RB	O
weight	TO	O
were	VB	O
measured,	NNS	O
and	IN	O
then	.	O
the	VBN	O
mouse	NNS	O
was	VBD	O
placed	VBN	O
in	CC	O
a	JJ	O
prone	NN	O
position	NN	O
on	,	O
the	NNP	O
platform	,	O
of	JJ	O
the	NN	O
PIXImus™	JJ	O
Densitometer	NN	O
(Lunar	,	O
Inc.)	JJ	O
for	NN	O
a	,	O
DEXA	NN	O
scan.	NNP	O
Using	CC	O
Lunar	JJ	O
PIXImus	NNP	O
software,	VBD	O
the	.	O
bone	DT	O
mineral	NN	O
density	VBD	O
(BMD)	VBN	O
and	IN	O
fat	JJ	O
composition	NN	O
(%	IN	O
fat)	NNP	O
and	NN	O
total	,	O
tissue	CD	O
mass	NN	O
(TTM)	NN	O
were	,	O
determined	NN	O
in	NN	O
the	CC	O
regions	NN	O
of	VBD	O
interest	,	O
(ROI)	CC	O
[i.e.,	RB	O
whole	DT	O
body,	NN	O
vertebrae,	VBD	O
and	VBN	O
both	IN	O
femurs].	DT	O
DEXA	NN	O
Results:	NN	O
Both	IN	O
the	DT	O
male	NN	O
and	IN	O
female	DT	O
(−/−)	NNP	O
mice	NNP	O
exhibited	NNP	O
decreased	)	O
mean	IN	O
total	DT	O
tissue	NNP	O
mass	.	O
and	VBG	O
lean	NNP	O
body	NNP	O
mass	,	O
when	DT	O
compared	NN	O
with	JJ	O
their	NN	O
gender-matched	)	O
(+/+)	CC	O
littermates	JJ	O
and	NN	O
the	NN	O
historical	)	O
means.	CC	O
These	JJ	O
mutant	NN	O
mice	NN	O
also	)	O
exhibited	VBD	O
decreased	VBN	O
mean	IN	O
bone	DT	O
mineral	NNS	O
content	IN	O
and	NN	O
bone	)	O
mineral	,	O
density	JJ	O
in	,	O
total	,	O
body,	CC	O
femur,	DT	O
and	.	O
vertebrae.	JJ	O
Bone	:	O
microCT	DT	O
Analysis:	DT	O
Procedure:	NN	O
MicroCT	CC	O
was	NN	O
also	)	O
used	NN	O
to	VBD	O
get	JJ	O
very	JJ	O
sensitive	JJ	O
measurements	NN	O
of	NN	O
BMD.	CC	O
One	JJ	O
vertebra	NN	O
and	NN	O
1	WRB	O
femur	VBN	O
were	IN	O
taken	PRP$	O
from	JJ	O
a	)	O
cohort	VBZ	O
of	CC	O
4	DT	O
wild	JJ	O
type	.	O
and	DT	O
8	JJ	O
homozygous	NN	O
mice.	RB	O
Measurements	VBD	O
were	JJ	O
taken	NN	O
of	NN	O
lumbar	NN	O
5	NN	O
veterbra	CC	O
traebecular	JJ	O
bone	JJ	O
volume,	NN	O
traebecular	IN	O
thickness,	JJ	O
connectivity	,	O
density	,	O
and	CC	O
midshaft	.	O
femur	NNP	O
total	NN	O
bone	:	O
area	:	O
and	NNP	O
cortical	VBD	O
thickness.	RB	O
The	VBN	O
μCT40	TO	O
scans	VB	O
provided	RB	O
detailed	JJ	O
information	NNS	O
on	IN	O
bone	.	O
mass	CD	O
and	NN	O
architecture.	CC	O
Multiple	CD	O
bones	NNS	O
were	VBD	O
placed	VBN	O
into	IN	O
sample	DT	O
holders	NN	O
and	IN	O
scanned	CD	O
automatically.	JJ	O
Instrument	NN	O
software	CC	O
was	CD	O
used	JJ	O
to	.	O
select	NNS	O
regions	VBD	O
of	VBN	O
interest	IN	O
for	NN	O
analysis.	CD	O
Trabecular	NN	O
bone	JJ	O
parameters	NN	O
were	,	O
analyzed	JJ	O
in	,	O
the	NN	O
fifth	NN	O
lumbar	CC	O
vertebrae	NN	O
(LV5)	NN	O
at	JJ	O
16	NN	O
micrometer	NN	O
resolution	CC	O
and	JJ	O
cortical	.	O
bone	DT	O
parameters	NN	O
were	NNS	O
analyzed	VBD	O
in	JJ	O
the	NN	O
femur	IN	O
midshaft	NN	O
at	NN	O
a	CC	O
resolution	.	O
of	JJ	O
20	NNS	O
micrometers.	VBD	O
Micro-CT	VBN	O
Analysis	IN	O
Results:	JJ	O
The	NNS	O
male	CC	O
(−/−)	VBD	O
mice	.	O
exhibited	NNP	O
decreased	NN	O
mean	VBD	O
vertebral	VBN	O
trabecular	TO	O
bone	VB	O
volume,	NNS	O
thickness,	IN	O
and	NN	O
connectivity	IN	O
density	.	O
when	JJ	O
compared	NN	O
with	NNS	O
their	VBD	O
gender-matched	VBN	O
(+/+)	IN	O
littermates	DT	O
and	JJ	O
the	NN	O
historical	NN	O
means.	)	O
These	IN	O
mutants	CD	O
also	NN	O
exhibited	NN	O
decreased	CC	O
mean	JJ	O
femoral	NN	O
mid-shaft	NNS	O
cortical	VBD	O
thickness	VBN	O
and	IN	O
cross-sectional	DT	O
area.	NN	O
[Analyzed	NN	O
wt/het/hom:	IN	O
4/4/8]	DT	O
Body	NN	O
Measurements:	IN	O
A	CD	O
measurement	.	O
of	JJ	O
length	NN	O
was	:	O
performed	DT	O
at	NN	O
approximately	)	O
16	NN	O
weeks	VBD	O
of	JJ	O
age.	JJ	O
The	JJ	O
(−/−)	JJ	O
mice	NN	O
exhibited	,	O
a	,	O
decreased	CC	O
weight	NN	O
gain	NN	O
and	WRB	O
decreased	VBN	O
mean	IN	O
body	PRP$	O
length,	JJ	O
decreased	)	O
total	VBZ	O
tissue	CC	O
mass	DT	O
and	JJ	O
decreased	.	O
lean	DT	O
body	NNS	O
mass	RB	O
when	VBD	O
compared	JJ	O
with	JJ	O
their	JJ	O
gender-matched	NN	O
(+/+)	JJ	O
littermates	NN	O
and	CC	O
the	JJ	O
historical	.	O
mean.	NNP	O
These	:	O
results	IN	O
demonstrate	NN	O
that	:	O
knockout	DT	O
mutant	NN	O
male	IN	O
mice	NN	O
deficient	VBD	O
in	VBN	O
the	IN	O
gene	RB	O
encoding	CD	O
PRO227	NNS	O
polypeptides	IN	O
exhibit	.	O
growth	DT	O
retardation	)	O
as	NN	O
well	VBD	O
as	DT	O
abnormal	JJ	O
bone	NN	O
metabolism	NN	O
with	CC	O
significant	JJ	O
bone	NN	O
loss	NN	O
characterized	,	O
by	VBD	O
a	JJ	O
decrease	NN	O
in	NN	O
bone	CC	O
mass	JJ	O
with	JJ	O
decreased	NN	O
density	NN	O
and	WRB	O
possibly	VBN	O
fragility	IN	O
leading	PRP$	O
to	JJ	O
bone	)	O
fractures.	VBZ	O
In	CC	O
addition	DT	O
to	JJ	O
the	.	O
observed	DT	O
bone	NNS	O
metabolism	VBP	O
abnormalities,	IN	O
these	NN	O
studies	JJ	O
indicated	JJ	O
that	NN	O
(−/−)	NN	O
mutant	IN	O
mice	DT	O
also	NN	O
showed	VBG	O
signs	NNP	O
of	NNS	O
growth	VBP	O
retardation.	NN	O
The	NN	O
bony	RB	O
changes	RB	O
may	IN	O
be	JJ	O
a	NN	O
result	NN	O
of	IN	O
the	JJ	O
decreased	NN	O
body	NN	O
size	VBN	O
and	IN	O
mass	DT	O
of	NN	O
these	IN	O
mice	NN	O
as	NN	O
suggested	IN	O
by	JJ	O
the	NN	O
fact	CC	O
that	RB	O
the	NN	O
gene	VBG	O
is	TO	O
not	VB	O
expressed	.	O
in	IN	O
the	NN	O
bone.	TO	O
Such	DT	O
growth	JJ	O
disorders	NN	O
are	NN	O
associated	,	O
with	DT	O
the	NNS	O
phenotype	VBD	O
or	IN	O
physiological	)	O
condition	NN	O
associated	NN	O
with	RB	O
tissue	VBD	O
wasting	NNS	O
diseases	IN	O
such	NN	O
as	.	O
diabetes	DT	O
or	NN	O
cachexia.	NNS	O
Thus,	MD	O
PRO227	VB	O
polypeptides	DT	O
or	NN	O
agonists	IN	O
thereof	DT	O
would	VBN	O
be	NN	O
useful	NN	O
for	CC	O
treating	NN	O
diabetes	IN	O
or	DT	O
cachexia.	NNS	O
No	IN	O
hypercalcemia,	VBN	O
or	IN	O
hyperglycemia	DT	O
was	NN	O
detected	IN	O
in	DT	O
blood	NN	O
chemistry	VBZ	O
tests	RB	O
to	VBN	O
suggest	IN	O
renal,	DT	O
parathyroid,	.	O
or	JJ	O
adrenal	NN	O
dysfunction	NNS	O
that	VBP	O
might	VBN	O
be	IN	O
related	DT	O
to	NN	O
the	CC	O
decrease	JJ	O
in	NN	O
bone	VBN	O
mineral	IN	O
density	NN	O
seen	VBG	O
on	NNS	O
the	JJ	O
Dexa	IN	O
scan.	NNS	O
However,	CC	O
the	.	O
(+/−)	,	O
and	NNP	O
(−/−)	VBZ	O
mice	CC	O
showed	NNS	O
more	RP	O
wide	MD	O
variation	VB	O
in	JJ	O
their	IN	O
alkaline	VBG	O
phosphatase	NNS	O
levels.	CC	O
Although	.	O
the	DT	O
PRO227	,	O
encoding	CC	O
gene	NN	O
is	VBD	O
not	VBN	O
expressed	IN	O
in	NN	O
the	NN	O
bone,	NNS	O
the	TO	O
secondary	VB	O
affects	,	O
caused	,	O
by	CC	O
growth	JJ	O
retardation	NN	O
suggests	WDT	O
that	MD	O
PRO227	VB	O
would	VBN	O
be	TO	O
important	DT	O
for	NN	O
maintaining	IN	O
bone	JJ	O
homeostasis	JJ	O
and	NN	O
bone	VBN	O
healing	IN	O
or	DT	O
would	NNP	O
be	.	O
useful	,	O
for	DT	O
the	)	O
treatment	CC	O
of	)	O
arthritis	NN	O
or	VBD	O
osteoporosis;	JJR	O
whereas	JJ	O
antagonists	NN	O
to	IN	O
PRO227	PRP$	O
or	JJ	O
its	NN	O
encoding	.	O
gene	IN	O
would	DT	O
lead	NNP	O
to	VBG	O
abnormal	NN	O
or	VBZ	O
pathological	RB	O
bone	VBN	O
disorders	IN	O
including	DT	O
inflammatory	,	O
diseases	DT	O
associated	JJ	O
with	NNS	O
abnormal	VBN	O
bone	IN	O
metabolism	NN	O
such	NN	O
as	VBZ	O
arthritis.	IN	O
[Analyzed	NNP	O
wt/het/hom:	MD	O
14/29/17]	VB	O
(c)	JJ	O
Phenotypic	IN	O
Analysis:	VBG	O
Cardiology	NN	O
In	NN	O
the	CC	O
area	NN	O
of	NN	O
cardiovascular	CC	O
biology,	MD	O
targets	VB	O
were	JJ	O
identified	IN	O
herein	DT	O
for	NN	O
the	IN	O
treatment	NN	O
of	CC	O
hypertension,	:	O
atherosclerosis,	JJ	O
heart	NNS	O
failure,	TO	O
stroke,	NNP	O
various	CC	O
coronary	PRP$	O
artery	JJ	O
diseases,	NN	O
dyslipidemias	MD	O
such	VB	O
as	TO	O
high	JJ	O
cholesterol	CC	O
(hypercholesterolemia)	JJ	O
and	NN	O
elevated	NNS	O
serum	VBG	O
triglycerides	JJ	O
(hypertriglyceridemia),	NNS	O
diabetes,	VBN	O
cancer	IN	O
and/or	JJ	O
obesity.	NN	O
The	NN	O
phenotypic	JJ	O
tests	IN	O
in	.	O
this	NNP	O
instance	:	O
included	NN	O
the	)	O
measurement	NNP	O
of	:	O
serum	NN	O
cholesterol	IN	O
and	DT	O
triglycerides	NN	O
Blood	IN	O
Lipids	JJ	O
Procedure:	,	O
A	NNS	O
cohort	VBD	O
of	VBN	O
4	NN	O
wild	IN	O
type,	DT	O
4	NN	O
heterozygotes	IN	O
and	,	O
8	,	O
homozygotes	NN	O
were	,	O
tested	,	O
in	JJ	O
this	JJ	O
assay.	NN	O
High	,	O
cholesterol	NNS	O
and	JJ	O
elevated	IN	O
triglyceride	JJ	O
levels	NN	O
are	)	O
recognized	CC	O
risk	VBN	O
factors	NN	O
in	NNS	O
the	,	O
development	,	O
of	NN	O
cardiovascular	NN	O
disease.	.	O
Measuring	DT	O
blood	NN	O
lipids	NNS	O
allowed	IN	O
finding	DT	O
of	NN	O
the	VBD	O
biological	DT	O
switches	NN	O
that	IN	O
regulate	NN	O
blood	NN	O
lipid	CC	O
levels	NNS	O
and	NNP	O
that	NNP	O
upon	:	O
inhibition	DT	O
would	NN	O
lead	IN	O
to	CD	O
a	JJ	O
reduction	,	O
in	CD	O
the	NNS	O
risk	CC	O
for	CD	O
cardiovascular	NNS	O
disease.	VBD	O
Cholesterol	VBN	O
measurements	IN	O
were	DT	O
recorded.	.	O
The	JJ	O
COBAS	NN	O
Integra	CC	O
400	VBD	O
(mfr:	NN	O
Roche)	NNS	O
was	VBP	O
used	VBN	O
for	NN	O
running	NNS	O
blood	IN	O
chemistry	DT	O
tests	NN	O
on	IN	O
mice.	JJ	O
Results:	.	O
Both	VBG	O
heterozygous	NN	O
(+/−)	NNS	O
and	VBD	O
homozygous	NN	O
(−/−)	IN	O
mutant	DT	O
mice	JJ	O
exhibited	NNS	O
an	WDT	O
increased	VBP	O
mean	NN	O
serum	JJ	O
cholesterol	NNS	O
and	CC	O
triglyceride	DT	O
levels	JJ	O
when	NN	O
compared	MD	O
with	VB	O
their	TO	O
gender-matched	DT	O
(+/+)	NN	O
littermates	IN	O
and	DT	O
the	NN	O
historical	IN	O
mean.	JJ	O
(Analyzed	.	O
wt/het/hom:	NN	O
4/4/8)	NNS	O
Thus,	VBD	O
mutant	.	O
mice	DT	O
deficient	NNP	O
in	NNP	O
the	CD	O
PRO227	:	O
gene	)	O
can	VBD	O
serve	VBN	O
as	IN	O
a	VBG	O
model	NN	O
for	NN	O
cardiovascular	NNS	O
disease.	IN	O
PRO227	.	O
or	:	O
its	DT	O
encoding	JJ	O
gene	)	O
would	CC	O
be	JJ	O
useful	)	O
in	NN	O
regulating	NN	O
blood	VBD	O
lipids	DT	O
and	VBN	O
in	NN	O
particular	NN	O
maintaining	NN	O
normal	CC	O
cholesterol	NN	O
and	NNS	O
triglyceride	WRB	O
levels.	VBN	O
Thus	IN	O
PRO227	PRP$	O
polypeptides	JJ	O
would	)	O
be	VBZ	O
useful	CC	O
in	DT	O
the	JJ	O
treatment	.	O
of	JJ	O
such	:	O
cardiovascular	)	O
diseases	,	O
as:	JJ	O
hypertension,	NN	O
atherosclerosis,	NN	O
heart	IN	O
failure,	DT	O
stroke,	NNP	O
various	NN	O
coronary	MD	O
artery	VB	O
diseases	IN	O
and/or	DT	O
diabetes.	NN	O
B.	IN	O
Generation	JJ	O
and	.	O
Analysis	NNP	O
of	CC	O
Mice	PRP$	O
Comprising	JJ	O
DNA34436-1238	NN	O
(UNQ207)	MD	O
Gene	VB	O
Disruptions	JJ	O
In	IN	O
these	VBG	O
knockout	NN	O
experiments,	NNS	O
the	CC	O
gene	IN	O
encoding	JJ	O
PRO233	VBG	O
polypeptides	JJ	O
(designated	NN	O
as	CC	O
DNA34436-1238	NN	O
(UNQ207)	.	O
was	RB	O
disrupted.	NNP	O
The	NNS	O
gene	MD	O
specific	VB	O
information	JJ	O
for	IN	O
these	DT	O
studies	NN	O
is	IN	O
as	JJ	O
follows:	JJ	O
the	NNS	O
mutated	:	O
mouse	,	O
gene	,	O
corresponds	NN	O
to	,	O
nucleotide	,	O
reference:	JJ	O
NM—053262:	JJ	O
or	NN	O
Mus	VBZ	O
musculus	JJ	O
retinal	.	O
short-chain	.	O
dehydrogenase/reductase	NN	O
2	CC	O
gene;	NNP	O
protein	IN	O
reference:	NNP	O
NP—444492	NNP	O
or	NNP	O
Mus	)	O
musculus	NNP	O
retinal	NNP	O
short-chain	IN	O
dehydrogenase/reductase	DT	O
2;	NN	O
the	,	O
human	DT	O
gene	NN	O
sequence	VBG	O
reference:	NNP	O
BQ927122	NNS	O
(AGENCOURT—8802906	VBN	O
NIH_MGC—40	IN	O
Homo	NNP	O
sapiens	)	O
cDNA	VBD	O
clone	.	O
IMAGE:	DT	O
638241);	NN	O
the	JJ	O
human	NN	O
protein	IN	O
sequence	DT	O
corresponds	NNS	O
to	VBZ	O
reference:	IN	O
AAH21673	:	O
or	DT	O
Homo	VBN	O
sapiens	NN	O
retinal	NN	O
short-chain	NNS	O
dehydrogenase/reductase	TO	O
2.	JJ	O
Mutation	:	O
Specific	:	O
Information	CC	O
corresponds	NNP	O
to	JJ	O
retroviral	JJ	O
insertion	JJ	O
(OST).	NN	O
Retroviral	CD	O
insertion	:	O
disrupted	CC	O
the	:	O
gene	NN	O
prior	CC	O
to	NNP	O
the	JJ	O
exon	JJ	O
encoding	JJ	O
amino	NN	O
acid	:	O
55	DT	O
in	JJ	O
a	NN	O
protein	NN	O
of	:	O
298	NNP	O
amino	NNP	O
acids	NNP	O
(NCBI	NNP	O
accession	VBZ	O
number	NN	O
NP—444492).	NN	O
The	:	O
disrupted	:	O
mouse	DT	O
gene	JJ	O
is	NN	O
retinal	NN	O
short-chain	NNS	O
dehydrogenase/reductase	TO	O
2	:	O
(retsdr2),	NNP	O
ortholog	CC	O
of	NNP	O
human	JJ	O
RETSDR2.	JJ	O
Aliases	JJ	O
include	NN	O
SDR2,	.	O
Pan1b,	NNP	O
RetSDR2,	NNP	O
Hsd17b11,	NNP	O
hydroxysteroid	VBZ	O
(17-beta)	TO	O
dehydrogenase	VB	O
11,	NN	O
retinal	.	O
short-chain	JJ	O
dehydrogenase/reductase	NN	O
SDR2,	VBD	O
17-BETA-HSD11,	DT	O
17betaHSD11,	NN	O
17-BETA-HSDXI,	RB	O
and	TO	O
17-beta-hydroxysteroid	DT	O
dehydrogenase	NN	O
type	VBG	O
XI.	JJ	O
RETSDR2	JJ	O
converts	CD	O
5	IN	O
alpha-androstane-3	DT	O
alpha,	NN	O
17	IN	O
beta-diol	CD	O
(a	JJ	O
metabolite	NNS	O
of	NNP	O
dihydrostestosterone)	NN	O
into	NN	O
androsterone,	.	O
such	DT	O
activity	VBN	O
being	NN	O
first	NN	O
documented	VBZ	O
in	JJ	O
lung	JJ	O
Brereton	NN	B
et	CD	I
al.,	,	I
Mol.	NN	I
Cell.	IN	I
Endocrinol.,	JJ	I
171(1-2):	.	I
111-7	NNS	I
(2001))	VBP	I
(though	,	O
expression	,	O
of	,	O
the	,	O
gene	NN	O
is	)	O
reported	NN	O
in	,	O
other	JJ	O
tissues.	JJ	O
Overall,	NN	O
RETSDR2	,	O
is	,	O
well	,	O
expressed	,	O
in	CC	O
cells	JJ	O
involved	NN	O
with	NN	O
steroidogeneisis	.	O
and	NNP	O
the	VBZ	O
enzyme	CD	O
is	JJ	O
proposed	,	O
to	CD	O
have	NN	O
an	DT	O
important	NN	O
role	IN	O
in	)	O
androgen	IN	O
metabolism	,	O
Li	JJ	B
et	NN	I
al.,	VBG	I
Endocr.	JJ	I
Res.,	VBN	I
24(3-4):663-7	IN	I
(1998);	NN	I
Chai	NNP	B
et	VBZ	I
al.,	,	I
Endocrinology,	.	I
144(5):2084-91	.	I
(2003)).(	,	O
Targeted	:	O
or	JJ	O
gene	)	O
trap	IN	O
mutations	NN	O
were	IN	O
generated	DT	O
in	NN	O
strain	VBZ	O
129SvEvBrd-derived	VBN	O
embryonic	IN	O
stem	JJ	O
(ES)	.	O
cells.	,	O
The	NNP	O
wild-type	VBZ	O
expression	RB	O
panel	VBN	O
resulted	IN	O
in	NNS	O
the	VBN	O
following	IN	O
observation:	NN	O
expression	CC	O
of	DT	O
the	NN	O
target	VBZ	O
gene	VBN	O
was	TO	O
detected	VB	O
in	DT	O
embryonic	JJ	O
stem	NN	O
(ES)	IN	O
cells	NN	O
and,	NN	O
among	NNP	O
the	RB	O
13	,	O
adult	.	O
tissue	,	O
samples	NN	O
tested	:	O
by	NNP	O
RT-PCR,	FW	O
in	,	O
bone,	,	O
skin	NN	O
fibroblast,	.	O
adipose,	VBN	O
and	CC	O
tail.	NN	O
Disruption	JJ	O
of	NNS	O
the	VBD	O
target	VBN	O
gene	IN	O
was	JJ	O
confirmed	JJ	O
by	JJ	O
Southern	NN	O
hybridization	)	O
analysis.	.	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	NN	O
bred	VBD	O
to	IN	O
C57BL/6J	DT	O
albino	JJ	O
mice	:	O
to	NN	O
generate	IN	O
F1	DT	O
heterozygous	NN	O
animals.	NN	O
These	VBD	O
progeny	VBN	O
were	IN	O
intercrossed	JJ	O
to	NN	O
generate	)	O
F2	NNS	O
wild	,	O
type,	IN	O
heterozygous,	DT	O
and	CD	O
homozygous	NN	O
mutant	NN	O
progeny.	NNS	O
On	VBN	O
rare	IN	O
occasions,	,	O
for	IN	O
example	,	O
when	FW	O
very	,	O
few	,	O
F1	CC	O
mice	.	O
were	NN	O
obtained	IN	O
from	DT	O
the	NN	O
chimera,	NN	O
F1	VBD	O
heterozygous	VBN	O
mice	IN	O
were	NNP	O
crossed	NN	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
The	VBD	O
wild-type	VBN	O
expression	TO	O
panel	VB	O
showed	NNP	O
that	JJ	O
the	,	O
expression	,	O
of	CC	O
the	JJ	O
gene	NN	O
was	.	O
detected	IN	O
in	JJ	O
embryonic	,	O
stem	IN	O
(ES)	NN	O
cells	WRB	O
and,	RB	O
among	JJ	O
the	NNP	O
13	NN	O
adult	VBD	O
tissue	VBN	O
samples	IN	O
tested	DT	O
by	,	O
RT-PCR,	NNP	O
in	JJ	O
brain,	NNS	O
spinal	VBD	O
cord,	VBN	O
thymus,	TO	O
bone,	CD	O
and	JJ	O
adipose.	NN	O
RT-PCR	TO	O
analysis	VB	O
revealed	JJ	O
that	JJ	O
the	NNS	O
transcript	IN	O
was	DT	O
absent	NN	O
in	TO	O
the	VB	O
(−/−)	DT	O
mouse	NNP	O
analyzed.	.	O
Phenotypic	DT	O
analysis	JJ	O
was	NN	O
performed	NN	O
on	VBD	O
mice	IN	O
from	DT	O
this	NN	O
generation	IN	O
as	DT	O
described	NN	O
below.	VBD	O
1.	VBN	O
Phenotypic	IN	O
Analysis	JJ	O
(for	NN	O
Disrupted	)	O
Gene:	NNS	O
DNA34436-1238	,	O
(UNQ207)	IN	O
(a)	DT	O
Overall	CD	O
Phenotypic	NN	O
Summary:	NN	O
Mutation	NNS	O
of	VBN	O
the	IN	O
gene	,	O
encoding	IN	O
the	,	O
ortholog	JJ	O
of	,	O
human	,	O
retinal	,	O
short-chain	CC	O
dehydrogenase/reductase	.	O
2	JJ	O
(RETSDR2)	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
2½	NN	O
fold	VBD	O
increased	JJ	O
percentage	IN	O
of	DT	O
immature	)	O
B	NN	O
cells	.	O
in	NNP	O
bone	NN	O
marrow.	VBD	O
In	VBN	O
addition,	IN	O
(−/−)	NN	O
mice	IN	O
exhibited	DT	O
consistent	NN	O
alterations	IN	O
in	VBN	O
bone	.	O
marrow,	.	O
but	NNP	O
no	NNP	O
effects	IN	O
were	VBN	O
seen	:	O
in	NNP	O
thymus	)	O
or	)	O
spleen.	JJ	O
Lymph	NNP	O
node	:	O
FACS	NN	O
showed	IN	O
trends	DT	O
in	NN	O
increased	VBG	O
cell	DT	O
number	NN	O
for	IN	O
certain	JJ	O
cell	JJ	O
types.	NN	O
RT-PCR	NN	O
analyses	CD	O
revealed	)	O
that	VBD	O
the	IN	O
transcript	DT	O
was	CD	O
absent	NN	O
in	VBD	O
the	NN	O
homozygous	IN	O
mutant	NN	O
mice.	NNP	O
(b)	NNS	O
Immunology	IN	O
Phenotypic	NN	O
Analysis	.	O
Immune	IN	O
related	,	O
and	)	O
inflammatory	NN	O
diseases	VBD	O
are	JJ	O
the	NNS	O
manifestation	IN	O
or	NN	O
consequence	,	O
of	CC	O
fairly	DT	O
complex,	NNS	O
often	VBD	O
multiple	VBN	O
interconnected	IN	O
biological	NN	O
pathways	CC	O
which	.	O
in	NNP	O
normal	NN	O
physiology	NNP	O
are	VBD	O
critical	NNS	O
to	IN	O
respond	VBN	O
to	NN	O
insult	NN	O
or	IN	O
injury,	JJ	O
initiate	NN	O
repair	.	O
from	JJ	O
insult	NNS	O
or	VBD	O
injury,	IN	O
and	DT	O
mount	NN	O
innate	VBD	O
and	JJ	O
acquired	IN	O
defense	DT	O
against	JJ	O
foreign	JJ	O
organisms.	.	O
Disease	)	O
or	NNP	O
pathology	NNP	O
occurs	NNP	O
when	NNP	O
these	VBN	O
normal	CC	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	DT	O
insult	NN	O
or	CC	O
injury	NN	O
either	IN	O
as	RB	O
directly	,	O
related	RB	O
to	JJ	O
the	JJ	O
intensity	NN	O
of	NNS	O
the	WDT	O
response,	IN	O
as	JJ	O
a	NN	O
consequence	VBP	O
of	JJ	O
abnormal	TO	O
regulation	VB	O
or	TO	O
excessive	VB	O
stimulation,	CC	O
as	,	O
a	VB	O
reaction	NN	O
to	IN	O
self,	NN	O
or	CC	O
as	,	O
a	CC	O
combination	VB	O
of	NN	O
these.	CC	O
Though	VBD	O
the	NN	O
genesis	IN	O
of	JJ	O
these	.	O
diseases	NNP	O
often	CC	O
involves	NN	O
multistep	NNS	O
pathways	WRB	O
and	DT	O
often	JJ	O
multiple	JJ	O
different	NNS	O
biological	VBP	O
systems/pathways,	JJ	O
intervention	NN	O
at	CC	O
critical	NN	O
points	CC	O
in	IN	O
one	RB	O
or	VBN	O
more	TO	O
of	DT	O
these	NN	O
pathways	IN	O
can	DT	O
have	,	O
an	IN	O
ameliorative	DT	O
or	NN	O
therapeutic	IN	O
effect.	JJ	O
Therapeutic	NN	O
intervention	CC	O
can	JJ	O
occur	,	O
by	IN	O
either	DT	O
antagonism	NN	O
of	TO	O
a	,	O
detrimental	CC	O
process/pathway	IN	O
or	DT	O
stimulation	NN	O
of	IN	O
a	.	O
beneficial	IN	O
process/pathway.	DT	O
T	NN	O
lymphocytes	IN	O
(T	DT	O
cells)	NNS	O
are	RB	O
an	VBZ	O
important	NNS	O
component	NNS	O
of	CC	O
a	RB	O
mammalian	JJ	O
immune	JJ	O
response.	JJ	O
T	,	O
cells	NN	O
recognize	IN	O
antigens	JJ	O
which	NNS	O
are	IN	O
associated	CD	O
with	CC	O
a	JJR	O
self-molecule	IN	O
encoded	DT	O
by	NNS	O
genes	MD	O
within	VB	O
the	DT	O
major	JJ	O
histocompatibility	CC	O
complex	JJ	O
(MHC).	.	O
The	JJ	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	IN	O
together	DT	O
with	NN	O
MHC	IN	O
molecules	DT	O
on	JJ	O
the	NN	O
surface	CC	O
of	NN	O
antigen	IN	O
presenting	DT	O
cells,	JJ	O
virus	.	O
infected	NNP	O
cells,	VBZ	O
cancer	NNP	O
cells,	)	O
grafts,	VBP	O
etc.	DT	O
The	JJ	O
T	NN	O
cell	IN	O
system	DT	O
eliminates	JJ	O
these	NN	O
altered	.	O
cells	NNP	O
which	NNS	O
pose	VBP	O
a	NNS	O
health	WDT	O
threat	VBP	O
to	VBN	O
the	IN	O
host	DT	O
mammal	NN	O
T	VBN	O
cells	IN	O
include	NNS	O
helper	IN	O
T	DT	O
cells	JJ	O
and	NN	O
cytotoxic	NN	O
T	.	O
cells.	DT	O
Helper	NN	O
T	MD	O
cells	VB	O
proliferate	VBN	O
extensively	RB	O
following	IN	O
recognition	NNP	O
of	NNS	O
an	IN	O
antigen-MHC	DT	O
complex	NN	O
on	IN	O
an	NN	O
antigen	VBG	O
presenting	,	O
cell.	NN	O
Helper	VBD	O
T	,	O
cells	NN	O
also	,	O
secrete	,	O
a	.	O
variety	DT	O
of	NNP	O
cytokines,	NN	O
i.e.,	NN	O
lymphokines,	VBZ	O
which	DT	O
play	JJ	O
a	NNS	O
central	WDT	O
role	VBP	O
in	DT	O
the	NN	O
activation	NN	O
of	TO	O
B	DT	O
cells,	NN	O
cytotoxic	JJ	O
T	NNP	O
cells	NNS	O
and	VBP	O
a	JJ	O
variety	NNP	O
of	NNS	O
other	CC	O
cells	NN	O
which	NNP	O
participate	.	O
in	NNP	O
the	NNP	O
immune	NNS	O
response.	VBP	O
In	RB	O
many	VBG	O
immune	NN	O
responses,	IN	O
inflammatory	DT	O
cells	JJ	O
infiltrate	NN	O
the	IN	O
site	DT	O
of	NN	O
injury	NN	O
or	.	O
infection.	NNP	O
The	NNP	O
migrating	NNS	O
cells	RB	O
may	VBP	O
be	DT	O
neutrophilic,	NN	O
eosinophilic,	IN	O
monocytic	,	O
or	,	O
lymphocytic	,	O
as	WDT	O
can	VBP	O
be	DT	O
determined	JJ	O
by	NN	O
histologic	IN	O
examination	DT	O
of	NN	O
the	IN	O
affected	NNP	O
tissues.	,	O
Current	NN	O
Protocols	NNP	O
in	NNS	O
Immunology,	CC	O
ed.	DT	O
John	NN	O
E.	IN	O
Coligan,	JJ	O
1994,	NNS	O
John	WDT	O
Wiley	VBP	O
&	IN	O
Sons,	DT	O
Inc.	JJ	O
Many	.	O
immune	IN	O
related	JJ	O
diseases	JJ	O
are	,	O
known	JJ	O
and	NNS	O
have	VBP	O
been	DT	O
extensively	NN	O
studied.	IN	O
Such	NN	O
diseases	CC	O
include	.	O
immune-mediated	DT	O
inflammatory	NN	O
diseases	NNS	O
(such	MD	O
as	VB	O
rheumatoid	,	O
arthritis,	,	O
immune	JJ	O
mediated	CC	O
renal	JJ	O
disease,	IN	O
hepatobiliary	MD	O
diseases,	VB	O
inflammatory	VBN	O
bowel	IN	O
disease	JJ	O
(IBD),	NN	O
psoriasis,	IN	O
and	DT	O
asthma),	JJ	O
non-immune-mediated	.	O
inflammatory	JJ	O
diseases,	NNP	O
infectious	IN	O
diseases,	,	O
immunodeficiency	.	O
diseases,	NNP	O
neoplasia,	NNP	O
and	,	O
graft	,	O
rejection,	NNP	O
etc.	NNP	O
In	CC	O
the	,	O
area	.	O
of	JJ	O
immunology,	NNS	O
targets	JJ	O
were	NNS	O
identified	VBP	O
for	VBN	O
the	CC	O
treatment	VBP	O
of	VBN	O
inflammation	RB	O
and	.	O
inflammatory	JJ	O
disorders.	NNS	O
In	VBP	O
the	JJ	O
area	JJ	O
of	NNS	O
immunology,	JJ	O
targets	IN	O
have	JJ	O
been	,	O
identified	NN	O
herein	VBD	O
for	JJ	O
the	,	O
treatment	JJ	O
of	,	O
inflammation	NN	O
and	NN	O
inflammatory	NN	O
disorders.	,	O
Immune	,	O
related	CC	O
diseases,	,	O
in	JJ	O
one	NN	O
instance,	,	O
could	JJ	O
be	,	O
treated	NN	O
by	,	O
suppressing	,	O
the	CC	O
immune	NN	O
response.	,	O
Using	.	O
neutralizing	IN	O
antibodies	DT	O
that	NN	O
inhibit	IN	O
molecules	,	O
having	NNS	O
immune	VBD	O
stimulatory	VBN	O
activity	IN	O
would	DT	O
be	NN	O
beneficial	IN	O
in	NN	O
the	CC	O
treatment	NN	O
of	.	O
immune-mediated	IN	O
and	DT	O
inflammatory	NN	O
diseases.	IN	O
Molecules	,	O
which	NNS	O
inhibit	VBP	O
the	VBN	O
immune	VBN	O
response	NN	O
can	IN	O
be	DT	O
utilized	NN	O
(proteins	IN	O
directly	NN	O
or	CC	O
via	NN	O
the	.	O
use	NNP	O
of	JJ	O
antibody	,	O
agonists)	IN	O
to	CD	O
inhibit	,	O
the	MD	O
immune	VB	O
response	VBN	O
and	IN	O
thus	VBG	O
ameliorate	DT	O
immune	JJ	O
related	.	O
disease.	VBG	O
The	VBG	O
following	NNS	O
tests	WDT	O
were	VBP	O
performed:	NNS	O
Flourescence-Activated	VBG	O
Cell-Sorting	JJ	O
(FACS)	JJ	O
Analysis/Tissue	NN	O
Specific	MD	O
FACS	VB	O
Analysis	JJ	O
Procedure:	IN	O
FACS	DT	O
analysis	NN	O
of	IN	O
immune	JJ	O
cell	CC	O
composition	JJ	O
from	.	O
peripheral	NNS	O
blood	WDT	O
was	VBP	O
performed	DT	O
including	JJ	O
analysis	NN	O
of	MD	O
CD4,	VB	O
CD8	VBN	O
and	NNS	O
T	RB	O
cell	CC	O
receptors	IN	O
to	DT	O
evaluate	NN	O
T	IN	O
lymphocytes,	NN	O
CD19	)	O
for	TO	O
B	VB	O
lymphocytes,	DT	O
CD45	JJ	O
as	NN	O
a	CC	O
leukocyte	RB	O
marker	VB	O
and	NN	O
pan	JJ	O
NK	.	O
for	DT	O
natural	JJ	O
killer	NNS	O
cells.	VBD	O
The	:	O
FACS	JJ	O
analysis	NNP	O
was	)	O
carried	NNP	O
out	NNP	O
on	NNP	O
2	NNP	O
wild	:	O
type	NNP	O
and	NN	O
6	IN	O
homozygous	NN	O
mice	NN	O
and	NN	O
included	IN	O
cells	JJ	O
derived	NN	O
from	VBD	O
thymus,	VBN	O
spleen,	VBG	O
bone	NN	O
marrow	IN	O
and	,	O
lymph	NNP	O
node.	CC	O
In	NNP	O
these	NN	O
studies,	NNS	O
analyzed	TO	O
cells	VB	O
were	NNP	O
isolated	,	O
from	NNP	O
thymus,	IN	O
peripheral	NNP	O
blood,	,	O
spleen,	NNP	O
bone	IN	O
marrow	DT	O
and	NN	O
lymph	NN	O
nodes.	CC	O
Flow	NN	O
cytometry	NNP	O
was	IN	O
designed	JJ	O
to	NN	O
determine	.	O
the	DT	O
relative	NNP	O
proportions	NN	O
of	VBD	O
CD4	VBN	O
and	RP	O
CD8	IN	O
positive	CD	O
T	JJ	O
cells,	NN	O
B	CC	O
cells,	CD	O
NK	JJ	O
cells	NN	O
and	CC	O
monocytes	VBD	O
in	NNS	O
the	VBN	O
mononuclear	IN	O
cell	,	O
population.	,	O
A	NN	O
Becton-Dickinson	NN	O
FACSCalibur	CC	O
3-laser	JJ	O
FACS	.	O
machine	IN	O
was	DT	O
used	,	O
to	JJ	O
assess	NNS	O
immune	VBD	O
status.	VBN	O
For	IN	O
Phenotypic	,	O
Assays	JJ	O
and	,	O
Screening,	,	O
this	NN	O
machine	NN	O
records	CC	O
CD4+/CD8−,	NN	O
CD8+/CD4−,	.	O
NK,	NNP	O
B	NN	O
cell	VBD	O
and	VBN	O
monocyte	TO	O
numbers	VB	O
in	DT	O
addition	JJ	O
to	NNS	O
the	IN	O
CD4+/CD8+	NNP	O
ratio.	CC	O
The	NNP	O
mononuclear	JJ	O
cell	NNP	O
profile	,	O
was	NNP	O
derived	,	O
by	NNP	O
staining	NNS	O
a	CC	O
single	NNS	O
sample	IN	O
of	DT	O
lysed	NN	O
peripheral	NN	O
blood	.	O
from	DT	O
each	NNP	O
mouse	NNP	O
with	CD	O
a	NNP	O
panel	NN	O
of	VBD	O
six	VBN	O
lineage-specific	TO	O
antibodies:	VB	O
CD45	JJ	O
PerCP,	.	O
anti-TCRb	IN	O
APC,	NNP	O
CD4	NNP	O
PE,	CC	O
CD8	,	O
FITC,	DT	O
pan-NK	NN	O
PE,	NNS	O
and	,	O
CD19	,	O
FITC.	,	O
The	NNP	O
two	NN	O
FITC	CC	O
and	NN	O
PE	NNS	O
labeled	IN	O
antibodies	NN	O
stain	TO	O
mutually	DT	O
exclusive	NNP	O
cell	.	O
types.	DT	O
The	NN	O
samples	NN	O
were	NN	O
analyzed	VBD	O
using	VBN	O
a	IN	O
Becton	VBG	O
Dickinson	DT	O
FACSCalibur	JJ	O
flow	NN	O
cytometer	IN	O
with	JJ	O
CellQuest	JJ	O
software.	NN	O
Results:	IN	O
Tissue	DT	O
specific	NN	O
FACS	IN	O
analysis	DT	O
gave	NN	O
the	IN	O
following	CD	O
results:	JJ	O
The	:	O
(−/−)	NNP	O
mice	,	O
exhibited	JJ	O
a	,	O
2½	NNP	O
fold	,	O
increase	NNP	O
percentage	,	O
of	JJ	O
immature	,	O
B	CC	O
cells	NNP	O
in	.	O
bone	DT	O
marrow	CD	O
when	NNP	O
compared	CC	O
with	NNP	O
their	VBD	O
(+/+)	NNS	O
littermates	VBP	O
and	RB	O
the	JJ	O
historical	NN	O
mean.	.	O
Lymph	DT	O
node	NNS	O
FACS	VBD	O
analysis	VBN	O
showed	VBG	O
increased	DT	O
cell	NNP	O
number	NNP	O
for	NNP	O
certain	NN	O
cell	NN	O
types	IN	O
(TcR+	NNP	O
cells;	.	O
CD19+	:	O
cells;	NNP	O
and	JJ	O
GR1-cells).	NNP	O
In	NN	O
summary,	VBD	O
tissue	DT	O
specific	JJ	O
FACS	:	O
analysis	DT	O
indicate	)	O
that	NN	O
knockout	VBD	O
mice	DT	O
deficient	CD	O
in	JJ	O
the	NN	O
gene	NN	O
encoding	IN	O
PRO233	NN	O
polypeptides	NNP	O
exhibit	NNS	O
immunological	IN	O
abnormalities	NN	O
when	NN	O
compared	WRB	O
with	VBN	O
their	IN	O
wild-type	PRP$	O
littermates.	)	O
The	VBZ	O
mutant	CC	O
mice	DT	O
exhibited	JJ	O
an	.	O
abnormal	NNP	O
immune	CC	O
cell	NNP	O
composition	NN	O
and	VBD	O
tissue	VBN	O
specific	NN	O
FACS	NN	O
analysis,	IN	O
suggesting	JJ	O
that	NN	O
inhibitors	NNS	O
or	NNP	O
antagonists	:	O
to	NNP	O
PRO233	:	O
polypeptides	CC	O
would	.	O
stimulate	IN	O
the	,	O
immune	NN	O
system	JJ	O
(such	NNP	O
as	NN	O
T	NN	O
cell	IN	O
proliferation)	NN	O
and	NN	O
would	NN	O
find	IN	O
utility	DT	O
in	NN	O
the	VBG	O
cases	NNP	O
wherein	NNS	O
this	VBP	O
effect	JJ	O
would	NNS	O
be	WRB	O
beneficial	VBN	O
to	IN	O
the	PRP$	O
individual	JJ	O
such	.	O
as	DT	O
in	JJ	O
the	NN	O
case	VBD	O
of	DT	O
leukemia,	JJ	O
and	NN	O
other	NN	O
types	NN	O
of	CC	O
cancer,	NN	O
and	JJ	O
in	NNP	O
immunocompromised	,	O
patients,	VBG	O
such	IN	O
as	NNS	O
AIDS	CC	O
sufferers.	NNS	O
Accordingly,	TO	O
PRO233	NNP	O
polypeptides	NNS	O
or	MD	O
agonists	VB	O
thereof	DT	O
would	NN	O
inhibit	NN	O
the	JJ	O
immune	IN	O
response	NNP	O
and	NN	O
would	)	O
be	CC	O
useful	MD	O
candidates	VB	O
for	NN	O
suppressing	IN	O
harmful	DT	O
immune	NNS	O
responses,	VBP	O
e.g.	DT	O
in	NN	O
the	MD	O
case	VB	O
of	JJ	O
graft	TO	O
rejection	DT	O
or	NN	O
graft-versus-host	JJ	O
diseases.	IN	O
C.	IN	O
Generation	DT	O
and	NN	O
Analysis	IN	O
of	,	O
Mice	CC	O
Comprising	JJ	O
DNA35600-1162	NNS	O
(UNQ212)	IN	O
Gene	,	O
Disruptions	CC	O
In	IN	O
these	JJ	O
knockout	,	O
experiments,	JJ	O
the	IN	O
gene	NNP	O
encoding	.	O
PRO238	,	O
polypeptides	NNP	O
(designated	VBZ	O
as	CC	O
DNA35600-1162	NNS	O
(UNQ212)	RB	O
was	MD	O
disrupted.	VB	O
The	DT	O
gene	JJ	O
specific	NN	O
information	CC	O
for	MD	O
these	VB	O
studies	JJ	O
is	NNS	O
as	IN	O
follows:	VBG	O
the	JJ	O
mutated	JJ	O
mouse	,	O
gene	.	O
corresponds	IN	O
to	DT	O
nucleotide	NN	O
reference:	IN	O
NM—145428:	NN	O
or	NN	O
Mus	CC	O
musculus	NN	O
similar	.	O
to	NNP	O
DKFZP566O084	NNP	O
protein	CC	O
(LOC216820);	NNP	O
protein	IN	O
reference:	NNP	O
NP—663403	NNP	O
or	NNP	O
Mus	)	O
musculus	NNP	O
similar	NNP	O
to	IN	O
DKFZP566O084	DT	O
protein;	NN	O
the	,	O
human	DT	O
gene	NN	O
sequence	VBG	O
reference:	NNP	O
NM—015510	NNS	O
or	VBN	O
DKFZP566O084	IN	O
protein	NNP	O
gene;	)	O
the	VBD	O
human	.	O
protein	DT	O
sequence	NN	O
corresponds	JJ	O
to	NN	O
reference:	IN	O
NP—056325	DT	O
or	NNS	O
Homo	VBZ	O
sapiens	IN	O
DKFZP566O084	:	O
protein.	DT	O
Mutation	VBN	O
Specific	NN	O
Information	NN	O
corresponds	NNS	O
to	TO	O
retroviral	JJ	O
insertion	:	O
(OST).	:	O
Retroviral	CC	O
insertion	NNP	O
disrupted	CC	O
the	JJ	O
gene	TO	O
prior	NNP	O
to	NN	O
the	:	O
exon	JJ	O
encoding	:	O
amino	NN	O
acid	CC	O
18	NNP	O
in	CC	O
a	JJ	O
protein	TO	O
of	NNP	O
323	:	O
amino	DT	O
acids	JJ	O
(NCBI	NN	O
accession	NN	O
number	:	O
NP—663403).	NN	O
The	CC	O
gene	NNP	O
of	JJ	O
interest	:	O
is	DT	O
represented	JJ	O
by	NN	O
NCBI	NN	O
accession	NNS	O
NM—145428,	TO	O
ortholog	:	O
of	NNP	O
human	CC	O
DKFZP566O084	NNP	O
protein.	JJ	O
Aliases	NNP	O
include	.	O
cDNA	NNP	O
sequence	NNP	O
BC003479,	NNP	O
LOC216820,	VBZ	O
CGI-93	TO	O
and	VB	O
MGC8916.	NN	O
DKFZp566O084	.	O
is	JJ	O
a	NN	O
hypothetical	VBD	O
protein	DT	O
containing	NN	O
a	RB	O
short	TO	O
chain	DT	O
dehydrogenase	NN	O
domain	VBG	O
(Pfam	JJ	O
PF00106).	JJ	O
Typically,	CD	O
such	IN	O
proteins	DT	O
are	NN	O
NAD-	IN	O
or	CD	O
NADP-dependent	JJ	O
oxidoreductases.	NNS	O
A	NNP	O
signal	NN	O
peptide	NN	O
is	.	O
predicted	DT	O
at	NN	O
the	IN	O
N-terminus,	NN	O
and	VBZ	O
ProtComp	VBN	O
(Softberry,	IN	O
Inc.	NNP	O
Mount	NN	O
Kisco,	,	O
N.Y.)	NN	O
software	IN	O
analysis	JJ	O
indicates	NNP	O
the	.	O
protein	NNS	O
may	VBP	O
be	JJ	O
targeted	NN	O
to	,	O
the	,	O
mitochondrion.	NNP	O
Targeted	CC	O
or	.	O
gene	NNP	O
trap	VBZ	O
mutations	DT	O
were	JJ	O
generated	NN	O
in	VBG	O
strain	DT	O
129SvEvBrd-derived	JJ	O
embryonic	NN	O
stem	NN	O
(ES)	NN	O
cells.	NNP	O
The	.	O
chimeric	,	O
mice	JJ	O
were	NNS	O
bred	VBP	O
to	JJ	O
C57BL/6J	CC	O
albino	JJ	O
mice	.	O
to	DT	O
generate	JJ	O
F1	NN	O
heterozygous	VBZ	O
animals.	VBN	O
These	IN	O
progeny	DT	O
were	,	O
intercrossed	CC	O
to	NNP	O
generate	,	O
F2	NNP	O
wild	NNP	O
type,	,	O
heterozygous,	)	O
and	NN	O
homozygous	NN	O
mutant	VBZ	O
progeny.	DT	O
On	NN	O
rare	MD	O
occasions,	VB	O
for	VBN	O
example	TO	O
when	DT	O
very	.	O
few	VBN	O
F1	CC	O
mice	NN	O
were	JJ	O
obtained	NNS	O
from	VBD	O
the	VBN	O
chimera,	IN	O
F1	JJ	O
heterozygous	JJ	O
mice	JJ	O
were	NN	O
crossed	)	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
In	VBD	O
the	VBN	O
wild-type	TO	O
animals,	VB	O
expression	NNP	O
of	JJ	O
the	,	O
target	,	O
gene	CC	O
was	JJ	O
detected	NN	O
in	.	O
embryonic	IN	O
stem	JJ	O
(ES)	,	O
cells	IN	O
and	NN	O
in	WRB	O
all	RB	O
19	JJ	O
adult	NNP	O
tissue	NN	O
samples	VBD	O
tested	VBN	O
by	IN	O
RT-PCR,	DT	O
except	,	O
asthmatic	NNP	O
lung,	JJ	O
skeletal	NNS	O
muscle,	VBD	O
and	VBN	O
adipose	TO	O
tissue.	CD	O
Genetic	JJ	O
data	NN	O
indicate	TO	O
that	VB	O
this	JJ	O
retroviral	JJ	O
insertion	NNS	O
resulted	IN	O
in	DT	O
lethality	NN	O
of	TO	O
the	VB	O
homozygous	DT	O
mutants.	NNP	O
Due	.	O
to	IN	O
lethality,	DT	O
transcript	JJ	O
expression	,	O
analysis	NN	O
was	IN	O
not	DT	O
performed.	NN	O
It	NN	O
is	VBD	O
not	VBN	O
clear	IN	O
when	JJ	O
lethality	NN	O
occurs	)	O
but	NNS	O
by	CC	O
three	IN	O
weeks	DT	O
of	CD	O
age	NNS	O
all	NN	O
of	NNS	O
the	VBN	O
(−/−)	IN	O
mutant	,	O
mice	IN	O
were	JJ	O
dead.	,	O
Discussion	JJ	O
Related	,	O
to	CC	O
Embryonic	JJ	O
Developmental	.	O
Abnormality	NNP	O
of	NNS	O
Lethality:	NN	O
Embryonic	IN	O
lethality	DT	O
in	JJ	O
knockout	NN	O
mice	VBD	O
usually	IN	O
results	NN	O
from	IN	O
various	DT	O
serious	JJ	O
developmental	.	O
problems	JJ	O
including	TO	O
but	,	O
not	JJ	O
limited	NN	O
to	NN	O
neurodegenerative	VBD	O
diseases,	RB	O
angiogenic	.	O
disorders,	PRP	O
inflammatory	VBZ	O
diseases,	RB	O
or	JJ	O
where	WRB	O
the	NN	O
gene/protein	VBZ	O
has	CC	O
an	IN	O
important	CD	O
role	NNS	O
in	IN	O
basic	NN	O
cell	DT	O
signaling	IN	O
processes	DT	O
in	)	O
many	NN	O
cell	NN	O
types.	VBD	O
In	.	O
addition,	NN	O
embryonic	VBN	O
lethals	TO	O
are	NNP	O
useful	NNP	O
as	NNP	O
potential	IN	O
cancer	:	O
models.	JJ	O
Likewise,	NN	O
the	IN	O
corresponding	NN	O
heterozygous	NNS	O
(+/−)	RB	O
mutant	NNS	O
animals	IN	O
are	JJ	O
particularly	JJ	O
useful	NN	O
when	NNS	O
they	VBG	O
exhibit	CC	O
a	RB	O
phenotype	JJ	O
and/or	TO	O
a	JJ	O
pathology	,	O
report	JJ	O
which	,	O
reveals	NN	O
highly	,	O
informative	CC	O
clues	WRB	O
as	DT	O
to	NN	O
the	VBZ	O
function	DT	O
of	JJ	O
the	NN	O
knocked-out	IN	O
gene.	JJ	O
For	NN	O
instance,	VBG	O
EPO	NNS	O
knockout	IN	O
animals	JJ	O
were	NN	O
embryonic	.	O
lethals,	IN	O
but	,	O
the	JJ	O
pathology	NNS	O
reports	VBP	O
on	JJ	O
the	IN	O
embryos	JJ	O
showed	NN	O
a	.	O
profound	,	O
lack	DT	O
of	VBG	O
RBCs.	JJ	O
In	)	O
the	NN	O
instant	NNS	O
example,	VBP	O
PRO238	RB	O
mutant	JJ	O
mice	WRB	O
showed	PRP	O
serious	VBP	O
and	DT	O
multiple	NN	O
physiological	NN	O
abnormalities	DT	O
involving	NN	O
the	NN	O
gastrointestinal	WDT	O
tract	VBZ	O
(GI),	RB	O
hematopoietic,	JJ	O
respiratory,	NNS	O
neuromuscular,	IN	O
and	TO	O
reproductive	DT	O
systems.	NN	O
1.	IN	O
Overall	DT	O
Phenotypic	JJ	O
Analysis	.	O
(for	IN	O
Disrupted	,	O
Gene:	NNP	O
DNA35600-1162	NN	O
(UNQ212)	NNS	O
(a)	VBD	O
Overall	JJ	O
Phenotypic	,	O
Summary:	CC	O
Multiple	DT	O
histological	NN	O
defects	NNS	O
were	IN	O
observed	DT	O
in	NN	O
KO	VBD	O
mice	DT	O
involving	JJ	O
GI,	NN	O
hematopoietic,	IN	O
respiratory,	.	O
neuromuscular,	IN	O
and	DT	O
reproductive	JJ	O
systems.	,	O
Necropsy	NNP	O
revealed	NN	O
that	NN	O
the	VBD	O
13	JJ	O
day-old	CC	O
homozygous	JJ	O
mutants	JJ	O
exhibited	NNS	O
numerous	VBG	O
lesions,	DT	O
including	JJ	O
megaesophagus	NN	O
and	,	O
hypoplasia	,	O
of	,	O
the	,	O
glandular	CC	O
stomach.	JJ	O
Three	.	O
fourths	.	O
of	JJ	O
the	NNP	O
(−/−)	NNP	O
mice	IN	O
exhibited	VBN	O
thymic	:	O
atrophy,	NNP	O
lymphoid	)	O
depletion,	)	O
and	JJ	O
muscle	NNP	O
degeneration.	:	O
Exophthalmus	JJ	O
was	JJ	O
present	NNS	O
in	VBD	O
most	VBN	O
homozygotes.	IN	O
Homozygous	NNP	O
mutant	NN	O
mice	VBG	O
resulted	,	O
in	,	O
embryonic	,	O
lethality	,	O
by	CC	O
three	JJ	O
weeks	.	O
of	NNP	O
age.	VBD	O
Thus,	IN	O
PRO238	DT	O
polypeptides	CD	O
or	JJ	O
the	JJ	O
gene	NNS	O
encoding	VBD	O
PRO238	JJ	O
must	,	O
be	VBG	O
essential	NN	O
for	CC	O
embryonic	NN	O
development.	IN	O
(b)	DT	O
Pathology	JJ	O
Analysis	.	O
Multiple	CD	O
histological	NNS	O
defects	IN	O
were	DT	O
observed	)	O
in	NN	O
KO	VBD	O
mice	JJ	O
involving	,	O
GI,	JJ	O
hematopoietic,	,	O
respiratory,	CC	O
neuromuscular,	NN	O
and	.	O
reproductive	NNP	O
systems.	VBD	O
Necropsy	VBN	O
revealed	IN	O
that	JJS	O
the	.	O
13	JJ	O
day-old	JJ	O
homozygous	NN	O
mutants	VBD	O
exhibited	IN	O
numerous	JJ	O
lesions,	NN	O
including	IN	O
megaesophagus	CD	O
and	NNS	O
hypoplasia	IN	O
of	.	O
the	,	O
glandular	NNP	O
stomach.	VBZ	O
Three	CC	O
fourths	DT	O
of	NN	O
the	VBG	O
(−/−)	NNP	O
mice	MD	O
exhibited	VB	O
thymic	JJ	O
atrophy,	IN	O
lymphoid	JJ	O
depletion,	.	O
and	)	O
muscle	NNP	O
degeneration.	NNP	O
Exophthalmus	NNP	O
was	JJ	O
present	NNS	O
in	VBD	O
most	VBN	O
homozygotes.	IN	O
In	NNP	O
the	NN	O
GI	VBG	O
tract,	,	O
esophageal	,	O
dilatation	,	O
with	,	O
multifocal	CC	O
hyperkeratosis,	JJ	O
as	.	O
well	NNP	O
as	VBD	O
gastric	IN	O
hypoplasia	DT	O
was	CD	O
observed	JJ	O
with	JJ	O
significantly	NNS	O
reduced	VBD	O
parietal	JJ	O
cells	,	O
and	VBG	O
chief	NN	O
cells.	CC	O
These	NN	O
KO	IN	O
mice	DT	O
appeared	JJ	O
to	.	O
be	CD	O
stressed	NNS	O
with	IN	O
thymic	DT	O
atrophy/necrosis	)	O
and/or	NN	O
splenic	VBD	O
lymphoid	JJ	O
depletion.	,	O
Increased	JJ	O
hematopoiesis	,	O
was	CC	O
also	NN	O
noted	.	O
in	NNP	O
bone	VBD	O
marrow,	VBN	O
liver,	IN	O
spleen	JJS	O
and	.	O
thymus.	IN	O
Aspiration	DT	O
pneumonia	NNP	O
was	,	O
found	JJ	O
in	NN	O
several	IN	O
mice,	JJ	O
which	,	O
may	RB	O
be	RB	O
related	IN	O
to	JJ	O
esophageal	NN	O
dysfunction.	VBD	O
Other	VBN	O
findings	IN	O
included	RB	O
seminiferous	VBN	O
tubule	JJ	O
necrosis,	NNS	O
multifocal	CC	O
vacuolation	JJ	O
in	.	O
brain,	DT	O
focal	NNP	O
muscular	NN	O
degeneration,	VBD	O
and	TO	O
diffuse	VB	O
degeneration	VBN	O
in	IN	O
the	JJ	O
Harderia	NN	O
gland.	NN	O
All	JJ	O
the	JJ	O
(−/−)	.	O
mice	VBN	O
died	NN	O
by	VBD	O
three	RB	O
weeks	VBN	O
of	IN	O
age.	NN	O
As	,	O
summarized	,	O
above,	JJ	O
embryonic	CC	O
lethality	.	O
in	NNP	O
knockout	NN	O
mice	VBD	O
usually	VBN	O
results	IN	O
from	JJ	O
various	,	O
serious	WDT	O
developmental	MD	O
problems	VB	O
including	VBN	O
but	TO	O
not	VB	O
limited	.	O
to	JJ	O
neurodegenerative	NNS	O
diseases,	VBD	O
angiogenic	JJ	O
disorders,	NN	O
inflammatory	,	O
diseases,	JJ	O
or	NN	O
where	IN	O
the	,	O
gene/protein	JJ	O
has	JJ	O
an	,	O
important	CC	O
role	VB	O
in	NN	O
basic	IN	O
cell	DT	O
signaling	NNP	O
processes	.	O
in	PDT	O
many	DT	O
cell	)	O
types.	NN	O
In	VBN	O
addition,	IN	O
embryonic	CD	O
lethals	NNS	O
are	IN	O
useful	.	O
as	IN	O
potential	VBN	O
cancer	,	O
models.	JJ	O
In	NN	O
the	IN	O
instant	NN	O
example,	NNS	O
it	RB	O
is	NNS	O
likely	IN	O
that	JJ	O
antagonists	JJ	O
to	NN	O
PRO238	NNS	O
or	VBG	O
its	CC	O
encoding	RB	O
gene	JJ	O
results	TO	O
in	JJ	O
serious	,	O
disorders	JJ	O
of	,	O
the	NN	O
gastrointestinal	,	O
tract	CC	O
and	WRB	O
could	DT	O
lead	NN	O
to	VBZ	O
such	DT	O
disorders	JJ	O
as	NN	O
stomach	IN	O
or	JJ	O
esophageal	NN	O
cancer.	VBG	O
Likewise,	NNS	O
PRO238	IN	O
or	JJ	O
agonists	NN	O
would	.	O
be	IN	O
useful	,	O
in	JJ	O
the	NNS	O
treatment	VBP	O
of	JJ	O
gastrointestinal	IN	O
disorders	JJ	O
including	NN	O
cancer.	.	O
D.	IN	O
Generation	DT	O
and	JJ	O
Analysis	,	O
of	PRP	O
Mice	VBZ	O
Comprising	JJ	O
DNA66658-1584	IN	O
(UNQ688)	VBZ	O
Gene	TO	O
Disruptions	VB	O
In	CC	O
these	PRP$	O
knockout	JJ	O
experiments,	NN	O
the	NNS	O
gene	IN	O
encoding	JJ	O
PRO1328	NNS	O
polypeptides	IN	O
(designated	DT	O
as	JJ	O
DNA66658-1584	NN	O
(UNQ688)	CC	O
was	MD	O
disrupted.	VB	O
The	TO	O
gene	JJ	O
specific	NNS	O
information	IN	O
for	NN	O
these	CC	O
studies	JJ	O
is	.	O
as	,	O
follows:	NNP	O
the	CC	O
mutated	NNS	O
mouse	MD	O
gene	VB	O
corresponds	JJ	O
to	IN	O
nucleotide	DT	O
reference:	NN	O
NM—026674	IN	O
or	JJ	O
Mus	NNS	O
musculus	VBG	O
RIKEN	.	O
cDNA	NNP	O
0610008A10	NNP	O
gene	CC	O
(0610008A10Rik);	NNP	O
protein	IN	O
reference:	NNP	O
BAB22004;	NNP	O
the	NNP	O
human	)	O
gene	NNP	O
sequence	NNP	O
reference:	IN	O
NM—031301	DT	O
or	NN	O
Homo	,	O
sapiens	DT	O
which	NN	O
is	VBG	O
likely	NNP	O
the	NNS	O
ortholog	VBN	O
of	IN	O
C.	NNP	O
elegans	)	O
anterior	VBD	O
pharynx	.	O
defective	DT	O
1B	NN	O
(APH-1B);	JJ	O
protein	NN	O
reference:	IN	O
AAH20905	DT	O
or	NNS	O
hypothetical	VBZ	O
protein	IN	O
DKFZp564D0372	:	O
[Homo	DT	O
sapiens].	VBN	O
Mutation	NN	O
Specific	NN	O
Information	NNS	O
corresponds	TO	O
to	JJ	O
homologous	:	O
recombination	NN	O
(conditional)	CC	O
(codon	NNP	O
2	CC	O
was	NNP	O
targeted).	VBP	O
The	CD	O
mouse	NN	O
gene	:	O
targeted	JJ	O
is	:	O
represented	:	O
by	DT	O
RIKEN	JJ	O
cDNA	NN	O
0610008A10,	NN	O
which	:	O
is	NN	O
orthologous	CC	O
to	NNP	O
human	NNS	O
anterior	WDT	O
pharynx	VBZ	O
defective	JJ	O
1B-like	DT	O
(PSFL).	NN	O
Aliases	IN	O
include	NNP	O
presenilin	NNS	O
stabilization	JJ	O
factor-like	VBP	O
and	JJ	O
APH-1B.	CD	O
PSFL	:	O
consists	JJ	O
of	:	O
a	NNP	O
signal	CC	O
peptide	JJ	O
sequence	NN	O
and	NNP	O
six	NNP	O
or	.	O
seven	NNP	O
transmembrane	NNP	O
spanning	NNP	O
segments.	VBZ	O
The	TO	O
protein	JJ	O
is	NN	O
predicted	)	O
to	$	O
be	CD	O
located	VBD	O
at	.	O
the	DT	O
plasma	NN	O
membrane,	NN	O
as	VBN	O
determined	VBZ	O
by	VBN	O
ProtComp	IN	O
analysis	NNP	O
(Softberry,	NN	O
Inc.,	,	O
Mount	WDT	O
Kisco,	VBZ	O
N.Y.,	JJ	O
2003).	TO	O
PSFL	JJ	O
interacts	JJ	O
with	NN	O
presenilin	JJ	O
enhancer	JJ	O
2,	.	O
nicastrin,	NNS	O
and	VBP	O
presenilin.	JJ	O
PSFL	NN	O
is	NN	O
required	CC	O
for	.	O
the	NNP	O
activity	VBZ	O
and	IN	O
accumulation	DT	O
of	JJ	O
gamma-secretase,	NN	O
which	NN	O
is	CC	O
involved	CD	O
in	CC	O
Notch	CD	O
and	NN	O
beta-amyloid	VBG	O
precursor	.	O
protein	DT	O
signaling.	NN	O
Notch	VBZ	O
is	VBN	O
involved	TO	O
in	VB	O
developmental	VBN	O
cell	IN	O
fate,	DT	O
and	NN	O
beta-amyloid	,	O
precursor	IN	O
protein	VBN	O
is	IN	O
involved	NNP	O
in	NN	O
gene	,	O
expression	,	O
and	NNP	O
Alzheimer's	,	O
disease.	,	O
Targeted	.	O
or	NNP	O
gene	VBZ	O
trap	IN	O
mutations	JJ	O
were	NN	O
generated	,	O
in	,	O
strain	CC	O
129SvEvBrd-derived	.	O
embryonic	NNP	O
stem	VBZ	O
(ES)	VBN	O
cells.	IN	O
The	DT	O
chimeric	NN	O
mice	CC	O
were	NN	O
bred	IN	O
to	,	O
C57BL/6J	WDT	O
albino	VBZ	O
mice	VBN	O
to	IN	O
generate	NNP	O
F1	CC	O
heterozygous	JJ	O
animals.	NN	O
These	NN	O
progeny	.	O
were	NN	O
intercrossed	VBZ	O
to	VBN	O
generate	IN	O
F2	JJ	O
wild	NN	O
type,	,	O
heterozygous,	CC	O
and	JJ	O
homozygous	NN	O
mutant	NN	O
progeny.	VBZ	O
On	VBN	O
rare	IN	O
occasions,	NN	O
for	NN	O
example	CC	O
when	POS	O
very	.	O
few	VBN	O
F1	CC	O
mice	NN	O
were	JJ	O
obtained	NNS	O
from	VBD	O
the	VBN	O
chimera,	IN	O
F1	JJ	O
heterozygous	JJ	O
mice	JJ	O
were	NN	O
crossed	)	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
Level	VBD	O
I	VBN	O
phenotypic	TO	O
analysis	VB	O
was	NNP	O
performed	JJ	O
on	,	O
mice	,	O
from	CC	O
this	JJ	O
generation	NN	O
as	.	O
described	IN	O
below.	JJ	O
Wild-type	,	O
expression	IN	O
of	NN	O
the	WRB	O
target	RB	O
gene	JJ	O
was	NNP	O
detected	NN	O
in	VBD	O
embryonic	VBN	O
stem	IN	O
(ES)	DT	O
cells	,	O
and	NNP	O
in	JJ	O
all	NNS	O
13	VBD	O
adult	VBN	O
tissue	TO	O
samples	CD	O
tested	JJ	O
by	NN	O
RT-PCR,	TO	O
except	VB	O
tail.	JJ	O
Disruption	JJ	O
of	NNS	O
the	IN	O
target	DT	O
gene	NN	O
was	TO	O
confirmed	VB	O
by	DT	O
Southern	NNP	O
hybridization	.	O
analysis.	NN	O
1.	PRP	O
Phenotypic	VBP	O
Analysis	NN	O
(for	VBD	O
Disrupted	VBN	O
Gene:	IN	O
DNA66658-1584	NN	O
(UNQ688)	IN	O
(a)	DT	O
Overall	NN	O
Phenotypic	IN	O
Summary	VBN	O
The	.	O
male	JJ	O
and	NN	O
female	IN	O
(−/−)	DT	O
mice	NN	O
exhibited	NN	O
increased	VBD	O
mean	VBN	O
serum	IN	O
cholesterol	JJ	O
levels	NN	O
when	)	O
compared	NNS	O
with	CC	O
their	IN	O
gender-matched	DT	O
(+/+)	CD	O
littermates	NNS	O
and	NN	O
the	NNS	O
historical	VBN	O
means.	IN	O
In	,	O
addition,	IN	O
abnormalities	.	O
in	NN	O
the	IN	O
urinalysis	DT	O
was	NN	O
observed	NN	O
in	VBD	O
the	VBN	O
homozygous	IN	O
mice.	NNP	O
(b)	NN	O
Phenotypic	.	O
Analysis:	.	O
Cardiology	NNP	O
In	NNP	O
the	IN	O
area	VBN	O
of	:	O
cardiovascular	NNP	O
biology,	)	O
targets	)	O
were	JJ	O
identified	NNP	O
herein	NNP	O
for	DT	O
the	NN	O
treatment	CC	O
of	NN	O
hypertension,	)	O
atherosclerosis,	NN	O
heart	VBD	O
failure,	JJ	O
stroke,	NN	O
various	NN	O
coronary	NN	O
artery	NNS	O
diseases,	WRB	O
dyslipidemias	VBN	O
such	IN	O
as	PRP$	O
high	JJ	O
cholesterol	)	O
(hypercholesterolemia)	VBZ	O
and	CC	O
elevated	DT	O
serum	JJ	O
triglycerides	.	O
(hypertriglyceridemia),	IN	O
cancer	,	O
and/or	NNS	O
obesity.	IN	O
The	DT	O
phenotypic	NN	O
tests	VBD	O
included	VBN	O
the	IN	O
measurement	DT	O
of	JJ	O
serum	.	O
cholesterol	)	O
and	NNP	O
triglycerides.	:	O
Blood	NN	O
Lipids	IN	O
Procedure:	DT	O
A	NN	O
cohort	IN	O
of	JJ	O
4	,	O
wild	NNS	O
type,	VBD	O
4	VBN	O
heterozygotes	NN	O
and	IN	O
8	DT	O
homozygotes	NN	O
were	IN	O
tested	,	O
in	,	O
this	NN	O
assay.	,	O
High	,	O
cholesterol	JJ	O
levels	JJ	O
are	NN	O
recognized	,	O
risk	NNS	O
factors	JJ	O
in	IN	O
the	JJ	O
development	NN	O
of	)	O
cardiovascular	CC	O
disease.	VBN	O
Measuring	NN	O
blood	NNS	O
lipids	,	O
allowed	NN	O
finding	NN	O
of	.	O
the	DT	O
biological	NN	O
switches	NNS	O
that	VBD	O
regulate	DT	O
blood	NN	O
lipid	IN	O
levels	NN	O
and	NN	O
that	CC	O
upon	.	O
inhibition	NNP	O
would	NNP	O
lead	:	O
to	DT	O
a	NN	O
reduction	IN	O
in	CD	O
the	JJ	O
risk	,	O
for	CD	O
cardiovascular	NNS	O
disease.	CC	O
Cholesterol	CD	O
measurements	NNS	O
were	VBD	O
recorded.	VBN	O
The	IN	O
COBAS	DT	O
Integra	.	O
400	JJ	O
(mfr:	NN	O
Roche)	NNS	O
was	VBP	O
used	VBN	O
for	NN	O
running	NNS	O
blood	IN	O
chemistry	DT	O
tests	NN	O
on	IN	O
mice.	JJ	O
Results:	.	O
As	VBG	O
summarized	NN	O
above,	NNS	O
the	VBD	O
(−/−)	NN	O
mice	IN	O
exhibited	DT	O
an	JJ	O
increased	NNS	O
mean	WDT	O
serum	VBP	O
cholesterol	NN	O
level	JJ	O
(compared	NNS	O
to	CC	O
normal	DT	O
levels)	JJ	O
when	NN	O
compared	MD	O
with	VB	O
their	TO	O
gender-matched	DT	O
(+/+)	NN	O
littermates	IN	O
and	DT	O
the	NN	O
historical	IN	O
mean.	JJ	O
No	.	O
change	NN	O
in	NNS	O
triglycerides	VBD	O
was	.	O
observed.	DT	O
(Analyzed	NNP	O
Wt/Het/Hom:	NNP	O
4/4/8)	CD	O
Thus,	:	O
mutant	)	O
mice	VBD	O
deficient	VBN	O
in	IN	O
the	VBG	O
PRO1328	NN	O
can	NN	O
serve	NNS	O
as	IN	O
a	.	O
model	:	O
for	IN	O
cardiovascular	VBN	O
disease.	,	O
PRO1328	DT	O
or	)	O
its	NN	O
encoding	VBD	O
gene	DT	O
would	VBN	O
be	NN	O
useful	NN	O
for	NN	O
regulating	NN	O
blood	VBN	O
lipids	TO	O
and	JJ	O
in	)	O
particular	WRB	O
maintaining	VBN	O
normal	IN	O
cholesterol	PRP$	O
and	JJ	O
triglyceride	)	O
levels.	VBZ	O
Thus,	CC	O
PRO1328	DT	O
polypeptides	JJ	O
would	.	O
be	DT	O
useful	NN	O
in	IN	O
the	NNS	O
treatment	VBD	O
of	.	O
such	JJ	O
cardiovascular	:	O
diseases	)	O
as:	,	O
hypertension,	JJ	O
atherosclerosis,	NN	O
heart	NN	O
failure,	IN	O
stroke,	DT	O
various	NNP	O
coronary	MD	O
artery	VB	O
diseases,	IN	O
and/or	DT	O
obesity	NN	O
or	IN	O
diabetes.	JJ	O
Urinalysis:	.	O
Test	NNP	O
Description:	CC	O
The	PRP$	O
routine	JJ	O
urinalysis	NN	O
is	MD	O
a	VB	O
screening	JJ	O
test	IN	O
done	VBG	O
to	NN	O
provide	NNS	O
a	CC	O
general	IN	O
evaluation	JJ	O
of	VBG	O
the	JJ	O
renal/urinary	NN	O
system.	CC	O
The	NN	O
characteristics	.	O
for	,	O
which	NNP	O
urine	NNS	O
is	MD	O
routinely	VB	O
examined	JJ	O
includes	IN	O
tests	DT	O
for	NN	O
protein,	IN	O
glucose,	JJ	O
ketones,	JJ	O
blood,	NNS	O
bilirubin,	:	O
urobilinogen,	,	O
nitrate	,	O
and	NN	O
leukocyte	,	O
esterase,	,	O
as	JJ	O
well	JJ	O
as	NN	O
pH	,	O
and	JJ	O
specific	NN	O
gravity.	CC	O
The	.	O
histograms	:	O
show	JJS	O
9	:	O
measurements	DT	O
grouped	JJ	O
by	NN	O
genotype:	VBZ	O
Leukocyte,	DT	O
nitrate,	JJ	O
protein,	NN	O
glucose,	VBN	O
osmolality,	TO	O
ketone,	VB	O
urobilinogen,	DT	O
bilirubin,	JJ	O
blood.	NN	O
Results:	IN	O
The	DT	O
(−/−)	JJ	O
mutant	.	O
mice	DT	O
showed	NNS	O
abnormalities	IN	O
in	WDT	O
the	NN	O
urinalysis	VBZ	O
as	RB	O
described	JJ	O
above.	VBZ	O
Elevated	NNS	O
levels	IN	O
of	,	O
urobilinogen,	,	O
ketones	,	O
and	,	O
blood	,	O
were	,	O
observed.	NN	O
The	CC	O
presence	JJ	O
of	,	O
ketones	RB	O
in	RB	O
the	IN	O
urine	NN	O
is	CC	O
indicative	JJ	O
of	.	O
an	DT	O
abnormal	NN	O
lipid	VBP	O
metabolism	CD	O
or	NNS	O
dyslipidemia	VBN	O
which	IN	O
may	:	O
be	,	O
an	,	O
early	,	O
sign	,	O
of	,	O
the	,	O
onset	,	O
of	,	O
diabetes.	.	O
E.	:	O
Generation	DT	O
and	)	O
Analysis	NN	O
of	NN	O
Mice	VBD	O
Comprising	NNS	O
DNA96787-2534-1	IN	O
(UNQ1896)	DT	O
Gene	NN	O
Disruptions	IN	O
In	VBN	O
these	.	O
knockout	JJ	O
experiments,	NNS	O
the	IN	O
gene	,	O
encoding	NNS	O
PRO4342	CC	O
polypeptides	NN	O
(designated	VBD	O
as	.	O
DNA96787-2534-1	DT	O
(UNQ1896)	NN	O
was	IN	O
disrupted.	NNS	O
The	IN	O
gene	DT	O
specific	NN	O
information	VBZ	O
for	JJ	O
these	IN	O
studies	DT	O
is	JJ	O
as	JJ	O
follows:	NN	O
the	CC	O
mutated	NN	O
mouse	WDT	O
gene	MD	O
corresponds	VB	O
to	DT	O
nucleotide	JJ	O
reference:	NN	O
NM—019451	IN	O
or	DT	O
Mus	NN	O
musculus	IN	O
interleukin	.	O
1	NNP	O
family,	NNP	O
member	CC	O
5	NNP	O
(delta)	IN	O
(Il1f5);	NNP	O
protein	NNP	O
reference:	NNP	O
NP—062324	)	O
or	NNP	O
interleukin	NNP	O
1	IN	O
family,	DT	O
member	NN	O
5;	,	O
interleukin	DT	O
1	NN	O
receptor	VBG	O
antagonist	NNP	O
homolog	NNS	O
1	VBN	O
[Mus	IN	O
musculus];	NNP	O
the	)	O
human	VBD	O
gene	.	O
sequence	DT	O
reference:	NN	O
NM—012275	JJ	O
or	NN	O
Homo	IN	O
sapiens	DT	O
interleukin	NNS	O
1	VBZ	O
family,	IN	O
member	:	O
5	DT	O
(delta)	VBN	O
(IL1F5),	NN	O
transcript	NN	O
variant	NNS	O
1;	TO	O
protein	JJ	O
reference:	:	O
NP—036407	NN	O
or	CC	O
interleukin	NNP	O
1	CC	O
family,	JJ	O
member	CD	O
5;	,	O
interleukin-1	NN	O
receptor	CD	O
antagonist	)	O
homolog	:	O
1;	JJ	O
interleukin	:	O
1,	NN	O
delta;	CC	O
interleukin-1-like	VB	O
protein	CD	O
1;	,	O
family	NN	O
of	:	O
interleukin	JJ	O
1-delta;	CD	O
interleukin-1	NN	O
HY1;	NN	O
IL-1ra	NN	O
homolog;	CD	O
IL-1	NNP	O
related	:	O
protein	DT	O
3	JJ	O
[Homo	NN	O
sapiens].	NN	O
Mutation	:	O
Specific	NN	O
Information	CC	O
corresponds	NN	O
to	NNS	O
homologous	VBP	O
recombination	CD	O
(standard)	,	O
(exons	NN	O
3,	CD	O
4	)	O
and	,	O
5	JJ	O
were	JJ	O
targeted—AK014576).	:	O
The	JJ	O
disrupted	:	O
mouse	NN	O
gene	CC	O
is	VB	O
an	CD	O
interleukin	,	O
1	NN	O
family,	:	O
member	JJ	O
5	NN	O
(delta)	NN	O
(Il1f5),	NN	O
ortholog	:	O
of	JJ	O
human	,	O
interleukin	:	O
1	JJ	O
family,	NN	O
member	:	O
5	NN	O
(delta)	IN	O
(IL1F5).	JJ	O
Aliases	:	O
include	JJ	O
IL-1H3,	:	O
IL1HY1,	NNP	O
FIL1delta,	:	O
interleukin	NNP	O
1	VBD	O
receptor	RB	O
antagonist	CD	O
homolog	NNP	O
1,	.	O
FIL1,	NNP	O
FIL1D,	NNP	O
IL1L1,	NNP	O
IL1RP3,	VBZ	O
MGC29840,	TO	O
IL-1ra	JJ	O
homolog,	NN	O
interleukin-1	)	O
HY1,	$	O
IL-1	,	O
related	CD	O
protein	CC	O
3,	CD	O
interleukin-1-like	VBD	O
protein	.	O
1,	DT	O
family	VBN	O
of	NN	O
interleukin	NN	O
1-delta,	VBZ	O
and	DT	O
interleukin-1	JJ	O
receptor	CD	O
antagonist	,	O
homolog	NN	O
1.	CD	O
IL1F5,	)	O
a	,	O
member	NN	O
of	IN	O
the	JJ	O
interleukin	FW	O
1	CD	O
cytokine	,	O
family,	NN	O
specifically	CD	O
inhibits	)	O
activation	.	O
of	NNS	O
nuclear	VBP	O
factor-kappaB	,	O
by	,	O
IL1F6	,	O
(interleukin	VBZ	O
1	CD	O
family,	NN	O
member	NN	O
6	NN	O
[epsilon];	,	O
Debets	,	B
et	,	I
al.,	,	I
J.	,	I
Immunol.	,	I
167(3):1440-6	NNP	I
(2001)).(	,	O
However,	JJ	O
IL1F5	,	O
does	NNP	O
not	VBD	O
have	RB	O
antagonist	,	O
activities	JJ	O
associated	NN	O
with	,	O
its	NN	O
close	IN	O
paralog,	JJ	O
IL1RN	,	O
(interleukin	CC	O
1	JJ	O
receptor	NN	O
antagonist;	NN	O
Barton	NN	B
et	.	I
al.,	,	I
Eur	DT	I
J	NN	I
Immunol	IN	I
30(11):3299-308	DT	I
(2000)).(	JJ	O
Allelic	CD	O
variation	JJ	O
in	,	O
IL1F5	RB	O
has	VBZ	O
been	NN	O
suggested	IN	O
as	JJ	O
a	JJ	O
predisposing	IN	O
factor	NNP	O
in	JJ	O
some	CD	O
forms	,	O
of	NN	O
severe	CD	O
alopecia	:	O
areata	NNPS	O
Tazi-Ahnini	RB	B
et	,	I
al.,	NNP	I
Eur	.	I
J	NN	I
Immunogenet	.	I
29(1):25-30	,	I
(2002)).(	NNP	O
By	VBZ	O
similarity	RB	O
with	VB	O
other	NN	O
members	NNS	O
of	VBN	O
the	IN	O
interleukin	PRP$	O
1	JJ	O
family,	,	O
an	NNP	O
extracellular	JJ	O
location	CD	O
is	NN	O
inferred.	:	O
Targeted	NNP	O
or	VBZ	O
gene	,	O
trap	NNP	O
mutations	NNP	O
were	NNP	O
generated	NN	O
in	.	O
strain	JJ	O
129SvEvBrd-derived	NN	O
embryonic	IN	O
stem	NNP	O
(ES)	VBZ	O
cells.	VBN	O
The	VBN	O
chimeric	IN	O
mice	DT	O
were	NN	O
bred	NN	O
to	IN	O
C57BL/6J	DT	O
albino	NNS	O
mice	IN	O
to	JJ	O
generate	NN	O
F1	NN	O
heterozygous	NNP	O
animals.	FW	O
These	,	O
progeny	NNP	O
were	NNP	O
intercrossed	NNP	O
to	NN	O
generate	.	O
F2	IN	O
wild	NN	O
type,	IN	O
heterozygous,	JJ	O
and	NNS	O
homozygous	IN	O
mutant	DT	O
progeny.	JJ	O
On	CD	O
rare	,	O
occasions,	DT	O
for	JJ	O
example	NN	O
when	VBZ	O
very	.	O
few	VBN	O
F1	CC	O
mice	NN	O
were	JJ	O
obtained	NNS	O
from	VBD	O
the	VBN	O
chimera,	IN	O
F1	JJ	O
heterozygous	JJ	O
mice	JJ	O
were	NN	O
crossed	)	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
Level	VBD	O
I	VBN	O
phenotypic	TO	O
analysis	VB	O
was	NNP	O
performed	JJ	O
on	,	O
mice	,	O
from	CC	O
this	JJ	O
generation	NN	O
as	.	O
described	IN	O
below.	JJ	O
Wild-type	,	O
expression	IN	O
of	NN	O
the	WRB	O
target	RB	O
gene	JJ	O
was	NNP	O
detected	NN	O
in	VBD	O
embryonic	VBN	O
stem	IN	O
(ES)	DT	O
cells	,	O
and	NNP	O
in	JJ	O
all	NNS	O
13	VBD	O
adult	VBN	O
samples	TO	O
tested	CD	O
by	JJ	O
RT-PCR,	NN	O
except	TO	O
lung,	VB	O
liver,	JJ	O
skeletal	JJ	O
muscle,	NNS	O
bone,	IN	O
and	DT	O
heart.	NN	O
Disruption	TO	O
of	VB	O
the	DT	O
target	NNP	O
gene	.	O
was	NN	O
confirmed	PRP	O
by	VBP	O
Southern	NN	O
hybridization	VBD	O
analysis.	VBN	O
1.	IN	O
Phenotypic	NN	O
Analysis	IN	O
(for	DT	O
disrupted	NN	O
gene:	IN	O
DNA96787-2534-1	VBN	O
(UNQ1896)	.	O
(a)	JJ	O
Overall	NN	O
Phenotypic	IN	O
Summary	DT	O
The	NN	O
female	NN	O
(−/−)	VBD	O
mice	VBN	O
exhibited	IN	O
increased	JJ	O
activity	NN	O
during	)	O
home-cage	NNS	O
activity	CC	O
testing	IN	O
when	DT	O
compared	CD	O
with	NN	O
their	NNS	O
wild-type	VBN	O
littermates	IN	O
and	,	O
the	IN	O
historical	,	O
means.	,	O
Whiskers	JJ	O
were	,	O
absent	,	O
on	CC	O
most	.	O
homozygotes,	NN	O
with	IN	O
bald	DT	O
patches	NN	O
on	NN	O
the	VBD	O
snouts.	VBN	O
There	IN	O
was	NNP	O
moderate	NN	O
degeneration	.	O
of	.	O
the	NNP	O
seminiferous	NNP	O
tubules	IN	O
in	VBN	O
the	:	O
male	NNP	O
(−/−)	)	O
mice	)	O
examined.	JJ	O
(b)	NNP	O
Phenotypic	NNP	O
Analysis:	DT	O
CNS/Neurology	NN	O
In	)	O
the	NN	O
area	VBD	O
of	JJ	O
neurology,	NN	O
analysis	IN	O
focused	NN	O
herein	NN	O
on	VBG	O
identifying	WRB	O
in	VBN	O
vivo	IN	O
validated	PRP$	O
targets	JJ	O
for	NNS	O
the	CC	O
treatment	DT	O
of	JJ	O
neurological	.	O
and	NNS	O
psychiatric	VBD	O
disorders	VBN	O
including	IN	O
depression,	JJS	O
generalized	,	O
anxiety	IN	O
disorders,	JJ	O
attention	NNS	O
deficit	IN	O
hyperactivity	DT	O
disorder,	.	O
obsessive	EX	O
compulsive	VBD	O
disorder,	JJ	O
schizophrenia,	NN	O
cognitive	IN	O
disorders,	DT	O
hyperalgesia	JJ	O
and	NNS	O
sensory	IN	O
disorders.	DT	O
Neurological	NN	O
disorders	)	O
include	NN	O
include	.	O
but	)	O
are	NNP	O
not	:	O
limited	NN	O
to:	IN	O
depression,	DT	O
generalized	NN	O
anxiety	IN	O
disorders,	,	O
attention	NN	O
deficit	VBD	O
disorder,	NN	O
sleep	IN	O
disorder,	VBG	O
hyperactivity	IN	O
disorder,	NN	O
obsessive	VBN	O
compulsive	NNS	O
disorder,	IN	O
schizophrenia,	DT	O
cognitive	NN	O
disorders,	IN	O
hyperalgesia	JJ	O
and	CC	O
sensory	JJ	O
disorders,	NNS	O
mild	VBG	O
to	,	O
moderate	VBN	O
anxiety,	NN	O
anxiety	,	O
disorder	NN	O
due	NN	O
to	NN	O
a	,	O
general	JJ	O
medical	JJ	O
condition,	,	O
anxiety	,	O
disorder	JJ	O
not	,	O
otherwise	NN	O
specified,	CC	O
generalized	JJ	O
anxiety	.	O
disorder,	JJ	O
panic	NNS	O
attack,	VBP	O
panic	VBP	O
disorder	CC	O
with	VBP	O
agoraphobia,	RB	O
panic	VBN	O
disorder	:	O
without	,	O
agoraphobia,	VBN	O
posttraumatic	NN	O
stress	,	O
disorder,	NN	O
social	NN	O
phobia,	,	O
social	JJ	O
anxiety,	,	O
autism,	NN	O
specific	,	O
phobia,	JJ	O
substance-induced	JJ	O
anxiety	,	O
disorder,	,	O
acute	JJ	O
alcohol	,	O
withdrawal,	NN	O
obsessive	CC	O
compulsive	NN	O
disorder,	,	O
agoraphobia,	NN	O
monopolar	TO	O
disorders,	VB	O
bipolar	,	O
disorder	NN	O
I	NN	O
or	JJ	O
II,	TO	O
bipolar	DT	O
disorder	JJ	O
not	JJ	O
otherwise	,	O
specified,	NN	O
cyclothymic	NN	O
disorder,	RB	O
depressive	RB	O
disorder,	,	O
major	VBN	O
depressive	NN	O
disorder,	,	O
mood	JJ	O
disorder,	,	O
substance-induced	JJ	O
mood	NN	O
disorder,	IN	O
enhancement	,	O
of	JJ	O
cognitive	NN	O
function,	IN	O
loss	,	O
of	JJ	O
cognitive	NN	O
function	,	O
associated	JJ	O
with	,	O
but	JJ	O
not	,	O
limited	,	O
to	JJ	O
Alzheimer's	,	O
disease,	JJ	O
stroke,	NN	O
or	,	O
traumatic	JJ	O
injury	NN	O
to	,	O
the	JJ	O
brain,	JJ	O
seizures	,	O
resulting	,	O
from	JJ	O
disease	,	O
or	JJ	O
injury	NN	O
including	PRP	O
but	CC	O
not	,	O
limited	JJ	O
to	NN	O
epilepsy,	RB	O
learning	RB	O
disorders/disabilities,	,	O
cerebral	JJ	O
palsy.	,	O
In	JJ	O
addition,	,	O
anxiety	JJ	O
disorders	JJ	O
may	,	O
apply	NN	O
to	,	O
personality	JJ	O
disorders	NN	O
including	,	O
but	NN	O
not	IN	O
limited	JJ	O
to	,	O
the	NN	O
following	IN	O
types:	JJ	O
paranoid,	NN	O
antisocial,	VBN	O
avoidant	IN	O
behavior,	CC	O
borderline	RB	O
personality	JJ	O
disorders,	TO	O
dependent,	POS	O
histronic,	,	O
narcissistic,	,	O
obsessive-compulsive,	CC	O
schizoid,	JJ	O
and	NN	O
schizotypal.	TO	O
Procedure:	DT	O
Behavioral	,	O
screens	NNS	O
were	VBG	O
performed	IN	O
on	NN	O
a	CC	O
cohort	NN	O
of	VBG	O
4	CC	O
wild	RB	O
type,	JJ	O
4	TO	O
heterozygous	,	O
and	VBG	O
8	,	O
homozygous	JJ	O
mutant	.	O
mice.	IN	O
All	,	O
behavioral	NN	O
tests	NNS	O
were	MD	O
done	VB	O
between	TO	O
12	NN	O
and	NNS	O
16	VBG	O
weeks	CC	O
of	RB	O
age	JJ	O
unless	TO	O
reduced	DT	O
viability	JJ	O
necessitates	:	O
earlier	,	O
testing.	,	O
These	JJ	O
tests	,	O
included	JJ	O
measurements	NN	O
of	,	O
circadian	,	O
rhythms	,	O
as	,	O
well	,	O
as	,	O
a	CC	O
functional	.	O
observational	:	O
battery	JJ	O
(FOB)	NNS	O
to	VBD	O
measure	VBN	O
anxiety,	IN	O
or	DT	O
activity	NN	O
levels.	IN	O
Circadian	CD	O
Test	JJ	O
Description:	,	O
Female	CD	O
mice	JJ	O
are	CC	O
individually	CD	O
housed	JJ	O
at	JJ	O
4	.	O
pm	DT	O
on	JJ	O
the	NNS	O
first	VBD	O
day	VBN	O
of	IN	O
testing	CD	O
in	CC	O
48.2	CD	O
cm×26.5	NNS	O
cm	IN	O
home	NN	O
cages	IN	O
and	VBN	O
administered	NN	O
food	NNS	O
and	RBR	O
water	.	O
ad	DT	O
libitum.	NNS	O
Animals	VBD	O
are	NNS	O
exposed	IN	O
to	JJ	O
a	NN	O
12-hour	RB	O
light/dark	RB	O
cycle	IN	O
with	DT	O
lights	JJ	O
turning	JJ	O
on	NN	O
at	)	O
7	TO	O
am	VB	O
and	,	O
turning	CC	O
off	NN	O
at	.	O
7	JJ	O
pm.	NNP	O
The	:	O
system	JJ	O
software	NNS	O
records	VBP	O
the	RB	O
number	VBN	O
of	IN	O
beam	CD	O
interruptions	NN	O
caused	IN	O
by	DT	O
the	JJ	O
animal's	NN	O
movements,	IN	O
with	VBG	O
beam	IN	O
breaks	CD	O
automatically	NN	O
divided	NN	O
into	NN	O
ambulations.	NNS	O
Activity	CC	O
is	VBN	O
recorded	NN	O
in	CC	O
60,	NN	O
one-hour	NN	O
intervals	.	O
during	NNS	O
the	VBP	O
three-day	VBN	O
test.	TO	O
Data	DT	O
generated	JJ	O
are	NN	O
displayed	NN	O
by	IN	O
median	NNS	O
activity	VBG	O
levels	IN	O
recorded	IN	O
for	CD	O
each	VBP	O
hour	CC	O
(circadian	VBG	O
rhythm)	RP	O
and	IN	O
median	CD	O
total	.	O
activity	DT	O
during	NN	O
each	NN	O
light/dark	VBZ	O
cycle	DT	O
(locomotor	NN	O
activity)	IN	O
over	NN	O
the	NNS	O
three-day	VBN	O
testing	IN	O
period.	DT	O
Results:	POS	O
The	,	O
female	IN	O
(−/−)	NN	O
mice	NNS	O
exhibited	RB	O
increased	VBD	O
ambulatory	IN	O
counts	.	O
during	NN	O
the	VBZ	O
12	VBN	O
hour	IN	O
habituation	,	O
and	JJ	O
both	NNS	O
dark	IN	O
phases	DT	O
when	JJ	O
compared	.	O
with	NNP	O
their	VBD	O
gender-matched	VBP	O
(+/+)	VBN	O
littermates	IN	O
and	JJ	O
the	NN	O
historical	NNS	O
means.	VBN	O
These	IN	O
results	DT	O
are	NN	O
indicative	JJ	O
of	)	O
increased	CC	O
anxiety	JJ	O
of	NN	O
the	NN	O
(−/−)	IN	O
mutant	DT	O
mice.	NN	O
Functional	NN	O
Observational	JJ	O
Battery	)	O
(FOB)	IN	O
Test:	DT	O
Test	JJ	O
Description	NN	O
The	.	O
FOB	:	O
is	DT	O
a	NN	O
series	)	O
of	NN	O
situations	VBD	O
applied	JJ	O
to	NN	O
the	NNS	O
animal	IN	O
to	DT	O
determine	CD	O
gross	NN	O
sensory	NN	O
and	CC	O
motor	DT	O
deficits.	JJ	O
A	NNS	O
subset	WRB	O
of	VBN	O
tests	IN	O
from	PRP$	O
the	JJ	O
Irwin	)	O
neurological	VBZ	O
screen	CC	O
that	DT	O
evaluates	JJ	O
gross	.	O
neurological	DT	O
function	NNS	O
is	VBP	O
used.	JJ	O
In	IN	O
general,	JJ	O
short-duration,	NN	O
tactile,	IN	O
olfactory,	DT	O
and	)	O
visual	NN	O
stimuli	.	O
are	NNP	O
applied	NNP	O
to	NNP	O
the	)	O
animal	:	O
to	NN	O
determine	NN	O
their	DT	O
ability	NNP	O
to	VBZ	O
detect	DT	O
and	NN	O
respond	IN	O
normally.	NNS	O
These	VBN	O
simple	TO	O
tests	DT	O
take	NN	O
approximately	TO	O
10	VB	O
minutes	JJ	O
and	NN	O
the	CC	O
mouse	NN	O
is	.	O
returned	DT	O
to	NN	O
its	IN	O
home	NNS	O
cage	IN	O
at	DT	O
the	NNP	O
end	JJ	O
of	NN	O
testing.	WDT	O
Results:	VBZ	O
Whiskers	JJ	O
were	JJ	O
absent	NN	O
on	VBZ	O
most	.	O
homozygotes	IN	O
with	,	O
bald	,	O
patches	,	O
on	,	O
the	CC	O
snout.	JJ	O
This	NNS	O
finding	VBP	O
is	VBN	O
indicative	TO	O
of	DT	O
an	NN	O
increased	TO	O
anxiety	VB	O
level	PRP$	O
of	NN	O
the	TO	O
mutant	VB	O
(−/−)	CC	O
mice.	VB	O
In	.	O
addition,	DT	O
the	JJ	O
negative	NNS	O
phenotype	VBP	O
of	RB	O
alopecia	CD	O
(baldness)	NNS	O
was	CC	O
observed.	DT	O
Thus,	NN	O
antagonists	VBZ	O
to	VBN	O
PRO4342	TO	O
would	PRP$	O
be	NN	O
a	NN	O
causative	IN	O
factor	DT	O
for	NN	O
alopecia	IN	O
(baldness).	.	O
In	:	O
this	NNS	O
regard,	VBD	O
PRO4342	VBN	O
or	IN	O
agonists	JJS	O
would	NNS	O
be	IN	O
useful	JJ	O
in	NNS	O
the	IN	O
treatment	DT	O
of	.	O
balding	DT	O
or	NN	O
premature	VBZ	O
hair	JJ	O
loss.	IN	O
In	DT	O
summary,	VBN	O
both	NN	O
the	NN	O
circadian	IN	O
rhythm	DT	O
testing	NN	O
and	)	O
functional	.	O
observational	IN	O
battery	,	O
tests	DT	O
indicated	JJ	O
an	NN	O
increased	IN	O
anxiety	NN	O
behavior	)	O
pattern	VBD	O
for	.	O
the	,	O
(−/−)	NNS	O
mice.	TO	O
Thus,	NNP	O
knockout	MD	O
mice	VB	O
demonstrated	DT	O
a	JJ	O
phenotype	NN	O
consistent	IN	O
with	NN	O
“anxiety	.	O
disorders”	IN	O
which	DT	O
include	,	O
but	NNP	O
are	CC	O
not	NNS	O
limited	MD	O
to:	VB	O
mild	JJ	O
to	IN	O
moderate	DT	O
anxiety,	NN	O
generalized	IN	O
anxiety	NN	O
disorder,	CC	O
panic	JJ	O
attack,	NN	O
panic	.	O
disorder	IN	O
with	,	O
agoraphobia,	PDT	O
panic	DT	O
disorder	JJ	O
without	NN	O
agoraphobia,	NN	O
obsessive	CC	O
compulsive	JJ	O
disorder,	JJ	O
agoraphobia,	NN	O
bipolar	NNS	O
disorder	VBD	O
I	DT	O
or	VBN	O
II,	NN	O
or	NN	O
cyclothymic	NN	O
disorder.	IN	O
In	DT	O
view	)	O
of	.	O
these	,	O
findings,	IN	O
PRO4342	RB	O
or	VBD	O
agonists	DT	O
thereof	JJ	O
would	NN	O
be	IN	O
useful	NNP	O
for	NN	O
treating	WDT	O
such	VBP	O
neurological	CC	O
anxiety	VBP	O
disorders.	RB	O
(c)	VBN	O
Pathology	:	O
Microscopic	VB	O
observations	TO	O
on	VB	O
the	,	O
two	VBN	O
male	NN	O
(−/−)	,	O
mice	JJ	O
examined	,	O
exhibited	JJ	O
a	NN	O
moderate	IN	O
degeneration	,	O
of	JJ	O
the	NN	O
seminiferous	IN	O
tubules.	,	O
This	JJ	O
negative	JJ	O
phenotype	,	O
suggests	,	O
that	JJ	O
antagonists	NN	O
to	PRP	O
PRO4342	CC	O
may	,	O
lead	CC	O
to	JJ	O
reproductive	.	O
disorders.	IN	O
In	NN	O
contrast,	IN	O
PRO4342	DT	O
or	,	O
agonists	NNP	O
thereof	CC	O
would	NNS	O
be	RP	O
useful	MD	O
in	VB	O
the	JJ	O
prevention	IN	O
or	VBG	O
treatment	JJ	O
of	JJ	O
such	NN	O
reproductive	.	O
disorders.	)	O
F.	NNP	O
Generation	NNP	O
and	NNS	O
Analysis	IN	O
of	DT	O
Mice	CD	O
Comprising	NN	O
DNA108809	)	O
(UNQ2964)	NN	O
Gene	VBD	O
Disruptions	VBD	O
In	DT	O
these	JJ	O
knockout	NN	O
experiments,	IN	O
the	DT	O
gene	JJ	O
encoding	.	O
PRO7423	DT	O
polypeptides	JJ	O
(designated	NN	O
as	VBZ	O
DNA108809	IN	O
(UNQ2964)	NNS	O
was	TO	O
disrupted.	NNP	O
The	MD	O
gene	VB	O
specific	TO	O
information	JJ	O
for	.	O
these	IN	O
studies	,	O
is	NNP	O
as	CC	O
follows:	NNS	O
the	RP	O
mutated	MD	O
mouse	VB	O
gene	JJ	O
corresponds	IN	O
to	DT	O
nucleotide	NN	O
reference:	CC	O
AJ245857	NN	O
or	IN	O
Mus	JJ	O
musculus	JJ	O
mRNA	.	O
for	NNP	O
carbonic	NNP	O
anhydrase	CC	O
(MN/CA9	NNP	O
gene);	IN	O
protein	NNP	O
reference:	NNP	O
NP—647466	NNP	O
or	)	O
carbonic	NNP	O
anhydrase	NNP	O
9	IN	O
[Mus	DT	O
musculus];	NN	O
the	,	O
human	DT	O
gene	NN	O
sequence	VBG	O
reference:	NNP	O
BC014950	NNS	O
or	VBN	O
Homo	IN	O
sapiens,	NNP	O
carbonic	)	O
anhydrase	VBD	O
IX,	.	O
clone	DT	O
MGC:22967	NN	O
IMAGE:4865275;	JJ	O
protein	NN	O
reference:	IN	O
NP—001207	DT	O
or	NNS	O
carbonic	VBZ	O
anhydrase	IN	O
IX	:	O
precursor;	DT	O
RCC-associated	VBN	O
protein	NN	O
G250;	NN	O
carbonic	NNS	O
dehydratase	TO	O
[Homo	JJ	O
sapiens].	:	O
Mutation	NNP	O
type	CC	O
corresponds	NNP	O
to	CC	O
Homologous	NN	O
Recombination	IN	O
(standard).	JJ	O
Coding	NN	O
exons	NNP	O
1	:	O
through	JJ	O
6	:	O
were	NN	O
targeted	CC	O
(NM—139305).	JJ	O
The	NN	O
disrupted	CD	O
mouse	NNP	O
gene	:	O
is	DT	O
carbonic	JJ	O
anhydrase	NN	O
9	NN	O
(Car9),	:	O
ortholog	NNP	O
of	CC	O
human	NNP	O
carbonic	,	O
anhydrase	JJ	O
9	NN	O
(CA9).	,	O
Aliases	NN	O
include	NNP	O
CAIX,	:	O
MN/CA9,	JJ	O
MN,	:	O
membrane	NN	O
antigen	CC	O
MN,	JJ	O
carbonic	NN	O
dehydratase,	NNP	O
and	:	O
RCC-associated	JJ	O
protein	NN	O
G250.	:	O
Carbonic	JJ	O
anhydrases	NN	O
(CAs)	NNP	O
are	.	O
a	NNP	O
large	NN	O
group	NNS	O
of	TO	O
enzymes	NNP	O
involved	NNP	O
in	.	O
numerous	VBG	O
physiological	NNS	O
functions	CD	O
such	IN	O
as	CD	O
respiration,	VBD	O
bone	VBN	O
resorption,	.	O
and	DT	O
the	VBN	O
formation	NN	O
of	NN	O
saliva,	VBZ	O
etc.	JJ	O
Three	NN	O
major	CD	O
families	,	O
of	NN	O
CAs	IN	O
are	JJ	O
known;	JJ	O
alpha,	NN	O
beta,	CD	O
and	.	O
gamma	NNS	O
CA9,	VBP	O
an	,	O
alpha	,	O
family	,	O
member,	NN	O
binds	NN	O
zinc	,	O
and	JJ	O
DNA,	,	O
and	CC	O
has	JJ	O
some	NN	O
similarity	.	O
with	JJ	O
transcription	NNS	O
factors	)	O
Pastorek	VBP	B
et	DT	I
al,	JJ	I
Oncogene	NN	I
9(10):2877-88	IN	I
(1994)).(	NNS	O
CA9	VBN	O
expression	IN	O
has	JJ	O
been	JJ	O
proposed	NNS	O
as	JJ	O
a	IN	O
marker	,	O
for	NN	O
certain	,	O
aggressive	CC	O
tumors	DT	O
Potter	NN	B
and	IN	I
Harris,	,	I
Br	.	I
J	CD	I
Cancer	JJ	I
89(1):2-7	NNS	I
(2003),	IN	I
(and	NNP	O
its	VBP	O
expression	:	O
is	,	O
induced	,	O
by	CC	O
hypoxia	NN	O
Olive	,	B
et	DT	I
al,	JJ	I
Cancer	NN	I
Res	,	I
61(24):8924-9	VBZ	I
(2001)).(	NN	O
CA9	CC	O
is	,	O
reported	CC	O
to	VBZ	O
reside	DT	O
in	NN	O
the	IN	O
plasma	NN	O
membrane,	NNS	O
cytoplasm	NNP	O
or	RB	O
extracellular	,	O
spaces	NNP	O
Ivanov	NN	B
et	.	I
al,	NNP	I
Am	NN	I
J	VBZ	I
Pathol	VBN	I
158(3):905-19	VBN	I
(2001);	IN	I
Zavada	DT	B
et	NN	I
al.,	IN	I
Br	JJ	I
J	JJ	I
Cancer	NNS	I
89(6):1067-71	NNP	I
(2003)).(	CC	O
Targeted	,	O
or	NNP	O
gene	NNP	O
trap	NNP	O
mutations	NN	O
were	,	O
generated	CC	O
in	PRP$	O
strain	NN	O
129SvEvBrd-derived	VBZ	O
embryonic	VBN	O
stem	IN	O
(ES)	NN	O
cells.	JJ	O
The	NN	O
chimeric	,	O
mice	NNP	O
were	NNP	O
bred	NN	O
to	.	O
C57BL/6J	NNP	O
albino	VBZ	O
mice	VBN	O
to	TO	O
generate	VB	O
F1	IN	O
heterozygous	DT	O
animals.	NN	O
These	,	O
progeny	NN	O
were	CC	O
intercrossed	JJ	O
to	NNS	O
generate	NNP	O
F2	RB	O
wild	,	O
type,	NNP	O
heterozygous,	NNP	O
and	NNP	O
homozygous	NN	O
mutant	:	O
progeny.	NNP	O
On	FW	O
rare	,	O
occasions,	NNP	O
for	NNP	O
example	NNP	O
when	NN	O
very	.	O
few	VBN	O
F1	CC	O
mice	NN	O
were	JJ	O
obtained	NNS	O
from	VBD	O
the	VBN	O
chimera,	IN	O
F1	JJ	O
heterozygous	JJ	O
mice	JJ	O
were	NN	O
crossed	)	O
to	.	O
129SvEvBrd/C57	DT	O
hybrid	JJ	O
mice	NN	O
to	VBD	O
yield	VBN	O
additional	TO	O
heterozygous	NNP	O
animals	NN	O
for	NN	O
the	TO	O
intercross	VB	O
to	NNP	O
generate	JJ	O
the	.	O
F2	DT	O
mice.	NNS	O
In	VBD	O
the	VBN	O
wild-type	TO	O
animals,	VB	O
expression	NNP	O
of	JJ	O
the	,	O
target	,	O
gene	CC	O
was	JJ	O
detected	NN	O
in	.	O
embryonic	IN	O
stem	JJ	O
(ES)	,	O
cells	IN	O
and	NN	O
in	WRB	O
all	RB	O
13	JJ	O
adult	NNP	O
tissues	NN	O
samples	VBD	O
tested	VBN	O
by	IN	O
RT-PCR,	DT	O
except	,	O
thymus,	NNP	O
liver,	JJ	O
testis,	NNS	O
bone,	VBD	O
heart,	VBN	O
adipose,	TO	O
and	CD	O
blood.	JJ	O
Disruption	NN	O
of	TO	O
the	VB	O
target	JJ	O
gene	JJ	O
was	NNS	O
confirmed	IN	O
by	DT	O
Southern	NN	O
hybridization	TO	O
analysis.	VB	O
1.	DT	O
Phenotypic	NNP	O
Analysis	.	O
(for	IN	O
Disrupted	DT	O
Gene:	JJ	O
DNA108809	,	O
(UNQ2964)	NN	O
(a)	IN	O
Overall	DT	O
Phenotypic	NN	O
Summary	NN	O
The	VBD	O
homozygous	VBN	O
mutant	IN	O
mice	JJ	O
exhibited	NN	O
an	)	O
increased	NNS	O
ability	CC	O
to	IN	O
respond	DT	O
to	CD	O
an	NN	O
inflammatory	NNS	O
response	NNS	O
after	VBN	O
a	IN	O
zymosan	,	O
challenge.	IN	O
(b)	,	O
Immunology	,	O
Phenotypic	,	O
Analysis	,	O
Immune	,	O
related	,	O
and	CC	O
inflammatory	.	O
diseases	NN	O
are	IN	O
the	DT	O
manifestation	NN	O
or	NN	O
consequence	VBD	O
of	VBN	O
fairly	IN	O
complex,	NNP	O
often	NN	O
multiple	.	O
interconnected	.	O
biological	NNP	O
pathways	NNP	O
which	IN	O
in	VBN	O
normal	:	O
physiology	NNP	O
are	)	O
critical	)	O
to	JJ	O
respond	NNP	O
to	NNP	O
insult	DT	O
or	JJ	O
injury,	JJ	O
initiate	NN	O
repair	VBD	O
from	DT	O
insult	VBN	O
or	NN	O
injury,	TO	O
and	VB	O
mount	TO	O
innate	DT	O
and	JJ	O
acquired	NN	O
defense	IN	O
against	DT	O
foreign	JJ	O
organisms.	.	O
Disease	)	O
or	NNP	O
pathology	NNP	O
occurs	NNP	O
when	NNP	O
these	VBN	O
normal	CC	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	DT	O
insult	NN	O
or	CC	O
injury	NN	O
either	IN	O
as	RB	O
directly	,	O
related	RB	O
to	JJ	O
the	JJ	O
intensity	NN	O
of	NNS	O
the	WDT	O
response,	IN	O
as	JJ	O
a	NN	O
consequence	VBP	O
of	JJ	O
abnormal	TO	O
regulation	VB	O
or	TO	O
excessive	VB	O
stimulation,	CC	O
as	,	O
a	VB	O
reaction	NN	O
to	IN	O
self,	NN	O
or	CC	O
as	,	O
a	CC	O
combination	VB	O
of	NN	O
these.	CC	O
Though	VBD	O
the	NN	O
genesis	IN	O
of	JJ	O
these	.	O
diseases	NNP	O
often	CC	O
involves	NN	O
multistep	NNS	O
pathways	WRB	O
and	DT	O
often	JJ	O
multiple	JJ	O
different	NNS	O
biological	VBP	O
systems/pathways,	JJ	O
intervention	NN	O
at	CC	O
critical	NN	O
points	CC	O
in	IN	O
one	RB	O
or	VBN	O
more	TO	O
of	DT	O
these	NN	O
pathways	IN	O
can	DT	O
have	,	O
an	IN	O
ameliorative	DT	O
or	NN	O
therapeutic	IN	O
effect.	JJ	O
Therapeutic	NN	O
intervention	CC	O
can	JJ	O
occur	,	O
by	IN	O
either	DT	O
antagonism	NN	O
of	TO	O
a	,	O
detrimental	CC	O
process/pathway	IN	O
or	DT	O
stimulation	NN	O
of	IN	O
a	.	O
beneficial	IN	O
process/pathway.	DT	O
T	NN	O
lymphocytes	IN	O
(T	DT	O
cells)	NNS	O
are	RB	O
an	VBZ	O
important	NNS	O
component	NNS	O
of	CC	O
a	RB	O
mammalian	JJ	O
immune	JJ	O
response.	JJ	O
T	,	O
cells	NN	O
recognize	IN	O
antigens	JJ	O
which	NNS	O
are	IN	O
associated	CD	O
with	CC	O
a	JJR	O
self-molecule	IN	O
encoded	DT	O
by	NNS	O
genes	MD	O
within	VB	O
the	DT	O
major	JJ	O
histocompatibility	CC	O
complex	JJ	O
(MHC).	.	O
The	JJ	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	IN	O
together	DT	O
with	NN	O
MHC	IN	O
molecules	DT	O
on	JJ	O
the	NN	O
surface	CC	O
of	NN	O
antigen	IN	O
presenting	DT	O
cells,	JJ	O
virus	.	O
infected	NNP	O
cells,	VBZ	O
cancer	NNP	O
cells,	)	O
grafts,	VBP	O
etc.	DT	O
The	JJ	O
T	NN	O
cell	IN	O
system	DT	O
eliminates	JJ	O
these	NN	O
altered	.	O
cells	NNP	O
which	NNS	O
pose	VBP	O
a	NNS	O
health	WDT	O
threat	VBP	O
to	VBN	O
the	IN	O
host	DT	O
mammal	NN	O
T	VBN	O
cells	IN	O
include	NNS	O
helper	IN	O
T	DT	O
cells	JJ	O
and	NN	O
cytotoxic	NN	O
T	.	O
cells.	DT	O
Helper	NN	O
T	MD	O
cells	VB	O
proliferate	VBN	O
extensively	RB	O
following	IN	O
recognition	NNP	O
of	NNS	O
an	IN	O
antigen-MHC	DT	O
complex	NN	O
on	IN	O
an	NN	O
antigen	VBG	O
presenting	,	O
cell.	NN	O
Helper	VBD	O
T	,	O
cells	NN	O
also	,	O
secrete	,	O
a	.	O
variety	DT	O
of	NNP	O
cytokines,	NN	O
i.e.,	NN	O
lymphokines,	VBZ	O
which	DT	O
play	JJ	O
a	NNS	O
central	WDT	O
role	VBP	O
in	DT	O
the	NN	O
activation	NN	O
of	TO	O
B	DT	O
cells,	NN	O
cytotoxic	JJ	O
T	NNP	O
cells	NNS	O
and	VBP	O
a	JJ	O
variety	NNP	O
of	NNS	O
other	CC	O
cells	NN	O
which	NNP	O
participate	.	O
in	NNP	O
the	NNP	O
immune	NNS	O
response.	VBP	O
In	RB	O
many	VBG	O
immune	NN	O
responses,	IN	O
inflammatory	DT	O
cells	JJ	O
infiltrate	NN	O
the	IN	O
site	DT	O
of	NN	O
injury	NN	O
or	.	O
infection.	NNP	O
The	NNP	O
migrating	NNS	O
cells	RB	O
may	VBP	O
be	DT	O
neutrophilic,	NN	O
eosinophilic,	IN	O
monocytic	,	O
or	,	O
lymphocytic	,	O
as	WDT	O
can	VBP	O
be	DT	O
determined	JJ	O
by	NN	O
histologic	IN	O
examination	DT	O
of	NN	O
the	IN	O
affected	NNP	O
tissues.	,	O
Current	NN	O
Protocols	NNP	O
in	NNS	O
Immunology,	CC	O
ed.	DT	O
John	NN	O
E.	IN	O
Coligan,	JJ	O
1994,	NNS	O
John	WDT	O
Wiley	VBP	O
&	IN	O
Sons,	DT	O
Inc.	JJ	O
Many	.	O
immune	IN	O
related	JJ	O
diseases	JJ	O
are	,	O
known	JJ	O
and	NNS	O
have	VBP	O
been	DT	O
extensively	NN	O
studied.	IN	O
Such	NN	O
diseases	CC	O
include	.	O
immune-mediated	DT	O
inflammatory	NN	O
diseases	NNS	O
(such	MD	O
as	VB	O
rheumatoid	,	O
arthritis,	,	O
immune	JJ	O
mediated	CC	O
renal	JJ	O
disease,	IN	O
hepatobiliary	MD	O
diseases,	VB	O
inflammatory	VBN	O
bowel	IN	O
disease	JJ	O
(IBD),	NN	O
psoriasis,	IN	O
and	DT	O
asthma),	JJ	O
non-immune-mediated	.	O
inflammatory	JJ	O
diseases,	NNP	O
infectious	IN	O
diseases,	,	O
immunodeficiency	.	O
diseases,	NNP	O
neoplasia,	NNP	O
and	,	O
graft	,	O
rejection,	NNP	O
etc.	NNP	O
In	CC	O
the	,	O
area	.	O
of	JJ	O
immunology,	NNS	O
targets	JJ	O
were	NNS	O
identified	VBP	O
herein	VBN	O
for	CC	O
the	VBP	O
treatment	VBN	O
of	RB	O
inflammation	.	O
and	JJ	O
inflammatory	NNS	O
disorders.	VBP	O
Immune	JJ	O
related	JJ	O
diseases	NNS	O
could	JJ	O
be	IN	O
treated	JJ	O
by	,	O
suppressing	NN	O
the	VBD	O
immune	JJ	O
response.	,	O
Using	JJ	O
neutralizing	,	O
antibodies	NN	O
that	NN	O
inhibit	NN	O
molecules	,	O
having	,	O
immune	CC	O
stimulatory	,	O
activity	JJ	O
would	NN	O
be	,	O
beneficial	JJ	O
in	,	O
the	NN	O
treatment	,	O
of	,	O
immune-mediated	CC	O
and	NN	O
inflammatory	,	O
diseases.	.	O
Molecules	IN	O
which	DT	O
inhibit	NN	O
the	IN	O
immune	,	O
response	NNS	O
can	VBD	O
be	VBN	O
utilized	NN	O
(proteins	IN	O
directly	DT	O
or	NN	O
via	IN	O
the	NN	O
use	CC	O
of	NN	O
antibody	.	O
agonists)	NNP	O
to	JJ	O
inhibit	NNS	O
the	MD	O
immune	VB	O
response	VBN	O
and	IN	O
thus	VBG	O
ameliorate	DT	O
immune	JJ	O
related	.	O
disease.	VBG	O
The	VBG	O
following	NNS	O
test	WDT	O
was	VBP	O
performed:	NNS	O
Zymosan	VBG	O
Challenge	JJ	O
Assay—Peritoneal	JJ	O
Inflammation:	NN	O
Procedure:	MD	O
A	VB	O
cohort	JJ	O
of	IN	O
1	DT	O
wild	NN	O
type	IN	O
and	JJ	O
2	CC	O
homozygous	JJ	O
mutants	.	O
were	NNS	O
used	WDT	O
in	VBP	O
this	DT	O
assay.	JJ	O
Peritoneal	NN	O
leukocyte	MD	O
recruitment	VB	O
assays	VBN	O
were	NNS	O
used	RB	O
to	CC	O
identify	IN	O
targets	DT	O
that	NN	O
may	IN	O
regulate	NN	O
the	)	O
inflammatory	TO	O
component	VB	O
of	DT	O
atherosclerosis.	JJ	O
These	NN	O
assays	CC	O
detect	RB	O
abnormalities	VB	O
in	NN	O
immune	JJ	O
cell	.	O
recruitment	DT	O
to	JJ	O
a	NN	O
site	VBD	O
of	:	O
inflammation.	JJ	O
Zymosan	NNP	O
(an	NNP	O
agent	:	O
which	:	O
induces	DT	O
inflammation)	NN	O
was	IN	O
injected	CD	O
into	JJ	O
the	NN	O
intraperitoneal	CC	O
cavity	CD	O
and	JJ	O
fluid	NNS	O
was	VBD	O
later	VBN	O
removed	IN	O
and	DT	O
measurements	.	O
were	NNP	O
taken	JJ	O
of	NN	O
total	NNS	O
WBC	VBD	O
counts,	VBN	O
neutrophil/monocyte	TO	O
ratio	VB	O
and	NNS	O
percent	WDT	O
granulocytes,	MD	O
monocytes,	VB	O
lymphocytes	DT	O
and	JJ	O
eosinophils	NN	O
in	IN	O
the	.	O
ip	DT	O
fluid.	NNS	O
Results:	VBP	O
The	NNS	O
(−/−)	IN	O
mice	NN	O
exhibited	NN	O
a	NN	O
notably	TO	O
increased	DT	O
total	NN	O
white	IN	O
blood	.	O
cell	NNP	O
count	DT	O
after	NN	O
zymosan	WDT	O
challenge	VBZ	O
when	)	O
compared	VBD	O
with	VBN	O
their	IN	O
(+/+)	DT	O
littermate	JJ	O
and	NN	O
the	CC	O
historical	NN	O
range,	VBD	O
suggestive	RB	O
of	VBN	O
an	CC	O
increased	NNS	O
response	VBD	O
to	VBN	O
an	IN	O
inflammatory	JJ	O
stimulus	NNP	O
in	,	O
these	JJ	O
mutants.	NN	O
In	CC	O
summary,	NN	O
the	,	O
zymosan	,	O
challenge	NNS	O
studies	CC	O
indicate	NNS	O
that	IN	O
knockout	DT	O
mice	NN	O
deficient	.	O
in	:	O
the	DT	O
gene	)	O
encoding	NN	O
PRO7423	VBD	O
polypeptides	DT	O
exhibit	RB	O
a	JJ	O
proinflammatory	JJ	O
response	JJ	O
when	NN	O
compared	NN	O
with	NN	O
their	IN	O
wild-type	JJ	O
littermates.	NN	O
Thus,	WRB	O
antagonists	VBN	O
of	IN	O
PRO7423	PRP$	O
polypeptides	)	O
would	NN	O
stimulate	CC	O
the	DT	O
immune	JJ	O
system	,	O
(such	NN	O
as	IN	O
T	DT	O
cell	VBN	O
proliferation)	NN	O
and	TO	O
would	DT	O
find	JJ	O
utility	NN	O
in	IN	O
the	DT	O
cases	.	O
wherein	IN	O
this	,	O
effect	DT	O
would	NN	O
be	NN	O
beneficial	NNS	O
to	VBP	O
the	IN	O
individual	NN	O
such	NN	O
as	NN	O
in	IN	O
the	DT	O
case	NN	O
of	VBG	O
leukemia,	NNP	O
and	NNS	O
other	VBP	O
types	DT	O
of	NN	O
cancer,	NN	O
and	WRB	O
in	VBN	O
immunocompromised	IN	O
patients,	PRP$	O
such	JJ	O
as	.	O
AIDS	,	O
sufferers.	NNS	O
Accordingly,	IN	O
PRO7423	NNP	O
polypeptides	NNS	O
or	MD	O
agonists	VB	O
thereto	DT	O
would	NN	O
inhibit	NN	O
the	JJ	O
immune	IN	O
response	NNP	O
and	NN	O
would	)	O
be	CC	O
useful	MD	O
candidates	VB	O
for	NN	O
suppressing	IN	O
harmful	DT	O
immune	NNS	O
responses,	VBP	O
e.g.	DT	O
in	NN	O
the	MD	O
case	VB	O
of	JJ	O
graft	TO	O
rejection	DT	O
or	NN	O
graft-versus-host	JJ	O
diseases.	IN	O
G.	IN	O
Generation	DT	O
and	NN	O
Analysis	IN	O
of	,	O
Mice	CC	O
Comprising	JJ	O
DNA125185-2806	NNS	O
(UNQ3099)	IN	O
Gene	,	O
Disruptions	CC	O
In	IN	O
these	JJ	O
knockout	,	O
experiments,	JJ	O
the	IN	O
gene	NNP	O
encoding	.	O
PRO10096	,	O
polypeptides	NNP	O
(designated	VBZ	O
as	CC	O
DNA125185-2806	NNS	O
(UNQ3099)	NN	O
was	MD	O
disrupted.	VB	O
The	DT	O
gene	JJ	O
specific	NN	O
information	CC	O
for	MD	O
these	VB	O
studies	JJ	O
is	NNS	O
as	IN	O
follows:	VBG	O
the	JJ	O
mutated	JJ	O
mouse	,	O
gene	.	O
corresponds	IN	O
to	DT	O
nucleotide	NN	O
reference:	IN	O
NM—016971	NN	O
or	NN	O
Mus	CC	O
musculus	NN	O
interleukin	.	O
22	NNP	O
(Il122);	NNP	O
protein	CC	O
reference:	NNP	O
NP—058667	IN	O
or	NNP	O
interleukin	NNP	O
22;	NNP	O
interleukin	)	O
10-related	NNP	O
T	NNP	O
cell-derived	IN	O
inducible	DT	O
factor;	NN	O
the	,	O
human	DT	O
gene	NN	O
sequence	VBG	O
reference:	NNP	O
NM—020525	NNS	O
or	VBN	O
Homo	IN	O
sapiens	NNP	O
interleukin	)	O
22	VBD	O
(IL22);	.	O
protein	DT	O
reference:	NN	O
NP—065386	JJ	O
or	NN	O
IL-10-related	IN	O
T-cell-derived	DT	O
inducible	NNS	O
factor;	VBZ	O
interleukin	IN	O
21	:	O
[Homo	DT	O
sapiens].	VBN	O
Mutation	NN	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	JJ	O
Recombination	:	O
(conditional).	NN	O
Coding	CC	O
exons	NNP	O
1	CC	O
through	JJ	O
4	CD	O
were	:	O
targeted	JJ	O
(NM—016971).	:	O
The	NN	O
gene	CC	O
of	JJ	O
interest	:	O
is	JJ	O
interleukin	JJ	O
22	NNP	O
(IL22),	JJ	O
ortholog	JJ	O
of	:	O
human	DT	O
IL22.	JJ	O
Aliases	NN	O
include	NN	O
IL-22,	:	O
ILtif,	NN	O
IL-TIF,	CC	O
interleukin	NN	O
10-related	NNS	O
T	VBP	O
cell-derived	CD	O
inducible	:	O
factor,	JJ	O
interleukin	:	O
21,	NN	O
IL21,	CC	O
TIFa,	JJ	O
IL-21,	JJ	O
ILTIF,	JJ	O
IL-IL-D110,	:	O
zcytol8,	CC	O
and	CD	O
TIFIL-23.	NNP	O
IL22,	.	O
a	NNP	O
homolog	NN	O
of	NNS	O
IL-10,	TO	O
is	NNP	O
a	NNP	O
cytokine	.	O
that	VBG	O
binds	NNS	O
to	CD	O
and	IN	O
signals	CD	O
through	VBD	O
the	VBN	O
class	.	O
II	DT	O
cytokine	NN	O
receptor	IN	O
heterodimer	NN	O
IL-22RA1/CRF2-4	VBZ	O
Xu	JJ	B
et	CD	I
al,	,	I
Proc	NN	I
Natl	IN	I
Acad	JJ	I
Sci	.	I
USA	NNS	I
98(17):9511-6	VBP	I
(2001)).(	,	O
IL22	,	O
triggers	,	O
all	JJ	O
three	JJ	O
major	NNP	O
mitogen-activated	JJ	O
protein	JJ	O
kinase	,	O
pathways	JJ	O
Lejeune	,	B
et	,	I
al,	,	I
J	,	I
Biol	,	I
Chem	,	I
277(37):33676-82	,	I
(2002)),(	CC	O
activating	.	O
signal	,	O
transducer	DT	O
and	NN	O
activator	IN	O
of	,	O
transcription	VBZ	O
(STAT)	DT	O
1	NN	O
STAT3,	WDT	O
and	VBZ	O
STAT5	TO	O
Xie	CC	B
et	NNS	I
al,	IN	I
J	DT	I
Biol	NN	I
Chem	NNP	I
275(40):31335-9	NN	I
(2000)).(	NN	O
T	VBD	O
cells	NNP	O
and	NNP	O
mast	RB	O
cells	,	O
produce	NNP	O
IL22	NNP	O
to	NNP	O
induce	NNP	O
acute-phase	NNP	O
reactants	NN	O
in	.	O
other	NNP	O
tissues,	NNS	O
suggesting	DT	O
IL22	CD	O
is	JJ	O
involved	JJ	O
in	NN	O
inflammation	NN	O
Xu	NNS	B
et	NNP	I
al,	RB	I
2001	,	I
supra).(	NNP	O
Moreover,	NNP	O
IL22	NNP	O
modulates	NN	O
IL-4	,	O
production	VBG	O
from	JJ	O
Th2T	NN	O
cells	CC	O
Xie	NN	B
et	IN	I
al,	NN	I
2000	)	I
supra).(	CD	O
The	,	O
cytokine	CC	O
receptor	NNP	O
IL22RA2	NNP	O
is	RB	O
a	,	O
naturally	NNP	O
occurring	NNP	O
antagonist	NNP	O
of	NN	O
IL22	.	O
and	NNP	O
may	NNS	O
be	CC	O
an	NN	O
important	NNS	O
regulator	VBP	O
of	NNP	O
IL22	TO	O
in	VB	O
the	JJ	O
immune	NNS	O
response	IN	O
(Xu	JJ	O
et	,	O
al,	VBG	O
2001	NNP	O
supra).	VBZ	O
The	VBN	O
interleukin	IN	O
10	NN	O
family	NNP	O
of	RB	O
cytokines	,	O
have	CD	O
been	.	O
the	,	O
subject	NNP	O
of	VBZ	O
several	JJ	O
reviews	NN	O
Wolk	IN	B
et	NNP	I
al.,	NNS	I
J	NNP	I
Immunol	RB	I
168(11):5397-402	,	I
(2002);	CD	I
Kotenko,	.	B
S.	DT	I
V.,	NN	I
Cytokine	NN	I
Growth	NNP	I
Factor	VBZ	I
Rev	DT	I
13(3):223-40	RB	I
(2003);	VBG	I
Conti	NN	B
et	IN	I
al.,	NNP	I
Immunol	CC	I
Lett	MD	I
88(3):171-4	VB	I
(2003))	DT	I
(and	JJ	O
a	NN	O
crystal	IN	O
structure	NNP	O
has	IN	O
been	DT	O
proposed	JJ	O
for	NN	O
IL22	NNP	O
Nagem	RB	B
et	,	I
al.,	CD	I
Structure	.	I
(Camb)	DT	I
10(8):1051-62	JJ	I
(2002)).(	CD	O
Interpreting	NN	O
the	IN	O
literature	NNS	O
is	VBP	O
done	VBN	O
with	DT	O
caution	NN	O
because	IN	O
two	JJ	O
of	NNS	O
the	NNP	O
aliases	RB	O
encountered	,	O
for	NNP	O
IL22	NNP	O
have	NN	O
been	:	O
used	,	O
to	NNP	O
refer	,	O
to	NNP	O
other	NNP	O
genes;	NNP	O
IL-21	NNP	O
is	NN	O
an	:	O
synonym	NNP	O
for	FW	O
interleukin	,	O
21	NNP	O
(LocusLink	NNP	O
50616),	NN	O
and	)	O
IL-22	CC	O
is	DT	O
an	JJ	O
alias	NN	O
for	VBZ	O
interleukin	VBN	O
17D	VBN	O
(LocusLink	IN	O
53342).	NNP	O
Current	NNP	O
knowledge	RB	O
of	,	O
IL-22	NNP	O
suggests	)	O
it	NN	O
can	.	O
induce	VBG	O
a	DT	O
variety	NN	O
of	VBZ	O
“acute	VBN	O
phase”	IN	O
proteins	NN	O
including	IN	O
serum	CD	O
amyloid	IN	O
A,	DT	O
PAP1,	NNS	O
osteopontin,	VBD	O
alpha1-antichymotrypsin,	IN	O
and	NNP	O
haptoglobin,	VBP	O
and	VBN	O
S100A8,	VBN	O
MMP-3,	TO	O
and	VB	O
mucins.	TO	O
Targeted	JJ	O
or	:	O
gene	NNP	O
trap	VBZ	O
mutations	DT	O
are	NN	O
generated	IN	O
in	JJ	O
strain	CD	O
129SvEvBrd-derived	NNP	O
embryonic	,	O
stem	CC	O
(ES)	NNP	O
cells.	VBZ	O
The	DT	O
chimeric	NN	O
mice	IN	O
are	JJ	O
bred	CD	O
to	NNP	O
C57BL/6J	.	O
albino	JJ	O
mice	NN	O
to	IN	O
generate	NNP	O
F1	VBZ	O
heterozygous	PRP	O
animals.	MD	O
These	VB	O
progeny	DT	O
are	NN	O
crossed	IN	O
to	JJ	O
hybrid	NN	O
129SvEvBrd/C57	NNS	O
Cre	VBG	O
homozygous	NN	O
mice	NN	O
to	,	O
generate	,	O
mice	,	O
carrying	,	O
both	CC	O
the	,	O
mutant	CC	O
and	,	O
Cre	,	O
alleles	CC	O
(compound	.	O
heterozygous	VBN	O
mice).	CC	O
The	NN	O
male	JJ	O
compound	NNS	O
heterozygous	VBP	O
mice	VBN	O
are	IN	O
then	JJ	O
crossed	JJ	O
to	JJ	O
hybrid	NN	O
129SvEvBrd/C57	)	O
F1	.	O
mice,	DT	O
derived	JJ	O
from	NN	O
crossing	VBP	O
129SvEvBrd	VBN	O
mice	TO	O
to	NNP	O
C57BL/6J	NN	O
mice,	NN	O
to	TO	O
generate	VB	O
heterozygous	NNP	O
Cre-excised	JJ	O
animals.	.	O
Finally,	DT	O
these	NNS	O
progeny	VBP	O
are	VBN	O
intercrossed	TO	O
to	VB	O
generate	CD	O
wild-type,	NNP	O
Cre-excised	JJ	O
heterozygous,	NN	O
and	TO	O
Cre-excised	VB	O
homozygous	NN	O
mice.	VBG	O
Level	CC	O
I	DT	O
phenotypic	NN	O
analysis	CC	O
is	NNP	O
performed	NNS	O
on	NN	O
mice	JJ	O
from	.	O
this	DT	O
generation.	NN	O
1.	NN	O
Phenotypic	JJ	O
Analysis	NNS	O
(for	VBP	O
disrupted	RB	O
gene:	VBN	O
DNA125185-2806	TO	O
(UNQ3099)	VB	O
(a)	CD	O
Overall	NNP	O
Phenotypic	,	O
Summary:	VBN	O
Mutation	IN	O
of	VBG	O
the	CD	O
gene	NN	O
encoding	TO	O
the	NNP	O
ortholog	,	O
of	TO	O
human	VB	O
interleukin	JJ	O
22	JJ	O
(IL22)	.	O
resulted	,	O
in	DT	O
anxiety-related	NNS	O
phenotypes	VBP	O
and	VBN	O
an	TO	O
abnormal	VB	O
exploratory	,	O
response	JJ	O
in	,	O
(−/−)	CC	O
mice.	JJ	O
Females	JJ	O
showed	.	O
an	NN	O
increased	PRP	O
anxiety	VBP	O
response	NN	O
in	VBZ	O
open	VBN	O
field	IN	O
testing.	NN	O
The	IN	O
(−/−)	DT	O
mice	.	O
also	.	O
exhibited	NNP	O
an	NNP	O
increased	IN	O
percentage	VBN	O
of	:	O
CD4	NNP	O
cells	)	O
and	)	O
a	JJ	O
decreased	NNP	O
percentage	:	O
of	NN	O
B	IN	O
cells	DT	O
in	NN	O
the	VBG	O
peripheral	DT	O
blood.	NN	O
Gene	IN	O
disruption	JJ	O
was	FW	O
confirmed	CD	O
by	)	O
Southern	VBD	O
blot.	IN	O
(b)	JJ	O
Immunology	NNS	O
Phenotypic	CC	O
Analysis	DT	O
Immune	JJ	O
related	NN	O
and	NN	O
inflammatory	IN	O
diseases	)	O
are	.	O
the	NNS	O
manifestation	VBD	O
or	DT	O
consequence	VBN	O
of	NN	O
fairly	NN	O
complex,	IN	O
often	JJ	O
multiple	NN	O
interconnected	.	O
biological	DT	O
pathways	)	O
which	NN	O
in	RB	O
normal	VBD	O
physiology	DT	O
are	JJ	O
critical	NN	O
to	IN	O
respond	NNP	O
to	NNS	O
insult	CC	O
or	DT	O
injury,	JJ	O
initiate	NN	O
repair	IN	O
from	NNP	O
insult	NNS	O
or	IN	O
injury,	DT	O
and	JJ	O
mount	.	O
innate	NNP	O
and	NN	O
acquired	VBD	O
defense	VBN	O
against	IN	O
foreign	NNP	O
organisms.	.	O
Disease	)	O
or	NNP	O
pathology	NNP	O
occurs	NNP	O
when	NNP	O
these	VBN	O
normal	CC	O
physiological	JJ	O
pathways	NNS	O
cause	VBP	O
additional	DT	O
insult	NN	O
or	CC	O
injury	NN	O
either	IN	O
as	RB	O
directly	,	O
related	RB	O
to	JJ	O
the	JJ	O
intensity	NN	O
of	NNS	O
the	WDT	O
response,	IN	O
as	JJ	O
a	NN	O
consequence	VBP	O
of	JJ	O
abnormal	TO	O
regulation	VB	O
or	TO	O
excessive	VB	O
stimulation,	CC	O
as	,	O
a	VB	O
reaction	NN	O
to	IN	O
self,	NN	O
or	CC	O
as	,	O
a	CC	O
combination	VB	O
of	NN	O
these.	CC	O
Though	VBD	O
the	NN	O
genesis	IN	O
of	JJ	O
these	.	O
diseases	NNP	O
often	CC	O
involves	NN	O
multistep	NNS	O
pathways	WRB	O
and	DT	O
often	JJ	O
multiple	JJ	O
different	NNS	O
biological	VBP	O
systems/pathways,	JJ	O
intervention	NN	O
at	CC	O
critical	NN	O
points	CC	O
in	IN	O
one	RB	O
or	VBN	O
more	TO	O
of	DT	O
these	NN	O
pathways	IN	O
can	DT	O
have	,	O
an	IN	O
ameliorative	DT	O
or	NN	O
therapeutic	IN	O
effect.	JJ	O
Therapeutic	NN	O
intervention	CC	O
can	JJ	O
occur	,	O
by	IN	O
either	DT	O
antagonism	NN	O
of	TO	O
a	,	O
detrimental	CC	O
process/pathway	IN	O
or	DT	O
stimulation	NN	O
of	IN	O
a	.	O
beneficial	IN	O
process/pathway.	DT	O
T	NN	O
lymphocytes	IN	O
(T	DT	O
cells)	NNS	O
are	RB	O
an	VBZ	O
important	NNS	O
component	NNS	O
of	CC	O
a	RB	O
mammalian	JJ	O
immune	JJ	O
response.	JJ	O
T	,	O
cells	NN	O
recognize	IN	O
antigens	JJ	O
which	NNS	O
are	IN	O
associated	CD	O
with	CC	O
a	JJR	O
self-molecule	IN	O
encoded	DT	O
by	NNS	O
genes	MD	O
within	VB	O
the	DT	O
major	JJ	O
histocompatibility	CC	O
complex	JJ	O
(MHC).	.	O
The	JJ	O
antigen	NN	O
may	MD	O
be	VB	O
displayed	IN	O
together	DT	O
with	NN	O
MHC	IN	O
molecules	DT	O
on	JJ	O
the	NN	O
surface	CC	O
of	NN	O
antigen	IN	O
presenting	DT	O
cells,	JJ	O
virus	.	O
infected	NNP	O
cells,	VBZ	O
cancer	NNP	O
cells,	)	O
grafts,	VBP	O
etc.	DT	O
The	JJ	O
T	NN	O
cell	IN	O
system	DT	O
eliminates	JJ	O
these	NN	O
altered	.	O
cells	NNP	O
which	NNS	O
pose	VBP	O
a	NNS	O
health	WDT	O
threat	VBP	O
to	VBN	O
the	IN	O
host	DT	O
mammal	NN	O
T	VBN	O
cells	IN	O
include	NNS	O
helper	IN	O
T	DT	O
cells	JJ	O
and	NN	O
cytotoxic	NN	O
T	.	O
cells.	DT	O
Helper	NN	O
T	MD	O
cells	VB	O
proliferate	VBN	O
extensively	RB	O
following	IN	O
recognition	NNP	O
of	NNS	O
an	IN	O
antigen-MHC	DT	O
complex	NN	O
on	IN	O
an	NN	O
antigen	VBG	O
presenting	,	O
cell.	NN	O
Helper	VBD	O
T	,	O
cells	NN	O
also	,	O
secrete	,	O
a	.	O
variety	DT	O
of	NNP	O
cytokines,	NN	O
i.e.,	NN	O
lymphokines,	VBZ	O
which	DT	O
play	JJ	O
a	NNS	O
central	WDT	O
role	VBP	O
in	DT	O
the	NN	O
activation	NN	O
of	TO	O
B	DT	O
cells,	NN	O
cytotoxic	JJ	O
T	NNP	O
cells	NNS	O
and	VBP	O
a	JJ	O
variety	NNP	O
of	NNS	O
other	CC	O
cells	NN	O
which	NNP	O
participate	.	O
in	NNP	O
the	NNP	O
immune	NNS	O
response.	VBP	O
In	RB	O
many	VBG	O
immune	NN	O
responses,	IN	O
inflammatory	DT	O
cells	JJ	O
infiltrate	NN	O
the	IN	O
site	DT	O
of	NN	O
injury	NN	O
or	.	O
infection.	NNP	O
The	NNP	O
migrating	NNS	O
cells	RB	O
may	VBP	O
be	DT	O
neutrophilic,	NN	O
eosinophilic,	IN	O
monocytic	,	O
or	,	O
lymphocytic	,	O
as	WDT	O
can	VBP	O
be	DT	O
determined	JJ	O
by	NN	O
histologic	IN	O
examination	DT	O
of	NN	O
the	IN	O
affected	NNP	O
tissues.	,	O
Current	NN	B
Protocols	NNP	I
in	NNS	I
Immunology,	CC	I
ed.	DT	I
John	NN	I
E.	IN	I
Coligan,	JJ	I
1994,	NNS	I
John	WDT	I
Wiley	VBP	I
&	IN	I
Sons,	DT	I
Inc.
Many	JJ	O
immune	.	O
related	IN	O
diseases	JJ	O
are	JJ	O
known	,	O
and	JJ	O
have	NNS	O
been	VBP	O
extensively	DT	O
studied.	NN	O
Such	IN	O
diseases	NN	O
include	CC	O
immune-mediated	.	O
inflammatory	DT	O
diseases	NN	O
(such	NNS	O
as	MD	O
rheumatoid	VB	O
arthritis,	,	O
immune	,	O
mediated	JJ	O
renal	CC	O
disease,	JJ	O
hepatobiliary	IN	O
diseases,	MD	O
inflammatory	VB	O
bowel	VBN	O
disease	IN	O
(IBD),	JJ	O
psoriasis,	NN	O
and	IN	O
asthma),	DT	O
non-immune-mediated	JJ	O
inflammatory	.	O
diseases,	JJ	O
infectious	NNP	O
diseases,	IN	O
immunodeficiency	,	O
diseases,	.	O
neoplasia,	NNP	O
and	NNP	O
graft	,	O
rejection,	,	O
etc.	NNP	O
In	NNP	O
the	CC	O
area	,	O
of	.	O
immunology,	JJ	O
targets	NNS	O
were	JJ	O
identified	NNS	O
herein	VBP	O
for	VBN	O
the	CC	O
treatment	VBP	O
of	VBN	O
inflammation	RB	O
and	.	O
inflammatory	JJ	O
disorders.	NNS	O
Immune	VBP	O
related	JJ	O
diseases	JJ	O
could	NNS	O
be	JJ	O
treated	IN	O
by	JJ	O
suppressing	,	O
the	NN	O
immune	VBD	O
response.	JJ	O
Using	,	O
neutralizing	JJ	O
antibodies	,	O
that	NN	O
inhibit	NN	O
molecules	NN	O
having	,	O
immune	,	O
stimulatory	CC	O
activity	,	O
would	JJ	O
be	NN	O
beneficial	,	O
in	JJ	O
the	,	O
treatment	NN	O
of	,	O
immune-mediated	,	O
and	CC	O
inflammatory	NN	O
diseases.	,	O
Molecules	.	O
which	IN	O
inhibit	DT	O
the	NN	O
immune	IN	O
response	,	O
can	NNS	O
be	VBD	O
utilized	VBN	O
(proteins	NN	O
directly	IN	O
or	DT	O
via	NN	O
the	IN	O
use	NN	O
of	CC	O
antibody	NN	O
agonists)	.	O
to	NNP	O
inhibit	JJ	O
the	NNS	O
immune	MD	O
response	VB	O
and	VBN	O
thus	IN	O
ameliorate	VBG	O
immune	DT	O
related	JJ	O
disease.	.	O
The	VBG	O
following	VBG	O
tests	NNS	O
were	WDT	O
performed:	VBP	O
Flourescence-Activated	NNS	O
Cell-Sorting	VBG	O
(FACS)	JJ	O
Analysis	JJ	O
Procedure:	NN	O
FACS	MD	O
analysis	VB	O
of	JJ	O
immune	IN	O
cell	DT	O
composition	NN	O
from	IN	O
peripheral	JJ	O
blood	CC	O
was	JJ	O
performed	.	O
including	NNS	O
CD4,	WDT	O
CD8	VBP	O
and	DT	O
T	JJ	O
cell	NN	O
receptor	MD	O
to	VB	O
evaluate	VBN	O
T	NNS	O
lymphocytes,	RB	O
CD19	CC	O
for	IN	O
B	DT	O
lymphocytes,	NN	O
CD45	IN	O
as	NN	O
a	)	O
leukocyte	TO	O
marker	VB	O
and	DT	O
pan	JJ	O
NK	NN	O
for	CC	O
natural	RB	O
killer	VB	O
cells.	NN	O
The	JJ	O
FACS	.	O
analysis	DT	O
was	JJ	O
carried	NNS	O
out	VBD	O
on	:	O
6	JJ	O
wild	NNP	O
type	)	O
and	NNP	O
8	:	O
homozygous	NNP	O
mice	NN	O
and	IN	O
included	NN	O
cells	NN	O
derived	NN	O
from	IN	O
thymus,	JJ	O
spleen,	NN	O
bone	VBD	O
marrow	VBN	O
and	VBG	O
lymph	,	O
node.	NNP	O
In	CC	O
these	NNP	O
studies,	NN	O
analyzed	NN	O
cells	TO	O
were	VB	O
isolated	NNP	O
from	,	O
thymus,	NNP	O
peripheral	IN	O
blood,	NNP	O
spleen,	,	O
bone	NNP	O
marrow	IN	O
and	DT	O
lymph	NN	O
nodes.	NN	O
Flow	CC	O
cytometry	NN	O
was	NNP	O
designed	IN	O
to	JJ	O
determine	NN	O
the	.	O
relative	DT	O
proportions	NNP	O
of	NN	O
CD4	VBD	O
and	VBN	O
CD8	RP	O
positive	IN	O
T	CD	O
cells,	JJ	O
B	NN	O
cells,	CC	O
NK	CD	O
cells	JJ	O
and	NN	O
monocytes	CC	O
in	VBD	O
the	NNS	O
mononuclear	VBN	O
cell	IN	O
population.	,	O
A	,	O
Becton-Dickinson	NN	O
FACSCalibur	NN	O
3-laser	CC	O
FACS	JJ	O
machine	.	O
was	IN	O
used	DT	O
to	,	O
assess	JJ	O
immune	NNS	O
status.	VBD	O
For	VBN	O
Phenotypic	IN	O
Assays	,	O
and	JJ	O
Screening,	,	O
this	,	O
machine	NN	O
records	NN	O
CD4+/CD8−,	CC	O
CD8+/CD4−,	NN	O
NK,	.	O
B	NNP	O
cell	NN	O
and	VBD	O
monocyte	VBN	O
numbers	TO	O
in	VB	O
addition	DT	O
to	JJ	O
the	NNS	O
CD4+/CD8+	IN	O
ratio.	NNP	O
The	CC	O
mononuclear	NNP	O
cell	JJ	O
profile	NNP	O
was	,	O
derived	NNP	O
by	,	O
staining	NNP	O
a	NNS	O
single	CC	O
sample	NNS	O
of	IN	O
lysed	DT	O
peripheral	NN	O
blood	NN	O
from	.	O
each	DT	O
mouse	NNP	O
with	NNP	O
a	CD	O
panel	NNP	O
of	NN	O
six	VBD	O
lineage-specific	VBN	O
antibodies:	TO	O
CD45	VB	O
PerCP,	JJ	O
anti-TCRb	.	O
APC,	IN	O
CD4	NNP	O
PE,	NNP	O
CD8	CC	O
FITC,	,	O
pan-NK	DT	O
PE,	NN	O
and	NNS	O
CD19	,	O
FITC.	,	O
The	,	O
two	NNP	O
FITC	NN	O
and	CC	O
PE	NN	O
labeled	NNS	O
antibodies	IN	O
stain	NN	O
mutually	TO	O
exclusive	DT	O
cell	NNP	O
types.	.	O
The	DT	O
samples	NN	O
were	NN	O
analyzed	NN	O
using	VBD	O
a	VBN	O
Becton	IN	O
Dickinson	VBG	O
FACSCalibur	DT	O
flow	JJ	O
cytometer	NN	O
with	IN	O
CellQuest	JJ	O
software.	JJ	O
Results:	NN	O
The	IN	O
homozygous	DT	O
mutant	NN	O
mice	IN	O
exhibited	DT	O
an	NN	O
increased	IN	O
mean	CD	O
percentage	JJ	O
of	:	O
CD4+	NNP	O
cells	,	O
and	JJ	O
a	,	O
decreased	NNP	O
mean	,	O
percentage	NNP	O
of	,	O
B	JJ	O
cells	,	O
when	CC	O
compared	NNP	O
with	.	O
their	DT	O
wild-type	CD	O
littermates.	NNP	O
In	CC	O
summary,	NNP	O
FACS	VBD	O
analysis	NNS	O
of	VBP	O
immune	RB	O
cell	JJ	O
composition	NN	O
from	.	O
peripheral	DT	O
blood	NNS	O
indicates	VBD	O
that	VBN	O
knockout	VBG	O
mice	DT	O
exhibit	NNP	O
immunological	NNP	O
differences	NNP	O
with	NN	O
respect	NN	O
to	IN	O
CD4	NNP	O
cells	.	O
when	:	O
compared	DT	O
with	JJ	O
their	JJ	O
wild-type	NN	O
littermates.	VBD	O
Thus,	DT	O
antagonists	VBN	O
of	NN	O
PRO10096	NN	O
polypeptides	IN	O
or	NNP	O
its	NNS	O
encoding	CC	O
gene	DT	O
would	JJ	O
elicit	JJ	O
increased	NN	O
levels	IN	O
of	NNP	O
CD4.	NNS	O
The	WRB	O
co-receptor	VBN	O
CD4	IN	O
molecule	PRP$	O
cooperates	JJ	O
with	.	O
the	IN	O
T-cell	,	O
receptor	NNP	O
which	NN	O
differentially	IN	O
recognizes	NN	O
MHC	NN	O
class	NN	O
II	IN	O
molecules	JJ	O
in	NN	O
the	VBZ	O
antigen	IN	O
recognition	NN	O
process.	NN	O
(c)	NN	O
Phenotypic	JJ	O
Analysis:	NNS	O
CNS/Neurology	IN	O
In	NN	O
the	TO	O
area	NNP	O
of	NNS	O
neurology,	WRB	O
analysis	VBN	O
focused	IN	O
herein	PRP$	O
on	JJ	O
identifying	.	O
in	,	O
vivo	NNS	O
validated	IN	O
targets	NNP	O
for	NNS	O
the	CC	O
treatment	PRP$	O
of	JJ	O
neurological	NN	O
and	MD	O
psychiatric	VB	O
disorders	JJ	O
including	NNS	O
depression,	IN	O
generalized	.	O
anxiety	DT	O
disorders,	NN	O
attention	NNP	O
deficit	NN	O
hyperactivity	NNS	O
disorder,	IN	O
obsessive	DT	O
compulsive	NNP	O
disorder,	NN	O
schizophrenia,	WDT	O
cognitive	RB	O
disorders,	VBZ	O
hyperalgesia	NNP	O
and	NN	O
sensory	NNP	O
disorders.	NNS	O
Neurological	IN	O
disorders	DT	O
include	NN	O
include	NN	O
but	.	O
are	)	O
not	NNP	O
limited	:	O
to:	NN	O
depression,	IN	O
generalized	DT	O
anxiety	NN	O
disorders,	IN	O
attention	,	O
deficit	NN	O
disorder,	VBD	O
sleep	NN	O
disorder,	IN	O
hyperactivity	VBG	O
disorder,	IN	O
obsessive	NN	O
compulsive	VBN	O
disorder,	NNS	O
schizophrenia,	IN	O
cognitive	DT	O
disorders,	NN	O
hyperalgesia	IN	O
and	JJ	O
sensory	CC	O
disorders,	JJ	O
mild	NNS	O
to	VBG	O
moderate	,	O
anxiety,	VBN	O
anxiety	NN	O
disorder	,	O
due	NN	O
to	NN	O
a	NN	O
general	,	O
medical	JJ	O
condition,	JJ	O
anxiety	,	O
disorder	,	O
not	JJ	O
otherwise	,	O
specified,	NN	O
generalized	CC	O
anxiety	JJ	O
disorder,	.	O
panic	JJ	O
attack,	NNS	O
panic	VBP	O
disorder	VBP	O
with	CC	O
agoraphobia,	VBP	O
panic	RB	O
disorder	VBN	O
without	:	O
agoraphobia,	,	O
posttraumatic	VBN	O
stress	NN	O
disorder,	,	O
social	NN	O
phobia,	NN	O
social	,	O
anxiety,	JJ	O
autism,	,	O
specific	NN	O
phobia,	,	O
substance-induced	JJ	O
anxiety	JJ	O
disorder,	,	O
acute	,	O
alcohol	JJ	O
withdrawal,	,	O
obsessive	NN	O
compulsive	CC	O
disorder,	NN	O
agoraphobia,	,	O
monopolar	NN	O
disorders,	TO	O
bipolar	VB	O
disorder	,	O
I	NN	O
or	NN	O
II,	JJ	O
bipolar	TO	O
disorder	DT	O
not	JJ	O
otherwise	JJ	O
specified,	,	O
cyclothymic	NN	O
disorder,	NN	O
depressive	RB	O
disorder,	RB	O
major	,	O
depressive	VBN	O
disorder,	NN	O
mood	,	O
disorder,	JJ	O
substance-induced	,	O
mood	JJ	O
disorder,	NN	O
enhancement	IN	O
of	,	O
cognitive	JJ	O
function,	NN	O
loss	IN	O
of	,	O
cognitive	JJ	O
function	NN	O
associated	,	O
with	JJ	O
but	,	O
not	JJ	O
limited	,	O
to	,	O
Alzheimer's	JJ	O
disease,	,	O
stroke,	JJ	O
or	NN	O
traumatic	,	O
injury	JJ	O
to	NN	O
the	,	O
brain,	JJ	O
seizures	JJ	O
resulting	,	O
from	,	O
disease	JJ	O
or	,	O
injury	JJ	O
including	NN	O
but	PRP	O
not	CC	O
limited	,	O
to	JJ	O
epilepsy,	NN	O
learning	RB	O
disorders/disabilities,	RB	O
cerebral	,	O
palsy.	JJ	O
In	,	O
addition,	JJ	O
anxiety	,	O
disorders	JJ	O
may	JJ	O
apply	,	O
to	NN	O
personality	,	O
disorders	JJ	O
including	NN	O
but	,	O
not	NN	O
limited	IN	O
to	JJ	O
the	,	O
following	NN	O
types:	IN	O
paranoid,	JJ	O
antisocial,	NN	O
avoidant	VBN	O
behavior,	IN	O
borderline	CC	O
personality	RB	O
disorders,	JJ	O
dependent,	TO	O
histronic,	POS	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	CC	O
and	JJ	O
schizotypal.	NN	O
Procedure:	TO	O
Behavioral	DT	O
screens	,	O
were	NNS	O
performed	VBG	O
on	IN	O
a	NN	O
cohort	CC	O
of	NN	O
4	VBG	O
wild	CC	O
type,	RB	O
4	JJ	O
heterozygous	TO	O
and	,	O
8	VBG	O
homozygous	,	O
mutant	JJ	O
mice.	.	O
All	IN	O
behavioral	,	O
tests	NN	O
were	NNS	O
done	MD	O
between	VB	O
12	TO	O
and	NN	O
16	NNS	O
weeks	VBG	O
of	CC	O
age	RB	O
unless	JJ	O
reduced	TO	O
viability	DT	O
necessitates	JJ	O
earlier	:	O
testing.	,	O
These	,	O
tests	JJ	O
included	,	O
open	JJ	O
field	NN	O
to	,	O
measure	,	O
anxiety,	,	O
activity	,	O
levels	,	O
and	,	O
exploration.	CC	O
Open	.	O
Field	:	O
Test:	JJ	O
Several	NNS	O
targets	VBD	O
of	VBN	O
known	IN	O
drugs	DT	O
have	NN	O
exhibited	IN	O
phenotypes	CD	O
in	JJ	O
the	,	O
open	CD	O
field	JJ	O
test.	CC	O
These	CD	O
include	JJ	O
knockouts	JJ	O
of	.	O
the	DT	O
serotonin	JJ	O
transporter,	NNS	O
the	VBD	O
dopamine	VBN	O
transporter	IN	O
Giros	CD	B
et	CC	I
al.,	CD	I
Nature.	NNS	I
1996	IN	I
Feb.	NN	I
15;	IN	I
379(6566):606-12),(	VBN	O
and	NN	O
the	NNS	O
GABA	RBR	O
receptor	.	O
Homanics	DT	B
et	NNS	I
al.,	VBD	I
Proc	JJ	I
Natl	NN	I
Acad	TO	I
Sci	VB	I
USA.	,	I
1997	NN	I
Apr.	NNS	I
15;	CC	I
94(8):4143-8).(	.	O
An	JJ	O
automated	NNP	O
open-field	:	O
assay	JJ	O
was	NNS	O
customized	IN	O
to	VBN	O
address	NNS	O
changes	VBP	O
related	VBN	O
to	NNS	O
affective	IN	O
state	DT	O
and	JJ	O
exploratory	NN	O
patterns	.	O
related	DT	O
to	VBP	O
learning.	NNS	O
First,	IN	O
the	DT	O
field	NN	O
(40×40	,	O
cm)	DT	O
was	NN	O
selected	NN	O
to	NNP	O
be	RB	O
relatively	,	O
large	.	O
for	CD	O
a	NNP	O
mouse,	:	O
thus	,	O
designed	CC	O
to	DT	O
pick	NNP	O
up	NN	O
changes	NNP	O
in	FW	O
locomotor	,	O
activity	NNP	O
associated	NNP	O
with	NNP	O
exploration.	NNP	O
In	.	O
addition,	CD	O
there	.	O
were	:	O
4	.	O
holes	DT	O
in	JJ	O
the	JJ	O
floor	NN	O
to	VBD	O
allow	VBN	O
for	TO	O
nose-poking,	VB	O
an	NNS	O
activity	VBN	O
specifically	TO	O
related	JJ	O
to	NN	O
exploration.	CC	O
Several	NN	O
factors	NNS	O
were	VBN	O
also	TO	O
designed	.	O
to	,	O
heighten	DT	O
the	NN	O
affective	CD	O
state	)	O
associated	VBD	O
with	VBN	O
this	TO	O
test.	VB	O
The	RB	O
open-field	JJ	O
test	IN	O
is	DT	O
the	,	O
first	RB	O
experimental	VBN	O
procedure	TO	O
in	VB	O
which	RP	O
the	NNS	O
mice	IN	O
are	NN	O
tested,	NN	O
and	VBN	O
the	IN	O
measurements	.	O
that	IN	O
were	,	O
taken	EX	O
were	VBD	O
the	CD	O
subjects'	NNS	O
first	IN	O
experience	DT	O
with	NN	O
the	TO	O
chamber.	VB	O
In	IN	O
addition,	,	O
the	DT	O
open-field	NN	O
was	RB	O
brightly	VBN	O
lit.	TO	O
All	.	O
these	JJ	O
factors	NNS	O
will	VBD	O
heighten	RB	O
the	VBN	O
natural	TO	O
anxiety	VB	O
associated	DT	O
with	JJ	O
novel	NN	O
and	VBN	O
open	IN	O
spaces.	DT	O
The	.	O
pattern	DT	O
and	JJ	O
extent	NN	O
of	VBZ	O
exploratory	DT	O
activity,	JJ	O
and	JJ	O
especially	NN	O
the	IN	O
center-to-total	WDT	O
distance	DT	O
traveled	NN	O
ratio,	VBP	O
may	,	O
then	CC	O
be	DT	O
able	NNS	O
to	WDT	O
discern	VBD	O
changes	VBN	O
related	VBD	O
to	DT	O
susceptibility	POS	O
to	JJ	O
anxiety	NN	O
or	IN	O
depression.	DT	O
A	.	O
large	IN	O
arena	,	O
(40	DT	O
cm×40	NN	O
cm,	VBD	O
VersaMax	RB	O
animal	.	O
activity	PDT	O
monitoring	DT	O
system	NNS	O
from	MD	O
AccuScan	VB	O
Instruments)	DT	O
with	JJ	O
infrared	NN	O
beams	VBN	O
at	IN	O
three	NN	O
different	CC	O
levels	JJ	O
was	.	O
used	DT	O
to	NN	O
record	CC	O
rearing,	NN	O
hole	IN	O
poke,	NN	O
and	,	O
locomotor	CC	O
activity.	RB	O
The	DT	O
animal	JJ	O
was	NN	O
placed	VBD	O
in	,	O
the	MD	O
center	RB	O
and	VB	O
its	JJ	O
activity	TO	O
was	VB	O
measured	NNS	O
for	VBN	O
20	TO	O
minutes.	NN	O
Data	TO	O
from	NN	O
this	CC	O
test	.	O
was	DT	O
analyzed	JJ	O
in	NN	O
five,	CD	O
4-minute	NN	O
intervals.	,	O
The	NNP	O
total	NN	O
distance	NN	O
traveled	VBG	O
(cm),	NN	O
vertical	IN	O
movement	JJ	O
number	)	O
(rearing),	IN	O
number	JJ	O
of	NNS	O
hole	IN	O
pokes,	CD	O
and	JJ	O
the	NNS	O
center	VBD	O
to	VBN	O
total	TO	O
distance	VB	O
ratio	,	O
were	NN	O
recorded.	,	O
The	CC	O
propensity	NN	O
for	.	O
mice	DT	O
to	NN	O
exhibit	VBD	O
normal	VBN	O
habituation	IN	O
responses	DT	O
to	NN	O
a	CC	O
novel	PRP$	O
environment	NN	O
is	VBD	O
assessed	VBN	O
by	IN	O
determining	CD	O
the	.	O
overall	NNS	O
change	IN	O
in	DT	O
their	NN	O
horizontal	VBD	O
locomotor	VBN	O
activity	IN	O
across	,	O
the	JJ	O
5	.	O
time	DT	O
intervals.	JJ	O
This	NN	O
calculated	VBD	O
slope	,	O
of	JJ	O
the	NN	O
change	NN	O
in	,	O
activity	NN	O
over	IN	O
time	JJ	O
is	,	O
determined	CC	O
using	DT	O
normalized,	NN	O
rather	TO	O
than	JJ	O
absolute,	NN	O
total	NN	O
distance	VBD	O
traveled.	.	O
The	DT	O
slope	NN	O
is	IN	O
determined	NN	O
from	TO	O
the	VB	O
regression	JJ	O
line	NN	O
through	NNS	O
the	TO	O
normalized	DT	O
activity	JJ	O
at	NN	O
each	VBZ	O
of	VBN	O
the	IN	O
5	VBG	O
time	DT	O
intervals.	JJ	O
Normal	NN	O
habituation	IN	O
is	PRP$	O
represented	JJ	O
by	NN	O
a	NN	O
negative	IN	O
slope	DT	O
value.	CD	O
Results:	NN	O
A	.	O
notable	DT	O
difference	VBD	O
was	NN	O
observed	IN	O
during	DT	O
open	NN	O
field	IN	O
activity	NN	O
testing.	IN	O
The	NN	O
female	VBZ	O
(−/−)	VBN	O
mice	VBG	O
exhibited	,	O
a	RB	O
decreased	IN	O
median	,	O
sum	JJ	O
time	NN	O
in	.	O
the	DT	O
center	NN	O
area	VBZ	O
when	VBN	O
compared	IN	O
with	DT	O
their	NN	O
gender-matched	NN	O
(+/+)	IN	O
littermates.	DT	O
This	JJ	O
type	NN	O
of	IN	O
behavior	DT	O
is	IN	O
consistent	DT	O
with	CD	O
an	NN	O
increased	.	O
anxiety	JJ	O
like	NN	O
response.	VBZ	O
Knockout	VBN	O
mice	IN	O
demonstrated	DT	O
a	JJ	O
phenotype	NN	O
consistent	.	O
with	:	O
anxiety	DT	O
related	JJ	O
disorders	NN	O
which	VBD	O
are	VBN	O
associated	IN	O
with	JJ	O
mild	NN	O
to	NN	O
moderate	.	O
anxiety,	DT	O
anxiety	NN	O
due	)	O
to	NN	O
a	VBD	O
general	DT	O
medical	JJ	O
condition,	JJ	O
and/or	NN	O
bipolar	NN	O
disorders;	IN	O
hyperactivity;	DT	O
sensory	NN	O
disorders;	NN	O
obsessive-compulsive	WRB	O
disorders,	VBN	O
schizophrenia	IN	O
or	PRP$	O
a	JJ	O
paranoid	)	O
personality.	.	O
Thus,	DT	O
PRO10096	NN	O
polypeptides	IN	O
or	NN	O
agonists	VBZ	O
thereof	JJ	O
would	IN	O
be	DT	O
useful	VBN	O
in	NN	O
the	IN	O
treatment	.	O
of	NNP	O
such	NN	O
neurological	VBD	O
disorders	DT	O
or	JJ	O
the	NN	O
amelioration	IN	O
of	NN	O
the	VBN	O
symptoms	NNS	O
associated	WDT	O
with	VBP	O
anxiety	VBN	O
disorders.	IN	O
H.	NN	O
Generation	TO	O
and	VB	O
Analysis	,	O
of	NN	O
Mice	JJ	O
Comprising	TO	O
DNA177313-2982	DT	O
(UNQ6368)	JJ	O
Gene	JJ	O
Disruptions	,	O
In	JJ	O
these	NN	O
knockout	:	O
experiments,	:	O
the	JJ	O
gene	:	O
encoding	JJ	O
PRO21384	,	O
polypeptides	NN	O
(designated	CC	O
as	DT	O
DNA177313-2982	JJ	O
(UNQ6368)	.	O
was	,	O
disrupted.	NNP	O
The	VBZ	O
gene	CC	O
specific	NNS	O
information	RP	O
for	MD	O
these	VB	O
studies	JJ	O
is	IN	O
as	DT	O
follows:	NN	O
the	IN	O
mutated	JJ	O
mouse	JJ	O
gene	NNS	O
corresponds	CC	O
to	DT	O
nucleotide	NN	O
reference:	IN	O
NM—139299	DT	O
or	NNS	O
Mus	VBN	O
musculus	IN	O
gp130-like	NN	O
monocyte	.	O
receptor	NNP	O
(Glmr-pending);	NNP	O
protein	CC	O
reference:	NNP	O
NP—647460	IN	O
or	NNP	O
gp130-like	NNP	O
monocyte	NNP	O
receptor;	)	O
cytokine	NNP	O
receptor	NNP	O
NR10	IN	O
[Mus	DT	O
musculus];	NN	O
the	,	O
human	DT	O
gene	NN	O
sequence	VBG	O
reference:	NNP	O
NM—139017	NNS	O
or	VBN	O
Homo	IN	O
sapiens	NNP	O
gp130-like	)	O
monocyte	VBD	O
receptor	.	O
(CRL3);	DT	O
protein	NN	O
reference:	JJ	O
NP—620586	NN	O
or	IN	O
gp130-like	DT	O
monocyte	NNS	O
receptor;	VBZ	O
soluble	IN	O
type	:	O
I	DT	O
cytokine	VBN	O
receptor	NN	O
CRL3	NN	O
[Homo	NNS	O
sapiens].	TO	O
Mutation	JJ	O
type	:	O
corresponds	NN	O
to	CC	O
Homologous	NNP	O
Recombination	CC	O
(standard).	JJ	O
Coding	NN	O
exon	NN	O
4	:	O
was	JJ	O
targeted.	:	O
The	NN	O
disrupted	CC	O
mouse	JJ	O
gene	NN	O
is	:	O
Gp130-like	JJ	O
monocyte	NN	O
receptor	NNP	O
(Glmr),	NNP	O
ortholog	:	O
of	DT	O
human	JJ	O
gp130-like	NN	O
monocyte	NN	O
receptor	:	O
(CRL3).	NN	O
Aliases	CC	O
include	NN	O
NR10,	JJ	O
GLM-R,	JJ	O
cytokine	NN	O
receptor	NN	O
NR10,	:	O
GLMR,	JJ	O
and	:	O
soluble	NN	O
type	CC	O
I	JJ	O
cytokine	NN	O
receptor	:	O
CRL3.	JJ	O
CRL3	NN	O
is	PRP	O
a	VBP	O
novel	NN	O
type	NNP	O
I	NNP	O
cytokine	.	O
receptor	NNP	O
with	NN	O
homology	NNS	O
to	TO	O
interleukin-6	NNP	O
receptor	NNP	O
gp130	.	O
and	VBG	O
granulocyte	$	O
colony-stimulating	CD	O
factor	VBD	O
receptor.	.	O
CRL3	DT	O
is	VBN	O
expressed	NN	O
on	NN	O
CD14-positive	VBZ	O
cells,	JJ	O
activates	NN	O
STAT3	NN	O
and	,	O
STAT5,	NN	O
and	IN	O
may	JJ	O
be	JJ	O
involved	NN	O
in	NN	O
monocyte	.	O
maturation	NNS	O
and	VBP	O
development.	,	O
Bioinformatic	,	O
analyses	NN	O
indicate	NN	O
the	,	O
receptor	,	O
has	CC	O
a	JJ	O
signal	NN	O
peptide	PRP	O
sequence,	VBP	O
a	NN	O
large	.	O
extracellular	NNP	O
domain,	VBZ	O
and	DT	O
a	JJ	O
cytoplasmic	NN	O
signaling	PRP	O
domain.	VBP	O
Targeted	NN	O
or	IN	O
gene	NN	O
trap	TO	O
mutations	JJ	O
were	NN	O
generated	NN	O
in	CC	O
strain	JJ	O
129SvEvBrd-derived	JJ	O
embryonic	NN	O
stem	.	O
(ES)	NNP	O
cells.	VBZ	O
The	VBN	O
chimeric	IN	O
mice	NNP	O
were	,	O
bred	VBZ	O
to	NNP	O
C57BL/6J	CC	O
albino	,	O
mice	CC	O
to	MD	O
generate	VB	O
F1	VBN	O
heterozygous	IN	O
animals.	JJ	O
These	NN	O
progeny	CC	O
were	.	O
intercrossed	JJ	O
to	NNS	O
generate	VBP	O
F2	DT	O
wild	NN	O
type,	VBZ	O
heterozygous,	DT	O
and	JJ	O
homozygous	NN	O
mutant	,	O
progeny.	DT	O
On	JJ	O
rare	JJ	O
occasions,	,	O
for	CC	O
example	DT	O
when	JJ	O
very	NN	O
few	.	O
F1	VBN	O
mice	CC	O
were	NN	O
obtained	JJ	O
from	NNS	O
the	VBD	O
chimera,	VBN	O
F1	IN	O
heterozygous	JJ	O
mice	JJ	O
were	JJ	O
crossed	NN	O
to	)	O
129SvEvBrd/C57	.	O
hybrid	DT	O
mice	JJ	O
to	NN	O
yield	VBD	O
additional	VBN	O
heterozygous	TO	O
animals	NNP	O
for	NN	O
the	NN	O
intercross	TO	O
to	VB	O
generate	NNP	O
the	JJ	O
F2	.	O
mice.	DT	O
Level	NNS	O
I	VBD	O
phenotypic	VBN	O
analysis	TO	O
was	VB	O
performed	NNP	O
on	JJ	O
mice	,	O
from	,	O
this	CC	O
generation	JJ	O
as	NN	O
shown	.	O
below.	IN	O
Wild-type	JJ	O
expression	,	O
of	IN	O
the	NN	O
target	WRB	O
gene	RB	O
was	JJ	O
detected	NNP	O
all	NN	O
13	VBD	O
adult	VBN	O
tissue	IN	O
samples	DT	O
tested	,	O
by	NNP	O
RT-PCR,	JJ	O
except	NNS	O
liver,	VBD	O
testis,	VBN	O
small	TO	O
intestine	CD	O
and	JJ	O
colon,	NN	O
heart,	TO	O
and	VB	O
tail.	JJ	O
Disruption	JJ	O
of	NNS	O
the	IN	O
target	DT	O
gene	NN	O
was	TO	O
confirmed	VB	O
by	DT	O
Southern	NNP	O
hybridization	.	O
analysis.	NN	O
1.	PRP	O
Phenotypic	VBP	O
Analysis	NN	O
(for	VBD	O
Disrupted	VBN	O
Gene:	IN	O
DNA177313-2982	NN	O
(UNQ6368)	IN	O
(a)	DT	O
Overall	NN	O
Phenotypic	IN	O
Summary:	VBN	O
The	.	O
male	JJ	O
homozygous	NN	O
mutant	IN	O
mice	DT	O
exhibited	NN	O
a	NN	O
decreased	VBD	O
anxiety-like	VBN	O
response	DT	O
during	CD	O
open	NNS	O
field	NN	O
activity	NNS	O
testing	VBN	O
when	IN	O
compared	,	O
with	IN	O
their	,	O
gender-matched	,	O
wild-type	JJ	O
littermates	NN	O
and	CC	O
the	,	O
historical	,	O
mean.	CC	O
No	.	O
other	NN	O
notable	IN	O
phenotype	DT	O
was	NN	O
observed	NN	O
for	VBD	O
the	VBN	O
homozygous	IN	O
mutant	NNP	O
mice.	NN	O
Disruption	.	O
of	.	O
the	NNP	O
target	NNP	O
gene	IN	O
was	VBN	O
confirmed	:	O
by	NNP	O
Southern	)	O
hybridization	)	O
analysis.	JJ	O
(b)	NNP	O
Phenotypic	:	O
Analysis:	DT	O
CNS/Neurology	NN	O
In	JJ	O
the	JJ	O
area	NN	O
of	VBD	O
neurology,	DT	O
analysis	JJ	O
focused	JJ	O
herein	NN	O
on	IN	O
identifying	JJ	O
in	NN	O
vivo	NN	O
validated	VBG	O
targets	WRB	O
for	VBN	O
the	IN	O
treatment	PRP$	O
of	JJ	O
neurological	JJ	O
and	NNS	O
psychiatric	CC	O
disorders	DT	O
including	JJ	O
depression,	.	O
generalized	DT	O
anxiety	JJ	O
disorders,	JJ	O
attention	NN	O
deficit	VBD	O
hyperactivity	VBN	O
disorder,	IN	O
obsessive	DT	O
compulsive	JJ	O
disorder,	JJ	O
schizophrenia,	.	O
cognitive	NN	O
disorders,	IN	O
hyperalgesia	DT	O
and	NN	O
sensory	NN	O
disorders.	VBD	O
Neurological	VBN	O
disorders	IN	O
include	NNP	O
include	NN	O
but	.	O
are	)	O
not	NNP	O
limited	:	O
to:	NN	O
depression,	IN	O
generalized	DT	O
anxiety	NN	O
disorders,	IN	O
attention	,	O
deficit	NN	O
disorder,	VBD	O
sleep	NN	O
disorder,	IN	O
hyperactivity	VBG	O
disorder,	IN	O
obsessive	NN	O
compulsive	VBN	O
disorder,	NNS	O
schizophrenia,	IN	O
cognitive	DT	O
disorders,	NN	O
hyperalgesia	IN	O
and	JJ	O
sensory	CC	O
disorders,	JJ	O
mild	NNS	O
to	VBG	O
moderate	,	O
anxiety,	VBN	O
anxiety	NN	O
disorder	,	O
due	NN	O
to	NN	O
a	NN	O
general	,	O
medical	JJ	O
condition,	JJ	O
anxiety	,	O
disorder	,	O
not	JJ	O
otherwise	,	O
specified,	NN	O
generalized	CC	O
anxiety	JJ	O
disorder,	.	O
panic	JJ	O
attack,	NNS	O
panic	VBP	O
disorder	VBP	O
with	CC	O
agoraphobia,	VBP	O
panic	RB	O
disorder	VBN	O
without	:	O
agoraphobia,	,	O
posttraumatic	VBN	O
stress	NN	O
disorder,	,	O
social	NN	O
phobia,	NN	O
social	,	O
anxiety,	JJ	O
autism,	,	O
specific	NN	O
phobia,	,	O
substance-induced	JJ	O
anxiety	JJ	O
disorder,	,	O
acute	,	O
alcohol	JJ	O
withdrawal,	,	O
obsessive	NN	O
compulsive	CC	O
disorder,	NN	O
agoraphobia,	,	O
monopolar	NN	O
disorders,	TO	O
bipolar	VB	O
disorder	,	O
I	NN	O
or	NN	O
II,	JJ	O
bipolar	TO	O
disorder	DT	O
not	JJ	O
otherwise	JJ	O
specified,	,	O
cyclothymic	NN	O
disorder,	NN	O
depressive	RB	O
disorder,	RB	O
major	,	O
depressive	VBN	O
disorder,	NN	O
mood	,	O
disorder,	JJ	O
substance-induced	,	O
mood	JJ	O
disorder,	NN	O
enhancement	IN	O
of	,	O
cognitive	JJ	O
function,	NN	O
loss	IN	O
of	,	O
cognitive	JJ	O
function	NN	O
associated	,	O
with	JJ	O
but	,	O
not	JJ	O
limited	,	O
to	,	O
Alzheimer's	JJ	O
disease,	,	O
stroke,	JJ	O
or	NN	O
traumatic	,	O
injury	JJ	O
to	NN	O
the	,	O
brain,	JJ	O
seizures	JJ	O
resulting	,	O
from	,	O
disease	JJ	O
or	,	O
injury	JJ	O
including	NN	O
but	PRP	O
not	CC	O
limited	,	O
to	JJ	O
epilepsy,	NN	O
learning	RB	O
disorders/disabilities,	RB	O
cerebral	,	O
palsy.	JJ	O
In	,	O
addition,	JJ	O
anxiety	,	O
disorders	JJ	O
may	JJ	O
apply	,	O
to	NN	O
personality	,	O
disorders	JJ	O
including	NN	O
but	,	O
not	NN	O
limited	IN	O
to	JJ	O
the	,	O
following	NN	O
types:	IN	O
paranoid,	JJ	O
antisocial,	NN	O
avoidant	VBN	O
behavior,	IN	O
borderline	CC	O
personality	RB	O
disorders,	JJ	O
dependent,	TO	O
histronic,	POS	O
narcissistic,	,	O
obsessive-compulsive,	,	O
schizoid,	CC	O
and	JJ	O
schizotypal.	NN	O
Procedure:	TO	O
Behavioral	DT	O
screens	,	O
were	NNS	O
performed	VBG	O
on	IN	O
a	NN	O
cohort	CC	O
of	NN	O
4	VBG	O
wild	CC	O
type,	RB	O
4	JJ	O
heterozygous	TO	O
and	,	O
8	VBG	O
homozygous	,	O
mutant	JJ	O
mice.	.	O
All	IN	O
behavioral	,	O
tests	NN	O
were	NNS	O
done	MD	O
between	VB	O
12	TO	O
and	NN	O
16	NNS	O
weeks	VBG	O
of	CC	O
age	RB	O
unless	JJ	O
reduced	TO	O
viability	DT	O
necessitates	JJ	O
earlier	:	O
testing.	,	O
These	,	O
tests	JJ	O
included	,	O
open	JJ	O
field	NN	O
to	,	O
measure	,	O
anxiety,	,	O
activity	,	O
levels	,	O
and	,	O
exploration.	CC	O
Open	.	O
Field	:	O
Test:	JJ	O
Several	NNS	O
targets	VBD	O
of	VBN	O
known	IN	O
drugs	DT	O
have	NN	O
exhibited	IN	O
phenotypes	CD	O
in	JJ	O
the	,	O
open	CD	O
field	JJ	O
test.	CC	O
These	CD	O
include	JJ	O
knockouts	JJ	O
of	.	O
the	DT	O
serotonin	JJ	O
transporter,	NNS	O
the	VBD	O
dopamine	VBN	O
transporter	IN	O
Giros	CD	B
et	CC	I
al.,	CD	I
Nature.	NNS	I
1996	IN	I
Feb.	NN	I
15;	IN	I
379(6566):606-12),(	VBN	O
and	NN	O
the	NNS	O
GABA	RBR	O
receptor	.	O
Homanics	DT	B
et	NNS	I
al.,	VBD	I
Proc	JJ	I
Natl	NN	I
Acad	TO	I
Sci	VB	I
USA.	,	I
1997	NN	I
Apr.	NNS	I
15;	CC	I
94(8):4143-8).(	.	O
An	JJ	O
automated	NNP	O
open-field	:	O
assay	JJ	O
was	NNS	O
customized	IN	O
to	VBN	O
address	NNS	O
changes	VBP	O
related	VBN	O
to	NNS	O
affective	IN	O
state	DT	O
and	JJ	O
exploratory	NN	O
patterns	.	O
related	DT	O
to	VBP	O
learning.	NNS	O
First,	IN	O
the	DT	O
field	NN	O
(40×40	,	O
cm)	DT	O
was	NN	O
selected	NN	O
to	NNP	O
be	RB	O
relatively	,	O
large	.	O
for	CD	O
a	NNP	O
mouse,	:	O
thus	,	O
designed	CC	O
to	DT	O
pick	NNP	O
up	NN	O
changes	NNP	O
in	FW	O
locomotor	,	O
activity	NNP	O
associated	NNP	O
with	NNP	O
exploration.	NNP	O
In	.	O
addition,	CD	O
there	.	O
were	:	O
4	.	O
holes	DT	O
in	JJ	O
the	JJ	O
floor	NN	O
to	VBD	O
allow	VBN	O
for	TO	O
nose-poking,	VB	O
an	NNS	O
activity	VBN	O
specifically	TO	O
related	JJ	O
to	NN	O
exploration.	CC	O
Several	NN	O
factors	NNS	O
were	VBN	O
also	TO	O
designed	.	O
to	,	O
heighten	DT	O
the	NN	O
affective	CD	O
state	)	O
associated	VBD	O
with	VBN	O
this	TO	O
test.	VB	O
The	RB	O
open-field	JJ	O
test	IN	O
is	DT	O
the	,	O
first	RB	O
experimental	VBN	O
procedure	TO	O
in	VB	O
which	RP	O
the	NNS	O
mice	IN	O
are	NN	O
tested,	NN	O
and	VBN	O
the	IN	O
measurements	.	O
that	IN	O
were	,	O
taken	EX	O
were	VBD	O
the	CD	O
subjects'	NNS	O
first	IN	O
experience	DT	O
with	NN	O
the	TO	O
chamber.	VB	O
In	IN	O
addition,	,	O
the	DT	O
open-field	NN	O
was	RB	O
brightly	VBN	O
lit.	TO	O
All	.	O
these	JJ	O
factors	NNS	O
will	VBD	O
heighten	RB	O
the	VBN	O
natural	TO	O
anxiety	VB	O
associated	DT	O
with	JJ	O
novel	NN	O
and	VBN	O
open	IN	O
spaces.	DT	O
The	.	O
pattern	DT	O
and	JJ	O
extent	NN	O
of	VBZ	O
exploratory	DT	O
activity,	JJ	O
and	JJ	O
especially	NN	O
the	IN	O
center-to-total	WDT	O
distance	DT	O
traveled	NN	O
ratio,	VBP	O
may	,	O
then	CC	O
be	DT	O
able	NNS	O
to	WDT	O
discern	VBD	O
changes	VBN	O
related	VBD	O
to	DT	O
susceptibility	POS	O
to	JJ	O
anxiety	NN	O
or	IN	O
depression.	DT	O
A	.	O
large	IN	O
arena	,	O
(40	DT	O
cm×40	NN	O
cm,	VBD	O
VersaMax	RB	O
animal	.	O
activity	PDT	O
monitoring	DT	O
system	NNS	O
from	MD	O
AccuScan	VB	O
Instruments)	DT	O
with	JJ	O
infrared	NN	O
beams	VBN	O
at	IN	O
three	NN	O
different	CC	O
levels	JJ	O
was	.	O
used	DT	O
to	NN	O
record	CC	O
rearing,	NN	O
hole	IN	O
poke,	NN	O
and	,	O
locomotor	CC	O
activity.	RB	O
The	DT	O
animal	JJ	O
was	NN	O
placed	VBD	O
in	,	O
the	MD	O
center	RB	O
and	VB	O
its	JJ	O
activity	TO	O
was	VB	O
measured	NNS	O
for	VBN	O
20	TO	O
minutes.	NN	O
Data	TO	O
from	NN	O
this	CC	O
test	.	O
was	DT	O
analyzed	JJ	O
in	NN	O
five,	CD	O
4-minute	NN	O
intervals.	,	O
The	NNP	O
total	NN	O
distance	NN	O
traveled	VBG	O
(cm),	NN	O
vertical	IN	O
movement	JJ	O
number	)	O
(rearing),	IN	O
number	JJ	O
of	NNS	O
hole	IN	O
pokes,	CD	O
and	JJ	O
the	NNS	O
center	VBD	O
to	VBN	O
total	TO	O
distance	VB	O
ratio	,	O
were	NN	O
recorded.	,	O
The	CC	O
propensity	NN	O
for	.	O
mice	DT	O
to	NN	O
exhibit	VBD	O
normal	VBN	O
habituation	IN	O
responses	DT	O
to	NN	O
a	CC	O
novel	PRP$	O
environment	NN	O
is	VBD	O
assessed	VBN	O
by	IN	O
determining	CD	O
the	.	O
overall	NNS	O
change	IN	O
in	DT	O
their	NN	O
horizontal	VBD	O
locomotor	VBN	O
activity	IN	O
across	,	O
the	JJ	O
5	.	O
time	DT	O
intervals.	JJ	O
This	NN	O
calculated	VBD	O
slope	,	O
of	JJ	O
the	NN	O
change	NN	O
in	,	O
activity	NN	O
over	IN	O
time	JJ	O
is	,	O
determined	CC	O
using	DT	O
normalized,	NN	O
rather	TO	O
than	JJ	O
absolute,	NN	O
total	NN	O
distance	VBD	O
traveled.	.	O
The	DT	O
slope	NN	O
is	IN	O
determined	NN	O
from	TO	O
the	VB	O
regression	JJ	O
line	NN	O
through	NNS	O
the	TO	O
normalized	DT	O
activity	JJ	O
at	NN	O
each	VBZ	O
of	VBN	O
the	IN	O
5	VBG	O
time	DT	O
intervals.	JJ	O
Normal	NN	O
habituation	IN	O
is	PRP$	O
represented	JJ	O
by	NN	O
a	NN	O
negative	IN	O
slope	DT	O
value.	CD	O
Results:	NN	O
A	.	O
notable	DT	O
difference	VBD	O
was	NN	O
observed	IN	O
during	DT	O
open	NN	O
field	IN	O
activity	NN	O
testing.	IN	O
The	NN	O
male	VBZ	O
(−/−)	VBN	O
mice	VBG	O
exhibited	,	O
an	RB	O
increased	IN	O
median	,	O
sum	JJ	O
time	NN	O
in	.	O
the	DT	O
center	NN	O
area	VBZ	O
when	VBN	O
compared	IN	O
with	DT	O
their	NN	O
gender-matched	NN	O
(+/+)	IN	O
littermates,	DT	O
which	JJ	O
is	NN	O
indicative	IN	O
of	DT	O
a	IN	O
decreased	DT	O
anxiety-like	CD	O
response	NN	O
in	.	O
the	JJ	O
mutants.	NN	O
Thus,	VBZ	O
male	VBN	O
knockout	IN	O
mice	DT	O
demonstrated	JJ	O
a	NN	O
phenotype	.	O
consistent	:	O
with	DT	O
depressive	JJ	O
disorders,	NN	O
including	VBD	O
depression,	VBN	O
generalized	IN	O
anxiety	JJ	O
disorders,	NN	O
attention	NN	O
deficit	.	O
disorder,	DT	O
sleep	NN	O
disorder,	)	O
hypoactivity	NN	O
disorder,	VBD	O
obsessive	DT	O
compulsive	JJ	O
disorder,	JJ	O
schizophrenia,	NN	O
cognitive	NN	O
disorders,	IN	O
hyperalgesia	DT	O
and/or	NN	O
sensory	NN	O
disorders.	WRB	O
Thus,	VBN	O
PRO21384	IN	O
polypeptides	PRP$	O
and	JJ	O
agonists	)	O
thereof	,	O
would	WDT	O
be	VBZ	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	JJ	O
or	JJ	O
amelioration	NN	O
of	IN	O
the	DT	O
symptoms	.	O
associated	,	O
with	NN	O
depressive	NN	O
disorders.	NN	O
I.	VBD	O
Generation	DT	O
and	JJ	O
Analysis	NN	O
of	IN	O
Mice	JJ	O
Comprising	,	O
DNA41234-1242-1	VBG	O
(UNQ310)	,	O
Gene	VBN	O
Disruptions	NN	O
In	,	O
these	NN	O
knockout	NN	O
experiments,	,	O
the	JJ	O
gene	,	O
encoding	NN	O
PRO353	,	O
polypeptides	JJ	O
(designated	JJ	O
as	,	O
DNA41234-1242-1	,	O
(UNQ310)	JJ	O
was	,	O
disrupted.	NN	O
The	JJ	O
gene	NN	O
specific	.	O
information	,	O
for	NNP	O
these	NNS	O
studies	CC	O
is	NNS	O
as	NNS	O
follows:	MD	O
the	VB	O
mutated	JJ	O
mouse	IN	O
gene	DT	O
corresponds	NN	O
to	CC	O
nucleotide	NN	O
reference:	IN	O
NM—019959	DT	O
or	NNS	O
Mus	VBN	O
musculus	IN	O
putative	JJ	O
secreted	.	O
protein	.	O
ZSIG37	NN	O
(Zsig37);	CC	O
protein	NNP	O
reference:	IN	O
NP—064343	NNP	O
or	NNP	O
putative	NNP	O
secreted	)	O
protein	NNP	O
ZSIG37	NNP	O
[Mus	IN	O
musculus];	DT	O
the	NN	O
human	,	O
gene	DT	O
sequence	NN	O
reference:	VBG	O
AF232905	NNP	O
or	NNS	O
Homo	VBN	O
sapiens	IN	O
putative	NNP	O
GPCR	)	O
interacting	VBD	O
protein	.	O
GIP;	DT	O
protein	NN	O
reference:	JJ	O
AAG44303	NN	O
or	IN	O
putative	DT	O
GPCR	NNS	O
interacting	VBZ	O
protein	IN	O
GIP	:	O
[Homo	DT	O
sapiens].	VBN	O
Mutation	NN	O
type	NN	O
corresponds	NNS	O
to	TO	O
Homologous	JJ	O
Recombination	:	O
(standard).	NN	O
Coding	CC	O
exon	NNP	O
4	CC	O
was	JJ	O
targeted	VBN	O
(NM—019959).	NN	O
The	NNP	O
gene	:	O
that	JJ	O
is	:	O
mutated	NN	O
in	CC	O
these	JJ	O
animals	VBN	O
is	NN	O
represented	NNP	O
by	NNP	O
mouse	:	O
UniGene	DT	O
cluster	JJ	O
Mm.23845,	NN	O
which	NN	O
is	:	O
the	NNP	O
ortholog	CC	O
of	NNP	O
human	JJ	O
cluster	JJ	O
Hs.201398	NNP	O
(C1QTNF1).	VBG	O
C1QTNF1	NN	O
encodes	:	O
G	JJ	O
protein	:	O
coupled	NNP	O
receptor	CC	O
interacting	JJ	O
protein	NNP	O
[that	VBG	O
is]	NN	O
complement-C1q	NNP	O
tumor	NNP	O
necrosis	.	O
factor-related.	NNP	O
Alternate	NN	O
names	NNS	O
include	TO	O
GIP,	NNP	O
CTRP1,	NNP	O
ZSIG37	.	O
and	VBG	O
FLJ90694.	$	O
C1QTNF1	CD	O
encodes	VBD	O
several	VBN	O
distinct	.	O
domains.	DT	O
The	NN	O
N-terminus	WDT	O
contains	VBZ	O
two	VBN	O
overlapping	IN	O
cysteine-rich	DT	O
regions	NNS	O
characteristic	VBZ	O
of	VBN	O
the	IN	O
TNFR/NGFR	NN	O
motif	NNP	O
Receptors	NN	O
in	,	O
this	WDT	O
family	VBZ	O
include	DT	O
certain	NN	O
tumor	IN	O
necrosis	JJ	O
factor	NN	O
receptors	NNP	O
and	.	O
nerve	NNP	O
growth	VBZ	O
factor	NNP	O
receptors.	NN	O
The	VBD	O
C-terminus	NN	O
contains	VBG	O
a	NN	O
C1q-like	WDT	O
domain,	JJ	O
a	JJ	O
globular	NN	O
domain	NN	O
found	.	O
in	NNP	O
many	NNS	O
collagens.	VBP	O
Overall,	,	O
the	,	O
protein	NNP	O
has	CC	O
similarities	.	O
to	NNP	O
a	VBZ	O
variety	JJ	O
of	JJ	O
soluble	.	O
collagens	DT	O
that	NNP	O
are	NNS	O
thought	CD	O
to	VBG	O
be	JJ	O
involved	NNS	O
in	NN	O
defense	IN	O
processes,	DT	O
and	NNP	O
may	NN	O
be	NNPS	O
membrane	IN	O
bound	DT	O
or	NN	O
secreted	VBP	O
(by	JJ	O
similarity).	JJ	O
Targeted	NN	O
or	NN	O
gene	NNS	O
trap	CC	O
mutations	NN	O
were	NN	O
generated	NN	O
in	.	O
strain	DT	O
129SvEvBrd-derived	NNP	O
embryonic	VBZ	O
stem	DT	O
(ES)	JJ	O
cells.	,	O
The	DT	O
chimeric	JJ	O
mice	NN	O
were	VBD	O
bred	IN	O
to	JJ	O
C57BL/6J	.	O
albino	,	O
mice	DT	O
to	NN	O
generate	VBZ	O
F1	NNS	O
heterozygous	TO	O
animals.	DT	O
These	NN	O
progeny	IN	O
were	JJ	O
intercrossed	NNS	O
to	WDT	O
generate	VBP	O
F2	VBN	O
wild	TO	O
type,	VB	O
heterozygous,	VBN	O
and	IN	O
homozygous	NN	O
mutant	,	O
progeny.	CC	O
On	MD	O
rare	VB	O
occasions,	VBN	O
for	NN	O
example	CC	O
when	VBN	O
very	IN	O
few	.	O
F1	VBN	O
mice	CC	O
were	NN	O
obtained	JJ	O
from	NNS	O
the	VBD	O
chimera,	VBN	O
F1	IN	O
heterozygous	JJ	O
mice	JJ	O
were	JJ	O
crossed	NN	O
to	)	O
129SvEvBrd/C57	.	O
hybrid	DT	O
mice	JJ	O
to	NN	O
yield	VBD	O
additional	VBN	O
heterozygous	TO	O
animals	NNP	O
for	NN	O
the	NN	O
intercross	TO	O
to	VB	O
generate	NNP	O
the	JJ	O
F2	.	O
mice.	DT	O
Level	NNS	O
I	VBD	O
phenotypic	VBN	O
analysis	TO	O
was	VB	O
performed	NNP	O
on	JJ	O
mice	,	O
from	,	O
this	CC	O
generation	JJ	O
as	NN	O
shown	.	O
below.	IN	O
Disruption	JJ	O
of	,	O
the	IN	O
target	NN	O
gene	WRB	O
was	RB	O
confirmed	JJ	O
by	NNP	O
Southern	NN	O
hybridization	VBD	O
analysis.	VBN	O
1.	IN	O
Phenotypic	DT	O
Analysis	,	O
(for	NNP	O
Disrupted	JJ	O
Gene:	NNS	O
DNA41234-1242-1	VBD	O
(UNQ310)	VBN	O
(a)	TO	O
Overall	CD	O
Phenotypic	JJ	O
Summary:	NN	O
Knockout	TO	O
homozygous	VB	O
(−/−)	JJ	O
and	JJ	O
heterozygous	NNS	O
(+/−)	IN	O
mice	DT	O
showed	NN	O
an	TO	O
increased	VB	O
blood	DT	O
glucose	NNP	O
level.	.	O
In	NN	O
addition,	PRP	O
both	VBP	O
also	NN	O
showed	VBD	O
an	VBN	O
increased	IN	O
level	NN	O
of	IN	O
ketones	DT	O
and	NN	O
proteins	IN	O
in	VBN	O
the	.	O
urine	NN	O
compared	IN	O
with	DT	O
wild-type	NN	O
littermates	NN	O
and	VBD	O
the	VBN	O
historical	IN	O
mean.	NNP	O
(b)	NN	O
Phenotypic	.	O
Analysis:	.	O
Metabolism—Blood	NNP	O
Chemistry	NNP	O
&	IN	O
Urinalysis	VBN	O
In	:	O
the	NNP	O
area	)	O
of	)	O
metabolism,	JJ	O
targets	NNP	O
may	:	O
be	NNP	O
identified	JJ	O
for	)	O
the	CC	O
treatment	JJ	O
of	)	O
diabetes.	NN	O
Blood	VBD	O
chemistry	DT	O
phenotypic	VBN	O
analysis	NN	O
includes	JJ	O
blood	.	O
glucose	IN	O
measurements	,	O
as	DT	O
well	RB	O
as	VBD	O
urinalysis	DT	O
to	VBN	O
determine	NN	O
if	IN	O
protein	NNS	O
and/or	CC	O
ketone	NNS	O
bodies	IN	O
may	DT	O
be	JJ	O
present.	VBN	O
Abnormal	IN	O
glucose	JJ	O
metabolism	NNS	O
may	CC	O
indicate	DT	O
the	JJ	O
following	.	O
disorders	)	O
or	NNP	O
conditions:	:	O
cachexia,	NNP	O
Diabetes	NNP	O
Type	CC	O
1	NNP	O
and	IN	O
Type	DT	O
2,	NN	O
Syndrome	IN	O
X,	,	O
and	NNS	O
various	MD	O
cardiovascular	VB	O
diseases.	VBN	O
The	IN	O
COBAS	DT	O
Integra	NN	O
400	IN	O
(mfr:	.	O
Roche)	NNP	O
was	NN	O
used	NN	O
for	NN	O
running	VBZ	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
on	RB	O
the	RB	O
mice.	IN	O
The	NN	O
routine	TO	O
urinalysis	VB	O
is	IN	O
a	JJ	O
screening	VBP	O
test	JJ	O
done	NNS	O
to	MD	O
provide	VB	O
a	.	O
general	NNP	O
evaluation	JJ	O
of	NN	O
the	MD	O
renal/urinary	VB	O
system.	DT	O
The	JJ	O
characteristics	NNS	O
for	CC	O
which	:	O
urine	,	O
is	NNP	O
routinely	NNP	O
examined	CD	O
includes	CC	O
tests	NNP	O
for	,	O
protein,	NNP	O
glucose,	,	O
ketones,	CC	O
blood,	JJ	O
bilirubin,	JJ	O
urobilinogen,	.	O
nitrate	DT	O
and	NNP	O
leukocyte	NNP	O
esterase,	CD	O
as	:	O
well	)	O
as	VBD	O
pH	VBN	O
and	IN	O
specific	VBG	O
gravity.	NN	O
Results:	NN	O
Blood	NNS	O
chemistry	IN	O
and	DT	O
urinalysis	.	O
tests	DT	O
results	JJ	O
indicated	NN	O
increased	VBZ	O
levels	DT	O
of	JJ	O
glucose	NN	O
in	VBN	O
the	TO	O
blood	VB	O
as	DT	O
well	JJ	O
as	NN	O
the	IN	O
presence	DT	O
of	JJ	O
both	.	O
protein	DT	O
and	NNS	O
ketones	IN	O
in	WDT	O
the	NN	O
urine	VBZ	O
for	RB	O
homozygous	JJ	O
(−/−)	VBZ	O
mutant	NNS	O
mice	IN	O
and	,	O
heterozygous	,	O
(+/−)	,	O
mice	,	O
compared	,	O
with	,	O
wild-type	NN	O
littermates	CC	O
and	JJ	O
the	,	O
historical	RB	O
mean.	RB	O
These	IN	O
results	NN	O
suggest	CC	O
a	JJ	O
phenotype	.	O
associated	:	O
with	NNP	O
diabetes.	NN	O
As	CC	O
such,	NN	O
PRO353	NNS	O
polypeptides	NNS	O
and/or	VBD	O
its	JJ	O
encoding	NNS	O
gene	IN	O
would	NN	O
be	IN	O
useful	DT	O
in	NN	O
maintaining	RB	O
normal	RB	O
glucose	IN	O
metabolism.	DT	O
J.	NN	O
Generation	IN	O
and	DT	O
Analysis	NN	O
of	CC	O
Mice	NNS	O
Comprising	IN	O
DNA79302-2521	DT	O
(UNQ868)	NN	O
Gene	IN	O
Disruptions	JJ	O
In	)	O
these	NN	O
knockout	NN	O
experiments,	CC	O
the	JJ	O
gene	)	O
encoding	NN	O
PRO1885	VBN	O
polypeptides	IN	O
(designated	JJ	O
as	NNS	O
DNA79302-2521	CC	O
(UNQ868)	DT	O
was	JJ	O
disrupted.	.	O
The	DT	O
gene	NNS	O
specific	VBP	O
information	DT	O
for	NN	O
these	VBN	O
studies	IN	O
is	.	O
as	IN	O
follows:	,	O
the	NNP	O
mutated	VBZ	O
mouse	VB	O
gene	PRP$	O
corresponds	VBG	O
to	NN	O
nucleotide	MD	O
reference:	VB	O
AB053181	JJ	O
or	IN	O
Mus	VBG	O
musculus	JJ	O
ACE2	JJ	O
mRNA	.	O
for	.	O
angiotensin-converting	NN	O
enzyme-related	CC	O
carboxypeptidase;	NNP	O
protein	IN	O
reference:	NNP	O
BAB40431	NNP	O
or	NNP	O
angiotensin-converting	)	O
enzyme-related	NNP	O
carboxypeptidase	NNP	O
[Mus	IN	O
musculus];	DT	O
the	NN	O
human	,	O
gene	DT	O
sequence	NN	O
reference:	VBG	O
NM—021804	NNP	O
or	NNS	O
Homo	VBN	O
sapiens	IN	O
angiotensin	NNP	O
I	)	O
converting	VBD	O
enzyme	.	O
(peptidyl-dipeptidase	DT	O
A)	NN	O
2	JJ	O
(ACE2);	NN	O
protein	IN	O
reference:	DT	O
BAB40370	NNS	O
or	VBZ	O
ACE2.	IN	O
Mutation	:	O
type	DT	O
corresponds	VBN	O
to	NN	O
Homologous	NN	O
Recombination	NNS	O
(standard).	TO	O
Coding	JJ	O
exon	:	O
1	NNP	O
was	CC	O
targeted.	NNP	O
Mutation	CC	O
appears	NNP	O
to	NN	O
be	IN	O
X-linked.	JJ	O
The	JJ	O
gene	:	O
that	CC	O
is	:	O
mutated	NNP	O
in	CC	O
these	JJ	O
animals	JJ	O
is	NN	O
represented	NNP	O
by	:	O
mouse	DT	O
UniGene	JJ	O
cluster	NN	O
Mm.13451,	NN	O
which	:	O
is	NN	O
the	CC	O
ortholog	NN	O
of	JJ	O
human	NN	O
UniGene	PRP	O
cluster	VBG	O
Hs.178098	JJ	O
(ACE2).	VB	O
ACE2	)	O
encodes	CD	O
angiotensin	:	O
I	JJ	O
converting	:	O
enzyme	NNP	O
(peptidyl-dipeptidase	CC	O
A)	.	O
2,	NNP	O
also	NN	O
known	NNS	O
as	TO	O
angiotensin-converting	NNP	O
enzyme-related	NNP	O
carboxypeptidase	.	O
and	VBG	O
ACEH	$	O
(OMIM	CD	O
300335).	VBD	O
The	.	O
physiological	NN	O
substrate	VBZ	O
for	TO	O
ACE2	VB	O
is	.	O
not	DT	O
precisely	NN	O
known.	WDT	O
Unlike	VBZ	O
ACE,	VBN	O
which	IN	O
catalyzes	DT	O
the	NNS	O
cleavage	VBZ	O
of	VBN	O
the	IN	O
carboxy-terminal	NN	O
dipeptide	NNP	O
of	NN	O
biologically	,	O
inactive	WDT	O
Ang1-10	VBZ	O
to	DT	O
the	NN	O
potent	IN	O
vasoconstrictor	JJ	O
Ang1-8,	NNP	O
ACE2	NN	O
catalyzes	NNP	O
the	.	O
cleavage	NNP	O
of	VBZ	O
the	NN	O
carboxy-terminal	PRP	O
residue	VBG	O
of	JJ	O
Ang1-10	VB	O
to	)	O
form	,	O
Ang1-9,	RB	O
and	VBN	O
the	IN	O
carboxy-terminal	JJ	O
residue	JJ	O
of	NN	O
Ang1-8	CC	O
to	NNP	O
form	NNP	O
Ang1-7.	.	O
Moreover,	DT	O
Ang1-8	JJ	O
is	NN	O
a	IN	O
400-fold	NNP	O
better	VBZ	O
substrate	RB	O
than	RB	O
Ang1-10.	.	O
ACE2	IN	O
is	,	O
not	WDT	O
inhibited	VBZ	O
by	DT	O
the	NN	O
ACE	IN	O
inhibitors	DT	O
linesopril	JJ	O
or	NN	O
captopril.	IN	O
Male	RB	O
ACE2	JJ	O
knockout	NNP	O
mice	TO	O
at	DT	O
6	JJ	O
months	NN	O
(but	,	O
not	NNP	O
3	VBZ	O
months)	DT	O
display	NN	O
decreased	IN	O
cardiac	DT	O
contractility	JJ	O
and	NN	O
decreased	IN	O
blood	NNP	O
pressure,	TO	O
which	VB	O
is	,	O
a	CC	O
consequence	DT	O
of	JJ	O
decreased	NN	O
cardiac	IN	O
function.	NNP	O
Apparently,	TO	O
lack	VB	O
of	.	O
ACE2	,	O
activity	NNP	O
in	VBZ	O
ace2	DT	O
null	JJ	O
mice	RBR	O
locally	NN	O
elevates	IN	O
Ang1-8	.	O
and	NNP	O
causes	VBZ	O
vasoconstriction	RB	O
of	VBN	O
coronary	IN	O
arteries	DT	O
and	NNP	O
hypoxia	NNS	O
in	VBD	O
cardiomyocytes,	CC	O
which	.	O
damages	JJ	O
cardiac	NNP	O
tissue	NN	O
and	NN	O
culminates	IN	O
in	CD	O
heart	NNS	O
dysfunction.	CC	O
Targeted	RB	O
or	CD	O
gene	)	O
trap	VBP	O
mutations	VBN	O
are	JJ	O
generated	NN	O
in	CC	O
strain	VBD	O
129SvEvBrd-derived	NN	O
embryonic	,	O
stem	WDT	O
(ES)	VBZ	O
cells.	DT	O
The	NN	O
chimeric	IN	O
mice	JJ	O
are	JJ	O
bred	.	O
to	,	O
C57BL/6J	NN	O
albino	IN	O
mice	NNP	O
to	NN	O
generate	IN	O
F1	JJ	O
female	JJ	O
heterozygous	NN	O
animals.	RB	O
These	VBZ	O
progeny	NNP	O
are	CC	O
crossed	VBZ	O
to	NN	O
hybrid	IN	O
129SvEvBrd/C57	JJ	O
F1	NNS	O
mice,	CC	O
derived	NN	O
from	IN	O
crossing	,	O
129SvEvBrd	WDT	O
mice	NNS	O
to	VBP	O
C57BL/6J	NN	O
mice,	CC	O
to	NNS	O
generate	IN	O
F1A	NN	O
wild-type,	.	O
female	VBN	O
heterozygous,	CC	O
and	NN	O
male	JJ	O
hemizygous	NNS	O
mice.	VBP	O
Level	VBN	O
I	IN	O
phenotypic	JJ	O
analysis	JJ	O
is	JJ	O
performed	NN	O
on	)	O
mice	.	O
from	DT	O
this	JJ	O
generation.	NN	O
Summary	VBP	O
of	VBN	O
X-linked	TO	O
Gene	NNP	O
Distributions	NN	O
for	NN	O
Sex	TO	O
by	VB	O
Genotype:	NNP	O
Disruption	JJ	O
of	JJ	O
the	.	O
target	DT	O
gene	NNS	O
was	VBP	O
confirmed	VBN	O
by	TO	O
Southern	VB	O
hybridization	CD	O
analysis.	NNP	O
1.	,	O
Phenotypic	VBN	O
Analysis	IN	O
(for	VBG	O
Disrupted	CD	O
Gene:	NN	O
DNA79302-2521	TO	O
(UNQ868)	NNP	O
(a)	,	O
Overall	TO	O
Phenotypic	VB	O
Summary:	NNP	O
This	,	O
retroviral	JJ	O
insertion	,	O
is	CC	O
in	JJ	O
an	JJ	O
X-linked	.	O
gene.	NN	O
Only	PRP	O
male	VBP	O
hemizygous	NN	O
(0/−)	VBZ	O
and	VBN	O
female	IN	O
heterozygous	NN	O
(+/−)	IN	O
mice	DT	O
were	.	O
analyzed,	NNP	O
whereas	IN	O
the	JJ	O
wild-type	NNP	O
mice	NNP	O
analyzed	IN	O
were	NN	O
both	IN	O
male	:	O
and	NN	O
female.	IN	O
General	DT	O
Observations:	NN	O
The	NN	O
female	VBD	O
(+/−)	VBN	O
and	IN	O
male	NNP	O
(0/−)	NN	O
albino	.	O
mice	.	O
had	NNP	O
yellow-tinted	NNP	O
coats	IN	O
when	VBN	O
compared	:	O
with	NNP	O
their	)	O
(+/+)	)	O
albino	JJ	O
littermates.	NNP	O
[Analyzed	:	O
wt/het/hom:	DT	O
35/16/18]	JJ	O
Male	NN	O
hemizygous	VBZ	O
(0/−)	IN	O
mice	DT	O
(M-105	JJ	O
and	.	O
M-112)	RB	O
exhibited	JJ	O
heterogeneous	JJ	O
retinal	)	O
backgrounds	CC	O
with	JJ	O
mild	JJ	O
depigmentation	)	O
spots,	NN	O
which	VBD	O
indicates	,	O
early	IN	O
signs	DT	O
of	JJ	O
retinal	NN	O
degeneration.	VBN	O
[Analyzed	VBD	O
wt/het/hemi:	DT	O
4/4/8]	JJ	O
(b	CC	O
Cardiovascular	.	O
Phenotypic	JJ	O
Analysis:	:	O
In	DT	O
the	NN	O
area	)	O
of	CC	O
cardiovascular	NN	O
biology,	)	O
phenotypic	NN	O
testing	NN	O
was	VBD	O
performed	JJ	O
to	NNS	O
identify	WRB	O
potential	VBN	O
targets	IN	O
for	PRP$	O
the	)	O
treatment	NN	O
of	.	O
cardiovascular,	NNP	O
endothelial	:	O
or	NNS	O
angiogenic	NNP	O
disorders.	JJ	O
One	)	O
such	NN	O
phenotypic	JJ	O
test	CC	O
included	)	O
optic	VBD	O
fundus	JJ	O
photography	JJ	O
and	NNS	O
angiography	IN	O
to	JJ	O
determine	NN	O
the	,	O
retinal	WDT	O
arteriovenous	VBZ	O
ratio	JJ	O
(A/V	NNS	O
ratio)	IN	O
in	JJ	O
order	.	O
to	NNP	O
flag	:	O
various	NN	O
eye	IN	O
abnormalities.	NNP	O
An	NNP	O
abnormal	:	O
A/V	IN	O
ratio	DT	O
signals	NN	O
such	IN	O
systemic	JJ	O
diseases	,	O
or	NN	O
disorders	NN	O
that	VBD	O
may	VBN	O
be	TO	O
related	VB	O
to	JJ	O
the	NNS	O
vascular	IN	O
disease	DT	O
of	NN	O
hypertension	IN	O
(and	,	O
any	JJ	O
disease	CC	O
that	JJ	O
causes	.	O
hypertension,	CD	O
e.g.	JJ	O
atherosclerosis),	JJ	O
diabetes	NN	O
or	VBD	O
other	JJ	O
ocular	NN	O
diseases	NN	O
corresponding	CC	O
to	NN	O
ophthalmological	TO	O
disorders.	VB	O
Such	DT	O
eye	JJ	O
abnormalities	JJ	O
may	NN	O
include	NNP	O
but	)	O
are	IN	O
not	NN	O
limited	TO	O
to	VB	O
the	JJ	O
following:	NN	O
retinal	.	O
abnormality	DT	O
is	JJ	O
retinal	NNP	O
dysplasia,	NN	O
various	NNS	O
retinopathies,	JJ	O
restenosis,	JJ	O
retinal	NNS	O
artery	CC	O
obstruction	NNS	O
or	WDT	O
occlusion;	MD	O
retinal	VB	O
degeneration	VBN	O
causing	TO	O
secondary	DT	O
atrophy	JJ	O
of	NN	O
the	IN	O
retinal	NN	O
vasculature,	CC	O
retinitis	DT	O
pigmentosa,	NN	O
macular	WDT	O
dystrophies,	VBZ	O
Stargardt's	,	O
disease,	.	O
congenital	,	O
stationary	VBZ	O
night	CC	O
blindness,	JJ	O
choroideremia,	JJ	O
gyrate	NNS	O
atrophy,	VBG	O
Leber's	TO	O
congenital	JJ	O
amaurosis,	.	O
retinoschisis	JJ	O
disorders,	NN	O
Wagner's	NNS	O
syndrome,	MD	O
Usher	VB	O
syndromes,	CC	O
Zellweger	VBP	O
syndrome,	RB	O
Saldino-Mainzer	VBN	O
syndrome,	TO	O
Senior-Loken	DT	O
syndrome,	:	O
Bardet-Biedl	JJ	O
syndrome,	NN	O
Alport's	VBZ	O
syndrome,	JJ	O
Alstom's	,	O
syndrome,	JJ	O
Cockayne's	,	O
syndrome,	,	O
dysplaisa	JJ	O
spondyloepiphysaria	NN	O
congentia,	NN	O
Flynn-Aird	CC	O
syndrome,	:	O
Friedreich	JJ	O
ataxia,	NN	O
Hallgren	VBG	O
syndrome,	JJ	O
Marshall	NN	O
syndrome,	IN	O
Albers-Schnoberg	DT	O
disease,	JJ	O
Refsum's	,	O
disease,	NN	O
Kearns-Sayre	,	O
syndrome,	JJ	O
Waardenburg's	,	O
syndrome,	POS	O
Alagile	,	O
syndrome,	JJ	O
myotonic	JJ	O
dystrophy,	NN	O
olivopontocerebellar	,	O
atrophy,	,	O
Pierre-Marie	NN	O
dunsdrome,	,	O
Stickler	POS	O
syndrome,	JJ	O
carotinemeia,	,	O
cystinosis,	NN	O
Wolfram	,	O
syndrome,	POS	O
Bassen-Kornzweig	,	O
syndrome,	NNP	O
abetalipoproteinemia,	,	O
incontinentia	NNP	O
pigmenti,	,	O
Batten's	NNP	O
disease,	,	O
mucopolysaccharidoses,	NNP	O
homocystinuria,	,	O
or	NNP	O
mannosidosis.	,	O
Procedure:	POS	O
Optic	,	O
fundus	POS	O
photography	,	O
was	POS	O
performed	,	O
on	JJ	O
conscious	NN	O
animals	,	O
using	NNP	O
a	,	O
Kowa	NNP	O
Genesis	,	O
small	NNP	O
animal	,	O
fundus	NNP	O
camera	,	O
modified	NNP	O
according	,	O
to	POS	O
Hawes	,	O
and	NNP	O
coauthors	,	O
Hawes	POS	B
et	,	I
al.,	NNP	I
1999	,	I
Molecular	JJ	I
Vision	,	I
1999;	JJ	I
5:22).(	,	O
Intra-peritoneal	NNP	O
injection	,	O
of	NNP	O
fluorescein	,	O
permitted	,	O
the	,	O
acquisition	NNP	O
of	,	O
direct	NNP	O
light	,	O
fundus	,	O
images	NN	O
and	,	O
fluorescent	POS	O
angiograms	,	O
for	,	O
each	,	O
examination.	CC	O
In	.	O
addition	:	O
to	JJ	O
direct	NN	O
ophthalmological	NN	O
changes,	VBD	O
this	VBN	O
test	IN	O
can	JJ	O
detect	NNS	O
retinal	VBG	O
changes	DT	O
associated	NNP	O
with	NNP	O
systemic	JJ	O
diseases	NN	O
such	NN	O
as	NN	O
diabetes	VBD	O
and	VBG	O
atherosclerosis	TO	O
or	NNP	O
other	CC	O
retinal	NNS	O
abnormalities.	NNP	O
Pictures	RB	O
were	,	O
provided	CD	O
of	NNP	O
the	NNP	O
optic	:	O
fundus	.	O
under	JJ	O
normal	NN	O
light.	IN	O
The	NN	O
angiographic	VBD	O
pictures	DT	O
allowed	NN	O
examination	IN	O
of	JJ	O
the	NN	O
arteries	NN	O
and	NNS	O
veins	CC	O
of	JJ	O
the	NNS	O
eye.	IN	O
In	DT	O
addition	.	O
an	IN	O
artery	NN	O
to	TO	O
vein	VB	O
(A/V)	JJ	O
ratio	,	O
was	DT	O
determined	NN	O
for	MD	O
the	VB	O
eye.	JJ	O
Ophthalmology	NNS	O
analysis	VBN	O
was	IN	O
performed	JJ	O
on	NNS	O
generated	JJ	O
F2	IN	O
wild	NNS	O
type,	CC	O
heterozygous,	NN	O
and	CC	O
hemizygous	JJ	O
mutant	JJ	O
progeny	.	O
using	NNS	O
the	VBD	O
protocol	VBN	O
described	IN	O
above.	DT	O
Specifically,	JJ	O
the	NN	O
A/V	IN	O
ratio	JJ	O
was	.	O
measured	DT	O
and	JJ	O
calculated	NNS	O
according	VBN	O
to	NN	O
the	IN	O
fundus	DT	O
images	NNS	O
with	CC	O
Kowa	NNS	O
COMIT+	IN	O
software.	DT	O
This	.	O
test	IN	O
takes	NN	O
color	DT	O
photographs	NN	O
through	TO	O
a	VB	O
dilated	)	O
pupil:	NN	O
the	VBD	O
images	VBN	O
help	IN	O
in	DT	O
detecting	.	O
and	NNP	O
classifying	NN	O
many	VBD	O
diseases.	VBN	O
The	IN	O
artery	JJ	O
to	NNP	O
vein	JJ	O
ratio	,	O
(A/V)	,	O
is	CC	O
the	JJ	O
ratio	NN	O
of	NN	O
the	VBG	O
artery	DT	O
diameter	NN	O
to	VBN	O
the	.	O
vein	,	O
diameter	DT	O
(measured	NNP	O
before	NN	O
the	VBD	O
bifurcation	VBN	O
of	CC	O
the	VBN	O
vessels).	VBG	O
Many	TO	O
diseases	DT	O
will	NN	O
influence	VBZ	O
the	IN	O
ratio,	NNP	O
i.e.,	NNP	O
diabetes,	.	O
cardiovascular	DT	O
disorders,	NN	O
papilledema,	VBZ	O
optic	NN	O
atrophy	NN	O
or	IN	O
other	DT	O
eye	JJ	O
abnormalities	:	O
such	DT	O
as	NNS	O
retinal	VBP	O
degeneration	IN	O
(known	NN	O
as	CC	O
retinitis	VBG	O
pigmentosa)	JJ	O
or	.	O
retinal	DT	O
dysplasia,	NN	O
vision	TO	O
problems	VB	O
or	NN	O
blindness.	)	O
Thus,	VBZ	O
phenotypic	DT	O
observations	NN	O
which	IN	O
result	DT	O
in	NN	O
an	NN	O
increased	TO	O
artery-to-vein	DT	O
ratio	NN	O
in	NN	O
homozygous	VBN	O
(−/−)	IN	O
and	DT	O
heterozygous	NN	O
(+/−)	IN	O
mutant	DT	O
progeny	.	O
compared	JJ	O
to	NNS	O
wildtype	MD	O
(+/+)	VB	O
littermates	DT	O
would	,	O
be	,	O
indicative	,	O
of	JJ	O
such	,	O
pathological	,	O
conditions.	JJ	O
Results:	NN	O
In	CC	O
this	JJ	O
study,	NN	O
male	NNS	O
hemizygous	JJ	O
(0/−)	IN	O
mice	JJ	O
(M-105	NN	O
and	VBN	O
M-112)	IN	O
exhibited	NN	O
heterogeneous	)	O
retinal	CC	O
backgrounds	JJ	O
with	,	O
mild	NN	O
depigmentation	NNS	O
spots,	CC	O
which	.	O
indicates	,	O
early	NN	O
signs	NNS	O
of	WDT	O
retinal	VBP	O
degeneration.	IN	O
In	DT	O
addition,	JJ	O
the	NN	O
hemizygous	NN	O
mice	IN	O
exhibited	JJ	O
an	)	O
increased	CC	O
mean	JJ	O
artery-to-vein	)	O
(A/V)	NN	O
ratio	NN	O
when	VBN	O
compared	TO	O
with	VB	O
their	)	O
(+/+)	VBZ	O
littermates	MD	O
indicative	VB	O
of	JJ	O
retinal	IN	O
degeneration.	JJ	O
In	JJ	O
summary,	.	O
by	:	O
knocking	IN	O
out	DT	O
the	,	O
gene	NN	O
identified	JJ	O
as	)	O
DNA79302-2521	NN	O
encoding	JJ	O
PRO1885	CC	O
polypeptides,	)	O
hemizygous	VBD	O
mutant	JJ	O
progeny	JJ	O
exhibit	NNS	O
phenotypes	IN	O
which	JJ	O
are	NN	O
associated	,	O
with	WDT	O
retinal	VBZ	O
degeneration.	JJ	O
Such	NNS	O
detected	IN	O
retinal	JJ	O
changes	.	O
are	IN	O
most	,	O
commonly	DT	O
associated	JJ	O
with	NN	O
cardiovascular	VBD	O
systemic	DT	O
diseases	VBN	O
or	NN	O
disorders	NN	O
that	)	O
are	NN	O
related	WRB	O
to	VBN	O
the	IN	O
vascular	PRP$	O
disease	)	O
of	VBZ	O
hypertension	JJ	O
(and/or	IN	O
any	JJ	O
disease	.	O
that	IN	O
causes	,	O
hypertension,	IN	O
e.g.	VBG	O
atherosclerosis),	RP	O
diabetes	DT	O
or	NN	O
other	VBD	O
ocular	IN	O
diseases	NNP	O
corresponding	VBG	O
to	NNP	O
ophthalmological	,	O
disorders	JJ	O
such	JJ	O
as	NN	O
retinal	NN	O
degeneration.	NNS	O
Thus,	WDT	O
antagonists	VBP	O
of	VBN	O
PRO1885	IN	O
encoding	JJ	O
genes	.	O
would	JJ	O
lead	VBD	O
to	JJ	O
similar	NNS	O
pathological	VBP	O
retinal	RBS	O
changes,	RB	O
whereas	VBN	O
agonists	IN	O
would	JJ	O
be	JJ	O
useful	NNS	O
as	CC	O
therapeutic	NNS	O
agents	WDT	O
in	VBP	O
the	VBN	O
treatment	TO	O
of	DT	O
hypertension,	JJ	O
atherosclerosis	NN	O
or	IN	O
other	NN	O
opthamological	IN	O
disorders	DT	O
including	NN	O
retinal	WDT	O
degeneration	VBZ	O
and	,	O
diseases	.	O
associated	,	O
with	VBZ	O
this	CC	O
condition	JJ	O
(as	JJ	O
indicated	NNS	O
above).	VBG	O
Example	TO	O
14	JJ	O
Use	NNS	O
of	JJ	O
PRO227,	IN	O
PRO233,	JJ	O
PRO238,	.	O
PRO1328,	,	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	NNP	O
PRO21384,	VBG	O
PRO353	NNS	O
or	MD	O
PRO1885	VB	O
as	TO	O
a	JJ	O
Hybridization	JJ	O
Probe	NN	O
The	,	O
following	JJ	O
method	NNS	O
describes	MD	O
use	VB	O
of	JJ	O
a	IN	O
nucleotide	JJ	O
sequence	NNS	O
encoding	IN	O
a	DT	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	,	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	JJ	O
PRO10096,	JJ	O
PRO21384,	NNS	O
PRO353	VBG	O
or	JJ	O
PRO1885	NN	O
polypeptide	CC	O
as	NNS	O
a	VBN	O
hybridization	IN	O
probe.	DT	O
DNA	NN	O
comprising	IN	O
the	VBN	O
coding	.	O
sequence	RB	O
of	CD	O
full-length	NNP	O
or	IN	O
mature	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	IN	O
polypeptides	DT	O
as	NNP	O
disclosed	NNP	O
herein	DT	O
is	JJ	O
employed	NN	O
as	NNS	O
a	NN	O
probe	IN	O
to	DT	O
screen	JJ	O
for	NN	O
homologous	VBG	O
DNAs	DT	O
(such	,	O
as	,	O
those	,	O
encoding	,	O
naturally-occurring	,	O
variants	,	O
of	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	RB	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	.	O
or	NN	O
PRO1885	VBG	O
polypeptides)	DT	O
in	VBG	O
human	NN	O
tissue	IN	O
cDNA	JJ	O
libraries	CC	O
or	JJ	O
human	,	O
tissue	,	O
genomic	,	O
libraries.	,	O
Hybridization	,	O
and	,	O
washing	,	O
of	,	O
filters	NNP	O
containing	CC	O
either	NNP	O
library	NNS	O
DNAs	IN	O
is	JJ	O
performed	NN	O
under	VBZ	O
the	VBN	O
following	IN	O
high	DT	O
stringency	NN	O
conditions.	TO	O
Hybridization	VB	O
of	IN	O
radiolabeled	JJ	O
PRO227-,	NNP	O
PRO233-,	JJ	O
PRO238-,	IN	O
PRO1328-,	DT	O
PRO4342-,	VBG	O
PRO7423-,	JJ	O
PRO10096-,	NNS	O
PRO21384-,	IN	O
PRO353-	,	O
or	,	O
PRO1885-derived	,	O
probe	,	O
to	,	O
the	,	O
filters	,	O
is	,	O
performed	NNP	O
in	CC	O
a	NNP	O
solution	)	O
of	IN	O
50%	JJ	O
formamide,	NN	O
5×SSC,	NN	O
0.1%	NNS	O
SDS,	CC	O
0.1%	JJ	O
sodium	NN	O
pyrophosphate,	JJ	O
50	.	O
mM	NN	O
sodium	CC	O
phosphate,	NN	O
pH	IN	O
6.8,	NNS	O
2×Denhardt's	VBG	O
solution,	CC	O
and	JJ	O
10%	NNP	O
dextran	VBZ	O
sulfate	VBN	O
at	IN	O
42°	DT	O
C.	JJ	O
for	JJ	O
20	NN	O
hours.	.	O
Washing	NN	O
of	IN	O
the	JJ	O
filters	,	O
is	,	O
performed	,	O
in	,	O
an	,	O
aqueous	,	O
solution	,	O
of	,	O
0.1×SSC	NNP	O
and	CC	O
0.1%	NNP	O
SDS	NN	O
at	TO	O
42°	DT	O
C.	NNS	O
DNAs	VBZ	O
having	VBN	O
a	IN	O
desired	DT	O
sequence	NN	O
identity	IN	O
with	NN	O
the	,	O
DNA	,	O
encoding	NN	O
full-length	,	O
native	NN	O
sequence	NN	O
PRO227,	,	O
PRO233,	CD	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	,	O
PRO7423,	NN	O
PRO10096,	,	O
PRO21384,	POS	O
PRO353	,	O
or	CC	O
PRO1885	NN	O
polypeptides	NN	O
can	NN	O
then	IN	O
be	CD	O
identified	NNP	O
using	IN	O
standard	CD	O
techniques	.	O
known	VBG	O
in	IN	O
the	DT	O
art.	NNS	O
Example	VBZ	O
15	VBN	O
Expression	IN	O
of	DT	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	CD	O
PRO4342,	CC	O
PRO7423,	NN	O
PRO10096,	NNP	O
PRO21384,	IN	O
PRO353	CD	O
or	NNP	O
PRO1885	NNP	O
in	VBG	O
E.	DT	O
coli	JJ	O
This	NN	O
example	NN	O
illustrates	IN	O
preparation	DT	O
of	NN	O
an	VBG	O
unglycosylated	JJ	O
form	JJ	O
of	NN	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptides	NNS	O
by	MD	O
recombinant	RB	O
expression	VB	O
in	VBN	O
E.	VBG	O
coli.	JJ	O
The	NNS	O
DNA	VBN	O
sequence	IN	O
encoding	DT	O
a	.	O
PRO227,	RB	O
PRO233,	CD	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
is	NNP	O
initially	CC	O
amplified	NNP	O
using	IN	O
selected	NNP	O
PCR	VBP	O
primers.	DT	O
The	NN	O
primers	VBZ	O
should	NN	O
contain	IN	O
restriction	DT	O
enzyme	JJ	O
sites	NN	O
which	IN	O
correspond	,	O
to	,	O
the	,	O
restriction	,	O
enzyme	,	O
sites	,	O
on	,	O
the	,	O
selected	NNP	O
expression	CC	O
vector.	NNP	O
A	NNS	O
variety	IN	O
of	JJ	O
expression	NN	O
vectors	IN	O
may	NNP	O
be	.	O
employed.	DT	O
An	NNP	O
example	NN	O
of	VBG	O
a	DT	O
suitable	,	O
vector	,	O
is	,	O
pBR322	,	O
(derived	,	O
from	,	O
E.	,	O
coli;	,	O
see	NNP	O
Bolivar	CC	B
et	NNP	I
al.,	NN	I
Gene,	VBZ	I
2:95	RB	I
(1977))	JJ	I
which	VBG	O
contains	VBN	O
genes	NNP	O
for	.	O
ampicillin	DT	O
and	NNS	O
tetracycline	MD	O
resistance.	VB	O
The	NN	O
vector	NN	O
is	NNS	O
digested	WDT	O
with	VBP	O
restriction	TO	O
enzyme	DT	O
and	NN	O
dephosphorylated.	NN	O
The	VBZ	O
PCR	IN	O
amplified	DT	O
sequences	VBN	O
are	NN	O
then	.	O
ligated	DT	O
into	NN	O
the	IN	O
vector.	NN	O
The	NNS	O
vector	MD	O
will	VB	O
preferably	.	O
include	DT	O
sequences	NN	O
which	IN	O
encode	DT	O
for	JJ	O
an	NN	O
antibiotic	VBZ	O
resistance	JJ	O
gene,	VBN	O
a	IN	O
trp	NNP	O
promoter,	:	O
a	VB	O
polyhis	NNP	O
leader	FW	O
(including	,	O
the	,	O
first	CD	O
six	)	O
STII	WDT	O
codons,	VBZ	O
polyhis	NNS	O
sequence,	IN	O
and	NN	O
enterokinase	CC	O
cleavage	NN	O
site),	.	O
the	DT	O
PRO227,	NN	O
PRO233,	VBZ	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	NN	O
PRO7423,	NN	O
PRO10096,	CC	O
PRO21384,	.	O
PRO353	DT	O
or	NNP	O
PRO1885	VBD	O
coding	NNS	O
region,	VBP	O
lambda	RB	O
transcriptional	VBN	O
terminator,	IN	O
and	DT	O
an	.	O
argU	DT	O
gene.	NN	O
The	MD	O
ligation	RB	O
mixture	VB	O
is	NNS	O
then	WDT	O
used	VBP	O
to	IN	O
transform	DT	O
a	JJ	O
selected	NN	O
E.	,	O
coli	DT	O
strain	NN	O
using	,	O
the	DT	O
methods	JJ	O
described	NN	O
in	VBG	O
Sambrook	DT	O
et	JJ	O
al.,	CD	O
supra.	NNP	O
Transformants	,	O
are	NN	O
identified	,	O
by	CC	O
their	JJ	O
ability	NN	O
to	,	O
grow	DT	O
on	,	O
LB	,	O
plates	,	O
and	,	O
antibiotic	,	O
resistant	,	O
colonies	,	O
are	,	O
then	NNP	O
selected.	CC	O
Plasmid	NNP	O
DNA	VBG	O
can	,	O
be	JJ	O
isolated	JJ	O
and	,	O
confirmed	CC	O
by	DT	O
restriction	JJ	O
analysis	.	O
and	DT	O
DNA	NN	O
sequencing.	NN	O
Selected	VBZ	O
clones	RB	O
can	VBN	O
be	TO	O
grown	VB	O
overnight	DT	O
in	VBN	O
liquid	NNP	O
culture	NNS	O
medium	VBP	O
such	VBG	O
as	DT	O
LB	NNS	O
broth	VBN	O
supplemented	IN	O
with	NNP	O
antibiotics.	CC	O
The	,	O
overnight	.	O
culture	NNS	O
may	VBP	O
subsequently	VBN	O
be	IN	O
used	PRP$	O
to	NN	O
inoculate	TO	O
a	VB	O
larger	IN	O
scale	NNP	O
culture.	NNS	O
The	CC	O
cells	JJ	O
are	NN	O
then	NNS	O
grown	VBP	O
to	RB	O
a	.	O
desired	NNP	O
optical	NNP	O
density,	MD	O
during	VB	O
which	VBN	O
the	CC	O
expression	VBN	O
promoter	IN	O
is	NN	O
turned	NN	O
on.	CC	O
After	NNP	O
culturing	.	O
the	VBN	O
cells	NNS	O
for	MD	O
several	VB	O
more	VBN	O
hours,	RB	O
the	IN	O
cells	JJ	O
can	NN	O
be	NN	O
harvested	JJ	O
by	IN	O
centrifugation.	NNP	O
The	CC	O
cell	VBN	O
pellet	IN	O
obtained	.	O
by	DT	O
the	JJ	O
centrifugation	NN	O
can	MD	O
be	RB	O
solubilized	VB	O
using	VBN	O
various	TO	O
agents	VB	O
known	DT	O
in	JJR	O
the	JJ	O
art,	.	O
and	DT	O
the	NNS	O
solubilized	VBP	O
PRO227,	RB	O
PRO233,	VBN	O
PRO238,	TO	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	JJ	O
PRO10096,	,	O
PRO21384,	IN	O
PRO353	WDT	O
or	DT	O
PRO1885	NN	O
protein	NN	O
can	VBZ	O
then	VBN	O
be	.	O
purified	IN	O
using	VBG	O
a	DT	O
metal	NNS	O
chelating	IN	O
column	JJ	O
under	JJR	O
conditions	,	O
that	DT	O
allow	NNS	O
tight	MD	O
binding	VB	O
of	VBN	O
the	IN	O
protein.	.	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	NN	O
PRO1328,	VBN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	MD	O
PRO353	VB	O
or	VBN	O
PRO1885	VBG	O
may	JJ	O
be	NNS	O
expressed	VBN	O
in	IN	O
E.	DT	O
coli	,	O
in	CC	O
a	DT	O
poly-His	JJ	O
tagged	,	O
form,	,	O
using	,	O
the	,	O
following	,	O
procedure.	,	O
The	,	O
DNA	,	O
encoding	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NN	O
PRO1328,	MD	O
PRO4342,	RB	O
PRO7423,	VB	O
PRO10096,	VBN	O
PRO21384,	VBG	O
PRO353	DT	O
or	NN	O
PRO1885	VBG	O
is	NN	O
initially	IN	O
amplified	NNS	O
using	WDT	O
selected	VBP	O
PCR	JJ	O
primers.	NN	O
The	IN	O
primers	DT	O
will	.	O
contain	,	O
restriction	,	O
enzyme	,	O
sites	,	O
which	,	O
correspond	,	O
to	,	O
the	,	O
restriction	NNP	O
enzyme	CC	O
sites	NNP	O
on	MD	O
the	VB	O
selected	VBN	O
expression	IN	O
vector,	NNP	O
and	NNS	O
other	IN	O
useful	DT	O
sequences	JJ	O
providing	JJ	O
for	,	O
efficient	VBG	O
and	DT	O
reliable	JJ	O
translation	.	O
initiation,	DT	O
rapid	NN	O
purification	VBG	O
on	,	O
a	,	O
metal	,	O
chelation	,	O
column,	,	O
and	,	O
proteolytic	,	O
removal	,	O
with	NNP	O
enterokinase.	CC	O
The	NNP	O
PCR-amplified,	VBZ	O
poly-His	RB	O
tagged	JJ	O
sequences	VBG	O
are	VBN	O
then	NNP	O
ligated	.	O
into	DT	O
an	NNS	O
expression	MD	O
vector,	VB	O
which	NN	O
is	NN	O
used	NNS	O
to	WDT	O
transform	VBP	O
an	TO	O
E.	DT	O
coli	NN	O
host	NN	O
based	VBZ	O
on	IN	O
strain	DT	O
52	VBN	O
(W3110	NN	O
fuhA	,	O
(tonA)	CC	O
lon	JJ	O
galE	JJ	O
rpoHts	NNS	O
(htpRts)	VBG	O
clpP	IN	O
(lacIq).	JJ	O
Transformants	CC	O
are	JJ	O
first	NN	O
grown	,	O
in	JJ	O
LB	NN	O
containing	IN	O
50	DT	O
mg/ml	NN	O
carbenicillin	NN	O
at	,	O
30°	CC	O
C.	JJ	O
with	NN	O
shaking	IN	O
until	.	O
an	DT	O
O.D.	,	O
600	JJ	O
of	JJ	O
3-5	NNS	O
is	VBP	O
reached.	RB	O
Cultures	VBN	O
are	IN	O
then	DT	O
diluted	NN	O
50-100	,	O
fold	WDT	O
into	VBZ	O
CRAP	VBN	O
media	TO	O
(prepared	VB	O
by	DT	O
mixing	NNP	O
3.57	NNS	O
g	NN	O
(NH4)2SO4,	VBN	O
0.71	IN	O
g	NN	O
sodium	CD	O
citrate.2H20,	NNP	O
1.07	NN	O
g	)	O
KCl,	NN	O
5.36	NN	O
g	NN	O
Difco	)	O
yeast	NN	O
extract,	.	O
5.36	NNS	O
g	VBP	O
Sheffield	JJ	O
hycase	VBN	O
SF	IN	O
in	NNP	O
500	VBG	O
mL	CD	O
water,	JJ	O
as	NN	O
well	IN	O
as	CD	O
110	NNP	O
mM	IN	O
MPOS,	VBG	O
pH	IN	O
7.3,	DT	O
0.55%	.	O
(w/v)	CD	O
glucose	IN	O
and	JJ	O
7	VBZ	O
mM	.	O
MgSO4)	NNS	O
and	VBP	O
grown	RB	O
for	VBN	O
approximately	JJ	O
20-30	NN	O
hours	IN	O
at	NNP	O
30°	NNS	O
C.	VBN	O
with	IN	O
shaking.	VBG	O
Samples	CD	O
are	NN	O
removed	,	O
to	CD	O
verify	NN	O
expression	NN	O
by	,	O
SDS-PAGE	CD	O
analysis,	NN	O
and	,	O
the	CD	O
bulk	NN	O
culture	NNP	O
is	NNP	O
centrifuged	,	O
to	CD	O
pellet	NN	O
the	NNP	O
cells.	NN	O
Cell	NNP	O
pellets	IN	O
are	CD	O
frozen	JJ	O
until	,	O
purification	RB	O
and	RB	O
refolding.	IN	O
E.	CD	O
coli	NN	O
paste	,	O
from	NN	O
0.5	,	O
to	NN	O
1	)	O
L	NN	O
fermentations	CC	O
(6-10	CD	O
g	NNS	O
pellets)	)	O
is	CC	O
resuspended	VBN	O
in	IN	O
10	RB	O
volumes	JJ	O
(w/v)	NNS	O
in	IN	O
7	CD	O
M	NNP	O
guanidine,	IN	O
20	.	O
mM	NNS	O
Tris,	VBP	O
pH	VBN	O
8	TO	O
buffer.	VB	O
Solid	NN	O
sodium	IN	O
sulfite	NNP	O
and	,	O
sodium	CC	O
tetrathionate	DT	O
is	JJ	O
added	NN	O
to	VBZ	O
make	VBN	O
final	TO	O
concentrations	VB	O
of	DT	O
0.1M	.	O
and	NNP	O
0.02	NNS	O
M,	VBP	O
respectively,	JJ	O
and	IN	O
the	NN	O
solution	CC	O
is	.	O
stirred	NNP	O
overnight	NNS	O
at	NN	O
4°	IN	O
C.	CD	O
This	TO	O
step	CD	O
results	NNP	O
in	NNS	O
a	JJ	O
denatured	NN	O
protein	)	O
with	VBZ	O
all	VBN	O
cysteine	IN	O
residues	CD	O
blocked	NNS	O
by	)	O
sulfitolization.	IN	O
The	CD	O
solution	NNP	O
is	,	O
centrifuged	CD	O
at	NN	O
40,000	,	O
rpm	VBZ	O
in	CD	O
a	.	O
Beckman	JJ	O
Ultracentifuge	NN	O
for	NN	O
30	CC	O
min.	NN	O
The	NN	O
supernatant	VBZ	O
is	VBN	O
diluted	TO	O
with	VB	O
3-5	JJ	O
volumes	NNS	O
of	IN	O
metal	CD	O
chelate	CC	O
column	CD	O
buffer	,	O
(6	,	O
M	CC	O
guanidine,	DT	O
20	NN	O
mM	VBZ	O
Tris,	VBN	O
pH	RB	O
7.4)	IN	O
and	CD	O
filtered	NNP	O
through	DT	O
0.22	NN	O
micron	NNS	O
filters	IN	O
to	DT	O
clarify.	JJ	O
The	NN	O
clarified	IN	O
extract	DT	O
is	NN	O
loaded	NNS	O
onto	VBN	O
a	IN	O
5	.	O
ml	DT	O
Qiagen	NN	O
Ni-NTA	VBZ	O
metal	VBN	O
chelate	IN	O
column	CD	O
equilibrated	NN	O
in	IN	O
the	DT	O
metal	NNP	O
chelate	NNP	O
column	IN	O
buffer.	CD	O
The	.	O
column	DT	O
is	NN	O
washed	VBZ	O
with	VBN	O
additional	IN	O
buffer	JJ	O
containing	NNS	O
50	IN	O
mM	NN	O
imidazole	NN	O
(Calbiochem,	NN	O
Utrol	NN	O
grade),	CD	O
pH	NNP	O
7.4.	,	O
The	CD	O
protein	NN	O
is	,	O
eluted	RB	O
with	)	O
buffer	CC	O
containing	VBN	O
250	IN	O
mM	CD	O
imidazole.	NN	O
Fractions	NNS	O
containing	TO	O
the	.	O
desired	DT	O
protein	JJ	O
are	NN	O
pooled	VBZ	O
and	VBN	O
stored	IN	O
at	DT	O
4°	CD	O
C.	NN	O
Protein	NNP	O
concentration	NNP	O
is	NN	O
estimated	NN	O
by	NN	O
its	VBN	O
absorbance	IN	O
at	DT	O
280	NN	O
nm	NN	O
using	NN	O
the	.	O
calculated	DT	O
extinction	NN	O
coefficient	VBZ	O
based	VBN	O
on	IN	O
its	JJ	O
amino	NN	O
acid	VBG	O
sequence.	CD	O
The	JJ	O
proteins	NN	O
are	,	O
refolded	NNP	O
by	,	O
diluting	JJ	O
the	.	O
sample	DT	O
slowly	NN	O
into	VBZ	O
freshly	VBN	O
prepared	IN	O
refolding	NN	O
buffer	VBG	O
consisting	CD	O
of:	JJ	O
20	.	O
mM	NNS	O
Tris,	VBG	O
pH	DT	O
8.6,	VBN	O
0.3	NN	O
M	VBP	O
NaCl,	VBN	O
2.5	CC	O
M	VBN	O
urea,	IN	O
5	CD	O
mM	NNP	O
cysteine,	NNP	O
20	NN	O
mM	VBZ	O
glycine	VBN	O
and	IN	O
1	PRP$	O
mM	NN	O
EDTA.	IN	O
Refolding	CD	O
volumes	NNS	O
are	VBG	O
chosen	DT	O
so	JJ	O
that	NN	O
the	NN	O
final	VBN	O
protein	IN	O
concentration	PRP$	O
is	NN	O
between	NN	O
50	.	O
to	DT	O
100	NNS	O
micrograms/ml.	VBP	O
The	VBN	O
refolding	IN	O
solution	VBG	O
is	DT	O
stirred	NN	O
gently	RB	O
at	IN	O
4°	RB	O
C.	JJ	O
for	VBG	O
12-36	NN	O
hours.	NN	O
The	:	O
refolding	CD	O
reaction	NN	O
is	,	O
quenched	NN	O
by	,	O
the	CD	O
addition	NNP	O
of	,	O
TFA	CD	O
to	NNP	O
a	,	O
final	CD	O
concentration	NN	O
of	,	O
0.4%	CD	O
(pH	NN	O
of	NN	O
approximately	CC	O
3).	CD	O
Before	NN	O
further	.	O
purification	VBG	O
of	NNS	O
the	VBP	O
protein,	VBN	O
the	RB	O
solution	IN	O
is	DT	O
filtered	JJ	O
through	NN	O
a	NN	O
0.22	VBZ	O
micron	IN	O
filter	CD	O
and	TO	O
acetonitrile	CD	O
is	.	O
added	DT	O
to	VBG	O
2-10%	NN	O
final	VBZ	O
concentration.	VBN	O
The	RB	O
refolded	IN	O
protein	CD	O
is	NNP	O
chromatographed	IN	O
on	JJ	O
a	.	O
Poros	DT	O
R1/H	VBG	O
reversed	NN	O
phase	VBZ	O
column	VBN	O
using	IN	O
a	DT	O
mobile	NN	O
buffer	IN	O
of	NNP	O
0.1%	TO	O
TFA	DT	O
with	JJ	O
elution	NN	O
with	IN	O
a	NN	O
gradient	NN	O
of	IN	O
acetonitrile	RB	O
from	.	O
10	IN	O
to	JJ	O
80%.	NN	O
Aliquots	IN	O
of	DT	O
fractions	,	O
with	DT	O
A280	NN	O
absorbance	VBZ	O
are	VBN	O
analyzed	IN	O
on	DT	O
SDS	CD	O
polyacrylamide	NN	O
gels	NN	O
and	CC	O
fractions	NN	O
containing	VBZ	O
homogeneous	VBN	O
refolded	TO	O
protein	NN	O
are	JJ	O
pooled.	.	O
Generally,	DT	O
the	JJ	O
properly	NN	O
refolded	VBZ	O
species	VBN	O
of	IN	O
most	DT	O
proteins	NNP	O
are	NNP	O
eluted	VBD	O
at	NN	O
the	NN	O
lowest	VBG	O
concentrations	DT	O
of	JJ	O
acetonitrile	NN	O
since	IN	O
those	NN	O
species	NNP	O
are	IN	O
the	NN	O
most	IN	O
compact	DT	O
with	NN	O
their	IN	O
hydrophobic	NN	O
interiors	IN	O
shielded	CD	O
from	TO	O
interaction	.	O
with	NNS	O
the	IN	O
reversed	NNS	O
phase	IN	O
resin.	NNP	O
Aggregated	NN	O
species	VBP	O
are	VBN	O
usually	IN	O
eluted	NNP	O
at	NN	O
higher	NNS	O
acetonitrile	CC	O
concentrations.	NNS	O
In	VBG	O
addition	JJ	O
to	VBN	O
resolving	NN	O
misfolded	VBP	O
forms	.	O
of	,	O
proteins	DT	O
from	RB	O
the	JJ	O
desired	NNS	O
form,	IN	O
the	JJS	O
reversed	NNS	O
phase	VBP	O
step	VBN	O
also	IN	O
removes	DT	O
endotoxin	JJS	O
from	NNS	O
the	IN	O
samples.	NN	O
Fractions	IN	O
containing	DT	O
the	NNS	O
desired	VBP	O
folded	DT	O
PRO227,	RBS	O
PRO233,	JJ	O
PRO238,	IN	O
PRO1328,	PRP$	O
PRO4342,	JJ	O
PRO7423,	NNS	O
PRO10096,	VBD	O
PRO21384,	IN	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
polypeptide	JJ	O
are	NN	O
pooled	.	O
and	VBN	O
the	NNS	O
acetonitrile	VBP	O
removed	RB	O
using	VBN	O
a	IN	O
gentle	JJR	O
stream	NN	O
of	.	O
nitrogen	IN	O
directed	NN	O
at	TO	O
the	VBG	O
solution.	JJ	O
Proteins	NNS	O
are	IN	O
formulated	NNS	O
into	IN	O
20	DT	O
mM	JJ	O
Hepes,	,	O
pH	DT	O
6.8	JJ	O
with	NN	O
0.14	NN	O
M	RB	O
sodium	VBZ	O
chloride	NN	O
and	IN	O
4%	DT	O
mannitol	.	O
by	NNS	O
dialysis	VBG	O
or	DT	O
by	VBN	O
gel	VBD	O
filtration	,	O
using	,	O
G25	,	O
Superfine	,	O
(Pharmacia)	,	O
resins	,	O
equilibrated	,	O
in	,	O
the	NNP	O
formulation	CC	O
buffer	NNP	O
and	NN	O
sterile	VBP	O
filtered.	VBN	O
Example	CC	O
16	DT	O
Expression	NN	O
of	VBD	O
PRO227,	VBG	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	NN	O
PRO10096,	VBN	O
PRO21384,	IN	O
PRO353	DT	O
or	.	O
PRO1885	NNS	O
in	VBP	O
Mammalian	VBN	O
Cells	IN	O
This	CD	O
example	NN	O
illustrates	,	O
preparation	VBZ	O
of	CD	O
a	IN	O
potentially	CD	O
glycosylated	NNP	O
form	NN	O
of	NN	O
a	CC	O
PRO227,	NN	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	VBG	O
or	NNP	O
PRO1885	NNP	O
polypeptide	)	O
by	VBZ	O
recombinant	VBN	O
expression	IN	O
in	DT	O
mammalian	NN	O
cells.	NN	O
The	CC	O
vector,	JJ	O
pRK5	.	O
(see	RB	O
EP	CD	O
307,247,	NN	O
published	IN	O
Mar.	,	O
15,	,	O
1989),	,	O
is	,	O
employed	,	O
as	,	O
the	,	O
expression	,	O
vector.	NNP	O
Optionally,	CC	O
the	NNP	O
PRO227,	IN	O
PRO233,	NNP	O
PRO238,	NNP	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	VBZ	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	DT	O
or	RB	O
PRO1885	JJ	O
DNA	NN	O
is	IN	O
ligated	DT	O
into	,	O
pRK5	,	O
with	,	O
selected	,	O
restriction	,	O
enzymes	,	O
to	,	O
allow	,	O
insertion	NNP	O
of	CC	O
the	NNP	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	JJ	O
PRO10096,	.	O
PRO21384,	DT	O
PRO353	,	O
or	NN	O
PRO1885	VB	O
DNA	NNP	O
using	,	O
ligation	VBN	O
methods	.	O
such	,	O
as	,	O
described	VBZ	O
in	VBN	O
Sambrook	IN	O
et	DT	O
al.,	NN	O
supra.	.	O
The	,	O
resulting	DT	O
vector	,	O
is	,	O
called	,	O
pRK5-PRO227,	,	O
pRK5-pRK5-PRO233,	,	O
pRK5-PRO238,	,	O
pRK5-PRO1328,	,	O
pRK5-PRO4342,	,	O
pRK5-PRO7423;	NNP	O
pRK5-PRO10096;	CC	O
pRK5-PRO21384;	NNP	O
pRK5-PRO353	NNP	O
or	VBZ	O
pRK5-PRO1885.	VBN	O
The	IN	O
selected	NN	O
host	IN	O
cells	VBN	O
may	NN	O
be	VBZ	O
293	TO	O
cells.	VB	O
Human	NN	O
293	IN	O
cells	DT	O
(ATCC	,	O
CCL	,	O
1573)	,	O
are	,	O
grown	,	O
to	,	O
confluence	,	O
in	,	O
tissue	NNP	O
culture	CC	O
plates	NNP	O
in	NNP	O
medium	VBG	O
such	NN	O
as	NNS	O
DMEM	JJ	O
supplemented	IN	O
with	NNS	O
fetal	IN	O
calf	NNP	O
serum	CC	O
and	,	O
optionally,	.	O
nutrient	DT	O
components	VBG	O
and/or	NN	O
antibiotics.	VBZ	O
About	VBN	O
10	,	O
μg	,	O
pRK5-PRO227,	,	O
pRK5-pRK5-PRO233,	,	O
pRK5-PRO238,	,	O
pRK5-PRO1328,	:	O
pRK5-PRO4342,	:	O
pRK5-PRO7423;	:	O
pRK5-PRO10096;	JJ	O
pRK5-PRO21384;	CC	O
pRK5-PRO353	.	O
or	DT	O
pRK5-PRO1885	VBN	O
DNA	NN	O
is	NNS	O
mixed	MD	O
with	VB	O
about	CD	O
1	.	O
μg	JJ	O
DNA	CD	O
encoding	NNS	O
the	NNP	O
VA	NNP	O
RNA	)	O
gene	VBP	O
Thimmappaya	VBN	B
et	TO	I
al.,	VB	I
Cell,	IN	I
31:543	NN	I
(1982)]	NN	I
[and	VBZ	O
dissolved	IN	O
in	NN	O
500	JJ	O
μl	IN	O
of	NNP	O
1	VBD	O
mM	IN	O
Tris-HCl,	JJ	O
0.1	NN	O
mM	NN	O
EDTA,	CC	O
0.227	,	O
M	JJ	O
CaCl2.	NNS	O
To	JJ	O
this	.	O
mixture	IN	O
is	CD	O
added,	JJ	O
dropwise,	,	O
500	,	O
μl	,	O
of	,	O
50	,	O
mM	:	O
HEPES	:	O
(pH	:	O
7.35),	JJ	O
280	CC	O
mM	JJ	O
NaCl,	NN	O
1.5	VBZ	O
mM	JJ	O
NaPO4,	IN	O
and	IN	O
a	CD	O
precipitate	NNS	O
is	NNP	O
allowed	VBG	O
to	DT	O
form	NNP	O
for	NNP	O
10	NN	O
minutes	NNP	O
at	FW	O
25°	,	O
C.	,	O
The	CD	O
precipitate	NN	O
is	CC	O
suspended	VBN	O
and	IN	O
added	CD	O
to	NN	O
the	IN	O
293	CD	O
cells	JJ	O
and	,	O
allowed	CD	O
to	NN	O
settle	,	O
for	CD	O
about	NNP	O
four	.	O
hours	TO	O
at	DT	O
37°	NN	O
C.	VBZ	O
The	,	O
culture	,	O
medium	CD	O
is	NN	O
aspirated	IN	O
off	CD	O
and	NNS	O
2	NNP	O
ml	VB	O
of	,	O
20%	CD	O
glycerol	NN	O
in	,	O
PBS	CD	O
is	NN	O
added	,	O
for	CC	O
30	DT	O
seconds.	NN	O
The	VBZ	O
293	VBN	O
cells	TO	O
are	VB	O
then	IN	O
washed	CD	O
with	NNS	O
serum	IN	O
free	CD	O
medium,	NNP	O
fresh	DT	O
medium	NN	O
is	VBZ	O
added	VBN	O
and	CC	O
the	VBN	O
cells	TO	O
are	DT	O
incubated	CD	O
for	NNS	O
about	CC	O
5	VBN	O
days.	TO	O
Approximately	VB	O
24	IN	O
hours	RB	O
after	CD	O
the	NNS	O
transfections,	IN	O
the	CD	O
culture	NNP	O
medium	DT	O
is	NN	O
removed	NN	O
and	VBZ	O
replaced	VBN	O
with	RB	O
culture	CC	O
medium	CD	O
(alone)	NN	O
or	IN	O
culture	NN	O
medium	NN	O
containing	IN	O
200	NNP	O
μCi/ml	VBZ	O
35S-cysteine	VBN	O
and	IN	O
200	CD	O
μCi/ml	.	O
35S-methionine.	DT	O
After	CD	O
a	NNS	O
12	VBP	O
hour	RB	O
incubation,	VBN	O
the	IN	O
conditioned	JJ	O
medium	JJ	O
is	,	O
collected,	JJ	O
concentrated	NN	O
on	VBZ	O
a	VBN	O
spin	CC	O
filter,	DT	O
and	NNS	O
loaded	VBP	O
onto	VBN	O
a	IN	O
15%	RB	O
SDS	CD	O
gel.	.	O
The	RB	O
processed	CD	O
gel	NNS	O
may	IN	O
be	DT	O
dried	,	O
and	DT	O
exposed	NN	O
to	NN	O
film	VBZ	O
for	VBN	O
a	CC	O
selected	VBN	O
period	IN	O
of	NN	O
time	NN	O
to	)	O
reveal	CC	O
the	NN	O
presence	NN	O
of	VBG	O
PRO227,	CD	O
PRO233,	JJ	O
PRO238,	JJ	O
PRO1328,	CC	O
PRO4342,	CD	O
PRO7423,	JJ	O
PRO10096,	.	O
PRO21384,	IN	O
PRO353	DT	O
or	CD	O
PRO1885	NN	O
polypeptides.	,	O
The	DT	O
cultures	JJ	O
containing	NN	O
transfected	VBZ	O
cells	,	O
may	VBN	O
undergo	IN	O
further	DT	O
incubation	NN	O
(in	,	O
serum	CC	O
free	VBD	O
medium)	IN	O
and	DT	O
the	NN	O
medium	NNP	O
is	.	O
tested	DT	O
in	JJ	O
selected	NN	O
bioassays.	MD	O
In	VB	O
an	VBN	O
alternative	CC	O
technique,	VBN	O
PRO227,	TO	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	JJ	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	NN	O
PRO353	TO	O
or	VB	O
PRO1885	DT	O
may	NN	O
be	IN	O
introduced	,	O
into	,	O
293	,	O
cells	,	O
transiently	,	O
using	,	O
the	,	O
dextran	,	O
sulfate	NNP	O
method	CC	O
described	NNP	O
by	.	O
Somparyrac	DT	B
et	NNS	I
al.,	VBG	I
Proc.	JJ	I
Natl.	NNS	I
Acad.	MD	I
Sci.,	VB	I
12:7575	JJ	I
(1981).	NN	I
293	IN	O
cells	NN	O
are	JJ	O
grown	)	O
to	CC	O
maximal	DT	O
density	NN	O
in	VBZ	O
a	VBN	O
spinner	IN	O
flask	VBN	O
and	.	O
700	IN	O
μg	DT	O
pRK5-PRO227,	JJ	O
pRK5-pRK5-PRO233,	,	O
pRK5-PRO238,	,	O
pRK5-PRO1328,	,	O
pRK5-PRO4342,	,	O
pRK5-PRO7423;	,	O
pRK5-PRO10096;	,	O
pRK5-PRO21384;	,	O
pRK5-PRO353	,	O
or	,	O
pRK5-PRO1885	NNP	O
DNA	CC	O
is	NNP	O
added.	MD	O
The	VB	O
cells	VBN	O
are	IN	O
first	CD	O
concentrated	NNS	O
from	RB	O
the	VBG	O
spinner	DT	O
flask	NN	O
by	NN	O
centrifugation	NN	O
and	VBN	O
washed	IN	O
with	NNP	O
PBS.	FW	O
The	,	O
DNA-dextran	.	O
precipitate	.	O
is	.	O
incubated	,	O
on	CD	O
the	.	O
cell	CD	O
pellet	NNS	O
for	VBP	O
four	VBN	O
hours.	TO	O
The	JJ	O
cells	NN	O
are	IN	O
treated	DT	O
with	NN	O
20%	NN	O
glycerol	CC	O
for	CD	O
90	JJ	O
seconds,	,	O
washed	,	O
with	,	O
tissue	,	O
culture	,	O
medium,	:	O
and	:	O
re-introduced	:	O
into	JJ	O
the	CC	O
spinner	JJ	O
flask	NN	O
containing	VBZ	O
tissue	.	O
culture	DT	O
medium,	NNS	O
5	VBP	O
μg/ml	RB	O
bovine	VBN	O
insulin	IN	O
and	DT	O
0.1	NN	O
μg/ml	NN	O
bovine	IN	O
transferrin.	NN	O
After	CC	O
about	VBD	O
four	IN	O
days,	.	O
the	DT	O
conditioned	NNP	O
media	NN	O
is	VBZ	O
centrifuged	VBN	O
and	IN	O
filtered	DT	O
to	NN	O
remove	NN	O
cells	IN	O
and	CD	O
debris.	.	O
The	DT	O
sample	NNS	O
containing	VBP	O
expressed	VBN	O
PRO227,	IN	O
PRO233,	NN	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	CD	O
PRO7423,	,	O
PRO10096,	VBN	O
PRO21384,	IN	O
PRO353	NN	O
or	NN	O
PRO1885	,	O
can	CC	O
then	JJ	O
be	IN	O
concentrated	DT	O
and	NN	O
purified	NN	O
by	VBG	O
any	NN	O
selected	NN	O
method,	,	O
such	CD	O
as	JJ	O
dialysis	NN	O
and/or	NN	O
column	CC	O
chromatography.	CD	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	.	O
PRO1328,	IN	O
PRO4342,	RB	O
PRO7423,	CD	O
PRO10096,	,	O
PRO21384,	DT	O
PRO353	JJ	O
or	NNS	O
PRO1885	VBZ	O
can	VBN	O
be	CC	O
expressed	VBN	O
in	TO	O
CHO	VB	O
cells.	NNS	O
The	CC	O
pRK5-PRO227,	.	O
pRK5-pRK5-PRO233,	DT	O
pRK5-PRO238,	NN	O
pRK5-PRO1328,	VBG	O
pRK5-PRO4342,	VBN	O
pRK5-PRO7423;	,	O
pRK5-PRO10096;	,	O
pRK5-PRO21384;	,	O
pRK5-PRO353	,	O
or	,	O
pRK5-PRO1885	,	O
can	,	O
be	,	O
transfected	NNP	O
into	CC	O
CHO	NNP	O
cells	MD	O
using	RB	O
known	VB	O
reagents	VBN	O
such	CC	O
as	VBN	O
CaPO4	IN	O
or	DT	O
DEAE-dextran.	VBN	O
As	,	O
described	JJ	O
above,	IN	O
the	NN	O
cell	NN	O
cultures	NN	O
can	.	O
be	,	O
incubated,	,	O
and	,	O
the	,	O
medium	,	O
replaced	,	O
with	,	O
culture	,	O
medium	NNP	O
(alone)	CC	O
or	NNP	O
medium	MD	O
containing	VB	O
a	VBN	O
radiolabel	IN	O
such	NNP	O
as	.	O
35S-methionine.	DT	O
After	,	O
determining	,	O
the	,	O
presence	,	O
of	,	O
PRO227,	:	O
PRO233,	:	O
PRO238,	:	O
PRO1328,	JJ	O
PRO4342,	CC	O
PRO7423,	JJ	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	VBN	O
or	IN	O
PRO1885	NNP	O
polypeptide,	NNS	O
the	VBG	O
culture	JJ	O
medium	NNS	O
may	JJ	O
be	IN	O
replaced	NNP	O
with	CC	O
serum	.	O
free	IN	O
medium.	VBN	O
Preferably,	,	O
the	DT	O
cultures	NN	O
are	NNS	O
incubated	MD	O
for	VB	O
about	,	O
6	CC	O
days,	DT	O
and	NN	O
then	VBD	O
the	IN	O
conditioned	NN	O
medium	NN	O
is	)	O
harvested.	CC	O
The	NN	O
medium	VBG	O
containing	DT	O
the	NN	O
expressed	JJ	O
PRO227,	IN	O
PRO233,	.	O
PRO238,	IN	O
PRO1328,	VBG	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
can	,	O
then	,	O
be	,	O
concentrated	,	O
and	NNP	O
purified	CC	O
by	NNP	O
any	,	O
selected	DT	O
method.	NN	O
Epitope-tagged	NN	O
PRO227,	MD	O
PRO233,	VB	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	JJ	O
PRO10096,	.	O
PRO21384,	,	O
PRO353	DT	O
or	NNS	O
PRO1885	VBP	O
may	VBN	O
also	IN	O
be	RB	O
expressed	CD	O
in	,	O
host	CC	O
CHO	RB	O
cells.	DT	O
The	JJ	O
PRO227,	NN	O
PRO233,	VBZ	O
PRO238,	.	O
PRO1328,	DT	O
PRO4342,	NN	O
PRO7423,	VBG	O
PRO10096,	DT	O
PRO21384,	VBN	O
PRO353	,	O
or	,	O
PRO1885	,	O
may	,	O
be	,	O
subcloned	,	O
out	,	O
of	,	O
the	NNP	O
pRK5	CC	O
vector.	NNP	O
The	MD	O
subclone	RB	O
insert	VB	O
can	VBN	O
undergo	CC	O
PCR	VBN	O
to	IN	O
fuse	DT	O
in	VBN	O
frame	.	O
with	JJ	O
a	,	O
selected	,	O
epitope	,	O
tag	,	O
such	,	O
as	,	O
a	,	O
poly-his	,	O
tag	NNP	O
into	CC	O
a	NNP	O
Baculovirus	MD	O
expression	RB	O
vector.	VB	O
The	VBN	O
poly-his	IN	O
tagged	NN	O
PRO227,	NNP	O
PRO233,	.	O
PRO238,	DT	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
insert	NNP	O
can	CC	O
then	NNP	O
be	MD	O
subcloned	VB	O
into	VBN	O
a	IN	O
SV40	IN	O
driven	DT	O
vector	NN	O
containing	.	O
a	DT	O
selection	NN	O
marker	NN	O
such	MD	O
as	VB	O
DHFR	NNP	O
for	TO	O
selection	VB	O
of	IN	O
stable	NN	O
clones.	IN	O
Finally,	DT	O
the	VBN	O
CHO	NN	O
cells	NN	O
can	JJ	O
be	IN	O
transfected	DT	O
(as	JJ	O
described	NN	O
above)	IN	O
with	DT	O
the	NNP	O
SV40	NN	O
driven	.	O
vector.	DT	O
Labeling	JJ	O
may	JJ	O
be	,	O
performed,	,	O
as	,	O
described	,	O
above,	,	O
to	,	O
verify	,	O
expression.	,	O
The	NNP	O
culture	CC	O
medium	NNP	O
containing	NN	O
the	MD	O
expressed	RB	O
poly-His	VB	O
tagged	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NNP	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	VBG	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	NN	O
or	JJ	O
PRO1885	IN	O
can	NNP	O
then	IN	O
be	NN	O
concentrated	IN	O
and	JJ	O
purified	.	O
by	,	O
any	DT	O
selected	NNP	O
method,	NNS	O
such	MD	O
as	VB	O
by	VBN	O
Ni2+-chelate	IN	O
affinity	VBN	O
chromatography.	)	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	NNP	O
PRO1328,	NN	O
PRO4342,	.	O
PRO7423,	VBG	O
PRO10096,	MD	O
PRO21384,	VB	O
PRO353	,	O
or	IN	O
PRO1885	VBN	O
may	,	O
also	TO	O
be	VB	O
expressed	.	O
in	DT	O
CHO	NN	O
and/or	NN	O
COS	VBG	O
cells	DT	O
by	VBN	O
a	NN	O
transient	NN	O
expression	,	O
procedure	,	O
or	,	O
in	,	O
CHO	,	O
cells	,	O
by	,	O
another	,	O
stable	NNP	O
expression	CC	O
procedure.	NNP	O
Stable	MD	O
expression	RB	O
in	VB	O
CHO	VBN	O
cells	CC	O
is	VBN	O
performed	IN	O
using	DT	O
the	VBN	O
following	,	O
procedure.	JJ	O
The	IN	O
proteins	IN	O
are	NNP	O
expressed	NN	O
as	.	O
an	,	O
IgG	,	O
construct	,	O
(immunoadhesin),	,	O
in	,	O
which	,	O
the	,	O
coding	,	O
sequences	NNP	O
for	CC	O
the	NNP	O
soluble	MD	O
forms	RB	O
(e.g.	VB	O
extracellular	VBN	O
domains)	IN	O
of	NNP	O
the	NN	O
respective	NNP	O
proteins	NNS	O
are	IN	O
fused	DT	O
to	JJ	O
an	NN	O
IgG1	NN	O
constant	CC	O
region	IN	O
sequence	NNP	O
containing	NNS	O
the	IN	O
hinge,	DT	O
CH2	JJ	O
and	NN	O
CH2	.	O
domains	JJ	O
and/or	NN	O
is	IN	O
a	NNP	O
poly-His	NNS	O
tagged	VBZ	O
form.	VBN	O
Following	VBG	O
PCR	DT	O
amplification,	JJ	O
the	.	O
respective	DT	O
DNAs	NNS	O
are	VBP	O
subcloned	VBN	O
in	IN	O
a	DT	O
CHO	NNP	O
expression	NN	O
vector	,	O
using	IN	O
standard	WDT	O
techniques	DT	O
as	NN	O
described	NNS	O
in	IN	O
Ausubel	DT	B
et	JJ	I
al.,	NNS	I
Current	.	I
Protocols	JJ	I
of	)	I
Molecular	IN	I
Biology,	DT	I
Unit	JJ	I
3.16,	NNS	I
John	VBP	I
Wiley	VBN	I
and	TO	I
Sons	DT	I
(1997).	NNP	I
CHO	JJ	O
expression	NN	O
vectors	NN	O
are	VBG	O
constructed	DT	O
to	,	O
have	NNP	O
compatible	CC	O
restriction	NNP	O
sites	NNS	O
5′	VBP	O
and	VBZ	O
3′	DT	O
of	JJ	O
the	JJ	O
DNA	.	O
of	VBG	O
interest	NNP	O
to	,	O
allow	DT	O
the	JJ	O
convenient	NNP	O
shuttling	VBP	O
of	VBN	O
cDNA's.	IN	O
The	DT	O
vector	NNP	O
used	NN	O
expression	NN	O
in	VBG	O
CHO	JJ	O
cells	NNS	O
is	IN	O
as	VBN	O
described	IN	O
in	NNP	O
Lucas	CC	B
et	,	I
al.,	NNP	I
Nucl.	NNP	I
Acids	IN	I
Res.	NNP	I
24:9	,	I
(1774-1779	NNP	I
(1996),	,	I
and	NNP	O
uses	NNP	O
the	CC	O
SV40	NNP	O
early	.	O
promoter/enhancer	NNP	O
to	NN	O
drive	NNS	O
expression	VBP	O
of	VBN	O
the	TO	O
cDNA	VB	O
of	JJ	O
interest	NN	O
and	VBZ	O
dihydrofolate	CD	O
reductase	CC	O
(DHFR).	CD	O
DHFR	IN	O
expression	DT	O
permits	NN	O
selection	IN	O
for	NN	O
stable	TO	O
maintenance	VB	O
of	DT	O
the	NN	O
plasmid	NN	O
following	IN	O
transfection.	.	O
Twelve	DT	O
micrograms	NN	O
of	VBN	O
the	NN	O
desired	IN	O
plasmid	NNP	O
DNA	NNS	O
is	VBZ	O
introduced	IN	O
into	VBN	O
approximately	IN	O
10	NNP	O
million	CC	O
CHO	,	O
cells	.	O
using	NNP	O
commercially	.	O
available	CD	O
transfection	CD	O
reagents	,	O
Superfect®	CC	O
(Qiagen),	VBZ	O
Dosper®	DT	O
or	NNP	O
Fugene®	JJ	O
(Boehringer	NN	O
Mannheim).	TO	O
The	VB	O
cells	NN	O
are	IN	O
grown	DT	O
as	NN	O
described	IN	O
in	NN	O
Lucas	CC	O
et	JJ	O
al.,	NN	O
supra.	.	O
Approximately	NNP	O
3×107	NN	O
cells	VBZ	O
are	NN	O
frozen	IN	O
in	JJ	O
an	NN	O
ampule	IN	O
for	DT	O
further	NN	O
growth	VBG	O
and	.	O
production	NNP	O
as	NNS	O
described	IN	O
below.	DT	O
The	VBN	O
ampules	NN	O
containing	NN	O
the	VBZ	O
plasmid	VBN	O
DNA	IN	O
are	RB	O
thawed	CD	O
by	CD	O
placement	NNP	O
into	NNS	O
water	VBG	O
bath	RB	O
and	JJ	O
mixed	NN	O
by	NNS	O
vortexing.	NNP	O
The	,	O
contents	NNP	O
are	CC	O
pipetted	NNP	O
into	NNP	O
a	.	O
centrifuge	DT	O
tube	NNS	O
containing	VBP	O
10	VBN	O
mLs	IN	O
of	VBN	O
media	IN	O
and	NNP	O
centrifuged	CC	O
at	,	O
1000	.	O
rpm	RB	O
for	CD	O
5	NNS	O
minutes.	VBP	O
The	VBN	O
supernatant	IN	O
is	DT	O
aspirated	NN	O
and	IN	O
the	JJ	O
cells	NN	O
are	CC	O
resuspended	NN	O
in	IN	O
10	VBN	O
mL	.	O
of	DT	O
selective	NNS	O
media	VBG	O
(0.2	DT	O
μm	NN	O
filtered	NNP	O
PS20	VBP	O
with	VBN	O
5%	IN	O
0.2	NN	O
μm	IN	O
diafiltered	NN	O
fetal	NN	O
bovine	CC	O
serum).	JJ	O
The	IN	O
cells	.	O
are	DT	O
then	NNS	O
aliquoted	VBP	O
into	VBN	O
a	IN	O
100	DT	O
mL	NN	O
spinner	NN	O
containing	VBG	O
90	CD	O
mL	NN	O
of	IN	O
selective	NNS	O
media.	CC	O
After	VBN	O
1-2	IN	O
days,	CD	O
the	NN	O
cells	IN	O
are	CD	O
transferred	.	O
into	DT	O
a	NN	O
250	VBZ	O
mL	VBN	O
spinner	CC	O
filled	DT	O
with	NNS	O
150	VBP	O
mL	VBN	O
selective	IN	O
growth	CD	O
medium	NN	O
and	IN	O
incubated	JJ	O
at	NNS	O
37°	CD	O
C.	RB	O
After	VBN	O
another	NNP	O
2-3	IN	O
days,	NN	O
250	CD	O
mL,	NN	O
500	VBD	O
mL	JJ	O
and	NN	O
2000	.	O
mL	DT	O
spinners	NNS	O
are	VBP	O
seeded	RB	O
with	VBN	O
3×105	IN	O
cells/mL.	DT	O
The	CD	O
cell	NN	O
media	NN	O
is	VBG	O
exchanged	CD	O
with	NN	O
fresh	IN	O
media	JJ	O
by	.	O
centrifugation	IN	O
and	JJ	O
resuspension	,	O
in	DT	O
production	NNS	O
medium.	VBP	O
Although	VBN	O
any	IN	O
suitable	DT	O
CHO	CD	O
media	NN	O
may	NN	O
be	VBN	O
employed,	IN	O
a	CD	O
production	NNS	O
medium	JJ	O
described	NN	O
in	NN	O
U.S.	CC	O
Pat.	VBN	O
No.	IN	O
5,122,469,	CD	O
issued	NNP	O
Jun.	IN	O
16,	DT	O
1992	JJ	O
may	,	O
actually	CD	O
be	,	O
used.	CD	O
A	NN	O
3L	CC	O
production	CD	O
spinner	NN	O
is	NNS	O
seeded	VBP	O
at	VBN	O
1.2×106	IN	O
cells/mL.	CD	O
On	.	O
day	DT	O
0,	NN	O
the	NNS	O
cell	VBZ	O
number	VBN	O
pH	IN	O
ie	JJ	O
determined.	NNS	O
On	IN	O
day	NN	O
1,	CC	O
the	NN	O
spinner	IN	O
is	NN	O
sampled	.	O
and	IN	O
sparging	DT	O
with	JJ	O
filtered	NNP	O
air	NNS	O
is	MD	O
commenced.	VB	O
On	,	O
day	DT	O
2,	NN	O
the	NN	O
spinner	VBN	O
is	IN	O
sampled,	NNP	O
the	.	O
temperature	.	O
shifted	,	O
to	VBN	O
33°	.	O
C.,	,	O
and	CD	O
30	MD	O
mL	RB	O
of	VB	O
500	.	O
g/L	DT	O
glucose	CD	O
and	NN	O
0.6	NN	O
mL	VBZ	O
of	VBN	O
10%	IN	O
antifoam	CD	O
(e.g.,	.	O
35%	IN	O
polydimethylsiloxane	NN	O
emulsion,	,	O
Dow	DT	O
Corning	NN	O
365	NN	O
Medical	NN	O
Grade	NN	O
Emulsion)	.	O
taken.	IN	O
Throughout	NN	O
the	,	O
production,	DT	O
the	NN	O
pH	VBZ	O
is	VBN	O
adjusted	CC	O
as	VBG	O
necessary	IN	O
to	JJ	O
keep	NN	O
it	VBZ	O
at	.	O
around	IN	O
7.2.	NN	O
After	,	O
10	DT	O
days,	NN	O
or	VBZ	O
until	,	O
the	DT	O
viability	NN	O
dropped	VBD	O
below	TO	O
70%,	CD	O
the	,	O
cell	CC	O
culture	CD	O
is	NN	O
harvested	IN	O
by	CD	O
centrifugation	NNS	O
and	JJ	O
filtering	CC	O
through	CD	O
a	NN	O
0.22	IN	O
μm	NN	O
filter.	NN	O
The	,	O
filtrate	NN	O
was	NN	O
either	,	O
stored	NNP	O
at	NNP	O
4°	CD	O
C.	NNP	O
or	NNP	O
immediately	)	O
loaded	.	O
onto	IN	O
columns	DT	O
for	,	O
purification.	DT	O
For	NN	O
the	VBZ	O
poly-His	VBN	O
tagged	IN	O
constructs,	JJ	O
the	TO	O
proteins	VB	O
are	PRP	O
purified	IN	O
using	IN	O
a	.	O
Ni-NTA	IN	O
column	CD	O
(Qiagen).	,	O
Before	CC	O
purification,	IN	O
imidazole	DT	O
is	NN	O
added	VBD	O
to	IN	O
the	,	O
conditioned	DT	O
media	NN	O
to	NN	O
a	VBZ	O
concentration	VBN	O
of	IN	O
5	NN	O
mM.	CC	O
The	VBG	O
conditioned	IN	O
media	DT	O
is	CD	O
pumped	NN	O
onto	.	O
a	DT	O
6	NN	O
ml	VBD	O
Ni-NTA	RB	O
column	VBN	O
equilibrated	IN	O
in	CD	O
20	NNP	O
mM	CC	O
Hepes,	RB	O
pH	VBN	O
7.4,	IN	O
buffer	NN	O
containing	IN	O
0.3	.	O
M	IN	O
NaCl	DT	O
and	JJ	O
5	JJ	O
mM	,	O
imidazole	DT	O
at	NNS	O
a	VBP	O
flow	VBN	O
rate	VBG	O
of	DT	O
4-5	JJ	O
ml/min.	NN	O
at	.	O
4°	IN	O
C.	,	O
After	NN	O
loading,	VBZ	O
the	VBN	O
column	TO	O
is	DT	O
washed	VBN	O
with	NNS	O
additional	TO	O
equilibration	DT	O
buffer	NN	O
and	IN	O
the	CD	O
protein	.	O
eluted	DT	O
with	JJ	O
equilibration	NNS	O
buffer	VBZ	O
containing	VBN	O
0.25	IN	O
M	DT	O
imidazole.	CD	O
The	NN	O
highly	NNP	O
purified	NN	O
protein	VBD	O
is	IN	O
subsequently	CD	O
desalted	NN	O
into	,	O
a	NN	O
storage	,	O
buffer	VBP	O
containing	VBG	O
10	CD	O
mM	NNP	O
Hepes,	NNP	O
0.14	CC	O
M	CD	O
NaCl	JJ	O
and	NN	O
4%	IN	O
mannitol,	DT	O
pH	JJ	O
6.8,	NN	O
with	IN	O
a	JJ	O
25	.	O
ml	IN	O
G25	CD	O
Superfine	NNP	O
(Pharmacia)	IN	O
column	,	O
and	DT	O
stored	NN	O
at	VBZ	O
−80°	VBN	O
C.	IN	O
Immunoadhesin	JJ	O
(Fc-containing)	NN	O
constructs	NN	O
are	CC	O
purified	DT	O
from	NN	O
the	VBD	O
conditioned	IN	O
media	NN	O
as	NN	O
follows.	VBG	O
The	CD	O
conditioned	NNP	O
medium	.	O
is	DT	O
pumped	RB	O
onto	JJ	O
a	NN	O
5	VBZ	O
ml	RB	O
Protein	VBN	O
A	IN	O
column	DT	O
(Pharmacia)	NN	O
which	NN	O
had	VBG	O
been	CD	O
equilibrated	JJ	O
in	,	O
20	CD	O
mM	NNP	O
Na	NNP	O
phosphate	CC	O
buffer,	NN	O
pH	,	O
6.8.	NN	O
After	,	O
loading,	IN	O
the	DT	O
column	CD	O
is	NN	O
washed	NNP	O
extensively	NNP	O
with	)	O
equilibration	NN	O
buffer	CC	O
before	VBN	O
elution	IN	O
with	NNP	O
100	NNP	O
mM	NNP	O
citric	)	O
acid,	NNS	O
pH	VBP	O
3.5.	VBN	O
The	IN	O
eluted	DT	O
protein	JJ	O
is	NNS	O
immediately	IN	O
neutralized	.	O
by	DT	O
collecting	JJ	O
1	NN	O
ml	VBZ	O
fractions	VBN	O
into	IN	O
tubes	DT	O
containing	CD	O
275	NN	O
μL	NNP	O
of	NNP	O
1	NN	O
M	)	O
Tris	WDT	O
buffer,	VBD	O
pH	VBN	O
9.	VBN	O
The	IN	O
highly	CD	O
purified	NNS	O
protein	NNP	O
is	NN	O
subsequently	,	O
desalted	JJ	O
into	.	O
storage	IN	O
buffer	,	O
as	DT	O
described	NN	O
above	VBZ	O
for	VBN	O
the	RB	O
poly-His	IN	O
tagged	NN	O
proteins.	NN	O
The	IN	O
homogeneity	NN	O
is	IN	O
assessed	CD	O
by	NNS	O
SDS	JJ	O
polyacrylamide	,	O
gels	JJ	O
and	.	O
by	DT	O
N-terminal	JJ	O
amino	NN	O
acid	VBZ	O
sequencing	RB	O
by	VBN	O
Edman	IN	O
degradation.	VBG	O
Example	CD	O
17	JJ	O
Expression	NNS	O
of	IN	O
PRO227,	NNS	O
PRO233,	VBG	O
PRO238,	CD	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	CD	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	,	O
or	JJ	O
PRO1885	.	O
in	DT	O
Yeast	RB	O
The	JJ	O
following	NN	O
method	VBZ	O
describes	RB	O
recombinant	VBN	O
expression	IN	O
of	NN	O
PRO227,	NN	O
PRO233,	IN	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	JJ	O
PRO353	.	O
or	DT	O
PRO1885	NN	O
in	VBZ	O
yeast.	VBN	O
First,	IN	O
yeast	NNP	O
expression	NN	O
vectors	NNS	O
are	CC	O
constructed	IN	O
for	NNP	O
intracellular	NN	O
production	NN	O
or	NN	O
secretion	IN	O
of	NNP	O
PRO227,	.	O
PRO233,	RB	O
PRO238,	CD	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
from	,	O
the	,	O
ADH2/GAPDH	NNP	O
promoter.	CC	O
DNA	NNP	O
encoding	IN	O
PRO227,	NNP	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	NN	O
PRO4342,	NNS	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	,	O
or	,	O
PRO1885	,	O
and	,	O
the	,	O
promoter	,	O
is	,	O
inserted	,	O
into	NNP	O
suitable	CC	O
restriction	NNP	O
enzyme	IN	O
sites	.	O
in	,	O
the	PRP	O
selected	NN	O
plasmid	NNS	O
to	VBP	O
direct	VBN	O
intracellular	IN	O
expression	JJ	O
of	NN	O
PRO227,	CC	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885.	,	O
For	NNP	O
secretion,	CC	O
DNA	NNP	O
encoding	IN	O
PRO227,	DT	O
PRO233,	NNP	O
PRO238,	.	O
PRO1328,	NN	O
PRO4342,	VBG	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
can	,	O
be	,	O
cloned	NNP	O
into	CC	O
the	NNP	O
selected	CC	O
plasmid,	DT	O
together	NN	O
with	VBZ	O
DNA	VBN	O
encoding	IN	O
the	JJ	O
ADH2/GAPDH	NN	O
promoter,	NN	O
a	NNS	O
native	IN	O
PRO227,	DT	O
PRO233,	VBN	O
PRO238,	NN	O
PRO1328,	TO	O
PRO4342,	VB	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	,	O
or	,	O
PRO1885	,	O
signal	,	O
peptide	,	O
or	,	O
other	,	O
mammalian	,	O
signal	NNP	O
peptide,	CC	O
or,	.	O
for	IN	O
example,	,	O
a	NNP	O
yeast	VBG	O
alpha-factor	,	O
or	,	O
invertase	,	O
secretory	,	O
signal/leader	,	O
sequence,	,	O
and	,	O
linker	,	O
sequences	NNP	O
(if	CC	O
needed)	NNP	O
for	MD	O
expression	VB	O
of	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	VBN	O
PRO1328,	,	O
PRO4342,	RB	O
PRO7423,	IN	O
PRO10096,	NNP	O
PRO21384,	VBG	O
PRO353	DT	O
or	NNP	O
PRO1885.	,	O
Yeast	DT	O
cells,	JJ	O
such	,	O
as	,	O
yeast	,	O
strain	,	O
AB110,	,	O
can	,	O
then	,	O
be	,	O
transformed	NNP	O
with	CC	O
the	NNP	O
expression	JJ	O
plasmids	NN	O
described	CC	O
above	JJ	O
and	JJ	O
cultured	NN	O
in	,	O
selected	,	O
fermentation	IN	O
media.	,	O
The	DT	O
transformed	JJ	O
yeast	NN	O
supernatants	CC	O
can	VB	O
be	JJ	O
analyzed	NN	O
by	,	O
precipitation	CC	O
with	NN	O
10%	NNS	O
trichloroacetic	IN	O
acid	)	O
and	IN	O
separation	NN	O
by	IN	O
SDS-PAGE,	,	O
followed	,	O
by	,	O
staining	,	O
of	,	O
the	,	O
gels	,	O
with	,	O
Coomassie	NNP	O
Blue	CC	O
stain.	.	O
Recombinant	NNP	O
PRO227,	,	O
PRO233,	JJ	O
PRO238,	IN	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	,	O
PRO10096,	MD	O
PRO21384,	RB	O
PRO353	VB	O
or	VBN	O
PRO1885	IN	O
can	DT	O
subsequently	NN	O
be	NNS	O
isolated	VBN	O
and	IN	O
purified	CC	O
by	VBD	O
removing	IN	O
the	VBN	O
yeast	NN	O
cells	.	O
from	DT	O
the	VBN	O
fermentation	NN	O
medium	NNS	O
by	MD	O
centrifugation	VB	O
and	VBN	O
then	IN	O
concentrating	NN	O
the	IN	O
medium	NN	O
using	JJ	O
selected	NN	O
cartridge	CC	O
filters.	NN	O
The	IN	O
concentrate	,	O
containing	VBN	O
PRO227,	IN	O
PRO233,	VBG	O
PRO238,	IN	O
PRO1328,	DT	O
PRO4342,	NNS	O
PRO7423,	IN	O
PRO10096,	NNP	O
PRO21384,	NNP	O
PRO353	.	O
or	JJ	O
PRO1885	,	O
may	,	O
further	,	O
be	,	O
purified	,	O
using	,	O
selected	,	O
column	,	O
chromatography	NNP	O
resins.	CC	O
Example	NNP	O
18	MD	O
Expression	RB	O
of	VB	O
PRO227,	VBN	O
PRO233,	CC	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	VBG	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	IN	O
or	DT	O
PRO1885	NN	O
in	NN	O
Baculovirus-Infected	IN	O
Insect	NN	O
Cells	CC	O
The	RB	O
following	VBG	O
method	DT	O
describes	NN	O
recombinant	VBG	O
expression	VBN	O
of	NN	O
PRO227,	.	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	VBG	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
in	,	O
Baculovirus-infected	NNP	O
insect	CC	O
cells.	NNP	O
The	MD	O
sequence	RB	O
coding	VB	O
for	VBN	O
PRO227,	VBG	O
PRO233,	VBN	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	.	O
PRO7423,	RB	O
PRO10096,	CD	O
PRO21384,	NN	O
PRO353	IN	O
or	,	O
PRO1885	,	O
is	,	O
fused	,	O
upstream	,	O
of	,	O
an	,	O
epitope	,	O
tag	NNP	O
contained	CC	O
within	NNP	O
a	IN	O
baculovirus	NNP	O
expression	NNP	O
vector.	NNP	O
Such	DT	O
epitope	JJ	O
tags	NN	O
include	NNS	O
poly-his	JJ	O
tags	NN	O
and	IN	O
immunoglobulin	,	O
tags	,	O
(like	,	O
Fc	,	O
regions	,	O
of	,	O
IgG).	,	O
A	,	O
variety	NNP	O
of	CC	O
plasmids	NNP	O
may	IN	O
be	NNP	O
employed,	NN	O
including	.	O
plasmids	DT	O
derived	NN	O
from	VBG	O
commercially	IN	O
available	,	O
plasmids	,	O
such	,	O
as	,	O
pVL1393	,	O
(Novagen).	,	O
Briefly,	,	O
the	,	O
sequence	NNP	O
encoding	CC	O
PRO227,	NNP	O
PRO233,	VBZ	O
PRO238,	VBN	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	NN	O
PRO353	VBD	O
or	IN	O
PRO1885	DT	O
or	JJ	O
the	NN	O
desired	.	O
portion	JJ	O
of	NN	O
the	NNS	O
coding	VBP	O
sequence	JJ	O
of	NNS	O
PRO227,	CC	O
PRO233,	NN	O
PRO238,	NNS	O
PRO1328,	IN	O
PRO4342,	NNP	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	.	O
PRO353	DT	O
or	NN	O
PRO1885	IN	O
such	NNS	O
as	MD	O
the	VB	O
sequence	,	O
encoding	VBG	O
the	NNS	O
extracellular	VBN	O
domain	IN	O
of	RB	O
a	JJ	O
transmembrane	NNS	O
protein	JJ	O
or	IN	O
the	NN	O
sequence	.	O
encoding	,	O
the	DT	O
mature	NN	O
protein	VBG	O
if	,	O
the	,	O
protein	,	O
is	,	O
extracellular	,	O
is	,	O
amplified	,	O
by	,	O
PCR	NNP	O
with	CC	O
primers	NNP	O
complementary	CC	O
to	DT	O
the	JJ	O
5′	NN	O
and	IN	O
3′	DT	O
regions.	VBG	O
The	NN	O
5′	IN	O
primer	,	O
may	,	O
incorporate	,	O
flanking	,	O
(selected)	,	O
restriction	,	O
enzyme	,	O
sites.	,	O
The	NNP	O
product	CC	O
is	NNP	O
then	JJ	O
digested	IN	O
with	DT	O
those	NN	O
selected	VBG	O
restriction	DT	O
enzymes	JJ	O
and	NN	O
subcloned	IN	O
into	DT	O
the	NN	O
expression	NN	O
vector.	CC	O
Recombinant	DT	O
baculovirus	NN	O
is	VBG	O
generated	DT	O
by	NN	O
co-transfecting	NN	O
the	IN	O
above	DT	O
plasmid	NN	O
and	VBZ	O
BaculoGold™	JJ	O
virus	VBZ	O
DNA	VBN	O
(Pharmingen)	IN	O
into	NNP	O
Spodoptera	IN	O
frugiperda	NNS	O
(“Sf9”)	VBP	O
cells	TO	O
(ATCC	DT	O
CRL	CD	O
1711)	CC	O
using	CD	O
lipofectin	.	O
(commercially	DT	O
available	CD	O
from	NN	O
GIBCO-BRL).	MD	O
After	VB	O
4-5	NN	O
days	)	O
of	NN	O
incubation	NN	O
at	.	O
28°	DT	O
C.,	NN	O
the	VBZ	O
released	RB	O
viruses	VBN	O
are	IN	O
harvested	DT	O
and	VBN	O
used	NN	O
for	NNS	O
further	CC	O
amplifications.	VBD	O
Viral	IN	O
infection	DT	O
and	NN	O
protein	.	O
expression	JJ	O
are	NN	O
performed	VBZ	O
as	VBN	O
described	IN	O
by	VBG	O
O'Reilley	DT	O
et	NN	O
al.,	NN	O
Baculovirus	CC	O
expression	NNP	O
vectors:	NN	O
A	NNP	O
Laboratory	)	O
Manual,	IN	O
Oxford:	NNP	O
Oxford	NN	O
University	)	O
Press	NNS	O
(1994).	NNP	O
Expressed	NNP	O
poly-his	)	O
tagged	VBG	O
PRO227,	NN	O
PRO233,	RB	O
PRO238,	JJ	O
PRO1328,	IN	O
PRO4342,	.	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NNS	O
PRO353	IN	O
or	NN	O
PRO1885	IN	O
can	CD	O
then	,	O
be	DT	O
purified,	VBN	O
for	NNS	O
example,	VBP	O
by	VBN	O
Ni2+-chelate	CC	O
affinity	VBN	O
chromatography	IN	O
as	JJ	O
follows.	.	O
Extracts	JJ	O
are	NN	O
prepared	CC	O
from	NN	O
recombinant	NN	O
virus-infected	VBP	O
Sf9	VBN	O
cells	IN	O
as	VBN	O
described	IN	O
by	NNP	O
Rupert	FW	B
et	,	I
al.,	NNP	I
Nature,	NN	I
362:175-179	:	I
(1993).	DT	I
Briefly,	NNP	O
Sf9	,	O
cells	:	O
are	NNP	O
washed,	NNP	O
resuspended	NNP	O
in	.	O
sonication	VBN	O
buffer	JJ	O
(25	NN	O
mL	,	O
Hepes,	,	O
pH	,	O
7.9;	,	O
12.5	,	O
mM	,	O
MgCl2;	,	O
0.1	,	O
mM	NNP	O
EDTA;	CC	O
10%	NNP	O
glycerol;	MD	O
0.1%	RB	O
NP-40;	VB	O
0.4	,	O
M	IN	O
KCl),	,	O
and	IN	O
sonicated	NNP	O
twice	NN	O
for	NN	O
20	IN	O
seconds	.	O
on	NNS	O
ice.	VBP	O
The	VBN	O
sonicates	IN	O
are	JJ	O
cleared	JJ	O
by	NNP	O
centrifugation,	NNS	O
and	IN	O
the	VBN	O
supernatant	IN	O
is	NNP	O
diluted	FW	O
50-fold	,	O
in	,	O
loading	NNP	O
buffer	.	O
(50	,	O
mM	NNP	O
phosphate,	NNS	O
300	VBP	O
mM	,	O
NaCl,	VBN	O
10%	IN	O
glycerol,	NN	O
pH	NN	O
7.8)	CD	O
and	NN	O
filtered	,	O
through	VBZ	O
a	:	O
0.45	CD	O
μm	NN	O
filter.	:	O
A	CD	O
Ni2+-NTA	NN	O
agarose	:	O
column	NN	O
(commercially	:	O
available	NN	O
from	:	O
Qiagen)	CD	O
is	NNP	O
prepared	,	O
with	CC	O
a	VBD	O
bed	RB	O
volume	IN	O
of	CD	O
5	NNS	O
mL,	IN	O
washed	.	O
with	DT	O
25	NNS	O
mL	VBP	O
of	VBN	O
water	IN	O
and	,	O
equilibrated	CC	O
with	DT	O
25	NN	O
mL	VBZ	O
of	VBN	O
loading	JJ	O
buffer.	IN	O
The	VBG	O
filtered	NN	O
cell	CD	O
extract	NN	O
is	,	O
loaded	CD	O
onto	NN	O
the	,	O
column	NN	O
at	,	O
0.5	RB	O
mL	)	O
per	CC	O
minute.	VBN	O
The	IN	O
column	DT	O
is	CD	O
washed	NN	O
to	.	O
baseline	DT	O
A280	JJ	O
with	JJ	O
loading	NN	O
buffer,	RB	O
at	JJ	O
which	IN	O
point	)	O
fraction	VBZ	O
collection	JJ	O
is	IN	O
started.	DT	O
Next,	NN	O
the	NN	O
column	IN	O
is	CD	O
washed	,	O
with	VBD	O
a	IN	O
secondary	CD	O
wash	NNS	O
buffer	IN	O
(50	NN	O
mM	CC	O
phosphate;	VBN	O
300	IN	O
mM	CD	O
NaCl,	NNS	O
10%	IN	O
glycerol,	VBG	O
pH	.	O
6.0),	DT	O
which	VBN	O
elutes	NN	O
nonspecifically	NN	O
bound	VBZ	O
protein.	VBN	O
After	IN	O
reaching	DT	O
A280	NN	O
baseline	IN	O
again,	CD	O
the	NNS	O
column	IN	O
is	.	O
developed	DT	O
with	NN	O
a	VBZ	O
0	VBN	O
to	TO	O
500	VB	O
mM	NNP	O
Imidazole	IN	O
gradient	VBG	O
in	,	O
the	IN	O
secondary	WDT	O
wash	NN	O
buffer.	NN	O
One	NN	O
mL	VBZ	O
fractions	.	O
are	,	O
collected	DT	O
and	NN	O
analyzed	VBZ	O
by	VBN	O
SDS-PAGE	IN	O
and	DT	O
silver	JJ	O
staining	NN	O
or	NN	O
Western	CD	O
blot	NN	O
with	:	O
Ni2+-NTA-conjugated	CD	O
to	NN	O
alkaline	,	O
phosphatase	NN	O
(Qiagen).	,	O
Fractions	RB	O
containing	,	O
the	WDT	O
eluted	VBZ	O
His10-tagged	RB	O
PRO227,	VBN	O
PRO233,	.	O
PRO238,	IN	O
PRO1328,	VBG	O
PRO4342,	NNP	O
PRO7423,	NN	O
PRO10096,	,	O
PRO21384,	DT	O
PRO353	NN	O
or	VBZ	O
PRO1885	VBN	O
are	IN	O
pooled	DT	O
and	CD	O
dialyzed	TO	O
against	CD	O
loading	NNS	O
buffer.	NNP	O
Alternatively,	NN	O
purification	IN	O
of	DT	O
the	JJ	O
IgG	NN	O
tagged	.	O
(or	CD	O
Fc	NN	O
tagged)	NNS	O
PRO227,	VBP	O
PRO233,	VBN	O
PRO238,	CC	O
PRO1328,	VBN	O
PRO4342,	IN	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	VB	O
PRO353	NN	O
or	CC	O
PRO1885	JJ	O
can	NN	O
be	IN	O
performed	NNP	O
using	TO	O
known	VB	O
chromatography	NN	O
techniques,	.	O
including	NNS	O
for	VBG	O
instance,	DT	O
Protein	JJ	O
A	NNP	O
or	,	O
protein	,	O
G	,	O
column	,	O
chromatography.	,	O
Example	,	O
19	,	O
Preparation	,	O
of	NNP	O
Antibodies	CC	O
that	NNP	O
Bind	VBP	O
PRO227,	VBN	O
PRO233,	CC	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	VBG	O
PRO7423,	.	O
PRO10096,	,	O
PRO21384,	NN	O
PRO353	IN	O
or	DT	O
PRO1885	NNP	O
This	VBD	O
example	CC	O
illustrates	NNP	O
preparation	)	O
of	,	O
monoclonal	,	O
antibodies	,	O
which	,	O
can	,	O
specifically	,	O
bind	,	O
PRO227,	,	O
PRO233,	NNP	O
PRO238,	CC	O
PRO1328,	NNP	O
PRO4342,	MD	O
PRO7423,	VB	O
PRO10096,	VBN	O
PRO21384,	VBG	O
PRO353	VBN	O
or	NN	O
PRO1885.	,	O
Techniques	VBG	O
for	IN	O
producing	,	O
the	NNP	O
monoclonal	NNP	O
antibodies	CC	O
are	NN	O
known	NNP	O
in	NN	O
the	.	O
art	RB	O
and	CD	O
are	NN	O
described,	IN	O
for	NNS	O
instance,	WDT	O
in	NNP	O
Goding,	,	O
supra.	,	O
Immunogens	,	O
that	,	O
may	,	O
be	,	O
employed	,	O
include	,	O
purified	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	JJ	O
PRO353	NNS	O
or	WDT	O
PRO1885	MD	O
polypeptides,	RB	O
fusion	VB	O
proteins	,	O
containing	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	.	O
or	NNS	O
PRO1885	IN	O
polypeptides,	VBG	O
and	DT	O
cells	JJ	O
expressing	NNS	O
recombinant	VBP	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	VBP	O
PRO10096,	,	O
PRO21384,	IN	O
PRO353	,	O
or	IN	O
PRO1885	,	O
polypeptides	.	O
on	NNS	O
the	WDT	O
cell	MD	O
surface.	VB	O
Selection	VBN	O
of	VBP	O
the	JJ	O
immunogen	,	O
can	,	O
be	,	O
made	,	O
by	,	O
the	,	O
skilled	,	O
artisan	,	O
without	NNP	O
undue	CC	O
experimentation.	NNP	O
Mice,	,	O
such	NN	O
as	NNS	O
Balb/c,	VBG	O
are	,	O
immunized	,	O
with	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	,	O
PRO353	CC	O
or	NNS	O
PRO1885	VBG	O
immunogen	JJ	O
emulsified	,	O
in	,	O
complete	,	O
Freund's	,	O
adjuvant	,	O
and	,	O
injected	,	O
subcutaneously	,	O
or	NNP	O
intraperitoneally	CC	O
in	NNP	O
an	NNS	O
amount	IN	O
from	DT	O
1-100	NN	O
micrograms.	.	O
Alternatively,	NN	O
the	IN	O
immunogen	DT	O
is	NN	O
emulsified	MD	O
in	VB	O
MPL-TDM	VBN	O
adjuvant	IN	O
(Ribi	DT	O
Immunochemical	JJ	O
Research,	NN	O
Hamilton,	IN	O
Mont.)	JJ	O
and	.	O
injected	,	O
into	JJ	O
the	IN	O
animal's	,	O
hind	VBP	O
foot	VBN	O
pads.	IN	O
The	DT	O
immunized	,	O
mice	,	O
are	,	O
then	,	O
boosted	,	O
10	,	O
to	,	O
12	,	O
days	NNP	O
later	CC	O
with	NNP	O
additional	NN	O
immunogen	VBD	O
emulsified	IN	O
in	JJ	O
the	POS	O
selected	NN	O
adjuvant.	CC	O
Thereafter,	VBD	O
for	RB	O
several	CC	O
weeks,	RB	O
the	IN	O
mice	DT	O
may	NN	O
also	IN	O
be	JJ	O
boosted	.	O
with	,	O
additional	DT	O
immunization	NN	O
injections.	VBZ	O
Serum	VBN	O
samples	IN	O
may	NNP	O
be	NN	O
periodically	NNP	O
obtained	NNP	O
from	,	O
the	,	O
mice	)	O
by	CC	O
retro-orbital	VBN	O
bleeding	IN	O
for	DT	O
testing	POS	O
in	JJ	O
ELISA	NN	O
assays	.	O
to	DT	O
detect	JJ	O
anti-PRO227,	NN	O
anti-PRO233,	VBP	O
anti-PRO238,	RB	O
anti-PRO1328,	VBD	O
anti-PRO4342,	CD	O
anti-PRO7423,	TO	O
anti-PRO10096,	CD	O
anti-PRO21384,	NNS	O
anti-PRO353	RB	O
or	IN	O
anti-PRO1885	JJ	O
antibodies.	NN	O
After	VBN	O
a	IN	O
suitable	DT	O
antibody	VBN	O
titer	.	O
has	,	O
been	IN	O
detected,	JJ	O
the	,	O
animals	DT	O
“positive”	NN	O
for	MD	O
antibodies	RB	O
can	VB	O
be	VBN	O
injected	IN	O
with	JJ	O
a	NN	O
final	.	O
intravenous	NNP	O
injection	NNS	O
of	MD	O
PRO227,	VB	O
PRO233,	RB	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	JJ	O
PRO353	NN	O
or	IN	O
PRO1885.	VBG	O
Three	IN	O
to	NNP	O
four	NNS	O
days	TO	O
later,	VB	O
the	,	O
mice	,	O
are	,	O
sacrificed	,	O
and	,	O
the	,	O
spleen	,	O
cells	,	O
are	JJ	O
harvested.	CC	O
The	JJ	O
spleen	.	O
cells	IN	O
are	DT	O
then	JJ	O
fused	NN	O
(using	NN	O
35%	VBZ	O
polyethylene	VBN	O
glycol)	,	O
to	DT	O
a	NNS	O
selected	VBP	O
murine	IN	O
myeloma	NNS	O
cell	MD	O
line	VB	O
such	VBN	O
as	IN	O
P3X63AgU.1,	DT	O
available	JJ	O
from	JJ	O
ATCC,	NN	O
No.	IN	O
CRL	,	O
1597.	,	O
The	,	O
fusions	,	O
generate	,	O
hybridoma	,	O
cells	,	O
which	,	O
can	NNP	O
then	CC	O
be	.	O
plated	CD	O
in	TO	O
96	CD	O
well	NNS	O
tissue	,	O
culture	DT	O
plates	NN	O
containing	VBP	O
HAT	VBN	O
(hypoxanthine,	CC	O
aminopterin,	DT	O
and	JJ	O
thymidine)	NNS	O
medium	VBP	O
to	.	O
inhibit	DT	O
proliferation	JJ	O
of	NNS	O
non-fused	VBP	O
cells,	RB	O
myeloma	VBN	O
hybrids,	VBG	O
and	NN	O
spleen	NN	O
cell	)	O
hybrids.	TO	O
The	DT	O
hybridoma	VBN	O
cells	NN	O
will	NN	O
be	NN	O
screened	NN	O
in	JJ	O
an	IN	O
ELISA	,	O
for	JJ	O
reactivity	IN	O
against	,	O
PRO227,	.	O
PRO233,	NN	O
PRO238,	.	O
PRO1328,	DT	O
PRO4342,	NNS	O
PRO7423,	VBP	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	WDT	O
or	MD	O
PRO1885.	RB	O
Determination	VB	O
of	VBN	O
“positive”	IN	O
hybridoma	CD	O
cells	RB	O
secreting	JJ	O
the	NN	O
desired	VBZ	O
monoclonal	VBG	O
antibodies	NNP	O
against	,	O
PRO227,	,	O
PRO233,	CC	O
PRO238,	)	O
PRO1328,	NN	O
PRO4342,	TO	O
PRO7423,	VB	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	JJ	O
or	,	O
PRO1885	NN	O
is	,	O
within	CC	O
the	JJ	O
skill	NN	O
in	.	O
the	DT	O
art.	NN	O
The	NNS	O
positive	MD	O
hybridoma	VB	O
cells	VBN	O
can	IN	O
be	DT	O
injected	NNP	O
intraperitoneally	IN	O
into	NN	O
syngeneic	IN	O
Balb/c	,	O
mice	,	O
to	,	O
produce	,	O
ascites	,	O
containing	,	O
the	,	O
anti-PRO227,	,	O
anti-PRO233,	NNP	O
anti-PRO238,	CC	O
anti-PRO1328,	.	O
anti-PRO4342,	NN	O
anti-PRO7423,	IN	O
anti-PRO10096,	NNP	O
anti-PRO21384,	NN	O
anti-PRO353	NNS	O
or	VBG	O
anti-PRO1885	DT	O
monoclonal	JJ	O
antibodies.	JJ	O
Alternatively,	NNS	O
the	IN	O
hybridoma	,	O
cells	,	O
can	,	O
be	,	O
grown	,	O
in	,	O
tissue	,	O
culture	,	O
flasks	NNP	O
or	CC	O
roller	NNP	O
bottles.	VBZ	O
Purification	IN	O
of	DT	O
the	NN	O
monoclonal	IN	O
antibodies	DT	O
produced	.	O
in	DT	O
the	JJ	O
ascites	NN	O
can	NNS	O
be	MD	O
accomplished	VB	O
using	VBN	O
ammonium	RB	O
sulfate	IN	O
precipitation,	JJ	O
followed	NNP	O
by	NN	O
gel	TO	O
exclusion	VB	O
chromatography.	NNS	O
Alternatively,	VBG	O
affinity	DT	O
chromatography	,	O
based	,	O
upon	,	O
binding	,	O
of	,	O
antibody	,	O
to	,	O
protein	,	O
A	JJ	O
or	CC	O
protein	JJ	O
G	JJ	O
can	.	O
be	,	O
employed.	DT	O
Example	NN	O
20	NNS	O
Purification	MD	O
of	VB	O
PRO227,	VBN	O
PRO233,	IN	O
PRO238,	NN	O
PRO1328,	NN	O
PRO4342,	NNS	O
PRO7423	CC	O
PRO10096	NN	O
PRO21384	.	O
PRO353	NN	O
or	IN	O
PRO1885	DT	O
Polypeptides	JJ	O
Using	NNS	O
Specific	VBN	O
Antibodies	IN	O
Native	DT	O
or	NNS	O
recombinant	MD	O
PRO227,	VB	O
PRO233,	VBN	O
PRO238,	VBG	O
PRO1328,	NN	O
PRO4342,	NN	O
PRO7423,	,	O
PRO10096,	VBN	O
PRO21384,	IN	O
PRO353	JJ	O
or	NN	O
PRO1885	.	O
polypeptides	,	O
may	NN	O
be	NN	O
purified	VBN	O
by	IN	O
a	NN	O
variety	IN	O
of	NN	O
standard	TO	O
techniques	VB	O
in	DT	O
the	CC	O
art	JJ	O
of	NNP	O
protein	MD	O
purification.	VB	O
For	.	O
example,	RB	O
pro-PRO227,	CD	O
pro-PRO233,	NN	O
pro-PRO238,	IN	O
pro-PRO1328,	,	O
pro-PRO4342,	,	O
pro-PRO7423;	,	O
pro-PRO10096;	,	O
pro-PRO21384;	,	O
pro-PRO353	NNP	O
or	NNP	O
pro-PRO1885	NNP	O
polypeptide,	NNP	O
mature	CC	O
PRO227,	NNP	O
PRO233,	NNP	O
PRO238,	NNP	O
PRO1328,	NNP	O
PRO4342,	NNP	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	JJ	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide,	,	O
or	,	O
pre-PRO227,	,	O
pre-PRO233,	,	O
pre-PRO238,	,	O
pre-PRO1328,	NNP	O
pre-PRO4342,	CC	O
pre-PRO7423;	NNP	O
pre-PRO10096;	NNS	O
pre-PRO21384;	MD	O
pre-PRO353	VB	O
or	VBN	O
pre-PRO1885	IN	O
polypeptide	DT	O
is	NN	O
purified	IN	O
by	JJ	O
immunoaffinity	NNS	O
chromatography	IN	O
using	DT	O
antibodies	NN	O
specific	IN	O
for	NN	O
the	.	O
PRO227,	IN	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	:	O
PRO353	:	O
or	:	O
PRO1885	JJ	O
polypeptide	CC	O
of	JJ	O
interest.	,	O
In	NN	O
general,	,	O
an	,	O
immunoaffinity	,	O
column	,	O
is	,	O
constructed	,	O
by	,	O
covalently	,	O
coupling	NNP	O
the	CC	O
anti-PRO227,	NNP	O
anti-PRO233,	,	O
anti-PRO238,	CC	O
anti-PRO1328,	,	O
anti-PRO4342,	,	O
anti-PRO7423,	,	O
anti-PRO10096,	,	O
anti-PRO21384,	,	O
anti-PRO353	:	O
or	:	O
anti-PRO1885	:	O
polypeptide	JJ	O
antibody	CC	O
to	JJ	O
an	NN	O
activated	VBZ	O
chromatographic	VBN	O
resin.	IN	O
Polyclonal	NN	O
immunoglobulins	NN	O
are	VBG	O
prepared	NNS	O
from	JJ	O
immune	IN	O
sera	DT	O
either	,	O
by	,	O
precipitation	,	O
with	,	O
ammonium	,	O
sulfate	,	O
or	,	O
by	,	O
purification	NNP	O
on	CC	O
immobilized	NNP	O
Protein	IN	O
A	IN	O
(Pharmacia	.	O
LKB	IN	O
Biotechnology,	,	O
Piscataway,	DT	O
N.J.).	NN	O
Likewise,	NN	O
monoclonal	VBZ	O
antibodies	VBN	O
are	IN	O
prepared	RB	O
from	VBG	O
mouse	DT	O
ascites	,	O
fluid	,	O
by	,	O
ammonium	,	O
sulfate	,	O
precipitation	,	O
or	,	O
chromatography	,	O
on	JJ	O
immobilized	CC	O
Protein	JJ	O
A.	NN	O
Partially	NN	O
purified	TO	O
immunoglobulin	DT	O
is	JJ	O
covalently	JJ	O
attached	.	O
to	JJ	O
a	NNS	O
chromatographic	VBP	O
resin	VBN	O
such	IN	O
as	JJ	O
CnBr-activated	NN	O
SEPHAROSE™	CC	O
(Pharmacia	IN	O
LKB	NN	O
Biotechnology).	IN	O
The	NN	O
antibody	NN	O
is	CC	O
coupled	IN	O
to	NN	O
the	IN	O
resin,	JJ	O
the	NNP	O
resin	NNP	O
is	NNP	O
blocked,	NNP	O
and	,	O
the	,	O
derivative	.	O
resin	,	O
is	JJ	O
washed	NNS	O
according	VBP	O
to	VBN	O
the	IN	O
manufacturer's	NN	O
instructions.	NNS	O
Such	VBN	O
an	IN	O
immunoaffinity	NN	O
column	NN	O
is	NN	O
utilized	CC	O
in	NN	O
the	IN	O
purification	JJ	O
of	NNP	O
PRO227,	.	O
PRO233,	RB	O
PRO238,	VBN	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	RB	O
PRO10096,	VBN	O
PRO21384,	TO	O
PRO353	DT	O
or	JJ	O
PRO1885	NN	O
polypeptide	JJ	O
by	IN	O
preparing	JJ	O
a	NNP	O
fraction	NNP	O
from	NNP	O
cells	.	O
containing	DT	O
PRO227,	NN	O
PRO233,	VBZ	O
PRO238,	VBN	O
PRO1328,	TO	O
PRO4342,	DT	O
PRO7423,	,	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	VBZ	O
or	,	O
PRO1885	CC	O
polypeptide	DT	O
in	JJ	O
a	NN	O
soluble	VBZ	O
form.	VBN	O
This	VBG	O
preparation	TO	O
is	DT	O
derived	POS	O
by	.	O
solubilization	JJ	O
of	DT	O
the	NN	O
whole	NN	O
cell	VBZ	O
or	VBN	O
of	IN	O
a	DT	O
subcellular	NN	O
fraction	IN	O
obtained	,	O
via	,	O
differential	,	O
centrifugation	,	O
by	,	O
the	,	O
addition	,	O
of	,	O
detergent	NNP	O
or	CC	O
by	NNP	O
other	NN	O
methods	IN	O
well	VBG	O
known	DT	O
in	NN	O
the	IN	O
art.	NNS	O
Alternatively,	VBG	O
soluble	,	O
polypeptide	,	O
containing	,	O
a	,	O
signal	,	O
sequence	,	O
may	,	O
be	,	O
secreted	NNP	O
in	CC	O
useful	NNP	O
quantity	VBP	O
into	IN	O
the	DT	O
medium	JJ	O
in	.	O
which	DT	O
the	NN	O
cells	VBZ	O
are	VBN	O
grown.	IN	O
A	NN	O
soluble	IN	O
PRO227,	DT	O
PRO233,	JJ	O
PRO238,	NN	O
PRO1328,	CC	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	VBN	O
or	IN	O
PRO1885	JJ	O
polypeptide-containing	NN	O
preparation	IN	O
is	DT	O
passed	NN	O
over	IN	O
the	NN	O
immunoaffinity	CC	O
column,	IN	O
and	JJ	O
the	NNS	O
column	RB	O
is	VBN	O
washed	IN	O
under	DT	O
conditions	.	O
that	,	O
allow	JJ	O
the	NN	O
preferential	VBG	O
absorbance	DT	O
of	JJ	O
PRO227,	NN	O
PRO233,	MD	O
PRO238,	VB	O
PRO1328,	VBN	O
PRO4342,	IN	O
PRO7423,	JJ	O
PRO10096,	NN	O
PRO21384,	IN	O
PRO353	DT	O
or	NN	O
PRO1885	IN	O
polypeptide	WDT	O
(e.g.,	DT	O
high	NNS	O
ionic	VBP	O
strength	.	O
buffers	DT	O
in	JJ	O
the	,	O
presence	,	O
of	,	O
detergent).	,	O
Then,	,	O
the	,	O
column	,	O
is	,	O
eluted	NNP	O
under	CC	O
conditions	NNP	O
that	JJ	O
disrupt	NN	O
antibody/PRO227,	VBZ	O
antibody/PRO233,	VBN	O
antibody/PRO238,	IN	O
antibody/PRO1328,	DT	O
antibody/PRO4342,	NN	O
antibody/PRO7423;	,	O
antibody/PRO10096;	CC	O
antibody/PRO21384;	DT	O
antibody/PRO353	NN	O
or	VBZ	O
antibody/PRO1885	VBN	O
polypeptide	IN	O
binding	NNS	O
(e.g.,	WDT	O
a	VBP	O
low	DT	O
pH	JJ	O
buffer	NN	O
such	IN	O
as	,	O
approximately	,	O
pH	,	O
2-3,	,	O
or	,	O
a	,	O
high	,	O
concentration	,	O
of	NNP	O
a	CC	O
chaotrope	NNP	O
such	NN	O
as	,	O
urea	JJ	O
or	JJ	O
thiocyanate	NN	O
ion),	NNS	O
and	IN	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	.	O
PRO4342,	,	O
PRO7423,	DT	O
PRO10096,	NN	O
PRO21384,	VBZ	O
PRO353	VBN	O
or	IN	O
PRO1885	NNS	O
polypeptide	WDT	O
is	VBP	O
collected.	,	O
Example	,	O
21	,	O
Drug	,	O
Screening	,	O
This	:	O
invention	:	O
is	:	O
particularly	CC	O
useful	CC	O
for	JJ	O
screening	NN	O
compounds	NN	O
by	,	O
using	DT	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	NN	O
PRO1328,	JJ	O
PRO4342,	IN	O
PRO7423,	RB	O
PRO10096,	JJ	O
PRO21384,	,	O
PRO353	CC	O
or	DT	O
PRO1885	JJ	O
polypeptides	NN	O
or	IN	O
binding	DT	O
fragment	NN	O
thereof	JJ	O
in	IN	O
any	JJ	O
of	CC	O
a	JJ	O
variety	,	O
of	CC	O
drug	,	O
screening	,	O
techniques.	,	O
The	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NN	O
PRO353	VBZ	O
or	.	O
PRO1885	JJ	O
polypeptide	CD	O
or	NNP	O
fragment	NNP	O
employed	DT	O
in	NN	O
such	VBZ	O
a	RB	O
test	JJ	O
may	IN	O
either	VBG	O
be	NNS	O
free	IN	O
in	VBG	O
solution,	,	O
affixed	,	O
to	,	O
a	,	O
solid	,	O
support,	,	O
borne	,	O
on	,	O
a	NNP	O
cell	CC	O
surface,	NNP	O
or	NNS	O
located	CC	O
intracellularly.	VBG	O
One	JJ	O
method	NN	O
of	IN	O
drug	DT	O
screening	IN	O
utilizes	DT	O
eukaryotic	NN	O
or	IN	O
prokaryotic	NN	O
host	VBG	O
cells	.	O
which	DT	O
are	,	O
stably	,	O
transformed	,	O
with	,	O
recombinant	,	O
nucleic	,	O
acids	,	O
expressing	,	O
the	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	NN	O
PRO1328,	CC	O
PRO4342,	JJ	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	JJ	O
PRO353	DT	O
or	NN	O
PRO1885	MD	O
polypeptide	RB	O
or	VB	O
fragment.	JJ	O
Drugs	IN	O
are	,	O
screened	VBN	O
against	TO	O
such	DT	O
transformed	JJ	O
cells	,	O
in	NN	O
competitive	IN	O
binding	DT	O
assays.	NN	O
Such	,	O
cells,	CC	O
either	VBN	O
in	.	O
viable	CD	O
or	NN	O
fixed	IN	O
form,	NN	O
can	VBG	O
be	JJ	O
used	JJ	O
for	CC	O
standard	JJ	O
binding	NN	O
assays.	NNS	O
One	WDT	O
may	VBP	O
measure,	RB	O
for	VBN	O
example,	IN	O
the	JJ	O
formation	JJ	O
of	NNS	O
complexes	VBG	O
between	DT	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	NNP	O
or	CC	O
PRO1885	NNP	O
polypeptide	NN	O
or	CC	O
a	.	O
fragment	NNS	O
and	VBP	O
the	VBN	O
agent	IN	O
being	JJ	O
tested.	JJ	O
Alternatively,	NNS	O
one	IN	O
can	JJ	O
examine	NN	O
the	.	O
diminution	JJ	O
in	,	O
complex	RB	O
formation	IN	O
between	JJ	O
the	CC	O
PRO227,	JJ	O
PRO233,	,	O
PRO238,	MD	O
PRO1328,	VB	O
PRO4342,	VBN	O
PRO7423,	IN	O
PRO10096,	JJ	O
PRO21384,	NN	O
PRO353	.	O
or	CD	O
PRO1885	MD	O
polypeptide	,	O
and	IN	O
its	,	O
target	DT	O
cell	NN	O
or	IN	O
target	NNS	O
receptors	IN	O
caused	,	O
by	,	O
the	,	O
agent	,	O
being	,	O
tested.	,	O
Thus,	,	O
the	,	O
present	NNP	O
invention	CC	O
provides	NNP	O
methods	VBP	O
of	CC	O
screening	DT	O
for	NN	O
drugs	CC	O
or	DT	O
any	NN	O
other	VBG	O
agents	.	O
which	,	O
can	CD	O
affect	MD	O
a	VB	O
PRO227,	DT	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	JJ	O
PRO4342,	NN	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide-associated	,	O
disease	,	O
or	,	O
disorder.	,	O
These	NNP	O
methods	CC	O
comprise	NNP	O
contacting	RB	O
such	CC	O
an	PRP$	O
agent	NN	O
with	NN	O
an	CC	O
PRO227,	NN	O
PRO233,	NNS	O
PRO238,	VBN	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	VBG	O
PRO21384,	.	O
PRO353	,	O
or	DT	O
PRO1885	JJ	O
polypeptide	NN	O
or	VBZ	O
fragment	NNS	O
thereof	IN	O
and	VBG	O
assaying	IN	O
(I)	NNS	O
for	CC	O
the	DT	O
presence	JJ	O
of	NNS	O
a	WDT	O
complex	MD	O
between	VB	O
the	DT	O
agent	,	O
and	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	JJ	O
or	NN	O
PRO1885	CC	O
polypeptide	.	O
or	DT	O
fragment,	NNS	O
or	VBP	O
(ii)	VBG	O
for	PDT	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
complex	,	O
between	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	NNP	O
PRO10096,	CC	O
PRO21384,	NNP	O
PRO353	NN	O
or	CC	O
PRO1885	NN	O
polypeptide	NN	O
or	CC	O
fragment	NN	O
and	)	O
the	IN	O
cell,	DT	O
by	NN	O
methods	IN	O
well	DT	O
known	NN	O
in	IN	O
the	DT	O
art.	NN	O
In	CC	O
such	DT	O
competitive	,	O
binding	,	O
assays,	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	NNP	O
PRO7423,	CC	O
PRO10096,	NNP	O
PRO21384,	NN	O
PRO353	CC	O
or	,	O
PRO1885	CC	O
polypeptide	)	O
or	IN	O
fragment	DT	O
is	NN	O
typically	IN	O
labeled.	DT	O
After	NN	O
suitable	IN	O
incubation,	DT	O
free	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	NNP	O
PRO353	CC	O
or	NNP	O
PRO1885	NN	O
polypeptide	CC	O
or	NN	O
fragment	CC	O
is	DT	O
separated	,	O
from	IN	O
that	NNS	O
present	RB	O
in	VBN	O
bound	IN	O
form,	DT	O
and	.	O
the	IN	O
amount	JJ	O
of	JJ	O
free	NN	O
or	,	O
uncomplexed	DT	O
label	,	O
is	,	O
a	,	O
measure	,	O
of	,	O
the	,	O
ability	,	O
of	,	O
the	NNP	O
particular	CC	O
agent	NNP	O
to	NN	O
bind	CC	O
to	NN	O
PRO227,	VBZ	O
PRO233,	RB	O
PRO238,	.	O
PRO1328,	IN	O
PRO4342,	JJ	O
PRO7423,	,	O
PRO10096,	JJ	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
or	,	O
to	,	O
interfere	,	O
with	NNP	O
the	CC	O
PRO227,	NNP	O
PRO233,	NN	O
PRO238,	CC	O
PRO1328,	NN	O
PRO4342,	VBZ	O
PRO7423,	VBN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	JJ	O
or	IN	O
PRO1885	NN	O
polypeptide/cell	,	O
complex.	CC	O
Another	DT	O
technique	NN	O
for	IN	O
drug	JJ	O
screening	CC	O
provides	JJ	O
high	NN	O
throughput	VBZ	O
screening	DT	O
for	NN	O
compounds	IN	O
having	DT	O
suitable	NN	O
binding	IN	O
affinity	DT	O
to	JJ	O
a	NN	O
polypeptide	TO	O
and	VB	O
is	TO	O
described	,	O
in	,	O
detail	,	O
in	,	O
WO	,	O
84/03564,	,	O
published	,	O
on	,	O
Sep.	NNP	O
13,	CC	O
1984.	NNP	O
Briefly	RB	O
stated,	CC	O
large	TO	O
numbers	VB	O
of	IN	O
different	DT	O
small	,	O
peptide	,	O
test	,	O
compounds	,	O
are	,	O
synthesized	,	O
on	,	O
a	,	O
solid	NNP	O
substrate,	CC	O
such	NNP	O
as	VBP	O
plastic	.	O
pins	DT	O
or	NN	O
some	IN	O
other	NN	O
surface.	VBG	O
As	VBZ	O
applied	JJ	O
to	NN	O
a	VBG	O
PRO227,	IN	O
PRO233,	NNS	O
PRO238,	VBG	O
PRO1328,	JJ	O
PRO4342,	VBG	O
PRO7423,	NN	O
PRO10096,	TO	O
PRO21384,	DT	O
PRO353	NN	O
or	CC	O
PRO1885	VBZ	O
polypeptide,	VBN	O
the	IN	O
peptide	NN	O
test	IN	O
compounds	NNP	O
are	,	O
reacted	VBN	O
with	IN	O
PRO227,	NNP	O
PRO233,	,	O
PRO238,	.	O
PRO1328,	NNP	O
PRO4342,	,	O
PRO7423,	JJ	O
PRO10096,	NNS	O
PRO21384,	IN	O
PRO353	JJ	O
or	JJ	O
PRO1885	NN	O
polypeptide	NN	O
and	NNS	O
washed.	VBP	O
Bound	VBN	O
PRO227,	IN	O
PRO233,	DT	O
PRO238,	JJ	O
PRO1328,	,	O
PRO4342,	JJ	O
PRO7423,	IN	O
PRO10096,	NN	O
PRO21384,	NNS	O
PRO353	CC	O
or	DT	O
PRO1885	JJ	O
polypeptide	.	O
is	IN	O
detected	VBN	O
by	TO	O
methods	DT	O
well	,	O
known	,	O
in	,	O
the	,	O
art.	,	O
Purified	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	NNP	O
PRO1328,	CC	O
PRO4342,	NNP	O
PRO7423,	,	O
PRO10096,	DT	O
PRO21384,	JJ	O
PRO353	NN	O
or	NNS	O
PRO1885	VBP	O
polypeptide	VBN	O
can	IN	O
also	,	O
be	,	O
coated	,	O
directly	,	O
onto	,	O
plates	,	O
for	,	O
use	,	O
in	NNP	O
the	CC	O
aforementioned	NNP	O
drug	NN	O
screening	CC	O
techniques.	.	O
In	NNP	O
addition,	,	O
non-neutralizing	,	O
antibodies	,	O
can	,	O
be	,	O
used	,	O
to	,	O
capture	,	O
the	NNP	O
peptide	CC	O
and	NNP	O
immobilize	NN	O
it	VBZ	O
on	VBN	O
the	IN	O
solid	NNS	O
support.	RB	O
This	VBN	O
invention	IN	O
also	DT	O
contemplates	.	O
the	NNP	O
use	,	O
of	,	O
competitive	,	O
drug	,	O
screening	,	O
assays	,	O
in	,	O
which	,	O
neutralizing	NNP	O
antibodies	CC	O
capable	NNP	O
of	NN	O
binding	MD	O
PRO227,	RB	O
PRO233,	VB	O
PRO238,	VBN	O
PRO1328,	RB	O
PRO4342,	IN	O
PRO7423,	NNS	O
PRO10096,	IN	O
PRO21384,	NN	O
PRO353	IN	O
or	DT	O
PRO1885	JJ	O
polypeptide	NN	O
specifically	VBG	O
compete	.	O
with	IN	O
a	,	O
test	JJ	O
compound	NNS	O
for	MD	O
binding	VB	O
to	VBN	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	CC	O
PRO7423,	VB	O
PRO10096,	PRP	O
PRO21384,	IN	O
PRO353	DT	O
or	JJ	O
PRO1885	.	O
polypeptide	DT	O
or	NN	O
fragments	RB	O
thereof.	VBZ	O
In	DT	O
this	NN	O
manner,	IN	O
the	JJ	O
antibodies	NN	O
can	VBG	O
be	NNS	O
used	IN	O
to	WDT	O
detect	VBG	O
the	NNS	O
presence	JJ	O
of	IN	O
any	VBG	O
peptide	,	O
which	,	O
shares	,	O
one	,	O
or	,	O
more	,	O
antigenic	,	O
determinants	,	O
with	NNP	O
PRO227,	CC	O
PRO233,	NNP	O
PRO238,	VBP	O
PRO1328,	RB	O
PRO4342,	JJ	O
PRO7423,	IN	O
PRO10096,	DT	O
PRO21384,	NN	O
PRO353	NN	O
or	IN	O
PRO1885	VBG	O
polypeptide.	TO	O
Example	,	O
22	,	O
Rational	,	O
Drug	,	O
Design	,	O
The	,	O
goal	,	O
of	,	O
rational	NNP	O
drug	CC	O
design	NNP	O
is	NN	O
to	CC	O
produce	NNS	O
structural	.	O
analogs	IN	O
of	DT	O
biologically	,	O
active	DT	O
polypeptide	NNS	O
of	MD	O
interest	VB	O
(i.e.,	VBN	O
a	TO	O
PRO227,	VB	O
PRO233,	DT	O
PRO238,	NN	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	WDT	O
PRO21384,	NNS	O
PRO353	CD	O
or	CC	O
PRO1885	JJR	O
polypeptide)	JJ	O
or	NNS	O
of	IN	O
small	,	O
molecules	,	O
with	,	O
which	,	O
they	,	O
interact,	,	O
e.g.,	,	O
agonists,	,	O
antagonists,	NNP	O
or	CC	O
inhibitors.	NNP	O
Any	.	O
of	JJ	O
these	CD	O
examples	JJ	O
can	NNP	O
be	NNP	O
used	DT	O
to	NN	O
fashion	IN	O
drugs	JJ	O
which	NN	O
are	NN	O
more	VBZ	O
active	TO	O
or	VB	O
stable	JJ	O
forms	NNS	O
of	IN	O
the	RB	O
PRO227,	JJ	O
PRO233,	NN	O
PRO238,	IN	O
PRO1328,	NN	O
PRO4342,	,	O
PRO7423,	DT	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide	,	O
or	,	O
which	,	O
enhance	NNP	O
or	CC	O
interfere	NNP	O
with	)	O
the	CC	O
function	IN	O
of	JJ	O
the	NNS	O
PRO227,	IN	O
PRO233,	WDT	O
PRO238,	PRP	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	CC	O
PRO353	.	O
or	DT	O
PRO1885	IN	O
polypeptide	DT	O
in	NNS	O
vivo	MD	O
(c.f.,	VB	O
Hodgson,	VBN	B
Bio/Technology,	TO	I
9:	NN	I
19-21	NNS	I
(1991)).In	WDT	O
one	VBP	O
approach,	RBR	O
the	JJ	O
three-dimensional	CC	O
structure	JJ	O
of	NNS	O
the	IN	O
PRO227,	DT	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	,	O
PRO21384,	,	O
PRO353	,	O
or	NNP	O
PRO1885	CC	O
polypeptide,	NNP	O
or	NN	O
of	CC	O
a	WDT	O
PRO227,	NN	O
PRO233,	CC	O
PRO238,	VB	O
PRO1328,	IN	O
PRO4342,	DT	O
PRO7423,	NN	O
PRO10096,	IN	O
PRO21384,	DT	O
PRO353	,	O
or	,	O
PRO1885	,	O
polypeptide-inhibitor	,	O
complex,	,	O
is	,	O
determined	,	O
by	,	O
x-ray	NNP	O
crystallography,	CC	O
by	NNP	O
computer	VBP	O
modeling	IN	O
or,	NN	O
most	,	O
typically,	,	O
by	,	O
a	:	O
combination	JJ	O
of	.	O
the	IN	O
two	CD	O
approaches.	,	O
Both	DT	O
the	JJ	O
shape	NN	O
and	IN	O
charges	DT	O
of	,	O
the	,	O
PRO227,	,	O
PRO233,	,	O
PRO238,	,	O
PRO1328,	,	O
PRO4342,	,	O
PRO7423,	,	O
PRO10096,	NNP	O
PRO21384,	CC	O
PRO353	NNP	O
or	,	O
PRO1885	CC	O
polypeptide	IN	O
must	DT	O
be	,	O
ascertained	,	O
to	,	O
elucidate	,	O
the	,	O
structure	,	O
and	,	O
to	,	O
determine	NNP	O
active	CC	O
site(s)	NNP	O
of	NN	O
the	,	O
molecule.	VBZ	O
Less	VBN	O
often,	IN	O
useful	JJ	O
information	,	O
regarding	IN	O
the	NN	O
structure	NN	O
of	,	O
the	JJS	O
PRO227,	,	O
PRO233,	IN	O
PRO238,	DT	O
PRO1328,	NN	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	CD	O
PRO21384,	.	O
PRO353	DT	O
or	DT	O
PRO1885	NN	O
polypeptide	CC	O
may	NNS	O
be	IN	O
gained	DT	O
by	,	O
modeling	,	O
based	,	O
on	,	O
the	,	O
structure	,	O
of	,	O
homologous	,	O
proteins.	NNP	O
In	CC	O
both	NNP	O
cases,	NN	O
relevant	MD	O
structural	VB	O
information	VBN	O
is	TO	O
used	VB	O
to	DT	O
design	NN	O
analogous	CC	O
PRO227,	TO	O
PRO233,	VB	O
PRO238,	JJ	O
PRO1328,	)	O
PRO4342,	IN	O
PRO7423,	DT	O
PRO10096,	.	O
PRO21384,	RBR	O
PRO353	,	O
or	JJ	O
PRO1885	NN	O
polypeptide-like	VBG	O
molecules	DT	O
or	NN	O
to	IN	O
identify	DT	O
efficient	,	O
inhibitors.	,	O
Useful	,	O
examples	,	O
of	,	O
rational	,	O
drug	,	O
design	,	O
may	NNP	O
include	CC	O
molecules	NNP	O
which	NN	O
have	MD	O
improved	VB	O
activity	VBN	O
or	IN	O
stability	VBG	O
as	VBN	O
shown	IN	O
by	DT	O
Braxton	NN	B
and	IN	I
Wells,	JJ	I
Biochemistry,	.	I
31:7796-7801	IN	I
(1992)	DT	I
or	,	O
which	JJ	O
act	JJ	O
as	NN	O
inhibitors,	VBZ	O
agonists,	VBN	O
or	TO	O
antagonists	VB	O
of	JJ	O
native	,	O
peptides	,	O
as	,	O
shown	,	O
by	,	O
Athauda	,	B
et	,	I
al.,	,	I
J.	NNP	I
Biochem.,	CC	I
113:742-746	NNP	I
(1993).
